{"doc_id": "10030778_1", "wnd_id": "10030778_1_1", "text": "Intravenous azithromycin - induced ototoxicity .", "tokens": ["Intravenous", "azithromycin", "-", "induced", "ototoxicity", "."], "event_mentions": [{"id": "10030778_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "10030778_1_Ent1", "role": "Treatment", "text": "azithromycin", "start": 1, "end": 2}, {"entity_id": "10030778_1_Ent2", "role": "Treatment_Drug", "text": "azithromycin", "start": 1, "end": 2}, {"entity_id": "10030778_1_Ent0", "role": "Effect", "text": "ototoxicity", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "10030778_1_Ent1", "text": "azithromycin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10030778_1_Ent2", "text": "azithromycin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10030778_1_Ent0", "text": "ototoxicity", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "10048291_1", "wnd_id": "10048291_1_1", "text": "Immobilization , while Paget 's bone disease was present , and perhaps enhanced activation of dihydrotachysterol by rifampicin , could have led to increased calcium - release into the circulation .", "tokens": ["Immobilization", ",", "while", "Paget", "'s", "bone", "disease", "was", "present", ",", "and", "perhaps", "enhanced", "activation", "of", "dihydrotachysterol", "by", "rifampicin", ",", "could", "have", "led", "to", "increased", "calcium", "-", "release", "into", "the", "circulation", "."], "event_mentions": [{"id": "10048291_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "led", "start": 21, "end": 22}, "arguments": [{"entity_id": "10048291_1_Ent1", "role": "Treatment", "text": "dihydrotachysterol", "start": 15, "end": 16}, {"entity_id": "10048291_1_Ent2", "role": "Treatment_Drug", "text": "dihydrotachysterol", "start": 15, "end": 16}, {"entity_id": "10048291_1_Ent0", "role": "Effect", "text": "increased calcium - release", "start": 23, "end": 27}]}], "entity_mentions": [{"id": "10048291_1_Ent1", "text": "dihydrotachysterol", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10048291_1_Ent2", "text": "dihydrotachysterol", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10048291_1_Ent0", "text": "increased calcium - release", "entity_type": "Entity", "start": 23, "end": 27}], "lang": "en"}
{"doc_id": "10084639_1", "wnd_id": "10084639_1_1", "text": "BACKGROUND : How to best treat psychotic patients who have had past clozapine - induced agranulocytosis or granulocytopenia remains a problem .", "tokens": ["BACKGROUND", ":", "How", "to", "best", "treat", "psychotic", "patients", "who", "have", "had", "past", "clozapine", "-", "induced", "agranulocytosis", "or", "granulocytopenia", "remains", "a", "problem", "."], "event_mentions": [{"id": "10084639_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "10084639_1_Ent4", "role": "Treatment_Disorder", "text": "psychotic", "start": 6, "end": 7}, {"entity_id": "10084639_1_Ent0", "role": "Subject", "text": "psychotic patients", "start": 6, "end": 8}, {"entity_id": "10084639_1_Ent2", "role": "Treatment", "text": "clozapine", "start": 12, "end": 13}, {"entity_id": "10084639_1_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 12, "end": 13}, {"entity_id": "10084639_1_Ent1", "role": "Effect", "text": "agranulocytosis or granulocytopenia", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "10084639_1_Ent4", "text": "psychotic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10084639_1_Ent0", "text": "psychotic patients", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "10084639_1_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10084639_1_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10084639_1_Ent1", "text": "agranulocytosis or granulocytopenia", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "10102531_2", "wnd_id": "10102531_2_1", "text": "We report a case of reversible encephalopathy syndrome in a 16 - year - old girl with acute myelogenous leukemia ( AML ) , who is undergoing during consolidation chemotherapy composed of BH - AC ( N4 - behenoyl - 1 - beta - D - arabinofuranosyl cytosine ) and idarubicin .", "tokens": ["We", "report", "a", "case", "of", "reversible", "encephalopathy", "syndrome", "in", "a", "16", "-", "year", "-", "old", "girl", "with", "acute", "myelogenous", "leukemia", "(", "AML", ")", ",", "who", "is", "undergoing", "during", "consolidation", "chemotherapy", "composed", "of", "BH", "-", "AC", "(", "N4", "-", "behenoyl", "-", "1", "-", "beta", "-", "D", "-", "arabinofuranosyl", "cytosine", ")", "and", "idarubicin", "."], "event_mentions": [{"id": "10102531_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "undergoing", "start": 26, "end": 27}, "arguments": [{"entity_id": "10102531_2_Ent3", "role": "Effect", "text": "reversible encephalopathy syndrome", "start": 5, "end": 8}, {"entity_id": "10102531_2_Ent0", "role": "Subject", "text": "a 16 - year - old girl with acute myelogenous leukemia ( AML )", "start": 9, "end": 23}, {"entity_id": "10102531_2_Ent1", "role": "Subject_Age", "text": "16 - year - old", "start": 10, "end": 15}, {"entity_id": "10102531_2_Ent2", "role": "Subject_Gender", "text": "girl", "start": 15, "end": 16}, {"entity_id": "10102531_2_Ent5", "role": "Treatment_Disorder", "text": "acute myelogenous leukemia", "start": 17, "end": 20}, {"entity_id": "10102531_2_Ent4", "role": "Treatment", "text": "consolidation chemotherapy composed of BH - AC ( N4 - behenoyl - 1 - beta - D - arabinofuranosyl cytosine ) and idarubicin", "start": 28, "end": 51}, {"entity_id": "10102531_2_Ent7", "role": "Treatment_Drug", "text": "BH - AC", "start": 32, "end": 35}, {"entity_id": "10102531_2_Ent9", "role": "Combination_Drug", "text": "BH - AC", "start": 32, "end": 35}, {"entity_id": "10102531_2_Ent6", "role": "Treatment_Drug", "text": "idarubicin", "start": 50, "end": 51}, {"entity_id": "10102531_2_Ent8", "role": "Combination_Drug", "text": "idarubicin", "start": 50, "end": 51}]}], "entity_mentions": [{"id": "10102531_2_Ent3", "text": "reversible encephalopathy syndrome", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "10102531_2_Ent0", "text": "a 16 - year - old girl with acute myelogenous leukemia ( AML )", "entity_type": "Entity", "start": 9, "end": 23}, {"id": "10102531_2_Ent1", "text": "16 - year - old", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "10102531_2_Ent2", "text": "girl", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10102531_2_Ent5", "text": "acute myelogenous leukemia", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "10102531_2_Ent4", "text": "consolidation chemotherapy composed of BH - AC ( N4 - behenoyl - 1 - beta - D - arabinofuranosyl cytosine ) and idarubicin", "entity_type": "Entity", "start": 28, "end": 51}, {"id": "10102531_2_Ent7", "text": "BH - AC", "entity_type": "Entity", "start": 32, "end": 35}, {"id": "10102531_2_Ent9", "text": "BH - AC", "entity_type": "Entity", "start": 32, "end": 35}, {"id": "10102531_2_Ent6", "text": "idarubicin", "entity_type": "Entity", "start": 50, "end": 51}, {"id": "10102531_2_Ent8", "text": "idarubicin", "entity_type": "Entity", "start": 50, "end": 51}], "lang": "en"}
{"doc_id": "10190739_2", "wnd_id": "10190739_2_1", "text": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose ( 100 mg daily ) for 7 and 4 weeks , respectively .", "tokens": ["We", "report", "the", "cases", "of", "two", "patients", "who", "developed", "acute", "hepatitis", "after", "taking", "riluzole", "at", "the", "recommended", "dose", "(", "100", "mg", "daily", ")", "for", "7", "and", "4", "weeks", ",", "respectively", "."], "event_mentions": [{"id": "10190739_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 12, "end": 13}, "arguments": [{"entity_id": "10190739_2_Ent1", "role": "Subject_Population", "text": "two", "start": 5, "end": 6}, {"entity_id": "10190739_2_Ent0", "role": "Subject", "text": "two patients", "start": 5, "end": 7}, {"entity_id": "10190739_2_Ent2", "role": "Effect", "text": "acute hepatitis", "start": 9, "end": 11}, {"entity_id": "10190739_2_Ent4", "role": "Treatment_Drug", "text": "riluzole", "start": 13, "end": 14}, {"entity_id": "10190739_2_Ent3", "role": "Treatment", "text": "riluzole at the recommended dose ( 100 mg daily ) for 7 and 4 weeks", "start": 13, "end": 28}, {"entity_id": "10190739_2_Ent6", "role": "Treatment_Dosage", "text": "100 mg", "start": 19, "end": 21}, {"entity_id": "10190739_2_Ent7", "role": "Treatment_Freq", "text": "daily", "start": 21, "end": 22}, {"entity_id": "10190739_2_Ent5", "role": "Treatment_Duration", "text": "7 and 4 weeks", "start": 24, "end": 28}]}], "entity_mentions": [{"id": "10190739_2_Ent1", "text": "two", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10190739_2_Ent0", "text": "two patients", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "10190739_2_Ent2", "text": "acute hepatitis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10190739_2_Ent4", "text": "riluzole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "10190739_2_Ent3", "text": "riluzole at the recommended dose ( 100 mg daily ) for 7 and 4 weeks", "entity_type": "Entity", "start": 13, "end": 28}, {"id": "10190739_2_Ent6", "text": "100 mg", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "10190739_2_Ent7", "text": "daily", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "10190739_2_Ent5", "text": "7 and 4 weeks", "entity_type": "Entity", "start": 24, "end": 28}], "lang": "en"}
{"doc_id": "10212021_1", "wnd_id": "10212021_1_1", "text": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine .", "tokens": ["Methadone", "withdrawal", "when", "starting", "an", "antiretroviral", "regimen", "including", "nevirapine", "."], "event_mentions": [{"id": "10212021_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "starting", "start": 3, "end": 4}, "arguments": [{"entity_id": "10212021_1_Ent0", "role": "Effect", "text": "Methadone withdrawal", "start": 0, "end": 2}, {"entity_id": "10212021_1_Ent1", "role": "Treatment", "text": "an antiretroviral regimen including nevirapine", "start": 4, "end": 9}, {"entity_id": "10212021_1_Ent2", "role": "Treatment_Drug", "text": "nevirapine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "10212021_1_Ent0", "text": "Methadone withdrawal", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10212021_1_Ent1", "text": "an antiretroviral regimen including nevirapine", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "10212021_1_Ent2", "text": "nevirapine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "10212021_4", "wnd_id": "10212021_4_1", "text": "Methadone has two roles in human immunodeficiency viral infection : pain management and treatment of opioid abuse .", "tokens": ["Methadone", "has", "two", "roles", "in", "human", "immunodeficiency", "viral", "infection", ":", "pain", "management", "and", "treatment", "of", "opioid", "abuse", "."], "event_mentions": [{"id": "10212021_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "has two roles", "start": 1, "end": 4}, "arguments": [{"entity_id": "10212021_4_Ent1", "role": "Treatment", "text": "Methadone", "start": 0, "end": 1}, {"entity_id": "10212021_4_Ent3", "role": "Treatment_Drug", "text": "Methadone", "start": 0, "end": 1}, {"entity_id": "10212021_4_Ent2", "role": "Treatment_Disorder", "text": "human immunodeficiency viral infection", "start": 5, "end": 9}, {"entity_id": "10212021_4_Ent0", "role": "Effect", "text": "pain management and treatment of opioid abuse", "start": 10, "end": 17}]}], "entity_mentions": [{"id": "10212021_4_Ent1", "text": "Methadone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10212021_4_Ent3", "text": "Methadone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10212021_4_Ent2", "text": "human immunodeficiency viral infection", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "10212021_4_Ent0", "text": "pain management and treatment of opioid abuse", "entity_type": "Entity", "start": 10, "end": 17}], "lang": "en"}
{"doc_id": "10225085_3", "wnd_id": "10225085_3_1", "text": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field .", "tokens": ["We", "report", "a", "patient", "with", "chronic", "renal", "failure", "and", "ischemic", "heart", "disease", "who", "developed", "clinically", "significant", "methemoglobinemia", "after", "an", "axillary", "block", "with", "bupivacaine", "and", "additional", "injection", "of", "lidocaine", "in", "the", "operative", "field", "."], "event_mentions": [{"id": "10225085_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "10225085_3_Ent0", "role": "Subject", "text": "a patient with chronic renal failure and ischemic heart disease", "start": 2, "end": 12}, {"entity_id": "10225085_3_Ent3", "role": "Treatment_Disorder", "text": "chronic renal failure and ischemic heart disease", "start": 5, "end": 12}, {"entity_id": "10225085_3_Ent1", "role": "Effect", "text": "clinically significant methemoglobinemia", "start": 14, "end": 17}, {"entity_id": "10225085_3_Ent2", "role": "Treatment", "text": "an axillary block with bupivacaine and additional injection of lidocaine in the operative field", "start": 18, "end": 32}, {"entity_id": "10225085_3_Ent4", "role": "Treatment_Drug", "text": "bupivacaine", "start": 22, "end": 23}, {"entity_id": "10225085_3_Ent7", "role": "Combination_Drug", "text": "bupivacaine", "start": 22, "end": 23}, {"entity_id": "10225085_3_Ent6", "role": "Treatment_Route", "text": "injection", "start": 25, "end": 26}, {"entity_id": "10225085_3_Ent5", "role": "Treatment_Drug", "text": "lidocaine", "start": 27, "end": 28}, {"entity_id": "10225085_3_Ent8", "role": "Combination_Drug", "text": "lidocaine", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "10225085_3_Ent0", "text": "a patient with chronic renal failure and ischemic heart disease", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "10225085_3_Ent3", "text": "chronic renal failure and ischemic heart disease", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "10225085_3_Ent1", "text": "clinically significant methemoglobinemia", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "10225085_3_Ent2", "text": "an axillary block with bupivacaine and additional injection of lidocaine in the operative field", "entity_type": "Entity", "start": 18, "end": 32}, {"id": "10225085_3_Ent4", "text": "bupivacaine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "10225085_3_Ent7", "text": "bupivacaine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "10225085_3_Ent6", "text": "injection", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "10225085_3_Ent5", "text": "lidocaine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "10225085_3_Ent8", "text": "lidocaine", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "10323129_1", "wnd_id": "10323129_1_1", "text": "Possible theophylline toxicity during anesthesia .", "tokens": ["Possible", "theophylline", "toxicity", "during", "anesthesia", "."], "event_mentions": [{"id": "10323129_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "10323129_1_Ent0", "role": "Effect", "text": "theophylline toxicity", "start": 1, "end": 3}, {"entity_id": "10323129_1_Ent1", "role": "Treatment", "text": "anesthesia", "start": 4, "end": 5}, {"entity_id": "10323129_1_Ent2", "role": "Treatment_Drug", "text": "anesthesia", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "10323129_1_Ent0", "text": "theophylline toxicity", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "10323129_1_Ent1", "text": "anesthesia", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10323129_1_Ent2", "text": "anesthesia", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "10327035_1", "wnd_id": "10327035_1_1", "text": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate ( 1500 mg / m2 ) ( MTX ) is reported in a young adult with metastastic gastric cancer .", "tokens": ["An", "episode", "of", "subacute", "encephalopathy", "after", "the", "infusion", "of", "a", "moderate", "dose", "of", "methotrexate", "(", "1500", "mg", "/", "m2", ")", "(", "MTX", ")", "is", "reported", "in", "a", "young", "adult", "with", "metastastic", "gastric", "cancer", "."], "event_mentions": [{"id": "10327035_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "10327035_1_Ent2", "role": "Effect", "text": "subacute encephalopathy", "start": 3, "end": 5}, {"entity_id": "10327035_1_Ent3", "role": "Treatment", "text": "a moderate dose of methotrexate ( 1500 mg / m2 ) ( MTX )", "start": 9, "end": 23}, {"entity_id": "10327035_1_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 13, "end": 14}, {"entity_id": "10327035_1_Ent4", "role": "Treatment_Dosage", "text": "1500 mg / m2", "start": 15, "end": 19}, {"entity_id": "10327035_1_Ent0", "role": "Subject", "text": "a young adult with metastastic gastric cancer", "start": 26, "end": 33}, {"entity_id": "10327035_1_Ent1", "role": "Subject_Age", "text": "young adult", "start": 27, "end": 29}, {"entity_id": "10327035_1_Ent6", "role": "Treatment_Disorder", "text": "metastastic gastric cancer", "start": 30, "end": 33}]}], "entity_mentions": [{"id": "10327035_1_Ent2", "text": "subacute encephalopathy", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10327035_1_Ent3", "text": "a moderate dose of methotrexate ( 1500 mg / m2 ) ( MTX )", "entity_type": "Entity", "start": 9, "end": 23}, {"id": "10327035_1_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "10327035_1_Ent4", "text": "1500 mg / m2", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "10327035_1_Ent0", "text": "a young adult with metastastic gastric cancer", "entity_type": "Entity", "start": 26, "end": 33}, {"id": "10327035_1_Ent1", "text": "young adult", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "10327035_1_Ent6", "text": "metastastic gastric cancer", "entity_type": "Entity", "start": 30, "end": 33}], "lang": "en"}
{"doc_id": "10332990_2", "wnd_id": "10332990_2_1", "text": "Epoprostenol ( prostacyclin ) is currently approved for treatment of primary pulmonary hypertension ; however , it is being evaluated in other forms of pulmonary hypertension , particularly scleroderma .", "tokens": ["Epoprostenol", "(", "prostacyclin", ")", "is", "currently", "approved", "for", "treatment", "of", "primary", "pulmonary", "hypertension", ";", "however", ",", "it", "is", "being", "evaluated", "in", "other", "forms", "of", "pulmonary", "hypertension", ",", "particularly", "scleroderma", "."], "event_mentions": [{"id": "10332990_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 8, "end": 9}, "arguments": [{"entity_id": "10332990_2_Ent1", "role": "Treatment_Drug", "text": "Epoprostenol", "start": 0, "end": 1}, {"entity_id": "10332990_2_Ent0", "role": "Treatment", "text": "Epoprostenol ( prostacyclin )", "start": 0, "end": 4}, {"entity_id": "10332990_2_Ent2", "role": "Treatment_Drug", "text": "prostacyclin", "start": 2, "end": 3}, {"entity_id": "10332990_2_Ent3", "role": "Treatment_Disorder", "text": "primary pulmonary hypertension", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "10332990_2_Ent1", "text": "Epoprostenol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10332990_2_Ent0", "text": "Epoprostenol ( prostacyclin )", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10332990_2_Ent2", "text": "prostacyclin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10332990_2_Ent3", "text": "primary pulmonary hypertension", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "10337682_1", "wnd_id": "10337682_1_1", "text": "A 14 - year - old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone .", "tokens": ["A", "14", "-", "year", "-", "old", "girl", "with", "newly", "diagnosed", "SLE", "developed", "a", "pruritic", "bullous", "eruption", "while", "on", "prednisone", "."], "event_mentions": [{"id": "10337682_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "10337682_1_Ent0", "role": "Subject", "text": "A 14 - year - old girl with newly diagnosed SLE", "start": 0, "end": 11}, {"entity_id": "10337682_1_Ent1", "role": "Subject_Age", "text": "14 - year - old", "start": 1, "end": 6}, {"entity_id": "10337682_1_Ent2", "role": "Subject_Gender", "text": "girl", "start": 6, "end": 7}, {"entity_id": "10337682_1_Ent6", "role": "Treatment_Disorder", "text": "SLE", "start": 10, "end": 11}, {"entity_id": "10337682_1_Ent3", "role": "Effect", "text": "a pruritic bullous eruption", "start": 12, "end": 16}, {"entity_id": "10337682_1_Ent4", "role": "Treatment", "text": "prednisone", "start": 18, "end": 19}, {"entity_id": "10337682_1_Ent5", "role": "Treatment_Drug", "text": "prednisone", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "10337682_1_Ent0", "text": "A 14 - year - old girl with newly diagnosed SLE", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "10337682_1_Ent1", "text": "14 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10337682_1_Ent2", "text": "girl", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10337682_1_Ent6", "text": "SLE", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10337682_1_Ent3", "text": "a pruritic bullous eruption", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "10337682_1_Ent4", "text": "prednisone", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "10337682_1_Ent5", "text": "prednisone", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "10348150_1", "wnd_id": "10348150_1_1", "text": "Hydroxyurea - induced acute interstitial pneumonitis in a patient with essential thrombocythemia .", "tokens": ["Hydroxyurea", "-", "induced", "acute", "interstitial", "pneumonitis", "in", "a", "patient", "with", "essential", "thrombocythemia", "."], "event_mentions": [{"id": "10348150_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "10348150_1_Ent2", "role": "Treatment", "text": "Hydroxyurea", "start": 0, "end": 1}, {"entity_id": "10348150_1_Ent3", "role": "Treatment_Drug", "text": "Hydroxyurea", "start": 0, "end": 1}, {"entity_id": "10348150_1_Ent1", "role": "Effect", "text": "interstitial pneumonitis", "start": 4, "end": 6}, {"entity_id": "10348150_1_Ent0", "role": "Subject", "text": "a patient with essential thrombocythemia", "start": 7, "end": 12}, {"entity_id": "10348150_1_Ent4", "role": "Treatment_Disorder", "text": "essential thrombocythemia", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "10348150_1_Ent2", "text": "Hydroxyurea", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10348150_1_Ent3", "text": "Hydroxyurea", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10348150_1_Ent1", "text": "interstitial pneumonitis", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "10348150_1_Ent0", "text": "a patient with essential thrombocythemia", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "10348150_1_Ent4", "text": "essential thrombocythemia", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "10357715_2", "wnd_id": "10357715_2_1", "text": "Calcipotriol ( Daivonex R ; Leo Pharmaceuticals , Zurich , Switzerland ) may cause irritation of the skin , whereas allergic reactions are less common .", "tokens": ["Calcipotriol", "(", "Daivonex", "R", ";", "Leo", "Pharmaceuticals", ",", "Zurich", ",", "Switzerland", ")", "may", "cause", "irritation", "of", "the", "skin", ",", "whereas", "allergic", "reactions", "are", "less", "common", "."], "event_mentions": [{"id": "10357715_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 13, "end": 14}, "arguments": [{"entity_id": "10357715_2_Ent1", "role": "Treatment", "text": "Calcipotriol", "start": 0, "end": 1}, {"entity_id": "10357715_2_Ent2", "role": "Treatment_Drug", "text": "Calcipotriol", "start": 0, "end": 1}, {"entity_id": "10357715_2_Ent0", "role": "Effect", "text": "irritation of the skin", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "10357715_2_Ent1", "text": "Calcipotriol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10357715_2_Ent2", "text": "Calcipotriol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10357715_2_Ent0", "text": "irritation of the skin", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "10367184_3", "wnd_id": "10367184_3_1", "text": "This case suggests that sarcoidosis and pravastatin , two entities not frequently associated with myotonia , may interact in a synergistic manner to produce severe clinical myotonia in humans .", "tokens": ["This", "case", "suggests", "that", "sarcoidosis", "and", "pravastatin", ",", "two", "entities", "not", "frequently", "associated", "with", "myotonia", ",", "may", "interact", "in", "a", "synergistic", "manner", "to", "produce", "severe", "clinical", "myotonia", "in", "humans", "."], "event_mentions": [{"id": "10367184_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "interact", "start": 17, "end": 18}, "arguments": [{"entity_id": "10367184_3_Ent2", "role": "Treatment", "text": "pravastatin", "start": 6, "end": 7}, {"entity_id": "10367184_3_Ent3", "role": "Treatment_Drug", "text": "pravastatin", "start": 6, "end": 7}, {"entity_id": "10367184_3_Ent1", "role": "Effect", "text": "severe clinical myotonia", "start": 24, "end": 27}, {"entity_id": "10367184_3_Ent0", "role": "Subject", "text": "humans .", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "10367184_3_Ent2", "text": "pravastatin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10367184_3_Ent3", "text": "pravastatin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10367184_3_Ent1", "text": "severe clinical myotonia", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "10367184_3_Ent0", "text": "humans .", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "10395123_2", "wnd_id": "10395123_2_1", "text": "Fixed drug eruption in hands caused by omeprazole .", "tokens": ["Fixed", "drug", "eruption", "in", "hands", "caused", "by", "omeprazole", "."], "event_mentions": [{"id": "10395123_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 5, "end": 6}, "arguments": [{"entity_id": "10395123_2_Ent0", "role": "Effect", "text": "Fixed drug eruption in hands", "start": 0, "end": 5}, {"entity_id": "10395123_2_Ent1", "role": "Treatment", "text": "omeprazole", "start": 7, "end": 8}, {"entity_id": "10395123_2_Ent2", "role": "Treatment_Drug", "text": "omeprazole", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "10395123_2_Ent0", "text": "Fixed drug eruption in hands", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "10395123_2_Ent1", "text": "omeprazole", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10395123_2_Ent2", "text": "omeprazole", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "10410183_10", "wnd_id": "10410183_10_1", "text": "CONCLUSIONS : Marked elevation of serum CK may be a possible complication of olanzapine therapy .", "tokens": ["CONCLUSIONS", ":", "Marked", "elevation", "of", "serum", "CK", "may", "be", "a", "possible", "complication", "of", "olanzapine", "therapy", "."], "event_mentions": [{"id": "10410183_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 11, "end": 12}, "arguments": [{"entity_id": "10410183_10_Ent0", "role": "Effect", "text": "Marked elevation of serum CK", "start": 2, "end": 7}, {"entity_id": "10410183_10_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 13, "end": 14}, {"entity_id": "10410183_10_Ent1", "role": "Treatment", "text": "olanzapine therapy", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "10410183_10_Ent0", "text": "Marked elevation of serum CK", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "10410183_10_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "10410183_10_Ent1", "text": "olanzapine therapy", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "10410183_9", "wnd_id": "10410183_9_1", "text": "For those patients with a history of NMS , or even of isolated serum CK elevation during antipsychotic therapy , follow - up should be stricter .", "tokens": ["For", "those", "patients", "with", "a", "history", "of", "NMS", ",", "or", "even", "of", "isolated", "serum", "CK", "elevation", "during", "antipsychotic", "therapy", ",", "follow", "-", "up", "should", "be", "stricter", "."], "event_mentions": [{"id": "10410183_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 16, "end": 17}, "arguments": [{"entity_id": "10410183_9_Ent0", "role": "Subject", "text": "patients with a history of NMS", "start": 2, "end": 8}, {"entity_id": "10410183_9_Ent1", "role": "Subject_Disorder", "text": "a history of NMS", "start": 4, "end": 8}, {"entity_id": "10410183_9_Ent2", "role": "Effect", "text": "isolated serum CK elevation", "start": 12, "end": 16}, {"entity_id": "10410183_9_Ent3", "role": "Treatment", "text": "antipsychotic therapy", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "10410183_9_Ent0", "text": "patients with a history of NMS", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "10410183_9_Ent1", "text": "a history of NMS", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "10410183_9_Ent2", "text": "isolated serum CK elevation", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "10410183_9_Ent3", "text": "antipsychotic therapy", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "10414481_1", "wnd_id": "10414481_1_1", "text": "Diclofenac - associated hepatitis .", "tokens": ["Diclofenac", "-", "associated", "hepatitis", "."], "event_mentions": [{"id": "10414481_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "10414481_1_Ent1", "role": "Treatment", "text": "Diclofenac", "start": 0, "end": 1}, {"entity_id": "10414481_1_Ent2", "role": "Treatment_Drug", "text": "Diclofenac", "start": 0, "end": 1}, {"entity_id": "10414481_1_Ent0", "role": "Effect", "text": "hepatitis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "10414481_1_Ent1", "text": "Diclofenac", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10414481_1_Ent2", "text": "Diclofenac", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10414481_1_Ent0", "text": "hepatitis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "10456487_15", "wnd_id": "10456487_15_1", "text": "Whether concomitant fluvoxamine treatment reduces tacrine - induced hepatotoxicity needs further study .", "tokens": ["Whether", "concomitant", "fluvoxamine", "treatment", "reduces", "tacrine", "-", "induced", "hepatotoxicity", "needs", "further", "study", "."], "event_mentions": [{"id": "10456487_15_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reduces", "start": 4, "end": 5}, "arguments": [{"entity_id": "10456487_15_Ent3", "role": "Treatment", "text": "concomitant fluvoxamine", "start": 1, "end": 3}, {"entity_id": "10456487_15_Ent5", "role": "Treatment_Drug", "text": "fluvoxamine", "start": 2, "end": 3}, {"entity_id": "10456487_15_Ent4", "role": "Treatment_Disorder", "text": "tacrine - induced hepatotoxicity", "start": 5, "end": 9}]}, {"id": "10456487_15_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "10456487_15_Ent1", "role": "Treatment", "text": "tacrine", "start": 5, "end": 6}, {"entity_id": "10456487_15_Ent2", "role": "Treatment_Drug", "text": "tacrine", "start": 5, "end": 6}, {"entity_id": "10456487_15_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "10456487_15_Ent3", "text": "concomitant fluvoxamine", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "10456487_15_Ent5", "text": "fluvoxamine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10456487_15_Ent1", "text": "tacrine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10456487_15_Ent2", "text": "tacrine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10456487_15_Ent4", "text": "tacrine - induced hepatotoxicity", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "10456487_15_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "10458196_2", "wnd_id": "10458196_2_1", "text": "An 11 - day - old infant became lethargic and apneic after a single drop of brimonidine .", "tokens": ["An", "11", "-", "day", "-", "old", "infant", "became", "lethargic", "and", "apneic", "after", "a", "single", "drop", "of", "brimonidine", "."], "event_mentions": [{"id": "10458196_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "became", "start": 7, "end": 8}, "arguments": [{"entity_id": "10458196_2_Ent0", "role": "Subject", "text": "An 11 - day - old infant", "start": 0, "end": 7}, {"entity_id": "10458196_2_Ent1", "role": "Subject_Age", "text": "11 - day - old", "start": 1, "end": 6}, {"entity_id": "10458196_2_Ent2", "role": "Subject_Age", "text": "infant", "start": 6, "end": 7}, {"entity_id": "10458196_2_Ent3", "role": "Effect", "text": "lethargic and apneic", "start": 8, "end": 11}, {"entity_id": "10458196_2_Ent4", "role": "Treatment", "text": "a single drop of brimonidine", "start": 12, "end": 17}, {"entity_id": "10458196_2_Ent5", "role": "Treatment_Dosage", "text": "single drop", "start": 13, "end": 15}, {"entity_id": "10458196_2_Ent6", "role": "Treatment_Drug", "text": "brimonidine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "10458196_2_Ent0", "text": "An 11 - day - old infant", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "10458196_2_Ent1", "text": "11 - day - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10458196_2_Ent2", "text": "infant", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10458196_2_Ent3", "text": "lethargic and apneic", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "10458196_2_Ent4", "text": "a single drop of brimonidine", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "10458196_2_Ent5", "text": "single drop", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "10458196_2_Ent6", "text": "brimonidine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "10458196_3", "wnd_id": "10458196_3_1", "text": "Apparent central nervous system depression in infants after the use of topical brimonidine .", "tokens": ["Apparent", "central", "nervous", "system", "depression", "in", "infants", "after", "the", "use", "of", "topical", "brimonidine", "."], "event_mentions": [{"id": "10458196_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "10458196_3_Ent2", "role": "Effect", "text": "Apparent central nervous system depression", "start": 0, "end": 5}, {"entity_id": "10458196_3_Ent0", "role": "Subject", "text": "infants", "start": 6, "end": 7}, {"entity_id": "10458196_3_Ent1", "role": "Subject_Age", "text": "infants", "start": 6, "end": 7}, {"entity_id": "10458196_3_Ent5", "role": "Treatment_Route", "text": "topical", "start": 11, "end": 12}, {"entity_id": "10458196_3_Ent3", "role": "Treatment", "text": "topical brimonidine", "start": 11, "end": 13}, {"entity_id": "10458196_3_Ent4", "role": "Treatment_Drug", "text": "brimonidine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "10458196_3_Ent2", "text": "Apparent central nervous system depression", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "10458196_3_Ent0", "text": "infants", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10458196_3_Ent1", "text": "infants", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10458196_3_Ent5", "text": "topical", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10458196_3_Ent3", "text": "topical brimonidine", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "10458196_3_Ent4", "text": "brimonidine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "10461415_2", "wnd_id": "10461415_2_1", "text": "Hepato - biliary abnormalities secondary to ceftriaxone use : a case report .", "tokens": ["Hepato", "-", "biliary", "abnormalities", "secondary", "to", "ceftriaxone", "use", ":", "a", "case", "report", "."], "event_mentions": [{"id": "10461415_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary to", "start": 4, "end": 6}, "arguments": [{"entity_id": "10461415_2_Ent0", "role": "Effect", "text": "Hepato - biliary abnormalities", "start": 0, "end": 4}, {"entity_id": "10461415_2_Ent2", "role": "Treatment_Drug", "text": "ceftriaxone", "start": 6, "end": 7}, {"entity_id": "10461415_2_Ent1", "role": "Treatment", "text": "ceftriaxone use", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "10461415_2_Ent0", "text": "Hepato - biliary abnormalities", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10461415_2_Ent2", "text": "ceftriaxone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10461415_2_Ent1", "text": "ceftriaxone use", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "10465148_2", "wnd_id": "10465148_2_1", "text": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children .", "tokens": ["Intrathecal", "chemotherapy", "with", "methotrexate", "or", "cytosine", "arabinoside", "is", "the", "standard", "approach", "to", "prophylaxis", "and", "treatment", "of", "central", "nervous", "system", "leukemia", "in", "children", "."], "event_mentions": [{"id": "10465148_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 14, "end": 15}, "arguments": [{"entity_id": "10465148_2_Ent6", "role": "Treatment_Route", "text": "Intrathecal chemotherapy", "start": 0, "end": 2}, {"entity_id": "10465148_2_Ent2", "role": "Treatment", "text": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside", "start": 0, "end": 7}, {"entity_id": "10465148_2_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "10465148_2_Ent5", "role": "Treatment_Drug", "text": "cytosine arabinoside", "start": 5, "end": 7}, {"entity_id": "10465148_2_Ent3", "role": "Treatment_Disorder", "text": "central nervous system leukemia", "start": 16, "end": 20}, {"entity_id": "10465148_2_Ent0", "role": "Subject", "text": "children", "start": 21, "end": 22}, {"entity_id": "10465148_2_Ent1", "role": "Subject_Age", "text": "children", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "10465148_2_Ent6", "text": "Intrathecal chemotherapy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10465148_2_Ent2", "text": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "10465148_2_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10465148_2_Ent5", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "10465148_2_Ent3", "text": "central nervous system leukemia", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "10465148_2_Ent0", "text": "children", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "10465148_2_Ent1", "text": "children", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "10465148_4", "wnd_id": "10465148_4_1", "text": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery .", "tokens": ["Reported", "are", "three", "children", "who", "developed", "progressive", "paraparesis", "after", "intrathecal", "methotrexate", "administration", "followed", "by", "complete", "or", "partial", "recovery", "."], "event_mentions": [{"id": "10465148_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "10465148_4_Ent1", "role": "Subject_Population", "text": "three", "start": 2, "end": 3}, {"entity_id": "10465148_4_Ent0", "role": "Subject", "text": "three children", "start": 2, "end": 4}, {"entity_id": "10465148_4_Ent2", "role": "Subject_Age", "text": "children", "start": 3, "end": 4}, {"entity_id": "10465148_4_Ent3", "role": "Effect", "text": "paraparesis", "start": 7, "end": 8}, {"entity_id": "10465148_4_Ent6", "role": "Treatment_Route", "text": "intrathecal", "start": 9, "end": 10}, {"entity_id": "10465148_4_Ent4", "role": "Treatment", "text": "intrathecal methotrexate", "start": 9, "end": 11}, {"entity_id": "10465148_4_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "10465148_4_Ent1", "text": "three", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10465148_4_Ent0", "text": "three children", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "10465148_4_Ent2", "text": "children", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10465148_4_Ent3", "text": "paraparesis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10465148_4_Ent6", "text": "intrathecal", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10465148_4_Ent4", "text": "intrathecal methotrexate", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10465148_4_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "10467499_1", "wnd_id": "10467499_1_1", "text": "A 22 - year - old black man developed fever , chills , fatigue , night sweats , tender lymphadenopathy , and a generalized , pruritic , macular eruption 3 weeks after starting minocycline therapy for acne .", "tokens": ["A", "22", "-", "year", "-", "old", "black", "man", "developed", "fever", ",", "chills", ",", "fatigue", ",", "night", "sweats", ",", "tender", "lymphadenopathy", ",", "and", "a", "generalized", ",", "pruritic", ",", "macular", "eruption", "3", "weeks", "after", "starting", "minocycline", "therapy", "for", "acne", "."], "event_mentions": [{"id": "10467499_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "10467499_1_Ent0", "role": "Subject", "text": "A 22 - year - old black man", "start": 0, "end": 8}, {"entity_id": "10467499_1_Ent1", "role": "Subject_Age", "text": "22 - year - old", "start": 1, "end": 6}, {"entity_id": "10467499_1_Ent2", "role": "Subject_Race", "text": "black", "start": 6, "end": 7}, {"entity_id": "10467499_1_Ent3", "role": "Subject_Gender", "text": "man", "start": 7, "end": 8}, {"entity_id": "10467499_1_Ent4", "role": "Effect", "text": "fever , chills , fatigue , night sweats , tender lymphadenopathy , and a generalized , pruritic , macular eruption", "start": 9, "end": 29}, {"entity_id": "10467499_1_Ent8", "role": "Treatment_Time_elapsed", "text": "3 weeks", "start": 29, "end": 31}, {"entity_id": "10467499_1_Ent7", "role": "Treatment_Drug", "text": "minocycline", "start": 33, "end": 34}, {"entity_id": "10467499_1_Ent5", "role": "Treatment", "text": "minocycline therapy", "start": 33, "end": 35}, {"entity_id": "10467499_1_Ent6", "role": "Treatment_Disorder", "text": "acne", "start": 36, "end": 37}]}], "entity_mentions": [{"id": "10467499_1_Ent0", "text": "A 22 - year - old black man", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "10467499_1_Ent1", "text": "22 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10467499_1_Ent2", "text": "black", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10467499_1_Ent3", "text": "man", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10467499_1_Ent4", "text": "fever , chills , fatigue , night sweats , tender lymphadenopathy , and a generalized , pruritic , macular eruption", "entity_type": "Entity", "start": 9, "end": 29}, {"id": "10467499_1_Ent8", "text": "3 weeks", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "10467499_1_Ent7", "text": "minocycline", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "10467499_1_Ent5", "text": "minocycline therapy", "entity_type": "Entity", "start": 33, "end": 35}, {"id": "10467499_1_Ent6", "text": "acne", "entity_type": "Entity", "start": 36, "end": 37}], "lang": "en"}
{"doc_id": "10475726_2", "wnd_id": "10475726_2_1", "text": "The association of venlafaxine treatment with ischaemic events could be explained by its unique pharmacological and haemodynamic properties .", "tokens": ["The", "association", "of", "venlafaxine", "treatment", "with", "ischaemic", "events", "could", "be", "explained", "by", "its", "unique", "pharmacological", "and", "haemodynamic", "properties", "."], "event_mentions": [{"id": "10475726_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 1, "end": 2}, "arguments": [{"entity_id": "10475726_2_Ent2", "role": "Treatment_Drug", "text": "venlafaxine", "start": 3, "end": 4}, {"entity_id": "10475726_2_Ent1", "role": "Treatment", "text": "venlafaxine treatment", "start": 3, "end": 5}, {"entity_id": "10475726_2_Ent0", "role": "Effect", "text": "ischaemic events", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "10475726_2_Ent2", "text": "venlafaxine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10475726_2_Ent1", "text": "venlafaxine treatment", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10475726_2_Ent0", "text": "ischaemic events", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "10475726_4", "wnd_id": "10475726_4_1", "text": "We present a case of an elderly woman with a pre - existing history of ischaemic heart disease , who was treated with venlafaxine , and developed acute myocardial ischaemia within the first week of treatment .", "tokens": ["We", "present", "a", "case", "of", "an", "elderly", "woman", "with", "a", "pre", "-", "existing", "history", "of", "ischaemic", "heart", "disease", ",", "who", "was", "treated", "with", "venlafaxine", ",", "and", "developed", "acute", "myocardial", "ischaemia", "within", "the", "first", "week", "of", "treatment", "."], "event_mentions": [{"id": "10475726_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 26, "end": 27}, "arguments": [{"entity_id": "10475726_4_Ent0", "role": "Subject", "text": "an elderly woman with a pre - existing history of ischaemic heart disease", "start": 5, "end": 18}, {"entity_id": "10475726_4_Ent1", "role": "Subject_Age", "text": "elderly", "start": 6, "end": 7}, {"entity_id": "10475726_4_Ent2", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "10475726_4_Ent3", "role": "Subject_Disorder", "text": "ischaemic heart disease", "start": 15, "end": 18}, {"entity_id": "10475726_4_Ent5", "role": "Treatment", "text": "venlafaxine", "start": 23, "end": 24}, {"entity_id": "10475726_4_Ent6", "role": "Treatment_Drug", "text": "venlafaxine", "start": 23, "end": 24}, {"entity_id": "10475726_4_Ent4", "role": "Effect", "text": "acute myocardial ischaemia within the first week of treatment", "start": 27, "end": 36}, {"entity_id": "10475726_4_Ent7", "role": "Treatment_Duration", "text": "within the first week", "start": 30, "end": 34}]}], "entity_mentions": [{"id": "10475726_4_Ent0", "text": "an elderly woman with a pre - existing history of ischaemic heart disease", "entity_type": "Entity", "start": 5, "end": 18}, {"id": "10475726_4_Ent1", "text": "elderly", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10475726_4_Ent2", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10475726_4_Ent3", "text": "ischaemic heart disease", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "10475726_4_Ent5", "text": "venlafaxine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "10475726_4_Ent6", "text": "venlafaxine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "10475726_4_Ent4", "text": "acute myocardial ischaemia within the first week of treatment", "entity_type": "Entity", "start": 27, "end": 36}, {"id": "10475726_4_Ent7", "text": "within the first week", "entity_type": "Entity", "start": 30, "end": 34}], "lang": "en"}
{"doc_id": "10494874_1", "wnd_id": "10494874_1_1", "text": "We report the case of a female acromegalic patient in whom multiple hepatic adenomas appeared soon after danazol treatment for uterine fibromatosis .", "tokens": ["We", "report", "the", "case", "of", "a", "female", "acromegalic", "patient", "in", "whom", "multiple", "hepatic", "adenomas", "appeared", "soon", "after", "danazol", "treatment", "for", "uterine", "fibromatosis", "."], "event_mentions": [{"id": "10494874_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appeared", "start": 14, "end": 15}, "arguments": [{"entity_id": "10494874_1_Ent0", "role": "Subject", "text": "a female acromegalic patient", "start": 5, "end": 9}, {"entity_id": "10494874_1_Ent2", "role": "Subject_Gender", "text": "female", "start": 6, "end": 7}, {"entity_id": "10494874_1_Ent1", "role": "Subject_Disorder", "text": "acromegalic", "start": 7, "end": 8}, {"entity_id": "10494874_1_Ent3", "role": "Effect", "text": "hepatic adenomas", "start": 12, "end": 14}, {"entity_id": "10494874_1_Ent6", "role": "Treatment_Drug", "text": "danazol", "start": 17, "end": 18}, {"entity_id": "10494874_1_Ent4", "role": "Treatment", "text": "danazol treatment", "start": 17, "end": 19}, {"entity_id": "10494874_1_Ent5", "role": "Treatment_Disorder", "text": "uterine fibromatosis .", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "10494874_1_Ent0", "text": "a female acromegalic patient", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "10494874_1_Ent2", "text": "female", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10494874_1_Ent1", "text": "acromegalic", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10494874_1_Ent3", "text": "hepatic adenomas", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "10494874_1_Ent6", "text": "danazol", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10494874_1_Ent4", "text": "danazol treatment", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "10494874_1_Ent5", "text": "uterine fibromatosis .", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "10510017_3", "wnd_id": "10510017_3_1", "text": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin - induced thrombocytopenia , especially in children .", "tokens": ["There", "remains", "a", "paucity", "of", "information", "pertaining", "to", "alternative", "anticoagulation", "strategies", "for", "use", "during", "cardiopulmonary", "bypass", "concomitant", "with", "heparin", "-", "induced", "thrombocytopenia", ",", "especially", "in", "children", "."], "event_mentions": [{"id": "10510017_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 20, "end": 21}, "arguments": [{"entity_id": "10510017_3_Ent3", "role": "Treatment", "text": "heparin", "start": 18, "end": 19}, {"entity_id": "10510017_3_Ent4", "role": "Treatment_Drug", "text": "heparin", "start": 18, "end": 19}, {"entity_id": "10510017_3_Ent2", "role": "Effect", "text": "thrombocytopenia", "start": 21, "end": 22}, {"entity_id": "10510017_3_Ent0", "role": "Subject", "text": "children", "start": 25, "end": 26}, {"entity_id": "10510017_3_Ent1", "role": "Subject_Age", "text": "children", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "10510017_3_Ent3", "text": "heparin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "10510017_3_Ent4", "text": "heparin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "10510017_3_Ent2", "text": "thrombocytopenia", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "10510017_3_Ent0", "text": "children", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "10510017_3_Ent1", "text": "children", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "10513720_1", "wnd_id": "10513720_1_1", "text": "Taxane - induced glaucoma .", "tokens": ["Taxane", "-", "induced", "glaucoma", "."], "event_mentions": [{"id": "10513720_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "10513720_1_Ent1", "role": "Treatment", "text": "Taxane", "start": 0, "end": 1}, {"entity_id": "10513720_1_Ent2", "role": "Treatment_Drug", "text": "Taxane", "start": 0, "end": 1}, {"entity_id": "10513720_1_Ent0", "role": "Effect", "text": "glaucoma", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "10513720_1_Ent1", "text": "Taxane", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10513720_1_Ent2", "text": "Taxane", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10513720_1_Ent0", "text": "glaucoma", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "10555917_3", "wnd_id": "10555917_3_1", "text": "In vitro inhibition of hematopoiesis in a patient with systemic sclerosis treated with D - penicillamine .", "tokens": ["In", "vitro", "inhibition", "of", "hematopoiesis", "in", "a", "patient", "with", "systemic", "sclerosis", "treated", "with", "D", "-", "penicillamine", "."], "event_mentions": [{"id": "10555917_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "inhibition", "start": 2, "end": 3}, "arguments": [{"entity_id": "10555917_3_Ent1", "role": "Effect", "text": "vitro inhibition of hematopoiesis", "start": 1, "end": 5}, {"entity_id": "10555917_3_Ent0", "role": "Subject", "text": "a patient with systemic sclerosis", "start": 6, "end": 11}, {"entity_id": "10555917_3_Ent3", "role": "Treatment_Disorder", "text": "systemic sclerosis", "start": 9, "end": 11}, {"entity_id": "10555917_3_Ent2", "role": "Treatment", "text": "D - penicillamine", "start": 13, "end": 16}, {"entity_id": "10555917_3_Ent4", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "10555917_3_Ent1", "text": "vitro inhibition of hematopoiesis", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "10555917_3_Ent0", "text": "a patient with systemic sclerosis", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "10555917_3_Ent3", "text": "systemic sclerosis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10555917_3_Ent2", "text": "D - penicillamine", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "10555917_3_Ent4", "text": "D - penicillamine", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "10555917_4", "wnd_id": "10555917_4_1", "text": "These findings suggest that bicytopenia in this patient was caused by D - Pen and may be due to different sensitivities in the hematopoietic lineage .", "tokens": ["These", "findings", "suggest", "that", "bicytopenia", "in", "this", "patient", "was", "caused", "by", "D", "-", "Pen", "and", "may", "be", "due", "to", "different", "sensitivities", "in", "the", "hematopoietic", "lineage", "."], "event_mentions": [{"id": "10555917_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 9, "end": 10}, "arguments": [{"entity_id": "10555917_4_Ent1", "role": "Effect", "text": "bicytopenia", "start": 4, "end": 5}, {"entity_id": "10555917_4_Ent0", "role": "Subject", "text": "patient", "start": 7, "end": 8}, {"entity_id": "10555917_4_Ent2", "role": "Treatment", "text": "D - Pen", "start": 11, "end": 14}, {"entity_id": "10555917_4_Ent3", "role": "Treatment_Drug", "text": "D - Pen", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "10555917_4_Ent1", "text": "bicytopenia", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10555917_4_Ent0", "text": "patient", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10555917_4_Ent2", "text": "D - Pen", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "10555917_4_Ent3", "text": "D - Pen", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "10579985_1", "wnd_id": "10579985_1_1", "text": "The first patient was a 61 - year - old man with a 30 - year history of fistulizing CD in whom B - cell non - Hodgkin 's lymphoma was diagnosed 9 months after treatment with infliximab .", "tokens": ["The", "first", "patient", "was", "a", "61", "-", "year", "-", "old", "man", "with", "a", "30", "-", "year", "history", "of", "fistulizing", "CD", "in", "whom", "B", "-", "cell", "non", "-", "Hodgkin", "'s", "lymphoma", "was", "diagnosed", "9", "months", "after", "treatment", "with", "infliximab", "."], "event_mentions": [{"id": "10579985_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "diagnosed", "start": 31, "end": 32}, "arguments": [{"entity_id": "10579985_1_Ent0", "role": "Subject", "text": "The first patient was a 61 - year - old man with a 30 - year history of fistulizing CD", "start": 0, "end": 20}, {"entity_id": "10579985_1_Ent1", "role": "Subject_Age", "text": "61 - year - old", "start": 5, "end": 10}, {"entity_id": "10579985_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 10, "end": 11}, {"entity_id": "10579985_1_Ent5", "role": "Treatment_Disorder", "text": "fistulizing CD", "start": 18, "end": 20}, {"entity_id": "10579985_1_Ent3", "role": "Effect", "text": "B - cell non - Hodgkin 's lymphoma", "start": 22, "end": 30}, {"entity_id": "10579985_1_Ent6", "role": "Treatment_Time_elapsed", "text": "9 months", "start": 32, "end": 34}, {"entity_id": "10579985_1_Ent4", "role": "Treatment", "text": "9 months after treatment with infliximab", "start": 32, "end": 38}, {"entity_id": "10579985_1_Ent7", "role": "Treatment_Drug", "text": "infliximab", "start": 37, "end": 38}]}], "entity_mentions": [{"id": "10579985_1_Ent0", "text": "The first patient was a 61 - year - old man with a 30 - year history of fistulizing CD", "entity_type": "Entity", "start": 0, "end": 20}, {"id": "10579985_1_Ent1", "text": "61 - year - old", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "10579985_1_Ent2", "text": "man", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10579985_1_Ent5", "text": "fistulizing CD", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "10579985_1_Ent3", "text": "B - cell non - Hodgkin 's lymphoma", "entity_type": "Entity", "start": 22, "end": 30}, {"id": "10579985_1_Ent6", "text": "9 months", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "10579985_1_Ent4", "text": "9 months after treatment with infliximab", "entity_type": "Entity", "start": 32, "end": 38}, {"id": "10579985_1_Ent7", "text": "infliximab", "entity_type": "Entity", "start": 37, "end": 38}], "lang": "en"}
{"doc_id": "10579985_4", "wnd_id": "10579985_4_1", "text": "We describe the clinical course of 2 patients with Crohn 's disease ( CD ) in whom lymphoma was diagnosed after treatment with infliximab .", "tokens": ["We", "describe", "the", "clinical", "course", "of", "2", "patients", "with", "Crohn", "'s", "disease", "(", "CD", ")", "in", "whom", "lymphoma", "was", "diagnosed", "after", "treatment", "with", "infliximab", "."], "event_mentions": [{"id": "10579985_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "diagnosed", "start": 19, "end": 20}, "arguments": [{"entity_id": "10579985_4_Ent1", "role": "Subject_Population", "text": "2", "start": 6, "end": 7}, {"entity_id": "10579985_4_Ent0", "role": "Subject", "text": "2 patients with Crohn 's disease ( CD )", "start": 6, "end": 15}, {"entity_id": "10579985_4_Ent4", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 9, "end": 12}, {"entity_id": "10579985_4_Ent2", "role": "Effect", "text": "lymphoma", "start": 17, "end": 18}, {"entity_id": "10579985_4_Ent3", "role": "Treatment", "text": "treatment with infliximab", "start": 21, "end": 24}, {"entity_id": "10579985_4_Ent5", "role": "Treatment_Drug", "text": "infliximab", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "10579985_4_Ent1", "text": "2", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10579985_4_Ent0", "text": "2 patients with Crohn 's disease ( CD )", "entity_type": "Entity", "start": 6, "end": 15}, {"id": "10579985_4_Ent4", "text": "Crohn 's disease", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "10579985_4_Ent2", "text": "lymphoma", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10579985_4_Ent3", "text": "treatment with infliximab", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "10579985_4_Ent5", "text": "infliximab", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "10589077_1", "wnd_id": "10589077_1_1", "text": "Hydroxyurea ( HU ) and sodium phenylbutyrate ( SPB ) have been shown to increase fetal hemoglobin ( Hb F ) levels in patients with thalassemia intermedia .", "tokens": ["Hydroxyurea", "(", "HU", ")", "and", "sodium", "phenylbutyrate", "(", "SPB", ")", "have", "been", "shown", "to", "increase", "fetal", "hemoglobin", "(", "Hb", "F", ")", "levels", "in", "patients", "with", "thalassemia", "intermedia", "."], "event_mentions": [{"id": "10589077_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increase", "start": 14, "end": 15}, "arguments": [{"entity_id": "10589077_1_Ent3", "role": "Treatment_Drug", "text": "Hydroxyurea", "start": 0, "end": 1}, {"entity_id": "10589077_1_Ent6", "role": "Combination_Drug", "text": "Hydroxyurea", "start": 0, "end": 1}, {"entity_id": "10589077_1_Ent2", "role": "Treatment", "text": "Hydroxyurea ( HU ) and sodium phenylbutyrate ( SPB )", "start": 0, "end": 10}, {"entity_id": "10589077_1_Ent4", "role": "Treatment_Drug", "text": "sodium phenylbutyrate", "start": 5, "end": 7}, {"entity_id": "10589077_1_Ent7", "role": "Combination_Drug", "text": "sodium phenylbutyrate", "start": 5, "end": 7}, {"entity_id": "10589077_1_Ent1", "role": "Effect", "text": "hemoglobin ( Hb F ) levels", "start": 16, "end": 22}, {"entity_id": "10589077_1_Ent0", "role": "Subject", "text": "patients with thalassemia intermedia", "start": 23, "end": 27}, {"entity_id": "10589077_1_Ent5", "role": "Treatment_Disorder", "text": "thalassemia intermedia", "start": 25, "end": 27}]}], "entity_mentions": [{"id": "10589077_1_Ent3", "text": "Hydroxyurea", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10589077_1_Ent6", "text": "Hydroxyurea", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10589077_1_Ent2", "text": "Hydroxyurea ( HU ) and sodium phenylbutyrate ( SPB )", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "10589077_1_Ent4", "text": "sodium phenylbutyrate", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "10589077_1_Ent7", "text": "sodium phenylbutyrate", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "10589077_1_Ent1", "text": "hemoglobin ( Hb F ) levels", "entity_type": "Entity", "start": 16, "end": 22}, {"id": "10589077_1_Ent0", "text": "patients with thalassemia intermedia", "entity_type": "Entity", "start": 23, "end": 27}, {"id": "10589077_1_Ent5", "text": "thalassemia intermedia", "entity_type": "Entity", "start": 25, "end": 27}], "lang": "en"}
{"doc_id": "10589077_3", "wnd_id": "10589077_3_1", "text": "Prolonged responses were achieved with low doses of HU ( 3 - 10 mg / kg / day ) and higher doses were associated with mild reversible hematologic or hepatic toxicity and no further increases in Hb .", "tokens": ["Prolonged", "responses", "were", "achieved", "with", "low", "doses", "of", "HU", "(", "3", "-", "10", "mg", "/", "kg", "/", "day", ")", "and", "higher", "doses", "were", "associated", "with", "mild", "reversible", "hematologic", "or", "hepatic", "toxicity", "and", "no", "further", "increases", "in", "Hb", "."], "event_mentions": [{"id": "10589077_3_Evt1", "event_type": "Adverse_event", "trigger": {"text": "achieved", "start": 3, "end": 4}, "arguments": [{"entity_id": "10589077_3_Ent4", "role": "Effect", "text": "Prolonged responses", "start": 0, "end": 2}, {"entity_id": "10589077_3_Ent6", "role": "Treatment_Dosage", "text": "low doses", "start": 5, "end": 7}, {"entity_id": "10589077_3_Ent5", "role": "Treatment", "text": "low doses of HU", "start": 5, "end": 9}, {"entity_id": "10589077_3_Ent7", "role": "Treatment_Drug", "text": "HU", "start": 8, "end": 9}]}, {"id": "10589077_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 23, "end": 24}, "arguments": [{"entity_id": "10589077_3_Ent2", "role": "Treatment_Drug", "text": "HU", "start": 8, "end": 9}, {"entity_id": "10589077_3_Ent1", "role": "Treatment", "text": "HU ( 3 - 10 mg / kg / day ) and higher doses", "start": 8, "end": 22}, {"entity_id": "10589077_3_Ent3", "role": "Treatment_Dosage", "text": "higher doses", "start": 20, "end": 22}, {"entity_id": "10589077_3_Ent0", "role": "Effect", "text": "mild reversible hematologic or hepatic toxicity and no further increases in Hb", "start": 25, "end": 37}]}], "entity_mentions": [{"id": "10589077_3_Ent4", "text": "Prolonged responses", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10589077_3_Ent6", "text": "low doses", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "10589077_3_Ent5", "text": "low doses of HU", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "10589077_3_Ent2", "text": "HU", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10589077_3_Ent7", "text": "HU", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10589077_3_Ent1", "text": "HU ( 3 - 10 mg / kg / day ) and higher doses", "entity_type": "Entity", "start": 8, "end": 22}, {"id": "10589077_3_Ent3", "text": "higher doses", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "10589077_3_Ent0", "text": "mild reversible hematologic or hepatic toxicity and no further increases in Hb", "entity_type": "Entity", "start": 25, "end": 37}], "lang": "en"}
{"doc_id": "10589077_5", "wnd_id": "10589077_5_1", "text": "We conclude that low - dose HU therapy in patients with thalassemia intermedia may increase total Hb levels sufficiently to eliminate the need for transfusions .", "tokens": ["We", "conclude", "that", "low", "-", "dose", "HU", "therapy", "in", "patients", "with", "thalassemia", "intermedia", "may", "increase", "total", "Hb", "levels", "sufficiently", "to", "eliminate", "the", "need", "for", "transfusions", "."], "event_mentions": [{"id": "10589077_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "therapy", "start": 7, "end": 8}, "arguments": [{"entity_id": "10589077_5_Ent5", "role": "Treatment_Dosage", "text": "low - dose", "start": 3, "end": 6}, {"entity_id": "10589077_5_Ent2", "role": "Treatment", "text": "low - dose HU therapy", "start": 3, "end": 8}, {"entity_id": "10589077_5_Ent4", "role": "Treatment_Drug", "text": "HU", "start": 6, "end": 7}, {"entity_id": "10589077_5_Ent0", "role": "Subject", "text": "in patients with thalassemia intermedia", "start": 8, "end": 13}, {"entity_id": "10589077_5_Ent3", "role": "Treatment_Disorder", "text": "thalassemia intermedia", "start": 11, "end": 13}, {"entity_id": "10589077_5_Ent1", "role": "Effect", "text": "increase total Hb levels", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "10589077_5_Ent5", "text": "low - dose", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "10589077_5_Ent2", "text": "low - dose HU therapy", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "10589077_5_Ent4", "text": "HU", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10589077_5_Ent0", "text": "in patients with thalassemia intermedia", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "10589077_5_Ent3", "text": "thalassemia intermedia", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "10589077_5_Ent1", "text": "increase total Hb levels", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "10646879_2", "wnd_id": "10646879_2_1", "text": "Ten to 15 % of patients treated with ifosfamide develop an encephalopathy .", "tokens": ["Ten", "to", "15", "%", "of", "patients", "treated", "with", "ifosfamide", "develop", "an", "encephalopathy", "."], "event_mentions": [{"id": "10646879_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 9, "end": 10}, "arguments": [{"entity_id": "10646879_2_Ent1", "role": "Subject_Population", "text": "Ten to 15 %", "start": 0, "end": 4}, {"entity_id": "10646879_2_Ent0", "role": "Subject", "text": "Ten to 15 % of patients", "start": 0, "end": 6}, {"entity_id": "10646879_2_Ent3", "role": "Treatment", "text": "ifosfamide", "start": 8, "end": 9}, {"entity_id": "10646879_2_Ent4", "role": "Treatment_Drug", "text": "ifosfamide", "start": 8, "end": 9}, {"entity_id": "10646879_2_Ent2", "role": "Effect", "text": "encephalopathy .", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "10646879_2_Ent1", "text": "Ten to 15 %", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10646879_2_Ent0", "text": "Ten to 15 % of patients", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "10646879_2_Ent3", "text": "ifosfamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10646879_2_Ent4", "text": "ifosfamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10646879_2_Ent2", "text": "encephalopathy .", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "10679548_5", "wnd_id": "10679548_5_1", "text": "The spectrum of nitrofurantoin lung injury continues to widen .", "tokens": ["The", "spectrum", "of", "nitrofurantoin", "lung", "injury", "continues", "to", "widen", "."], "event_mentions": [{"id": "10679548_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "widen", "start": 8, "end": 9}, "arguments": [{"entity_id": "10679548_5_Ent1", "role": "Treatment", "text": "nitrofurantoin", "start": 3, "end": 4}, {"entity_id": "10679548_5_Ent2", "role": "Treatment_Drug", "text": "nitrofurantoin", "start": 3, "end": 4}, {"entity_id": "10679548_5_Ent0", "role": "Effect", "text": "lung injury", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "10679548_5_Ent1", "text": "nitrofurantoin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10679548_5_Ent2", "text": "nitrofurantoin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10679548_5_Ent0", "text": "lung injury", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "10682234_1", "wnd_id": "10682234_1_1", "text": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon - alpha .", "tokens": ["Intravenous", "administration", "of", "levodopa", "ameliorated", "a", "refractory", "akathisia", "case", "induced", "by", "interferon", "-", "alpha", "."], "event_mentions": [{"id": "10682234_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "ameliorated", "start": 4, "end": 5}, "arguments": [{"entity_id": "10682234_1_Ent2", "role": "Treatment_Route", "text": "Intravenous", "start": 0, "end": 1}, {"entity_id": "10682234_1_Ent0", "role": "Treatment", "text": "Intravenous administration of levodopa", "start": 0, "end": 4}, {"entity_id": "10682234_1_Ent3", "role": "Treatment_Drug", "text": "levodopa", "start": 3, "end": 4}, {"entity_id": "10682234_1_Ent1", "role": "Treatment_Disorder", "text": "a refractory akathisia case induced by interferon - alpha", "start": 5, "end": 14}]}, {"id": "10682234_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "10682234_1_Ent4", "role": "Effect", "text": "refractory akathisia", "start": 6, "end": 8}, {"entity_id": "10682234_1_Ent6", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 11, "end": 14}, {"entity_id": "10682234_1_Ent5", "role": "Treatment", "text": "interferon - alpha .", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "10682234_1_Ent2", "text": "Intravenous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10682234_1_Ent0", "text": "Intravenous administration of levodopa", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10682234_1_Ent3", "text": "levodopa", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10682234_1_Ent1", "text": "a refractory akathisia case induced by interferon - alpha", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "10682234_1_Ent4", "text": "refractory akathisia", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "10682234_1_Ent6", "text": "interferon - alpha", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "10682234_1_Ent5", "text": "interferon - alpha .", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "10682234_5", "wnd_id": "10682234_5_1", "text": "Clonazepam , thioridazine , beta - blockers , anticholinergics , and bromocriptine did not ameliorate his akathisia .", "tokens": ["Clonazepam", ",", "thioridazine", ",", "beta", "-", "blockers", ",", "anticholinergics", ",", "and", "bromocriptine", "did", "not", "ameliorate", "his", "akathisia", "."], "event_mentions": [{"id": "10682234_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "ameliorate", "start": 14, "end": 15}, "arguments": [{"entity_id": "10682234_5_Ent4", "role": "Treatment_Drug", "text": "Clonazepam", "start": 0, "end": 1}, {"entity_id": "10682234_5_Ent2", "role": "Treatment", "text": "Clonazepam , thioridazine , beta - blockers , anticholinergics , and bromocriptine", "start": 0, "end": 12}, {"entity_id": "10682234_5_Ent5", "role": "Treatment_Drug", "text": "thioridazine", "start": 2, "end": 3}, {"entity_id": "10682234_5_Ent6", "role": "Treatment_Drug", "text": "beta - blockers", "start": 4, "end": 7}, {"entity_id": "10682234_5_Ent7", "role": "Treatment_Drug", "text": "anticholinergics", "start": 8, "end": 9}, {"entity_id": "10682234_5_Ent8", "role": "Treatment_Drug", "text": "bromocriptine", "start": 11, "end": 12}, {"entity_id": "10682234_5_Ent0", "role": "Subject", "text": "his", "start": 15, "end": 16}, {"entity_id": "10682234_5_Ent1", "role": "Subject_Gender", "text": "his", "start": 15, "end": 16}, {"entity_id": "10682234_5_Ent3", "role": "Treatment_Disorder", "text": "akathisia", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "10682234_5_Ent4", "text": "Clonazepam", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10682234_5_Ent2", "text": "Clonazepam , thioridazine , beta - blockers , anticholinergics , and bromocriptine", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "10682234_5_Ent5", "text": "thioridazine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10682234_5_Ent6", "text": "beta - blockers", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "10682234_5_Ent7", "text": "anticholinergics", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10682234_5_Ent8", "text": "bromocriptine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10682234_5_Ent0", "text": "his", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10682234_5_Ent1", "text": "his", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10682234_5_Ent3", "text": "akathisia", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "10682234_6", "wnd_id": "10682234_6_1", "text": "Two days ' administration of levomepromazine 100 mg led him to a coma for 2 days .", "tokens": ["Two", "days", "'", "administration", "of", "levomepromazine", "100", "mg", "led", "him", "to", "a", "coma", "for", "2", "days", "."], "event_mentions": [{"id": "10682234_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "led", "start": 8, "end": 9}, "arguments": [{"entity_id": "10682234_6_Ent4", "role": "Treatment_Duration", "text": "Two days", "start": 0, "end": 2}, {"entity_id": "10682234_6_Ent1", "role": "Treatment", "text": "Two days ' administration of levomepromazine 100 mg", "start": 0, "end": 8}, {"entity_id": "10682234_6_Ent2", "role": "Treatment_Drug", "text": "levomepromazine", "start": 5, "end": 6}, {"entity_id": "10682234_6_Ent3", "role": "Treatment_Dosage", "text": "100 mg", "start": 6, "end": 8}, {"entity_id": "10682234_6_Ent0", "role": "Effect", "text": "a coma for 2 days", "start": 11, "end": 16}]}], "entity_mentions": [{"id": "10682234_6_Ent4", "text": "Two days", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10682234_6_Ent1", "text": "Two days ' administration of levomepromazine 100 mg", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "10682234_6_Ent2", "text": "levomepromazine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10682234_6_Ent3", "text": "100 mg", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "10682234_6_Ent0", "text": "a coma for 2 days", "entity_type": "Entity", "start": 11, "end": 16}], "lang": "en"}
{"doc_id": "10682234_7", "wnd_id": "10682234_7_1", "text": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically .", "tokens": ["Intravenous", "levodopa", "25", "mg", "ameliorated", "his", "akathisia", "symptoms", "drastically", "."], "event_mentions": [{"id": "10682234_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "ameliorated", "start": 4, "end": 5}, "arguments": [{"entity_id": "10682234_7_Ent2", "role": "Treatment_Route", "text": "Intravenous", "start": 0, "end": 1}, {"entity_id": "10682234_7_Ent0", "role": "Treatment", "text": "Intravenous levodopa 25 mg", "start": 0, "end": 4}, {"entity_id": "10682234_7_Ent3", "role": "Treatment_Drug", "text": "levodopa", "start": 1, "end": 2}, {"entity_id": "10682234_7_Ent1", "role": "Treatment_Disorder", "text": "akathisia", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "10682234_7_Ent2", "text": "Intravenous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10682234_7_Ent0", "text": "Intravenous levodopa 25 mg", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10682234_7_Ent3", "text": "levodopa", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10682234_7_Ent1", "text": "akathisia", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "10715308_12", "wnd_id": "10715308_12_1", "text": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies .", "tokens": ["The", "CATAPULT", "I", "study", "shows", "that", "tirapazamine", "enhances", "the", "activity", "of", "cisplatin", "in", "patients", "with", "advanced", "NSCLC", "and", "confirms", "that", "hypoxia", "is", "an", "exploitable", "therapeutic", "target", "in", "human", "malignancies", "."], "event_mentions": [{"id": "10715308_12_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "enhances", "start": 7, "end": 8}, "arguments": [{"entity_id": "10715308_12_Ent2", "role": "Treatment", "text": "tirapazamine", "start": 6, "end": 7}, {"entity_id": "10715308_12_Ent3", "role": "Treatment_Drug", "text": "tirapazamine", "start": 6, "end": 7}, {"entity_id": "10715308_12_Ent1", "role": "Effect", "text": "enhances the activity of cisplatin", "start": 7, "end": 12}, {"entity_id": "10715308_12_Ent0", "role": "Subject", "text": "patients with advanced NSCLC", "start": 13, "end": 17}, {"entity_id": "10715308_12_Ent4", "role": "Treatment_Disorder", "text": "advanced NSCLC", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "10715308_12_Ent2", "text": "tirapazamine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10715308_12_Ent3", "text": "tirapazamine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10715308_12_Ent1", "text": "enhances the activity of cisplatin", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "10715308_12_Ent0", "text": "patients with advanced NSCLC", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "10715308_12_Ent4", "text": "advanced NSCLC", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "10715308_3", "wnd_id": "10715308_3_1", "text": "A phase III trial , Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non - Small - Cell Lung Tumors ( CATAPULT I ) , was designed to determine the efficacy and safety of tirapazamine plus cisplatin for the treatment of non - small - cell lung cancer ( NSCLC ) .", "tokens": ["A", "phase", "III", "trial", ",", "Cisplatin", "and", "Tirapazamine", "in", "Subjects", "with", "Advanced", "Previously", "Untreated", "Non", "-", "Small", "-", "Cell", "Lung", "Tumors", "(", "CATAPULT", "I", ")", ",", "was", "designed", "to", "determine", "the", "efficacy", "and", "safety", "of", "tirapazamine", "plus", "cisplatin", "for", "the", "treatment", "of", "non", "-", "small", "-", "cell", "lung", "cancer", "(", "NSCLC", ")", "."], "event_mentions": [{"id": "10715308_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 40, "end": 41}, "arguments": [{"entity_id": "10715308_3_Ent1", "role": "Treatment_Drug", "text": "tirapazamine", "start": 35, "end": 36}, {"entity_id": "10715308_3_Ent4", "role": "Combination_Drug", "text": "tirapazamine", "start": 35, "end": 36}, {"entity_id": "10715308_3_Ent0", "role": "Treatment", "text": "tirapazamine plus cisplatin", "start": 35, "end": 38}, {"entity_id": "10715308_3_Ent2", "role": "Treatment_Drug", "text": "cisplatin", "start": 37, "end": 38}, {"entity_id": "10715308_3_Ent5", "role": "Combination_Drug", "text": "cisplatin", "start": 37, "end": 38}, {"entity_id": "10715308_3_Ent3", "role": "Treatment_Disorder", "text": "non - small - cell lung cancer ( NSCLC )", "start": 42, "end": 52}]}], "entity_mentions": [{"id": "10715308_3_Ent1", "text": "tirapazamine", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "10715308_3_Ent4", "text": "tirapazamine", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "10715308_3_Ent0", "text": "tirapazamine plus cisplatin", "entity_type": "Entity", "start": 35, "end": 38}, {"id": "10715308_3_Ent2", "text": "cisplatin", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "10715308_3_Ent5", "text": "cisplatin", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "10715308_3_Ent3", "text": "non - small - cell lung cancer ( NSCLC )", "entity_type": "Entity", "start": 42, "end": 52}], "lang": "en"}
{"doc_id": "10715308_4", "wnd_id": "10715308_4_1", "text": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine ( 390 mg / m(2 ) infused over 2 hours ) followed 1 hour later by cisplatin ( 75 mg / m(2 ) over 1 hour ) or 75 mg / m(2 ) of cisplatin alone , every 3 weeks for a maximum of eight cycles .", "tokens": ["Patients", "with", "previously", "untreated", "NSCLC", "were", "randomized", "to", "receive", "either", "tirapazamine", "(", "390", "mg", "/", "m(2", ")", "infused", "over", "2", "hours", ")", "followed", "1", "hour", "later", "by", "cisplatin", "(", "75", "mg", "/", "m(2", ")", "over", "1", "hour", ")", "or", "75", "mg", "/", "m(2", ")", "of", "cisplatin", "alone", ",", "every", "3", "weeks", "for", "a", "maximum", "of", "eight", "cycles", "."], "event_mentions": [{"id": "10715308_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receive", "start": 8, "end": 9}, "arguments": [{"entity_id": "10715308_4_Ent0", "role": "Subject", "text": "Patients with previously untreated NSCLC", "start": 0, "end": 5}, {"entity_id": "10715308_4_Ent12", "role": "Treatment_Disorder", "text": "NSCLC", "start": 4, "end": 5}, {"entity_id": "10715308_4_Ent1", "role": "Treatment", "text": "either tirapazamine ( 390 mg / m(2 ) infused over 2 hours ) followed 1 hour later by cisplatin ( 75 mg / m(2 ) over 1 hour ) or 75 mg / m(2 ) of cisplatin alone , every 3 weeks for a maximum of eight cycles", "start": 9, "end": 57}, {"entity_id": "10715308_4_Ent2", "role": "Treatment_Drug", "text": "tirapazamine", "start": 10, "end": 11}, {"entity_id": "10715308_4_Ent13", "role": "Combination_Drug", "text": "tirapazamine", "start": 10, "end": 11}, {"entity_id": "10715308_4_Ent5", "role": "Treatment_Dosage", "text": "390 mg / m(2 )", "start": 12, "end": 17}, {"entity_id": "10715308_4_Ent8", "role": "Treatment_Route", "text": "infused", "start": 17, "end": 18}, {"entity_id": "10715308_4_Ent9", "role": "Treatment_Time_elapsed", "text": "over 2 hours", "start": 18, "end": 21}, {"entity_id": "10715308_4_Ent3", "role": "Treatment_Drug", "text": "cisplatin", "start": 27, "end": 28}, {"entity_id": "10715308_4_Ent14", "role": "Combination_Drug", "text": "cisplatin", "start": 27, "end": 28}, {"entity_id": "10715308_4_Ent6", "role": "Treatment_Dosage", "text": "75 mg / m(2 )", "start": 29, "end": 34}, {"entity_id": "10715308_4_Ent10", "role": "Treatment_Time_elapsed", "text": "over 1 hour", "start": 34, "end": 37}, {"entity_id": "10715308_4_Ent7", "role": "Treatment_Dosage", "text": "75 mg / m(2 )", "start": 39, "end": 44}, {"entity_id": "10715308_4_Ent4", "role": "Treatment_Drug", "text": "cisplatin", "start": 45, "end": 46}, {"entity_id": "10715308_4_Ent11", "role": "Treatment_Freq", "text": "every 3 weeks for a maximum of eight cycles", "start": 48, "end": 57}]}], "entity_mentions": [{"id": "10715308_4_Ent0", "text": "Patients with previously untreated NSCLC", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "10715308_4_Ent12", "text": "NSCLC", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10715308_4_Ent1", "text": "either tirapazamine ( 390 mg / m(2 ) infused over 2 hours ) followed 1 hour later by cisplatin ( 75 mg / m(2 ) over 1 hour ) or 75 mg / m(2 ) of cisplatin alone , every 3 weeks for a maximum of eight cycles", "entity_type": "Entity", "start": 9, "end": 57}, {"id": "10715308_4_Ent2", "text": "tirapazamine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10715308_4_Ent13", "text": "tirapazamine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10715308_4_Ent5", "text": "390 mg / m(2 )", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "10715308_4_Ent8", "text": "infused", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10715308_4_Ent9", "text": "over 2 hours", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "10715308_4_Ent3", "text": "cisplatin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "10715308_4_Ent14", "text": "cisplatin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "10715308_4_Ent6", "text": "75 mg / m(2 )", "entity_type": "Entity", "start": 29, "end": 34}, {"id": "10715308_4_Ent10", "text": "over 1 hour", "entity_type": "Entity", "start": 34, "end": 37}, {"id": "10715308_4_Ent7", "text": "75 mg / m(2 )", "entity_type": "Entity", "start": 39, "end": 44}, {"id": "10715308_4_Ent4", "text": "cisplatin", "entity_type": "Entity", "start": 45, "end": 46}, {"id": "10715308_4_Ent11", "text": "every 3 weeks for a maximum of eight cycles", "entity_type": "Entity", "start": 48, "end": 57}], "lang": "en"}
{"doc_id": "10723699_1", "wnd_id": "10723699_1_1", "text": "Tetracycline - induced benign intracranial hypertension .", "tokens": ["Tetracycline", "-", "induced", "benign", "intracranial", "hypertension", "."], "event_mentions": [{"id": "10723699_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "10723699_1_Ent1", "role": "Treatment", "text": "Tetracycline", "start": 0, "end": 1}, {"entity_id": "10723699_1_Ent2", "role": "Treatment_Drug", "text": "Tetracycline", "start": 0, "end": 1}, {"entity_id": "10723699_1_Ent0", "role": "Effect", "text": "benign intracranial hypertension", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "10723699_1_Ent1", "text": "Tetracycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10723699_1_Ent2", "text": "Tetracycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10723699_1_Ent0", "text": "benign intracranial hypertension", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "10749332_1", "wnd_id": "10749332_1_1", "text": "However , as illustrated by these and other cases reported to date , the onset of troglitazone - induced liver injury is insidious and temporally variable .", "tokens": ["However", ",", "as", "illustrated", "by", "these", "and", "other", "cases", "reported", "to", "date", ",", "the", "onset", "of", "troglitazone", "-", "induced", "liver", "injury", "is", "insidious", "and", "temporally", "variable", "."], "event_mentions": [{"id": "10749332_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 18, "end": 19}, "arguments": [{"entity_id": "10749332_1_Ent1", "role": "Treatment", "text": "troglitazone", "start": 16, "end": 17}, {"entity_id": "10749332_1_Ent2", "role": "Treatment_Drug", "text": "troglitazone", "start": 16, "end": 17}, {"entity_id": "10749332_1_Ent0", "role": "Effect", "text": "liver injury is insidious and temporally variable", "start": 19, "end": 26}]}], "entity_mentions": [{"id": "10749332_1_Ent1", "text": "troglitazone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10749332_1_Ent2", "text": "troglitazone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10749332_1_Ent0", "text": "liver injury is insidious and temporally variable", "entity_type": "Entity", "start": 19, "end": 26}], "lang": "en"}
{"doc_id": "10749332_3", "wnd_id": "10749332_3_1", "text": "Other thiazolidinediones currently in clinical trials may be able to provide the therapeutic benefits of troglitazone without significant hepatotoxicity .", "tokens": ["Other", "thiazolidinediones", "currently", "in", "clinical", "trials", "may", "be", "able", "to", "provide", "the", "therapeutic", "benefits", "of", "troglitazone", "without", "significant", "hepatotoxicity", "."], "event_mentions": [{"id": "10749332_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "provide", "start": 10, "end": 11}, "arguments": [{"entity_id": "10749332_3_Ent0", "role": "Treatment", "text": "thiazolidinediones", "start": 1, "end": 2}, {"entity_id": "10749332_3_Ent1", "role": "Treatment_Drug", "text": "thiazolidinediones", "start": 1, "end": 2}]}], "entity_mentions": [{"id": "10749332_3_Ent0", "text": "thiazolidinediones", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10749332_3_Ent1", "text": "thiazolidinediones", "entity_type": "Entity", "start": 1, "end": 2}], "lang": "en"}
{"doc_id": "10755579_2", "wnd_id": "10755579_2_1", "text": "The medical examiner 's report indicated death caused by fluoxetine toxicity .", "tokens": ["The", "medical", "examiner", "'s", "report", "indicated", "death", "caused", "by", "fluoxetine", "toxicity", "."], "event_mentions": [{"id": "10755579_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 7, "end": 8}, "arguments": [{"entity_id": "10755579_2_Ent0", "role": "Effect", "text": "death", "start": 6, "end": 7}, {"entity_id": "10755579_2_Ent2", "role": "Treatment_Drug", "text": "fluoxetine", "start": 9, "end": 10}, {"entity_id": "10755579_2_Ent1", "role": "Treatment", "text": "fluoxetine toxicity", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "10755579_2_Ent0", "text": "death", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10755579_2_Ent2", "text": "fluoxetine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10755579_2_Ent1", "text": "fluoxetine toxicity", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "10774758_2", "wnd_id": "10774758_2_1", "text": "This is the first report of an adverse effect of fetal renal circulation by maternal ingestion of nimesulide .", "tokens": ["This", "is", "the", "first", "report", "of", "an", "adverse", "effect", "of", "fetal", "renal", "circulation", "by", "maternal", "ingestion", "of", "nimesulide", "."], "event_mentions": [{"id": "10774758_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse effect", "start": 7, "end": 9}, "arguments": [{"entity_id": "10774758_2_Ent0", "role": "Subject", "text": "first report of an adverse effect of fetal renal circulation", "start": 3, "end": 13}, {"entity_id": "10774758_2_Ent1", "role": "Effect", "text": "fetal renal circulation", "start": 10, "end": 13}, {"entity_id": "10774758_2_Ent5", "role": "Treatment_Route", "text": "maternal ingestion", "start": 14, "end": 16}, {"entity_id": "10774758_2_Ent2", "role": "Treatment", "text": "maternal ingestion of nimesulide", "start": 14, "end": 18}, {"entity_id": "10774758_2_Ent3", "role": "Treatment", "text": "nimesulide", "start": 17, "end": 18}, {"entity_id": "10774758_2_Ent4", "role": "Treatment_Drug", "text": "nimesulide", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "10774758_2_Ent0", "text": "first report of an adverse effect of fetal renal circulation", "entity_type": "Entity", "start": 3, "end": 13}, {"id": "10774758_2_Ent1", "text": "fetal renal circulation", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "10774758_2_Ent5", "text": "maternal ingestion", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "10774758_2_Ent2", "text": "maternal ingestion of nimesulide", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "10774758_2_Ent3", "text": "nimesulide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10774758_2_Ent4", "text": "nimesulide", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "10803790_2", "wnd_id": "10803790_2_1", "text": "Case 2 : A 43 - year - old male alcoholic remained completely abstinent with cyanamide treatment for 5 years and complained of general fatigue .", "tokens": ["Case", "2", ":", "A", "43", "-", "year", "-", "old", "male", "alcoholic", "remained", "completely", "abstinent", "with", "cyanamide", "treatment", "for", "5", "years", "and", "complained", "of", "general", "fatigue", "."], "event_mentions": [{"id": "10803790_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complained", "start": 21, "end": 22}, "arguments": [{"entity_id": "10803790_2_Ent0", "role": "Subject", "text": "A 43 - year - old male alcoholic", "start": 3, "end": 11}, {"entity_id": "10803790_2_Ent1", "role": "Subject_Age", "text": "43 - year - old", "start": 4, "end": 9}, {"entity_id": "10803790_2_Ent2", "role": "Subject_Gender", "text": "male", "start": 9, "end": 10}, {"entity_id": "10803790_2_Ent5", "role": "Treatment_Disorder", "text": "alcoholic", "start": 10, "end": 11}, {"entity_id": "10803790_2_Ent4", "role": "Treatment", "text": "completely abstinent with cyanamide treatment for 5 years", "start": 12, "end": 20}, {"entity_id": "10803790_2_Ent6", "role": "Treatment_Drug", "text": "cyanamide", "start": 15, "end": 16}, {"entity_id": "10803790_2_Ent7", "role": "Treatment_Duration", "text": "5 years", "start": 18, "end": 20}, {"entity_id": "10803790_2_Ent3", "role": "Effect", "text": "general fatigue", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "10803790_2_Ent0", "text": "A 43 - year - old male alcoholic", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "10803790_2_Ent1", "text": "43 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "10803790_2_Ent2", "text": "male", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10803790_2_Ent5", "text": "alcoholic", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10803790_2_Ent4", "text": "completely abstinent with cyanamide treatment for 5 years", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "10803790_2_Ent6", "text": "cyanamide", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10803790_2_Ent7", "text": "5 years", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "10803790_2_Ent3", "text": "general fatigue", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "10803790_4", "wnd_id": "10803790_4_1", "text": "Case 4 : A 61 - year - old male alcoholic who remained completely abstinent while taking cyanamide for 3 years showed slight elevation of serum transaminases .", "tokens": ["Case", "4", ":", "A", "61", "-", "year", "-", "old", "male", "alcoholic", "who", "remained", "completely", "abstinent", "while", "taking", "cyanamide", "for", "3", "years", "showed", "slight", "elevation", "of", "serum", "transaminases", "."], "event_mentions": [{"id": "10803790_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 16, "end": 17}, "arguments": [{"entity_id": "10803790_4_Ent1", "role": "Subject_Age", "text": "61 - year - old", "start": 4, "end": 9}, {"entity_id": "10803790_4_Ent0", "role": "Subject", "text": "61 - year - old male alcoholic who remained completely abstinent", "start": 4, "end": 15}, {"entity_id": "10803790_4_Ent2", "role": "Subject_Gender", "text": "male", "start": 9, "end": 10}, {"entity_id": "10803790_4_Ent7", "role": "Treatment_Disorder", "text": "alcoholic", "start": 10, "end": 11}, {"entity_id": "10803790_4_Ent5", "role": "Treatment_Drug", "text": "cyanamide", "start": 17, "end": 18}, {"entity_id": "10803790_4_Ent4", "role": "Treatment", "text": "cyanamide for 3 years", "start": 17, "end": 21}, {"entity_id": "10803790_4_Ent6", "role": "Treatment_Duration", "text": "3 years", "start": 19, "end": 21}, {"entity_id": "10803790_4_Ent3", "role": "Effect", "text": "elevation of serum transaminases", "start": 23, "end": 27}]}], "entity_mentions": [{"id": "10803790_4_Ent1", "text": "61 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "10803790_4_Ent0", "text": "61 - year - old male alcoholic who remained completely abstinent", "entity_type": "Entity", "start": 4, "end": 15}, {"id": "10803790_4_Ent2", "text": "male", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10803790_4_Ent7", "text": "alcoholic", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10803790_4_Ent5", "text": "cyanamide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10803790_4_Ent4", "text": "cyanamide for 3 years", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "10803790_4_Ent6", "text": "3 years", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "10803790_4_Ent3", "text": "elevation of serum transaminases", "entity_type": "Entity", "start": 23, "end": 27}], "lang": "en"}
{"doc_id": "10812579_2", "wnd_id": "10812579_2_1", "text": "A generalized tonic - clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone .", "tokens": ["A", "generalized", "tonic", "-", "clonic", "seizure", "occurred", "a", "few", "minutes", "after", "injection", "of", "the", "morphine", "antagonist", "naloxone", "."], "event_mentions": [{"id": "10812579_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 6, "end": 7}, "arguments": [{"entity_id": "10812579_2_Ent0", "role": "Effect", "text": "generalized tonic - clonic seizure", "start": 1, "end": 6}, {"entity_id": "10812579_2_Ent2", "role": "Treatment_Time_elapsed", "text": "a few minutes", "start": 7, "end": 10}, {"entity_id": "10812579_2_Ent1", "role": "Treatment", "text": "a few minutes after injection of the morphine antagonist naloxone", "start": 7, "end": 17}, {"entity_id": "10812579_2_Ent3", "role": "Treatment_Route", "text": "injection", "start": 11, "end": 12}, {"entity_id": "10812579_2_Ent4", "role": "Treatment_Drug", "text": "naloxone", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "10812579_2_Ent0", "text": "generalized tonic - clonic seizure", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10812579_2_Ent2", "text": "a few minutes", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "10812579_2_Ent1", "text": "a few minutes after injection of the morphine antagonist naloxone", "entity_type": "Entity", "start": 7, "end": 17}, {"id": "10812579_2_Ent3", "text": "injection", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10812579_2_Ent4", "text": "naloxone", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "1082426_1", "wnd_id": "1082426_1_1", "text": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy .", "tokens": ["Spontaneous", "bacterial", "peritonitis", "induced", "by", "intraarterial", "vasopressin", "therapy", "."], "event_mentions": [{"id": "1082426_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "1082426_1_Ent0", "role": "Effect", "text": "Spontaneous bacterial peritonitis", "start": 0, "end": 3}, {"entity_id": "1082426_1_Ent3", "role": "Treatment_Route", "text": "intraarterial", "start": 5, "end": 6}, {"entity_id": "1082426_1_Ent1", "role": "Treatment", "text": "intraarterial vasopressin therapy", "start": 5, "end": 8}, {"entity_id": "1082426_1_Ent2", "role": "Treatment_Drug", "text": "vasopressin", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "1082426_1_Ent0", "text": "Spontaneous bacterial peritonitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "1082426_1_Ent3", "text": "intraarterial", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1082426_1_Ent1", "text": "intraarterial vasopressin therapy", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "1082426_1_Ent2", "text": "vasopressin", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "10870095_2", "wnd_id": "10870095_2_1", "text": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise - induced asthma .", "tokens": ["Zafirlukast", "is", "a", "cysteinyl", "leukotriene", "antagonist", "used", "to", "treat", "allergic", "and", "exercise", "-", "induced", "asthma", "."], "event_mentions": [{"id": "10870095_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treat", "start": 8, "end": 9}, "arguments": [{"entity_id": "10870095_2_Ent2", "role": "Treatment_Drug", "text": "Zafirlukast", "start": 0, "end": 1}, {"entity_id": "10870095_2_Ent0", "role": "Treatment", "text": "Zafirlukast is a cysteinyl leukotriene antagonist", "start": 0, "end": 6}, {"entity_id": "10870095_2_Ent1", "role": "Treatment_Disorder", "text": "allergic and exercise - induced asthma", "start": 9, "end": 15}]}], "entity_mentions": [{"id": "10870095_2_Ent2", "text": "Zafirlukast", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10870095_2_Ent0", "text": "Zafirlukast is a cysteinyl leukotriene antagonist", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "10870095_2_Ent1", "text": "allergic and exercise - induced asthma", "entity_type": "Entity", "start": 9, "end": 15}], "lang": "en"}
{"doc_id": "10870095_7", "wnd_id": "10870095_7_1", "text": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of   S - warfarin and enhanced anti - thrombotic effects , although the in vitro IC(50 ) value is higher than the usual range of clinically relevant plasma concentrations .", "tokens": ["In", "vitro", "inhibition", "of", "CYP2C9", "by", "zafirlukast", "is", "consistent", "with", "clinical", "studies", "showing", "impaired", "clearance", "of", " ", "S", "-", "warfarin", "and", "enhanced", "anti", "-", "thrombotic", "effects", ",", "although", "the", "in", "vitro", "IC(50", ")", "value", "is", "higher", "than", "the", "usual", "range", "of", "clinically", "relevant", "plasma", "concentrations", "."], "event_mentions": [{"id": "10870095_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "showing", "start": 12, "end": 13}, "arguments": [{"entity_id": "10870095_7_Ent1", "role": "Treatment", "text": "zafirlukast", "start": 6, "end": 7}, {"entity_id": "10870095_7_Ent2", "role": "Treatment_Drug", "text": "zafirlukast", "start": 6, "end": 7}, {"entity_id": "10870095_7_Ent0", "role": "Effect", "text": "impaired clearance of   S - warfarin and enhanced anti - thrombotic effects", "start": 13, "end": 26}]}], "entity_mentions": [{"id": "10870095_7_Ent1", "text": "zafirlukast", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10870095_7_Ent2", "text": "zafirlukast", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10870095_7_Ent0", "text": "impaired clearance of   S - warfarin and enhanced anti - thrombotic effects", "entity_type": "Entity", "start": 13, "end": 26}], "lang": "en"}
{"doc_id": "10870485_1", "wnd_id": "10870485_1_1", "text": "Three months following splenectomy , multiple abscesses occurred in the muscles of both thighs while the patient was receiving the third course of the CHOP regimen .", "tokens": ["Three", "months", "following", "splenectomy", ",", "multiple", "abscesses", "occurred", "in", "the", "muscles", "of", "both", "thighs", "while", "the", "patient", "was", "receiving", "the", "third", "course", "of", "the", "CHOP", "regimen", "."], "event_mentions": [{"id": "10870485_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "while", "start": 14, "end": 15}, "arguments": [{"entity_id": "10870485_1_Ent4", "role": "Treatment_Duration", "text": "Three months", "start": 0, "end": 2}, {"entity_id": "10870485_1_Ent2", "role": "Treatment", "text": "Three months following splenectomy", "start": 0, "end": 4}, {"entity_id": "10870485_1_Ent5", "role": "Treatment_Drug", "text": "splenectomy", "start": 3, "end": 4}, {"entity_id": "10870485_1_Ent9", "role": "Combination_Drug", "text": "splenectomy", "start": 3, "end": 4}, {"entity_id": "10870485_1_Ent1", "role": "Effect", "text": "multiple abscesses occurred in the muscles of both thighs", "start": 5, "end": 14}, {"entity_id": "10870485_1_Ent0", "role": "Subject", "text": "the patient", "start": 15, "end": 17}, {"entity_id": "10870485_1_Ent7", "role": "Treatment_Dosage", "text": "third course", "start": 20, "end": 22}, {"entity_id": "10870485_1_Ent3", "role": "Treatment", "text": "third course of the CHOP regimen", "start": 20, "end": 26}, {"entity_id": "10870485_1_Ent6", "role": "Treatment_Drug", "text": "CHOP", "start": 24, "end": 25}, {"entity_id": "10870485_1_Ent8", "role": "Combination_Drug", "text": "CHOP", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "10870485_1_Ent4", "text": "Three months", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10870485_1_Ent2", "text": "Three months following splenectomy", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10870485_1_Ent5", "text": "splenectomy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10870485_1_Ent9", "text": "splenectomy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10870485_1_Ent1", "text": "multiple abscesses occurred in the muscles of both thighs", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "10870485_1_Ent0", "text": "the patient", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "10870485_1_Ent7", "text": "third course", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "10870485_1_Ent3", "text": "third course of the CHOP regimen", "entity_type": "Entity", "start": 20, "end": 26}, {"id": "10870485_1_Ent6", "text": "CHOP", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "10870485_1_Ent8", "text": "CHOP", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "1087773_1", "wnd_id": "1087773_1_1", "text": "After seven months ' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine - year - old boy developed polyarthritis , rash and hepatitis in association with anti - native DNA antibodies and positive antinuclear factor .", "tokens": ["After", "seven", "months", "'", "continuous", "treatment", "for", "suspected", "tuberculosis", "with", "rifampicin", "and", "ethambutol", "a", "nine", "-", "year", "-", "old", "boy", "developed", "polyarthritis", ",", "rash", "and", "hepatitis", "in", "association", "with", "anti", "-", "native", "DNA", "antibodies", "and", "positive", "antinuclear", "factor", "."], "event_mentions": [{"id": "1087773_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "1087773_1_Ent9", "role": "Treatment_Time_elapsed", "text": "seven months", "start": 1, "end": 3}, {"entity_id": "1087773_1_Ent4", "role": "Treatment", "text": "seven months ' continuous treatment", "start": 1, "end": 6}, {"entity_id": "1087773_1_Ent8", "role": "Treatment_Disorder", "text": "tuberculosis", "start": 8, "end": 9}, {"entity_id": "1087773_1_Ent5", "role": "Treatment", "text": "with rifampicin and ethambutol", "start": 9, "end": 13}, {"entity_id": "1087773_1_Ent6", "role": "Treatment_Drug", "text": "rifampicin", "start": 10, "end": 11}, {"entity_id": "1087773_1_Ent11", "role": "Combination_Drug", "text": "rifampicin", "start": 10, "end": 11}, {"entity_id": "1087773_1_Ent7", "role": "Treatment_Drug", "text": "ethambutol", "start": 12, "end": 13}, {"entity_id": "1087773_1_Ent10", "role": "Combination_Drug", "text": "ethambutol", "start": 12, "end": 13}, {"entity_id": "1087773_1_Ent0", "role": "Subject", "text": "a nine - year - old boy", "start": 13, "end": 20}, {"entity_id": "1087773_1_Ent1", "role": "Subject_Age", "text": "nine - year - old", "start": 14, "end": 19}, {"entity_id": "1087773_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 19, "end": 20}, {"entity_id": "1087773_1_Ent3", "role": "Effect", "text": "polyarthritis , rash and hepatitis in association with anti - native DNA antibodies and positive antinuclear factor", "start": 21, "end": 38}]}], "entity_mentions": [{"id": "1087773_1_Ent9", "text": "seven months", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "1087773_1_Ent4", "text": "seven months ' continuous treatment", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "1087773_1_Ent8", "text": "tuberculosis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1087773_1_Ent5", "text": "with rifampicin and ethambutol", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "1087773_1_Ent6", "text": "rifampicin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1087773_1_Ent11", "text": "rifampicin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1087773_1_Ent7", "text": "ethambutol", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1087773_1_Ent10", "text": "ethambutol", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1087773_1_Ent0", "text": "a nine - year - old boy", "entity_type": "Entity", "start": 13, "end": 20}, {"id": "1087773_1_Ent1", "text": "nine - year - old", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "1087773_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "1087773_1_Ent3", "text": "polyarthritis , rash and hepatitis in association with anti - native DNA antibodies and positive antinuclear factor", "entity_type": "Entity", "start": 21, "end": 38}], "lang": "en"}
{"doc_id": "10891991_6", "wnd_id": "10891991_6_1", "text": "RESULTS : Replacing valproate with lamotrigine resulted in a decrease in serum testosterone concentrations in all 3 women .", "tokens": ["RESULTS", ":", "Replacing", "valproate", "with", "lamotrigine", "resulted", "in", "a", "decrease", "in", "serum", "testosterone", "concentrations", "in", "all", "3", "women", "."], "event_mentions": [{"id": "10891991_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 6, "end": 7}, "arguments": [{"entity_id": "10891991_6_Ent4", "role": "Treatment", "text": "Replacing valproate with lamotrigine", "start": 2, "end": 6}, {"entity_id": "10891991_6_Ent5", "role": "Treatment_Drug", "text": "lamotrigine", "start": 5, "end": 6}, {"entity_id": "10891991_6_Ent3", "role": "Effect", "text": "a decrease in serum testosterone concentrations", "start": 8, "end": 14}, {"entity_id": "10891991_6_Ent0", "role": "Subject", "text": "all 3 women", "start": 15, "end": 18}, {"entity_id": "10891991_6_Ent1", "role": "Subject_Population", "text": "3", "start": 16, "end": 17}, {"entity_id": "10891991_6_Ent2", "role": "Subject_Gender", "text": "women", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "10891991_6_Ent4", "text": "Replacing valproate with lamotrigine", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "10891991_6_Ent5", "text": "lamotrigine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10891991_6_Ent3", "text": "a decrease in serum testosterone concentrations", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "10891991_6_Ent0", "text": "all 3 women", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "10891991_6_Ent1", "text": "3", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10891991_6_Ent2", "text": "women", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "10891991_7", "wnd_id": "10891991_7_1", "text": "The polycystic changes disappeared from the ovaries in 2 of the women after valproate therapy was discontinued , and the 2 women who had gained weight and developed amenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication .", "tokens": ["The", "polycystic", "changes", "disappeared", "from", "the", "ovaries", "in", "2", "of", "the", "women", "after", "valproate", "therapy", "was", "discontinued", ",", "and", "the", "2", "women", "who", "had", "gained", "weight", "and", "developed", "amenorrhea", "while", "being", "treated", "with", "valproate", "lost", "weight", "and", "resumed", "menstruating", "after", "the", "change", "in", "medication", "."], "event_mentions": [{"id": "10891991_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "disappeared", "start": 3, "end": 4}, "arguments": [{"entity_id": "10891991_7_Ent3", "role": "Effect", "text": "polycystic changes disappeared from the ovaries", "start": 1, "end": 7}, {"entity_id": "10891991_7_Ent1", "role": "Subject_Population", "text": "2", "start": 8, "end": 9}, {"entity_id": "10891991_7_Ent0", "role": "Subject", "text": "2 of the women", "start": 8, "end": 12}, {"entity_id": "10891991_7_Ent2", "role": "Subject_Gender", "text": "women", "start": 11, "end": 12}, {"entity_id": "10891991_7_Ent5", "role": "Treatment", "text": "after valproate therapy was discontinued", "start": 12, "end": 17}, {"entity_id": "10891991_7_Ent6", "role": "Treatment_Drug", "text": "valproate", "start": 13, "end": 14}, {"entity_id": "10891991_7_Ent4", "role": "Effect", "text": "lost weight and resumed menstruating", "start": 34, "end": 39}]}, {"id": "10891991_7_Evt1", "event_type": "Adverse_event", "trigger": {"text": "while", "start": 29, "end": 30}, "arguments": [{"entity_id": "10891991_7_Ent8", "role": "Subject_Population", "text": "2", "start": 20, "end": 21}, {"entity_id": "10891991_7_Ent7", "role": "Subject", "text": "2 women", "start": 20, "end": 22}, {"entity_id": "10891991_7_Ent9", "role": "Subject_Gender", "text": "women", "start": 21, "end": 22}, {"entity_id": "10891991_7_Ent10", "role": "Effect", "text": "gained weight and developed amenorrhea", "start": 24, "end": 29}, {"entity_id": "10891991_7_Ent11", "role": "Treatment", "text": "valproate", "start": 33, "end": 34}, {"entity_id": "10891991_7_Ent12", "role": "Treatment_Drug", "text": "valproate", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "10891991_7_Ent3", "text": "polycystic changes disappeared from the ovaries", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "10891991_7_Ent1", "text": "2", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10891991_7_Ent0", "text": "2 of the women", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "10891991_7_Ent2", "text": "women", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10891991_7_Ent5", "text": "after valproate therapy was discontinued", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "10891991_7_Ent6", "text": "valproate", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "10891991_7_Ent8", "text": "2", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10891991_7_Ent7", "text": "2 women", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "10891991_7_Ent9", "text": "women", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "10891991_7_Ent10", "text": "gained weight and developed amenorrhea", "entity_type": "Entity", "start": 24, "end": 29}, {"id": "10891991_7_Ent11", "text": "valproate", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "10891991_7_Ent12", "text": "valproate", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "10891991_7_Ent4", "text": "lost weight and resumed menstruating", "entity_type": "Entity", "start": 34, "end": 39}], "lang": "en"}
{"doc_id": "10897389_2", "wnd_id": "10897389_2_1", "text": "Recurrent septicemia with lethal outcome during and after cyclosporine therapy in severe ulcerative colitis .", "tokens": ["Recurrent", "septicemia", "with", "lethal", "outcome", "during", "and", "after", "cyclosporine", "therapy", "in", "severe", "ulcerative", "colitis", "."], "event_mentions": [{"id": "10897389_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "10897389_2_Ent0", "role": "Effect", "text": "Recurrent septicemia with lethal outcome", "start": 0, "end": 5}, {"entity_id": "10897389_2_Ent1", "role": "Treatment", "text": "cyclosporine", "start": 8, "end": 9}, {"entity_id": "10897389_2_Ent3", "role": "Treatment_Drug", "text": "cyclosporine", "start": 8, "end": 9}, {"entity_id": "10897389_2_Ent2", "role": "Treatment_Disorder", "text": "severe ulcerative colitis", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "10897389_2_Ent0", "text": "Recurrent septicemia with lethal outcome", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "10897389_2_Ent1", "text": "cyclosporine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10897389_2_Ent3", "text": "cyclosporine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10897389_2_Ent2", "text": "severe ulcerative colitis", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "10907391_2", "wnd_id": "10907391_2_1", "text": "Phantom limb pain as a manifestation of paclitaxel neurotoxicity .", "tokens": ["Phantom", "limb", "pain", "as", "a", "manifestation", "of", "paclitaxel", "neurotoxicity", "."], "event_mentions": [{"id": "10907391_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "manifestation", "start": 5, "end": 6}, "arguments": [{"entity_id": "10907391_2_Ent0", "role": "Effect", "text": "Phantom limb pain", "start": 0, "end": 3}, {"entity_id": "10907391_2_Ent1", "role": "Treatment", "text": "paclitaxel", "start": 7, "end": 8}, {"entity_id": "10907391_2_Ent2", "role": "Treatment_Drug", "text": "paclitaxel", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "10907391_2_Ent0", "text": "Phantom limb pain", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "10907391_2_Ent1", "text": "paclitaxel", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10907391_2_Ent2", "text": "paclitaxel", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "11001600_1", "wnd_id": "11001600_1_1", "text": "The cases are important in documenting that drug - induced dystonias do occur in patients with dementia , that risperidone appears to have contributed to dystonia among elderly patients , and that the categorization of dystonic reactions needs further clarification .", "tokens": ["The", "cases", "are", "important", "in", "documenting", "that", "drug", "-", "induced", "dystonias", "do", "occur", "in", "patients", "with", "dementia", ",", "that", "risperidone", "appears", "to", "have", "contributed", "to", "dystonia", "among", "elderly", "patients", ",", "and", "that", "the", "categorization", "of", "dystonic", "reactions", "needs", "further", "clarification", "."], "event_mentions": [{"id": "11001600_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "contributed", "start": 23, "end": 24}, "arguments": [{"entity_id": "11001600_1_Ent0", "role": "Subject", "text": "patients with dementia", "start": 14, "end": 17}, {"entity_id": "11001600_1_Ent2", "role": "Subject_Disorder", "text": "dementia", "start": 16, "end": 17}, {"entity_id": "11001600_1_Ent5", "role": "Treatment", "text": "risperidone", "start": 19, "end": 20}, {"entity_id": "11001600_1_Ent6", "role": "Treatment_Drug", "text": "risperidone", "start": 19, "end": 20}, {"entity_id": "11001600_1_Ent4", "role": "Effect", "text": "dystonia", "start": 25, "end": 26}, {"entity_id": "11001600_1_Ent3", "role": "Subject_Age", "text": "elderly", "start": 27, "end": 28}, {"entity_id": "11001600_1_Ent1", "role": "Subject", "text": "elderly patients", "start": 27, "end": 29}]}], "entity_mentions": [{"id": "11001600_1_Ent0", "text": "patients with dementia", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "11001600_1_Ent2", "text": "dementia", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11001600_1_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11001600_1_Ent6", "text": "risperidone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11001600_1_Ent4", "text": "dystonia", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "11001600_1_Ent3", "text": "elderly", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "11001600_1_Ent1", "text": "elderly patients", "entity_type": "Entity", "start": 27, "end": 29}], "lang": "en"}
{"doc_id": "11008259_1", "wnd_id": "11008259_1_1", "text": "Provocation of non - convulsive status epilepticus by tiagabine in three adolescent patients .", "tokens": ["Provocation", "of", "non", "-", "convulsive", "status", "epilepticus", "by", "tiagabine", "in", "three", "adolescent", "patients", "."], "event_mentions": [{"id": "11008259_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Provocation", "start": 0, "end": 1}, "arguments": [{"entity_id": "11008259_1_Ent3", "role": "Effect", "text": "non - convulsive status epilepticus", "start": 2, "end": 7}, {"entity_id": "11008259_1_Ent4", "role": "Treatment", "text": "tiagabine", "start": 8, "end": 9}, {"entity_id": "11008259_1_Ent5", "role": "Treatment_Drug", "text": "tiagabine", "start": 8, "end": 9}, {"entity_id": "11008259_1_Ent1", "role": "Subject_Population", "text": "three", "start": 10, "end": 11}, {"entity_id": "11008259_1_Ent0", "role": "Subject", "text": "three adolescent patients", "start": 10, "end": 13}, {"entity_id": "11008259_1_Ent2", "role": "Subject_Age", "text": "adolescent", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "11008259_1_Ent3", "text": "non - convulsive status epilepticus", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "11008259_1_Ent4", "text": "tiagabine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11008259_1_Ent5", "text": "tiagabine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11008259_1_Ent1", "text": "three", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11008259_1_Ent0", "text": "three adolescent patients", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "11008259_1_Ent2", "text": "adolescent", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "11020127_2", "wnd_id": "11020127_2_1", "text": "Protease inhibitors ( ritonavir and saquinavir ) were added to the treatment and the patient developed progressive ataxia related to carbamazepine toxicity .", "tokens": ["Protease", "inhibitors", "(", "ritonavir", "and", "saquinavir", ")", "were", "added", "to", "the", "treatment", "and", "the", "patient", "developed", "progressive", "ataxia", "related", "to", "carbamazepine", "toxicity", "."], "event_mentions": [{"id": "11020127_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "11020127_2_Ent5", "role": "Treatment_Drug", "text": "Protease inhibitors", "start": 0, "end": 2}, {"entity_id": "11020127_2_Ent6", "role": "Combination_Drug", "text": "Protease inhibitors", "start": 0, "end": 2}, {"entity_id": "11020127_2_Ent2", "role": "Treatment", "text": "Protease inhibitors ( ritonavir and saquinavir ) were added to the treatment", "start": 0, "end": 12}, {"entity_id": "11020127_2_Ent0", "role": "Subject", "text": "the patient", "start": 13, "end": 15}, {"entity_id": "11020127_2_Ent1", "role": "Effect", "text": "progressive ataxia related to carbamazepine toxicity", "start": 16, "end": 22}, {"entity_id": "11020127_2_Ent3", "role": "Treatment", "text": "carbamazepine", "start": 20, "end": 21}, {"entity_id": "11020127_2_Ent4", "role": "Treatment_Drug", "text": "carbamazepine", "start": 20, "end": 21}, {"entity_id": "11020127_2_Ent7", "role": "Combination_Drug", "text": "carbamazepine", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "11020127_2_Ent5", "text": "Protease inhibitors", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11020127_2_Ent6", "text": "Protease inhibitors", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11020127_2_Ent2", "text": "Protease inhibitors ( ritonavir and saquinavir ) were added to the treatment", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "11020127_2_Ent0", "text": "the patient", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "11020127_2_Ent1", "text": "progressive ataxia related to carbamazepine toxicity", "entity_type": "Entity", "start": 16, "end": 22}, {"id": "11020127_2_Ent3", "text": "carbamazepine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11020127_2_Ent4", "text": "carbamazepine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11020127_2_Ent7", "text": "carbamazepine", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "11022272_3", "wnd_id": "11022272_3_1", "text": "The intramuscular challenge test with 25 UI of Miacalcic was positive with an immediate anaphylactic reaction .", "tokens": ["The", "intramuscular", "challenge", "test", "with", "25", "UI", "of", "Miacalcic", "was", "positive", "with", "an", "immediate", "anaphylactic", "reaction", "."], "event_mentions": [{"id": "11022272_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reaction", "start": 15, "end": 16}, "arguments": [{"entity_id": "11022272_3_Ent4", "role": "Treatment_Dosage", "text": "25 UI", "start": 5, "end": 7}, {"entity_id": "11022272_3_Ent1", "role": "Treatment", "text": "25 UI of Miacalcic", "start": 5, "end": 9}, {"entity_id": "11022272_3_Ent3", "role": "Treatment_Drug", "text": "Miacalcic", "start": 8, "end": 9}, {"entity_id": "11022272_3_Ent2", "role": "Treatment", "text": "immediate", "start": 13, "end": 14}, {"entity_id": "11022272_3_Ent5", "role": "Treatment_Time_elapsed", "text": "immediate", "start": 13, "end": 14}, {"entity_id": "11022272_3_Ent0", "role": "Effect", "text": "anaphylactic reaction", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "11022272_3_Ent4", "text": "25 UI", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11022272_3_Ent1", "text": "25 UI of Miacalcic", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "11022272_3_Ent3", "text": "Miacalcic", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11022272_3_Ent2", "text": "immediate", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11022272_3_Ent5", "text": "immediate", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11022272_3_Ent0", "text": "anaphylactic reaction", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "11026106_1", "wnd_id": "11026106_1_1", "text": "Minocycline as a cause of drug - induced autoimmune hepatitis .", "tokens": ["Minocycline", "as", "a", "cause", "of", "drug", "-", "induced", "autoimmune", "hepatitis", "."], "event_mentions": [{"id": "11026106_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "11026106_1_Ent1", "role": "Treatment", "text": "Minocycline", "start": 0, "end": 1}, {"entity_id": "11026106_1_Ent2", "role": "Treatment_Drug", "text": "Minocycline", "start": 0, "end": 1}, {"entity_id": "11026106_1_Ent0", "role": "Effect", "text": "autoimmune hepatitis", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "11026106_1_Ent1", "text": "Minocycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11026106_1_Ent2", "text": "Minocycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11026106_1_Ent0", "text": "autoimmune hepatitis", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "11026106_2", "wnd_id": "11026106_2_1", "text": "Minocycline - induced autoimmune hepatitis is usually identical to sporadic autoimmune hepatitis .", "tokens": ["Minocycline", "-", "induced", "autoimmune", "hepatitis", "is", "usually", "identical", "to", "sporadic", "autoimmune", "hepatitis", "."], "event_mentions": [{"id": "11026106_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "11026106_2_Ent1", "role": "Treatment", "text": "Minocycline", "start": 0, "end": 1}, {"entity_id": "11026106_2_Ent3", "role": "Treatment_Drug", "text": "Minocycline", "start": 0, "end": 1}, {"entity_id": "11026106_2_Ent0", "role": "Effect", "text": "autoimmune hepatitis", "start": 3, "end": 5}, {"entity_id": "11026106_2_Ent2", "role": "Treatment_Disorder", "text": "sporadic autoimmune hepatitis", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "11026106_2_Ent1", "text": "Minocycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11026106_2_Ent3", "text": "Minocycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11026106_2_Ent0", "text": "autoimmune hepatitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11026106_2_Ent2", "text": "sporadic autoimmune hepatitis", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "11030530_1", "wnd_id": "11030530_1_1", "text": "L - asparaginase - provoked seizures as singular expression of central nervous toxicity .", "tokens": ["L", "-", "asparaginase", "-", "provoked", "seizures", "as", "singular", "expression", "of", "central", "nervous", "toxicity", "."], "event_mentions": [{"id": "11030530_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "provoked", "start": 4, "end": 5}, "arguments": [{"entity_id": "11030530_1_Ent1", "role": "Treatment", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "11030530_1_Ent2", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "11030530_1_Ent0", "role": "Effect", "text": "seizures as singular expression of central nervous toxicity", "start": 5, "end": 13}]}], "entity_mentions": [{"id": "11030530_1_Ent1", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11030530_1_Ent2", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11030530_1_Ent0", "text": "seizures as singular expression of central nervous toxicity", "entity_type": "Entity", "start": 5, "end": 13}], "lang": "en"}
{"doc_id": "11033734_3", "wnd_id": "11033734_3_1", "text": "Proconvulsive tendency of imipenem / cilastatin is one of its well - known side effects .", "tokens": ["Proconvulsive", "tendency", "of", "imipenem", "/", "cilastatin", "is", "one", "of", "its", "well", "-", "known", "side", "effects", "."], "event_mentions": [{"id": "11033734_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 13, "end": 15}, "arguments": [{"entity_id": "11033734_3_Ent0", "role": "Effect", "text": "Proconvulsive tendency", "start": 0, "end": 2}, {"entity_id": "11033734_3_Ent3", "role": "Treatment_Drug", "text": "imipenem", "start": 3, "end": 4}, {"entity_id": "11033734_3_Ent4", "role": "Combination_Drug", "text": "imipenem", "start": 3, "end": 4}, {"entity_id": "11033734_3_Ent1", "role": "Treatment", "text": "imipenem / cilastatin", "start": 3, "end": 6}, {"entity_id": "11033734_3_Ent2", "role": "Treatment_Drug", "text": "cilastatin", "start": 5, "end": 6}, {"entity_id": "11033734_3_Ent5", "role": "Combination_Drug", "text": "cilastatin", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "11033734_3_Ent0", "text": "Proconvulsive tendency", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11033734_3_Ent3", "text": "imipenem", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11033734_3_Ent4", "text": "imipenem", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11033734_3_Ent1", "text": "imipenem / cilastatin", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "11033734_3_Ent2", "text": "cilastatin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11033734_3_Ent5", "text": "cilastatin", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "11059196_1", "wnd_id": "11059196_1_1", "text": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long - term 5 - aminosalicylic acid therapy .", "tokens": ["Acute", "pancreatitis", "in", "a", "child", "with", "idiopathic", "ulcerative", "colitis", "on", "long", "-", "term", "5", "-", "aminosalicylic", "acid", "therapy", "."], "event_mentions": [{"id": "11059196_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 2, "end": 3}, "arguments": [{"entity_id": "11059196_1_Ent2", "role": "Effect", "text": "Acute pancreatitis", "start": 0, "end": 2}, {"entity_id": "11059196_1_Ent0", "role": "Subject", "text": "a child with idiopathic ulcerative colitis", "start": 3, "end": 9}, {"entity_id": "11059196_1_Ent1", "role": "Subject_Age", "text": "child", "start": 4, "end": 5}, {"entity_id": "11059196_1_Ent5", "role": "Treatment_Disorder", "text": "idiopathic ulcerative colitis", "start": 6, "end": 9}, {"entity_id": "11059196_1_Ent6", "role": "Treatment_Duration", "text": "long - term", "start": 10, "end": 13}, {"entity_id": "11059196_1_Ent3", "role": "Treatment", "text": "long - term 5 - aminosalicylic acid therapy", "start": 10, "end": 18}, {"entity_id": "11059196_1_Ent4", "role": "Treatment_Drug", "text": "5 - aminosalicylic acid", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "11059196_1_Ent2", "text": "Acute pancreatitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11059196_1_Ent0", "text": "a child with idiopathic ulcerative colitis", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "11059196_1_Ent1", "text": "child", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11059196_1_Ent5", "text": "idiopathic ulcerative colitis", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "11059196_1_Ent6", "text": "long - term", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "11059196_1_Ent3", "text": "long - term 5 - aminosalicylic acid therapy", "entity_type": "Entity", "start": 10, "end": 18}, {"id": "11059196_1_Ent4", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "11093071_3", "wnd_id": "11093071_3_1", "text": "While for ribavirin antidepressant effects are not known , we suppose that antidepressants may prevent changes in serotonergic or noradrenergic neurotransmission caused by IFN - alpha .", "tokens": ["While", "for", "ribavirin", "antidepressant", "effects", "are", "not", "known", ",", "we", "suppose", "that", "antidepressants", "may", "prevent", "changes", "in", "serotonergic", "or", "noradrenergic", "neurotransmission", "caused", "by", "IFN", "-", "alpha", "."], "event_mentions": [{"id": "11093071_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prevent", "start": 14, "end": 15}, "arguments": [{"entity_id": "11093071_3_Ent0", "role": "Treatment", "text": "antidepressants", "start": 12, "end": 13}, {"entity_id": "11093071_3_Ent2", "role": "Treatment_Drug", "text": "antidepressants", "start": 12, "end": 13}, {"entity_id": "11093071_3_Ent1", "role": "Treatment_Disorder", "text": "changes in serotonergic or noradrenergic neurotransmission caused by IFN - alpha", "start": 15, "end": 26}]}, {"id": "11093071_3_Evt1", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 21, "end": 22}, "arguments": [{"entity_id": "11093071_3_Ent3", "role": "Effect", "text": "changes in serotonergic or noradrenergic neurotransmission", "start": 15, "end": 21}, {"entity_id": "11093071_3_Ent4", "role": "Treatment", "text": "IFN - alpha", "start": 23, "end": 26}, {"entity_id": "11093071_3_Ent5", "role": "Treatment_Drug", "text": "IFN - alpha", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "11093071_3_Ent0", "text": "antidepressants", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11093071_3_Ent2", "text": "antidepressants", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11093071_3_Ent3", "text": "changes in serotonergic or noradrenergic neurotransmission", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "11093071_3_Ent1", "text": "changes in serotonergic or noradrenergic neurotransmission caused by IFN - alpha", "entity_type": "Entity", "start": 15, "end": 26}, {"id": "11093071_3_Ent4", "text": "IFN - alpha", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "11093071_3_Ent5", "text": "IFN - alpha", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "11144696_10", "wnd_id": "11144696_10_1", "text": "Venlafaxine - associated seizures at therapeutic doses have not been reported in the literature .", "tokens": ["Venlafaxine", "-", "associated", "seizures", "at", "therapeutic", "doses", "have", "not", "been", "reported", "in", "the", "literature", "."], "event_mentions": [{"id": "11144696_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "11144696_10_Ent1", "role": "Treatment", "text": "Venlafaxine", "start": 0, "end": 1}, {"entity_id": "11144696_10_Ent2", "role": "Treatment_Drug", "text": "Venlafaxine", "start": 0, "end": 1}, {"entity_id": "11144696_10_Ent0", "role": "Effect", "text": "seizures", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "11144696_10_Ent1", "text": "Venlafaxine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11144696_10_Ent2", "text": "Venlafaxine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11144696_10_Ent0", "text": "seizures", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "11144696_9", "wnd_id": "11144696_9_1", "text": "Both venlafaxine and trimipramine have been associated with seizures , mainly after overdose .", "tokens": ["Both", "venlafaxine", "and", "trimipramine", "have", "been", "associated", "with", "seizures", ",", "mainly", "after", "overdose", "."], "event_mentions": [{"id": "11144696_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "11144696_9_Ent3", "role": "Treatment_Drug", "text": "venlafaxine", "start": 1, "end": 2}, {"entity_id": "11144696_9_Ent2", "role": "Treatment", "text": "venlafaxine and trimipramine", "start": 1, "end": 4}, {"entity_id": "11144696_9_Ent4", "role": "Treatment_Drug", "text": "trimipramine", "start": 3, "end": 4}, {"entity_id": "11144696_9_Ent0", "role": "Effect", "text": "seizures", "start": 8, "end": 9}, {"entity_id": "11144696_9_Ent1", "role": "Treatment", "text": "overdose", "start": 12, "end": 13}, {"entity_id": "11144696_9_Ent5", "role": "Treatment_Dosage", "text": "overdose", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "11144696_9_Ent3", "text": "venlafaxine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11144696_9_Ent2", "text": "venlafaxine and trimipramine", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "11144696_9_Ent4", "text": "trimipramine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11144696_9_Ent0", "text": "seizures", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11144696_9_Ent1", "text": "overdose", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11144696_9_Ent5", "text": "overdose", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "11147747_3", "wnd_id": "11147747_3_1", "text": "This concerns 2 male patients who experienced incontinence while taking venlafaxine .", "tokens": ["This", "concerns", "2", "male", "patients", "who", "experienced", "incontinence", "while", "taking", "venlafaxine", "."], "event_mentions": [{"id": "11147747_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 6, "end": 7}, "arguments": [{"entity_id": "11147747_3_Ent1", "role": "Subject_Population", "text": "2", "start": 2, "end": 3}, {"entity_id": "11147747_3_Ent0", "role": "Subject", "text": "2 male patients", "start": 2, "end": 5}, {"entity_id": "11147747_3_Ent2", "role": "Subject_Gender", "text": "male", "start": 3, "end": 4}, {"entity_id": "11147747_3_Ent3", "role": "Effect", "text": "incontinence", "start": 7, "end": 8}, {"entity_id": "11147747_3_Ent4", "role": "Treatment", "text": "venlafaxine", "start": 10, "end": 11}, {"entity_id": "11147747_3_Ent5", "role": "Treatment_Drug", "text": "venlafaxine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11147747_3_Ent1", "text": "2", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11147747_3_Ent0", "text": "2 male patients", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "11147747_3_Ent2", "text": "male", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11147747_3_Ent3", "text": "incontinence", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11147747_3_Ent4", "text": "venlafaxine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11147747_3_Ent5", "text": "venlafaxine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11197768_3", "wnd_id": "11197768_3_1", "text": "The toxicity of cadmium , zinc , and cadmium / zinc mixtures at concentrations ranging from 10000 to 10 microg / l was investigated .", "tokens": ["The", "toxicity", "of", "cadmium", ",", "zinc", ",", "and", "cadmium", "/", "zinc", "mixtures", "at", "concentrations", "ranging", "from", "10000", "to", "10", "microg", "/", "l", "was", "investigated", "."], "event_mentions": [{"id": "11197768_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 2, "end": 3}, "arguments": [{"entity_id": "11197768_3_Ent0", "role": "Effect", "text": "toxicity", "start": 1, "end": 2}, {"entity_id": "11197768_3_Ent3", "role": "Treatment_Drug", "text": "cadmium", "start": 3, "end": 4}, {"entity_id": "11197768_3_Ent1", "role": "Treatment", "text": "cadmium , zinc , and cadmium / zinc mixtures at concentrations ranging from 10000 to 10 microg / l", "start": 3, "end": 22}, {"entity_id": "11197768_3_Ent4", "role": "Treatment_Drug", "text": "zinc", "start": 5, "end": 6}, {"entity_id": "11197768_3_Ent5", "role": "Treatment_Drug", "text": "cadmium", "start": 8, "end": 9}, {"entity_id": "11197768_3_Ent7", "role": "Combination_Drug", "text": "cadmium", "start": 8, "end": 9}, {"entity_id": "11197768_3_Ent6", "role": "Treatment_Drug", "text": "zinc", "start": 10, "end": 11}, {"entity_id": "11197768_3_Ent8", "role": "Combination_Drug", "text": "zinc", "start": 10, "end": 11}, {"entity_id": "11197768_3_Ent2", "role": "Treatment_Dosage", "text": "from 10000 to 10 microg / l", "start": 15, "end": 22}]}], "entity_mentions": [{"id": "11197768_3_Ent0", "text": "toxicity", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11197768_3_Ent3", "text": "cadmium", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11197768_3_Ent1", "text": "cadmium , zinc , and cadmium / zinc mixtures at concentrations ranging from 10000 to 10 microg / l", "entity_type": "Entity", "start": 3, "end": 22}, {"id": "11197768_3_Ent4", "text": "zinc", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11197768_3_Ent5", "text": "cadmium", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11197768_3_Ent7", "text": "cadmium", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11197768_3_Ent6", "text": "zinc", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11197768_3_Ent8", "text": "zinc", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11197768_3_Ent2", "text": "from 10000 to 10 microg / l", "entity_type": "Entity", "start": 15, "end": 22}], "lang": "en"}
{"doc_id": "11202801_3", "wnd_id": "11202801_3_1", "text": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma .", "tokens": ["We", "propose", "that", "cyclophosphamide", "be", "added", "to", "the", "list", "of", "exposures", "potentially", "associated", "with", "hepatic", "angiosarcoma", "."], "event_mentions": [{"id": "11202801_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 12, "end": 13}, "arguments": [{"entity_id": "11202801_3_Ent1", "role": "Treatment", "text": "cyclophosphamide", "start": 3, "end": 4}, {"entity_id": "11202801_3_Ent2", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 3, "end": 4}, {"entity_id": "11202801_3_Ent0", "role": "Effect", "text": "hepatic angiosarcoma", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "11202801_3_Ent1", "text": "cyclophosphamide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11202801_3_Ent2", "text": "cyclophosphamide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11202801_3_Ent0", "text": "hepatic angiosarcoma", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "11212595_1", "wnd_id": "11212595_1_1", "text": "Quetiapine and obsessive - compulsive symptoms ( OCS ) : case report and review of atypical antipsychotic - induced OCS .", "tokens": ["Quetiapine", "and", "obsessive", "-", "compulsive", "symptoms", "(", "OCS", ")", ":", "case", "report", "and", "review", "of", "atypical", "antipsychotic", "-", "induced", "OCS", "."], "event_mentions": [{"id": "11212595_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 18, "end": 19}, "arguments": [{"entity_id": "11212595_1_Ent0", "role": "Effect", "text": "obsessive - compulsive symptoms ( OCS )", "start": 2, "end": 9}, {"entity_id": "11212595_1_Ent2", "role": "Treatment", "text": "antipsychotic", "start": 16, "end": 17}, {"entity_id": "11212595_1_Ent3", "role": "Treatment_Drug", "text": "antipsychotic", "start": 16, "end": 17}, {"entity_id": "11212595_1_Ent1", "role": "Effect", "text": "OCS", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "11212595_1_Ent0", "text": "obsessive - compulsive symptoms ( OCS )", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "11212595_1_Ent2", "text": "antipsychotic", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11212595_1_Ent3", "text": "antipsychotic", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11212595_1_Ent1", "text": "OCS", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "11213850_6", "wnd_id": "11213850_6_1", "text": "Each subject was treated according to the following sequence : baseline ; phase 1 ( days 1 - 6 ) : cisapride 10 mg 4 times / day ; washout ( days 7 - 13 ) ; phase 2 ( days 14 - 44 ) : fluoxetine 20 mg / day ; and phase 3 ( days 45 - 52 ) : cisapride 10 mg 4 times / day ( days 45 - 51 ) plus fluoxetine 20 mg / day ( days 45 - 52 ) .", "tokens": ["Each", "subject", "was", "treated", "according", "to", "the", "following", "sequence", ":", "baseline", ";", "phase", "1", "(", "days", "1", "-", "6", ")", ":", "cisapride", "10", "mg", "4", "times", "/", "day", ";", "washout", "(", "days", "7", "-", "13", ")", ";", "phase", "2", "(", "days", "14", "-", "44", ")", ":", "fluoxetine", "20", "mg", "/", "day", ";", "and", "phase", "3", "(", "days", "45", "-", "52", ")", ":", "cisapride", "10", "mg", "4", "times", "/", "day", "(", "days", "45", "-", "51", ")", "plus", "fluoxetine", "20", "mg", "/", "day", "(", "days", "45", "-", "52", ")", "."], "event_mentions": [{"id": "11213850_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 3, "end": 4}, "arguments": [{"entity_id": "11213850_6_Ent0", "role": "Subject", "text": "Each subject", "start": 0, "end": 2}, {"entity_id": "11213850_6_Ent1", "role": "Treatment", "text": "baseline ; phase 1 ( days 1 - 6 ) : cisapride 10 mg 4 times / day ; washout ( days 7 - 13 ) ; phase 2 ( days 14 - 44 ) : fluoxetine 20 mg / day ; and phase 3 ( days 45 - 52 ) : cisapride 10 mg 4 times / day ( days 45 - 51 ) plus fluoxetine 20 mg / day ( days 45 - 52 )", "start": 10, "end": 87}, {"entity_id": "11213850_6_Ent2", "role": "Treatment_Drug", "text": "cisapride", "start": 21, "end": 22}, {"entity_id": "11213850_6_Ent6", "role": "Treatment_Dosage", "text": "10 mg", "start": 22, "end": 24}, {"entity_id": "11213850_6_Ent10", "role": "Treatment_Freq", "text": "4 times / day", "start": 24, "end": 28}, {"entity_id": "11213850_6_Ent3", "role": "Treatment_Drug", "text": "fluoxetine", "start": 46, "end": 47}, {"entity_id": "11213850_6_Ent7", "role": "Treatment_Dosage", "text": "20 mg / day", "start": 47, "end": 51}, {"entity_id": "11213850_6_Ent4", "role": "Treatment_Drug", "text": "cisapride", "start": 62, "end": 63}, {"entity_id": "11213850_6_Ent12", "role": "Combination_Drug", "text": "cisapride", "start": 62, "end": 63}, {"entity_id": "11213850_6_Ent8", "role": "Treatment_Dosage", "text": "10 mg", "start": 63, "end": 65}, {"entity_id": "11213850_6_Ent11", "role": "Treatment_Freq", "text": "4 times / day", "start": 65, "end": 69}, {"entity_id": "11213850_6_Ent5", "role": "Treatment_Drug", "text": "fluoxetine", "start": 76, "end": 77}, {"entity_id": "11213850_6_Ent13", "role": "Combination_Drug", "text": "fluoxetine", "start": 76, "end": 77}, {"entity_id": "11213850_6_Ent9", "role": "Treatment_Dosage", "text": "20 mg / day", "start": 77, "end": 81}]}], "entity_mentions": [{"id": "11213850_6_Ent0", "text": "Each subject", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11213850_6_Ent1", "text": "baseline ; phase 1 ( days 1 - 6 ) : cisapride 10 mg 4 times / day ; washout ( days 7 - 13 ) ; phase 2 ( days 14 - 44 ) : fluoxetine 20 mg / day ; and phase 3 ( days 45 - 52 ) : cisapride 10 mg 4 times / day ( days 45 - 51 ) plus fluoxetine 20 mg / day ( days 45 - 52 )", "entity_type": "Entity", "start": 10, "end": 87}, {"id": "11213850_6_Ent2", "text": "cisapride", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11213850_6_Ent6", "text": "10 mg", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "11213850_6_Ent10", "text": "4 times / day", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "11213850_6_Ent3", "text": "fluoxetine", "entity_type": "Entity", "start": 46, "end": 47}, {"id": "11213850_6_Ent7", "text": "20 mg / day", "entity_type": "Entity", "start": 47, "end": 51}, {"id": "11213850_6_Ent4", "text": "cisapride", "entity_type": "Entity", "start": 62, "end": 63}, {"id": "11213850_6_Ent12", "text": "cisapride", "entity_type": "Entity", "start": 62, "end": 63}, {"id": "11213850_6_Ent8", "text": "10 mg", "entity_type": "Entity", "start": 63, "end": 65}, {"id": "11213850_6_Ent11", "text": "4 times / day", "entity_type": "Entity", "start": 65, "end": 69}, {"id": "11213850_6_Ent5", "text": "fluoxetine", "entity_type": "Entity", "start": 76, "end": 77}, {"id": "11213850_6_Ent13", "text": "fluoxetine", "entity_type": "Entity", "start": 76, "end": 77}, {"id": "11213850_6_Ent9", "text": "20 mg / day", "entity_type": "Entity", "start": 77, "end": 81}], "lang": "en"}
{"doc_id": "11225565_6", "wnd_id": "11225565_6_1", "text": "Delavirdine and efavirenz ( but not nevirapine ) also were strong inhibitors of CYP3A , consistent with clinical hazards of initial cotreatment with either of these drugs and substrates of CYP3A.", "tokens": ["Delavirdine", "and", "efavirenz", "(", "but", "not", "nevirapine", ")", "also", "were", "strong", "inhibitors", "of", "CYP3A", ",", "consistent", "with", "clinical", "hazards", "of", "initial", "cotreatment", "with", "either", "of", "these", "drugs", "and", "substrates", "of", "CYP3A."], "event_mentions": [{"id": "11225565_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "consistent with", "start": 15, "end": 17}, "arguments": [{"entity_id": "11225565_6_Ent2", "role": "Treatment_Drug", "text": "Delavirdine", "start": 0, "end": 1}, {"entity_id": "11225565_6_Ent1", "role": "Treatment", "text": "Delavirdine and efavirenz ( but not nevirapine )", "start": 0, "end": 8}, {"entity_id": "11225565_6_Ent3", "role": "Treatment_Drug", "text": "efavirenz", "start": 2, "end": 3}, {"entity_id": "11225565_6_Ent0", "role": "Effect", "text": "clinical hazards", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "11225565_6_Ent2", "text": "Delavirdine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11225565_6_Ent1", "text": "Delavirdine and efavirenz ( but not nevirapine )", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "11225565_6_Ent3", "text": "efavirenz", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11225565_6_Ent0", "text": "clinical hazards", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "11236070_1", "wnd_id": "11236070_1_1", "text": "Dose - dependent olanzapine - associated leukopenia : three case reports .", "tokens": ["Dose", "-", "dependent", "olanzapine", "-", "associated", "leukopenia", ":", "three", "case", "reports", "."], "event_mentions": [{"id": "11236070_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "11236070_1_Ent3", "role": "Treatment", "text": "olanzapine", "start": 3, "end": 4}, {"entity_id": "11236070_1_Ent4", "role": "Treatment_Drug", "text": "olanzapine", "start": 3, "end": 4}, {"entity_id": "11236070_1_Ent2", "role": "Effect", "text": "leukopenia", "start": 6, "end": 7}, {"entity_id": "11236070_1_Ent1", "role": "Subject_Population", "text": "three", "start": 8, "end": 9}, {"entity_id": "11236070_1_Ent0", "role": "Subject", "text": "three case", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "11236070_1_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11236070_1_Ent4", "text": "olanzapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11236070_1_Ent2", "text": "leukopenia", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11236070_1_Ent1", "text": "three", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11236070_1_Ent0", "text": "three case", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "11236070_2", "wnd_id": "11236070_2_1", "text": "These cases suggest the possibility that , in some patients , leukopenia or agranulocytosis during olanzapine treatment might be dose - related .", "tokens": ["These", "cases", "suggest", "the", "possibility", "that", ",", "in", "some", "patients", ",", "leukopenia", "or", "agranulocytosis", "during", "olanzapine", "treatment", "might", "be", "dose", "-", "related", "."], "event_mentions": [{"id": "11236070_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 14, "end": 15}, "arguments": [{"entity_id": "11236070_2_Ent0", "role": "Subject", "text": "in some patients", "start": 7, "end": 10}, {"entity_id": "11236070_2_Ent1", "role": "Effect", "text": "leukopenia or agranulocytosis", "start": 11, "end": 14}, {"entity_id": "11236070_2_Ent3", "role": "Treatment_Drug", "text": "olanzapine", "start": 15, "end": 16}, {"entity_id": "11236070_2_Ent2", "role": "Treatment", "text": "olanzapine treatment", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "11236070_2_Ent0", "text": "in some patients", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "11236070_2_Ent1", "text": "leukopenia or agranulocytosis", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "11236070_2_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11236070_2_Ent2", "text": "olanzapine treatment", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "11250985_4", "wnd_id": "11250985_4_1", "text": "Serious adverse events experienced by patients with chronic heart failure taking spironolactone .", "tokens": ["Serious", "adverse", "events", "experienced", "by", "patients", "with", "chronic", "heart", "failure", "taking", "spironolactone", "."], "event_mentions": [{"id": "11250985_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 3, "end": 4}, "arguments": [{"entity_id": "11250985_4_Ent2", "role": "Effect", "text": "Serious adverse events", "start": 0, "end": 3}, {"entity_id": "11250985_4_Ent0", "role": "Subject", "text": "patients with chronic heart failure", "start": 5, "end": 10}, {"entity_id": "11250985_4_Ent1", "role": "Subject_Disorder", "text": "chronic heart failure", "start": 7, "end": 10}, {"entity_id": "11250985_4_Ent3", "role": "Treatment", "text": "spironolactone", "start": 11, "end": 12}, {"entity_id": "11250985_4_Ent4", "role": "Treatment_Drug", "text": "spironolactone", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "11250985_4_Ent2", "text": "Serious adverse events", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11250985_4_Ent0", "text": "patients with chronic heart failure", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "11250985_4_Ent1", "text": "chronic heart failure", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "11250985_4_Ent3", "text": "spironolactone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11250985_4_Ent4", "text": "spironolactone", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "11283125_2", "wnd_id": "11283125_2_1", "text": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high - dose ( HD ) intravenous ( IV ) cytarabine ( Ara - C ) added to HD IV methotrexate ( MTX ) to reduce the incidence of CNS and systemic relapses in children with increased - risk acute lymphoblastic leukemia ( ALL ) or stage III and IV lymphoblastic lymphoma treated with a Berlin - Frankfurt - Munster ( BFM) - based regimen .", "tokens": ["The", "European", "Organization", "for", "Research", "and", "Treatment", "of", "Cancer", "58881", "study", "was", "designed", "to", "test", "in", "a", "prospective", "multicentric", "randomized", "trial", "the", "value", "of", "high", "-", "dose", "(", "HD", ")", "intravenous", "(", "IV", ")", "cytarabine", "(", "Ara", "-", "C", ")", "added", "to", "HD", "IV", "methotrexate", "(", "MTX", ")", "to", "reduce", "the", "incidence", "of", "CNS", "and", "systemic", "relapses", "in", "children", "with", "increased", "-", "risk", "acute", "lymphoblastic", "leukemia", "(", "ALL", ")", "or", "stage", "III", "and", "IV", "lymphoblastic", "lymphoma", "treated", "with", "a", "Berlin", "-", "Frankfurt", "-", "Munster", "(", "BFM)", "-", "based", "regimen", "."], "event_mentions": [{"id": "11283125_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "to", "start": 48, "end": 49}, "arguments": [{"entity_id": "11283125_2_Ent4", "role": "Treatment_Dosage", "text": "high - dose", "start": 24, "end": 27}, {"entity_id": "11283125_2_Ent3", "role": "Treatment", "text": "high - dose ( HD ) intravenous ( IV ) cytarabine ( Ara - C ) added to HD IV methotrexate ( MTX )", "start": 24, "end": 48}, {"entity_id": "11283125_2_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 30, "end": 31}, {"entity_id": "11283125_2_Ent6", "role": "Treatment_Drug", "text": "cytarabine", "start": 34, "end": 35}, {"entity_id": "11283125_2_Ent10", "role": "Combination_Drug", "text": "cytarabine", "start": 34, "end": 35}, {"entity_id": "11283125_2_Ent7", "role": "Treatment_Drug", "text": "methotrexate", "start": 44, "end": 45}, {"entity_id": "11283125_2_Ent11", "role": "Combination_Drug", "text": "methotrexate", "start": 44, "end": 45}, {"entity_id": "11283125_2_Ent2", "role": "Effect", "text": "reduce the incidence of CNS and systemic relapses", "start": 49, "end": 57}, {"entity_id": "11283125_2_Ent1", "role": "Subject_Age", "text": "children", "start": 58, "end": 59}, {"entity_id": "11283125_2_Ent0", "role": "Subject", "text": "children with increased - risk acute lymphoblastic leukemia ( ALL ) or stage III and IV lymphoblastic lymphoma", "start": 58, "end": 76}, {"entity_id": "11283125_2_Ent8", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 63, "end": 66}, {"entity_id": "11283125_2_Ent9", "role": "Treatment_Disorder", "text": "stage III and IV lymphoblastic lymphoma", "start": 70, "end": 76}]}], "entity_mentions": [{"id": "11283125_2_Ent4", "text": "high - dose", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "11283125_2_Ent3", "text": "high - dose ( HD ) intravenous ( IV ) cytarabine ( Ara - C ) added to HD IV methotrexate ( MTX )", "entity_type": "Entity", "start": 24, "end": 48}, {"id": "11283125_2_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "11283125_2_Ent6", "text": "cytarabine", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "11283125_2_Ent10", "text": "cytarabine", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "11283125_2_Ent7", "text": "methotrexate", "entity_type": "Entity", "start": 44, "end": 45}, {"id": "11283125_2_Ent11", "text": "methotrexate", "entity_type": "Entity", "start": 44, "end": 45}, {"id": "11283125_2_Ent2", "text": "reduce the incidence of CNS and systemic relapses", "entity_type": "Entity", "start": 49, "end": 57}, {"id": "11283125_2_Ent1", "text": "children", "entity_type": "Entity", "start": 58, "end": 59}, {"id": "11283125_2_Ent0", "text": "children with increased - risk acute lymphoblastic leukemia ( ALL ) or stage III and IV lymphoblastic lymphoma", "entity_type": "Entity", "start": 58, "end": 76}, {"id": "11283125_2_Ent8", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 63, "end": 66}, {"id": "11283125_2_Ent9", "text": "stage III and IV lymphoblastic lymphoma", "entity_type": "Entity", "start": 70, "end": 76}], "lang": "en"}
{"doc_id": "11328247_2", "wnd_id": "11328247_2_1", "text": "Increased libido in a woman treated with fluvoxamine : a case report .", "tokens": ["Increased", "libido", "in", "a", "woman", "treated", "with", "fluvoxamine", ":", "a", "case", "report", "."], "event_mentions": [{"id": "11328247_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 2, "end": 3}, "arguments": [{"entity_id": "11328247_2_Ent2", "role": "Effect", "text": "Increased libido", "start": 0, "end": 2}, {"entity_id": "11328247_2_Ent0", "role": "Subject", "text": "a woman", "start": 3, "end": 5}, {"entity_id": "11328247_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 4, "end": 5}, {"entity_id": "11328247_2_Ent3", "role": "Treatment", "text": "fluvoxamine", "start": 7, "end": 8}, {"entity_id": "11328247_2_Ent4", "role": "Treatment_Drug", "text": "fluvoxamine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "11328247_2_Ent2", "text": "Increased libido", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11328247_2_Ent0", "text": "a woman", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11328247_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11328247_2_Ent3", "text": "fluvoxamine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11328247_2_Ent4", "text": "fluvoxamine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "11335880_1", "wnd_id": "11335880_1_1", "text": "CONCLUSIONS : This case report showed that the clinical appearance of Hashimoto 's disease after IFN - alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition ( DR5 ) for this pathology .", "tokens": ["CONCLUSIONS", ":", "This", "case", "report", "showed", "that", "the", "clinical", "appearance", "of", "Hashimoto", "'s", "disease", "after", "IFN", "-", "alpha", "therapy", "for", "chronic", "C", "hepatitis", "in", "our", "patient", "was", "associated", "with", "a", "specific", "genetic", "predisposition", "(", "DR5", ")", "for", "this", "pathology", "."], "event_mentions": [{"id": "11335880_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 14, "end": 15}, "arguments": [{"entity_id": "11335880_1_Ent2", "role": "Effect", "text": "clinical appearance of Hashimoto 's disease", "start": 8, "end": 14}, {"entity_id": "11335880_1_Ent3", "role": "Treatment", "text": "IFN - alpha", "start": 15, "end": 18}, {"entity_id": "11335880_1_Ent5", "role": "Treatment_Drug", "text": "IFN - alpha", "start": 15, "end": 18}, {"entity_id": "11335880_1_Ent4", "role": "Treatment_Disorder", "text": "chronic C hepatitis", "start": 20, "end": 23}, {"entity_id": "11335880_1_Ent0", "role": "Subject", "text": "our patient", "start": 24, "end": 26}, {"entity_id": "11335880_1_Ent1", "role": "Subject_Disorder", "text": "a specific genetic predisposition ( DR5 ) for this pathology", "start": 29, "end": 39}]}], "entity_mentions": [{"id": "11335880_1_Ent2", "text": "clinical appearance of Hashimoto 's disease", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "11335880_1_Ent3", "text": "IFN - alpha", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "11335880_1_Ent5", "text": "IFN - alpha", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "11335880_1_Ent4", "text": "chronic C hepatitis", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "11335880_1_Ent0", "text": "our patient", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "11335880_1_Ent1", "text": "a specific genetic predisposition ( DR5 ) for this pathology", "entity_type": "Entity", "start": 29, "end": 39}], "lang": "en"}
{"doc_id": "11335880_4", "wnd_id": "11335880_4_1", "text": "OBJECTIVES : The authors described a case of Hashimoto 's disease during interferon - alpha ( IFN - alpha ) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease .", "tokens": ["OBJECTIVES", ":", "The", "authors", "described", "a", "case", "of", "Hashimoto", "'s", "disease", "during", "interferon", "-", "alpha", "(", "IFN", "-", "alpha", ")", "treatment", "for", "chronic", "viral", "C", "hepatitis", "in", "a", "patient", "with", "the", "specific", "genetic", "susceptibility", "associated", "with", "the", "thyroid", "disease", "."], "event_mentions": [{"id": "11335880_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 11, "end": 12}, "arguments": [{"entity_id": "11335880_4_Ent2", "role": "Effect", "text": "Hashimoto 's disease", "start": 8, "end": 11}, {"entity_id": "11335880_4_Ent4", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 12, "end": 15}, {"entity_id": "11335880_4_Ent3", "role": "Treatment", "text": "interferon - alpha ( IFN - alpha ) treatment", "start": 12, "end": 21}, {"entity_id": "11335880_4_Ent5", "role": "Treatment_Disorder", "text": "chronic viral C hepatitis", "start": 22, "end": 26}, {"entity_id": "11335880_4_Ent0", "role": "Subject", "text": "a patient with the specific genetic susceptibility associated with the thyroid disease", "start": 27, "end": 39}, {"entity_id": "11335880_4_Ent1", "role": "Subject_Disorder", "text": "specific genetic susceptibility", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "11335880_4_Ent2", "text": "Hashimoto 's disease", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "11335880_4_Ent4", "text": "interferon - alpha", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "11335880_4_Ent3", "text": "interferon - alpha ( IFN - alpha ) treatment", "entity_type": "Entity", "start": 12, "end": 21}, {"id": "11335880_4_Ent5", "text": "chronic viral C hepatitis", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "11335880_4_Ent0", "text": "a patient with the specific genetic susceptibility associated with the thyroid disease", "entity_type": "Entity", "start": 27, "end": 39}, {"id": "11335880_4_Ent1", "text": "specific genetic susceptibility", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "11352235_2", "wnd_id": "11352235_2_1", "text": "Leflunomide - associated weight loss in rheumatoid arthritis .", "tokens": ["Leflunomide", "-", "associated", "weight", "loss", "in", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "11352235_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "11352235_2_Ent1", "role": "Treatment", "text": "Leflunomide", "start": 0, "end": 1}, {"entity_id": "11352235_2_Ent0", "role": "Effect", "text": "weight loss", "start": 3, "end": 5}, {"entity_id": "11352235_2_Ent2", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "11352235_2_Ent1", "text": "Leflunomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11352235_2_Ent0", "text": "weight loss", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11352235_2_Ent2", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "11352235_5", "wnd_id": "11352235_5_1", "text": "RESULTS : Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies .", "tokens": ["RESULTS", ":", "Five", "of", "70", "patients", "who", "had", "begun", "leflunomide", "therapy", "had", "significant", "weight", "loss", "that", "could", "not", "be", "linked", "to", "other", "identifiable", "etiologies", "."], "event_mentions": [{"id": "11352235_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 11, "end": 12}, "arguments": [{"entity_id": "11352235_5_Ent1", "role": "Subject_Population", "text": "Five of 70", "start": 2, "end": 5}, {"entity_id": "11352235_5_Ent0", "role": "Subject", "text": "Five of 70 patients", "start": 2, "end": 6}, {"entity_id": "11352235_5_Ent3", "role": "Treatment", "text": "leflunomide", "start": 9, "end": 10}, {"entity_id": "11352235_5_Ent4", "role": "Treatment_Drug", "text": "leflunomide", "start": 9, "end": 10}, {"entity_id": "11352235_5_Ent2", "role": "Effect", "text": "significant weight loss", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "11352235_5_Ent1", "text": "Five of 70", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "11352235_5_Ent0", "text": "Five of 70 patients", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "11352235_5_Ent3", "text": "leflunomide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11352235_5_Ent4", "text": "leflunomide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11352235_5_Ent2", "text": "significant weight loss", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "11359026_2", "wnd_id": "11359026_2_1", "text": "Neurotoxicity of valacyclovir in peritoneal dialysis : a pharmacokinetic study .", "tokens": ["Neurotoxicity", "of", "valacyclovir", "in", "peritoneal", "dialysis", ":", "a", "pharmacokinetic", "study", "."], "event_mentions": [{"id": "11359026_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Neurotoxicity", "start": 0, "end": 1}, "arguments": [{"entity_id": "11359026_2_Ent0", "role": "Effect", "text": "Neurotoxicity", "start": 0, "end": 1}, {"entity_id": "11359026_2_Ent2", "role": "Treatment_Drug", "text": "valacyclovir", "start": 2, "end": 3}, {"entity_id": "11359026_2_Ent1", "role": "Treatment", "text": "valacyclovir in peritoneal dialysis", "start": 2, "end": 6}]}], "entity_mentions": [{"id": "11359026_2_Ent0", "text": "Neurotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11359026_2_Ent2", "text": "valacyclovir", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11359026_2_Ent1", "text": "valacyclovir in peritoneal dialysis", "entity_type": "Entity", "start": 2, "end": 6}], "lang": "en"}
{"doc_id": "11373877_1", "wnd_id": "11373877_1_1", "text": "Avascular necrosis of the femoral head in patients with prostate cancer treated with cyproterone acetate and radiotherapy .", "tokens": ["Avascular", "necrosis", "of", "the", "femoral", "head", "in", "patients", "with", "prostate", "cancer", "treated", "with", "cyproterone", "acetate", "and", "radiotherapy", "."], "event_mentions": [{"id": "11373877_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 6, "end": 7}, "arguments": [{"entity_id": "11373877_1_Ent1", "role": "Effect", "text": "Avascular necrosis of the femoral head", "start": 0, "end": 6}, {"entity_id": "11373877_1_Ent0", "role": "Subject", "text": "patients with prostate cancer", "start": 7, "end": 11}, {"entity_id": "11373877_1_Ent3", "role": "Treatment_Disorder", "text": "prostate cancer", "start": 9, "end": 11}, {"entity_id": "11373877_1_Ent4", "role": "Treatment_Drug", "text": "cyproterone acetate", "start": 13, "end": 15}, {"entity_id": "11373877_1_Ent2", "role": "Treatment", "text": "cyproterone acetate and radiotherapy", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "11373877_1_Ent1", "text": "Avascular necrosis of the femoral head", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "11373877_1_Ent0", "text": "patients with prostate cancer", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "11373877_1_Ent3", "text": "prostate cancer", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "11373877_1_Ent4", "text": "cyproterone acetate", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "11373877_1_Ent2", "text": "cyproterone acetate and radiotherapy", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "11399735_1", "wnd_id": "11399735_1_1", "text": "So far , few cases of pulmonary side effects caused by ticlopidine have been reported .", "tokens": ["So", "far", ",", "few", "cases", "of", "pulmonary", "side", "effects", "caused", "by", "ticlopidine", "have", "been", "reported", "."], "event_mentions": [{"id": "11399735_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 9, "end": 10}, "arguments": [{"entity_id": "11399735_1_Ent0", "role": "Effect", "text": "pulmonary side effects", "start": 6, "end": 9}, {"entity_id": "11399735_1_Ent1", "role": "Treatment", "text": "ticlopidine", "start": 11, "end": 12}, {"entity_id": "11399735_1_Ent2", "role": "Treatment_Drug", "text": "ticlopidine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "11399735_1_Ent0", "text": "pulmonary side effects", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "11399735_1_Ent1", "text": "ticlopidine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11399735_1_Ent2", "text": "ticlopidine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "11399735_2", "wnd_id": "11399735_2_1", "text": "Special care should be taken when pulmonary symptoms appear in association with ticlopidine treatment .", "tokens": ["Special", "care", "should", "be", "taken", "when", "pulmonary", "symptoms", "appear", "in", "association", "with", "ticlopidine", "treatment", "."], "event_mentions": [{"id": "11399735_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appear", "start": 8, "end": 9}, "arguments": [{"entity_id": "11399735_2_Ent0", "role": "Effect", "text": "pulmonary symptoms", "start": 6, "end": 8}, {"entity_id": "11399735_2_Ent2", "role": "Treatment_Drug", "text": "ticlopidine", "start": 12, "end": 13}, {"entity_id": "11399735_2_Ent1", "role": "Treatment", "text": "ticlopidine treatment", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "11399735_2_Ent0", "text": "pulmonary symptoms", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11399735_2_Ent2", "text": "ticlopidine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11399735_2_Ent1", "text": "ticlopidine treatment", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "11399735_3", "wnd_id": "11399735_3_1", "text": "Ticlopidine - induced interstitial pulmonary disease : a case report .", "tokens": ["Ticlopidine", "-", "induced", "interstitial", "pulmonary", "disease", ":", "a", "case", "report", "."], "event_mentions": [{"id": "11399735_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "11399735_3_Ent1", "role": "Treatment", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "11399735_3_Ent2", "role": "Treatment_Drug", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "11399735_3_Ent0", "role": "Effect", "text": "interstitial pulmonary disease", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "11399735_3_Ent1", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11399735_3_Ent2", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11399735_3_Ent0", "text": "interstitial pulmonary disease", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "11406880_1", "wnd_id": "11406880_1_1", "text": "Methadone - induced myoclonus in advanced cancer .", "tokens": ["Methadone", "-", "induced", "myoclonus", "in", "advanced", "cancer", "."], "event_mentions": [{"id": "11406880_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "11406880_1_Ent1", "role": "Treatment", "text": "Methadone", "start": 0, "end": 1}, {"entity_id": "11406880_1_Ent3", "role": "Treatment_Drug", "text": "Methadone", "start": 0, "end": 1}, {"entity_id": "11406880_1_Ent0", "role": "Effect", "text": "myoclonus", "start": 3, "end": 4}, {"entity_id": "11406880_1_Ent2", "role": "Treatment_Disorder", "text": "advanced cancer", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "11406880_1_Ent1", "text": "Methadone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11406880_1_Ent3", "text": "Methadone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11406880_1_Ent0", "text": "myoclonus", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11406880_1_Ent2", "text": "advanced cancer", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "11414270_1", "wnd_id": "11414270_1_1", "text": "Succinylcholine - induced hyperkalemia in a patient with mucositis secondary to chemotherapy .", "tokens": ["Succinylcholine", "-", "induced", "hyperkalemia", "in", "a", "patient", "with", "mucositis", "secondary", "to", "chemotherapy", "."], "event_mentions": [{"id": "11414270_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "11414270_1_Ent3", "role": "Treatment", "text": "Succinylcholine", "start": 0, "end": 1}, {"entity_id": "11414270_1_Ent4", "role": "Treatment_Drug", "text": "Succinylcholine", "start": 0, "end": 1}, {"entity_id": "11414270_1_Ent2", "role": "Effect", "text": "hyperkalemia", "start": 3, "end": 4}, {"entity_id": "11414270_1_Ent0", "role": "Subject", "text": "a patient with mucositis", "start": 5, "end": 9}, {"entity_id": "11414270_1_Ent1", "role": "Subject_Disorder", "text": "mucositis", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "11414270_1_Ent3", "text": "Succinylcholine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11414270_1_Ent4", "text": "Succinylcholine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11414270_1_Ent2", "text": "hyperkalemia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11414270_1_Ent0", "text": "a patient with mucositis", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "11414270_1_Ent1", "text": "mucositis", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "11435808_1", "wnd_id": "11435808_1_1", "text": "Continuous EEG monitoring is helpful in managing seizures that occur as a complication of CBZ OD , after the course of recovery or worsening , and in providing assistance with prognosis .", "tokens": ["Continuous", "EEG", "monitoring", "is", "helpful", "in", "managing", "seizures", "that", "occur", "as", "a", "complication", "of", "CBZ", "OD", ",", "after", "the", "course", "of", "recovery", "or", "worsening", ",", "and", "in", "providing", "assistance", "with", "prognosis", "."], "event_mentions": [{"id": "11435808_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 9, "end": 10}, "arguments": [{"entity_id": "11435808_1_Ent0", "role": "Effect", "text": "seizures", "start": 7, "end": 8}, {"entity_id": "11435808_1_Ent1", "role": "Treatment", "text": "a complication of CBZ OD", "start": 11, "end": 16}, {"entity_id": "11435808_1_Ent2", "role": "Treatment_Drug", "text": "CBZ OD", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "11435808_1_Ent0", "text": "seizures", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11435808_1_Ent1", "text": "a complication of CBZ OD", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "11435808_1_Ent2", "text": "CBZ OD", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "11468878_3", "wnd_id": "11468878_3_1", "text": "Digestive hemorrhage caused by a Meckel 's diverticulum in a metformin - treated patient : is there any connection ?", "tokens": ["Digestive", "hemorrhage", "caused", "by", "a", "Meckel", "'s", "diverticulum", "in", "a", "metformin", "-", "treated", "patient", ":", "is", "there", "any", "connection", "?"], "event_mentions": [{"id": "11468878_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 12, "end": 13}, "arguments": [{"entity_id": "11468878_3_Ent1", "role": "Effect", "text": "Digestive hemorrhage caused by a Meckel 's diverticulum", "start": 0, "end": 8}, {"entity_id": "11468878_3_Ent2", "role": "Treatment", "text": "metformin", "start": 10, "end": 11}, {"entity_id": "11468878_3_Ent3", "role": "Treatment_Drug", "text": "metformin", "start": 10, "end": 11}, {"entity_id": "11468878_3_Ent0", "role": "Subject", "text": "patient", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "11468878_3_Ent1", "text": "Digestive hemorrhage caused by a Meckel 's diverticulum", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "11468878_3_Ent2", "text": "metformin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11468878_3_Ent3", "text": "metformin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11468878_3_Ent0", "text": "patient", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "11476690_1", "wnd_id": "11476690_1_1", "text": "Ulcer became worse after tobramycin and gentamycin treatment for 2 days .", "tokens": ["Ulcer", "became", "worse", "after", "tobramycin", "and", "gentamycin", "treatment", "for", "2", "days", "."], "event_mentions": [{"id": "11476690_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "11476690_1_Ent2", "role": "Treatment_Disorder", "text": "Ulcer", "start": 0, "end": 1}, {"entity_id": "11476690_1_Ent0", "role": "Effect", "text": "Ulcer became worse", "start": 0, "end": 3}, {"entity_id": "11476690_1_Ent3", "role": "Treatment_Drug", "text": "tobramycin", "start": 4, "end": 5}, {"entity_id": "11476690_1_Ent6", "role": "Combination_Drug", "text": "tobramycin", "start": 4, "end": 5}, {"entity_id": "11476690_1_Ent1", "role": "Treatment", "text": "tobramycin and gentamycin", "start": 4, "end": 7}, {"entity_id": "11476690_1_Ent4", "role": "Treatment_Drug", "text": "gentamycin", "start": 6, "end": 7}, {"entity_id": "11476690_1_Ent5", "role": "Combination_Drug", "text": "gentamycin", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "11476690_1_Ent2", "text": "Ulcer", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11476690_1_Ent0", "text": "Ulcer became worse", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11476690_1_Ent3", "text": "tobramycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11476690_1_Ent6", "text": "tobramycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11476690_1_Ent1", "text": "tobramycin and gentamycin", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11476690_1_Ent4", "text": "gentamycin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11476690_1_Ent5", "text": "gentamycin", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "11489400_1", "wnd_id": "11489400_1_1", "text": "Relief by naloxone of morphine - induced spasm of the sphincter of Oddi in a post - cholecystectomy patient .", "tokens": ["Relief", "by", "naloxone", "of", "morphine", "-", "induced", "spasm", "of", "the", "sphincter", "of", "Oddi", "in", "a", "post", "-", "cholecystectomy", "patient", "."], "event_mentions": [{"id": "11489400_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Relief", "start": 0, "end": 1}, "arguments": [{"entity_id": "11489400_1_Ent1", "role": "Treatment", "text": "naloxone", "start": 2, "end": 3}, {"entity_id": "11489400_1_Ent3", "role": "Treatment_Drug", "text": "naloxone", "start": 2, "end": 3}, {"entity_id": "11489400_1_Ent2", "role": "Treatment_Disorder", "text": "morphine - induced spasm of the sphincter of Oddi", "start": 4, "end": 13}, {"entity_id": "11489400_1_Ent0", "role": "Subject", "text": "post - cholecystectomy patient .", "start": 15, "end": 20}]}, {"id": "11489400_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "11489400_1_Ent6", "role": "Treatment", "text": "morphine", "start": 4, "end": 5}, {"entity_id": "11489400_1_Ent7", "role": "Treatment_Drug", "text": "morphine", "start": 4, "end": 5}, {"entity_id": "11489400_1_Ent5", "role": "Effect", "text": "spasm of the sphincter of Oddi", "start": 7, "end": 13}, {"entity_id": "11489400_1_Ent4", "role": "Subject", "text": "post - cholecystectomy patient .", "start": 15, "end": 20}]}], "entity_mentions": [{"id": "11489400_1_Ent1", "text": "naloxone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11489400_1_Ent3", "text": "naloxone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11489400_1_Ent6", "text": "morphine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11489400_1_Ent7", "text": "morphine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11489400_1_Ent2", "text": "morphine - induced spasm of the sphincter of Oddi", "entity_type": "Entity", "start": 4, "end": 13}, {"id": "11489400_1_Ent5", "text": "spasm of the sphincter of Oddi", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "11489400_1_Ent0", "text": "post - cholecystectomy patient .", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "11489400_1_Ent4", "text": "post - cholecystectomy patient .", "entity_type": "Entity", "start": 15, "end": 20}], "lang": "en"}
{"doc_id": "11506739_1", "wnd_id": "11506739_1_1", "text": "Myasthenia gravis during low - dose IFN - alpha therapy for chronic hepatitis C.", "tokens": ["Myasthenia", "gravis", "during", "low", "-", "dose", "IFN", "-", "alpha", "therapy", "for", "chronic", "hepatitis", "C."], "event_mentions": [{"id": "11506739_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 2, "end": 3}, "arguments": [{"entity_id": "11506739_1_Ent0", "role": "Effect", "text": "Myasthenia gravis", "start": 0, "end": 2}, {"entity_id": "11506739_1_Ent2", "role": "Treatment_Dosage", "text": "low - dose", "start": 3, "end": 6}, {"entity_id": "11506739_1_Ent1", "role": "Treatment", "text": "low - dose IFN - alpha therapy", "start": 3, "end": 10}, {"entity_id": "11506739_1_Ent3", "role": "Treatment_Drug", "text": "IFN - alpha", "start": 6, "end": 9}, {"entity_id": "11506739_1_Ent4", "role": "Treatment_Disorder", "text": "chronic hepatitis C.", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "11506739_1_Ent0", "text": "Myasthenia gravis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11506739_1_Ent2", "text": "low - dose", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "11506739_1_Ent1", "text": "low - dose IFN - alpha therapy", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "11506739_1_Ent3", "text": "IFN - alpha", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "11506739_1_Ent4", "text": "chronic hepatitis C.", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "11510798_2", "wnd_id": "11510798_2_1", "text": "Diarrhoea , T - CD4 + lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age , who was treated with oxaliplatinum and 5 - fluorouracil for unresectable rectum carcinoma .", "tokens": ["Diarrhoea", ",", "T", "-", "CD4", "+", "lymphopenia", "and", "bilateral", "patchy", "pulmonary", "infiltrates", "developed", "in", "a", "male", "60", "yrs", "of", "age", ",", "who", "was", "treated", "with", "oxaliplatinum", "and", "5", "-", "fluorouracil", "for", "unresectable", "rectum", "carcinoma", "."], "event_mentions": [{"id": "11510798_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "11510798_2_Ent3", "role": "Effect", "text": "Diarrhoea , T - CD4 + lymphopenia and bilateral patchy pulmonary infiltrates", "start": 0, "end": 12}, {"entity_id": "11510798_2_Ent1", "role": "Subject_Gender", "text": "male", "start": 15, "end": 16}, {"entity_id": "11510798_2_Ent0", "role": "Subject", "text": "male 60 yrs of age", "start": 15, "end": 20}, {"entity_id": "11510798_2_Ent2", "role": "Subject_Age", "text": "60 yrs of age", "start": 16, "end": 20}, {"entity_id": "11510798_2_Ent5", "role": "Treatment_Drug", "text": "oxaliplatinum", "start": 25, "end": 26}, {"entity_id": "11510798_2_Ent8", "role": "Combination_Drug", "text": "oxaliplatinum", "start": 25, "end": 26}, {"entity_id": "11510798_2_Ent4", "role": "Treatment", "text": "oxaliplatinum and 5 - fluorouracil", "start": 25, "end": 30}, {"entity_id": "11510798_2_Ent6", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 27, "end": 30}, {"entity_id": "11510798_2_Ent9", "role": "Combination_Drug", "text": "5 - fluorouracil", "start": 27, "end": 30}, {"entity_id": "11510798_2_Ent7", "role": "Treatment_Disorder", "text": "unresectable rectum carcinoma", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "11510798_2_Ent3", "text": "Diarrhoea , T - CD4 + lymphopenia and bilateral patchy pulmonary infiltrates", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "11510798_2_Ent1", "text": "male", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11510798_2_Ent0", "text": "male 60 yrs of age", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "11510798_2_Ent2", "text": "60 yrs of age", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "11510798_2_Ent5", "text": "oxaliplatinum", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "11510798_2_Ent8", "text": "oxaliplatinum", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "11510798_2_Ent4", "text": "oxaliplatinum and 5 - fluorouracil", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "11510798_2_Ent6", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "11510798_2_Ent9", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "11510798_2_Ent7", "text": "unresectable rectum carcinoma", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "11554897_3", "wnd_id": "11554897_3_1", "text": "METHODS : A 55 - year - old woman became stuporous after overdose with lamotrigine ( LTG ) and valproic acid ( VPA ) tablets .", "tokens": ["METHODS", ":", "A", "55", "-", "year", "-", "old", "woman", "became", "stuporous", "after", "overdose", "with", "lamotrigine", "(", "LTG", ")", "and", "valproic", "acid", "(", "VPA", ")", "tablets", "."], "event_mentions": [{"id": "11554897_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "became", "start": 9, "end": 10}, "arguments": [{"entity_id": "11554897_3_Ent0", "role": "Subject", "text": "A 55 - year - old woman", "start": 2, "end": 9}, {"entity_id": "11554897_3_Ent1", "role": "Subject_Age", "text": "55 - year - old", "start": 3, "end": 8}, {"entity_id": "11554897_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "11554897_3_Ent3", "role": "Effect", "text": "stuporous", "start": 10, "end": 11}, {"entity_id": "11554897_3_Ent5", "role": "Treatment_Dosage", "text": "overdose", "start": 12, "end": 13}, {"entity_id": "11554897_3_Ent4", "role": "Treatment", "text": "overdose with lamotrigine ( LTG ) and valproic acid ( VPA ) tablets", "start": 12, "end": 25}, {"entity_id": "11554897_3_Ent6", "role": "Treatment_Drug", "text": "lamotrigine", "start": 14, "end": 15}, {"entity_id": "11554897_3_Ent9", "role": "Combination_Drug", "text": "lamotrigine", "start": 14, "end": 15}, {"entity_id": "11554897_3_Ent7", "role": "Treatment_Drug", "text": "valproic acid", "start": 19, "end": 21}, {"entity_id": "11554897_3_Ent10", "role": "Combination_Drug", "text": "valproic acid", "start": 19, "end": 21}, {"entity_id": "11554897_3_Ent8", "role": "Treatment_Route", "text": "tablets", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "11554897_3_Ent0", "text": "A 55 - year - old woman", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "11554897_3_Ent1", "text": "55 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "11554897_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11554897_3_Ent3", "text": "stuporous", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11554897_3_Ent5", "text": "overdose", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11554897_3_Ent4", "text": "overdose with lamotrigine ( LTG ) and valproic acid ( VPA ) tablets", "entity_type": "Entity", "start": 12, "end": 25}, {"id": "11554897_3_Ent6", "text": "lamotrigine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11554897_3_Ent9", "text": "lamotrigine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11554897_3_Ent7", "text": "valproic acid", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "11554897_3_Ent10", "text": "valproic acid", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "11554897_3_Ent8", "text": "tablets", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "11568758_2", "wnd_id": "11568758_2_1", "text": "This eruption emerged after 1 month of therapy with salsalate , persisted for as long as salsalate was administered , and cleared within 3 weeks of discontinuing the medication .", "tokens": ["This", "eruption", "emerged", "after", "1", "month", "of", "therapy", "with", "salsalate", ",", "persisted", "for", "as", "long", "as", "salsalate", "was", "administered", ",", "and", "cleared", "within", "3", "weeks", "of", "discontinuing", "the", "medication", "."], "event_mentions": [{"id": "11568758_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "emerged", "start": 2, "end": 3}, "arguments": [{"entity_id": "11568758_2_Ent0", "role": "Effect", "text": "eruption", "start": 1, "end": 2}, {"entity_id": "11568758_2_Ent1", "role": "Treatment", "text": "after 1 month of therapy with salsalate", "start": 3, "end": 10}, {"entity_id": "11568758_2_Ent2", "role": "Treatment_Time_elapsed", "text": "1 month", "start": 4, "end": 6}, {"entity_id": "11568758_2_Ent3", "role": "Treatment_Drug", "text": "salsalate", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "11568758_2_Ent0", "text": "eruption", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11568758_2_Ent1", "text": "after 1 month of therapy with salsalate", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "11568758_2_Ent2", "text": "1 month", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "11568758_2_Ent3", "text": "salsalate", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "11573852_7", "wnd_id": "11573852_7_1", "text": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient .", "tokens": ["The", "time", "course", "of", "events", "suggested", "that", "amphotericin", "B", "was", "the", "cause", "of", "the", "seizures", "in", "this", "AIDS", "patient", "."], "event_mentions": [{"id": "11573852_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 11, "end": 12}, "arguments": [{"entity_id": "11573852_7_Ent3", "role": "Treatment", "text": "amphotericin B", "start": 7, "end": 9}, {"entity_id": "11573852_7_Ent4", "role": "Treatment_Drug", "text": "amphotericin B", "start": 7, "end": 9}, {"entity_id": "11573852_7_Ent2", "role": "Effect", "text": "seizures", "start": 14, "end": 15}, {"entity_id": "11573852_7_Ent1", "role": "Subject_Disorder", "text": "AIDS", "start": 17, "end": 18}, {"entity_id": "11573852_7_Ent0", "role": "Subject", "text": "AIDS patient", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "11573852_7_Ent3", "text": "amphotericin B", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "11573852_7_Ent4", "text": "amphotericin B", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "11573852_7_Ent2", "text": "seizures", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11573852_7_Ent1", "text": "AIDS", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11573852_7_Ent0", "text": "AIDS patient", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "11590881_4", "wnd_id": "11590881_4_1", "text": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine .", "tokens": ["We", "recommend", "routine", "follow", "up", "by", "ECG", "of", "patients", "over", "the", "age", "of", "50", "treated", "with", "carbamazepine", "."], "event_mentions": [{"id": "11590881_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "of", "start": 7, "end": 8}, "arguments": [{"entity_id": "11590881_4_Ent2", "role": "Treatment", "text": "routine follow up by ECG", "start": 2, "end": 7}, {"entity_id": "11590881_4_Ent0", "role": "Subject", "text": "patients over the age of 50", "start": 8, "end": 14}, {"entity_id": "11590881_4_Ent1", "role": "Subject_Age", "text": "over the age of 50", "start": 9, "end": 14}, {"entity_id": "11590881_4_Ent3", "role": "Treatment_Drug", "text": "carbamazepine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "11590881_4_Ent2", "text": "routine follow up by ECG", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "11590881_4_Ent0", "text": "patients over the age of 50", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "11590881_4_Ent1", "text": "over the age of 50", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "11590881_4_Ent3", "text": "carbamazepine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "11642488_1", "wnd_id": "11642488_1_1", "text": "Cicatricial entropion associated with chronic dipivefrin application .", "tokens": ["Cicatricial", "entropion", "associated", "with", "chronic", "dipivefrin", "application", "."], "event_mentions": [{"id": "11642488_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "11642488_1_Ent0", "role": "Effect", "text": "Cicatricial entropion", "start": 0, "end": 2}, {"entity_id": "11642488_1_Ent1", "role": "Treatment", "text": "chronic dipivefrin application", "start": 4, "end": 7}, {"entity_id": "11642488_1_Ent2", "role": "Treatment_Drug", "text": "dipivefrin", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "11642488_1_Ent0", "text": "Cicatricial entropion", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11642488_1_Ent1", "text": "chronic dipivefrin application", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11642488_1_Ent2", "text": "dipivefrin", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "11642488_3", "wnd_id": "11642488_3_1", "text": "Nine eyes from 6 patients , 74 years to 90 years of age , referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice - a - day application of dipivefrin .", "tokens": ["Nine", "eyes", "from", "6", "patients", ",", "74", "years", "to", "90", "years", "of", "age", ",", "referred", "by", "ophthalmologists", "for", "repair", "of", "cicatricial", "entropion", "after", "at", "least", "2", "years", "of", "twice", "-", "a", "-", "day", "application", "of", "dipivefrin", "."], "event_mentions": [{"id": "11642488_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 22, "end": 23}, "arguments": [{"entity_id": "11642488_3_Ent0", "role": "Subject", "text": "Nine eyes from 6 patients , 74 years to 90 years of age", "start": 0, "end": 13}, {"entity_id": "11642488_3_Ent1", "role": "Subject_Population", "text": "6", "start": 3, "end": 4}, {"entity_id": "11642488_3_Ent2", "role": "Subject_Age", "text": "74 years to 90 years", "start": 6, "end": 11}, {"entity_id": "11642488_3_Ent3", "role": "Effect", "text": "cicatricial entropion", "start": 20, "end": 22}, {"entity_id": "11642488_3_Ent4", "role": "Treatment", "text": "at least 2 years of twice - a - day application of dipivefrin", "start": 23, "end": 36}, {"entity_id": "11642488_3_Ent5", "role": "Treatment_Duration", "text": "2 years", "start": 25, "end": 27}, {"entity_id": "11642488_3_Ent6", "role": "Treatment_Freq", "text": "twice - a - day", "start": 28, "end": 33}, {"entity_id": "11642488_3_Ent7", "role": "Treatment_Drug", "text": "dipivefrin", "start": 35, "end": 36}]}], "entity_mentions": [{"id": "11642488_3_Ent0", "text": "Nine eyes from 6 patients , 74 years to 90 years of age", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "11642488_3_Ent1", "text": "6", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11642488_3_Ent2", "text": "74 years to 90 years", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "11642488_3_Ent3", "text": "cicatricial entropion", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "11642488_3_Ent4", "text": "at least 2 years of twice - a - day application of dipivefrin", "entity_type": "Entity", "start": 23, "end": 36}, {"id": "11642488_3_Ent5", "text": "2 years", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "11642488_3_Ent6", "text": "twice - a - day", "entity_type": "Entity", "start": 28, "end": 33}, {"id": "11642488_3_Ent7", "text": "dipivefrin", "entity_type": "Entity", "start": 35, "end": 36}], "lang": "en"}
{"doc_id": "11675845_9", "wnd_id": "11675845_9_1", "text": "Furthermore , the warfarin dose was again increased after discontinuation of ropinirole due to common gastrointestinal adverse effects .", "tokens": ["Furthermore", ",", "the", "warfarin", "dose", "was", "again", "increased", "after", "discontinuation", "of", "ropinirole", "due", "to", "common", "gastrointestinal", "adverse", "effects", "."], "event_mentions": [{"id": "11675845_9_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "due to", "start": 12, "end": 14}, "arguments": [{"entity_id": "11675845_9_Ent0", "role": "Treatment", "text": "the warfarin dose was again increased after discontinuation of ropinirole", "start": 2, "end": 12}, {"entity_id": "11675845_9_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "11675845_9_Ent1", "role": "Treatment_Disorder", "text": "gastrointestinal adverse effects", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "11675845_9_Ent0", "text": "the warfarin dose was again increased after discontinuation of ropinirole", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "11675845_9_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11675845_9_Ent1", "text": "gastrointestinal adverse effects", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "11688826_1", "wnd_id": "11688826_1_1", "text": "Interestingly , the use of carboplatin ( CBDCA ) and VDS in the subsequent treatment course was well tolerated indicating that the SIADH was most likely to have been induced by administration of CDDP .", "tokens": ["Interestingly", ",", "the", "use", "of", "carboplatin", "(", "CBDCA", ")", "and", "VDS", "in", "the", "subsequent", "treatment", "course", "was", "well", "tolerated", "indicating", "that", "the", "SIADH", "was", "most", "likely", "to", "have", "been", "induced", "by", "administration", "of", "CDDP", "."], "event_mentions": [{"id": "11688826_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 29, "end": 30}, "arguments": [{"entity_id": "11688826_1_Ent0", "role": "Effect", "text": "SIADH", "start": 22, "end": 23}, {"entity_id": "11688826_1_Ent1", "role": "Treatment", "text": "CDDP", "start": 33, "end": 34}, {"entity_id": "11688826_1_Ent2", "role": "Treatment_Drug", "text": "CDDP", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "11688826_1_Ent0", "text": "SIADH", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "11688826_1_Ent1", "text": "CDDP", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "11688826_1_Ent2", "text": "CDDP", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "11688826_3", "wnd_id": "11688826_3_1", "text": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) following systemic chemotherapy with cisplatin ( CDDP ) and vindesine ( VDS ) .", "tokens": ["We", "report", "a", "patient", "with", "pulmonary", "adenocarcinoma", "complicated", "by", "the", "syndrome", "of", "inappropriate", "secretion", "of", "antidiuretic", "hormone", "(", "SIADH", ")", "following", "systemic", "chemotherapy", "with", "cisplatin", "(", "CDDP", ")", "and", "vindesine", "(", "VDS", ")", "."], "event_mentions": [{"id": "11688826_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 20, "end": 21}, "arguments": [{"entity_id": "11688826_3_Ent0", "role": "Subject", "text": "a patient with pulmonary adenocarcinoma", "start": 2, "end": 7}, {"entity_id": "11688826_3_Ent3", "role": "Treatment_Disorder", "text": "pulmonary adenocarcinoma", "start": 5, "end": 7}, {"entity_id": "11688826_3_Ent1", "role": "Effect", "text": "the syndrome of inappropriate secretion of antidiuretic hormone ( SIADH )", "start": 9, "end": 20}, {"entity_id": "11688826_3_Ent2", "role": "Treatment", "text": "systemic chemotherapy with cisplatin ( CDDP ) and vindesine ( VDS )", "start": 21, "end": 33}, {"entity_id": "11688826_3_Ent4", "role": "Treatment_Drug", "text": "cisplatin", "start": 24, "end": 25}, {"entity_id": "11688826_3_Ent7", "role": "Combination_Drug", "text": "cisplatin", "start": 24, "end": 25}, {"entity_id": "11688826_3_Ent5", "role": "Treatment_Drug", "text": "vindesine", "start": 29, "end": 30}, {"entity_id": "11688826_3_Ent6", "role": "Combination_Drug", "text": "vindesine", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "11688826_3_Ent0", "text": "a patient with pulmonary adenocarcinoma", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "11688826_3_Ent3", "text": "pulmonary adenocarcinoma", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11688826_3_Ent1", "text": "the syndrome of inappropriate secretion of antidiuretic hormone ( SIADH )", "entity_type": "Entity", "start": 9, "end": 20}, {"id": "11688826_3_Ent2", "text": "systemic chemotherapy with cisplatin ( CDDP ) and vindesine ( VDS )", "entity_type": "Entity", "start": 21, "end": 33}, {"id": "11688826_3_Ent4", "text": "cisplatin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "11688826_3_Ent7", "text": "cisplatin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "11688826_3_Ent5", "text": "vindesine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "11688826_3_Ent6", "text": "vindesine", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "11696132_1", "wnd_id": "11696132_1_1", "text": "After extensive neurological ' work up ' , we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid .", "tokens": ["After", "extensive", "neurological", "'", "work", "up", "'", ",", "we", "realized", "that", "the", "anisocoria", "was", "related", "to", "the", "transdermal", "scopolamine", "patch", "that", "we", "had", "prescribed", "for", "weaning", "off", "the", "opioid", "."], "event_mentions": [{"id": "11696132_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 14, "end": 15}, "arguments": [{"entity_id": "11696132_1_Ent0", "role": "Effect", "text": "anisocoria", "start": 12, "end": 13}, {"entity_id": "11696132_1_Ent3", "role": "Treatment_Route", "text": "transdermal", "start": 17, "end": 18}, {"entity_id": "11696132_1_Ent1", "role": "Treatment", "text": "transdermal scopolamine patch", "start": 17, "end": 20}, {"entity_id": "11696132_1_Ent2", "role": "Treatment_Drug", "text": "scopolamine", "start": 18, "end": 19}, {"entity_id": "11696132_1_Ent4", "role": "Treatment_Route", "text": "patch", "start": 19, "end": 20}, {"entity_id": "11696132_1_Ent5", "role": "Treatment_Disorder", "text": "weaning off the opioid", "start": 25, "end": 29}]}], "entity_mentions": [{"id": "11696132_1_Ent0", "text": "anisocoria", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11696132_1_Ent3", "text": "transdermal", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11696132_1_Ent1", "text": "transdermal scopolamine patch", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "11696132_1_Ent2", "text": "scopolamine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "11696132_1_Ent4", "text": "patch", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11696132_1_Ent5", "text": "weaning off the opioid", "entity_type": "Entity", "start": 25, "end": 29}], "lang": "en"}
{"doc_id": "11696132_2", "wnd_id": "11696132_2_1", "text": "Anisocoria from transdermal scopolamine .", "tokens": ["Anisocoria", "from", "transdermal", "scopolamine", "."], "event_mentions": [{"id": "11696132_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 1, "end": 2}, "arguments": [{"entity_id": "11696132_2_Ent0", "role": "Effect", "text": "Anisocoria", "start": 0, "end": 1}, {"entity_id": "11696132_2_Ent1", "role": "Treatment", "text": "transdermal scopolamine", "start": 2, "end": 4}, {"entity_id": "11696132_2_Ent2", "role": "Treatment_Drug", "text": "transdermal scopolamine", "start": 2, "end": 4}]}], "entity_mentions": [{"id": "11696132_2_Ent0", "text": "Anisocoria", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11696132_2_Ent1", "text": "transdermal scopolamine", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11696132_2_Ent2", "text": "transdermal scopolamine", "entity_type": "Entity", "start": 2, "end": 4}], "lang": "en"}
{"doc_id": "11703329_1", "wnd_id": "11703329_1_1", "text": "Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life - threatening vincristine neurotoxicity .", "tokens": ["Early", "recognition", "of", "hereditary", "motor", "and", "sensory", "neuropathy", "type", "1", "can", "avoid", "life", "-", "threatening", "vincristine", "neurotoxicity", "."], "event_mentions": [{"id": "11703329_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "can", "start": 10, "end": 11}, "arguments": [{"entity_id": "11703329_1_Ent0", "role": "Treatment", "text": "Early recognition of hereditary motor and sensory neuropathy type 1", "start": 0, "end": 10}]}], "entity_mentions": [{"id": "11703329_1_Ent0", "text": "Early recognition of hereditary motor and sensory neuropathy type 1", "entity_type": "Entity", "start": 0, "end": 10}], "lang": "en"}
{"doc_id": "11712064_1", "wnd_id": "11712064_1_1", "text": "Systemic allergic contact dermatitis to 8 - methoxypsoralen ( 8 - MOP ) .", "tokens": ["Systemic", "allergic", "contact", "dermatitis", "to", "8", "-", "methoxypsoralen", "(", "8", "-", "MOP", ")", "."], "event_mentions": [{"id": "11712064_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 4, "end": 5}, "arguments": [{"entity_id": "11712064_1_Ent0", "role": "Effect", "text": "Systemic allergic contact dermatitis", "start": 0, "end": 4}, {"entity_id": "11712064_1_Ent2", "role": "Treatment_Drug", "text": "8 - methoxypsoralen", "start": 5, "end": 8}, {"entity_id": "11712064_1_Ent1", "role": "Treatment", "text": "8 - methoxypsoralen ( 8 - MOP )", "start": 5, "end": 13}]}], "entity_mentions": [{"id": "11712064_1_Ent0", "text": "Systemic allergic contact dermatitis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "11712064_1_Ent2", "text": "8 - methoxypsoralen", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "11712064_1_Ent1", "text": "8 - methoxypsoralen ( 8 - MOP )", "entity_type": "Entity", "start": 5, "end": 13}], "lang": "en"}
{"doc_id": "11737689_1", "wnd_id": "11737689_1_1", "text": "A boy with chronic neutropenia and recurrent inflammatory skin lesions developed multiple erythematous nodules following administration of G - CSF .", "tokens": ["A", "boy", "with", "chronic", "neutropenia", "and", "recurrent", "inflammatory", "skin", "lesions", "developed", "multiple", "erythematous", "nodules", "following", "administration", "of", "G", "-", "CSF", "."], "event_mentions": [{"id": "11737689_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "11737689_1_Ent0", "role": "Subject", "text": "A boy with chronic neutropenia and recurrent inflammatory skin lesions", "start": 0, "end": 10}, {"entity_id": "11737689_1_Ent1", "role": "Subject_Gender", "text": "boy", "start": 1, "end": 2}, {"entity_id": "11737689_1_Ent4", "role": "Treatment_Disorder", "text": "chronic neutropenia and recurrent inflammatory skin lesions", "start": 3, "end": 10}, {"entity_id": "11737689_1_Ent2", "role": "Effect", "text": "multiple erythematous nodules", "start": 11, "end": 14}, {"entity_id": "11737689_1_Ent3", "role": "Treatment", "text": "G - CSF", "start": 17, "end": 20}, {"entity_id": "11737689_1_Ent5", "role": "Treatment_Drug", "text": "G - CSF", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "11737689_1_Ent0", "text": "A boy with chronic neutropenia and recurrent inflammatory skin lesions", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "11737689_1_Ent1", "text": "boy", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11737689_1_Ent4", "text": "chronic neutropenia and recurrent inflammatory skin lesions", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "11737689_1_Ent2", "text": "multiple erythematous nodules", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "11737689_1_Ent3", "text": "G - CSF", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "11737689_1_Ent5", "text": "G - CSF", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "11737689_5", "wnd_id": "11737689_5_1", "text": "We believe that these skin eruptions belong to a spectrum of neutrophilic dermatoses that can be induced or aggravated by G - CSF therapy .", "tokens": ["We", "believe", "that", "these", "skin", "eruptions", "belong", "to", "a", "spectrum", "of", "neutrophilic", "dermatoses", "that", "can", "be", "induced", "or", "aggravated", "by", "G", "-", "CSF", "therapy", "."], "event_mentions": [{"id": "11737689_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 16, "end": 17}, "arguments": [{"entity_id": "11737689_5_Ent0", "role": "Effect", "text": "skin eruptions", "start": 4, "end": 6}, {"entity_id": "11737689_5_Ent1", "role": "Treatment", "text": "G - CSF", "start": 20, "end": 23}, {"entity_id": "11737689_5_Ent2", "role": "Treatment_Drug", "text": "G - CSF", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "11737689_5_Ent0", "text": "skin eruptions", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "11737689_5_Ent1", "text": "G - CSF", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "11737689_5_Ent2", "text": "G - CSF", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "11757641_2", "wnd_id": "11757641_2_1", "text": "This is the second report of acute lung injury and diffuse alveolar damage caused by mefloquine .", "tokens": ["This", "is", "the", "second", "report", "of", "acute", "lung", "injury", "and", "diffuse", "alveolar", "damage", "caused", "by", "mefloquine", "."], "event_mentions": [{"id": "11757641_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 13, "end": 14}, "arguments": [{"entity_id": "11757641_2_Ent0", "role": "Effect", "text": "acute lung injury and diffuse alveolar damage", "start": 6, "end": 13}, {"entity_id": "11757641_2_Ent1", "role": "Treatment", "text": "mefloquine", "start": 15, "end": 16}, {"entity_id": "11757641_2_Ent2", "role": "Treatment_Drug", "text": "mefloquine", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "11757641_2_Ent0", "text": "acute lung injury and diffuse alveolar damage", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "11757641_2_Ent1", "text": "mefloquine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11757641_2_Ent2", "text": "mefloquine", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "11757641_3", "wnd_id": "11757641_3_1", "text": "This report presents a case of acute lung injury developing within hours after administration of mefloquine for a low - level Plasmodium falciparum malaria , which was persistent despite halofantrine therapy .", "tokens": ["This", "report", "presents", "a", "case", "of", "acute", "lung", "injury", "developing", "within", "hours", "after", "administration", "of", "mefloquine", "for", "a", "low", "-", "level", "Plasmodium", "falciparum", "malaria", ",", "which", "was", "persistent", "despite", "halofantrine", "therapy", "."], "event_mentions": [{"id": "11757641_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "11757641_3_Ent0", "role": "Effect", "text": "acute lung injury", "start": 6, "end": 9}, {"entity_id": "11757641_3_Ent4", "role": "Treatment_Time_elapsed", "text": "within hours", "start": 10, "end": 12}, {"entity_id": "11757641_3_Ent2", "role": "Treatment", "text": "administration of mefloquine for a low - level Plasmodium falciparum malaria", "start": 13, "end": 24}, {"entity_id": "11757641_3_Ent5", "role": "Treatment_Drug", "text": "mefloquine", "start": 15, "end": 16}, {"entity_id": "11757641_3_Ent7", "role": "Treatment_Disorder", "text": "low - level Plasmodium falciparum malaria", "start": 18, "end": 24}, {"entity_id": "11757641_3_Ent1", "role": "Effect", "text": "persistent despite halofantrine therapy", "start": 27, "end": 31}, {"entity_id": "11757641_3_Ent6", "role": "Treatment_Drug", "text": "halofantrine", "start": 29, "end": 30}, {"entity_id": "11757641_3_Ent3", "role": "Treatment", "text": "halofantrine therapy", "start": 29, "end": 31}]}], "entity_mentions": [{"id": "11757641_3_Ent0", "text": "acute lung injury", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "11757641_3_Ent4", "text": "within hours", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11757641_3_Ent2", "text": "administration of mefloquine for a low - level Plasmodium falciparum malaria", "entity_type": "Entity", "start": 13, "end": 24}, {"id": "11757641_3_Ent5", "text": "mefloquine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11757641_3_Ent7", "text": "low - level Plasmodium falciparum malaria", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "11757641_3_Ent1", "text": "persistent despite halofantrine therapy", "entity_type": "Entity", "start": 27, "end": 31}, {"id": "11757641_3_Ent6", "text": "halofantrine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "11757641_3_Ent3", "text": "halofantrine therapy", "entity_type": "Entity", "start": 29, "end": 31}], "lang": "en"}
{"doc_id": "11788010_5", "wnd_id": "11788010_5_1", "text": "This is the first reported case of hepatolithiasis during octreotide therapy .", "tokens": ["This", "is", "the", "first", "reported", "case", "of", "hepatolithiasis", "during", "octreotide", "therapy", "."], "event_mentions": [{"id": "11788010_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 8, "end": 9}, "arguments": [{"entity_id": "11788010_5_Ent0", "role": "Effect", "text": "hepatolithiasis", "start": 7, "end": 8}, {"entity_id": "11788010_5_Ent1", "role": "Treatment", "text": "octreotide", "start": 9, "end": 10}, {"entity_id": "11788010_5_Ent2", "role": "Treatment_Drug", "text": "octreotide", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "11788010_5_Ent0", "text": "hepatolithiasis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11788010_5_Ent1", "text": "octreotide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11788010_5_Ent2", "text": "octreotide", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "11795358_2", "wnd_id": "11795358_2_1", "text": "In this healthy population , the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54 , although when stratified by age , in women over 50 , the risk grew to 4.01 .", "tokens": ["In", "this", "healthy", "population", ",", "the", "relative", "risk", "of", "developing", "endometrial", "carcinoma", "in", "the", "tamoxifen", "arm", "was", "2.54", ",", "although", "when", "stratified", "by", "age", ",", "in", "women", "over", "50", ",", "the", "risk", "grew", "to", "4.01", "."], "event_mentions": [{"id": "11795358_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developing", "start": 9, "end": 10}, "arguments": [{"entity_id": "11795358_2_Ent0", "role": "Subject", "text": "healthy population", "start": 2, "end": 4}, {"entity_id": "11795358_2_Ent1", "role": "Effect", "text": "endometrial carcinoma", "start": 10, "end": 12}, {"entity_id": "11795358_2_Ent2", "role": "Treatment", "text": "tamoxifen", "start": 14, "end": 15}, {"entity_id": "11795358_2_Ent3", "role": "Treatment_Drug", "text": "tamoxifen", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "11795358_2_Ent0", "text": "healthy population", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11795358_2_Ent1", "text": "endometrial carcinoma", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11795358_2_Ent2", "text": "tamoxifen", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11795358_2_Ent3", "text": "tamoxifen", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "11807466_1", "wnd_id": "11807466_1_1", "text": "Linear IgA bullous dermatosis occurring after carbamazepine .", "tokens": ["Linear", "IgA", "bullous", "dermatosis", "occurring", "after", "carbamazepine", "."], "event_mentions": [{"id": "11807466_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 4, "end": 5}, "arguments": [{"entity_id": "11807466_1_Ent0", "role": "Effect", "text": "Linear IgA bullous dermatosis", "start": 0, "end": 4}, {"entity_id": "11807466_1_Ent1", "role": "Treatment", "text": "carbamazepine", "start": 6, "end": 7}, {"entity_id": "11807466_1_Ent2", "role": "Treatment_Drug", "text": "carbamazepine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "11807466_1_Ent0", "text": "Linear IgA bullous dermatosis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "11807466_1_Ent1", "text": "carbamazepine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11807466_1_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "11816261_5", "wnd_id": "11816261_5_1", "text": "She was administered metoclopramide because of nausea and , within 2 hours , developed agitation , dysarthria , diaphoresis , and a movement disorder .", "tokens": ["She", "was", "administered", "metoclopramide", "because", "of", "nausea", "and", ",", "within", "2", "hours", ",", "developed", "agitation", ",", "dysarthria", ",", "diaphoresis", ",", "and", "a", "movement", "disorder", "."], "event_mentions": [{"id": "11816261_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "11816261_5_Ent1", "role": "Treatment", "text": "metoclopramide", "start": 3, "end": 4}, {"entity_id": "11816261_5_Ent2", "role": "Treatment_Drug", "text": "metoclopramide", "start": 3, "end": 4}, {"entity_id": "11816261_5_Ent3", "role": "Treatment_Disorder", "text": "nausea", "start": 6, "end": 7}, {"entity_id": "11816261_5_Ent4", "role": "Treatment_Time_elapsed", "text": "within 2 hours", "start": 9, "end": 12}, {"entity_id": "11816261_5_Ent0", "role": "Effect", "text": "agitation , dysarthria , diaphoresis , and a movement disorder", "start": 14, "end": 24}]}], "entity_mentions": [{"id": "11816261_5_Ent1", "text": "metoclopramide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11816261_5_Ent2", "text": "metoclopramide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11816261_5_Ent3", "text": "nausea", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11816261_5_Ent4", "text": "within 2 hours", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "11816261_5_Ent0", "text": "agitation , dysarthria , diaphoresis , and a movement disorder", "entity_type": "Entity", "start": 14, "end": 24}], "lang": "en"}
{"doc_id": "11834188_4", "wnd_id": "11834188_4_1", "text": "We presented the case of a patient who developed a cutaneous reaction induced by captopril with positive patch test .", "tokens": ["We", "presented", "the", "case", "of", "a", "patient", "who", "developed", "a", "cutaneous", "reaction", "induced", "by", "captopril", "with", "positive", "patch", "test", "."], "event_mentions": [{"id": "11834188_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "11834188_4_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "11834188_4_Ent1", "role": "Effect", "text": "cutaneous reaction", "start": 10, "end": 12}, {"entity_id": "11834188_4_Ent2", "role": "Treatment", "text": "captopril", "start": 14, "end": 15}, {"entity_id": "11834188_4_Ent3", "role": "Treatment_Drug", "text": "captopril", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "11834188_4_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11834188_4_Ent1", "text": "cutaneous reaction", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11834188_4_Ent2", "text": "captopril", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11834188_4_Ent3", "text": "captopril", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "11837564_2", "wnd_id": "11837564_2_1", "text": "Warfarin - associated bleeding complication saved life .", "tokens": ["Warfarin", "-", "associated", "bleeding", "complication", "saved", "life", "."], "event_mentions": [{"id": "11837564_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "11837564_2_Ent1", "role": "Treatment", "text": "Warfarin", "start": 0, "end": 1}, {"entity_id": "11837564_2_Ent2", "role": "Treatment_Drug", "text": "Warfarin", "start": 0, "end": 1}, {"entity_id": "11837564_2_Ent0", "role": "Effect", "text": "bleeding complication saved life", "start": 3, "end": 7}]}], "entity_mentions": [{"id": "11837564_2_Ent1", "text": "Warfarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11837564_2_Ent2", "text": "Warfarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11837564_2_Ent0", "text": "bleeding complication saved life", "entity_type": "Entity", "start": 3, "end": 7}], "lang": "en"}
{"doc_id": "11837564_3", "wnd_id": "11837564_3_1", "text": "Warfarin - associated bleeding generally is considered deleterious ; however , in our patient it unmasked an early stage of colon cancer and thus may have saved the patient 's life .", "tokens": ["Warfarin", "-", "associated", "bleeding", "generally", "is", "considered", "deleterious", ";", "however", ",", "in", "our", "patient", "it", "unmasked", "an", "early", "stage", "of", "colon", "cancer", "and", "thus", "may", "have", "saved", "the", "patient", "'s", "life", "."], "event_mentions": [{"id": "11837564_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "11837564_3_Ent1", "role": "Treatment", "text": "Warfarin", "start": 0, "end": 1}, {"entity_id": "11837564_3_Ent2", "role": "Treatment_Drug", "text": "Warfarin", "start": 0, "end": 1}, {"entity_id": "11837564_3_Ent0", "role": "Effect", "text": "bleeding", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "11837564_3_Ent1", "text": "Warfarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11837564_3_Ent2", "text": "Warfarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11837564_3_Ent0", "text": "bleeding", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "11850606_2", "wnd_id": "11850606_2_1", "text": "In this case , interferon alpha induced polymyositis and cardiomyopathy is diagnosed in a 33 - yr - old male patient with history of chronic hepatitis B.", "tokens": ["In", "this", "case", ",", "interferon", "alpha", "induced", "polymyositis", "and", "cardiomyopathy", "is", "diagnosed", "in", "a", "33", "-", "yr", "-", "old", "male", "patient", "with", "history", "of", "chronic", "hepatitis", "B."], "event_mentions": [{"id": "11850606_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "11850606_2_Ent4", "role": "Treatment", "text": "interferon alpha", "start": 4, "end": 6}, {"entity_id": "11850606_2_Ent5", "role": "Treatment_Drug", "text": "interferon alpha", "start": 4, "end": 6}, {"entity_id": "11850606_2_Ent3", "role": "Effect", "text": "polymyositis and cardiomyopathy", "start": 7, "end": 10}, {"entity_id": "11850606_2_Ent0", "role": "Subject", "text": "a 33 - yr - old male patient with history of chronic hepatitis B.", "start": 13, "end": 27}, {"entity_id": "11850606_2_Ent1", "role": "Subject_Age", "text": "33 - yr - old", "start": 14, "end": 19}, {"entity_id": "11850606_2_Ent2", "role": "Subject_Gender", "text": "male", "start": 19, "end": 20}, {"entity_id": "11850606_2_Ent6", "role": "Treatment_Disorder", "text": "history of chronic hepatitis B.", "start": 22, "end": 27}]}], "entity_mentions": [{"id": "11850606_2_Ent4", "text": "interferon alpha", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "11850606_2_Ent5", "text": "interferon alpha", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "11850606_2_Ent3", "text": "polymyositis and cardiomyopathy", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "11850606_2_Ent0", "text": "a 33 - yr - old male patient with history of chronic hepatitis B.", "entity_type": "Entity", "start": 13, "end": 27}, {"id": "11850606_2_Ent1", "text": "33 - yr - old", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "11850606_2_Ent2", "text": "male", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11850606_2_Ent6", "text": "history of chronic hepatitis B.", "entity_type": "Entity", "start": 22, "end": 27}], "lang": "en"}
{"doc_id": "11850606_4", "wnd_id": "11850606_4_1", "text": "To treat hepatitis B , interferon alpha was administered until the proximal muscle weakness developed .", "tokens": ["To", "treat", "hepatitis", "B", ",", "interferon", "alpha", "was", "administered", "until", "the", "proximal", "muscle", "weakness", "developed", "."], "event_mentions": [{"id": "11850606_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "11850606_4_Ent2", "role": "Treatment_Disorder", "text": "hepatitis B", "start": 2, "end": 4}, {"entity_id": "11850606_4_Ent1", "role": "Treatment", "text": "interferon alpha", "start": 5, "end": 7}, {"entity_id": "11850606_4_Ent3", "role": "Treatment_Drug", "text": "interferon alpha", "start": 5, "end": 7}, {"entity_id": "11850606_4_Ent0", "role": "Effect", "text": "proximal muscle weakness", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "11850606_4_Ent2", "text": "hepatitis B", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11850606_4_Ent1", "text": "interferon alpha", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11850606_4_Ent3", "text": "interferon alpha", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11850606_4_Ent0", "text": "proximal muscle weakness", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "11918514_3", "wnd_id": "11918514_3_1", "text": "OBJECTIVE : To document a case of serotonin syndrome ( SS ) associated with mirtazapine monotherapy , review the previously reported cases of SS associated with this tetracyclic antidepressant , and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction .", "tokens": ["OBJECTIVE", ":", "To", "document", "a", "case", "of", "serotonin", "syndrome", "(", "SS", ")", "associated", "with", "mirtazapine", "monotherapy", ",", "review", "the", "previously", "reported", "cases", "of", "SS", "associated", "with", "this", "tetracyclic", "antidepressant", ",", "and", "discuss", "the", "possible", "pathogenic", "mechanisms", "leading", "to", "this", "serious", "adverse", "drug", "reaction", "."], "event_mentions": [{"id": "11918514_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 12, "end": 13}, "arguments": [{"entity_id": "11918514_3_Ent0", "role": "Subject", "text": "a case", "start": 4, "end": 6}, {"entity_id": "11918514_3_Ent1", "role": "Effect", "text": "serotonin syndrome ( SS )", "start": 7, "end": 12}, {"entity_id": "11918514_3_Ent3", "role": "Treatment_Drug", "text": "mirtazapine", "start": 14, "end": 15}, {"entity_id": "11918514_3_Ent2", "role": "Treatment", "text": "mirtazapine monotherapy", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "11918514_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "11918514_3_Ent1", "text": "serotonin syndrome ( SS )", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "11918514_3_Ent3", "text": "mirtazapine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11918514_3_Ent2", "text": "mirtazapine monotherapy", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "11961411_2", "wnd_id": "11961411_2_1", "text": "Minimal change nephrotic syndrome developing during postoperative interferon - beta therapy for malignant melanoma .", "tokens": ["Minimal", "change", "nephrotic", "syndrome", "developing", "during", "postoperative", "interferon", "-", "beta", "therapy", "for", "malignant", "melanoma", "."], "event_mentions": [{"id": "11961411_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developing", "start": 4, "end": 5}, "arguments": [{"entity_id": "11961411_2_Ent0", "role": "Effect", "text": "Minimal change nephrotic syndrome", "start": 0, "end": 4}, {"entity_id": "11961411_2_Ent3", "role": "Treatment_Drug", "text": "postoperative interferon - beta", "start": 6, "end": 10}, {"entity_id": "11961411_2_Ent1", "role": "Treatment", "text": "postoperative interferon - beta therapy for malignant melanoma", "start": 6, "end": 14}, {"entity_id": "11961411_2_Ent2", "role": "Treatment_Disorder", "text": "malignant melanoma", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "11961411_2_Ent0", "text": "Minimal change nephrotic syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "11961411_2_Ent3", "text": "postoperative interferon - beta", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "11961411_2_Ent1", "text": "postoperative interferon - beta therapy for malignant melanoma", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "11961411_2_Ent2", "text": "malignant melanoma", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "12022905_5", "wnd_id": "12022905_5_1", "text": "Priapism associated with zuclopenthixol .", "tokens": ["Priapism", "associated", "with", "zuclopenthixol", "."], "event_mentions": [{"id": "12022905_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "12022905_5_Ent0", "role": "Effect", "text": "Priapism", "start": 0, "end": 1}, {"entity_id": "12022905_5_Ent1", "role": "Treatment", "text": "zuclopenthixol", "start": 3, "end": 4}, {"entity_id": "12022905_5_Ent2", "role": "Treatment_Drug", "text": "zuclopenthixol", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "12022905_5_Ent0", "text": "Priapism", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12022905_5_Ent1", "text": "zuclopenthixol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12022905_5_Ent2", "text": "zuclopenthixol", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "12022905_6", "wnd_id": "12022905_6_1", "text": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha - adrenergic receptors .", "tokens": ["The", "capacity", "of", "zuclopenthixol", "to", "induce", "priapism", "is", "thought", "to", "be", "due", "to", "its", "antagonist", "activity", "on", "alpha", "-", "adrenergic", "receptors", "."], "event_mentions": [{"id": "12022905_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 5, "end": 6}, "arguments": [{"entity_id": "12022905_6_Ent1", "role": "Treatment", "text": "zuclopenthixol", "start": 3, "end": 4}, {"entity_id": "12022905_6_Ent2", "role": "Treatment_Drug", "text": "zuclopenthixol", "start": 3, "end": 4}, {"entity_id": "12022905_6_Ent0", "role": "Effect", "text": "priapism", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "12022905_6_Ent1", "text": "zuclopenthixol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12022905_6_Ent2", "text": "zuclopenthixol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12022905_6_Ent0", "text": "priapism", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "12149193_1", "wnd_id": "12149193_1_1", "text": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide : implications for therapy .", "tokens": ["Thrombogenic", "activity", "of", "doxorubicin", "in", "myeloma", "patients", "receiving", "thalidomide", ":", "implications", "for", "therapy", "."], "event_mentions": [{"id": "12149193_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 7, "end": 8}, "arguments": [{"entity_id": "12149193_1_Ent1", "role": "Effect", "text": "Thrombogenic activity", "start": 0, "end": 2}, {"entity_id": "12149193_1_Ent2", "role": "Treatment", "text": "doxorubicin", "start": 3, "end": 4}, {"entity_id": "12149193_1_Ent5", "role": "Treatment_Drug", "text": "doxorubicin", "start": 3, "end": 4}, {"entity_id": "12149193_1_Ent4", "role": "Treatment_Disorder", "text": "myeloma", "start": 5, "end": 6}, {"entity_id": "12149193_1_Ent0", "role": "Subject", "text": "myeloma patients", "start": 5, "end": 7}, {"entity_id": "12149193_1_Ent3", "role": "Treatment", "text": "thalidomide", "start": 8, "end": 9}, {"entity_id": "12149193_1_Ent6", "role": "Treatment_Drug", "text": "thalidomide", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "12149193_1_Ent1", "text": "Thrombogenic activity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12149193_1_Ent2", "text": "doxorubicin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12149193_1_Ent5", "text": "doxorubicin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12149193_1_Ent4", "text": "myeloma", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12149193_1_Ent0", "text": "myeloma patients", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12149193_1_Ent3", "text": "thalidomide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12149193_1_Ent6", "text": "thalidomide", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "12149193_9", "wnd_id": "12149193_9_1", "text": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT .", "tokens": ["MM", "patients", "treated", "with", "thalidomide", "and", "doxorubicin", "have", "a", "high", "risk", "of", "developing", "DVT", "."], "event_mentions": [{"id": "12149193_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "have", "start": 7, "end": 8}, "arguments": [{"entity_id": "12149193_9_Ent3", "role": "Treatment_Disorder", "text": "MM", "start": 0, "end": 1}, {"entity_id": "12149193_9_Ent0", "role": "Subject", "text": "MM patients", "start": 0, "end": 2}, {"entity_id": "12149193_9_Ent4", "role": "Treatment_Drug", "text": "thalidomide", "start": 4, "end": 5}, {"entity_id": "12149193_9_Ent6", "role": "Combination_Drug", "text": "thalidomide", "start": 4, "end": 5}, {"entity_id": "12149193_9_Ent2", "role": "Treatment", "text": "thalidomide and doxorubicin", "start": 4, "end": 7}, {"entity_id": "12149193_9_Ent5", "role": "Treatment_Drug", "text": "doxorubicin", "start": 6, "end": 7}, {"entity_id": "12149193_9_Ent7", "role": "Combination_Drug", "text": "doxorubicin", "start": 6, "end": 7}, {"entity_id": "12149193_9_Ent1", "role": "Effect", "text": "a high risk of developing DVT", "start": 8, "end": 14}]}], "entity_mentions": [{"id": "12149193_9_Ent3", "text": "MM", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12149193_9_Ent0", "text": "MM patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12149193_9_Ent4", "text": "thalidomide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12149193_9_Ent6", "text": "thalidomide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12149193_9_Ent2", "text": "thalidomide and doxorubicin", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "12149193_9_Ent5", "text": "doxorubicin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12149193_9_Ent7", "text": "doxorubicin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12149193_9_Ent1", "text": "a high risk of developing DVT", "entity_type": "Entity", "start": 8, "end": 14}], "lang": "en"}
{"doc_id": "12150593_2", "wnd_id": "12150593_2_1", "text": "We present a neonate with a seizure disorder who acutely developed pupillary mydriasis secondary to lidocaine overdose .", "tokens": ["We", "present", "a", "neonate", "with", "a", "seizure", "disorder", "who", "acutely", "developed", "pupillary", "mydriasis", "secondary", "to", "lidocaine", "overdose", "."], "event_mentions": [{"id": "12150593_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "12150593_2_Ent0", "role": "Subject", "text": "a neonate with a seizure disorder", "start": 2, "end": 8}, {"entity_id": "12150593_2_Ent1", "role": "Subject_Age", "text": "neonate", "start": 3, "end": 4}, {"entity_id": "12150593_2_Ent6", "role": "Treatment_Disorder", "text": "seizure disorder", "start": 6, "end": 8}, {"entity_id": "12150593_2_Ent2", "role": "Effect", "text": "pupillary mydriasis", "start": 11, "end": 13}, {"entity_id": "12150593_2_Ent4", "role": "Treatment_Drug", "text": "lidocaine", "start": 15, "end": 16}, {"entity_id": "12150593_2_Ent3", "role": "Treatment", "text": "lidocaine overdose", "start": 15, "end": 17}, {"entity_id": "12150593_2_Ent5", "role": "Treatment_Dosage", "text": "overdose", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "12150593_2_Ent0", "text": "a neonate with a seizure disorder", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "12150593_2_Ent1", "text": "neonate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12150593_2_Ent6", "text": "seizure disorder", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "12150593_2_Ent2", "text": "pupillary mydriasis", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "12150593_2_Ent4", "text": "lidocaine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12150593_2_Ent3", "text": "lidocaine overdose", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "12150593_2_Ent5", "text": "overdose", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "12163813_3", "wnd_id": "12163813_3_1", "text": "Skin necrosis after extravasation of low - dose vasopressin administered for septic shock .", "tokens": ["Skin", "necrosis", "after", "extravasation", "of", "low", "-", "dose", "vasopressin", "administered", "for", "septic", "shock", "."], "event_mentions": [{"id": "12163813_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "extravasation", "start": 3, "end": 4}, "arguments": [{"entity_id": "12163813_3_Ent0", "role": "Effect", "text": "Skin necrosis", "start": 0, "end": 2}, {"entity_id": "12163813_3_Ent1", "role": "Treatment", "text": "vasopressin", "start": 8, "end": 9}, {"entity_id": "12163813_3_Ent2", "role": "Treatment_Drug", "text": "vasopressin", "start": 8, "end": 9}, {"entity_id": "12163813_3_Ent3", "role": "Treatment_Disorder", "text": "septic shock", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "12163813_3_Ent0", "text": "Skin necrosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12163813_3_Ent1", "text": "vasopressin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12163813_3_Ent2", "text": "vasopressin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12163813_3_Ent3", "text": "septic shock", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "12166705_1", "wnd_id": "12166705_1_1", "text": "Mitomycin - C induced hemolytic uremic syndrome : a case report .", "tokens": ["Mitomycin", "-", "C", "induced", "hemolytic", "uremic", "syndrome", ":", "a", "case", "report", "."], "event_mentions": [{"id": "12166705_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "12166705_1_Ent1", "role": "Treatment", "text": "Mitomycin - C", "start": 0, "end": 3}, {"entity_id": "12166705_1_Ent2", "role": "Treatment_Drug", "text": "Mitomycin - C", "start": 0, "end": 3}, {"entity_id": "12166705_1_Ent0", "role": "Effect", "text": "hemolytic uremic syndrome", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "12166705_1_Ent1", "text": "Mitomycin - C", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12166705_1_Ent2", "text": "Mitomycin - C", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12166705_1_Ent0", "text": "hemolytic uremic syndrome", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "12187348_2", "wnd_id": "12187348_2_1", "text": "Drug - induced mammary hyperplasias have been reported as rare complications of D - penicillamine and Neothetazone .", "tokens": ["Drug", "-", "induced", "mammary", "hyperplasias", "have", "been", "reported", "as", "rare", "complications", "of", "D", "-", "penicillamine", "and", "Neothetazone", "."], "event_mentions": [{"id": "12187348_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "12187348_2_Ent1", "role": "Treatment", "text": "Drug", "start": 0, "end": 1}, {"entity_id": "12187348_2_Ent3", "role": "Treatment_Drug", "text": "Drug", "start": 0, "end": 1}, {"entity_id": "12187348_2_Ent0", "role": "Effect", "text": "mammary hyperplasias", "start": 3, "end": 5}, {"entity_id": "12187348_2_Ent5", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 12, "end": 15}, {"entity_id": "12187348_2_Ent6", "role": "Combination_Drug", "text": "D - penicillamine", "start": 12, "end": 15}, {"entity_id": "12187348_2_Ent2", "role": "Treatment", "text": "D - penicillamine and Neothetazone", "start": 12, "end": 17}, {"entity_id": "12187348_2_Ent4", "role": "Treatment_Drug", "text": "Neothetazone", "start": 16, "end": 17}, {"entity_id": "12187348_2_Ent7", "role": "Combination_Drug", "text": "Neothetazone", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "12187348_2_Ent1", "text": "Drug", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12187348_2_Ent3", "text": "Drug", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12187348_2_Ent0", "text": "mammary hyperplasias", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "12187348_2_Ent5", "text": "D - penicillamine", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "12187348_2_Ent6", "text": "D - penicillamine", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "12187348_2_Ent2", "text": "D - penicillamine and Neothetazone", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "12187348_2_Ent4", "text": "Neothetazone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12187348_2_Ent7", "text": "Neothetazone", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "12187348_3", "wnd_id": "12187348_3_1", "text": "The authors report the first case of bucillamine - induced giant mammary hyperplasia .", "tokens": ["The", "authors", "report", "the", "first", "case", "of", "bucillamine", "-", "induced", "giant", "mammary", "hyperplasia", "."], "event_mentions": [{"id": "12187348_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "12187348_3_Ent1", "role": "Treatment", "text": "bucillamine", "start": 7, "end": 8}, {"entity_id": "12187348_3_Ent2", "role": "Treatment_Drug", "text": "bucillamine", "start": 7, "end": 8}, {"entity_id": "12187348_3_Ent0", "role": "Effect", "text": "giant mammary hyperplasia", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "12187348_3_Ent1", "text": "bucillamine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12187348_3_Ent2", "text": "bucillamine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12187348_3_Ent0", "text": "giant mammary hyperplasia", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "12187348_8", "wnd_id": "12187348_8_1", "text": "Retrospectively , bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to D - penicillamine , which was the subject of an abundance of reports of mammary hyperplasia .", "tokens": ["Retrospectively", ",", "bucillamine", "was", "believed", "to", "be", "the", "cause", "of", "the", "giant", "hypertrophy", "because", "of", "its", "structural", "similarity", "to", "D", "-", "penicillamine", ",", "which", "was", "the", "subject", "of", "an", "abundance", "of", "reports", "of", "mammary", "hyperplasia", "."], "event_mentions": [{"id": "12187348_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause of", "start": 8, "end": 10}, "arguments": [{"entity_id": "12187348_8_Ent1", "role": "Treatment", "text": "bucillamine", "start": 2, "end": 3}, {"entity_id": "12187348_8_Ent2", "role": "Treatment_Drug", "text": "bucillamine", "start": 2, "end": 3}, {"entity_id": "12187348_8_Ent0", "role": "Effect", "text": "giant hypertrophy", "start": 11, "end": 13}, {"entity_id": "12187348_8_Ent3", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "12187348_8_Ent1", "text": "bucillamine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12187348_8_Ent2", "text": "bucillamine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12187348_8_Ent0", "text": "giant hypertrophy", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "12187348_8_Ent3", "text": "D - penicillamine", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "12221670_4", "wnd_id": "12221670_4_1", "text": "Ticlopidine - induced aplastic anemia : two new case reports , review , and meta - analysis of 55 additional cases .", "tokens": ["Ticlopidine", "-", "induced", "aplastic", "anemia", ":", "two", "new", "case", "reports", ",", "review", ",", "and", "meta", "-", "analysis", "of", "55", "additional", "cases", "."], "event_mentions": [{"id": "12221670_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "12221670_4_Ent1", "role": "Treatment", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "12221670_4_Ent2", "role": "Treatment_Drug", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "12221670_4_Ent0", "role": "Effect", "text": "aplastic anemia", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "12221670_4_Ent1", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12221670_4_Ent2", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12221670_4_Ent0", "text": "aplastic anemia", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "12234159_2", "wnd_id": "12234159_2_1", "text": "Rofecoxib , used for dysmenorrhea , caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red - brown lesion on the dorsal hand .", "tokens": ["Rofecoxib", ",", "used", "for", "dysmenorrhea", ",", "caused", "a", "herpetiform", "fixed", "drug", "eruption", "predominantly", "involving", "the", "lips", "with", "classic", "clinical", "and", "histological", "findings", "in", "a", "red", "-", "brown", "lesion", "on", "the", "dorsal", "hand", "."], "event_mentions": [{"id": "12234159_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 6, "end": 7}, "arguments": [{"entity_id": "12234159_2_Ent1", "role": "Treatment", "text": "Rofecoxib", "start": 0, "end": 1}, {"entity_id": "12234159_2_Ent3", "role": "Treatment_Drug", "text": "Rofecoxib", "start": 0, "end": 1}, {"entity_id": "12234159_2_Ent2", "role": "Treatment_Disorder", "text": "dysmenorrhea", "start": 4, "end": 5}, {"entity_id": "12234159_2_Ent0", "role": "Effect", "text": "herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red - brown lesion on the dorsal hand", "start": 8, "end": 32}]}], "entity_mentions": [{"id": "12234159_2_Ent1", "text": "Rofecoxib", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12234159_2_Ent3", "text": "Rofecoxib", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12234159_2_Ent2", "text": "dysmenorrhea", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12234159_2_Ent0", "text": "herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red - brown lesion on the dorsal hand", "entity_type": "Entity", "start": 8, "end": 32}], "lang": "en"}
{"doc_id": "12243603_6", "wnd_id": "12243603_6_1", "text": "Rhabdomyolysis has been reported in patients receiving hydroxymethylglutaryl coenzyme A ( HMG - CoA ) reductase inhibitors when coadministered with agents that may inhibit their metabolism .", "tokens": ["Rhabdomyolysis", "has", "been", "reported", "in", "patients", "receiving", "hydroxymethylglutaryl", "coenzyme", "A", "(", "HMG", "-", "CoA", ")", "reductase", "inhibitors", "when", "coadministered", "with", "agents", "that", "may", "inhibit", "their", "metabolism", "."], "event_mentions": [{"id": "12243603_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 6, "end": 7}, "arguments": [{"entity_id": "12243603_6_Ent1", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "12243603_6_Ent0", "role": "Subject", "text": "patients", "start": 5, "end": 6}, {"entity_id": "12243603_6_Ent3", "role": "Treatment_Drug", "text": "hydroxymethylglutaryl coenzyme A", "start": 7, "end": 10}, {"entity_id": "12243603_6_Ent5", "role": "Combination_Drug", "text": "hydroxymethylglutaryl coenzyme A", "start": 7, "end": 10}, {"entity_id": "12243603_6_Ent2", "role": "Treatment", "text": "hydroxymethylglutaryl coenzyme A ( HMG - CoA ) reductase inhibitors when coadministered with agents that may inhibit their metabolism", "start": 7, "end": 26}, {"entity_id": "12243603_6_Ent4", "role": "Treatment_Drug", "text": "agents that may inhibit their metabolism", "start": 20, "end": 26}, {"entity_id": "12243603_6_Ent6", "role": "Combination_Drug", "text": "agents that may inhibit their metabolism", "start": 20, "end": 26}]}], "entity_mentions": [{"id": "12243603_6_Ent1", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12243603_6_Ent0", "text": "patients", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12243603_6_Ent3", "text": "hydroxymethylglutaryl coenzyme A", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "12243603_6_Ent5", "text": "hydroxymethylglutaryl coenzyme A", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "12243603_6_Ent2", "text": "hydroxymethylglutaryl coenzyme A ( HMG - CoA ) reductase inhibitors when coadministered with agents that may inhibit their metabolism", "entity_type": "Entity", "start": 7, "end": 26}, {"id": "12243603_6_Ent4", "text": "agents that may inhibit their metabolism", "entity_type": "Entity", "start": 20, "end": 26}, {"id": "12243603_6_Ent6", "text": "agents that may inhibit their metabolism", "entity_type": "Entity", "start": 20, "end": 26}], "lang": "en"}
{"doc_id": "12324937_5", "wnd_id": "12324937_5_1", "text": "METHODS : A case is presented of a 45 - year - old woman on prolonged gemcitabine treatment for ovarian cancer who developed HUS and recovered after drug discontinuation .", "tokens": ["METHODS", ":", "A", "case", "is", "presented", "of", "a", "45", "-", "year", "-", "old", "woman", "on", "prolonged", "gemcitabine", "treatment", "for", "ovarian", "cancer", "who", "developed", "HUS", "and", "recovered", "after", "drug", "discontinuation", "."], "event_mentions": [{"id": "12324937_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 22, "end": 23}, "arguments": [{"entity_id": "12324937_5_Ent0", "role": "Subject", "text": "a 45 - year - old woman", "start": 7, "end": 14}, {"entity_id": "12324937_5_Ent1", "role": "Subject_Age", "text": "45 - year - old", "start": 8, "end": 13}, {"entity_id": "12324937_5_Ent2", "role": "Subject_Gender", "text": "woman", "start": 13, "end": 14}, {"entity_id": "12324937_5_Ent6", "role": "Treatment_Duration", "text": "prolonged", "start": 15, "end": 16}, {"entity_id": "12324937_5_Ent4", "role": "Treatment", "text": "prolonged gemcitabine treatment", "start": 15, "end": 18}, {"entity_id": "12324937_5_Ent5", "role": "Treatment_Drug", "text": "gemcitabine", "start": 16, "end": 17}, {"entity_id": "12324937_5_Ent7", "role": "Treatment_Disorder", "text": "ovarian cancer", "start": 19, "end": 21}, {"entity_id": "12324937_5_Ent3", "role": "Effect", "text": "HUS", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "12324937_5_Ent0", "text": "a 45 - year - old woman", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "12324937_5_Ent1", "text": "45 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "12324937_5_Ent2", "text": "woman", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12324937_5_Ent6", "text": "prolonged", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12324937_5_Ent4", "text": "prolonged gemcitabine treatment", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "12324937_5_Ent5", "text": "gemcitabine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12324937_5_Ent7", "text": "ovarian cancer", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "12324937_5_Ent3", "text": "HUS", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "12397859_1", "wnd_id": "12397859_1_1", "text": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone , an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme .", "tokens": ["A", "case", "is", "presented", "of", "a", "patient", "who", "experienced", "benzodiazepine", "withdrawal", "symptoms", "on", "discontinuation", "of", "nefazodone", ",", "an", "antidepressant", "that", "inhibits", "the", "cytochrome", "P450", "3A4", "isoenzyme", "."], "event_mentions": [{"id": "12397859_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "discontinuation", "start": 13, "end": 14}, "arguments": [{"entity_id": "12397859_1_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "12397859_1_Ent1", "role": "Effect", "text": "benzodiazepine withdrawal symptoms", "start": 9, "end": 12}, {"entity_id": "12397859_1_Ent2", "role": "Treatment", "text": "nefazodone", "start": 15, "end": 16}, {"entity_id": "12397859_1_Ent3", "role": "Treatment_Drug", "text": "nefazodone", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "12397859_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12397859_1_Ent1", "text": "benzodiazepine withdrawal symptoms", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12397859_1_Ent2", "text": "nefazodone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12397859_1_Ent3", "text": "nefazodone", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "12399645_1", "wnd_id": "12399645_1_1", "text": "A case of SIADH induced by mizoribin administration .", "tokens": ["A", "case", "of", "SIADH", "induced", "by", "mizoribin", "administration", "."], "event_mentions": [{"id": "12399645_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "12399645_1_Ent0", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "12399645_1_Ent1", "role": "Effect", "text": "SIADH", "start": 3, "end": 4}, {"entity_id": "12399645_1_Ent3", "role": "Treatment_Drug", "text": "mizoribin", "start": 6, "end": 7}, {"entity_id": "12399645_1_Ent2", "role": "Treatment", "text": "mizoribin administration", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "12399645_1_Ent0", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12399645_1_Ent1", "text": "SIADH", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12399645_1_Ent3", "text": "mizoribin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12399645_1_Ent2", "text": "mizoribin administration", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "12399645_4", "wnd_id": "12399645_4_1", "text": "We describe a 74 - year - old man with rheumatoid arthritis ( RA ) who developed syndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) 1.5 months after commencement of mizoribin prescription when his arthritis was improved .", "tokens": ["We", "describe", "a", "74", "-", "year", "-", "old", "man", "with", "rheumatoid", "arthritis", "(", "RA", ")", "who", "developed", "syndrome", "of", "inappropriate", "secretion", "of", "antidiuretic", "hormone", "(", "SIADH", ")", "1.5", "months", "after", "commencement", "of", "mizoribin", "prescription", "when", "his", "arthritis", "was", "improved", "."], "event_mentions": [{"id": "12399645_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "12399645_4_Ent0", "role": "Subject", "text": "a 74 - year - old man with rheumatoid arthritis ( RA )", "start": 2, "end": 15}, {"entity_id": "12399645_4_Ent1", "role": "Subject_Age", "text": "74 - year - old", "start": 3, "end": 8}, {"entity_id": "12399645_4_Ent2", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}, {"entity_id": "12399645_4_Ent7", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 10, "end": 12}, {"entity_id": "12399645_4_Ent3", "role": "Effect", "text": "syndrome of inappropriate secretion of antidiuretic hormone ( SIADH )", "start": 17, "end": 27}, {"entity_id": "12399645_4_Ent5", "role": "Treatment_Time_elapsed", "text": "1.5 months after", "start": 27, "end": 30}, {"entity_id": "12399645_4_Ent4", "role": "Treatment", "text": "1.5 months after commencement of mizoribin prescription", "start": 27, "end": 34}, {"entity_id": "12399645_4_Ent6", "role": "Treatment_Drug", "text": "mizoribin", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "12399645_4_Ent0", "text": "a 74 - year - old man with rheumatoid arthritis ( RA )", "entity_type": "Entity", "start": 2, "end": 15}, {"id": "12399645_4_Ent1", "text": "74 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "12399645_4_Ent2", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12399645_4_Ent7", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "12399645_4_Ent3", "text": "syndrome of inappropriate secretion of antidiuretic hormone ( SIADH )", "entity_type": "Entity", "start": 17, "end": 27}, {"id": "12399645_4_Ent5", "text": "1.5 months after", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "12399645_4_Ent4", "text": "1.5 months after commencement of mizoribin prescription", "entity_type": "Entity", "start": 27, "end": 34}, {"id": "12399645_4_Ent6", "text": "mizoribin", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "12410494_1", "wnd_id": "12410494_1_1", "text": "Simvastatin - nelfinavir interaction implicated in rhabdomyolysis and death .", "tokens": ["Simvastatin", "-", "nelfinavir", "interaction", "implicated", "in", "rhabdomyolysis", "and", "death", "."], "event_mentions": [{"id": "12410494_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "implicated", "start": 4, "end": 5}, "arguments": [{"entity_id": "12410494_1_Ent3", "role": "Treatment_Drug", "text": "Simvastatin", "start": 0, "end": 1}, {"entity_id": "12410494_1_Ent5", "role": "Combination_Drug", "text": "Simvastatin", "start": 0, "end": 1}, {"entity_id": "12410494_1_Ent1", "role": "Treatment", "text": "Simvastatin - nelfinavir interaction", "start": 0, "end": 4}, {"entity_id": "12410494_1_Ent2", "role": "Treatment_Drug", "text": "nelfinavir", "start": 2, "end": 3}, {"entity_id": "12410494_1_Ent4", "role": "Combination_Drug", "text": "nelfinavir", "start": 2, "end": 3}, {"entity_id": "12410494_1_Ent0", "role": "Effect", "text": "rhabdomyolysis and death", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "12410494_1_Ent3", "text": "Simvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12410494_1_Ent5", "text": "Simvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12410494_1_Ent1", "text": "Simvastatin - nelfinavir interaction", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12410494_1_Ent2", "text": "nelfinavir", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12410494_1_Ent4", "text": "nelfinavir", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12410494_1_Ent0", "text": "rhabdomyolysis and death", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "12439602_3", "wnd_id": "12439602_3_1", "text": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy .", "tokens": ["Hypersensitivity", "to", "carboplatin", "is", "a", "rare", "but", "real", "complication", "of", "therapy", "and", "should", "be", "considered", "in", "patients", "presenting", "with", "hyperacute", "changes", "on", "ECG", "whilst", "receiving", "carboplatin", "therapy", "."], "event_mentions": [{"id": "12439602_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 8, "end": 9}, "arguments": [{"entity_id": "12439602_3_Ent2", "role": "Effect", "text": "Hypersensitivity to carboplatin", "start": 0, "end": 3}, {"entity_id": "12439602_3_Ent0", "role": "Subject", "text": "patients presenting with hyperacute changes on ECG", "start": 16, "end": 23}, {"entity_id": "12439602_3_Ent1", "role": "Subject_Disorder", "text": "hyperacute changes on ECG", "start": 19, "end": 23}, {"entity_id": "12439602_3_Ent4", "role": "Treatment_Drug", "text": "carboplatin", "start": 25, "end": 26}, {"entity_id": "12439602_3_Ent3", "role": "Treatment", "text": "carboplatin therapy", "start": 25, "end": 27}]}], "entity_mentions": [{"id": "12439602_3_Ent2", "text": "Hypersensitivity to carboplatin", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12439602_3_Ent0", "text": "patients presenting with hyperacute changes on ECG", "entity_type": "Entity", "start": 16, "end": 23}, {"id": "12439602_3_Ent1", "text": "hyperacute changes on ECG", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "12439602_3_Ent4", "text": "carboplatin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "12439602_3_Ent3", "text": "carboplatin therapy", "entity_type": "Entity", "start": 25, "end": 27}], "lang": "en"}
{"doc_id": "1244265_1", "wnd_id": "1244265_1_1", "text": "A 60 - year - old white man with chronic bronchitis was noted to develop acute respiratory failure and metabolic acidosis four days after being started on methazolamide ( Neptazane ) for an ophthalmologic problem .", "tokens": ["A", "60", "-", "year", "-", "old", "white", "man", "with", "chronic", "bronchitis", "was", "noted", "to", "develop", "acute", "respiratory", "failure", "and", "metabolic", "acidosis", "four", "days", "after", "being", "started", "on", "methazolamide", "(", "Neptazane", ")", "for", "an", "ophthalmologic", "problem", "."], "event_mentions": [{"id": "1244265_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 14, "end": 15}, "arguments": [{"entity_id": "1244265_1_Ent0", "role": "Subject", "text": "A 60 - year - old white man with chronic bronchitis", "start": 0, "end": 11}, {"entity_id": "1244265_1_Ent1", "role": "Subject_Age", "text": "60 - year - old", "start": 1, "end": 6}, {"entity_id": "1244265_1_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "1244265_1_Ent3", "role": "Subject_Gender", "text": "man", "start": 7, "end": 8}, {"entity_id": "1244265_1_Ent4", "role": "Subject_Disorder", "text": "chronic bronchitis", "start": 9, "end": 11}, {"entity_id": "1244265_1_Ent5", "role": "Effect", "text": "acute respiratory failure and metabolic acidosis", "start": 15, "end": 21}, {"entity_id": "1244265_1_Ent9", "role": "Treatment_Time_elapsed", "text": "four days after", "start": 21, "end": 24}, {"entity_id": "1244265_1_Ent7", "role": "Treatment_Drug", "text": "methazolamide", "start": 27, "end": 28}, {"entity_id": "1244265_1_Ent6", "role": "Treatment", "text": "methazolamide ( Neptazane )", "start": 27, "end": 31}, {"entity_id": "1244265_1_Ent8", "role": "Treatment_Disorder", "text": "ophthalmologic problem", "start": 33, "end": 35}]}], "entity_mentions": [{"id": "1244265_1_Ent0", "text": "A 60 - year - old white man with chronic bronchitis", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "1244265_1_Ent1", "text": "60 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "1244265_1_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1244265_1_Ent3", "text": "man", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1244265_1_Ent4", "text": "chronic bronchitis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "1244265_1_Ent5", "text": "acute respiratory failure and metabolic acidosis", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "1244265_1_Ent9", "text": "four days after", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "1244265_1_Ent7", "text": "methazolamide", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "1244265_1_Ent6", "text": "methazolamide ( Neptazane )", "entity_type": "Entity", "start": 27, "end": 31}, {"id": "1244265_1_Ent8", "text": "ophthalmologic problem", "entity_type": "Entity", "start": 33, "end": 35}], "lang": "en"}
{"doc_id": "12452753_3", "wnd_id": "12452753_3_1", "text": "Fluorouracil for allergic reactions to capecitabine .", "tokens": ["Fluorouracil", "for", "allergic", "reactions", "to", "capecitabine", "."], "event_mentions": [{"id": "12452753_3_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 1, "end": 2}, "arguments": [{"entity_id": "12452753_3_Ent3", "role": "Treatment", "text": "Fluorouracil", "start": 0, "end": 1}, {"entity_id": "12452753_3_Ent5", "role": "Treatment_Drug", "text": "Fluorouracil", "start": 0, "end": 1}, {"entity_id": "12452753_3_Ent4", "role": "Treatment_Disorder", "text": "allergic reactions to capecitabine", "start": 2, "end": 6}]}, {"id": "12452753_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 4, "end": 5}, "arguments": [{"entity_id": "12452753_3_Ent0", "role": "Effect", "text": "allergic reactions", "start": 2, "end": 4}, {"entity_id": "12452753_3_Ent1", "role": "Treatment", "text": "capecitabine", "start": 5, "end": 6}, {"entity_id": "12452753_3_Ent2", "role": "Treatment_Drug", "text": "capecitabine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "12452753_3_Ent3", "text": "Fluorouracil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12452753_3_Ent5", "text": "Fluorouracil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12452753_3_Ent0", "text": "allergic reactions", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "12452753_3_Ent4", "text": "allergic reactions to capecitabine", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "12452753_3_Ent1", "text": "capecitabine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12452753_3_Ent2", "text": "capecitabine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "12477460_3", "wnd_id": "12477460_3_1", "text": "CONCLUSION : Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state .", "tokens": ["CONCLUSION", ":", "Tamoxifen", "may", "cause", "malignant", "transformation", "of", "endometriosis", "through", "atypical", "endometriosis", "even", "in", "the", "postmenopausal", "state", "."], "event_mentions": [{"id": "12477460_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "12477460_3_Ent1", "role": "Treatment", "text": "Tamoxifen", "start": 2, "end": 3}, {"entity_id": "12477460_3_Ent2", "role": "Treatment_Drug", "text": "Tamoxifen", "start": 2, "end": 3}, {"entity_id": "12477460_3_Ent0", "role": "Effect", "text": "malignant transformation of endometriosis through atypical endometriosis", "start": 5, "end": 12}]}], "entity_mentions": [{"id": "12477460_3_Ent1", "text": "Tamoxifen", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12477460_3_Ent2", "text": "Tamoxifen", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12477460_3_Ent0", "text": "malignant transformation of endometriosis through atypical endometriosis", "entity_type": "Entity", "start": 5, "end": 12}], "lang": "en"}
{"doc_id": "12477460_4", "wnd_id": "12477460_4_1", "text": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer : a case report .", "tokens": ["Ovarian", "endometrioid", "adenocarcinoma", "arising", "from", "an", "endometriotic", "cyst", "in", "a", "postmenopausal", "woman", "under", "tamoxifen", "therapy", "for", "breast", "cancer", ":", "a", "case", "report", "."], "event_mentions": [{"id": "12477460_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "under", "start": 12, "end": 13}, "arguments": [{"entity_id": "12477460_4_Ent3", "role": "Effect", "text": "Ovarian endometrioid adenocarcinoma", "start": 0, "end": 3}, {"entity_id": "12477460_4_Ent0", "role": "Subject", "text": "a postmenopausal woman", "start": 9, "end": 12}, {"entity_id": "12477460_4_Ent1", "role": "Subject_Age", "text": "postmenopausal", "start": 10, "end": 11}, {"entity_id": "12477460_4_Ent2", "role": "Subject_Gender", "text": "woman", "start": 11, "end": 12}, {"entity_id": "12477460_4_Ent5", "role": "Treatment_Drug", "text": "tamoxifen", "start": 13, "end": 14}, {"entity_id": "12477460_4_Ent4", "role": "Treatment", "text": "tamoxifen therapy", "start": 13, "end": 15}, {"entity_id": "12477460_4_Ent6", "role": "Treatment_Disorder", "text": "breast cancer", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "12477460_4_Ent3", "text": "Ovarian endometrioid adenocarcinoma", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12477460_4_Ent0", "text": "a postmenopausal woman", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12477460_4_Ent1", "text": "postmenopausal", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12477460_4_Ent2", "text": "woman", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12477460_4_Ent5", "text": "tamoxifen", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12477460_4_Ent4", "text": "tamoxifen therapy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "12477460_4_Ent6", "text": "breast cancer", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "12503933_6", "wnd_id": "12503933_6_1", "text": "OBJECTIVE : To report a patient developing fulminant liver failure while being treated with clarithromycin for pneumonia .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "patient", "developing", "fulminant", "liver", "failure", "while", "being", "treated", "with", "clarithromycin", "for", "pneumonia", "."], "event_mentions": [{"id": "12503933_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 12, "end": 13}, "arguments": [{"entity_id": "12503933_6_Ent0", "role": "Subject", "text": "a patient", "start": 4, "end": 6}, {"entity_id": "12503933_6_Ent1", "role": "Effect", "text": "fulminant liver failure", "start": 7, "end": 10}, {"entity_id": "12503933_6_Ent2", "role": "Treatment", "text": "clarithromycin", "start": 14, "end": 15}, {"entity_id": "12503933_6_Ent3", "role": "Treatment_Drug", "text": "clarithromycin", "start": 14, "end": 15}, {"entity_id": "12503933_6_Ent4", "role": "Treatment_Disorder", "text": "pneumonia", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "12503933_6_Ent0", "text": "a patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "12503933_6_Ent1", "text": "fulminant liver failure", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "12503933_6_Ent2", "text": "clarithromycin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12503933_6_Ent3", "text": "clarithromycin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12503933_6_Ent4", "text": "pneumonia", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "12503933_7", "wnd_id": "12503933_7_1", "text": "The most likely cause of liver failure in this patient was , therefore , clarithromycin , which undergoes hepatic metabolism and has been reported to cause fulminant hepatic failure .", "tokens": ["The", "most", "likely", "cause", "of", "liver", "failure", "in", "this", "patient", "was", ",", "therefore", ",", "clarithromycin", ",", "which", "undergoes", "hepatic", "metabolism", "and", "has", "been", "reported", "to", "cause", "fulminant", "hepatic", "failure", "."], "event_mentions": [{"id": "12503933_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 3, "end": 4}, "arguments": [{"entity_id": "12503933_7_Ent0", "role": "Effect", "text": "liver failure", "start": 5, "end": 7}, {"entity_id": "12503933_7_Ent1", "role": "Treatment", "text": "clarithromycin", "start": 14, "end": 15}, {"entity_id": "12503933_7_Ent2", "role": "Treatment_Drug", "text": "clarithromycin", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "12503933_7_Ent0", "text": "liver failure", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12503933_7_Ent1", "text": "clarithromycin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12503933_7_Ent2", "text": "clarithromycin", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "12504711_4", "wnd_id": "12504711_4_1", "text": "RESULTS : Brimonidine was observed to cause IOP elevation , confirmed on rechallenge , scoring 8 ( strong probability ) on an adverse drug reaction probability score .", "tokens": ["RESULTS", ":", "Brimonidine", "was", "observed", "to", "cause", "IOP", "elevation", ",", "confirmed", "on", "rechallenge", ",", "scoring", "8", "(", "strong", "probability", ")", "on", "an", "adverse", "drug", "reaction", "probability", "score", "."], "event_mentions": [{"id": "12504711_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 6, "end": 7}, "arguments": [{"entity_id": "12504711_4_Ent1", "role": "Treatment", "text": "Brimonidine", "start": 2, "end": 3}, {"entity_id": "12504711_4_Ent2", "role": "Treatment_Drug", "text": "Brimonidine", "start": 2, "end": 3}, {"entity_id": "12504711_4_Ent0", "role": "Effect", "text": "IOP elevation", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "12504711_4_Ent1", "text": "Brimonidine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12504711_4_Ent2", "text": "Brimonidine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12504711_4_Ent0", "text": "IOP elevation", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "12523465_2", "wnd_id": "12523465_2_1", "text": "Visual hallucinations associated with zonisamide .", "tokens": ["Visual", "hallucinations", "associated", "with", "zonisamide", "."], "event_mentions": [{"id": "12523465_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 2, "end": 4}, "arguments": [{"entity_id": "12523465_2_Ent0", "role": "Effect", "text": "Visual hallucinations", "start": 0, "end": 2}, {"entity_id": "12523465_2_Ent1", "role": "Treatment", "text": "zonisamide", "start": 4, "end": 5}, {"entity_id": "12523465_2_Ent2", "role": "Treatment_Drug", "text": "zonisamide", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "12523465_2_Ent0", "text": "Visual hallucinations", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12523465_2_Ent1", "text": "zonisamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12523465_2_Ent2", "text": "zonisamide", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "12587815_2", "wnd_id": "12587815_2_1", "text": "Concomitant administration of lithium with olanzapine may place patients at risk for NMS .", "tokens": ["Concomitant", "administration", "of", "lithium", "with", "olanzapine", "may", "place", "patients", "at", "risk", "for", "NMS", "."], "event_mentions": [{"id": "12587815_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "administration", "start": 1, "end": 2}, "arguments": [{"entity_id": "12587815_2_Ent2", "role": "Treatment", "text": "lithium", "start": 3, "end": 4}, {"entity_id": "12587815_2_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 3, "end": 4}, {"entity_id": "12587815_2_Ent6", "role": "Combination_Drug", "text": "lithium", "start": 3, "end": 4}, {"entity_id": "12587815_2_Ent3", "role": "Treatment", "text": "olanzapine", "start": 5, "end": 6}, {"entity_id": "12587815_2_Ent5", "role": "Treatment_Drug", "text": "olanzapine", "start": 5, "end": 6}, {"entity_id": "12587815_2_Ent7", "role": "Combination_Drug", "text": "olanzapine", "start": 5, "end": 6}, {"entity_id": "12587815_2_Ent0", "role": "Subject", "text": "patients", "start": 8, "end": 9}, {"entity_id": "12587815_2_Ent1", "role": "Effect", "text": "NMS", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "12587815_2_Ent2", "text": "lithium", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12587815_2_Ent4", "text": "lithium", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12587815_2_Ent6", "text": "lithium", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12587815_2_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12587815_2_Ent5", "text": "olanzapine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12587815_2_Ent7", "text": "olanzapine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12587815_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12587815_2_Ent1", "text": "NMS", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12587815_3", "wnd_id": "12587815_3_1", "text": "Neuroleptic malignant syndrome in an adolescent receiving olanzapine - lithium combination therapy .", "tokens": ["Neuroleptic", "malignant", "syndrome", "in", "an", "adolescent", "receiving", "olanzapine", "-", "lithium", "combination", "therapy", "."], "event_mentions": [{"id": "12587815_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 6, "end": 7}, "arguments": [{"entity_id": "12587815_3_Ent1", "role": "Effect", "text": "Neuroleptic malignant syndrome", "start": 0, "end": 3}, {"entity_id": "12587815_3_Ent0", "role": "Subject", "text": "adolescent", "start": 5, "end": 6}, {"entity_id": "12587815_3_Ent3", "role": "Treatment_Drug", "text": "olanzapine", "start": 7, "end": 8}, {"entity_id": "12587815_3_Ent6", "role": "Combination_Drug", "text": "olanzapine", "start": 7, "end": 8}, {"entity_id": "12587815_3_Ent2", "role": "Treatment", "text": "olanzapine - lithium combination therapy", "start": 7, "end": 12}, {"entity_id": "12587815_3_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 9, "end": 10}, {"entity_id": "12587815_3_Ent5", "role": "Combination_Drug", "text": "lithium", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "12587815_3_Ent1", "text": "Neuroleptic malignant syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12587815_3_Ent0", "text": "adolescent", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12587815_3_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12587815_3_Ent6", "text": "olanzapine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12587815_3_Ent2", "text": "olanzapine - lithium combination therapy", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "12587815_3_Ent4", "text": "lithium", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12587815_3_Ent5", "text": "lithium", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "1261772_3", "wnd_id": "1261772_3_1", "text": "These observations indicate that submassive hepatic necrosis may result from treatment with propylthiouracil and are consistent with the notion that sensitization mechanisms may be responsible for the hepatic injury induced by this drug .", "tokens": ["These", "observations", "indicate", "that", "submassive", "hepatic", "necrosis", "may", "result", "from", "treatment", "with", "propylthiouracil", "and", "are", "consistent", "with", "the", "notion", "that", "sensitization", "mechanisms", "may", "be", "responsible", "for", "the", "hepatic", "injury", "induced", "by", "this", "drug", "."], "event_mentions": [{"id": "1261772_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 8, "end": 9}, "arguments": [{"entity_id": "1261772_3_Ent0", "role": "Effect", "text": "submassive hepatic necrosis", "start": 4, "end": 7}, {"entity_id": "1261772_3_Ent1", "role": "Treatment", "text": "propylthiouracil", "start": 12, "end": 13}, {"entity_id": "1261772_3_Ent2", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "1261772_3_Ent0", "text": "submassive hepatic necrosis", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "1261772_3_Ent1", "text": "propylthiouracil", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1261772_3_Ent2", "text": "propylthiouracil", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12625995_1", "wnd_id": "12625995_1_1", "text": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents , particularly clozapine , and is easily misdiagnosed in children .", "tokens": ["Akathisia", "is", "a", "relatively", "rare", "side", "effect", "with", "the", "newer", "atypical", "antipsychotic", "agents", ",", "particularly", "clozapine", ",", "and", "is", "easily", "misdiagnosed", "in", "children", "."], "event_mentions": [{"id": "12625995_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 7, "end": 8}, "arguments": [{"entity_id": "12625995_1_Ent1", "role": "Effect", "text": "Akathisia", "start": 0, "end": 1}, {"entity_id": "12625995_1_Ent2", "role": "Treatment", "text": "clozapine", "start": 15, "end": 16}, {"entity_id": "12625995_1_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 15, "end": 16}, {"entity_id": "12625995_1_Ent0", "role": "Subject", "text": "children", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "12625995_1_Ent1", "text": "Akathisia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12625995_1_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12625995_1_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12625995_1_Ent0", "text": "children", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "12656748_1", "wnd_id": "12656748_1_1", "text": "A 58 - yr - old male patient with essential thrombocythaemia ( ET ) developed chronic myeloid leukaemia ( CML ) after continuous uneventful treatment with hydroxyurea for 18 yr .", "tokens": ["A", "58", "-", "yr", "-", "old", "male", "patient", "with", "essential", "thrombocythaemia", "(", "ET", ")", "developed", "chronic", "myeloid", "leukaemia", "(", "CML", ")", "after", "continuous", "uneventful", "treatment", "with", "hydroxyurea", "for", "18", "yr", "."], "event_mentions": [{"id": "12656748_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "12656748_1_Ent0", "role": "Subject", "text": "A 58 - yr - old male patient with essential thrombocythaemia ( ET )", "start": 0, "end": 14}, {"entity_id": "12656748_1_Ent1", "role": "Subject_Age", "text": "58 - yr - old", "start": 1, "end": 6}, {"entity_id": "12656748_1_Ent2", "role": "Subject_Gender", "text": "male", "start": 6, "end": 7}, {"entity_id": "12656748_1_Ent5", "role": "Treatment_Disorder", "text": "essential thrombocythaemia ( ET )", "start": 9, "end": 14}, {"entity_id": "12656748_1_Ent3", "role": "Effect", "text": "chronic myeloid leukaemia ( CML )", "start": 15, "end": 21}, {"entity_id": "12656748_1_Ent4", "role": "Treatment", "text": "continuous uneventful treatment with hydroxyurea for 18 yr", "start": 22, "end": 30}, {"entity_id": "12656748_1_Ent6", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 26, "end": 27}, {"entity_id": "12656748_1_Ent7", "role": "Treatment_Duration", "text": "18 yr", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "12656748_1_Ent0", "text": "A 58 - yr - old male patient with essential thrombocythaemia ( ET )", "entity_type": "Entity", "start": 0, "end": 14}, {"id": "12656748_1_Ent1", "text": "58 - yr - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12656748_1_Ent2", "text": "male", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12656748_1_Ent5", "text": "essential thrombocythaemia ( ET )", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "12656748_1_Ent3", "text": "chronic myeloid leukaemia ( CML )", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "12656748_1_Ent4", "text": "continuous uneventful treatment with hydroxyurea for 18 yr", "entity_type": "Entity", "start": 22, "end": 30}, {"id": "12656748_1_Ent6", "text": "hydroxyurea", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "12656748_1_Ent7", "text": "18 yr", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "12661801_3", "wnd_id": "12661801_3_1", "text": "We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor ( G - CSF ) .", "tokens": ["We", "present", "the", "management", "of", "agranulocytosis", "and", "neutropenic", "sepsis", "secondary", "to", "carbimazole", "with", "recombinant", "human", "granulocyte", "colony", "stimulating", "factor", "(", "G", "-", "CSF", ")", "."], "event_mentions": [{"id": "12661801_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 9, "end": 10}, "arguments": [{"entity_id": "12661801_3_Ent0", "role": "Effect", "text": "agranulocytosis and neutropenic sepsis", "start": 5, "end": 9}, {"entity_id": "12661801_3_Ent2", "role": "Treatment_Drug", "text": "carbimazole", "start": 11, "end": 12}, {"entity_id": "12661801_3_Ent5", "role": "Combination_Drug", "text": "carbimazole", "start": 11, "end": 12}, {"entity_id": "12661801_3_Ent1", "role": "Treatment", "text": "carbimazole with recombinant human granulocyte colony stimulating factor ( G - CSF )", "start": 11, "end": 24}, {"entity_id": "12661801_3_Ent3", "role": "Treatment_Drug", "text": "recombinant human granulocyte colony stimulating factor", "start": 13, "end": 19}, {"entity_id": "12661801_3_Ent4", "role": "Combination_Drug", "text": "recombinant human granulocyte colony stimulating factor", "start": 13, "end": 19}]}], "entity_mentions": [{"id": "12661801_3_Ent0", "text": "agranulocytosis and neutropenic sepsis", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "12661801_3_Ent2", "text": "carbimazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12661801_3_Ent5", "text": "carbimazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12661801_3_Ent1", "text": "carbimazole with recombinant human granulocyte colony stimulating factor ( G - CSF )", "entity_type": "Entity", "start": 11, "end": 24}, {"id": "12661801_3_Ent3", "text": "recombinant human granulocyte colony stimulating factor", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "12661801_3_Ent4", "text": "recombinant human granulocyte colony stimulating factor", "entity_type": "Entity", "start": 13, "end": 19}], "lang": "en"}
{"doc_id": "12692521_2", "wnd_id": "12692521_2_1", "text": "We present two cases in which both patients suffered with CLS , which we believe was caused following administration of granulocyte colony - stimulating factor , to our knowledge not described in the intensive care patient previously .", "tokens": ["We", "present", "two", "cases", "in", "which", "both", "patients", "suffered", "with", "CLS", ",", "which", "we", "believe", "was", "caused", "following", "administration", "of", "granulocyte", "colony", "-", "stimulating", "factor", ",", "to", "our", "knowledge", "not", "described", "in", "the", "intensive", "care", "patient", "previously", "."], "event_mentions": [{"id": "12692521_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "administration", "start": 18, "end": 19}, "arguments": [{"entity_id": "12692521_2_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "12692521_2_Ent0", "role": "Subject", "text": "two cases in which both patients suffered with CLS", "start": 2, "end": 11}, {"entity_id": "12692521_2_Ent2", "role": "Effect", "text": "CLS", "start": 10, "end": 11}, {"entity_id": "12692521_2_Ent3", "role": "Treatment", "text": "granulocyte colony - stimulating factor", "start": 20, "end": 25}, {"entity_id": "12692521_2_Ent4", "role": "Treatment_Drug", "text": "granulocyte colony - stimulating factor", "start": 20, "end": 25}]}], "entity_mentions": [{"id": "12692521_2_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12692521_2_Ent0", "text": "two cases in which both patients suffered with CLS", "entity_type": "Entity", "start": 2, "end": 11}, {"id": "12692521_2_Ent2", "text": "CLS", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12692521_2_Ent3", "text": "granulocyte colony - stimulating factor", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "12692521_2_Ent4", "text": "granulocyte colony - stimulating factor", "entity_type": "Entity", "start": 20, "end": 25}], "lang": "en"}
{"doc_id": "12699871_3", "wnd_id": "12699871_3_1", "text": "Tacrolimus ( FK506 ) , an immunosuppressant , has been associated with mutism in adults after liver transplant .", "tokens": ["Tacrolimus", "(", "FK506", ")", ",", "an", "immunosuppressant", ",", "has", "been", "associated", "with", "mutism", "in", "adults", "after", "liver", "transplant", "."], "event_mentions": [{"id": "12699871_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 10, "end": 12}, "arguments": [{"entity_id": "12699871_3_Ent5", "role": "Treatment_Drug", "text": "Tacrolimus", "start": 0, "end": 1}, {"entity_id": "12699871_3_Ent4", "role": "Treatment", "text": "Tacrolimus ( FK506 ) , an immunosuppressant", "start": 0, "end": 7}, {"entity_id": "12699871_3_Ent3", "role": "Effect", "text": "mutism", "start": 12, "end": 13}, {"entity_id": "12699871_3_Ent1", "role": "Subject_Age", "text": "adults", "start": 14, "end": 15}, {"entity_id": "12699871_3_Ent0", "role": "Subject", "text": "adults after liver transplant", "start": 14, "end": 18}, {"entity_id": "12699871_3_Ent2", "role": "Subject_Disorder", "text": "liver transplant .", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "12699871_3_Ent5", "text": "Tacrolimus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12699871_3_Ent4", "text": "Tacrolimus ( FK506 ) , an immunosuppressant", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12699871_3_Ent3", "text": "mutism", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12699871_3_Ent1", "text": "adults", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12699871_3_Ent0", "text": "adults after liver transplant", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "12699871_3_Ent2", "text": "liver transplant .", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "12702914_2", "wnd_id": "12702914_2_1", "text": "Soon after introduction of insulin therapy , she developed severe anasarca , including marked peripheral oedema , ascites and pleural effusion .", "tokens": ["Soon", "after", "introduction", "of", "insulin", "therapy", ",", "she", "developed", "severe", "anasarca", ",", "including", "marked", "peripheral", "oedema", ",", "ascites", "and", "pleural", "effusion", "."], "event_mentions": [{"id": "12702914_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "12702914_2_Ent3", "role": "Treatment", "text": "insulin", "start": 4, "end": 5}, {"entity_id": "12702914_2_Ent4", "role": "Treatment_Drug", "text": "insulin", "start": 4, "end": 5}, {"entity_id": "12702914_2_Ent0", "role": "Subject", "text": "she", "start": 7, "end": 8}, {"entity_id": "12702914_2_Ent1", "role": "Subject_Gender", "text": "she", "start": 7, "end": 8}, {"entity_id": "12702914_2_Ent2", "role": "Effect", "text": "anasarca , including marked peripheral oedema , ascites and pleural effusion", "start": 10, "end": 21}]}], "entity_mentions": [{"id": "12702914_2_Ent3", "text": "insulin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12702914_2_Ent4", "text": "insulin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12702914_2_Ent0", "text": "she", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12702914_2_Ent1", "text": "she", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12702914_2_Ent2", "text": "anasarca , including marked peripheral oedema , ascites and pleural effusion", "entity_type": "Entity", "start": 10, "end": 21}], "lang": "en"}
{"doc_id": "12702914_5", "wnd_id": "12702914_5_1", "text": "While 40 mg / day of prednisolone improved hepatic dysfunction dramatically , her diabetic milieu deteriorated seriously .", "tokens": ["While", "40", "mg", "/", "day", "of", "prednisolone", "improved", "hepatic", "dysfunction", "dramatically", ",", "her", "diabetic", "milieu", "deteriorated", "seriously", "."], "event_mentions": [{"id": "12702914_5_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improved", "start": 7, "end": 8}, "arguments": [{"entity_id": "12702914_5_Ent8", "role": "Treatment_Dosage", "text": "40 mg / day", "start": 1, "end": 5}, {"entity_id": "12702914_5_Ent5", "role": "Treatment", "text": "40 mg / day of prednisolone", "start": 1, "end": 7}, {"entity_id": "12702914_5_Ent7", "role": "Treatment_Drug", "text": "prednisolone", "start": 6, "end": 7}, {"entity_id": "12702914_5_Ent6", "role": "Treatment_Disorder", "text": "hepatic dysfunction", "start": 8, "end": 10}]}, {"id": "12702914_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "deteriorated", "start": 15, "end": 16}, "arguments": [{"entity_id": "12702914_5_Ent4", "role": "Treatment_Dosage", "text": "40 mg / day", "start": 1, "end": 5}, {"entity_id": "12702914_5_Ent1", "role": "Treatment", "text": "40 mg / day of prednisolone", "start": 1, "end": 7}, {"entity_id": "12702914_5_Ent3", "role": "Treatment_Drug", "text": "prednisolone", "start": 6, "end": 7}, {"entity_id": "12702914_5_Ent2", "role": "Treatment_Disorder", "text": "hepatic dysfunction", "start": 8, "end": 10}, {"entity_id": "12702914_5_Ent0", "role": "Effect", "text": "diabetic milieu deteriorated", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "12702914_5_Ent4", "text": "40 mg / day", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "12702914_5_Ent8", "text": "40 mg / day", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "12702914_5_Ent1", "text": "40 mg / day of prednisolone", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "12702914_5_Ent5", "text": "40 mg / day of prednisolone", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "12702914_5_Ent3", "text": "prednisolone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12702914_5_Ent7", "text": "prednisolone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12702914_5_Ent2", "text": "hepatic dysfunction", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "12702914_5_Ent6", "text": "hepatic dysfunction", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "12702914_5_Ent0", "text": "diabetic milieu deteriorated", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "1275625_4", "wnd_id": "1275625_4_1", "text": "A case is reported in which severe hypocalcemia , with a low plasma parathyroid hormone ( PTH ) concentration , resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy .", "tokens": ["A", "case", "is", "reported", "in", "which", "severe", "hypocalcemia", ",", "with", "a", "low", "plasma", "parathyroid", "hormone", "(", "PTH", ")", "concentration", ",", "resulted", "from", "the", "therapeutic", "use", "of", "magnesium", "sulfate", "for", "toxemia", "of", "pregnancy", "."], "event_mentions": [{"id": "1275625_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 20, "end": 21}, "arguments": [{"entity_id": "1275625_4_Ent0", "role": "Effect", "text": "severe hypocalcemia , with a low plasma parathyroid hormone ( PTH ) concentration", "start": 6, "end": 19}, {"entity_id": "1275625_4_Ent1", "role": "Treatment", "text": "magnesium sulfate", "start": 26, "end": 28}, {"entity_id": "1275625_4_Ent3", "role": "Treatment_Drug", "text": "magnesium sulfate", "start": 26, "end": 28}, {"entity_id": "1275625_4_Ent2", "role": "Treatment_Disorder", "text": "toxemia of pregnancy", "start": 29, "end": 32}]}], "entity_mentions": [{"id": "1275625_4_Ent0", "text": "severe hypocalcemia , with a low plasma parathyroid hormone ( PTH ) concentration", "entity_type": "Entity", "start": 6, "end": 19}, {"id": "1275625_4_Ent1", "text": "magnesium sulfate", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "1275625_4_Ent3", "text": "magnesium sulfate", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "1275625_4_Ent2", "text": "toxemia of pregnancy", "entity_type": "Entity", "start": 29, "end": 32}], "lang": "en"}
{"doc_id": "12763355_3", "wnd_id": "12763355_3_1", "text": "This clinical course suggests that the sensorimotor polyneuropathy may have been caused by 5 - ASA .", "tokens": ["This", "clinical", "course", "suggests", "that", "the", "sensorimotor", "polyneuropathy", "may", "have", "been", "caused", "by", "5", "-", "ASA", "."], "event_mentions": [{"id": "12763355_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 11, "end": 12}, "arguments": [{"entity_id": "12763355_3_Ent0", "role": "Effect", "text": "sensorimotor polyneuropathy", "start": 6, "end": 8}, {"entity_id": "12763355_3_Ent1", "role": "Treatment", "text": "5 - ASA", "start": 13, "end": 16}, {"entity_id": "12763355_3_Ent2", "role": "Treatment_Drug", "text": "5 - ASA", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "12763355_3_Ent0", "text": "sensorimotor polyneuropathy", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "12763355_3_Ent1", "text": "5 - ASA", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "12763355_3_Ent2", "text": "5 - ASA", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "12792223_2", "wnd_id": "12792223_2_1", "text": "A lupus - like syndrome associated with infliximab therapy .", "tokens": ["A", "lupus", "-", "like", "syndrome", "associated", "with", "infliximab", "therapy", "."], "event_mentions": [{"id": "12792223_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "12792223_2_Ent0", "role": "Effect", "text": "A lupus - like syndrome", "start": 0, "end": 5}, {"entity_id": "12792223_2_Ent1", "role": "Treatment", "text": "infliximab", "start": 7, "end": 8}, {"entity_id": "12792223_2_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "12792223_2_Ent0", "text": "A lupus - like syndrome", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "12792223_2_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12792223_2_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "12796597_2", "wnd_id": "12796597_2_1", "text": "Despite the underlying hepatitis C , this case represents renal abnormalities consistent with IFNalpha therapy for CML .", "tokens": ["Despite", "the", "underlying", "hepatitis", "C", ",", "this", "case", "represents", "renal", "abnormalities", "consistent", "with", "IFNalpha", "therapy", "for", "CML", "."], "event_mentions": [{"id": "12796597_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "consistent", "start": 11, "end": 12}, "arguments": [{"entity_id": "12796597_2_Ent0", "role": "Subject", "text": "this case", "start": 6, "end": 8}, {"entity_id": "12796597_2_Ent1", "role": "Effect", "text": "renal abnormalities", "start": 9, "end": 11}, {"entity_id": "12796597_2_Ent3", "role": "Treatment_Drug", "text": "IFNalpha", "start": 13, "end": 14}, {"entity_id": "12796597_2_Ent2", "role": "Treatment", "text": "IFNalpha therapy", "start": 13, "end": 15}, {"entity_id": "12796597_2_Ent4", "role": "Treatment_Disorder", "text": "CML", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "12796597_2_Ent0", "text": "this case", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "12796597_2_Ent1", "text": "renal abnormalities", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "12796597_2_Ent3", "text": "IFNalpha", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12796597_2_Ent2", "text": "IFNalpha therapy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "12796597_2_Ent4", "text": "CML", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "12796597_4", "wnd_id": "12796597_4_1", "text": "The renal biopsy showed focal segmental glomerulosclerosis , which has only been previously reported in two cases of CML treated with IFNalpha .", "tokens": ["The", "renal", "biopsy", "showed", "focal", "segmental", "glomerulosclerosis", ",", "which", "has", "only", "been", "previously", "reported", "in", "two", "cases", "of", "CML", "treated", "with", "IFNalpha", "."], "event_mentions": [{"id": "12796597_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 13, "end": 14}, "arguments": [{"entity_id": "12796597_4_Ent2", "role": "Effect", "text": "The renal biopsy showed focal segmental glomerulosclerosis", "start": 0, "end": 7}, {"entity_id": "12796597_4_Ent1", "role": "Subject_Population", "text": "two", "start": 15, "end": 16}, {"entity_id": "12796597_4_Ent0", "role": "Subject", "text": "two cases", "start": 15, "end": 17}, {"entity_id": "12796597_4_Ent4", "role": "Treatment_Disorder", "text": "CML", "start": 18, "end": 19}, {"entity_id": "12796597_4_Ent3", "role": "Treatment", "text": "IFNalpha", "start": 21, "end": 22}, {"entity_id": "12796597_4_Ent5", "role": "Treatment_Drug", "text": "IFNalpha", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "12796597_4_Ent2", "text": "The renal biopsy showed focal segmental glomerulosclerosis", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12796597_4_Ent1", "text": "two", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12796597_4_Ent0", "text": "two cases", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "12796597_4_Ent4", "text": "CML", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12796597_4_Ent3", "text": "IFNalpha", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "12796597_4_Ent5", "text": "IFNalpha", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "12802933_1", "wnd_id": "12802933_1_1", "text": "Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder .", "tokens": ["Severe", "autoimmune", "hemolytic", "anemia", "following", "rituximab", "therapy", "in", "a", "patient", "with", "a", "lymphoproliferative", "disorder", "."], "event_mentions": [{"id": "12802933_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 4, "end": 5}, "arguments": [{"entity_id": "12802933_1_Ent1", "role": "Effect", "text": "Severe autoimmune hemolytic anemia", "start": 0, "end": 4}, {"entity_id": "12802933_1_Ent3", "role": "Treatment_Drug", "text": "rituximab", "start": 5, "end": 6}, {"entity_id": "12802933_1_Ent2", "role": "Treatment", "text": "rituximab therapy", "start": 5, "end": 7}, {"entity_id": "12802933_1_Ent0", "role": "Subject", "text": "a patient with a lymphoproliferative disorder", "start": 8, "end": 14}, {"entity_id": "12802933_1_Ent4", "role": "Treatment_Disorder", "text": "lymphoproliferative disorder", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "12802933_1_Ent1", "text": "Severe autoimmune hemolytic anemia", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12802933_1_Ent3", "text": "rituximab", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12802933_1_Ent2", "text": "rituximab therapy", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12802933_1_Ent0", "text": "a patient with a lymphoproliferative disorder", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "12802933_1_Ent4", "text": "lymphoproliferative disorder", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "12811715_4", "wnd_id": "12811715_4_1", "text": "We describe 3 cases of diphenhydramine - induced cardiac toxicity that were responsive to bicarbonate .", "tokens": ["We", "describe", "3", "cases", "of", "diphenhydramine", "-", "induced", "cardiac", "toxicity", "that", "were", "responsive", "to", "bicarbonate", "."], "event_mentions": [{"id": "12811715_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "12811715_4_Ent1", "role": "Subject_Population", "text": "3", "start": 2, "end": 3}, {"entity_id": "12811715_4_Ent0", "role": "Subject", "text": "3 cases", "start": 2, "end": 4}, {"entity_id": "12811715_4_Ent3", "role": "Treatment", "text": "diphenhydramine", "start": 5, "end": 6}, {"entity_id": "12811715_4_Ent4", "role": "Treatment_Drug", "text": "diphenhydramine", "start": 5, "end": 6}, {"entity_id": "12811715_4_Ent2", "role": "Effect", "text": "cardiac toxicity", "start": 8, "end": 10}]}, {"id": "12811715_4_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "responsive", "start": 12, "end": 13}, "arguments": [{"entity_id": "12811715_4_Ent6", "role": "Subject_Population", "text": "3", "start": 2, "end": 3}, {"entity_id": "12811715_4_Ent5", "role": "Subject", "text": "3 cases", "start": 2, "end": 4}, {"entity_id": "12811715_4_Ent8", "role": "Treatment_Disorder", "text": "diphenhydramine - induced cardiac toxicity", "start": 5, "end": 10}, {"entity_id": "12811715_4_Ent7", "role": "Treatment", "text": "bicarbonate", "start": 14, "end": 15}, {"entity_id": "12811715_4_Ent9", "role": "Treatment_Drug", "text": "bicarbonate", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "12811715_4_Ent1", "text": "3", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12811715_4_Ent6", "text": "3", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12811715_4_Ent0", "text": "3 cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "12811715_4_Ent5", "text": "3 cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "12811715_4_Ent3", "text": "diphenhydramine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12811715_4_Ent4", "text": "diphenhydramine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12811715_4_Ent8", "text": "diphenhydramine - induced cardiac toxicity", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "12811715_4_Ent2", "text": "cardiac toxicity", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "12811715_4_Ent7", "text": "bicarbonate", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12811715_4_Ent9", "text": "bicarbonate", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "12880504_2", "wnd_id": "12880504_2_1", "text": "Obsessive - compulsive symptoms suddenly emerged 10 days after starting risperidone and resolved within 3 days of discontinuation .", "tokens": ["Obsessive", "-", "compulsive", "symptoms", "suddenly", "emerged", "10", "days", "after", "starting", "risperidone", "and", "resolved", "within", "3", "days", "of", "discontinuation", "."], "event_mentions": [{"id": "12880504_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "emerged", "start": 5, "end": 6}, "arguments": [{"entity_id": "12880504_2_Ent0", "role": "Effect", "text": "Obsessive - compulsive symptoms", "start": 0, "end": 4}, {"entity_id": "12880504_2_Ent1", "role": "Treatment", "text": "risperidone", "start": 10, "end": 11}, {"entity_id": "12880504_2_Ent2", "role": "Treatment_Drug", "text": "risperidone", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "12880504_2_Ent0", "text": "Obsessive - compulsive symptoms", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12880504_2_Ent1", "text": "risperidone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12880504_2_Ent2", "text": "risperidone", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "12889716_2", "wnd_id": "12889716_2_1", "text": "Only one case of a generalized maculopapular rash with enoxaparin has been reported in Europe .", "tokens": ["Only", "one", "case", "of", "a", "generalized", "maculopapular", "rash", "with", "enoxaparin", "has", "been", "reported", "in", "Europe", "."], "event_mentions": [{"id": "12889716_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 8, "end": 9}, "arguments": [{"entity_id": "12889716_2_Ent1", "role": "Subject_Population", "text": "one", "start": 1, "end": 2}, {"entity_id": "12889716_2_Ent0", "role": "Subject", "text": "one case", "start": 1, "end": 3}, {"entity_id": "12889716_2_Ent2", "role": "Effect", "text": "generalized maculopapular rash", "start": 5, "end": 8}, {"entity_id": "12889716_2_Ent3", "role": "Treatment", "text": "enoxaparin", "start": 9, "end": 10}, {"entity_id": "12889716_2_Ent4", "role": "Treatment_Drug", "text": "enoxaparin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "12889716_2_Ent1", "text": "one", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "12889716_2_Ent0", "text": "one case", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "12889716_2_Ent2", "text": "generalized maculopapular rash", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "12889716_2_Ent3", "text": "enoxaparin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12889716_2_Ent4", "text": "enoxaparin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "12921505_4", "wnd_id": "12921505_4_1", "text": "OBJECTIVE : To report a case of significant hepatic and renal failure with the use of argatroban in a patient with heparin - induced thrombocytopenia ( HIT ) requiring continuous veno - veno hemodialysis ( CVVHD ) .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "significant", "hepatic", "and", "renal", "failure", "with", "the", "use", "of", "argatroban", "in", "a", "patient", "with", "heparin", "-", "induced", "thrombocytopenia", "(", "HIT", ")", "requiring", "continuous", "veno", "-", "veno", "hemodialysis", "(", "CVVHD", ")", "."], "event_mentions": [{"id": "12921505_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "use", "start": 14, "end": 15}, "arguments": [{"entity_id": "12921505_4_Ent2", "role": "Effect", "text": "significant hepatic and renal failure", "start": 7, "end": 12}, {"entity_id": "12921505_4_Ent3", "role": "Treatment", "text": "argatroban", "start": 16, "end": 17}, {"entity_id": "12921505_4_Ent4", "role": "Treatment_Drug", "text": "argatroban", "start": 16, "end": 17}, {"entity_id": "12921505_4_Ent0", "role": "Subject", "text": "a patient with heparin - induced thrombocytopenia ( HIT ) requiring continuous veno - veno hemodialysis ( CVVHD )", "start": 18, "end": 37}, {"entity_id": "12921505_4_Ent1", "role": "Subject_Disorder", "text": "heparin - induced thrombocytopenia ( HIT )", "start": 21, "end": 28}]}, {"id": "12921505_4_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 23, "end": 24}, "arguments": [{"entity_id": "12921505_4_Ent6", "role": "Treatment", "text": "heparin", "start": 21, "end": 22}, {"entity_id": "12921505_4_Ent7", "role": "Treatment_Drug", "text": "heparin", "start": 21, "end": 22}, {"entity_id": "12921505_4_Ent5", "role": "Effect", "text": "thrombocytopenia", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "12921505_4_Ent2", "text": "significant hepatic and renal failure", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "12921505_4_Ent3", "text": "argatroban", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12921505_4_Ent4", "text": "argatroban", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12921505_4_Ent0", "text": "a patient with heparin - induced thrombocytopenia ( HIT ) requiring continuous veno - veno hemodialysis ( CVVHD )", "entity_type": "Entity", "start": 18, "end": 37}, {"id": "12921505_4_Ent6", "text": "heparin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "12921505_4_Ent7", "text": "heparin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "12921505_4_Ent1", "text": "heparin - induced thrombocytopenia ( HIT )", "entity_type": "Entity", "start": 21, "end": 28}, {"id": "12921505_4_Ent5", "text": "thrombocytopenia", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "12923827_3", "wnd_id": "12923827_3_1", "text": "This communication describes a patient who developed Schneiderian first - rank symptoms in the course of treatment with fluvoxamine .", "tokens": ["This", "communication", "describes", "a", "patient", "who", "developed", "Schneiderian", "first", "-", "rank", "symptoms", "in", "the", "course", "of", "treatment", "with", "fluvoxamine", "."], "event_mentions": [{"id": "12923827_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "12923827_3_Ent0", "role": "Subject", "text": "a patient", "start": 3, "end": 5}, {"entity_id": "12923827_3_Ent1", "role": "Effect", "text": "Schneiderian first - rank symptoms", "start": 7, "end": 12}, {"entity_id": "12923827_3_Ent2", "role": "Treatment", "text": "fluvoxamine", "start": 18, "end": 19}, {"entity_id": "12923827_3_Ent3", "role": "Treatment_Drug", "text": "fluvoxamine", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "12923827_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "12923827_3_Ent1", "text": "Schneiderian first - rank symptoms", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "12923827_3_Ent2", "text": "fluvoxamine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12923827_3_Ent3", "text": "fluvoxamine", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "12927328_1", "wnd_id": "12927328_1_1", "text": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS .", "tokens": ["We", "present", "a", "surprising", "case", "of", "a", "woman", "schizophrenic", "patient", "treated", "with", "clozapine", "suffering", "from", "EPS", "."], "event_mentions": [{"id": "12927328_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffering", "start": 13, "end": 14}, "arguments": [{"entity_id": "12927328_1_Ent0", "role": "Subject", "text": "a woman schizophrenic patient", "start": 6, "end": 10}, {"entity_id": "12927328_1_Ent1", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "12927328_1_Ent4", "role": "Treatment_Disorder", "text": "schizophrenic", "start": 8, "end": 9}, {"entity_id": "12927328_1_Ent3", "role": "Treatment", "text": "clozapine", "start": 12, "end": 13}, {"entity_id": "12927328_1_Ent5", "role": "Treatment_Drug", "text": "clozapine", "start": 12, "end": 13}, {"entity_id": "12927328_1_Ent2", "role": "Effect", "text": "EPS", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "12927328_1_Ent0", "text": "a woman schizophrenic patient", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "12927328_1_Ent1", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12927328_1_Ent4", "text": "schizophrenic", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12927328_1_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12927328_1_Ent5", "text": "clozapine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12927328_1_Ent2", "text": "EPS", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "12932249_3", "wnd_id": "12932249_3_1", "text": "We describe two dark - skinned patients who developed hyperpigmented skin and tongue lesions during combination therapy with IFN and ribavirin .", "tokens": ["We", "describe", "two", "dark", "-", "skinned", "patients", "who", "developed", "hyperpigmented", "skin", "and", "tongue", "lesions", "during", "combination", "therapy", "with", "IFN", "and", "ribavirin", "."], "event_mentions": [{"id": "12932249_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 14, "end": 15}, "arguments": [{"entity_id": "12932249_3_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "12932249_3_Ent0", "role": "Subject", "text": "two dark - skinned patients", "start": 2, "end": 7}, {"entity_id": "12932249_3_Ent2", "role": "Subject_Race", "text": "dark - skinned", "start": 3, "end": 6}, {"entity_id": "12932249_3_Ent3", "role": "Effect", "text": "hyperpigmented skin and tongue lesions", "start": 9, "end": 14}, {"entity_id": "12932249_3_Ent4", "role": "Treatment", "text": "combination therapy with IFN and ribavirin .", "start": 15, "end": 22}, {"entity_id": "12932249_3_Ent5", "role": "Treatment_Drug", "text": "IFN", "start": 18, "end": 19}, {"entity_id": "12932249_3_Ent7", "role": "Combination_Drug", "text": "IFN", "start": 18, "end": 19}, {"entity_id": "12932249_3_Ent6", "role": "Treatment_Drug", "text": "ribavirin", "start": 20, "end": 21}, {"entity_id": "12932249_3_Ent8", "role": "Combination_Drug", "text": "ribavirin", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "12932249_3_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12932249_3_Ent0", "text": "two dark - skinned patients", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "12932249_3_Ent2", "text": "dark - skinned", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "12932249_3_Ent3", "text": "hyperpigmented skin and tongue lesions", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "12932249_3_Ent4", "text": "combination therapy with IFN and ribavirin .", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "12932249_3_Ent5", "text": "IFN", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12932249_3_Ent7", "text": "IFN", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12932249_3_Ent6", "text": "ribavirin", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "12932249_3_Ent8", "text": "ribavirin", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "12944250_3", "wnd_id": "12944250_3_1", "text": "Thrombocytosis under ciprofloxacin and tazobactam / piperacillin .", "tokens": ["Thrombocytosis", "under", "ciprofloxacin", "and", "tazobactam", "/", "piperacillin", "."], "event_mentions": [{"id": "12944250_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "under", "start": 1, "end": 2}, "arguments": [{"entity_id": "12944250_3_Ent0", "role": "Effect", "text": "Thrombocytosis", "start": 0, "end": 1}, {"entity_id": "12944250_3_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 2, "end": 3}, {"entity_id": "12944250_3_Ent5", "role": "Combination_Drug", "text": "ciprofloxacin", "start": 2, "end": 3}, {"entity_id": "12944250_3_Ent1", "role": "Treatment", "text": "ciprofloxacin and tazobactam / piperacillin", "start": 2, "end": 7}, {"entity_id": "12944250_3_Ent3", "role": "Treatment_Drug", "text": "tazobactam", "start": 4, "end": 5}, {"entity_id": "12944250_3_Ent6", "role": "Combination_Drug", "text": "tazobactam", "start": 4, "end": 5}, {"entity_id": "12944250_3_Ent4", "role": "Treatment_Drug", "text": "piperacillin", "start": 6, "end": 7}, {"entity_id": "12944250_3_Ent7", "role": "Combination_Drug", "text": "piperacillin", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "12944250_3_Ent0", "text": "Thrombocytosis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12944250_3_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12944250_3_Ent5", "text": "ciprofloxacin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12944250_3_Ent1", "text": "ciprofloxacin and tazobactam / piperacillin", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "12944250_3_Ent3", "text": "tazobactam", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12944250_3_Ent6", "text": "tazobactam", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12944250_3_Ent4", "text": "piperacillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12944250_3_Ent7", "text": "piperacillin", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "12951892_2", "wnd_id": "12951892_2_1", "text": "The newborn manifested a four day course of lethargy with unexplained high lithium levels in the adult toxic range .", "tokens": ["The", "newborn", "manifested", "a", "four", "day", "course", "of", "lethargy", "with", "unexplained", "high", "lithium", "levels", "in", "the", "adult", "toxic", "range", "."], "event_mentions": [{"id": "12951892_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "manifested", "start": 2, "end": 3}, "arguments": [{"entity_id": "12951892_2_Ent0", "role": "Subject", "text": "newborn", "start": 1, "end": 2}, {"entity_id": "12951892_2_Ent1", "role": "Subject_Age", "text": "newborn", "start": 1, "end": 2}, {"entity_id": "12951892_2_Ent2", "role": "Effect", "text": "four day course of lethargy with unexplained high lithium levels", "start": 4, "end": 14}, {"entity_id": "12951892_2_Ent3", "role": "Treatment", "text": "lithium", "start": 12, "end": 13}, {"entity_id": "12951892_2_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "12951892_2_Ent0", "text": "newborn", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "12951892_2_Ent1", "text": "newborn", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "12951892_2_Ent2", "text": "four day course of lethargy with unexplained high lithium levels", "entity_type": "Entity", "start": 4, "end": 14}, {"id": "12951892_2_Ent3", "text": "lithium", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12951892_2_Ent4", "text": "lithium", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "1295628_1", "wnd_id": "1295628_1_1", "text": "Carbamazepine - induced systemic lupus erythematosus - like disease .", "tokens": ["Carbamazepine", "-", "induced", "systemic", "lupus", "erythematosus", "-", "like", "disease", "."], "event_mentions": [{"id": "1295628_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "1295628_1_Ent1", "role": "Treatment", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "1295628_1_Ent2", "role": "Treatment_Drug", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "1295628_1_Ent0", "role": "Effect", "text": "systemic lupus erythematosus - like disease", "start": 3, "end": 9}]}], "entity_mentions": [{"id": "1295628_1_Ent1", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1295628_1_Ent2", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1295628_1_Ent0", "text": "systemic lupus erythematosus - like disease", "entity_type": "Entity", "start": 3, "end": 9}], "lang": "en"}
{"doc_id": "1295628_3", "wnd_id": "1295628_3_1", "text": "Clinical symptoms and leukopenia normalized after discontinuation of CBZ and administration of prednisolone at 40 mg .", "tokens": ["Clinical", "symptoms", "and", "leukopenia", "normalized", "after", "discontinuation", "of", "CBZ", "and", "administration", "of", "prednisolone", "at", "40", "mg", "."], "event_mentions": [{"id": "1295628_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "normalized", "start": 4, "end": 5}, "arguments": [{"entity_id": "1295628_3_Ent0", "role": "Effect", "text": "Clinical symptoms and leukopenia normalized", "start": 0, "end": 5}, {"entity_id": "1295628_3_Ent1", "role": "Treatment", "text": "discontinuation of CBZ and administration of prednisolone at 40 mg", "start": 6, "end": 16}, {"entity_id": "1295628_3_Ent2", "role": "Treatment_Drug", "text": "CBZ", "start": 8, "end": 9}, {"entity_id": "1295628_3_Ent5", "role": "Combination_Drug", "text": "CBZ", "start": 8, "end": 9}, {"entity_id": "1295628_3_Ent3", "role": "Treatment_Drug", "text": "prednisolone", "start": 12, "end": 13}, {"entity_id": "1295628_3_Ent6", "role": "Combination_Drug", "text": "prednisolone", "start": 12, "end": 13}, {"entity_id": "1295628_3_Ent4", "role": "Treatment_Dosage", "text": "40 mg", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "1295628_3_Ent0", "text": "Clinical symptoms and leukopenia normalized", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "1295628_3_Ent1", "text": "discontinuation of CBZ and administration of prednisolone at 40 mg", "entity_type": "Entity", "start": 6, "end": 16}, {"id": "1295628_3_Ent2", "text": "CBZ", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1295628_3_Ent5", "text": "CBZ", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1295628_3_Ent3", "text": "prednisolone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1295628_3_Ent6", "text": "prednisolone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1295628_3_Ent4", "text": "40 mg", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "1348483_3", "wnd_id": "1348483_3_1", "text": "Thus cabergoline may cause similar pleuropulmonary abnormalities to bromocriptine .", "tokens": ["Thus", "cabergoline", "may", "cause", "similar", "pleuropulmonary", "abnormalities", "to", "bromocriptine", "."], "event_mentions": [{"id": "1348483_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 3, "end": 4}, "arguments": [{"entity_id": "1348483_3_Ent2", "role": "Treatment", "text": "cabergoline", "start": 1, "end": 2}, {"entity_id": "1348483_3_Ent3", "role": "Treatment_Drug", "text": "cabergoline", "start": 1, "end": 2}, {"entity_id": "1348483_3_Ent0", "role": "Effect", "text": "pleuropulmonary abnormalities", "start": 5, "end": 7}, {"entity_id": "1348483_3_Ent1", "role": "Treatment", "text": "bromocriptine", "start": 8, "end": 9}, {"entity_id": "1348483_3_Ent4", "role": "Treatment_Drug", "text": "bromocriptine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "1348483_3_Ent2", "text": "cabergoline", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "1348483_3_Ent3", "text": "cabergoline", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "1348483_3_Ent0", "text": "pleuropulmonary abnormalities", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "1348483_3_Ent1", "text": "bromocriptine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1348483_3_Ent4", "text": "bromocriptine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "1359782_3", "wnd_id": "1359782_3_1", "text": "Sulfasalazine - induced lung disorder is an extremely rare entity which must be considered in all ulcerative colitis patients while on sulfasalazine therapy , despite the absence of pulmonary symptomatology .", "tokens": ["Sulfasalazine", "-", "induced", "lung", "disorder", "is", "an", "extremely", "rare", "entity", "which", "must", "be", "considered", "in", "all", "ulcerative", "colitis", "patients", "while", "on", "sulfasalazine", "therapy", ",", "despite", "the", "absence", "of", "pulmonary", "symptomatology", "."], "event_mentions": [{"id": "1359782_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "1359782_3_Ent1", "role": "Treatment", "text": "Sulfasalazine", "start": 0, "end": 1}, {"entity_id": "1359782_3_Ent2", "role": "Treatment_Disorder", "text": "Sulfasalazine", "start": 0, "end": 1}, {"entity_id": "1359782_3_Ent0", "role": "Effect", "text": "lung disorder", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "1359782_3_Ent1", "text": "Sulfasalazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1359782_3_Ent2", "text": "Sulfasalazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1359782_3_Ent0", "text": "lung disorder", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "13680140_1", "wnd_id": "13680140_1_1", "text": "Reversible sclerotic changes of lumbar spine and femur due to long - term oral isotretinoin therapy .", "tokens": ["Reversible", "sclerotic", "changes", "of", "lumbar", "spine", "and", "femur", "due", "to", "long", "-", "term", "oral", "isotretinoin", "therapy", "."], "event_mentions": [{"id": "13680140_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 8, "end": 9}, "arguments": [{"entity_id": "13680140_1_Ent0", "role": "Effect", "text": "Reversible sclerotic changes of lumbar spine and femur", "start": 0, "end": 8}, {"entity_id": "13680140_1_Ent4", "role": "Treatment_Duration", "text": "long - term", "start": 10, "end": 13}, {"entity_id": "13680140_1_Ent1", "role": "Treatment", "text": "long - term oral isotretinoin", "start": 10, "end": 15}, {"entity_id": "13680140_1_Ent3", "role": "Treatment_Route", "text": "oral", "start": 13, "end": 14}, {"entity_id": "13680140_1_Ent2", "role": "Treatment_Drug", "text": "isotretinoin", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "13680140_1_Ent0", "text": "Reversible sclerotic changes of lumbar spine and femur", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "13680140_1_Ent4", "text": "long - term", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "13680140_1_Ent1", "text": "long - term oral isotretinoin", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "13680140_1_Ent3", "text": "oral", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "13680140_1_Ent2", "text": "isotretinoin", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "1378497_3", "wnd_id": "1378497_3_1", "text": "Scleroderma in association with the use of bleomycin : a report of 3 cases .", "tokens": ["Scleroderma", "in", "association", "with", "the", "use", "of", "bleomycin", ":", "a", "report", "of", "3", "cases", "."], "event_mentions": [{"id": "1378497_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 2, "end": 3}, "arguments": [{"entity_id": "1378497_3_Ent2", "role": "Effect", "text": "Scleroderma", "start": 0, "end": 1}, {"entity_id": "1378497_3_Ent3", "role": "Treatment", "text": "bleomycin", "start": 7, "end": 8}, {"entity_id": "1378497_3_Ent4", "role": "Treatment_Drug", "text": "bleomycin", "start": 7, "end": 8}, {"entity_id": "1378497_3_Ent1", "role": "Subject_Population", "text": "3", "start": 12, "end": 13}, {"entity_id": "1378497_3_Ent0", "role": "Subject", "text": "3 cases", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "1378497_3_Ent2", "text": "Scleroderma", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1378497_3_Ent3", "text": "bleomycin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1378497_3_Ent4", "text": "bleomycin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1378497_3_Ent1", "text": "3", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1378497_3_Ent0", "text": "3 cases", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "1393348_1", "wnd_id": "1393348_1_1", "text": "A 21 - year - old woman suffering from bipolar affective disorder developed systemic lupus erythematosus ( SLE ) with characteristic laboratory findings , 18 months after starting carbamazepine maintenance treatment .", "tokens": ["A", "21", "-", "year", "-", "old", "woman", "suffering", "from", "bipolar", "affective", "disorder", "developed", "systemic", "lupus", "erythematosus", "(", "SLE", ")", "with", "characteristic", "laboratory", "findings", ",", "18", "months", "after", "starting", "carbamazepine", "maintenance", "treatment", "."], "event_mentions": [{"id": "1393348_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "1393348_1_Ent0", "role": "Subject", "text": "A 21 - year - old woman suffering from bipolar affective disorder", "start": 0, "end": 12}, {"entity_id": "1393348_1_Ent1", "role": "Subject_Age", "text": "21 - year - old", "start": 1, "end": 6}, {"entity_id": "1393348_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "1393348_1_Ent5", "role": "Treatment_Disorder", "text": "bipolar affective disorder", "start": 9, "end": 12}, {"entity_id": "1393348_1_Ent3", "role": "Effect", "text": "systemic lupus erythematosus ( SLE )", "start": 13, "end": 19}, {"entity_id": "1393348_1_Ent6", "role": "Treatment_Time_elapsed", "text": "18 months", "start": 24, "end": 26}, {"entity_id": "1393348_1_Ent4", "role": "Treatment", "text": "18 months after starting carbamazepine maintenance treatment", "start": 24, "end": 31}, {"entity_id": "1393348_1_Ent7", "role": "Treatment_Drug", "text": "carbamazepine", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "1393348_1_Ent0", "text": "A 21 - year - old woman suffering from bipolar affective disorder", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "1393348_1_Ent1", "text": "21 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "1393348_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1393348_1_Ent5", "text": "bipolar affective disorder", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "1393348_1_Ent3", "text": "systemic lupus erythematosus ( SLE )", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "1393348_1_Ent6", "text": "18 months", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "1393348_1_Ent4", "text": "18 months after starting carbamazepine maintenance treatment", "entity_type": "Entity", "start": 24, "end": 31}, {"id": "1393348_1_Ent7", "text": "carbamazepine", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "1420650_1", "wnd_id": "1420650_1_1", "text": "Asterixis induced by carbamazepine therapy .", "tokens": ["Asterixis", "induced", "by", "carbamazepine", "therapy", "."], "event_mentions": [{"id": "1420650_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "1420650_1_Ent0", "role": "Effect", "text": "Asterixis", "start": 0, "end": 1}, {"entity_id": "1420650_1_Ent1", "role": "Treatment", "text": "carbamazepine", "start": 3, "end": 4}, {"entity_id": "1420650_1_Ent2", "role": "Treatment_Drug", "text": "carbamazepine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "1420650_1_Ent0", "text": "Asterixis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1420650_1_Ent1", "text": "carbamazepine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1420650_1_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "1433432_2", "wnd_id": "1433432_2_1", "text": "We report a case of hyponatremia associated with a grand mal seizure in a 28 month - old child after intra - nasal desmopressin administration for high fluid intake with nocturnal enuresis .", "tokens": ["We", "report", "a", "case", "of", "hyponatremia", "associated", "with", "a", "grand", "mal", "seizure", "in", "a", "28", "month", "-", "old", "child", "after", "intra", "-", "nasal", "desmopressin", "administration", "for", "high", "fluid", "intake", "with", "nocturnal", "enuresis", "."], "event_mentions": [{"id": "1433432_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 19, "end": 20}, "arguments": [{"entity_id": "1433432_2_Ent2", "role": "Effect", "text": "hyponatremia associated with a grand mal seizure", "start": 5, "end": 12}, {"entity_id": "1433432_2_Ent0", "role": "Subject", "text": "a 28 month - old child", "start": 13, "end": 19}, {"entity_id": "1433432_2_Ent1", "role": "Subject_Age", "text": "28 month - old child", "start": 14, "end": 19}, {"entity_id": "1433432_2_Ent6", "role": "Treatment_Route", "text": "intra - nasal", "start": 20, "end": 23}, {"entity_id": "1433432_2_Ent3", "role": "Treatment", "text": "intra - nasal desmopressin administration", "start": 20, "end": 25}, {"entity_id": "1433432_2_Ent5", "role": "Treatment_Drug", "text": "desmopressin", "start": 23, "end": 24}, {"entity_id": "1433432_2_Ent4", "role": "Treatment_Disorder", "text": "high fluid intake with nocturnal enuresis", "start": 26, "end": 32}]}], "entity_mentions": [{"id": "1433432_2_Ent2", "text": "hyponatremia associated with a grand mal seizure", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "1433432_2_Ent0", "text": "a 28 month - old child", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "1433432_2_Ent1", "text": "28 month - old child", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "1433432_2_Ent6", "text": "intra - nasal", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "1433432_2_Ent3", "text": "intra - nasal desmopressin administration", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "1433432_2_Ent5", "text": "desmopressin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "1433432_2_Ent4", "text": "high fluid intake with nocturnal enuresis", "entity_type": "Entity", "start": 26, "end": 32}], "lang": "en"}
{"doc_id": "1445134_2", "wnd_id": "1445134_2_1", "text": "However , follow - up revealed that gestational diabetes when associated with norethisterone had a lesser risk of emerging diabetes mellitus and impaired glucose tolerance .", "tokens": ["However", ",", "follow", "-", "up", "revealed", "that", "gestational", "diabetes", "when", "associated", "with", "norethisterone", "had", "a", "lesser", "risk", "of", "emerging", "diabetes", "mellitus", "and", "impaired", "glucose", "tolerance", "."], "event_mentions": [{"id": "1445134_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "emerging", "start": 18, "end": 19}, "arguments": [{"entity_id": "1445134_2_Ent1", "role": "Treatment", "text": "norethisterone", "start": 12, "end": 13}, {"entity_id": "1445134_2_Ent2", "role": "Treatment_Drug", "text": "norethisterone", "start": 12, "end": 13}, {"entity_id": "1445134_2_Ent0", "role": "Effect", "text": "diabetes mellitus and impaired glucose tolerance", "start": 19, "end": 25}]}], "entity_mentions": [{"id": "1445134_2_Ent1", "text": "norethisterone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1445134_2_Ent2", "text": "norethisterone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1445134_2_Ent0", "text": "diabetes mellitus and impaired glucose tolerance", "entity_type": "Entity", "start": 19, "end": 25}], "lang": "en"}
{"doc_id": "1450506_1", "wnd_id": "1450506_1_1", "text": "An adverse reaction to IFN was strongly suspected as the cause of CHF .", "tokens": ["An", "adverse", "reaction", "to", "IFN", "was", "strongly", "suspected", "as", "the", "cause", "of", "CHF", "."], "event_mentions": [{"id": "1450506_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 10, "end": 11}, "arguments": [{"entity_id": "1450506_1_Ent1", "role": "Treatment", "text": "IFN", "start": 4, "end": 5}, {"entity_id": "1450506_1_Ent2", "role": "Treatment_Drug", "text": "IFN", "start": 4, "end": 5}, {"entity_id": "1450506_1_Ent0", "role": "Effect", "text": "CHF", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "1450506_1_Ent1", "text": "IFN", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1450506_1_Ent2", "text": "IFN", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1450506_1_Ent0", "text": "CHF", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "1450506_3", "wnd_id": "1450506_3_1", "text": "Sixteen hours after the first administration of IFN , IFN was suspended by the symptoms of congestive heart failure ( CHF ) .", "tokens": ["Sixteen", "hours", "after", "the", "first", "administration", "of", "IFN", ",", "IFN", "was", "suspended", "by", "the", "symptoms", "of", "congestive", "heart", "failure", "(", "CHF", ")", "."], "event_mentions": [{"id": "1450506_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suspended", "start": 11, "end": 12}, "arguments": [{"entity_id": "1450506_3_Ent1", "role": "Treatment", "text": "IFN", "start": 9, "end": 10}, {"entity_id": "1450506_3_Ent2", "role": "Treatment_Drug", "text": "IFN", "start": 9, "end": 10}, {"entity_id": "1450506_3_Ent0", "role": "Effect", "text": "congestive heart failure ( CHF )", "start": 16, "end": 22}]}], "entity_mentions": [{"id": "1450506_3_Ent1", "text": "IFN", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1450506_3_Ent2", "text": "IFN", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1450506_3_Ent0", "text": "congestive heart failure ( CHF )", "entity_type": "Entity", "start": 16, "end": 22}], "lang": "en"}
{"doc_id": "14530108_3", "wnd_id": "14530108_3_1", "text": "Surgeons and physicians should therefore be aware of the potential for RTA to occur with FK506 after any organ transplantation .", "tokens": ["Surgeons", "and", "physicians", "should", "therefore", "be", "aware", "of", "the", "potential", "for", "RTA", "to", "occur", "with", "FK506", "after", "any", "organ", "transplantation", "."], "event_mentions": [{"id": "14530108_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 13, "end": 14}, "arguments": [{"entity_id": "14530108_3_Ent0", "role": "Effect", "text": "RTA", "start": 11, "end": 12}, {"entity_id": "14530108_3_Ent2", "role": "Treatment_Drug", "text": "FK506", "start": 15, "end": 16}, {"entity_id": "14530108_3_Ent1", "role": "Treatment", "text": "FK506 after any organ transplantation", "start": 15, "end": 20}]}], "entity_mentions": [{"id": "14530108_3_Ent0", "text": "RTA", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14530108_3_Ent2", "text": "FK506", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "14530108_3_Ent1", "text": "FK506 after any organ transplantation", "entity_type": "Entity", "start": 15, "end": 20}], "lang": "en"}
{"doc_id": "14530108_4", "wnd_id": "14530108_4_1", "text": "The mechanism of RTA induced by FK506 has not yet been clearly elucidated .", "tokens": ["The", "mechanism", "of", "RTA", "induced", "by", "FK506", "has", "not", "yet", "been", "clearly", "elucidated", "."], "event_mentions": [{"id": "14530108_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "14530108_4_Ent0", "role": "Effect", "text": "RTA", "start": 3, "end": 4}, {"entity_id": "14530108_4_Ent1", "role": "Treatment", "text": "FK506", "start": 6, "end": 7}, {"entity_id": "14530108_4_Ent2", "role": "Treatment_Drug", "text": "FK506", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "14530108_4_Ent0", "text": "RTA", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14530108_4_Ent1", "text": "FK506", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14530108_4_Ent2", "text": "FK506", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "14561622_1", "wnd_id": "14561622_1_1", "text": "Neurotoxicity of intrathecal methotrexate : MR imaging findings .", "tokens": ["Neurotoxicity", "of", "intrathecal", "methotrexate", ":", "MR", "imaging", "findings", "."], "event_mentions": [{"id": "14561622_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 1, "end": 2}, "arguments": [{"entity_id": "14561622_1_Ent0", "role": "Effect", "text": "Neurotoxicity", "start": 0, "end": 1}, {"entity_id": "14561622_1_Ent2", "role": "Treatment_Route", "text": "intrathecal", "start": 2, "end": 3}, {"entity_id": "14561622_1_Ent1", "role": "Treatment", "text": "intrathecal methotrexate", "start": 2, "end": 4}, {"entity_id": "14561622_1_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "14561622_1_Ent0", "text": "Neurotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14561622_1_Ent2", "text": "intrathecal", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "14561622_1_Ent1", "text": "intrathecal methotrexate", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "14561622_1_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "14566215_1", "wnd_id": "14566215_1_1", "text": "In this article lithium is not discussed , although there are a number of concerns about lithium 's potential teratogenicity , and it has been implicated in Epstein 's anomaly , a congenital heart defect among infants born to women taking lithium ; as with other medications , however , the data have specific limitations .", "tokens": ["In", "this", "article", "lithium", "is", "not", "discussed", ",", "although", "there", "are", "a", "number", "of", "concerns", "about", "lithium", "'s", "potential", "teratogenicity", ",", "and", "it", "has", "been", "implicated", "in", "Epstein", "'s", "anomaly", ",", "a", "congenital", "heart", "defect", "among", "infants", "born", "to", "women", "taking", "lithium", ";", "as", "with", "other", "medications", ",", "however", ",", "the", "data", "have", "specific", "limitations", "."], "event_mentions": [{"id": "14566215_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "implicated", "start": 25, "end": 26}, "arguments": [{"entity_id": "14566215_1_Ent0", "role": "Effect", "text": "Epstein 's anomaly", "start": 27, "end": 30}, {"entity_id": "14566215_1_Ent1", "role": "Treatment", "text": "lithium", "start": 41, "end": 42}, {"entity_id": "14566215_1_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 41, "end": 42}]}], "entity_mentions": [{"id": "14566215_1_Ent0", "text": "Epstein 's anomaly", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "14566215_1_Ent1", "text": "lithium", "entity_type": "Entity", "start": 41, "end": 42}, {"id": "14566215_1_Ent2", "text": "lithium", "entity_type": "Entity", "start": 41, "end": 42}], "lang": "en"}
{"doc_id": "14585456_1", "wnd_id": "14585456_1_1", "text": "We present a case of a 20 - year - old woman who ingested 900 mg of glyburide causing refractory hypoglycemia resistant to treatment with intravenous dextrose , glucagon , and diazoxide .", "tokens": ["We", "present", "a", "case", "of", "a", "20", "-", "year", "-", "old", "woman", "who", "ingested", "900", "mg", "of", "glyburide", "causing", "refractory", "hypoglycemia", "resistant", "to", "treatment", "with", "intravenous", "dextrose", ",", "glucagon", ",", "and", "diazoxide", "."], "event_mentions": [{"id": "14585456_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "ingested", "start": 13, "end": 14}, "arguments": [{"entity_id": "14585456_1_Ent0", "role": "Subject", "text": "a 20 - year - old woman", "start": 5, "end": 12}, {"entity_id": "14585456_1_Ent1", "role": "Subject_Age", "text": "20 - year - old", "start": 6, "end": 11}, {"entity_id": "14585456_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 11, "end": 12}, {"entity_id": "14585456_1_Ent5", "role": "Treatment_Dosage", "text": "900 mg", "start": 14, "end": 16}, {"entity_id": "14585456_1_Ent4", "role": "Treatment", "text": "900 mg of glyburide", "start": 14, "end": 18}, {"entity_id": "14585456_1_Ent6", "role": "Treatment_Drug", "text": "glyburide", "start": 17, "end": 18}, {"entity_id": "14585456_1_Ent3", "role": "Effect", "text": "refractory hypoglycemia", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "14585456_1_Ent0", "text": "a 20 - year - old woman", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "14585456_1_Ent1", "text": "20 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "14585456_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14585456_1_Ent5", "text": "900 mg", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "14585456_1_Ent4", "text": "900 mg of glyburide", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "14585456_1_Ent6", "text": "glyburide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "14585456_1_Ent3", "text": "refractory hypoglycemia", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "14601701_2", "wnd_id": "14601701_2_1", "text": "Ethambutol is an antimicrobial agent used frequently to treat tuberculosis .", "tokens": ["Ethambutol", "is", "an", "antimicrobial", "agent", "used", "frequently", "to", "treat", "tuberculosis", "."], "event_mentions": [{"id": "14601701_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treat", "start": 8, "end": 9}, "arguments": [{"entity_id": "14601701_2_Ent0", "role": "Treatment", "text": "Ethambutol", "start": 0, "end": 1}, {"entity_id": "14601701_2_Ent2", "role": "Treatment_Drug", "text": "Ethambutol", "start": 0, "end": 1}, {"entity_id": "14601701_2_Ent1", "role": "Treatment_Disorder", "text": "tuberculosis", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "14601701_2_Ent0", "text": "Ethambutol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14601701_2_Ent2", "text": "Ethambutol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14601701_2_Ent1", "text": "tuberculosis", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "14601701_3", "wnd_id": "14601701_3_1", "text": "The most commonly recognized toxic effect of ethambutol is optic neuropathy , which generally is considered uncommon and reversible in medical literature .", "tokens": ["The", "most", "commonly", "recognized", "toxic", "effect", "of", "ethambutol", "is", "optic", "neuropathy", ",", "which", "generally", "is", "considered", "uncommon", "and", "reversible", "in", "medical", "literature", "."], "event_mentions": [{"id": "14601701_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "effect", "start": 5, "end": 6}, "arguments": [{"entity_id": "14601701_3_Ent1", "role": "Treatment", "text": "ethambutol", "start": 7, "end": 8}, {"entity_id": "14601701_3_Ent2", "role": "Treatment_Drug", "text": "ethambutol", "start": 7, "end": 8}, {"entity_id": "14601701_3_Ent0", "role": "Effect", "text": "optic neuropathy", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "14601701_3_Ent1", "text": "ethambutol", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14601701_3_Ent2", "text": "ethambutol", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14601701_3_Ent0", "text": "optic neuropathy", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "14607011_2", "wnd_id": "14607011_2_1", "text": "The case history and toxicological findings of an infant fatality involving pseudoephedrine , brompheniramine , and dextromethorphan are presented .", "tokens": ["The", "case", "history", "and", "toxicological", "findings", "of", "an", "infant", "fatality", "involving", "pseudoephedrine", ",", "brompheniramine", ",", "and", "dextromethorphan", "are", "presented", "."], "event_mentions": [{"id": "14607011_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "involving", "start": 10, "end": 11}, "arguments": [{"entity_id": "14607011_2_Ent0", "role": "Subject", "text": "an infant", "start": 7, "end": 9}, {"entity_id": "14607011_2_Ent1", "role": "Subject_Age", "text": "infant", "start": 8, "end": 9}, {"entity_id": "14607011_2_Ent2", "role": "Effect", "text": "infant fatality", "start": 8, "end": 10}, {"entity_id": "14607011_2_Ent4", "role": "Treatment_Drug", "text": "pseudoephedrine", "start": 11, "end": 12}, {"entity_id": "14607011_2_Ent3", "role": "Treatment", "text": "pseudoephedrine , brompheniramine , and dextromethorphan", "start": 11, "end": 17}, {"entity_id": "14607011_2_Ent5", "role": "Treatment_Drug", "text": "brompheniramine", "start": 13, "end": 14}, {"entity_id": "14607011_2_Ent6", "role": "Treatment_Drug", "text": "dextromethorphan", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "14607011_2_Ent0", "text": "an infant", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "14607011_2_Ent1", "text": "infant", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "14607011_2_Ent2", "text": "infant fatality", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "14607011_2_Ent4", "text": "pseudoephedrine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14607011_2_Ent3", "text": "pseudoephedrine , brompheniramine , and dextromethorphan", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "14607011_2_Ent5", "text": "brompheniramine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14607011_2_Ent6", "text": "dextromethorphan", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "14632592_4", "wnd_id": "14632592_4_1", "text": "In our patient , an objective causality scale showed that therapeutic doses of colchicine for FMF were the definite cause of myopathy , even though his renal and hepatic function were normal .", "tokens": ["In", "our", "patient", ",", "an", "objective", "causality", "scale", "showed", "that", "therapeutic", "doses", "of", "colchicine", "for", "FMF", "were", "the", "definite", "cause", "of", "myopathy", ",", "even", "though", "his", "renal", "and", "hepatic", "function", "were", "normal", "."], "event_mentions": [{"id": "14632592_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 19, "end": 20}, "arguments": [{"entity_id": "14632592_4_Ent0", "role": "Subject", "text": "our patient", "start": 1, "end": 3}, {"entity_id": "14632592_4_Ent7", "role": "Treatment_Dosage", "text": "therapeutic doses", "start": 10, "end": 12}, {"entity_id": "14632592_4_Ent4", "role": "Treatment", "text": "therapeutic doses of colchicine for FMF", "start": 10, "end": 16}, {"entity_id": "14632592_4_Ent5", "role": "Treatment_Drug", "text": "colchicine", "start": 13, "end": 14}, {"entity_id": "14632592_4_Ent6", "role": "Treatment_Disorder", "text": "FMF", "start": 15, "end": 16}, {"entity_id": "14632592_4_Ent3", "role": "Effect", "text": "myopathy", "start": 21, "end": 22}, {"entity_id": "14632592_4_Ent2", "role": "Subject_Gender", "text": "his", "start": 25, "end": 26}, {"entity_id": "14632592_4_Ent1", "role": "Subject", "text": "his renal and hepatic function were normal", "start": 25, "end": 32}]}], "entity_mentions": [{"id": "14632592_4_Ent0", "text": "our patient", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "14632592_4_Ent7", "text": "therapeutic doses", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "14632592_4_Ent4", "text": "therapeutic doses of colchicine for FMF", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "14632592_4_Ent5", "text": "colchicine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14632592_4_Ent6", "text": "FMF", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "14632592_4_Ent3", "text": "myopathy", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "14632592_4_Ent2", "text": "his", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "14632592_4_Ent1", "text": "his renal and hepatic function were normal", "entity_type": "Entity", "start": 25, "end": 32}], "lang": "en"}
{"doc_id": "1467295_1", "wnd_id": "1467295_1_1", "text": "We describe a patient who developed NEH on three separate occasions provoked by two different chemotherapeutic agents -- cytarabine and mitoxantrone .", "tokens": ["We", "describe", "a", "patient", "who", "developed", "NEH", "on", "three", "separate", "occasions", "provoked", "by", "two", "different", "chemotherapeutic", "agents", "--", "cytarabine", "and", "mitoxantrone", "."], "event_mentions": [{"id": "1467295_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "provoked", "start": 11, "end": 12}, "arguments": [{"entity_id": "1467295_1_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "1467295_1_Ent1", "role": "Effect", "text": "NEH", "start": 6, "end": 7}, {"entity_id": "1467295_1_Ent3", "role": "Treatment_Drug", "text": "cytarabine", "start": 18, "end": 19}, {"entity_id": "1467295_1_Ent5", "role": "Combination_Drug", "text": "cytarabine", "start": 18, "end": 19}, {"entity_id": "1467295_1_Ent2", "role": "Treatment", "text": "cytarabine and mitoxantrone", "start": 18, "end": 21}, {"entity_id": "1467295_1_Ent4", "role": "Treatment_Drug", "text": "mitoxantrone", "start": 20, "end": 21}, {"entity_id": "1467295_1_Ent6", "role": "Combination_Drug", "text": "mitoxantrone", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "1467295_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1467295_1_Ent1", "text": "NEH", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1467295_1_Ent3", "text": "cytarabine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1467295_1_Ent5", "text": "cytarabine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1467295_1_Ent2", "text": "cytarabine and mitoxantrone", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "1467295_1_Ent4", "text": "mitoxantrone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "1467295_1_Ent6", "text": "mitoxantrone", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "14674674_4", "wnd_id": "14674674_4_1", "text": "Treatment with infliximab is known to produce an increase of autoantibodies ( antinuclear antibodies , anti - double - stranded DNA ) , but not clinical disease .", "tokens": ["Treatment", "with", "infliximab", "is", "known", "to", "produce", "an", "increase", "of", "autoantibodies", "(", "antinuclear", "antibodies", ",", "anti", "-", "double", "-", "stranded", "DNA", ")", ",", "but", "not", "clinical", "disease", "."], "event_mentions": [{"id": "14674674_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "produce", "start": 6, "end": 7}, "arguments": [{"entity_id": "14674674_4_Ent1", "role": "Treatment", "text": "Treatment with infliximab", "start": 0, "end": 3}, {"entity_id": "14674674_4_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 2, "end": 3}, {"entity_id": "14674674_4_Ent0", "role": "Effect", "text": "increase of autoantibodies ( antinuclear antibodies , anti - double - stranded DNA ) , but not clinical disease", "start": 8, "end": 27}]}], "entity_mentions": [{"id": "14674674_4_Ent1", "text": "Treatment with infliximab", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "14674674_4_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "14674674_4_Ent0", "text": "increase of autoantibodies ( antinuclear antibodies , anti - double - stranded DNA ) , but not clinical disease", "entity_type": "Entity", "start": 8, "end": 27}], "lang": "en"}
{"doc_id": "14679124_3", "wnd_id": "14679124_3_1", "text": "A prospective randomized clinical trial was implemented to assess whether the concomitant or the sequential addition of tamoxifen to chemotherapy provides improved clinical benefit in the adjuvant treatment of breast cancer in postmenopausal patients .", "tokens": ["A", "prospective", "randomized", "clinical", "trial", "was", "implemented", "to", "assess", "whether", "the", "concomitant", "or", "the", "sequential", "addition", "of", "tamoxifen", "to", "chemotherapy", "provides", "improved", "clinical", "benefit", "in", "the", "adjuvant", "treatment", "of", "breast", "cancer", "in", "postmenopausal", "patients", "."], "event_mentions": [{"id": "14679124_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "provides", "start": 20, "end": 21}, "arguments": [{"entity_id": "14679124_3_Ent3", "role": "Treatment", "text": "the concomitant or the sequential addition of tamoxifen to chemotherapy", "start": 10, "end": 20}, {"entity_id": "14679124_3_Ent4", "role": "Treatment_Drug", "text": "tamoxifen", "start": 17, "end": 18}, {"entity_id": "14679124_3_Ent5", "role": "Treatment_Route", "text": "chemotherapy", "start": 19, "end": 20}, {"entity_id": "14679124_3_Ent2", "role": "Effect", "text": "improved clinical benefit in the adjuvant treatment", "start": 21, "end": 28}, {"entity_id": "14679124_3_Ent6", "role": "Treatment_Disorder", "text": "breast cancer", "start": 29, "end": 31}, {"entity_id": "14679124_3_Ent1", "role": "Subject_Disorder", "text": "postmenopausal", "start": 32, "end": 33}, {"entity_id": "14679124_3_Ent0", "role": "Subject", "text": "postmenopausal patients", "start": 32, "end": 34}]}], "entity_mentions": [{"id": "14679124_3_Ent3", "text": "the concomitant or the sequential addition of tamoxifen to chemotherapy", "entity_type": "Entity", "start": 10, "end": 20}, {"id": "14679124_3_Ent4", "text": "tamoxifen", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "14679124_3_Ent5", "text": "chemotherapy", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "14679124_3_Ent2", "text": "improved clinical benefit in the adjuvant treatment", "entity_type": "Entity", "start": 21, "end": 28}, {"id": "14679124_3_Ent6", "text": "breast cancer", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "14679124_3_Ent1", "text": "postmenopausal", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "14679124_3_Ent0", "text": "postmenopausal patients", "entity_type": "Entity", "start": 32, "end": 34}], "lang": "en"}
{"doc_id": "14684937_2", "wnd_id": "14684937_2_1", "text": "Iatrogenic hypercalcemia due to vitamin D3 ointment ( 1,24(OH)2D3 ) combined with thiazide diuretics in a case of psoriasis .", "tokens": ["Iatrogenic", "hypercalcemia", "due", "to", "vitamin", "D3", "ointment", "(", "1,24(OH)2D3", ")", "combined", "with", "thiazide", "diuretics", "in", "a", "case", "of", "psoriasis", "."], "event_mentions": [{"id": "14684937_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 2, "end": 3}, "arguments": [{"entity_id": "14684937_2_Ent0", "role": "Effect", "text": "Iatrogenic hypercalcemia", "start": 0, "end": 2}, {"entity_id": "14684937_2_Ent3", "role": "Treatment_Drug", "text": "vitamin D3", "start": 4, "end": 6}, {"entity_id": "14684937_2_Ent6", "role": "Combination_Drug", "text": "vitamin D3", "start": 4, "end": 6}, {"entity_id": "14684937_2_Ent1", "role": "Treatment", "text": "vitamin D3 ointment ( 1,24(OH)2D3 ) combined with thiazide diuretics", "start": 4, "end": 14}, {"entity_id": "14684937_2_Ent5", "role": "Treatment_Route", "text": "ointment", "start": 6, "end": 7}, {"entity_id": "14684937_2_Ent4", "role": "Treatment_Drug", "text": "thiazide diuretics", "start": 12, "end": 14}, {"entity_id": "14684937_2_Ent7", "role": "Combination_Drug", "text": "thiazide diuretics", "start": 12, "end": 14}, {"entity_id": "14684937_2_Ent2", "role": "Treatment_Disorder", "text": "psoriasis", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "14684937_2_Ent0", "text": "Iatrogenic hypercalcemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "14684937_2_Ent3", "text": "vitamin D3", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "14684937_2_Ent6", "text": "vitamin D3", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "14684937_2_Ent1", "text": "vitamin D3 ointment ( 1,24(OH)2D3 ) combined with thiazide diuretics", "entity_type": "Entity", "start": 4, "end": 14}, {"id": "14684937_2_Ent5", "text": "ointment", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14684937_2_Ent4", "text": "thiazide diuretics", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "14684937_2_Ent7", "text": "thiazide diuretics", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "14684937_2_Ent2", "text": "psoriasis", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "14684937_4", "wnd_id": "14684937_4_1", "text": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide , respectively , resulting in hypercalciuria and hypercalcemia .", "tokens": ["We", "experienced", "a", "male", "patient", "with", "psoriasis", "and", "hypertension", "whose", "conditions", "were", "treated", "with", "tacalcitol", "ointment", "and", "thiazide", ",", "respectively", ",", "resulting", "in", "hypercalciuria", "and", "hypercalcemia", "."], "event_mentions": [{"id": "14684937_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 21, "end": 22}, "arguments": [{"entity_id": "14684937_4_Ent0", "role": "Subject", "text": "a male patient with psoriasis and hypertension", "start": 2, "end": 9}, {"entity_id": "14684937_4_Ent1", "role": "Subject_Gender", "text": "male", "start": 3, "end": 4}, {"entity_id": "14684937_4_Ent4", "role": "Treatment_Disorder", "text": "psoriasis", "start": 6, "end": 7}, {"entity_id": "14684937_4_Ent5", "role": "Treatment_Disorder", "text": "hypertension", "start": 8, "end": 9}, {"entity_id": "14684937_4_Ent6", "role": "Treatment_Drug", "text": "tacalcitol", "start": 14, "end": 15}, {"entity_id": "14684937_4_Ent9", "role": "Combination_Drug", "text": "tacalcitol", "start": 14, "end": 15}, {"entity_id": "14684937_4_Ent3", "role": "Treatment", "text": "tacalcitol ointment and thiazide", "start": 14, "end": 18}, {"entity_id": "14684937_4_Ent8", "role": "Treatment_Route", "text": "ointment", "start": 15, "end": 16}, {"entity_id": "14684937_4_Ent7", "role": "Treatment_Drug", "text": "thiazide", "start": 17, "end": 18}, {"entity_id": "14684937_4_Ent10", "role": "Combination_Drug", "text": "thiazide", "start": 17, "end": 18}, {"entity_id": "14684937_4_Ent2", "role": "Effect", "text": "hypercalciuria and hypercalcemia", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "14684937_4_Ent0", "text": "a male patient with psoriasis and hypertension", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "14684937_4_Ent1", "text": "male", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14684937_4_Ent4", "text": "psoriasis", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14684937_4_Ent5", "text": "hypertension", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "14684937_4_Ent6", "text": "tacalcitol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "14684937_4_Ent9", "text": "tacalcitol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "14684937_4_Ent3", "text": "tacalcitol ointment and thiazide", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "14684937_4_Ent8", "text": "ointment", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "14684937_4_Ent7", "text": "thiazide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "14684937_4_Ent10", "text": "thiazide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "14684937_4_Ent2", "text": "hypercalciuria and hypercalcemia", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "14690166_1", "wnd_id": "14690166_1_1", "text": "2 - Chloro - deoxyadenosine induces durable complete remission in Castleman 's disease but may accelerate its transformation to non - Hodgkin 's lymphoma .", "tokens": ["2", "-", "Chloro", "-", "deoxyadenosine", "induces", "durable", "complete", "remission", "in", "Castleman", "'s", "disease", "but", "may", "accelerate", "its", "transformation", "to", "non", "-", "Hodgkin", "'s", "lymphoma", "."], "event_mentions": [{"id": "14690166_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "accelerate", "start": 15, "end": 16}, "arguments": [{"entity_id": "14690166_1_Ent1", "role": "Treatment", "text": "2 - Chloro - deoxyadenosine", "start": 0, "end": 5}, {"entity_id": "14690166_1_Ent2", "role": "Treatment_Drug", "text": "2 - Chloro - deoxyadenosine", "start": 0, "end": 5}, {"entity_id": "14690166_1_Ent3", "role": "Treatment_Disorder", "text": "Castleman 's disease", "start": 10, "end": 13}, {"entity_id": "14690166_1_Ent0", "role": "Effect", "text": "non - Hodgkin 's lymphoma", "start": 19, "end": 24}]}], "entity_mentions": [{"id": "14690166_1_Ent1", "text": "2 - Chloro - deoxyadenosine", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "14690166_1_Ent2", "text": "2 - Chloro - deoxyadenosine", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "14690166_1_Ent3", "text": "Castleman 's disease", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "14690166_1_Ent0", "text": "non - Hodgkin 's lymphoma", "entity_type": "Entity", "start": 19, "end": 24}], "lang": "en"}
{"doc_id": "14711147_1", "wnd_id": "14711147_1_1", "text": "Doxycycline - induced photo - onycholysis .", "tokens": ["Doxycycline", "-", "induced", "photo", "-", "onycholysis", "."], "event_mentions": [{"id": "14711147_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "14711147_1_Ent1", "role": "Treatment", "text": "Doxycycline", "start": 0, "end": 1}, {"entity_id": "14711147_1_Ent2", "role": "Treatment_Drug", "text": "Doxycycline", "start": 0, "end": 1}, {"entity_id": "14711147_1_Ent0", "role": "Effect", "text": "photo - onycholysis", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "14711147_1_Ent1", "text": "Doxycycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14711147_1_Ent2", "text": "Doxycycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14711147_1_Ent0", "text": "photo - onycholysis", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "14712320_5", "wnd_id": "14712320_5_1", "text": "Rhabdomyolysis can occur with all statins when used alone and particularly when combined with other drugs that are themselves myotoxic or that elevate the concentration of the statin .", "tokens": ["Rhabdomyolysis", "can", "occur", "with", "all", "statins", "when", "used", "alone", "and", "particularly", "when", "combined", "with", "other", "drugs", "that", "are", "themselves", "myotoxic", "or", "that", "elevate", "the", "concentration", "of", "the", "statin", "."], "event_mentions": [{"id": "14712320_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 2, "end": 3}, "arguments": [{"entity_id": "14712320_5_Ent0", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "14712320_5_Ent1", "role": "Treatment", "text": "statins", "start": 5, "end": 6}, {"entity_id": "14712320_5_Ent3", "role": "Treatment_Drug", "text": "statins", "start": 5, "end": 6}, {"entity_id": "14712320_5_Ent2", "role": "Treatment", "text": "other drugs that are themselves myotoxic or that elevate the concentration of the statin", "start": 14, "end": 28}]}], "entity_mentions": [{"id": "14712320_5_Ent0", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14712320_5_Ent1", "text": "statins", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14712320_5_Ent3", "text": "statins", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14712320_5_Ent2", "text": "other drugs that are themselves myotoxic or that elevate the concentration of the statin", "entity_type": "Entity", "start": 14, "end": 28}], "lang": "en"}
{"doc_id": "14742791_1", "wnd_id": "14742791_1_1", "text": "Acute interstitial nephritis due to pantoprazole .", "tokens": ["Acute", "interstitial", "nephritis", "due", "to", "pantoprazole", "."], "event_mentions": [{"id": "14742791_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 3, "end": 4}, "arguments": [{"entity_id": "14742791_1_Ent0", "role": "Effect", "text": "Acute interstitial nephritis", "start": 0, "end": 3}, {"entity_id": "14742791_1_Ent1", "role": "Treatment", "text": "pantoprazole", "start": 5, "end": 6}, {"entity_id": "14742791_1_Ent2", "role": "Treatment_Drug", "text": "pantoprazole", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "14742791_1_Ent0", "text": "Acute interstitial nephritis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "14742791_1_Ent1", "text": "pantoprazole", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14742791_1_Ent2", "text": "pantoprazole", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "14766993_2", "wnd_id": "14766993_2_1", "text": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events .", "tokens": ["To", "report", "a", "case", "of", "possible", "interaction", "of", "smokeless", "tobacco", "with", "warfarin", "in", "a", "patient", "treated", "after", "several", "thromboembolic", "events", "."], "event_mentions": [{"id": "14766993_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 15, "end": 16}, "arguments": [{"entity_id": "14766993_2_Ent0", "role": "Effect", "text": "possible interaction of smokeless tobacco with warfarin", "start": 5, "end": 12}, {"entity_id": "14766993_2_Ent1", "role": "Treatment", "text": "warfarin", "start": 11, "end": 12}, {"entity_id": "14766993_2_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 11, "end": 12}, {"entity_id": "14766993_2_Ent2", "role": "Treatment_Disorder", "text": "several thromboembolic events", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "14766993_2_Ent0", "text": "possible interaction of smokeless tobacco with warfarin", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "14766993_2_Ent1", "text": "warfarin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14766993_2_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14766993_2_Ent2", "text": "several thromboembolic events", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "1477441_1", "wnd_id": "1477441_1_1", "text": "CASE SUMMARY : Two children with attention deficit disorder treated with methylphenidate as a simple drug developed fixed drug eruption of the scrotum .", "tokens": ["CASE", "SUMMARY", ":", "Two", "children", "with", "attention", "deficit", "disorder", "treated", "with", "methylphenidate", "as", "a", "simple", "drug", "developed", "fixed", "drug", "eruption", "of", "the", "scrotum", "."], "event_mentions": [{"id": "1477441_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "1477441_1_Ent1", "role": "Subject_Population", "text": "Two", "start": 3, "end": 4}, {"entity_id": "1477441_1_Ent0", "role": "Subject", "text": "Two children with attention deficit disorder", "start": 3, "end": 9}, {"entity_id": "1477441_1_Ent2", "role": "Subject_Age", "text": "children", "start": 4, "end": 5}, {"entity_id": "1477441_1_Ent6", "role": "Treatment_Disorder", "text": "attention deficit disorder", "start": 6, "end": 9}, {"entity_id": "1477441_1_Ent5", "role": "Treatment_Drug", "text": "methylphenidate", "start": 11, "end": 12}, {"entity_id": "1477441_1_Ent4", "role": "Treatment", "text": "methylphenidate as a simple drug", "start": 11, "end": 16}, {"entity_id": "1477441_1_Ent3", "role": "Effect", "text": "fixed drug eruption of the scrotum", "start": 17, "end": 23}]}], "entity_mentions": [{"id": "1477441_1_Ent1", "text": "Two", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1477441_1_Ent0", "text": "Two children with attention deficit disorder", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "1477441_1_Ent2", "text": "children", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1477441_1_Ent6", "text": "attention deficit disorder", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "1477441_1_Ent5", "text": "methylphenidate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "1477441_1_Ent4", "text": "methylphenidate as a simple drug", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "1477441_1_Ent3", "text": "fixed drug eruption of the scrotum", "entity_type": "Entity", "start": 17, "end": 23}], "lang": "en"}
{"doc_id": "1477441_3", "wnd_id": "1477441_3_1", "text": "Fixed drug eruption of the scrotum due to methylphenidate .", "tokens": ["Fixed", "drug", "eruption", "of", "the", "scrotum", "due", "to", "methylphenidate", "."], "event_mentions": [{"id": "1477441_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 6, "end": 7}, "arguments": [{"entity_id": "1477441_3_Ent0", "role": "Effect", "text": "Fixed drug eruption of the scrotum", "start": 0, "end": 6}, {"entity_id": "1477441_3_Ent1", "role": "Treatment", "text": "methylphenidate", "start": 8, "end": 9}, {"entity_id": "1477441_3_Ent2", "role": "Treatment_Drug", "text": "methylphenidate", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "1477441_3_Ent0", "text": "Fixed drug eruption of the scrotum", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "1477441_3_Ent1", "text": "methylphenidate", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1477441_3_Ent2", "text": "methylphenidate", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "14960440_2", "wnd_id": "14960440_2_1", "text": "CASE REPORT : A woman of 80 years , on long - term warfarin therapy presented with an acute dissecting thoracic aortic aneurysm ; on investigation the only precipitating factor found was an international normalised ratio of 4.8 .", "tokens": ["CASE", "REPORT", ":", "A", "woman", "of", "80", "years", ",", "on", "long", "-", "term", "warfarin", "therapy", "presented", "with", "an", "acute", "dissecting", "thoracic", "aortic", "aneurysm", ";", "on", "investigation", "the", "only", "precipitating", "factor", "found", "was", "an", "international", "normalised", "ratio", "of", "4.8", "."], "event_mentions": [{"id": "14960440_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 15, "end": 16}, "arguments": [{"entity_id": "14960440_2_Ent0", "role": "Subject", "text": "A woman of 80 years", "start": 3, "end": 8}, {"entity_id": "14960440_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 4, "end": 5}, {"entity_id": "14960440_2_Ent2", "role": "Subject_Age", "text": "80 years", "start": 6, "end": 8}, {"entity_id": "14960440_2_Ent4", "role": "Treatment", "text": "on long - term warfarin", "start": 9, "end": 14}, {"entity_id": "14960440_2_Ent5", "role": "Treatment_Duration", "text": "long - term", "start": 10, "end": 13}, {"entity_id": "14960440_2_Ent6", "role": "Treatment_Drug", "text": "warfarin", "start": 13, "end": 14}, {"entity_id": "14960440_2_Ent3", "role": "Effect", "text": "acute dissecting thoracic aortic aneurysm", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "14960440_2_Ent0", "text": "A woman of 80 years", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "14960440_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "14960440_2_Ent2", "text": "80 years", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "14960440_2_Ent4", "text": "on long - term warfarin", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "14960440_2_Ent5", "text": "long - term", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "14960440_2_Ent6", "text": "warfarin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14960440_2_Ent3", "text": "acute dissecting thoracic aortic aneurysm", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "14964753_7", "wnd_id": "14964753_7_1", "text": "Ramipril - induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before .", "tokens": ["Ramipril", "-", "induced", "cutaneous", "vasculitis", "is", "particularly", "rare", "and", "our", "case", "was", "atypical", "because", "the", "patient", "had", "tolerated", "lisinopril", "before", "."], "event_mentions": [{"id": "14964753_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "14964753_7_Ent3", "role": "Treatment", "text": "Ramipril", "start": 0, "end": 1}, {"entity_id": "14964753_7_Ent4", "role": "Treatment_Drug", "text": "Ramipril", "start": 0, "end": 1}, {"entity_id": "14964753_7_Ent2", "role": "Effect", "text": "cutaneous vasculitis", "start": 3, "end": 5}, {"entity_id": "14964753_7_Ent0", "role": "Subject", "text": "the patient had tolerated lisinopril before", "start": 14, "end": 20}, {"entity_id": "14964753_7_Ent1", "role": "Subject_Disorder", "text": "tolerated lisinopril", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "14964753_7_Ent3", "text": "Ramipril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14964753_7_Ent4", "text": "Ramipril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14964753_7_Ent2", "text": "cutaneous vasculitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "14964753_7_Ent0", "text": "the patient had tolerated lisinopril before", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "14964753_7_Ent1", "text": "tolerated lisinopril", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "14964753_9", "wnd_id": "14964753_9_1", "text": "Here we report ramipril - induced cutaneous vasculitis in a patient who required steroid therapy to control it .", "tokens": ["Here", "we", "report", "ramipril", "-", "induced", "cutaneous", "vasculitis", "in", "a", "patient", "who", "required", "steroid", "therapy", "to", "control", "it", "."], "event_mentions": [{"id": "14964753_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "14964753_9_Ent2", "role": "Treatment", "text": "ramipril", "start": 3, "end": 4}, {"entity_id": "14964753_9_Ent3", "role": "Treatment_Drug", "text": "ramipril", "start": 3, "end": 4}, {"entity_id": "14964753_9_Ent1", "role": "Effect", "text": "cutaneous vasculitis", "start": 6, "end": 8}, {"entity_id": "14964753_9_Ent0", "role": "Subject", "text": "a patient", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "14964753_9_Ent2", "text": "ramipril", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14964753_9_Ent3", "text": "ramipril", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14964753_9_Ent1", "text": "cutaneous vasculitis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "14964753_9_Ent0", "text": "a patient", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "14996269_2", "wnd_id": "14996269_2_1", "text": "We describe two ELBW infants affected by hyperkalaemia , treated with Kayexalate , who developed serious hypernatraemia , that has never been reported before in preterm infants .", "tokens": ["We", "describe", "two", "ELBW", "infants", "affected", "by", "hyperkalaemia", ",", "treated", "with", "Kayexalate", ",", "who", "developed", "serious", "hypernatraemia", ",", "that", "has", "never", "been", "reported", "before", "in", "preterm", "infants", "."], "event_mentions": [{"id": "14996269_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "14996269_2_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "14996269_2_Ent0", "role": "Subject", "text": "two ELBW infants affected by hyperkalaemia", "start": 2, "end": 8}, {"entity_id": "14996269_2_Ent3", "role": "Subject_Disorder", "text": "ELBW", "start": 3, "end": 4}, {"entity_id": "14996269_2_Ent2", "role": "Subject_Age", "text": "infants", "start": 4, "end": 5}, {"entity_id": "14996269_2_Ent6", "role": "Treatment_Disorder", "text": "hyperkalaemia", "start": 7, "end": 8}, {"entity_id": "14996269_2_Ent5", "role": "Treatment", "text": "Kayexalate", "start": 11, "end": 12}, {"entity_id": "14996269_2_Ent7", "role": "Treatment_Drug", "text": "Kayexalate", "start": 11, "end": 12}, {"entity_id": "14996269_2_Ent4", "role": "Effect", "text": "serious hypernatraemia", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "14996269_2_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "14996269_2_Ent0", "text": "two ELBW infants affected by hyperkalaemia", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "14996269_2_Ent3", "text": "ELBW", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14996269_2_Ent2", "text": "infants", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "14996269_2_Ent6", "text": "hyperkalaemia", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14996269_2_Ent5", "text": "Kayexalate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14996269_2_Ent7", "text": "Kayexalate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14996269_2_Ent4", "text": "serious hypernatraemia", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "14998226_10", "wnd_id": "14998226_10_1", "text": "Pravastatin does not appear to interact with warfarin but has caused an increased INR when combined with the anticoagulant fluindione .", "tokens": ["Pravastatin", "does", "not", "appear", "to", "interact", "with", "warfarin", "but", "has", "caused", "an", "increased", "INR", "when", "combined", "with", "the", "anticoagulant", "fluindione", "."], "event_mentions": [{"id": "14998226_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 10, "end": 11}, "arguments": [{"entity_id": "14998226_10_Ent1", "role": "Treatment", "text": "Pravastatin", "start": 0, "end": 1}, {"entity_id": "14998226_10_Ent3", "role": "Treatment_Drug", "text": "Pravastatin", "start": 0, "end": 1}, {"entity_id": "14998226_10_Ent5", "role": "Combination_Drug", "text": "Pravastatin", "start": 0, "end": 1}, {"entity_id": "14998226_10_Ent0", "role": "Effect", "text": "increased INR", "start": 12, "end": 14}, {"entity_id": "14998226_10_Ent2", "role": "Treatment", "text": "combined with the anticoagulant fluindione", "start": 15, "end": 20}, {"entity_id": "14998226_10_Ent4", "role": "Treatment_Drug", "text": "anticoagulant fluindione", "start": 18, "end": 20}, {"entity_id": "14998226_10_Ent6", "role": "Combination_Drug", "text": "anticoagulant fluindione", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "14998226_10_Ent1", "text": "Pravastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14998226_10_Ent3", "text": "Pravastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14998226_10_Ent5", "text": "Pravastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14998226_10_Ent0", "text": "increased INR", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "14998226_10_Ent2", "text": "combined with the anticoagulant fluindione", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "14998226_10_Ent4", "text": "anticoagulant fluindione", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "14998226_10_Ent6", "text": "anticoagulant fluindione", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "15013892_1", "wnd_id": "15013892_1_1", "text": "Bull's - eye maculopathy associated with quinacrine therapy for malaria .", "tokens": ["Bull's", "-", "eye", "maculopathy", "associated", "with", "quinacrine", "therapy", "for", "malaria", "."], "event_mentions": [{"id": "15013892_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "15013892_1_Ent0", "role": "Effect", "text": "Bull's - eye maculopathy", "start": 0, "end": 4}, {"entity_id": "15013892_1_Ent1", "role": "Treatment", "text": "quinacrine", "start": 6, "end": 7}, {"entity_id": "15013892_1_Ent2", "role": "Treatment_Drug", "text": "quinacrine", "start": 6, "end": 7}, {"entity_id": "15013892_1_Ent3", "role": "Treatment_Disorder", "text": "malaria", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "15013892_1_Ent0", "text": "Bull's - eye maculopathy", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "15013892_1_Ent1", "text": "quinacrine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15013892_1_Ent2", "text": "quinacrine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15013892_1_Ent3", "text": "malaria", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "15013892_4", "wnd_id": "15013892_4_1", "text": "The clinical picture was identical to that of chloroquine and hydroxychloroquine maculopathy .", "tokens": ["The", "clinical", "picture", "was", "identical", "to", "that", "of", "chloroquine", "and", "hydroxychloroquine", "maculopathy", "."], "event_mentions": [{"id": "15013892_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "identical", "start": 4, "end": 5}, "arguments": [{"entity_id": "15013892_4_Ent2", "role": "Treatment_Drug", "text": "chloroquine", "start": 8, "end": 9}, {"entity_id": "15013892_4_Ent1", "role": "Treatment", "text": "chloroquine and hydroxychloroquine", "start": 8, "end": 11}, {"entity_id": "15013892_4_Ent3", "role": "Treatment_Drug", "text": "hydroxychloroquine", "start": 10, "end": 11}, {"entity_id": "15013892_4_Ent0", "role": "Effect", "text": "maculopathy", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "15013892_4_Ent2", "text": "chloroquine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15013892_4_Ent1", "text": "chloroquine and hydroxychloroquine", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "15013892_4_Ent3", "text": "hydroxychloroquine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15013892_4_Ent0", "text": "maculopathy", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "15028328_1", "wnd_id": "15028328_1_1", "text": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine , a recalled medication .", "tokens": ["Cerebral", "infarcts", "in", "a", "pediatric", "patient", "secondary", "to", "phenylpropanolamine", ",", "a", "recalled", "medication", "."], "event_mentions": [{"id": "15028328_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 6, "end": 7}, "arguments": [{"entity_id": "15028328_1_Ent2", "role": "Effect", "text": "Cerebral infarcts", "start": 0, "end": 2}, {"entity_id": "15028328_1_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 4, "end": 5}, {"entity_id": "15028328_1_Ent0", "role": "Subject", "text": "pediatric patient", "start": 4, "end": 6}, {"entity_id": "15028328_1_Ent3", "role": "Treatment", "text": "phenylpropanolamine", "start": 8, "end": 9}, {"entity_id": "15028328_1_Ent4", "role": "Treatment_Drug", "text": "phenylpropanolamine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "15028328_1_Ent2", "text": "Cerebral infarcts", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15028328_1_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15028328_1_Ent0", "text": "pediatric patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15028328_1_Ent3", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15028328_1_Ent4", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "15028964_3", "wnd_id": "15028964_3_1", "text": "Beyond the predictable pharmacokinetic drug - drug interaction requiring a significant warfarin dose reduction , the iodine - rich amiodarone affects the thyroid gland , causing overt hypothyroidism or thyrotoxicosis in 14% - 18 % of cases .", "tokens": ["Beyond", "the", "predictable", "pharmacokinetic", "drug", "-", "drug", "interaction", "requiring", "a", "significant", "warfarin", "dose", "reduction", ",", "the", "iodine", "-", "rich", "amiodarone", "affects", "the", "thyroid", "gland", ",", "causing", "overt", "hypothyroidism", "or", "thyrotoxicosis", "in", "14%", "-", "18", "%", "of", "cases", "."], "event_mentions": [{"id": "15028964_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causing", "start": 25, "end": 26}, "arguments": [{"entity_id": "15028964_3_Ent1", "role": "Treatment", "text": "iodine - rich amiodarone", "start": 16, "end": 20}, {"entity_id": "15028964_3_Ent2", "role": "Treatment_Drug", "text": "iodine - rich amiodarone", "start": 16, "end": 20}, {"entity_id": "15028964_3_Ent0", "role": "Effect", "text": "overt hypothyroidism or thyrotoxicosis", "start": 26, "end": 30}]}], "entity_mentions": [{"id": "15028964_3_Ent1", "text": "iodine - rich amiodarone", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "15028964_3_Ent2", "text": "iodine - rich amiodarone", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "15028964_3_Ent0", "text": "overt hypothyroidism or thyrotoxicosis", "entity_type": "Entity", "start": 26, "end": 30}], "lang": "en"}
{"doc_id": "1504404_1", "wnd_id": "1504404_1_1", "text": "Central nervous system effects secondary to ciprofloxacin treatment are uncommon and usually consist only of minor dizziness or mild headache , although rare occurrences of seizures and hallucinations have been reported .", "tokens": ["Central", "nervous", "system", "effects", "secondary", "to", "ciprofloxacin", "treatment", "are", "uncommon", "and", "usually", "consist", "only", "of", "minor", "dizziness", "or", "mild", "headache", ",", "although", "rare", "occurrences", "of", "seizures", "and", "hallucinations", "have", "been", "reported", "."], "event_mentions": [{"id": "1504404_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "consist", "start": 12, "end": 13}, "arguments": [{"entity_id": "1504404_1_Ent1", "role": "Treatment", "text": "secondary to ciprofloxacin treatment", "start": 4, "end": 8}, {"entity_id": "1504404_1_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 6, "end": 7}, {"entity_id": "1504404_1_Ent0", "role": "Effect", "text": "minor dizziness or mild headache , although rare occurrences of seizures and hallucinations", "start": 15, "end": 28}]}], "entity_mentions": [{"id": "1504404_1_Ent1", "text": "secondary to ciprofloxacin treatment", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "1504404_1_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1504404_1_Ent0", "text": "minor dizziness or mild headache , although rare occurrences of seizures and hallucinations", "entity_type": "Entity", "start": 15, "end": 28}], "lang": "en"}
{"doc_id": "1504404_2", "wnd_id": "1504404_2_1", "text": "Ciprofloxacin - induced psychosis .", "tokens": ["Ciprofloxacin", "-", "induced", "psychosis", "."], "event_mentions": [{"id": "1504404_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "1504404_2_Ent1", "role": "Treatment", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "1504404_2_Ent2", "role": "Treatment_Drug", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "1504404_2_Ent0", "role": "Effect", "text": "psychosis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "1504404_2_Ent1", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1504404_2_Ent2", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1504404_2_Ent0", "text": "psychosis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "15053046_2", "wnd_id": "15053046_2_1", "text": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy , and is potentially serious , especially in end stage renal disease ( ESRD ) patients .", "tokens": ["Agranulocytosis", "is", "a", "rare", "adverse", "effect", "associated", "with", "prolonged", "vancomycin", "therapy", ",", "and", "is", "potentially", "serious", ",", "especially", "in", "end", "stage", "renal", "disease", "(", "ESRD", ")", "patients", "."], "event_mentions": [{"id": "15053046_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "15053046_2_Ent1", "role": "Effect", "text": "Agranulocytosis", "start": 0, "end": 1}, {"entity_id": "15053046_2_Ent3", "role": "Treatment_Duration", "text": "prolonged", "start": 8, "end": 9}, {"entity_id": "15053046_2_Ent2", "role": "Treatment", "text": "prolonged vancomycin therapy", "start": 8, "end": 11}, {"entity_id": "15053046_2_Ent4", "role": "Treatment_Drug", "text": "vancomycin", "start": 9, "end": 10}, {"entity_id": "15053046_2_Ent5", "role": "Treatment_Disorder", "text": "end stage renal disease ( ESRD )", "start": 19, "end": 26}, {"entity_id": "15053046_2_Ent0", "role": "Subject", "text": "end stage renal disease ( ESRD ) patients", "start": 19, "end": 27}]}], "entity_mentions": [{"id": "15053046_2_Ent1", "text": "Agranulocytosis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15053046_2_Ent3", "text": "prolonged", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15053046_2_Ent2", "text": "prolonged vancomycin therapy", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "15053046_2_Ent4", "text": "vancomycin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15053046_2_Ent5", "text": "end stage renal disease ( ESRD )", "entity_type": "Entity", "start": 19, "end": 26}, {"id": "15053046_2_Ent0", "text": "end stage renal disease ( ESRD ) patients", "entity_type": "Entity", "start": 19, "end": 27}], "lang": "en"}
{"doc_id": "15061230_3", "wnd_id": "15061230_3_1", "text": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug .", "tokens": ["Patients", "should", "be", "informed", "about", "the", "risk", "of", "osteonecrosis", "when", "taking", "dexamethasone", "as", "an", "antiemetic", "drug", "."], "event_mentions": [{"id": "15061230_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 6, "end": 7}, "arguments": [{"entity_id": "15061230_3_Ent0", "role": "Subject", "text": "Patients", "start": 0, "end": 1}, {"entity_id": "15061230_3_Ent1", "role": "Effect", "text": "osteonecrosis", "start": 8, "end": 9}, {"entity_id": "15061230_3_Ent2", "role": "Treatment", "text": "dexamethasone", "start": 11, "end": 12}, {"entity_id": "15061230_3_Ent3", "role": "Treatment_Drug", "text": "dexamethasone", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "15061230_3_Ent0", "text": "Patients", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15061230_3_Ent1", "text": "osteonecrosis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15061230_3_Ent2", "text": "dexamethasone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15061230_3_Ent3", "text": "dexamethasone", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "15093850_2", "wnd_id": "15093850_2_1", "text": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia , mild hypotension , and muscarinic symptoms in a patient with Sjogren 's syndrome .", "tokens": ["We", "report", "a", "case", "of", "unintentional", "overdose", "of", "oral", "pilocarpine", "tablets", "that", "resulted", "in", "bradycardia", ",", "mild", "hypotension", ",", "and", "muscarinic", "symptoms", "in", "a", "patient", "with", "Sjogren", "'s", "syndrome", "."], "event_mentions": [{"id": "15093850_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 12, "end": 13}, "arguments": [{"entity_id": "15093850_2_Ent2", "role": "Treatment_Route", "text": "oral", "start": 8, "end": 9}, {"entity_id": "15093850_2_Ent1", "role": "Treatment", "text": "pilocarpine", "start": 9, "end": 10}, {"entity_id": "15093850_2_Ent3", "role": "Treatment_Drug", "text": "pilocarpine", "start": 9, "end": 10}, {"entity_id": "15093850_2_Ent0", "role": "Effect", "text": "bradycardia , mild hypotension , and muscarinic symptoms", "start": 14, "end": 22}]}], "entity_mentions": [{"id": "15093850_2_Ent2", "text": "oral", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15093850_2_Ent1", "text": "pilocarpine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15093850_2_Ent3", "text": "pilocarpine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15093850_2_Ent0", "text": "bradycardia , mild hypotension , and muscarinic symptoms", "entity_type": "Entity", "start": 14, "end": 22}], "lang": "en"}
{"doc_id": "15097937_2", "wnd_id": "15097937_2_1", "text": "Anticonvulsant hypersensitivity syndrome associated with Bellamine S , a therapy for menopausal symptoms .", "tokens": ["Anticonvulsant", "hypersensitivity", "syndrome", "associated", "with", "Bellamine", "S", ",", "a", "therapy", "for", "menopausal", "symptoms", "."], "event_mentions": [{"id": "15097937_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "15097937_2_Ent0", "role": "Effect", "text": "Anticonvulsant hypersensitivity syndrome", "start": 0, "end": 3}, {"entity_id": "15097937_2_Ent3", "role": "Treatment_Drug", "text": "Bellamine S", "start": 5, "end": 7}, {"entity_id": "15097937_2_Ent1", "role": "Treatment", "text": "Bellamine S , a therapy for menopausal symptoms", "start": 5, "end": 13}, {"entity_id": "15097937_2_Ent2", "role": "Treatment_Disorder", "text": "menopausal symptoms .", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "15097937_2_Ent0", "text": "Anticonvulsant hypersensitivity syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15097937_2_Ent3", "text": "Bellamine S", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15097937_2_Ent1", "text": "Bellamine S , a therapy for menopausal symptoms", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "15097937_2_Ent2", "text": "menopausal symptoms .", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "15107195_2", "wnd_id": "15107195_2_1", "text": "Heat stroke in schizophrenia during clozapine treatment : rapid recognition and management .", "tokens": ["Heat", "stroke", "in", "schizophrenia", "during", "clozapine", "treatment", ":", "rapid", "recognition", "and", "management", "."], "event_mentions": [{"id": "15107195_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 4, "end": 5}, "arguments": [{"entity_id": "15107195_2_Ent0", "role": "Effect", "text": "Heat stroke", "start": 0, "end": 2}, {"entity_id": "15107195_2_Ent2", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 3, "end": 4}, {"entity_id": "15107195_2_Ent1", "role": "Treatment", "text": "clozapine", "start": 5, "end": 6}, {"entity_id": "15107195_2_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "15107195_2_Ent0", "text": "Heat stroke", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15107195_2_Ent2", "text": "schizophrenia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15107195_2_Ent1", "text": "clozapine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15107195_2_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "15133245_2", "wnd_id": "15133245_2_1", "text": "Oxatomide is an antiallergic drug used for the treatment of diseases mediated by type I allergy .", "tokens": ["Oxatomide", "is", "an", "antiallergic", "drug", "used", "for", "the", "treatment", "of", "diseases", "mediated", "by", "type", "I", "allergy", "."], "event_mentions": [{"id": "15133245_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used", "start": 5, "end": 6}, "arguments": [{"entity_id": "15133245_2_Ent0", "role": "Treatment", "text": "Oxatomide", "start": 0, "end": 1}, {"entity_id": "15133245_2_Ent2", "role": "Treatment_Drug", "text": "Oxatomide", "start": 0, "end": 1}, {"entity_id": "15133245_2_Ent1", "role": "Treatment_Disorder", "text": "diseases mediated by type I allergy", "start": 10, "end": 16}]}], "entity_mentions": [{"id": "15133245_2_Ent0", "text": "Oxatomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15133245_2_Ent2", "text": "Oxatomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15133245_2_Ent1", "text": "diseases mediated by type I allergy", "entity_type": "Entity", "start": 10, "end": 16}], "lang": "en"}
{"doc_id": "15133245_3", "wnd_id": "15133245_3_1", "text": "Recently , it has been reported that terfenadine and astemizole , which have antiallergic actions similar to those of oxatomide , show side effects on the cardiovascular system , such as QT prolongation , ventricular arrhythmia and cardiac arrest .", "tokens": ["Recently", ",", "it", "has", "been", "reported", "that", "terfenadine", "and", "astemizole", ",", "which", "have", "antiallergic", "actions", "similar", "to", "those", "of", "oxatomide", ",", "show", "side", "effects", "on", "the", "cardiovascular", "system", ",", "such", "as", "QT", "prolongation", ",", "ventricular", "arrhythmia", "and", "cardiac", "arrest", "."], "event_mentions": [{"id": "15133245_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "show", "start": 21, "end": 22}, "arguments": [{"entity_id": "15133245_3_Ent2", "role": "Treatment_Drug", "text": "terfenadine", "start": 7, "end": 8}, {"entity_id": "15133245_3_Ent4", "role": "Combination_Drug", "text": "terfenadine", "start": 7, "end": 8}, {"entity_id": "15133245_3_Ent1", "role": "Treatment", "text": "terfenadine and astemizole", "start": 7, "end": 10}, {"entity_id": "15133245_3_Ent3", "role": "Treatment_Drug", "text": "astemizole", "start": 9, "end": 10}, {"entity_id": "15133245_3_Ent5", "role": "Combination_Drug", "text": "astemizole", "start": 9, "end": 10}, {"entity_id": "15133245_3_Ent0", "role": "Effect", "text": "side effects on the cardiovascular system , such as QT prolongation , ventricular arrhythmia and cardiac arrest", "start": 22, "end": 39}]}], "entity_mentions": [{"id": "15133245_3_Ent2", "text": "terfenadine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15133245_3_Ent4", "text": "terfenadine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15133245_3_Ent1", "text": "terfenadine and astemizole", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "15133245_3_Ent3", "text": "astemizole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15133245_3_Ent5", "text": "astemizole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15133245_3_Ent0", "text": "side effects on the cardiovascular system , such as QT prolongation , ventricular arrhythmia and cardiac arrest", "entity_type": "Entity", "start": 22, "end": 39}], "lang": "en"}
{"doc_id": "15157248_1", "wnd_id": "15157248_1_1", "text": "An immediate hemolytic reaction induced by repeated administration of oxaliplatin .", "tokens": ["An", "immediate", "hemolytic", "reaction", "induced", "by", "repeated", "administration", "of", "oxaliplatin", "."], "event_mentions": [{"id": "15157248_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "15157248_1_Ent0", "role": "Effect", "text": "immediate hemolytic reaction", "start": 1, "end": 4}, {"entity_id": "15157248_1_Ent2", "role": "Treatment_Freq", "text": "repeated", "start": 6, "end": 7}, {"entity_id": "15157248_1_Ent1", "role": "Treatment", "text": "repeated administration of oxaliplatin", "start": 6, "end": 10}, {"entity_id": "15157248_1_Ent3", "role": "Treatment_Drug", "text": "oxaliplatin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "15157248_1_Ent0", "text": "immediate hemolytic reaction", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "15157248_1_Ent2", "text": "repeated", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15157248_1_Ent1", "text": "repeated administration of oxaliplatin", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "15157248_1_Ent3", "text": "oxaliplatin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "15162903_1", "wnd_id": "15162903_1_1", "text": "Although neurotoxicity is a frequent complication of methotrexate therapy , fatal acute neurotoxicity is extremely uncommon , especially in adults .", "tokens": ["Although", "neurotoxicity", "is", "a", "frequent", "complication", "of", "methotrexate", "therapy", ",", "fatal", "acute", "neurotoxicity", "is", "extremely", "uncommon", ",", "especially", "in", "adults", "."], "event_mentions": [{"id": "15162903_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 5, "end": 6}, "arguments": [{"entity_id": "15162903_1_Ent0", "role": "Effect", "text": "neurotoxicity", "start": 1, "end": 2}, {"entity_id": "15162903_1_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 7, "end": 8}, {"entity_id": "15162903_1_Ent1", "role": "Treatment", "text": "methotrexate therapy", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "15162903_1_Ent0", "text": "neurotoxicity", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15162903_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15162903_1_Ent1", "text": "methotrexate therapy", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "15162903_2", "wnd_id": "15162903_2_1", "text": "Clinicians should be aware of the signs and symptoms of neurotoxicity during treatment , as well as predisposing factors that put patients receiving methotrexate at risk for neurotoxic effects .", "tokens": ["Clinicians", "should", "be", "aware", "of", "the", "signs", "and", "symptoms", "of", "neurotoxicity", "during", "treatment", ",", "as", "well", "as", "predisposing", "factors", "that", "put", "patients", "receiving", "methotrexate", "at", "risk", "for", "neurotoxic", "effects", "."], "event_mentions": [{"id": "15162903_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 25, "end": 26}, "arguments": [{"entity_id": "15162903_2_Ent0", "role": "Subject", "text": "patients", "start": 21, "end": 22}, {"entity_id": "15162903_2_Ent2", "role": "Treatment", "text": "methotrexate", "start": 23, "end": 24}, {"entity_id": "15162903_2_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 23, "end": 24}, {"entity_id": "15162903_2_Ent1", "role": "Effect", "text": "neurotoxic effects", "start": 27, "end": 29}]}], "entity_mentions": [{"id": "15162903_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "15162903_2_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "15162903_2_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "15162903_2_Ent1", "text": "neurotoxic effects", "entity_type": "Entity", "start": 27, "end": 29}], "lang": "en"}
{"doc_id": "1517501_4", "wnd_id": "1517501_4_1", "text": "We report a third case of a 6 - week - old infant with Escherichia coli sepsis who received ampicillin and other antibiotics and subsequently developed TEN .", "tokens": ["We", "report", "a", "third", "case", "of", "a", "6", "-", "week", "-", "old", "infant", "with", "Escherichia", "coli", "sepsis", "who", "received", "ampicillin", "and", "other", "antibiotics", "and", "subsequently", "developed", "TEN", "."], "event_mentions": [{"id": "1517501_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 25, "end": 26}, "arguments": [{"entity_id": "1517501_4_Ent1", "role": "Subject_Age", "text": "6 - week - old", "start": 7, "end": 12}, {"entity_id": "1517501_4_Ent0", "role": "Subject", "text": "6 - week - old infant with Escherichia coli sepsis", "start": 7, "end": 17}, {"entity_id": "1517501_4_Ent2", "role": "Subject_Age", "text": "infant", "start": 12, "end": 13}, {"entity_id": "1517501_4_Ent7", "role": "Treatment_Disorder", "text": "Escherichia coli sepsis", "start": 14, "end": 17}, {"entity_id": "1517501_4_Ent4", "role": "Treatment", "text": "received ampicillin and other antibiotics", "start": 18, "end": 23}, {"entity_id": "1517501_4_Ent5", "role": "Treatment_Drug", "text": "ampicillin", "start": 19, "end": 20}, {"entity_id": "1517501_4_Ent8", "role": "Combination_Drug", "text": "ampicillin", "start": 19, "end": 20}, {"entity_id": "1517501_4_Ent6", "role": "Treatment_Drug", "text": "other antibiotics", "start": 21, "end": 23}, {"entity_id": "1517501_4_Ent9", "role": "Combination_Drug", "text": "other antibiotics", "start": 21, "end": 23}, {"entity_id": "1517501_4_Ent3", "role": "Effect", "text": "TEN", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "1517501_4_Ent1", "text": "6 - week - old", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "1517501_4_Ent0", "text": "6 - week - old infant with Escherichia coli sepsis", "entity_type": "Entity", "start": 7, "end": 17}, {"id": "1517501_4_Ent2", "text": "infant", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1517501_4_Ent7", "text": "Escherichia coli sepsis", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "1517501_4_Ent4", "text": "received ampicillin and other antibiotics", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "1517501_4_Ent5", "text": "ampicillin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "1517501_4_Ent8", "text": "ampicillin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "1517501_4_Ent6", "text": "other antibiotics", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "1517501_4_Ent9", "text": "other antibiotics", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "1517501_4_Ent3", "text": "TEN", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "15197722_1", "wnd_id": "15197722_1_1", "text": "A patient developed restless legs symptoms paralleling the course of interferon - alpha ( IFN alpha ) therapy for chronic hepatitis C.", "tokens": ["A", "patient", "developed", "restless", "legs", "symptoms", "paralleling", "the", "course", "of", "interferon", "-", "alpha", "(", "IFN", "alpha", ")", "therapy", "for", "chronic", "hepatitis", "C."], "event_mentions": [{"id": "15197722_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "15197722_1_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "15197722_1_Ent1", "role": "Effect", "text": "restless legs symptoms", "start": 3, "end": 6}, {"entity_id": "15197722_1_Ent3", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 10, "end": 13}, {"entity_id": "15197722_1_Ent2", "role": "Treatment", "text": "interferon - alpha ( IFN alpha ) therapy", "start": 10, "end": 18}, {"entity_id": "15197722_1_Ent4", "role": "Treatment_Disorder", "text": "chronic hepatitis C.", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "15197722_1_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15197722_1_Ent1", "text": "restless legs symptoms", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "15197722_1_Ent3", "text": "interferon - alpha", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "15197722_1_Ent2", "text": "interferon - alpha ( IFN alpha ) therapy", "entity_type": "Entity", "start": 10, "end": 18}, {"id": "15197722_1_Ent4", "text": "chronic hepatitis C.", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "15261876_1", "wnd_id": "15261876_1_1", "text": "Our patient was a 72 - year - old man with advanced Parkinson 's disease ( PD ) who received levodopa and anti - cholinergic drugs and whose head had become almost completely bald .", "tokens": ["Our", "patient", "was", "a", "72", "-", "year", "-", "old", "man", "with", "advanced", "Parkinson", "'s", "disease", "(", "PD", ")", "who", "received", "levodopa", "and", "anti", "-", "cholinergic", "drugs", "and", "whose", "head", "had", "become", "almost", "completely", "bald", "."], "event_mentions": [{"id": "15261876_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "become", "start": 30, "end": 31}, "arguments": [{"entity_id": "15261876_1_Ent0", "role": "Subject", "text": "a 72 - year - old man with advanced Parkinson 's disease ( PD )", "start": 3, "end": 18}, {"entity_id": "15261876_1_Ent1", "role": "Subject_Age", "text": "72 - year - old", "start": 4, "end": 9}, {"entity_id": "15261876_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 9, "end": 10}, {"entity_id": "15261876_1_Ent5", "role": "Treatment_Disorder", "text": "advanced Parkinson 's disease ( PD )", "start": 11, "end": 18}, {"entity_id": "15261876_1_Ent6", "role": "Treatment_Drug", "text": "levodopa", "start": 20, "end": 21}, {"entity_id": "15261876_1_Ent4", "role": "Treatment", "text": "levodopa and anti - cholinergic drugs", "start": 20, "end": 26}, {"entity_id": "15261876_1_Ent7", "role": "Treatment_Drug", "text": "anti - cholinergic drugs", "start": 22, "end": 26}, {"entity_id": "15261876_1_Ent3", "role": "Effect", "text": "completely bald", "start": 32, "end": 34}]}], "entity_mentions": [{"id": "15261876_1_Ent0", "text": "a 72 - year - old man with advanced Parkinson 's disease ( PD )", "entity_type": "Entity", "start": 3, "end": 18}, {"id": "15261876_1_Ent1", "text": "72 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "15261876_1_Ent2", "text": "man", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15261876_1_Ent5", "text": "advanced Parkinson 's disease ( PD )", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "15261876_1_Ent6", "text": "levodopa", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "15261876_1_Ent4", "text": "levodopa and anti - cholinergic drugs", "entity_type": "Entity", "start": 20, "end": 26}, {"id": "15261876_1_Ent7", "text": "anti - cholinergic drugs", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "15261876_1_Ent3", "text": "completely bald", "entity_type": "Entity", "start": 32, "end": 34}], "lang": "en"}
{"doc_id": "15279668_3", "wnd_id": "15279668_3_1", "text": "Of particular interest is that toxicity only occurred during the second course of FLA and sixth course of Ara - C containing chemotherapy .", "tokens": ["Of", "particular", "interest", "is", "that", "toxicity", "only", "occurred", "during", "the", "second", "course", "of", "FLA", "and", "sixth", "course", "of", "Ara", "-", "C", "containing", "chemotherapy", "."], "event_mentions": [{"id": "15279668_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 7, "end": 8}, "arguments": [{"entity_id": "15279668_3_Ent0", "role": "Effect", "text": "toxicity", "start": 5, "end": 6}, {"entity_id": "15279668_3_Ent1", "role": "Treatment", "text": "second course of FLA and sixth course of Ara - C containing chemotherapy", "start": 10, "end": 23}, {"entity_id": "15279668_3_Ent2", "role": "Treatment_Drug", "text": "FLA", "start": 13, "end": 14}, {"entity_id": "15279668_3_Ent6", "role": "Combination_Drug", "text": "FLA", "start": 13, "end": 14}, {"entity_id": "15279668_3_Ent4", "role": "Treatment_Time_elapsed", "text": "sixth course", "start": 15, "end": 17}, {"entity_id": "15279668_3_Ent3", "role": "Treatment_Drug", "text": "Ara - C", "start": 18, "end": 21}, {"entity_id": "15279668_3_Ent7", "role": "Combination_Drug", "text": "Ara - C", "start": 18, "end": 21}, {"entity_id": "15279668_3_Ent5", "role": "Treatment_Route", "text": "chemotherapy", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "15279668_3_Ent0", "text": "toxicity", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15279668_3_Ent1", "text": "second course of FLA and sixth course of Ara - C containing chemotherapy", "entity_type": "Entity", "start": 10, "end": 23}, {"id": "15279668_3_Ent2", "text": "FLA", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15279668_3_Ent6", "text": "FLA", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15279668_3_Ent4", "text": "sixth course", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "15279668_3_Ent3", "text": "Ara - C", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "15279668_3_Ent7", "text": "Ara - C", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "15279668_3_Ent5", "text": "chemotherapy", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "15300114_2", "wnd_id": "15300114_2_1", "text": "In each of the three reported patients , alteration of eyelid appearance with deepening of the lid sulcus was evident as the result of topical bimatoprost therapy .", "tokens": ["In", "each", "of", "the", "three", "reported", "patients", ",", "alteration", "of", "eyelid", "appearance", "with", "deepening", "of", "the", "lid", "sulcus", "was", "evident", "as", "the", "result", "of", "topical", "bimatoprost", "therapy", "."], "event_mentions": [{"id": "15300114_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "evident", "start": 19, "end": 20}, "arguments": [{"entity_id": "15300114_2_Ent1", "role": "Subject_Population", "text": "three", "start": 4, "end": 5}, {"entity_id": "15300114_2_Ent0", "role": "Subject", "text": "three reported patients", "start": 4, "end": 7}, {"entity_id": "15300114_2_Ent2", "role": "Effect", "text": "alteration of eyelid appearance with deepening of the lid sulcus", "start": 8, "end": 18}, {"entity_id": "15300114_2_Ent3", "role": "Treatment", "text": "topical bimatoprost", "start": 24, "end": 26}, {"entity_id": "15300114_2_Ent4", "role": "Treatment_Drug", "text": "bimatoprost", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "15300114_2_Ent1", "text": "three", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15300114_2_Ent0", "text": "three reported patients", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "15300114_2_Ent2", "text": "alteration of eyelid appearance with deepening of the lid sulcus", "entity_type": "Entity", "start": 8, "end": 18}, {"id": "15300114_2_Ent3", "text": "topical bimatoprost", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "15300114_2_Ent4", "text": "bimatoprost", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "15307435_2", "wnd_id": "15307435_2_1", "text": "In this report , we present a case of hypoglycaemic coma associated with SP , an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of SP increases .", "tokens": ["In", "this", "report", ",", "we", "present", "a", "case", "of", "hypoglycaemic", "coma", "associated", "with", "SP", ",", "an", "adverse", "reaction", "that", "is", "likely", "to", "be", "underreported", "and", "expected", "to", "occur", "with", "greater", "frequency", "as", "the", "use", "of", "SP", "increases", "."], "event_mentions": [{"id": "15307435_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 11, "end": 12}, "arguments": [{"entity_id": "15307435_2_Ent0", "role": "Effect", "text": "hypoglycaemic coma", "start": 9, "end": 11}, {"entity_id": "15307435_2_Ent2", "role": "Treatment", "text": "SP", "start": 13, "end": 14}, {"entity_id": "15307435_2_Ent3", "role": "Treatment_Drug", "text": "SP", "start": 13, "end": 14}, {"entity_id": "15307435_2_Ent1", "role": "Effect", "text": "an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of SP increases", "start": 15, "end": 37}]}], "entity_mentions": [{"id": "15307435_2_Ent0", "text": "hypoglycaemic coma", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "15307435_2_Ent2", "text": "SP", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15307435_2_Ent3", "text": "SP", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15307435_2_Ent1", "text": "an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of SP increases", "entity_type": "Entity", "start": 15, "end": 37}], "lang": "en"}
{"doc_id": "15373932_2", "wnd_id": "15373932_2_1", "text": "Fungal infection is a significant comorbidity in patients with diabetes mellitus , and ketoconazole , an antifungal agent , causes a number of drug interactions with coadministered drugs .", "tokens": ["Fungal", "infection", "is", "a", "significant", "comorbidity", "in", "patients", "with", "diabetes", "mellitus", ",", "and", "ketoconazole", ",", "an", "antifungal", "agent", ",", "causes", "a", "number", "of", "drug", "interactions", "with", "coadministered", "drugs", "."], "event_mentions": [{"id": "15373932_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 19, "end": 20}, "arguments": [{"entity_id": "15373932_2_Ent5", "role": "Treatment_Disorder", "text": "Fungal infection", "start": 0, "end": 2}, {"entity_id": "15373932_2_Ent0", "role": "Subject", "text": "patients with diabetes mellitus", "start": 7, "end": 11}, {"entity_id": "15373932_2_Ent1", "role": "Subject_Disorder", "text": "diabetes mellitus", "start": 9, "end": 11}, {"entity_id": "15373932_2_Ent3", "role": "Treatment", "text": "ketoconazole", "start": 13, "end": 14}, {"entity_id": "15373932_2_Ent4", "role": "Treatment_Drug", "text": "ketoconazole", "start": 13, "end": 14}, {"entity_id": "15373932_2_Ent2", "role": "Effect", "text": "a number of drug interactions with coadministered drugs", "start": 20, "end": 28}]}], "entity_mentions": [{"id": "15373932_2_Ent5", "text": "Fungal infection", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15373932_2_Ent0", "text": "patients with diabetes mellitus", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "15373932_2_Ent1", "text": "diabetes mellitus", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "15373932_2_Ent3", "text": "ketoconazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15373932_2_Ent4", "text": "ketoconazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15373932_2_Ent2", "text": "a number of drug interactions with coadministered drugs", "entity_type": "Entity", "start": 20, "end": 28}], "lang": "en"}
{"doc_id": "15379082_2", "wnd_id": "15379082_2_1", "text": "Fulminant hepatic failure is a rare complication of disulfiram treatment for alcoholism .", "tokens": ["Fulminant", "hepatic", "failure", "is", "a", "rare", "complication", "of", "disulfiram", "treatment", "for", "alcoholism", "."], "event_mentions": [{"id": "15379082_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 6, "end": 7}, "arguments": [{"entity_id": "15379082_2_Ent0", "role": "Effect", "text": "Fulminant hepatic failure", "start": 0, "end": 3}, {"entity_id": "15379082_2_Ent1", "role": "Treatment", "text": "disulfiram", "start": 8, "end": 9}, {"entity_id": "15379082_2_Ent3", "role": "Treatment_Drug", "text": "disulfiram", "start": 8, "end": 9}, {"entity_id": "15379082_2_Ent2", "role": "Treatment_Disorder", "text": "alcoholism", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "15379082_2_Ent0", "text": "Fulminant hepatic failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15379082_2_Ent1", "text": "disulfiram", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15379082_2_Ent3", "text": "disulfiram", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15379082_2_Ent2", "text": "alcoholism", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "15383642_13", "wnd_id": "15383642_13_1", "text": "This kind of reaction is seldom mentioned as occurring during co - administration with tizanidine .", "tokens": ["This", "kind", "of", "reaction", "is", "seldom", "mentioned", "as", "occurring", "during", "co", "-", "administration", "with", "tizanidine", "."], "event_mentions": [{"id": "15383642_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 8, "end": 9}, "arguments": [{"entity_id": "15383642_13_Ent0", "role": "Effect", "text": "This kind of reaction", "start": 0, "end": 4}, {"entity_id": "15383642_13_Ent1", "role": "Treatment", "text": "co - administration with tizanidine", "start": 10, "end": 15}, {"entity_id": "15383642_13_Ent2", "role": "Treatment_Drug", "text": "tizanidine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "15383642_13_Ent0", "text": "This kind of reaction", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "15383642_13_Ent1", "text": "co - administration with tizanidine", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "15383642_13_Ent2", "text": "tizanidine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "15388215_1", "wnd_id": "15388215_1_1", "text": "Tiagabine overdose causes an unusual array of neurological symptoms , many similar to reported adverse effects during therapeutic use .", "tokens": ["Tiagabine", "overdose", "causes", "an", "unusual", "array", "of", "neurological", "symptoms", ",", "many", "similar", "to", "reported", "adverse", "effects", "during", "therapeutic", "use", "."], "event_mentions": [{"id": "15388215_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 2, "end": 3}, "arguments": [{"entity_id": "15388215_1_Ent2", "role": "Treatment_Drug", "text": "Tiagabine", "start": 0, "end": 1}, {"entity_id": "15388215_1_Ent1", "role": "Treatment", "text": "Tiagabine overdose", "start": 0, "end": 2}, {"entity_id": "15388215_1_Ent3", "role": "Treatment_Dosage", "text": "overdose", "start": 1, "end": 2}, {"entity_id": "15388215_1_Ent0", "role": "Effect", "text": "an unusual array of neurological symptoms", "start": 3, "end": 9}]}], "entity_mentions": [{"id": "15388215_1_Ent2", "text": "Tiagabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15388215_1_Ent1", "text": "Tiagabine overdose", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15388215_1_Ent3", "text": "overdose", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15388215_1_Ent0", "text": "an unusual array of neurological symptoms", "entity_type": "Entity", "start": 3, "end": 9}], "lang": "en"}
{"doc_id": "15463865_2", "wnd_id": "15463865_2_1", "text": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin , particularly the elderly .", "tokens": ["Acute", "renal", "insufficiency", "is", "known", "to", "occur", "in", "patients", "who", "are", "taking", "ciprofloxacin", ",", "particularly", "the", "elderly", "."], "event_mentions": [{"id": "15463865_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 6, "end": 7}, "arguments": [{"entity_id": "15463865_2_Ent3", "role": "Effect", "text": "Acute renal insufficiency", "start": 0, "end": 3}, {"entity_id": "15463865_2_Ent0", "role": "Subject", "text": "patients", "start": 8, "end": 9}, {"entity_id": "15463865_2_Ent4", "role": "Treatment", "text": "ciprofloxacin", "start": 12, "end": 13}, {"entity_id": "15463865_2_Ent5", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 12, "end": 13}, {"entity_id": "15463865_2_Ent1", "role": "Subject", "text": "elderly", "start": 16, "end": 17}, {"entity_id": "15463865_2_Ent2", "role": "Subject_Age", "text": "elderly", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "15463865_2_Ent3", "text": "Acute renal insufficiency", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15463865_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15463865_2_Ent4", "text": "ciprofloxacin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15463865_2_Ent5", "text": "ciprofloxacin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15463865_2_Ent1", "text": "elderly", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15463865_2_Ent2", "text": "elderly", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "15468380_2", "wnd_id": "15468380_2_1", "text": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis , respectively , in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other .", "tokens": ["We", "describe", "2", "patients", "with", "severe", "erosive", "rheumatoid", "arthritis", "and", "rheumatoid", "vasculitis", ",", "respectively", ",", "in", "whom", "infliximab", "therapy", "was", "associated", "with", "peripheral", "neuropathy", "due", "to", "necrotizing", "vasculitis", "in", "one", "patient", "and", "to", "progression", "of", "preexisting", "mononeuritis", "multiplex", "in", "the", "other", "."], "event_mentions": [{"id": "15468380_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 20, "end": 21}, "arguments": [{"entity_id": "15468380_2_Ent4", "role": "Treatment_Drug", "text": "infliximab", "start": 17, "end": 18}, {"entity_id": "15468380_2_Ent2", "role": "Treatment", "text": "infliximab therapy", "start": 17, "end": 19}, {"entity_id": "15468380_2_Ent1", "role": "Effect", "text": "peripheral neuropathy", "start": 22, "end": 24}, {"entity_id": "15468380_2_Ent3", "role": "Treatment_Disorder", "text": "necrotizing vasculitis", "start": 26, "end": 28}, {"entity_id": "15468380_2_Ent0", "role": "Subject", "text": "one patient", "start": 29, "end": 31}]}, {"id": "15468380_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 20, "end": 21}, "arguments": [{"entity_id": "15468380_2_Ent10", "role": "Treatment_Drug", "text": "infliximab", "start": 17, "end": 18}, {"entity_id": "15468380_2_Ent8", "role": "Treatment", "text": "infliximab therapy", "start": 17, "end": 19}, {"entity_id": "15468380_2_Ent7", "role": "Effect", "text": "peripheral neuropathy", "start": 22, "end": 24}, {"entity_id": "15468380_2_Ent9", "role": "Treatment_Disorder", "text": "necrotizing vasculitis", "start": 26, "end": 28}, {"entity_id": "15468380_2_Ent6", "role": "Subject_Disorder", "text": "preexisting mononeuritis multiplex", "start": 35, "end": 38}, {"entity_id": "15468380_2_Ent5", "role": "Subject", "text": "preexisting mononeuritis multiplex in the other", "start": 35, "end": 41}]}], "entity_mentions": [{"id": "15468380_2_Ent4", "text": "infliximab", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15468380_2_Ent10", "text": "infliximab", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15468380_2_Ent2", "text": "infliximab therapy", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "15468380_2_Ent8", "text": "infliximab therapy", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "15468380_2_Ent1", "text": "peripheral neuropathy", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "15468380_2_Ent7", "text": "peripheral neuropathy", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "15468380_2_Ent3", "text": "necrotizing vasculitis", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "15468380_2_Ent9", "text": "necrotizing vasculitis", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "15468380_2_Ent0", "text": "one patient", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "15468380_2_Ent6", "text": "preexisting mononeuritis multiplex", "entity_type": "Entity", "start": 35, "end": 38}, {"id": "15468380_2_Ent5", "text": "preexisting mononeuritis multiplex in the other", "entity_type": "Entity", "start": 35, "end": 41}], "lang": "en"}
{"doc_id": "15494638_19", "wnd_id": "15494638_19_1", "text": "Knowledge regarding potential adverse effects of CAP is paramount and dose modification is indicated with development of neurotoxicity .", "tokens": ["Knowledge", "regarding", "potential", "adverse", "effects", "of", "CAP", "is", "paramount", "and", "dose", "modification", "is", "indicated", "with", "development", "of", "neurotoxicity", "."], "event_mentions": [{"id": "15494638_19_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse effects", "start": 3, "end": 5}, "arguments": [{"entity_id": "15494638_19_Ent1", "role": "Treatment", "text": "CAP", "start": 6, "end": 7}, {"entity_id": "15494638_19_Ent2", "role": "Treatment_Drug", "text": "CAP", "start": 6, "end": 7}, {"entity_id": "15494638_19_Ent0", "role": "Effect", "text": "neurotoxicity", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "15494638_19_Ent1", "text": "CAP", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15494638_19_Ent2", "text": "CAP", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15494638_19_Ent0", "text": "neurotoxicity", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "15494638_2", "wnd_id": "15494638_2_1", "text": "5 - fluorouracil ( 5 - FU) - associated peripheral neuropathy is an uncommon event .", "tokens": ["5", "-", "fluorouracil", "(", "5", "-", "FU)", "-", "associated", "peripheral", "neuropathy", "is", "an", "uncommon", "event", "."], "event_mentions": [{"id": "15494638_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "15494638_2_Ent1", "role": "Treatment", "text": "5 - fluorouracil", "start": 0, "end": 3}, {"entity_id": "15494638_2_Ent2", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 0, "end": 3}, {"entity_id": "15494638_2_Ent0", "role": "Effect", "text": "peripheral neuropathy", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "15494638_2_Ent1", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15494638_2_Ent2", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15494638_2_Ent0", "text": "peripheral neuropathy", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "15504988_2", "wnd_id": "15504988_2_1", "text": "We report three patients , all of whom had preexisting diabetic dyslipidemia , who showed a profound reduction in plasma HDL cholesterol and apolipoprotein AI levels soon after the initiation of rosiglitazone therapy .", "tokens": ["We", "report", "three", "patients", ",", "all", "of", "whom", "had", "preexisting", "diabetic", "dyslipidemia", ",", "who", "showed", "a", "profound", "reduction", "in", "plasma", "HDL", "cholesterol", "and", "apolipoprotein", "AI", "levels", "soon", "after", "the", "initiation", "of", "rosiglitazone", "therapy", "."], "event_mentions": [{"id": "15504988_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "initiation", "start": 29, "end": 30}, "arguments": [{"entity_id": "15504988_2_Ent1", "role": "Subject_Population", "text": "three", "start": 2, "end": 3}, {"entity_id": "15504988_2_Ent0", "role": "Subject", "text": "three patients", "start": 2, "end": 4}, {"entity_id": "15504988_2_Ent6", "role": "Treatment_Disorder", "text": "preexisting diabetic dyslipidemia", "start": 9, "end": 12}, {"entity_id": "15504988_2_Ent2", "role": "Effect", "text": "profound reduction in plasma HDL cholesterol and apolipoprotein AI levels", "start": 16, "end": 26}, {"entity_id": "15504988_2_Ent5", "role": "Treatment_Time_elapsed", "text": "soon after", "start": 26, "end": 28}, {"entity_id": "15504988_2_Ent4", "role": "Treatment_Drug", "text": "rosiglitazone", "start": 31, "end": 32}, {"entity_id": "15504988_2_Ent3", "role": "Treatment", "text": "rosiglitazone therapy", "start": 31, "end": 33}]}], "entity_mentions": [{"id": "15504988_2_Ent1", "text": "three", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15504988_2_Ent0", "text": "three patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15504988_2_Ent6", "text": "preexisting diabetic dyslipidemia", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "15504988_2_Ent2", "text": "profound reduction in plasma HDL cholesterol and apolipoprotein AI levels", "entity_type": "Entity", "start": 16, "end": 26}, {"id": "15504988_2_Ent5", "text": "soon after", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "15504988_2_Ent4", "text": "rosiglitazone", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "15504988_2_Ent3", "text": "rosiglitazone therapy", "entity_type": "Entity", "start": 31, "end": 33}], "lang": "en"}
{"doc_id": "15507779_1", "wnd_id": "15507779_1_1", "text": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine .", "tokens": ["Severe", "leukopenia", "associated", "with", "mild", "hepatotoxicity", "in", "an", "HIV", "carrier", "treated", "with", "nevirapine", "."], "event_mentions": [{"id": "15507779_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 11, "end": 12}, "arguments": [{"entity_id": "15507779_1_Ent1", "role": "Effect", "text": "leukopenia", "start": 1, "end": 2}, {"entity_id": "15507779_1_Ent0", "role": "Subject", "text": "an HIV carrier", "start": 7, "end": 10}, {"entity_id": "15507779_1_Ent4", "role": "Treatment_Disorder", "text": "HIV carrier", "start": 8, "end": 10}, {"entity_id": "15507779_1_Ent2", "role": "Treatment", "text": "nevirapine", "start": 12, "end": 13}, {"entity_id": "15507779_1_Ent3", "role": "Treatment_Drug", "text": "nevirapine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "15507779_1_Ent1", "text": "leukopenia", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15507779_1_Ent0", "text": "an HIV carrier", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "15507779_1_Ent4", "text": "HIV carrier", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15507779_1_Ent2", "text": "nevirapine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15507779_1_Ent3", "text": "nevirapine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "15507779_4", "wnd_id": "15507779_4_1", "text": "We report an HIV - infected woman who developed mild leukopenia as the first sign of a nevirapine - related adverse event , which was followed by skin and hepatic toxicity associated with a more severe leukopenia .", "tokens": ["We", "report", "an", "HIV", "-", "infected", "woman", "who", "developed", "mild", "leukopenia", "as", "the", "first", "sign", "of", "a", "nevirapine", "-", "related", "adverse", "event", ",", "which", "was", "followed", "by", "skin", "and", "hepatic", "toxicity", "associated", "with", "a", "more", "severe", "leukopenia", "."], "event_mentions": [{"id": "15507779_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "15507779_4_Ent6", "role": "Treatment_Disorder", "text": "HIV", "start": 3, "end": 4}, {"entity_id": "15507779_4_Ent0", "role": "Subject", "text": "HIV - infected woman", "start": 3, "end": 7}, {"entity_id": "15507779_4_Ent1", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "15507779_4_Ent2", "role": "Effect", "text": "mild leukopenia", "start": 9, "end": 11}, {"entity_id": "15507779_4_Ent4", "role": "Treatment", "text": "nevirapine", "start": 17, "end": 18}, {"entity_id": "15507779_4_Ent5", "role": "Treatment_Drug", "text": "nevirapine", "start": 17, "end": 18}, {"entity_id": "15507779_4_Ent3", "role": "Effect", "text": "followed by skin and hepatic toxicity associated with a more severe leukopenia", "start": 25, "end": 37}]}], "entity_mentions": [{"id": "15507779_4_Ent6", "text": "HIV", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15507779_4_Ent0", "text": "HIV - infected woman", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "15507779_4_Ent1", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15507779_4_Ent2", "text": "mild leukopenia", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "15507779_4_Ent4", "text": "nevirapine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15507779_4_Ent5", "text": "nevirapine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15507779_4_Ent3", "text": "followed by skin and hepatic toxicity associated with a more severe leukopenia", "entity_type": "Entity", "start": 25, "end": 37}], "lang": "en"}
{"doc_id": "15522120_1", "wnd_id": "15522120_1_1", "text": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment : case report .", "tokens": ["Itch", "and", "skin", "rash", "from", "chocolate", "during", "fluoxetine", "and", "sertraline", "treatment", ":", "case", "report", "."], "event_mentions": [{"id": "15522120_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 4, "end": 5}, "arguments": [{"entity_id": "15522120_1_Ent0", "role": "Effect", "text": "Itch and skin rash", "start": 0, "end": 4}, {"entity_id": "15522120_1_Ent2", "role": "Treatment_Drug", "text": "chocolate", "start": 5, "end": 6}, {"entity_id": "15522120_1_Ent6", "role": "Combination_Drug", "text": "chocolate", "start": 5, "end": 6}, {"entity_id": "15522120_1_Ent1", "role": "Treatment", "text": "chocolate during fluoxetine and sertraline treatment", "start": 5, "end": 11}, {"entity_id": "15522120_1_Ent3", "role": "Treatment_Drug", "text": "fluoxetine", "start": 7, "end": 8}, {"entity_id": "15522120_1_Ent5", "role": "Combination_Drug", "text": "fluoxetine", "start": 7, "end": 8}, {"entity_id": "15522120_1_Ent4", "role": "Treatment_Drug", "text": "sertraline", "start": 9, "end": 10}, {"entity_id": "15522120_1_Ent7", "role": "Combination_Drug", "text": "sertraline", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "15522120_1_Ent0", "text": "Itch and skin rash", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "15522120_1_Ent2", "text": "chocolate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15522120_1_Ent6", "text": "chocolate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15522120_1_Ent1", "text": "chocolate during fluoxetine and sertraline treatment", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "15522120_1_Ent3", "text": "fluoxetine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15522120_1_Ent5", "text": "fluoxetine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15522120_1_Ent4", "text": "sertraline", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15522120_1_Ent7", "text": "sertraline", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "15529178_1", "wnd_id": "15529178_1_1", "text": "Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy .", "tokens": ["Pulmonary", "lymphohistiocytic", "reactions", "temporally", "related", "to", "etanercept", "therapy", "."], "event_mentions": [{"id": "15529178_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 4, "end": 5}, "arguments": [{"entity_id": "15529178_1_Ent0", "role": "Effect", "text": "Pulmonary lymphohistiocytic reactions", "start": 0, "end": 3}, {"entity_id": "15529178_1_Ent1", "role": "Treatment", "text": "etanercept", "start": 6, "end": 7}, {"entity_id": "15529178_1_Ent2", "role": "Treatment_Drug", "text": "etanercept", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "15529178_1_Ent0", "text": "Pulmonary lymphohistiocytic reactions", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15529178_1_Ent1", "text": "etanercept", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15529178_1_Ent2", "text": "etanercept", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "15533031_1", "wnd_id": "15533031_1_1", "text": "Paradoxical cerebral cortical hyperexcitability following flupirtine overdose .", "tokens": ["Paradoxical", "cerebral", "cortical", "hyperexcitability", "following", "flupirtine", "overdose", "."], "event_mentions": [{"id": "15533031_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 4, "end": 5}, "arguments": [{"entity_id": "15533031_1_Ent0", "role": "Effect", "text": "Paradoxical cerebral cortical hyperexcitability", "start": 0, "end": 4}, {"entity_id": "15533031_1_Ent2", "role": "Treatment_Drug", "text": "flupirtine", "start": 5, "end": 6}, {"entity_id": "15533031_1_Ent1", "role": "Treatment", "text": "flupirtine overdose", "start": 5, "end": 7}, {"entity_id": "15533031_1_Ent3", "role": "Treatment_Dosage", "text": "overdose", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "15533031_1_Ent0", "text": "Paradoxical cerebral cortical hyperexcitability", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "15533031_1_Ent2", "text": "flupirtine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15533031_1_Ent1", "text": "flupirtine overdose", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15533031_1_Ent3", "text": "overdose", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "15580406_2", "wnd_id": "15580406_2_1", "text": "Retinal abnormalities , including retinal hemorrhage and \" cotton - wool \" spots , often occur within the first 8 weeks in the course of interferon therapy in patients with chronic hepatitis C.", "tokens": ["Retinal", "abnormalities", ",", "including", "retinal", "hemorrhage", "and", "\"", "cotton", "-", "wool", "\"", "spots", ",", "often", "occur", "within", "the", "first", "8", "weeks", "in", "the", "course", "of", "interferon", "therapy", "in", "patients", "with", "chronic", "hepatitis", "C."], "event_mentions": [{"id": "15580406_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 15, "end": 16}, "arguments": [{"entity_id": "15580406_2_Ent1", "role": "Effect", "text": "Retinal abnormalities , including retinal hemorrhage and \" cotton - wool \" spots", "start": 0, "end": 13}, {"entity_id": "15580406_2_Ent3", "role": "Treatment_Time_elapsed", "text": "8 weeks", "start": 19, "end": 21}, {"entity_id": "15580406_2_Ent2", "role": "Treatment", "text": "interferon", "start": 25, "end": 26}, {"entity_id": "15580406_2_Ent4", "role": "Treatment_Drug", "text": "interferon", "start": 25, "end": 26}, {"entity_id": "15580406_2_Ent0", "role": "Subject", "text": "patients with chronic hepatitis C.", "start": 28, "end": 33}, {"entity_id": "15580406_2_Ent5", "role": "Treatment_Disorder", "text": "chronic hepatitis C.", "start": 30, "end": 33}]}], "entity_mentions": [{"id": "15580406_2_Ent1", "text": "Retinal abnormalities , including retinal hemorrhage and \" cotton - wool \" spots", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "15580406_2_Ent3", "text": "8 weeks", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "15580406_2_Ent2", "text": "interferon", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "15580406_2_Ent4", "text": "interferon", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "15580406_2_Ent0", "text": "patients with chronic hepatitis C.", "entity_type": "Entity", "start": 28, "end": 33}, {"id": "15580406_2_Ent5", "text": "chronic hepatitis C.", "entity_type": "Entity", "start": 30, "end": 33}], "lang": "en"}
{"doc_id": "15595320_3", "wnd_id": "15595320_3_1", "text": "Previous studies have demonstrated the interaction of MTX and a variety of non - steroidal , anti - inflammatory drugs ( NSAIDs ) with various clinical manifestations including acute renal failure , pancytopenia , vomiting , diarrhea , elevated liver transaminases , jaundice , mucosal ulcerations , and pyrexia .", "tokens": ["Previous", "studies", "have", "demonstrated", "the", "interaction", "of", "MTX", "and", "a", "variety", "of", "non", "-", "steroidal", ",", "anti", "-", "inflammatory", "drugs", "(", "NSAIDs", ")", "with", "various", "clinical", "manifestations", "including", "acute", "renal", "failure", ",", "pancytopenia", ",", "vomiting", ",", "diarrhea", ",", "elevated", "liver", "transaminases", ",", "jaundice", ",", "mucosal", "ulcerations", ",", "and", "pyrexia", "."], "event_mentions": [{"id": "15595320_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "manifestations", "start": 26, "end": 27}, "arguments": [{"entity_id": "15595320_3_Ent2", "role": "Treatment_Drug", "text": "MTX", "start": 7, "end": 8}, {"entity_id": "15595320_3_Ent1", "role": "Treatment", "text": "MTX and a variety of non - steroidal , anti - inflammatory drugs ( NSAIDs )", "start": 7, "end": 23}, {"entity_id": "15595320_3_Ent3", "role": "Treatment_Drug", "text": "non - steroidal , anti - inflammatory drugs", "start": 12, "end": 20}, {"entity_id": "15595320_3_Ent0", "role": "Effect", "text": "acute renal failure , pancytopenia , vomiting , diarrhea , elevated liver transaminases , jaundice , mucosal ulcerations , and pyrexia", "start": 28, "end": 49}]}], "entity_mentions": [{"id": "15595320_3_Ent2", "text": "MTX", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15595320_3_Ent1", "text": "MTX and a variety of non - steroidal , anti - inflammatory drugs ( NSAIDs )", "entity_type": "Entity", "start": 7, "end": 23}, {"id": "15595320_3_Ent3", "text": "non - steroidal , anti - inflammatory drugs", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "15595320_3_Ent0", "text": "acute renal failure , pancytopenia , vomiting , diarrhea , elevated liver transaminases , jaundice , mucosal ulcerations , and pyrexia", "entity_type": "Entity", "start": 28, "end": 49}], "lang": "en"}
{"doc_id": "15681911_2", "wnd_id": "15681911_2_1", "text": "OBJECTIVES : To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib .", "tokens": ["OBJECTIVES", ":", "To", "describe", "clinical", "and", "pathologic", "findings", "in", "patients", "noted", "to", "develop", "lower", "gastrointestinal", "symptoms", "when", "exposed", "to", "rofecoxib", "."], "event_mentions": [{"id": "15681911_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 12, "end": 13}, "arguments": [{"entity_id": "15681911_2_Ent0", "role": "Subject", "text": "patients", "start": 9, "end": 10}, {"entity_id": "15681911_2_Ent1", "role": "Effect", "text": "lower gastrointestinal symptoms", "start": 13, "end": 16}, {"entity_id": "15681911_2_Ent2", "role": "Treatment", "text": "rofecoxib", "start": 19, "end": 20}, {"entity_id": "15681911_2_Ent3", "role": "Treatment_Drug", "text": "rofecoxib", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "15681911_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15681911_2_Ent1", "text": "lower gastrointestinal symptoms", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "15681911_2_Ent2", "text": "rofecoxib", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "15681911_2_Ent3", "text": "rofecoxib", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "1569260_1", "wnd_id": "1569260_1_1", "text": "To the best of our knowledge , this is the first reported patient with captopril - induced pemphigus in whom no new lesions developed after subsequent treatment with enalapril .", "tokens": ["To", "the", "best", "of", "our", "knowledge", ",", "this", "is", "the", "first", "reported", "patient", "with", "captopril", "-", "induced", "pemphigus", "in", "whom", "no", "new", "lesions", "developed", "after", "subsequent", "treatment", "with", "enalapril", "."], "event_mentions": [{"id": "1569260_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 16, "end": 17}, "arguments": [{"entity_id": "1569260_1_Ent0", "role": "Subject", "text": "patient", "start": 12, "end": 13}, {"entity_id": "1569260_1_Ent2", "role": "Treatment", "text": "captopril", "start": 14, "end": 15}, {"entity_id": "1569260_1_Ent3", "role": "Treatment_Drug", "text": "captopril", "start": 14, "end": 15}, {"entity_id": "1569260_1_Ent1", "role": "Effect", "text": "pemphigus", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "1569260_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1569260_1_Ent2", "text": "captopril", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1569260_1_Ent3", "text": "captopril", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1569260_1_Ent1", "text": "pemphigus", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "1569260_2", "wnd_id": "1569260_2_1", "text": "We report a case of drug - induced pemphigus caused by an angiotensin - converting enzyme inhibitor , captopril .", "tokens": ["We", "report", "a", "case", "of", "drug", "-", "induced", "pemphigus", "caused", "by", "an", "angiotensin", "-", "converting", "enzyme", "inhibitor", ",", "captopril", "."], "event_mentions": [{"id": "1569260_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "1569260_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "1569260_2_Ent1", "role": "Effect", "text": "pemphigus", "start": 8, "end": 9}, {"entity_id": "1569260_2_Ent2", "role": "Treatment", "text": "captopril", "start": 18, "end": 19}, {"entity_id": "1569260_2_Ent3", "role": "Treatment_Drug", "text": "captopril", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "1569260_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1569260_2_Ent1", "text": "pemphigus", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1569260_2_Ent2", "text": "captopril", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1569260_2_Ent3", "text": "captopril", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "15719254_1", "wnd_id": "15719254_1_1", "text": "Cis - retinoic acid ( RA ) may further increase the risk of developing BMTN .", "tokens": ["Cis", "-", "retinoic", "acid", "(", "RA", ")", "may", "further", "increase", "the", "risk", "of", "developing", "BMTN", "."], "event_mentions": [{"id": "15719254_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developing", "start": 13, "end": 14}, "arguments": [{"entity_id": "15719254_1_Ent2", "role": "Treatment_Drug", "text": "Cis - retinoic acid", "start": 0, "end": 4}, {"entity_id": "15719254_1_Ent1", "role": "Treatment", "text": "Cis - retinoic acid ( RA )", "start": 0, "end": 7}, {"entity_id": "15719254_1_Ent0", "role": "Effect", "text": "BMTN", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "15719254_1_Ent2", "text": "Cis - retinoic acid", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "15719254_1_Ent1", "text": "Cis - retinoic acid ( RA )", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "15719254_1_Ent0", "text": "BMTN", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "15760792_4", "wnd_id": "15760792_4_1", "text": "RESULTS : In a 22 - year - old Thai woman with Graves ' disease , tinnitus , hearing impairment in the left ear ( with progression to the right ear ) , and vertigo developed after 3 years of therapy with PTU .", "tokens": ["RESULTS", ":", "In", "a", "22", "-", "year", "-", "old", "Thai", "woman", "with", "Graves", "'", "disease", ",", "tinnitus", ",", "hearing", "impairment", "in", "the", "left", "ear", "(", "with", "progression", "to", "the", "right", "ear", ")", ",", "and", "vertigo", "developed", "after", "3", "years", "of", "therapy", "with", "PTU", "."], "event_mentions": [{"id": "15760792_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 35, "end": 36}, "arguments": [{"entity_id": "15760792_4_Ent0", "role": "Subject", "text": "a 22 - year - old Thai woman with Graves ' disease", "start": 3, "end": 15}, {"entity_id": "15760792_4_Ent1", "role": "Subject_Age", "text": "22 - year - old", "start": 4, "end": 9}, {"entity_id": "15760792_4_Ent2", "role": "Subject_Race", "text": "Thai", "start": 9, "end": 10}, {"entity_id": "15760792_4_Ent3", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "15760792_4_Ent6", "role": "Treatment_Disorder", "text": "Graves ' disease", "start": 12, "end": 15}, {"entity_id": "15760792_4_Ent4", "role": "Effect", "text": "tinnitus , hearing impairment in the left ear ( with progression to the right ear ) , and vertigo", "start": 16, "end": 35}, {"entity_id": "15760792_4_Ent8", "role": "Treatment_Time_elapsed", "text": "after 3 years", "start": 36, "end": 39}, {"entity_id": "15760792_4_Ent5", "role": "Treatment", "text": "after 3 years of therapy with PTU", "start": 36, "end": 43}, {"entity_id": "15760792_4_Ent7", "role": "Treatment_Drug", "text": "PTU", "start": 42, "end": 43}]}], "entity_mentions": [{"id": "15760792_4_Ent0", "text": "a 22 - year - old Thai woman with Graves ' disease", "entity_type": "Entity", "start": 3, "end": 15}, {"id": "15760792_4_Ent1", "text": "22 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "15760792_4_Ent2", "text": "Thai", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15760792_4_Ent3", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15760792_4_Ent6", "text": "Graves ' disease", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "15760792_4_Ent4", "text": "tinnitus , hearing impairment in the left ear ( with progression to the right ear ) , and vertigo", "entity_type": "Entity", "start": 16, "end": 35}, {"id": "15760792_4_Ent8", "text": "after 3 years", "entity_type": "Entity", "start": 36, "end": 39}, {"id": "15760792_4_Ent5", "text": "after 3 years of therapy with PTU", "entity_type": "Entity", "start": 36, "end": 43}, {"id": "15760792_4_Ent7", "text": "PTU", "entity_type": "Entity", "start": 42, "end": 43}], "lang": "en"}
{"doc_id": "15785053_2", "wnd_id": "15785053_2_1", "text": "The relation between tacrolimus treatment and staining was suggested by the appearance of pigmentation during topical tacrolimus treatment and its clinical disappearance when treatment was stopped .", "tokens": ["The", "relation", "between", "tacrolimus", "treatment", "and", "staining", "was", "suggested", "by", "the", "appearance", "of", "pigmentation", "during", "topical", "tacrolimus", "treatment", "and", "its", "clinical", "disappearance", "when", "treatment", "was", "stopped", "."], "event_mentions": [{"id": "15785053_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 14, "end": 15}, "arguments": [{"entity_id": "15785053_2_Ent0", "role": "Effect", "text": "appearance of pigmentation", "start": 11, "end": 14}, {"entity_id": "15785053_2_Ent3", "role": "Treatment_Route", "text": "topical", "start": 15, "end": 16}, {"entity_id": "15785053_2_Ent1", "role": "Treatment", "text": "topical tacrolimus", "start": 15, "end": 17}, {"entity_id": "15785053_2_Ent2", "role": "Treatment_Drug", "text": "tacrolimus", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "15785053_2_Ent0", "text": "appearance of pigmentation", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "15785053_2_Ent3", "text": "topical", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15785053_2_Ent1", "text": "topical tacrolimus", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "15785053_2_Ent2", "text": "tacrolimus", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "15795553_1", "wnd_id": "15795553_1_1", "text": "Risperidone is a frequently used member of a new class of atypical antipsychotics - the serotonin - dopamine antagonists ( SDAs) - due to its comparatively high efficacy and low D2/5HT2 binding ratio , which results in a low incidence of extrapyramidal side effects including tardive dyskinesia ( TD ) .", "tokens": ["Risperidone", "is", "a", "frequently", "used", "member", "of", "a", "new", "class", "of", "atypical", "antipsychotics", "-", "the", "serotonin", "-", "dopamine", "antagonists", "(", "SDAs)", "-", "due", "to", "its", "comparatively", "high", "efficacy", "and", "low", "D2/5HT2", "binding", "ratio", ",", "which", "results", "in", "a", "low", "incidence", "of", "extrapyramidal", "side", "effects", "including", "tardive", "dyskinesia", "(", "TD", ")", "."], "event_mentions": [{"id": "15795553_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "results", "start": 35, "end": 36}, "arguments": [{"entity_id": "15795553_1_Ent1", "role": "Treatment", "text": "Risperidone", "start": 0, "end": 1}, {"entity_id": "15795553_1_Ent2", "role": "Treatment_Drug", "text": "Risperidone", "start": 0, "end": 1}, {"entity_id": "15795553_1_Ent0", "role": "Effect", "text": "tardive dyskinesia", "start": 45, "end": 47}]}], "entity_mentions": [{"id": "15795553_1_Ent1", "text": "Risperidone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15795553_1_Ent2", "text": "Risperidone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15795553_1_Ent0", "text": "tardive dyskinesia", "entity_type": "Entity", "start": 45, "end": 47}], "lang": "en"}
{"doc_id": "15806568_3", "wnd_id": "15806568_3_1", "text": "Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections .", "tokens": ["Visual", "system", "side", "effects", "caused", "by", "parasympathetic", "dysfunction", "after", "botulinum", "toxin", "type", "B", "injections", "."], "event_mentions": [{"id": "15806568_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 8, "end": 9}, "arguments": [{"entity_id": "15806568_3_Ent0", "role": "Effect", "text": "Visual system side effects caused by parasympathetic dysfunction", "start": 0, "end": 8}, {"entity_id": "15806568_3_Ent2", "role": "Treatment_Drug", "text": "botulinum toxin type B", "start": 9, "end": 13}, {"entity_id": "15806568_3_Ent1", "role": "Treatment", "text": "botulinum toxin type B injections", "start": 9, "end": 14}, {"entity_id": "15806568_3_Ent3", "role": "Treatment_Route", "text": "injections", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "15806568_3_Ent0", "text": "Visual system side effects caused by parasympathetic dysfunction", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "15806568_3_Ent2", "text": "botulinum toxin type B", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "15806568_3_Ent1", "text": "botulinum toxin type B injections", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "15806568_3_Ent3", "text": "injections", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "15811174_3", "wnd_id": "15811174_3_1", "text": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin .", "tokens": ["We", "report", "on", "a", "patient", "who", "developed", "acute", "rhabdomyolysis", "after", "taking", "cerivastatin", "."], "event_mentions": [{"id": "15811174_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 9, "end": 10}, "arguments": [{"entity_id": "15811174_3_Ent0", "role": "Subject", "text": "a patient", "start": 3, "end": 5}, {"entity_id": "15811174_3_Ent1", "role": "Effect", "text": "acute rhabdomyolysis", "start": 7, "end": 9}, {"entity_id": "15811174_3_Ent2", "role": "Treatment", "text": "cerivastatin", "start": 11, "end": 12}, {"entity_id": "15811174_3_Ent3", "role": "Treatment_Drug", "text": "cerivastatin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "15811174_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15811174_3_Ent1", "text": "acute rhabdomyolysis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15811174_3_Ent2", "text": "cerivastatin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15811174_3_Ent3", "text": "cerivastatin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "15823103_2", "wnd_id": "15823103_2_1", "text": "However , one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea , and another four patients developed eruptions , hypotension , and tachycardia soon after administration of CBDCA .", "tokens": ["However", ",", "one", "patient", "exhibited", "severe", "hypersensitivity", "reactions", "including", "cardiac", "arrest", "and", "apnea", ",", "and", "another", "four", "patients", "developed", "eruptions", ",", "hypotension", ",", "and", "tachycardia", "soon", "after", "administration", "of", "CBDCA", "."], "event_mentions": [{"id": "15823103_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "administration", "start": 27, "end": 28}, "arguments": [{"entity_id": "15823103_2_Ent0", "role": "Subject", "text": "one patient", "start": 2, "end": 4}, {"entity_id": "15823103_2_Ent1", "role": "Effect", "text": "severe hypersensitivity reactions including cardiac arrest and apnea", "start": 5, "end": 13}, {"entity_id": "15823103_2_Ent2", "role": "Treatment", "text": "CBDCA", "start": 29, "end": 30}, {"entity_id": "15823103_2_Ent3", "role": "Treatment_Drug", "text": "CBDCA", "start": 29, "end": 30}]}, {"id": "15823103_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "administration", "start": 27, "end": 28}, "arguments": [{"entity_id": "15823103_2_Ent4", "role": "Subject", "text": "four patients", "start": 16, "end": 18}, {"entity_id": "15823103_2_Ent5", "role": "Effect", "text": "eruptions , hypotension , and tachycardia", "start": 19, "end": 25}, {"entity_id": "15823103_2_Ent6", "role": "Treatment", "text": "CBDCA", "start": 29, "end": 30}, {"entity_id": "15823103_2_Ent7", "role": "Treatment_Drug", "text": "CBDCA", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "15823103_2_Ent0", "text": "one patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15823103_2_Ent1", "text": "severe hypersensitivity reactions including cardiac arrest and apnea", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "15823103_2_Ent4", "text": "four patients", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "15823103_2_Ent5", "text": "eruptions , hypotension , and tachycardia", "entity_type": "Entity", "start": 19, "end": 25}, {"id": "15823103_2_Ent2", "text": "CBDCA", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "15823103_2_Ent3", "text": "CBDCA", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "15823103_2_Ent6", "text": "CBDCA", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "15823103_2_Ent7", "text": "CBDCA", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "15836666_1", "wnd_id": "15836666_1_1", "text": "Chronic fentanyl application induces adrenocortical insufficiency .", "tokens": ["Chronic", "fentanyl", "application", "induces", "adrenocortical", "insufficiency", "."], "event_mentions": [{"id": "15836666_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induces", "start": 3, "end": 4}, "arguments": [{"entity_id": "15836666_1_Ent3", "role": "Treatment_Duration", "text": "Chronic", "start": 0, "end": 1}, {"entity_id": "15836666_1_Ent1", "role": "Treatment", "text": "Chronic fentanyl", "start": 0, "end": 2}, {"entity_id": "15836666_1_Ent2", "role": "Treatment_Drug", "text": "fentanyl", "start": 1, "end": 2}, {"entity_id": "15836666_1_Ent0", "role": "Effect", "text": "adrenocortical insufficiency", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "15836666_1_Ent3", "text": "Chronic", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15836666_1_Ent1", "text": "Chronic fentanyl", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15836666_1_Ent2", "text": "fentanyl", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15836666_1_Ent0", "text": "adrenocortical insufficiency", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "15840734_1", "wnd_id": "15840734_1_1", "text": "Fluphenazine - induced neuroleptic malignant syndrome in a schizophrenic patient .", "tokens": ["Fluphenazine", "-", "induced", "neuroleptic", "malignant", "syndrome", "in", "a", "schizophrenic", "patient", "."], "event_mentions": [{"id": "15840734_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15840734_1_Ent2", "role": "Treatment", "text": "Fluphenazine", "start": 0, "end": 1}, {"entity_id": "15840734_1_Ent3", "role": "Treatment_Drug", "text": "Fluphenazine", "start": 0, "end": 1}, {"entity_id": "15840734_1_Ent1", "role": "Effect", "text": "neuroleptic malignant syndrome", "start": 3, "end": 6}, {"entity_id": "15840734_1_Ent0", "role": "Subject", "text": "a schizophrenic patient", "start": 7, "end": 10}, {"entity_id": "15840734_1_Ent4", "role": "Treatment_Disorder", "text": "schizophrenic", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "15840734_1_Ent2", "text": "Fluphenazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15840734_1_Ent3", "text": "Fluphenazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15840734_1_Ent1", "text": "neuroleptic malignant syndrome", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "15840734_1_Ent0", "text": "a schizophrenic patient", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "15840734_1_Ent4", "text": "schizophrenic", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "1584367_1", "wnd_id": "1584367_1_1", "text": "Intraventricular vancomycin - induced cerebrospinal fluid eosinophilia : report of two patients .", "tokens": ["Intraventricular", "vancomycin", "-", "induced", "cerebrospinal", "fluid", "eosinophilia", ":", "report", "of", "two", "patients", "."], "event_mentions": [{"id": "1584367_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "1584367_1_Ent4", "role": "Treatment_Route", "text": "Intraventricular", "start": 0, "end": 1}, {"entity_id": "1584367_1_Ent3", "role": "Treatment", "text": "Intraventricular vancomycin", "start": 0, "end": 2}, {"entity_id": "1584367_1_Ent5", "role": "Treatment_Drug", "text": "vancomycin", "start": 1, "end": 2}, {"entity_id": "1584367_1_Ent2", "role": "Effect", "text": "cerebrospinal fluid eosinophilia", "start": 4, "end": 7}, {"entity_id": "1584367_1_Ent1", "role": "Subject_Population", "text": "two", "start": 10, "end": 11}, {"entity_id": "1584367_1_Ent0", "role": "Subject", "text": "two patients .", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "1584367_1_Ent4", "text": "Intraventricular", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1584367_1_Ent3", "text": "Intraventricular vancomycin", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1584367_1_Ent5", "text": "vancomycin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "1584367_1_Ent2", "text": "cerebrospinal fluid eosinophilia", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "1584367_1_Ent1", "text": "two", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1584367_1_Ent0", "text": "two patients .", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "15852680_2", "wnd_id": "15852680_2_1", "text": "We report a case of interstitial pneumonitis induced by bicalutamide and/or leuprorelin acetate given as therapy for prostate cancer , in which the pneumonitis was successfully managed by steroid treatment .", "tokens": ["We", "report", "a", "case", "of", "interstitial", "pneumonitis", "induced", "by", "bicalutamide", "and/or", "leuprorelin", "acetate", "given", "as", "therapy", "for", "prostate", "cancer", ",", "in", "which", "the", "pneumonitis", "was", "successfully", "managed", "by", "steroid", "treatment", "."], "event_mentions": [{"id": "15852680_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "15852680_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "15852680_2_Ent1", "role": "Effect", "text": "interstitial pneumonitis", "start": 5, "end": 7}, {"entity_id": "15852680_2_Ent4", "role": "Treatment_Drug", "text": "bicalutamide", "start": 9, "end": 10}, {"entity_id": "15852680_2_Ent6", "role": "Combination_Drug", "text": "bicalutamide", "start": 9, "end": 10}, {"entity_id": "15852680_2_Ent2", "role": "Treatment", "text": "bicalutamide and/or leuprorelin acetate given as therapy for prostate cancer", "start": 9, "end": 19}, {"entity_id": "15852680_2_Ent5", "role": "Treatment_Drug", "text": "leuprorelin acetate", "start": 11, "end": 13}, {"entity_id": "15852680_2_Ent7", "role": "Combination_Drug", "text": "leuprorelin acetate", "start": 11, "end": 13}, {"entity_id": "15852680_2_Ent3", "role": "Treatment_Disorder", "text": "prostate cancer", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "15852680_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15852680_2_Ent1", "text": "interstitial pneumonitis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15852680_2_Ent4", "text": "bicalutamide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15852680_2_Ent6", "text": "bicalutamide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15852680_2_Ent2", "text": "bicalutamide and/or leuprorelin acetate given as therapy for prostate cancer", "entity_type": "Entity", "start": 9, "end": 19}, {"id": "15852680_2_Ent5", "text": "leuprorelin acetate", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "15852680_2_Ent7", "text": "leuprorelin acetate", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "15852680_2_Ent3", "text": "prostate cancer", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "15866658_4", "wnd_id": "15866658_4_1", "text": "The side effects of MMF , such as bone marrow toxicity , have been reported .", "tokens": ["The", "side", "effects", "of", "MMF", ",", "such", "as", "bone", "marrow", "toxicity", ",", "have", "been", "reported", "."], "event_mentions": [{"id": "15866658_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 14, "end": 15}, "arguments": [{"entity_id": "15866658_4_Ent1", "role": "Treatment", "text": "MMF", "start": 4, "end": 5}, {"entity_id": "15866658_4_Ent2", "role": "Treatment_Drug", "text": "MMF", "start": 4, "end": 5}, {"entity_id": "15866658_4_Ent0", "role": "Effect", "text": "bone marrow toxicity", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "15866658_4_Ent1", "text": "MMF", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15866658_4_Ent2", "text": "MMF", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15866658_4_Ent0", "text": "bone marrow toxicity", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "15878975_2", "wnd_id": "15878975_2_1", "text": "Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D ) immune globulin intravenous administration for immune thrombocytopenic purpura .", "tokens": ["Disseminated", "intravascular", "coagulation", "associated", "with", "acute", "hemoglobinemia", "or", "hemoglobinuria", "following", "Rh(0)(D", ")", "immune", "globulin", "intravenous", "administration", "for", "immune", "thrombocytopenic", "purpura", "."], "event_mentions": [{"id": "15878975_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "15878975_2_Ent0", "role": "Effect", "text": "Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria", "start": 0, "end": 9}, {"entity_id": "15878975_2_Ent2", "role": "Treatment_Drug", "text": "Rh(0)(D ) immune globulin", "start": 10, "end": 14}, {"entity_id": "15878975_2_Ent1", "role": "Treatment", "text": "Rh(0)(D ) immune globulin intravenous", "start": 10, "end": 15}, {"entity_id": "15878975_2_Ent3", "role": "Treatment_Route", "text": "intravenous", "start": 14, "end": 15}, {"entity_id": "15878975_2_Ent4", "role": "Treatment_Disorder", "text": "immune thrombocytopenic purpura", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "15878975_2_Ent0", "text": "Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "15878975_2_Ent2", "text": "Rh(0)(D ) immune globulin", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "15878975_2_Ent1", "text": "Rh(0)(D ) immune globulin intravenous", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "15878975_2_Ent3", "text": "intravenous", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15878975_2_Ent4", "text": "immune thrombocytopenic purpura", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "15895899_1", "wnd_id": "15895899_1_1", "text": "After the second infliximab infusion , he was found to have a severe transient neutropenia ( 0.5 x 10(9)/L ) .", "tokens": ["After", "the", "second", "infliximab", "infusion", ",", "he", "was", "found", "to", "have", "a", "severe", "transient", "neutropenia", "(", "0.5", "x", "10(9)/L", ")", "."], "event_mentions": [{"id": "15895899_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "found", "start": 8, "end": 9}, "arguments": [{"entity_id": "15895899_1_Ent3", "role": "Treatment", "text": "infliximab", "start": 3, "end": 4}, {"entity_id": "15895899_1_Ent4", "role": "Treatment_Drug", "text": "infliximab", "start": 3, "end": 4}, {"entity_id": "15895899_1_Ent5", "role": "Treatment_Route", "text": "infusion", "start": 4, "end": 5}, {"entity_id": "15895899_1_Ent0", "role": "Subject", "text": "he", "start": 6, "end": 7}, {"entity_id": "15895899_1_Ent1", "role": "Subject_Gender", "text": "he", "start": 6, "end": 7}, {"entity_id": "15895899_1_Ent2", "role": "Effect", "text": "severe transient neutropenia ( 0.5 x 10(9)/L )", "start": 12, "end": 20}]}], "entity_mentions": [{"id": "15895899_1_Ent3", "text": "infliximab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15895899_1_Ent4", "text": "infliximab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15895899_1_Ent5", "text": "infusion", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15895899_1_Ent0", "text": "he", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15895899_1_Ent1", "text": "he", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15895899_1_Ent2", "text": "severe transient neutropenia ( 0.5 x 10(9)/L )", "entity_type": "Entity", "start": 12, "end": 20}], "lang": "en"}
{"doc_id": "15895899_2", "wnd_id": "15895899_2_1", "text": "Drug - induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy .", "tokens": ["Drug", "-", "induced", "agranulocytosis", "during", "treatment", "with", "infliximab", "in", "enteropathic", "spondyloarthropathy", "."], "event_mentions": [{"id": "15895899_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 4, "end": 5}, "arguments": [{"entity_id": "15895899_2_Ent0", "role": "Effect", "text": "Drug - induced agranulocytosis", "start": 0, "end": 4}, {"entity_id": "15895899_2_Ent1", "role": "Treatment", "text": "infliximab", "start": 7, "end": 8}, {"entity_id": "15895899_2_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 7, "end": 8}, {"entity_id": "15895899_2_Ent3", "role": "Treatment_Disorder", "text": "enteropathic spondyloarthropathy", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "15895899_2_Ent0", "text": "Drug - induced agranulocytosis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "15895899_2_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15895899_2_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15895899_2_Ent3", "text": "enteropathic spondyloarthropathy", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "15927910_1", "wnd_id": "15927910_1_1", "text": "After only the third dose of pentamidine , it was noted that the patient 's heart rate had decreased to 48 beats / minute .", "tokens": ["After", "only", "the", "third", "dose", "of", "pentamidine", ",", "it", "was", "noted", "that", "the", "patient", "'s", "heart", "rate", "had", "decreased", "to", "48", "beats", "/", "minute", "."], "event_mentions": [{"id": "15927910_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "15927910_1_Ent3", "role": "Treatment_Dosage", "text": "third dose", "start": 3, "end": 5}, {"entity_id": "15927910_1_Ent2", "role": "Treatment", "text": "third dose of pentamidine", "start": 3, "end": 7}, {"entity_id": "15927910_1_Ent4", "role": "Treatment_Drug", "text": "pentamidine", "start": 6, "end": 7}, {"entity_id": "15927910_1_Ent0", "role": "Subject", "text": "patient 's", "start": 13, "end": 15}, {"entity_id": "15927910_1_Ent1", "role": "Effect", "text": "heart rate had decreased to 48 beats / minute", "start": 15, "end": 24}]}], "entity_mentions": [{"id": "15927910_1_Ent3", "text": "third dose", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15927910_1_Ent2", "text": "third dose of pentamidine", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "15927910_1_Ent4", "text": "pentamidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15927910_1_Ent0", "text": "patient 's", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "15927910_1_Ent1", "text": "heart rate had decreased to 48 beats / minute", "entity_type": "Entity", "start": 15, "end": 24}], "lang": "en"}
{"doc_id": "15927910_2", "wnd_id": "15927910_2_1", "text": "Although various manifestations of pentamidine - induced cardiotoxicity have been reported , to our knowledge , second - degree heart block associated with this agent has not been described .", "tokens": ["Although", "various", "manifestations", "of", "pentamidine", "-", "induced", "cardiotoxicity", "have", "been", "reported", ",", "to", "our", "knowledge", ",", "second", "-", "degree", "heart", "block", "associated", "with", "this", "agent", "has", "not", "been", "described", "."], "event_mentions": [{"id": "15927910_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "15927910_2_Ent1", "role": "Treatment", "text": "pentamidine", "start": 4, "end": 5}, {"entity_id": "15927910_2_Ent2", "role": "Treatment_Drug", "text": "pentamidine", "start": 4, "end": 5}, {"entity_id": "15927910_2_Ent0", "role": "Effect", "text": "cardiotoxicity", "start": 7, "end": 8}]}, {"id": "15927910_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 21, "end": 22}, "arguments": [{"entity_id": "15927910_2_Ent4", "role": "Treatment", "text": "pentamidine", "start": 4, "end": 5}, {"entity_id": "15927910_2_Ent5", "role": "Treatment_Drug", "text": "pentamidine", "start": 4, "end": 5}, {"entity_id": "15927910_2_Ent3", "role": "Effect", "text": "second - degree heart block", "start": 16, "end": 21}]}], "entity_mentions": [{"id": "15927910_2_Ent1", "text": "pentamidine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15927910_2_Ent2", "text": "pentamidine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15927910_2_Ent4", "text": "pentamidine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15927910_2_Ent5", "text": "pentamidine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15927910_2_Ent0", "text": "cardiotoxicity", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15927910_2_Ent3", "text": "second - degree heart block", "entity_type": "Entity", "start": 16, "end": 21}], "lang": "en"}
{"doc_id": "15927910_4", "wnd_id": "15927910_4_1", "text": "Early - onset pentamidine - associated second - degree heart block and sinus bradycardia : case report and review of the literature .", "tokens": ["Early", "-", "onset", "pentamidine", "-", "associated", "second", "-", "degree", "heart", "block", "and", "sinus", "bradycardia", ":", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "15927910_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "15927910_4_Ent1", "role": "Effect", "text": "Early - onset", "start": 0, "end": 3}, {"entity_id": "15927910_4_Ent3", "role": "Treatment", "text": "pentamidine", "start": 3, "end": 4}, {"entity_id": "15927910_4_Ent4", "role": "Treatment_Drug", "text": "pentamidine", "start": 3, "end": 4}, {"entity_id": "15927910_4_Ent2", "role": "Effect", "text": "second - degree heart block and sinus bradycardia", "start": 6, "end": 14}, {"entity_id": "15927910_4_Ent0", "role": "Subject", "text": "case", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "15927910_4_Ent1", "text": "Early - onset", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15927910_4_Ent3", "text": "pentamidine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15927910_4_Ent4", "text": "pentamidine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15927910_4_Ent2", "text": "second - degree heart block and sinus bradycardia", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "15927910_4_Ent0", "text": "case", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "15944830_4", "wnd_id": "15944830_4_1", "text": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia .", "tokens": ["Ophthalmologists", "should", "be", "aware", "of", "the", "ocular", "side", "effects", "of", "IFN", "therapy", "and", "carefully", "monitor", "patients", "for", "the", "possible", "occurrence", "of", "hypoalbuminemia", "and", "thrombocytopenia", "."], "event_mentions": [{"id": "15944830_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "aware", "start": 3, "end": 4}, "arguments": [{"entity_id": "15944830_4_Ent1", "role": "Effect", "text": "ocular side effects", "start": 6, "end": 9}, {"entity_id": "15944830_4_Ent3", "role": "Treatment", "text": "IFN", "start": 10, "end": 11}, {"entity_id": "15944830_4_Ent4", "role": "Treatment_Drug", "text": "IFN", "start": 10, "end": 11}, {"entity_id": "15944830_4_Ent0", "role": "Subject", "text": "patients", "start": 15, "end": 16}, {"entity_id": "15944830_4_Ent2", "role": "Effect", "text": "hypoalbuminemia and thrombocytopenia", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "15944830_4_Ent1", "text": "ocular side effects", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "15944830_4_Ent3", "text": "IFN", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15944830_4_Ent4", "text": "IFN", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15944830_4_Ent0", "text": "patients", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15944830_4_Ent2", "text": "hypoalbuminemia and thrombocytopenia", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "15961942_2", "wnd_id": "15961942_2_1", "text": "OBJECTIVE : To report the late development of immune - mediated diabetes mellitus after completion of alfa - interferon therapy for hepatitis C in an Asian patient .", "tokens": ["OBJECTIVE", ":", "To", "report", "the", "late", "development", "of", "immune", "-", "mediated", "diabetes", "mellitus", "after", "completion", "of", "alfa", "-", "interferon", "therapy", "for", "hepatitis", "C", "in", "an", "Asian", "patient", "."], "event_mentions": [{"id": "15961942_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "15961942_2_Ent2", "role": "Effect", "text": "the late development of immune - mediated diabetes mellitus", "start": 4, "end": 13}, {"entity_id": "15961942_2_Ent3", "role": "Treatment", "text": "alfa - interferon", "start": 16, "end": 19}, {"entity_id": "15961942_2_Ent4", "role": "Treatment_Drug", "text": "alfa - interferon", "start": 16, "end": 19}, {"entity_id": "15961942_2_Ent5", "role": "Treatment_Disorder", "text": "hepatitis C", "start": 21, "end": 23}, {"entity_id": "15961942_2_Ent0", "role": "Subject", "text": "an Asian patient", "start": 24, "end": 27}, {"entity_id": "15961942_2_Ent1", "role": "Subject_Race", "text": "Asian", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "15961942_2_Ent2", "text": "the late development of immune - mediated diabetes mellitus", "entity_type": "Entity", "start": 4, "end": 13}, {"id": "15961942_2_Ent3", "text": "alfa - interferon", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "15961942_2_Ent4", "text": "alfa - interferon", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "15961942_2_Ent5", "text": "hepatitis C", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "15961942_2_Ent0", "text": "an Asian patient", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "15961942_2_Ent1", "text": "Asian", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "15965422_4", "wnd_id": "15965422_4_1", "text": "We review the literature on previously reported cases of cutaneous necrosis after injection of standard interferon alfa or pegylated interferon alfa - 2b and discuss the different pathophysiologic mechanisms that might be involved .", "tokens": ["We", "review", "the", "literature", "on", "previously", "reported", "cases", "of", "cutaneous", "necrosis", "after", "injection", "of", "standard", "interferon", "alfa", "or", "pegylated", "interferon", "alfa", "-", "2b", "and", "discuss", "the", "different", "pathophysiologic", "mechanisms", "that", "might", "be", "involved", "."], "event_mentions": [{"id": "15965422_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "15965422_4_Ent0", "role": "Effect", "text": "cutaneous necrosis", "start": 9, "end": 11}, {"entity_id": "15965422_4_Ent3", "role": "Treatment_Route", "text": "injection", "start": 12, "end": 13}, {"entity_id": "15965422_4_Ent1", "role": "Treatment", "text": "standard interferon alfa", "start": 14, "end": 17}, {"entity_id": "15965422_4_Ent4", "role": "Treatment_Drug", "text": "standard interferon alfa", "start": 14, "end": 17}, {"entity_id": "15965422_4_Ent2", "role": "Treatment", "text": "pegylated interferon alfa - 2b", "start": 18, "end": 23}, {"entity_id": "15965422_4_Ent5", "role": "Treatment_Drug", "text": "pegylated interferon alfa - 2b", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "15965422_4_Ent0", "text": "cutaneous necrosis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "15965422_4_Ent3", "text": "injection", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15965422_4_Ent1", "text": "standard interferon alfa", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "15965422_4_Ent4", "text": "standard interferon alfa", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "15965422_4_Ent2", "text": "pegylated interferon alfa - 2b", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "15965422_4_Ent5", "text": "pegylated interferon alfa - 2b", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "15977922_1", "wnd_id": "15977922_1_1", "text": "Potential mechanisms involved in the occurrence of ischemic colitis in patients receiving tegaserod are also discussed .", "tokens": ["Potential", "mechanisms", "involved", "in", "the", "occurrence", "of", "ischemic", "colitis", "in", "patients", "receiving", "tegaserod", "are", "also", "discussed", "."], "event_mentions": [{"id": "15977922_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurrence", "start": 5, "end": 6}, "arguments": [{"entity_id": "15977922_1_Ent1", "role": "Effect", "text": "ischemic colitis", "start": 7, "end": 9}, {"entity_id": "15977922_1_Ent0", "role": "Subject", "text": "patients", "start": 10, "end": 11}, {"entity_id": "15977922_1_Ent2", "role": "Treatment", "text": "tegaserod", "start": 12, "end": 13}, {"entity_id": "15977922_1_Ent3", "role": "Treatment_Drug", "text": "tegaserod", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "15977922_1_Ent1", "text": "ischemic colitis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15977922_1_Ent0", "text": "patients", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15977922_1_Ent2", "text": "tegaserod", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15977922_1_Ent3", "text": "tegaserod", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "15977922_3", "wnd_id": "15977922_3_1", "text": "We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis , tegaserod use , and irritable bowel syndrome .", "tokens": ["We", "describe", "the", "development", "of", "ischemic", "colitis", "in", "a", "woman", "who", "was", "treated", "with", "tegaserod", "and", "review", "the", "relationship", "among", "ischemic", "colitis", ",", "tegaserod", "use", ",", "and", "irritable", "bowel", "syndrome", "."], "event_mentions": [{"id": "15977922_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 3, "end": 4}, "arguments": [{"entity_id": "15977922_3_Ent2", "role": "Effect", "text": "ischemic colitis", "start": 5, "end": 7}, {"entity_id": "15977922_3_Ent0", "role": "Subject", "text": "woman", "start": 9, "end": 10}, {"entity_id": "15977922_3_Ent1", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "15977922_3_Ent3", "role": "Treatment", "text": "tegaserod", "start": 14, "end": 15}, {"entity_id": "15977922_3_Ent4", "role": "Treatment_Drug", "text": "tegaserod", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "15977922_3_Ent2", "text": "ischemic colitis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15977922_3_Ent0", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15977922_3_Ent1", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15977922_3_Ent3", "text": "tegaserod", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15977922_3_Ent4", "text": "tegaserod", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "16008658_1", "wnd_id": "16008658_1_1", "text": "46 - year - old woman developed painful ulcers over her lower abdomen in the form of reticulate erythema after injecting interferon beta - 1b subcutaneously for multiple sclerosis .", "tokens": ["46", "-", "year", "-", "old", "woman", "developed", "painful", "ulcers", "over", "her", "lower", "abdomen", "in", "the", "form", "of", "reticulate", "erythema", "after", "injecting", "interferon", "beta", "-", "1b", "subcutaneously", "for", "multiple", "sclerosis", "."], "event_mentions": [{"id": "16008658_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "16008658_1_Ent1", "role": "Subject_Age", "text": "46 - year - old", "start": 0, "end": 5}, {"entity_id": "16008658_1_Ent0", "role": "Subject", "text": "46 - year - old woman", "start": 0, "end": 6}, {"entity_id": "16008658_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 5, "end": 6}, {"entity_id": "16008658_1_Ent3", "role": "Effect", "text": "painful ulcers over her lower abdomen in the form of reticulate erythema", "start": 7, "end": 19}, {"entity_id": "16008658_1_Ent6", "role": "Treatment_Route", "text": "injecting", "start": 20, "end": 21}, {"entity_id": "16008658_1_Ent4", "role": "Treatment", "text": "injecting interferon beta - 1b subcutaneously", "start": 20, "end": 26}, {"entity_id": "16008658_1_Ent5", "role": "Treatment_Drug", "text": "interferon beta - 1b", "start": 21, "end": 25}, {"entity_id": "16008658_1_Ent7", "role": "Treatment_Disorder", "text": "multiple sclerosis", "start": 27, "end": 29}]}], "entity_mentions": [{"id": "16008658_1_Ent1", "text": "46 - year - old", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "16008658_1_Ent0", "text": "46 - year - old woman", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "16008658_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16008658_1_Ent3", "text": "painful ulcers over her lower abdomen in the form of reticulate erythema", "entity_type": "Entity", "start": 7, "end": 19}, {"id": "16008658_1_Ent6", "text": "injecting", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "16008658_1_Ent4", "text": "injecting interferon beta - 1b subcutaneously", "entity_type": "Entity", "start": 20, "end": 26}, {"id": "16008658_1_Ent5", "text": "interferon beta - 1b", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "16008658_1_Ent7", "text": "multiple sclerosis", "entity_type": "Entity", "start": 27, "end": 29}], "lang": "en"}
{"doc_id": "16012330_11", "wnd_id": "16012330_11_1", "text": "The authors suggest that in the absence of any proven benefit of itraconazole prophylaxis , and given the interaction of this drug with vincristine leading to severe and even potentially fatal toxicities , the combination use of these drugs should be avoided .", "tokens": ["The", "authors", "suggest", "that", "in", "the", "absence", "of", "any", "proven", "benefit", "of", "itraconazole", "prophylaxis", ",", "and", "given", "the", "interaction", "of", "this", "drug", "with", "vincristine", "leading", "to", "severe", "and", "even", "potentially", "fatal", "toxicities", ",", "the", "combination", "use", "of", "these", "drugs", "should", "be", "avoided", "."], "event_mentions": [{"id": "16012330_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "leading", "start": 24, "end": 25}, "arguments": [{"entity_id": "16012330_11_Ent1", "role": "Treatment", "text": "itraconazole", "start": 12, "end": 13}, {"entity_id": "16012330_11_Ent3", "role": "Treatment_Drug", "text": "itraconazole", "start": 12, "end": 13}, {"entity_id": "16012330_11_Ent5", "role": "Combination_Drug", "text": "itraconazole", "start": 12, "end": 13}, {"entity_id": "16012330_11_Ent2", "role": "Treatment", "text": "vincristine", "start": 23, "end": 24}, {"entity_id": "16012330_11_Ent4", "role": "Treatment_Drug", "text": "vincristine", "start": 23, "end": 24}, {"entity_id": "16012330_11_Ent6", "role": "Combination_Drug", "text": "vincristine", "start": 23, "end": 24}, {"entity_id": "16012330_11_Ent0", "role": "Effect", "text": "severe and even potentially fatal toxicities", "start": 26, "end": 32}]}], "entity_mentions": [{"id": "16012330_11_Ent1", "text": "itraconazole", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16012330_11_Ent3", "text": "itraconazole", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16012330_11_Ent5", "text": "itraconazole", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16012330_11_Ent2", "text": "vincristine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16012330_11_Ent4", "text": "vincristine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16012330_11_Ent6", "text": "vincristine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16012330_11_Ent0", "text": "severe and even potentially fatal toxicities", "entity_type": "Entity", "start": 26, "end": 32}], "lang": "en"}
{"doc_id": "16012330_5", "wnd_id": "16012330_5_1", "text": "A 3 - year - old boy diagnosed with acute lymphoblastic leukemia received induction chemotherapy .", "tokens": ["A", "3", "-", "year", "-", "old", "boy", "diagnosed", "with", "acute", "lymphoblastic", "leukemia", "received", "induction", "chemotherapy", "."], "event_mentions": [{"id": "16012330_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 12, "end": 13}, "arguments": [{"entity_id": "16012330_5_Ent0", "role": "Subject", "text": "A 3 - year - old boy diagnosed with acute lymphoblastic leukemia", "start": 0, "end": 12}, {"entity_id": "16012330_5_Ent1", "role": "Subject_Age", "text": "3 - year - old", "start": 1, "end": 6}, {"entity_id": "16012330_5_Ent2", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "16012330_5_Ent4", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 9, "end": 12}, {"entity_id": "16012330_5_Ent3", "role": "Treatment", "text": "induction chemotherapy", "start": 13, "end": 15}, {"entity_id": "16012330_5_Ent5", "role": "Treatment_Route", "text": "induction chemotherapy", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "16012330_5_Ent0", "text": "A 3 - year - old boy diagnosed with acute lymphoblastic leukemia", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "16012330_5_Ent1", "text": "3 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "16012330_5_Ent2", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16012330_5_Ent4", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "16012330_5_Ent3", "text": "induction chemotherapy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "16012330_5_Ent5", "text": "induction chemotherapy", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "16018164_4", "wnd_id": "16018164_4_1", "text": "Since 1979 , over 30 published case reports have documented the relationship between phenylpropanolamine and stroke .", "tokens": ["Since", "1979", ",", "over", "30", "published", "case", "reports", "have", "documented", "the", "relationship", "between", "phenylpropanolamine", "and", "stroke", "."], "event_mentions": [{"id": "16018164_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship", "start": 11, "end": 12}, "arguments": [{"entity_id": "16018164_4_Ent1", "role": "Treatment", "text": "phenylpropanolamine", "start": 13, "end": 14}, {"entity_id": "16018164_4_Ent2", "role": "Treatment_Drug", "text": "phenylpropanolamine", "start": 13, "end": 14}, {"entity_id": "16018164_4_Ent0", "role": "Effect", "text": "stroke", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "16018164_4_Ent1", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16018164_4_Ent2", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16018164_4_Ent0", "text": "stroke", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "16029707_1", "wnd_id": "16029707_1_1", "text": "Eruptive epidermoid cysts resulting from treatment with imiquimod .", "tokens": ["Eruptive", "epidermoid", "cysts", "resulting", "from", "treatment", "with", "imiquimod", "."], "event_mentions": [{"id": "16029707_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 3, "end": 4}, "arguments": [{"entity_id": "16029707_1_Ent0", "role": "Effect", "text": "Eruptive epidermoid cysts", "start": 0, "end": 3}, {"entity_id": "16029707_1_Ent1", "role": "Treatment", "text": "imiquimod", "start": 7, "end": 8}, {"entity_id": "16029707_1_Ent2", "role": "Treatment_Drug", "text": "imiquimod", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "16029707_1_Ent0", "text": "Eruptive epidermoid cysts", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16029707_1_Ent1", "text": "imiquimod", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16029707_1_Ent2", "text": "imiquimod", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "16044093_2", "wnd_id": "16044093_2_1", "text": "The case reported here is of a child given a large dose of intravenous iron sucrose ( 16 mg / kg ) over 3 hours , who subsequently developed features of systemic iron toxicity .", "tokens": ["The", "case", "reported", "here", "is", "of", "a", "child", "given", "a", "large", "dose", "of", "intravenous", "iron", "sucrose", "(", "16", "mg", "/", "kg", ")", "over", "3", "hours", ",", "who", "subsequently", "developed", "features", "of", "systemic", "iron", "toxicity", "."], "event_mentions": [{"id": "16044093_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 28, "end": 29}, "arguments": [{"entity_id": "16044093_2_Ent0", "role": "Subject", "text": "a child", "start": 6, "end": 8}, {"entity_id": "16044093_2_Ent1", "role": "Subject_Age", "text": "child", "start": 7, "end": 8}, {"entity_id": "16044093_2_Ent3", "role": "Treatment", "text": "a large dose of intravenous iron sucrose", "start": 9, "end": 16}, {"entity_id": "16044093_2_Ent4", "role": "Treatment_Drug", "text": "iron sucrose", "start": 14, "end": 16}, {"entity_id": "16044093_2_Ent5", "role": "Treatment_Dosage", "text": "16 mg / kg", "start": 17, "end": 21}, {"entity_id": "16044093_2_Ent6", "role": "Treatment_Duration", "text": "3 hours", "start": 23, "end": 25}, {"entity_id": "16044093_2_Ent2", "role": "Effect", "text": "systemic iron toxicity", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "16044093_2_Ent0", "text": "a child", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16044093_2_Ent1", "text": "child", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16044093_2_Ent3", "text": "a large dose of intravenous iron sucrose", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "16044093_2_Ent4", "text": "iron sucrose", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "16044093_2_Ent5", "text": "16 mg / kg", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "16044093_2_Ent6", "text": "3 hours", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "16044093_2_Ent2", "text": "systemic iron toxicity", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "160443_1", "wnd_id": "160443_1_1", "text": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature .", "tokens": ["Five", "personal", "observations", "of", "an", "acute", "amnestic", "episode", "in", "younger", "individuals", "after", "intake", "of", "clioquinol", "are", "described", "together", "with", "three", "observations", "from", "the", "medical", "literature", "."], "event_mentions": [{"id": "160443_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "160443_1_Ent2", "role": "Effect", "text": "acute amnestic episode", "start": 5, "end": 8}, {"entity_id": "160443_1_Ent1", "role": "Subject_Age", "text": "younger", "start": 9, "end": 10}, {"entity_id": "160443_1_Ent0", "role": "Subject", "text": "younger individuals", "start": 9, "end": 11}, {"entity_id": "160443_1_Ent5", "role": "Treatment_Route", "text": "intake", "start": 12, "end": 13}, {"entity_id": "160443_1_Ent3", "role": "Treatment", "text": "intake of clioquinol", "start": 12, "end": 15}, {"entity_id": "160443_1_Ent4", "role": "Treatment_Drug", "text": "clioquinol", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "160443_1_Ent2", "text": "acute amnestic episode", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "160443_1_Ent1", "text": "younger", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "160443_1_Ent0", "text": "younger individuals", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "160443_1_Ent5", "text": "intake", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "160443_1_Ent3", "text": "intake of clioquinol", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "160443_1_Ent4", "text": "clioquinol", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "160443_2", "wnd_id": "160443_2_1", "text": "The clinical aspect closely resembled classical transient global amnesia but the episode after clioquinol lasted longer ( 24 hours to three days ) and a more or less extensive retrograde amnesia persisted permanently .", "tokens": ["The", "clinical", "aspect", "closely", "resembled", "classical", "transient", "global", "amnesia", "but", "the", "episode", "after", "clioquinol", "lasted", "longer", "(", "24", "hours", "to", "three", "days", ")", "and", "a", "more", "or", "less", "extensive", "retrograde", "amnesia", "persisted", "permanently", "."], "event_mentions": [{"id": "160443_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "160443_2_Ent0", "role": "Effect", "text": "classical transient global amnesia", "start": 5, "end": 9}, {"entity_id": "160443_2_Ent2", "role": "Treatment", "text": "clioquinol", "start": 13, "end": 14}, {"entity_id": "160443_2_Ent3", "role": "Treatment_Drug", "text": "clioquinol", "start": 13, "end": 14}, {"entity_id": "160443_2_Ent1", "role": "Effect", "text": "a more or less extensive retrograde amnesia", "start": 24, "end": 31}]}], "entity_mentions": [{"id": "160443_2_Ent0", "text": "classical transient global amnesia", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "160443_2_Ent2", "text": "clioquinol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "160443_2_Ent3", "text": "clioquinol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "160443_2_Ent1", "text": "a more or less extensive retrograde amnesia", "entity_type": "Entity", "start": 24, "end": 31}], "lang": "en"}
{"doc_id": "16046172_1", "wnd_id": "16046172_1_1", "text": "In the other patient , a 78 - year - old woman , Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection .", "tokens": ["In", "the", "other", "patient", ",", "a", "78", "-", "year", "-", "old", "woman", ",", "Neisseria", "mucosa", "knee", "arthritis", "occurred", "after", "a", "single", "sodium", "hyaluronate", "injection", "."], "event_mentions": [{"id": "16046172_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 17, "end": 18}, "arguments": [{"entity_id": "16046172_1_Ent0", "role": "Subject", "text": "a 78 - year - old woman", "start": 5, "end": 12}, {"entity_id": "16046172_1_Ent1", "role": "Subject_Age", "text": "78 - year - old", "start": 6, "end": 11}, {"entity_id": "16046172_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 11, "end": 12}, {"entity_id": "16046172_1_Ent3", "role": "Effect", "text": "Neisseria mucosa knee arthritis", "start": 13, "end": 17}, {"entity_id": "16046172_1_Ent4", "role": "Treatment", "text": "a single sodium hyaluronate injection", "start": 19, "end": 24}, {"entity_id": "16046172_1_Ent7", "role": "Treatment_Dosage", "text": "single", "start": 20, "end": 21}, {"entity_id": "16046172_1_Ent6", "role": "Treatment_Drug", "text": "sodium hyaluronate", "start": 21, "end": 23}, {"entity_id": "16046172_1_Ent5", "role": "Treatment_Route", "text": "injection", "start": 23, "end": 24}, {"entity_id": "16046172_1_Ent8", "role": "Treatment_Dosage", "text": "injection", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "16046172_1_Ent0", "text": "a 78 - year - old woman", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "16046172_1_Ent1", "text": "78 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "16046172_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16046172_1_Ent3", "text": "Neisseria mucosa knee arthritis", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "16046172_1_Ent4", "text": "a single sodium hyaluronate injection", "entity_type": "Entity", "start": 19, "end": 24}, {"id": "16046172_1_Ent7", "text": "single", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "16046172_1_Ent6", "text": "sodium hyaluronate", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "16046172_1_Ent5", "text": "injection", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16046172_1_Ent8", "text": "injection", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "16046172_3", "wnd_id": "16046172_3_1", "text": "Septic knee arthritis after intra - articular hyaluronate injection .", "tokens": ["Septic", "knee", "arthritis", "after", "intra", "-", "articular", "hyaluronate", "injection", "."], "event_mentions": [{"id": "16046172_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "16046172_3_Ent0", "role": "Effect", "text": "Septic knee arthritis", "start": 0, "end": 3}, {"entity_id": "16046172_3_Ent1", "role": "Treatment", "text": "intra - articular hyaluronate injection", "start": 4, "end": 9}, {"entity_id": "16046172_3_Ent3", "role": "Treatment_Drug", "text": "hyaluronate", "start": 7, "end": 8}, {"entity_id": "16046172_3_Ent2", "role": "Treatment_Route", "text": "injection", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "16046172_3_Ent0", "text": "Septic knee arthritis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16046172_3_Ent1", "text": "intra - articular hyaluronate injection", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "16046172_3_Ent3", "text": "hyaluronate", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16046172_3_Ent2", "text": "injection", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "16062101_3", "wnd_id": "16062101_3_1", "text": "The authors report two cases of acute dystonic reactions ( ADRs ) as a side effect of lamivudine .", "tokens": ["The", "authors", "report", "two", "cases", "of", "acute", "dystonic", "reactions", "(", "ADRs", ")", "as", "a", "side", "effect", "of", "lamivudine", "."], "event_mentions": [{"id": "16062101_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "effect", "start": 15, "end": 16}, "arguments": [{"entity_id": "16062101_3_Ent1", "role": "Subject_Population", "text": "two", "start": 3, "end": 4}, {"entity_id": "16062101_3_Ent0", "role": "Subject", "text": "two cases", "start": 3, "end": 5}, {"entity_id": "16062101_3_Ent2", "role": "Effect", "text": "acute dystonic reactions ( ADRs )", "start": 6, "end": 12}, {"entity_id": "16062101_3_Ent3", "role": "Treatment", "text": "lamivudine", "start": 17, "end": 18}, {"entity_id": "16062101_3_Ent4", "role": "Treatment_Drug", "text": "lamivudine", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "16062101_3_Ent1", "text": "two", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16062101_3_Ent0", "text": "two cases", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16062101_3_Ent2", "text": "acute dystonic reactions ( ADRs )", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "16062101_3_Ent3", "text": "lamivudine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16062101_3_Ent4", "text": "lamivudine", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "16101941_1", "wnd_id": "16101941_1_1", "text": "Anaphylactic reaction and unrelated , subsequent , known side effects during therapy with thiethylperazine .", "tokens": ["Anaphylactic", "reaction", "and", "unrelated", ",", "subsequent", ",", "known", "side", "effects", "during", "therapy", "with", "thiethylperazine", "."], "event_mentions": [{"id": "16101941_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 10, "end": 11}, "arguments": [{"entity_id": "16101941_1_Ent0", "role": "Effect", "text": "Anaphylactic reaction", "start": 0, "end": 2}, {"entity_id": "16101941_1_Ent1", "role": "Treatment", "text": "thiethylperazine", "start": 13, "end": 14}, {"entity_id": "16101941_1_Ent2", "role": "Treatment_Drug", "text": "thiethylperazine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "16101941_1_Ent0", "text": "Anaphylactic reaction", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16101941_1_Ent1", "text": "thiethylperazine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16101941_1_Ent2", "text": "thiethylperazine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "16101941_3", "wnd_id": "16101941_3_1", "text": "Both reactions were caused due to this anti - emetic drug , but an additive effect of clemastine fumarate , prescribed to treat the anaphylactic reaction , is suggested by the sequence of events .", "tokens": ["Both", "reactions", "were", "caused", "due", "to", "this", "anti", "-", "emetic", "drug", ",", "but", "an", "additive", "effect", "of", "clemastine", "fumarate", ",", "prescribed", "to", "treat", "the", "anaphylactic", "reaction", ",", "is", "suggested", "by", "the", "sequence", "of", "events", "."], "event_mentions": [{"id": "16101941_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suggested", "start": 28, "end": 29}, "arguments": [{"entity_id": "16101941_3_Ent0", "role": "Effect", "text": "additive effect", "start": 14, "end": 16}, {"entity_id": "16101941_3_Ent1", "role": "Treatment", "text": "clemastine fumarate", "start": 17, "end": 19}, {"entity_id": "16101941_3_Ent3", "role": "Treatment_Drug", "text": "clemastine fumarate", "start": 17, "end": 19}, {"entity_id": "16101941_3_Ent2", "role": "Treatment_Disorder", "text": "anaphylactic reaction", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "16101941_3_Ent0", "text": "additive effect", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "16101941_3_Ent1", "text": "clemastine fumarate", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "16101941_3_Ent3", "text": "clemastine fumarate", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "16101941_3_Ent2", "text": "anaphylactic reaction", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "16109609_1", "wnd_id": "16109609_1_1", "text": "Gemcitabine - induced pericardial effusion and tamponade after unblocked cardiac irradiation .", "tokens": ["Gemcitabine", "-", "induced", "pericardial", "effusion", "and", "tamponade", "after", "unblocked", "cardiac", "irradiation", "."], "event_mentions": [{"id": "16109609_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16109609_1_Ent1", "role": "Treatment", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "16109609_1_Ent2", "role": "Treatment_Drug", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "16109609_1_Ent0", "role": "Effect", "text": "pericardial effusion and tamponade", "start": 3, "end": 7}, {"entity_id": "16109609_1_Ent3", "role": "Treatment_Disorder", "text": "unblocked cardiac irradiation", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "16109609_1_Ent1", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16109609_1_Ent2", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16109609_1_Ent0", "text": "pericardial effusion and tamponade", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "16109609_1_Ent3", "text": "unblocked cardiac irradiation", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "16116136_4", "wnd_id": "16116136_4_1", "text": "Primary CNS lymphoma regressed on withdrawal of MM .", "tokens": ["Primary", "CNS", "lymphoma", "regressed", "on", "withdrawal", "of", "MM", "."], "event_mentions": [{"id": "16116136_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "regressed", "start": 3, "end": 4}, "arguments": [{"entity_id": "16116136_4_Ent0", "role": "Effect", "text": "Primary CNS lymphoma", "start": 0, "end": 3}, {"entity_id": "16116136_4_Ent1", "role": "Treatment", "text": "withdrawal of MM", "start": 5, "end": 8}, {"entity_id": "16116136_4_Ent2", "role": "Treatment_Drug", "text": "MM", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "16116136_4_Ent0", "text": "Primary CNS lymphoma", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16116136_4_Ent1", "text": "withdrawal of MM", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "16116136_4_Ent2", "text": "MM", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "16119501_4", "wnd_id": "16119501_4_1", "text": "We report a case of baclofen withdrawal syndrome resulting from oral baclofen underdosing .", "tokens": ["We", "report", "a", "case", "of", "baclofen", "withdrawal", "syndrome", "resulting", "from", "oral", "baclofen", "underdosing", "."], "event_mentions": [{"id": "16119501_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 8, "end": 9}, "arguments": [{"entity_id": "16119501_4_Ent0", "role": "Effect", "text": "baclofen withdrawal syndrome", "start": 5, "end": 8}, {"entity_id": "16119501_4_Ent2", "role": "Treatment_Route", "text": "oral", "start": 10, "end": 11}, {"entity_id": "16119501_4_Ent1", "role": "Treatment", "text": "oral baclofen underdosing", "start": 10, "end": 13}, {"entity_id": "16119501_4_Ent3", "role": "Treatment_Drug", "text": "baclofen", "start": 11, "end": 12}, {"entity_id": "16119501_4_Ent4", "role": "Treatment_Dosage", "text": "underdosing", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "16119501_4_Ent0", "text": "baclofen withdrawal syndrome", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "16119501_4_Ent2", "text": "oral", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16119501_4_Ent1", "text": "oral baclofen underdosing", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "16119501_4_Ent3", "text": "baclofen", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16119501_4_Ent4", "text": "underdosing", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "16132305_1", "wnd_id": "16132305_1_1", "text": "Captopril - induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease .", "tokens": ["Captopril", "-", "induced", "pulmonary", "infiltrates", "with", "eosinophilia", "in", "an", "infant", "with", "congenital", "heart", "disease", "."], "event_mentions": [{"id": "16132305_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16132305_1_Ent4", "role": "Treatment", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "16132305_1_Ent5", "role": "Treatment_Drug", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "16132305_1_Ent3", "role": "Effect", "text": "pulmonary infiltrates with eosinophilia", "start": 3, "end": 7}, {"entity_id": "16132305_1_Ent0", "role": "Subject", "text": "an infant with congenital heart disease", "start": 8, "end": 14}, {"entity_id": "16132305_1_Ent1", "role": "Subject_Age", "text": "infant", "start": 9, "end": 10}, {"entity_id": "16132305_1_Ent2", "role": "Subject_Disorder", "text": "congenital heart disease", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "16132305_1_Ent4", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16132305_1_Ent5", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16132305_1_Ent3", "text": "pulmonary infiltrates with eosinophilia", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "16132305_1_Ent0", "text": "an infant with congenital heart disease", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "16132305_1_Ent1", "text": "infant", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16132305_1_Ent2", "text": "congenital heart disease", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "16132305_5", "wnd_id": "16132305_5_1", "text": "After discontinuing captopril and starting systemic steroids , her symptomatology rapidly improved , and her eosinophilia and radiographic abnormalities both resolved .", "tokens": ["After", "discontinuing", "captopril", "and", "starting", "systemic", "steroids", ",", "her", "symptomatology", "rapidly", "improved", ",", "and", "her", "eosinophilia", "and", "radiographic", "abnormalities", "both", "resolved", "."], "event_mentions": [{"id": "16132305_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 20, "end": 21}, "arguments": [{"entity_id": "16132305_5_Ent1", "role": "Treatment", "text": "discontinuing captopril and starting systemic steroids", "start": 1, "end": 7}, {"entity_id": "16132305_5_Ent2", "role": "Treatment_Drug", "text": "captopril", "start": 2, "end": 3}, {"entity_id": "16132305_5_Ent3", "role": "Treatment_Drug", "text": "steroids", "start": 6, "end": 7}, {"entity_id": "16132305_5_Ent0", "role": "Effect", "text": "her eosinophilia and radiographic abnormalities both resolved", "start": 14, "end": 21}, {"entity_id": "16132305_5_Ent4", "role": "Treatment_Disorder", "text": "eosinophilia", "start": 15, "end": 16}, {"entity_id": "16132305_5_Ent5", "role": "Treatment_Disorder", "text": "radiographic abnormalities", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "16132305_5_Ent1", "text": "discontinuing captopril and starting systemic steroids", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "16132305_5_Ent2", "text": "captopril", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16132305_5_Ent3", "text": "steroids", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16132305_5_Ent0", "text": "her eosinophilia and radiographic abnormalities both resolved", "entity_type": "Entity", "start": 14, "end": 21}, {"id": "16132305_5_Ent4", "text": "eosinophilia", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16132305_5_Ent5", "text": "radiographic abnormalities", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "16160485_1", "wnd_id": "16160485_1_1", "text": "CD20 - negative T - cell - rich B - cell lymphoma as a progression of a nodular lymphocyte - predominant Hodgkin 's lymphoma treated with rituximab : a molecular analysis using laser capture microdissection .", "tokens": ["CD20", "-", "negative", "T", "-", "cell", "-", "rich", "B", "-", "cell", "lymphoma", "as", "a", "progression", "of", "a", "nodular", "lymphocyte", "-", "predominant", "Hodgkin", "'s", "lymphoma", "treated", "with", "rituximab", ":", "a", "molecular", "analysis", "using", "laser", "capture", "microdissection", "."], "event_mentions": [{"id": "16160485_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 24, "end": 25}, "arguments": [{"entity_id": "16160485_1_Ent0", "role": "Effect", "text": "CD20 - negative T - cell - rich B - cell lymphoma", "start": 0, "end": 12}, {"entity_id": "16160485_1_Ent3", "role": "Treatment_Disorder", "text": "nodular lymphocyte - predominant Hodgkin 's lymphoma", "start": 17, "end": 24}, {"entity_id": "16160485_1_Ent1", "role": "Treatment", "text": "rituximab", "start": 26, "end": 27}, {"entity_id": "16160485_1_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "16160485_1_Ent0", "text": "CD20 - negative T - cell - rich B - cell lymphoma", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "16160485_1_Ent3", "text": "nodular lymphocyte - predominant Hodgkin 's lymphoma", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "16160485_1_Ent1", "text": "rituximab", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "16160485_1_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "16160485_2", "wnd_id": "16160485_2_1", "text": "Recently , CD20 - negative tumors have been described after Rituximab therapy .", "tokens": ["Recently", ",", "CD20", "-", "negative", "tumors", "have", "been", "described", "after", "Rituximab", "therapy", "."], "event_mentions": [{"id": "16160485_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 9, "end": 10}, "arguments": [{"entity_id": "16160485_2_Ent0", "role": "Effect", "text": "CD20 - negative tumors", "start": 2, "end": 6}, {"entity_id": "16160485_2_Ent1", "role": "Treatment", "text": "Rituximab", "start": 10, "end": 11}, {"entity_id": "16160485_2_Ent2", "role": "Treatment_Drug", "text": "Rituximab", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "16160485_2_Ent0", "text": "CD20 - negative tumors", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "16160485_2_Ent1", "text": "Rituximab", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16160485_2_Ent2", "text": "Rituximab", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "16167682_1", "wnd_id": "16167682_1_1", "text": "She died within six weeks of developing congestive heart failure coupled with liver failure due to haemosiderosis despite regular use of desferrioxamine .", "tokens": ["She", "died", "within", "six", "weeks", "of", "developing", "congestive", "heart", "failure", "coupled", "with", "liver", "failure", "due", "to", "haemosiderosis", "despite", "regular", "use", "of", "desferrioxamine", "."], "event_mentions": [{"id": "16167682_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "despite", "start": 17, "end": 18}, "arguments": [{"entity_id": "16167682_1_Ent0", "role": "Effect", "text": "died within six weeks of developing congestive heart failure coupled with liver failure", "start": 1, "end": 14}, {"entity_id": "16167682_1_Ent3", "role": "Treatment_Disorder", "text": "haemosiderosis", "start": 16, "end": 17}, {"entity_id": "16167682_1_Ent1", "role": "Treatment", "text": "regular use of desferrioxamine", "start": 18, "end": 22}, {"entity_id": "16167682_1_Ent2", "role": "Treatment_Drug", "text": "desferrioxamine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "16167682_1_Ent0", "text": "died within six weeks of developing congestive heart failure coupled with liver failure", "entity_type": "Entity", "start": 1, "end": 14}, {"id": "16167682_1_Ent3", "text": "haemosiderosis", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16167682_1_Ent1", "text": "regular use of desferrioxamine", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "16167682_1_Ent2", "text": "desferrioxamine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "16196187_3", "wnd_id": "16196187_3_1", "text": "We present a case of acute epinephrine toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed severe allergic reaction to intravenous immunoglobulin , and was subsequently given epinephrine by mistake intravenously rather than subcutaneously .", "tokens": ["We", "present", "a", "case", "of", "acute", "epinephrine", "toxicity", "resulting", "in", "acute", "myocardial", "ischemia", "in", "a", "young", "boy", "with", "combined", "variable", "immunodeficiency", "syndrome", "who", "developed", "severe", "allergic", "reaction", "to", "intravenous", "immunoglobulin", ",", "and", "was", "subsequently", "given", "epinephrine", "by", "mistake", "intravenously", "rather", "than", "subcutaneously", "."], "event_mentions": [{"id": "16196187_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 7, "end": 8}, "arguments": [{"entity_id": "16196187_3_Ent5", "role": "Treatment", "text": "acute epinephrine", "start": 5, "end": 7}, {"entity_id": "16196187_3_Ent7", "role": "Treatment_Drug", "text": "epinephrine", "start": 6, "end": 7}, {"entity_id": "16196187_3_Ent3", "role": "Effect", "text": "acute myocardial ischemia", "start": 10, "end": 13}, {"entity_id": "16196187_3_Ent0", "role": "Subject", "text": "a young boy with combined variable immunodeficiency syndrome", "start": 14, "end": 22}, {"entity_id": "16196187_3_Ent1", "role": "Subject_Age", "text": "young", "start": 15, "end": 16}, {"entity_id": "16196187_3_Ent2", "role": "Subject_Gender", "text": "boy", "start": 16, "end": 17}, {"entity_id": "16196187_3_Ent9", "role": "Treatment_Disorder", "text": "combined variable immunodeficiency syndrome", "start": 18, "end": 22}, {"entity_id": "16196187_3_Ent4", "role": "Effect", "text": "severe allergic reaction", "start": 24, "end": 27}, {"entity_id": "16196187_3_Ent11", "role": "Treatment_Route", "text": "intravenous", "start": 28, "end": 29}, {"entity_id": "16196187_3_Ent6", "role": "Treatment", "text": "intravenous immunoglobulin , and was subsequently given epinephrine by mistake intravenously rather than subcutaneously", "start": 28, "end": 42}, {"entity_id": "16196187_3_Ent8", "role": "Treatment_Drug", "text": "immunoglobulin", "start": 29, "end": 30}, {"entity_id": "16196187_3_Ent10", "role": "Treatment_Route", "text": "intravenously", "start": 38, "end": 39}]}], "entity_mentions": [{"id": "16196187_3_Ent5", "text": "acute epinephrine", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16196187_3_Ent7", "text": "epinephrine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16196187_3_Ent3", "text": "acute myocardial ischemia", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "16196187_3_Ent0", "text": "a young boy with combined variable immunodeficiency syndrome", "entity_type": "Entity", "start": 14, "end": 22}, {"id": "16196187_3_Ent1", "text": "young", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16196187_3_Ent2", "text": "boy", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16196187_3_Ent9", "text": "combined variable immunodeficiency syndrome", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "16196187_3_Ent4", "text": "severe allergic reaction", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "16196187_3_Ent11", "text": "intravenous", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "16196187_3_Ent6", "text": "intravenous immunoglobulin , and was subsequently given epinephrine by mistake intravenously rather than subcutaneously", "entity_type": "Entity", "start": 28, "end": 42}, {"id": "16196187_3_Ent8", "text": "immunoglobulin", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "16196187_3_Ent10", "text": "intravenously", "entity_type": "Entity", "start": 38, "end": 39}], "lang": "en"}
{"doc_id": "16200540_3", "wnd_id": "16200540_3_1", "text": "Videopolysomnographic and pharmacokinetic studies with monitoring of plasma levodopa levels demonstrated marked motor hyperactivity during augmentation , with anarchic discharges of motor unit potentials , tonic grouped discharges and flexor spasms , associated with painful dysesthesia .", "tokens": ["Videopolysomnographic", "and", "pharmacokinetic", "studies", "with", "monitoring", "of", "plasma", "levodopa", "levels", "demonstrated", "marked", "motor", "hyperactivity", "during", "augmentation", ",", "with", "anarchic", "discharges", "of", "motor", "unit", "potentials", ",", "tonic", "grouped", "discharges", "and", "flexor", "spasms", ",", "associated", "with", "painful", "dysesthesia", "."], "event_mentions": [{"id": "16200540_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "demonstrated", "start": 10, "end": 11}, "arguments": [{"entity_id": "16200540_3_Ent1", "role": "Treatment", "text": "levodopa", "start": 8, "end": 9}, {"entity_id": "16200540_3_Ent2", "role": "Treatment_Drug", "text": "levodopa", "start": 8, "end": 9}, {"entity_id": "16200540_3_Ent0", "role": "Effect", "text": "marked motor hyperactivity during augmentation , with anarchic discharges of motor unit potentials , tonic grouped discharges and flexor spasms , associated with painful dysesthesia", "start": 11, "end": 36}]}], "entity_mentions": [{"id": "16200540_3_Ent1", "text": "levodopa", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16200540_3_Ent2", "text": "levodopa", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16200540_3_Ent0", "text": "marked motor hyperactivity during augmentation , with anarchic discharges of motor unit potentials , tonic grouped discharges and flexor spasms , associated with painful dysesthesia", "entity_type": "Entity", "start": 11, "end": 36}], "lang": "en"}
{"doc_id": "1621023_3", "wnd_id": "1621023_3_1", "text": "Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive - compulsive disorder .", "tokens": ["Prominent", "eye", "movements", "during", "NREM", "sleep", "and", "REM", "sleep", "behavior", "disorder", "associated", "with", "fluoxetine", "treatment", "of", "depression", "and", "obsessive", "-", "compulsive", "disorder", "."], "event_mentions": [{"id": "1621023_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 11, "end": 12}, "arguments": [{"entity_id": "1621023_3_Ent1", "role": "Effect", "text": "Prominent eye movements during NREM sleep and REM sleep behavior disorder", "start": 0, "end": 11}, {"entity_id": "1621023_3_Ent3", "role": "Treatment_Drug", "text": "fluoxetine", "start": 13, "end": 14}, {"entity_id": "1621023_3_Ent2", "role": "Treatment", "text": "fluoxetine treatment", "start": 13, "end": 15}, {"entity_id": "1621023_3_Ent4", "role": "Treatment_Disorder", "text": "depression", "start": 16, "end": 17}, {"entity_id": "1621023_3_Ent0", "role": "Subject", "text": "depression and obsessive - compulsive disorder", "start": 16, "end": 22}, {"entity_id": "1621023_3_Ent5", "role": "Treatment_Disorder", "text": "obsessive - compulsive disorder", "start": 18, "end": 22}]}], "entity_mentions": [{"id": "1621023_3_Ent1", "text": "Prominent eye movements during NREM sleep and REM sleep behavior disorder", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "1621023_3_Ent3", "text": "fluoxetine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "1621023_3_Ent2", "text": "fluoxetine treatment", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "1621023_3_Ent4", "text": "depression", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "1621023_3_Ent0", "text": "depression and obsessive - compulsive disorder", "entity_type": "Entity", "start": 16, "end": 22}, {"id": "1621023_3_Ent5", "text": "obsessive - compulsive disorder", "entity_type": "Entity", "start": 18, "end": 22}], "lang": "en"}
{"doc_id": "16221163_1", "wnd_id": "16221163_1_1", "text": "Sirolimus - associated hepatotoxicity in the kidney graft recipient .", "tokens": ["Sirolimus", "-", "associated", "hepatotoxicity", "in", "the", "kidney", "graft", "recipient", "."], "event_mentions": [{"id": "16221163_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "16221163_1_Ent2", "role": "Treatment", "text": "Sirolimus", "start": 0, "end": 1}, {"entity_id": "16221163_1_Ent3", "role": "Treatment_Drug", "text": "Sirolimus", "start": 0, "end": 1}, {"entity_id": "16221163_1_Ent1", "role": "Effect", "text": "hepatotoxicity", "start": 3, "end": 4}, {"entity_id": "16221163_1_Ent4", "role": "Treatment_Disorder", "text": "kidney graft recipient", "start": 6, "end": 9}, {"entity_id": "16221163_1_Ent0", "role": "Subject", "text": "kidney graft recipient .", "start": 6, "end": 10}]}], "entity_mentions": [{"id": "16221163_1_Ent2", "text": "Sirolimus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16221163_1_Ent3", "text": "Sirolimus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16221163_1_Ent1", "text": "hepatotoxicity", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16221163_1_Ent4", "text": "kidney graft recipient", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "16221163_1_Ent0", "text": "kidney graft recipient .", "entity_type": "Entity", "start": 6, "end": 10}], "lang": "en"}
{"doc_id": "16225183_1", "wnd_id": "16225183_1_1", "text": "Nephrotic syndrome in a multiple sclerosis patient treated with interferon beta 1a .", "tokens": ["Nephrotic", "syndrome", "in", "a", "multiple", "sclerosis", "patient", "treated", "with", "interferon", "beta", "1a", "."], "event_mentions": [{"id": "16225183_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 7, "end": 8}, "arguments": [{"entity_id": "16225183_1_Ent1", "role": "Effect", "text": "Nephrotic syndrome", "start": 0, "end": 2}, {"entity_id": "16225183_1_Ent0", "role": "Subject", "text": "a multiple sclerosis patient", "start": 3, "end": 7}, {"entity_id": "16225183_1_Ent4", "role": "Treatment_Disorder", "text": "multiple sclerosis", "start": 4, "end": 6}, {"entity_id": "16225183_1_Ent2", "role": "Treatment", "text": "interferon beta 1a", "start": 9, "end": 12}, {"entity_id": "16225183_1_Ent3", "role": "Treatment_Drug", "text": "interferon beta 1a", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "16225183_1_Ent1", "text": "Nephrotic syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16225183_1_Ent0", "text": "a multiple sclerosis patient", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "16225183_1_Ent4", "text": "multiple sclerosis", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "16225183_1_Ent2", "text": "interferon beta 1a", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "16225183_1_Ent3", "text": "interferon beta 1a", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "16244351_1", "wnd_id": "16244351_1_1", "text": "Atrial fibrillation after vardenafil therapy .", "tokens": ["Atrial", "fibrillation", "after", "vardenafil", "therapy", "."], "event_mentions": [{"id": "16244351_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "16244351_1_Ent0", "role": "Effect", "text": "Atrial fibrillation", "start": 0, "end": 2}, {"entity_id": "16244351_1_Ent2", "role": "Treatment_Drug", "text": "vardenafil", "start": 3, "end": 4}, {"entity_id": "16244351_1_Ent1", "role": "Treatment", "text": "vardenafil therapy", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "16244351_1_Ent0", "text": "Atrial fibrillation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16244351_1_Ent2", "text": "vardenafil", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16244351_1_Ent1", "text": "vardenafil therapy", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "16249064_1", "wnd_id": "16249064_1_1", "text": "We describe a case of infection with Mycobacterium abscessus in a 67 - year - old woman receiving infliximab as a component of her therapy for RA .", "tokens": ["We", "describe", "a", "case", "of", "infection", "with", "Mycobacterium", "abscessus", "in", "a", "67", "-", "year", "-", "old", "woman", "receiving", "infliximab", "as", "a", "component", "of", "her", "therapy", "for", "RA", "."], "event_mentions": [{"id": "16249064_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 17, "end": 18}, "arguments": [{"entity_id": "16249064_1_Ent4", "role": "Effect", "text": "infection with Mycobacterium abscessus", "start": 5, "end": 9}, {"entity_id": "16249064_1_Ent0", "role": "Subject", "text": "a 67 - year - old woman", "start": 10, "end": 17}, {"entity_id": "16249064_1_Ent2", "role": "Subject_Age", "text": "67 - year - old", "start": 11, "end": 16}, {"entity_id": "16249064_1_Ent3", "role": "Subject_Gender", "text": "woman", "start": 16, "end": 17}, {"entity_id": "16249064_1_Ent6", "role": "Treatment_Drug", "text": "infliximab", "start": 18, "end": 19}, {"entity_id": "16249064_1_Ent5", "role": "Treatment", "text": "infliximab as a component of her therapy", "start": 18, "end": 25}, {"entity_id": "16249064_1_Ent1", "role": "Subject", "text": "RA", "start": 26, "end": 27}, {"entity_id": "16249064_1_Ent7", "role": "Treatment_Disorder", "text": "RA", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "16249064_1_Ent4", "text": "infection with Mycobacterium abscessus", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "16249064_1_Ent0", "text": "a 67 - year - old woman", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "16249064_1_Ent2", "text": "67 - year - old", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "16249064_1_Ent3", "text": "woman", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16249064_1_Ent6", "text": "infliximab", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "16249064_1_Ent5", "text": "infliximab as a component of her therapy", "entity_type": "Entity", "start": 18, "end": 25}, {"id": "16249064_1_Ent1", "text": "RA", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "16249064_1_Ent7", "text": "RA", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "16265343_1", "wnd_id": "16265343_1_1", "text": "DIAGNOSIS : Interferon alpha - 2b - induced cardiomyopathy .", "tokens": ["DIAGNOSIS", ":", "Interferon", "alpha", "-", "2b", "-", "induced", "cardiomyopathy", "."], "event_mentions": [{"id": "16265343_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "16265343_1_Ent1", "role": "Treatment", "text": "Interferon alpha - 2b", "start": 2, "end": 6}, {"entity_id": "16265343_1_Ent2", "role": "Treatment_Drug", "text": "Interferon alpha - 2b", "start": 2, "end": 6}, {"entity_id": "16265343_1_Ent0", "role": "Effect", "text": "cardiomyopathy", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "16265343_1_Ent1", "text": "Interferon alpha - 2b", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "16265343_1_Ent2", "text": "Interferon alpha - 2b", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "16265343_1_Ent0", "text": "cardiomyopathy", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "16268429_1", "wnd_id": "16268429_1_1", "text": "In this case senna was likely the cause of a subacute cholestatic hepatitis exemplifying again the potential role of herbal related liver injury .", "tokens": ["In", "this", "case", "senna", "was", "likely", "the", "cause", "of", "a", "subacute", "cholestatic", "hepatitis", "exemplifying", "again", "the", "potential", "role", "of", "herbal", "related", "liver", "injury", "."], "event_mentions": [{"id": "16268429_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 7, "end": 8}, "arguments": [{"entity_id": "16268429_1_Ent2", "role": "Treatment", "text": "senna", "start": 3, "end": 4}, {"entity_id": "16268429_1_Ent3", "role": "Treatment_Drug", "text": "senna", "start": 3, "end": 4}, {"entity_id": "16268429_1_Ent0", "role": "Effect", "text": "a subacute cholestatic hepatitis", "start": 9, "end": 13}, {"entity_id": "16268429_1_Ent1", "role": "Effect", "text": "herbal related liver injury", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "16268429_1_Ent2", "text": "senna", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16268429_1_Ent3", "text": "senna", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16268429_1_Ent0", "text": "a subacute cholestatic hepatitis", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "16268429_1_Ent1", "text": "herbal related liver injury", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "16268429_3", "wnd_id": "16268429_3_1", "text": "We report a case of senna - induced cholestatic hepatitis which was not diagnosed at presentation .", "tokens": ["We", "report", "a", "case", "of", "senna", "-", "induced", "cholestatic", "hepatitis", "which", "was", "not", "diagnosed", "at", "presentation", "."], "event_mentions": [{"id": "16268429_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "16268429_3_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "16268429_3_Ent2", "role": "Treatment", "text": "senna", "start": 5, "end": 6}, {"entity_id": "16268429_3_Ent3", "role": "Treatment_Drug", "text": "senna", "start": 5, "end": 6}, {"entity_id": "16268429_3_Ent1", "role": "Effect", "text": "cholestatic hepatitis", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "16268429_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16268429_3_Ent2", "text": "senna", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16268429_3_Ent3", "text": "senna", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16268429_3_Ent1", "text": "cholestatic hepatitis", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "16284443_3", "wnd_id": "16284443_3_1", "text": "Thus , the possible in vivo effects of insulin on adipocytes were clearly observed in this case of insulin - induced lipohypertrophy .", "tokens": ["Thus", ",", "the", "possible", "in", "vivo", "effects", "of", "insulin", "on", "adipocytes", "were", "clearly", "observed", "in", "this", "case", "of", "insulin", "-", "induced", "lipohypertrophy", "."], "event_mentions": [{"id": "16284443_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 20, "end": 21}, "arguments": [{"entity_id": "16284443_3_Ent1", "role": "Treatment", "text": "insulin", "start": 18, "end": 19}, {"entity_id": "16284443_3_Ent2", "role": "Treatment_Drug", "text": "insulin", "start": 18, "end": 19}, {"entity_id": "16284443_3_Ent0", "role": "Effect", "text": "lipohypertrophy", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "16284443_3_Ent1", "text": "insulin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "16284443_3_Ent2", "text": "insulin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "16284443_3_Ent0", "text": "lipohypertrophy", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "16298824_1", "wnd_id": "16298824_1_1", "text": "Acute respiratory distress syndrome after rituximab infusion .", "tokens": ["Acute", "respiratory", "distress", "syndrome", "after", "rituximab", "infusion", "."], "event_mentions": [{"id": "16298824_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "16298824_1_Ent0", "role": "Effect", "text": "Acute respiratory distress syndrome", "start": 0, "end": 4}, {"entity_id": "16298824_1_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 5, "end": 6}, {"entity_id": "16298824_1_Ent1", "role": "Treatment", "text": "rituximab infusion", "start": 5, "end": 7}, {"entity_id": "16298824_1_Ent3", "role": "Treatment_Route", "text": "infusion", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "16298824_1_Ent0", "text": "Acute respiratory distress syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16298824_1_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16298824_1_Ent1", "text": "rituximab infusion", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16298824_1_Ent3", "text": "infusion", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "16341621_1", "wnd_id": "16341621_1_1", "text": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence .", "tokens": ["Massive", "prolapse", "of", "the", "urethral", "mucosa", "following", "periurethral", "injection", "of", "calcium", "hydroxylapatite", "for", "stress", "urinary", "incontinence", "."], "event_mentions": [{"id": "16341621_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "16341621_1_Ent0", "role": "Effect", "text": "Massive prolapse of the urethral mucosa", "start": 0, "end": 6}, {"entity_id": "16341621_1_Ent3", "role": "Treatment_Route", "text": "periurethral injection", "start": 7, "end": 9}, {"entity_id": "16341621_1_Ent1", "role": "Treatment", "text": "periurethral injection of calcium hydroxylapatite", "start": 7, "end": 12}, {"entity_id": "16341621_1_Ent2", "role": "Treatment_Drug", "text": "calcium hydroxylapatite", "start": 10, "end": 12}, {"entity_id": "16341621_1_Ent4", "role": "Treatment_Disorder", "text": "stress urinary incontinence", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "16341621_1_Ent0", "text": "Massive prolapse of the urethral mucosa", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "16341621_1_Ent3", "text": "periurethral injection", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "16341621_1_Ent1", "text": "periurethral injection of calcium hydroxylapatite", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "16341621_1_Ent2", "text": "calcium hydroxylapatite", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16341621_1_Ent4", "text": "stress urinary incontinence", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "16341621_3", "wnd_id": "16341621_3_1", "text": "To our knowledge , this is the first granulomatous reaction described after calcium hydroxylapatite injection .", "tokens": ["To", "our", "knowledge", ",", "this", "is", "the", "first", "granulomatous", "reaction", "described", "after", "calcium", "hydroxylapatite", "injection", "."], "event_mentions": [{"id": "16341621_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "16341621_3_Ent0", "role": "Effect", "text": "granulomatous reaction", "start": 8, "end": 10}, {"entity_id": "16341621_3_Ent2", "role": "Treatment_Drug", "text": "calcium hydroxylapatite", "start": 12, "end": 14}, {"entity_id": "16341621_3_Ent1", "role": "Treatment", "text": "calcium hydroxylapatite injection", "start": 12, "end": 15}, {"entity_id": "16341621_3_Ent3", "role": "Treatment_Route", "text": "injection", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "16341621_3_Ent0", "text": "granulomatous reaction", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16341621_3_Ent2", "text": "calcium hydroxylapatite", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "16341621_3_Ent1", "text": "calcium hydroxylapatite injection", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "16341621_3_Ent3", "text": "injection", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "16352777_1", "wnd_id": "16352777_1_1", "text": "CASE SUMMARY : A 57 - year - old female with cardiomyopathy and \" sulfa \" ( trimethoprim / sulfamethoxazole ) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide .", "tokens": ["CASE", "SUMMARY", ":", "A", "57", "-", "year", "-", "old", "female", "with", "cardiomyopathy", "and", "\"", "sulfa", "\"", "(", "trimethoprim", "/", "sulfamethoxazole", ")", "allergy", "documented", "as", "pancreatitis", "presented", "with", "symptoms", "consistent", "with", "pancreatitis", "after", "use", "of", "furosemide", "."], "event_mentions": [{"id": "16352777_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after use", "start": 31, "end": 33}, "arguments": [{"entity_id": "16352777_1_Ent0", "role": "Subject", "text": "A 57 - year - old female with cardiomyopathy and \" sulfa \" ( trimethoprim / sulfamethoxazole ) allergy", "start": 3, "end": 22}, {"entity_id": "16352777_1_Ent1", "role": "Subject_Age", "text": "57 - year - old", "start": 4, "end": 9}, {"entity_id": "16352777_1_Ent2", "role": "Subject_Gender", "text": "female", "start": 9, "end": 10}, {"entity_id": "16352777_1_Ent3", "role": "Subject_Disorder", "text": "cardiomyopathy", "start": 11, "end": 12}, {"entity_id": "16352777_1_Ent4", "role": "Subject_Disorder", "text": "\" sulfa \" ( trimethoprim / sulfamethoxazole ) allergy", "start": 13, "end": 22}, {"entity_id": "16352777_1_Ent5", "role": "Effect", "text": "pancreatitis", "start": 24, "end": 25}, {"entity_id": "16352777_1_Ent6", "role": "Treatment", "text": "furosemide", "start": 34, "end": 35}, {"entity_id": "16352777_1_Ent7", "role": "Treatment_Drug", "text": "furosemide", "start": 34, "end": 35}]}], "entity_mentions": [{"id": "16352777_1_Ent0", "text": "A 57 - year - old female with cardiomyopathy and \" sulfa \" ( trimethoprim / sulfamethoxazole ) allergy", "entity_type": "Entity", "start": 3, "end": 22}, {"id": "16352777_1_Ent1", "text": "57 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "16352777_1_Ent2", "text": "female", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16352777_1_Ent3", "text": "cardiomyopathy", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16352777_1_Ent4", "text": "\" sulfa \" ( trimethoprim / sulfamethoxazole ) allergy", "entity_type": "Entity", "start": 13, "end": 22}, {"id": "16352777_1_Ent5", "text": "pancreatitis", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "16352777_1_Ent6", "text": "furosemide", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "16352777_1_Ent7", "text": "furosemide", "entity_type": "Entity", "start": 34, "end": 35}], "lang": "en"}
{"doc_id": "16352777_3", "wnd_id": "16352777_3_1", "text": "Torsemide appears to also be a part of a long list of agents that can cause pancreatitis .", "tokens": ["Torsemide", "appears", "to", "also", "be", "a", "part", "of", "a", "long", "list", "of", "agents", "that", "can", "cause", "pancreatitis", "."], "event_mentions": [{"id": "16352777_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 15, "end": 16}, "arguments": [{"entity_id": "16352777_3_Ent1", "role": "Treatment", "text": "Torsemide", "start": 0, "end": 1}, {"entity_id": "16352777_3_Ent2", "role": "Treatment_Drug", "text": "Torsemide", "start": 0, "end": 1}, {"entity_id": "16352777_3_Ent0", "role": "Effect", "text": "pancreatitis", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "16352777_3_Ent1", "text": "Torsemide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16352777_3_Ent2", "text": "Torsemide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16352777_3_Ent0", "text": "pancreatitis", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "16371793_2", "wnd_id": "16371793_2_1", "text": "PURPOSE : The intravitreal application of triamcinolone acetonide as treatment of long - standing , therapy - resistant cystoid macular edema after penetrating keratoplasty is reported .", "tokens": ["PURPOSE", ":", "The", "intravitreal", "application", "of", "triamcinolone", "acetonide", "as", "treatment", "of", "long", "-", "standing", ",", "therapy", "-", "resistant", "cystoid", "macular", "edema", "after", "penetrating", "keratoplasty", "is", "reported", "."], "event_mentions": [{"id": "16371793_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 9, "end": 10}, "arguments": [{"entity_id": "16371793_2_Ent0", "role": "Treatment", "text": "The intravitreal application of triamcinolone acetonide", "start": 2, "end": 8}, {"entity_id": "16371793_2_Ent1", "role": "Treatment_Route", "text": "intravitreal", "start": 3, "end": 4}, {"entity_id": "16371793_2_Ent2", "role": "Treatment_Drug", "text": "triamcinolone acetonide", "start": 6, "end": 8}, {"entity_id": "16371793_2_Ent3", "role": "Treatment_Disorder", "text": "cystoid macular edema", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "16371793_2_Ent0", "text": "The intravitreal application of triamcinolone acetonide", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "16371793_2_Ent1", "text": "intravitreal", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16371793_2_Ent2", "text": "triamcinolone acetonide", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16371793_2_Ent3", "text": "cystoid macular edema", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "16393774_1", "wnd_id": "16393774_1_1", "text": "Arthritis and bursitis in multiple sclerosis patients treated with interferon - beta .", "tokens": ["Arthritis", "and", "bursitis", "in", "multiple", "sclerosis", "patients", "treated", "with", "interferon", "-", "beta", "."], "event_mentions": [{"id": "16393774_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 7, "end": 8}, "arguments": [{"entity_id": "16393774_1_Ent3", "role": "Treatment_Disorder", "text": "multiple sclerosis", "start": 4, "end": 6}, {"entity_id": "16393774_1_Ent0", "role": "Subject", "text": "multiple sclerosis patients", "start": 4, "end": 7}, {"entity_id": "16393774_1_Ent1", "role": "Treatment", "text": "interferon - beta", "start": 9, "end": 12}, {"entity_id": "16393774_1_Ent2", "role": "Treatment_Drug", "text": "interferon - beta", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "16393774_1_Ent3", "text": "multiple sclerosis", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "16393774_1_Ent0", "text": "multiple sclerosis patients", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "16393774_1_Ent1", "text": "interferon - beta", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "16393774_1_Ent2", "text": "interferon - beta", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "16393774_7", "wnd_id": "16393774_7_1", "text": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN - beta .", "tokens": ["Our", "literature", "review", "revealed", "an", "additional", "six", "cases", "of", "onset", "of", "inflammatory", "arthritis", "in", "MS", "patients", "receiving", "IFN", "-", "beta", "."], "event_mentions": [{"id": "16393774_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "onset", "start": 9, "end": 10}, "arguments": [{"entity_id": "16393774_7_Ent2", "role": "Subject_Population", "text": "six", "start": 6, "end": 7}, {"entity_id": "16393774_7_Ent0", "role": "Subject", "text": "six cases", "start": 6, "end": 8}, {"entity_id": "16393774_7_Ent3", "role": "Effect", "text": "inflammatory arthritis", "start": 11, "end": 13}, {"entity_id": "16393774_7_Ent1", "role": "Subject", "text": "in MS patients", "start": 13, "end": 16}, {"entity_id": "16393774_7_Ent6", "role": "Treatment_Disorder", "text": "MS", "start": 14, "end": 15}, {"entity_id": "16393774_7_Ent4", "role": "Treatment", "text": "receiving IFN - beta", "start": 16, "end": 20}, {"entity_id": "16393774_7_Ent5", "role": "Treatment_Drug", "text": "IFN - beta", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "16393774_7_Ent2", "text": "six", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16393774_7_Ent0", "text": "six cases", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16393774_7_Ent3", "text": "inflammatory arthritis", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "16393774_7_Ent1", "text": "in MS patients", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "16393774_7_Ent6", "text": "MS", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16393774_7_Ent4", "text": "receiving IFN - beta", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "16393774_7_Ent5", "text": "IFN - beta", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "16404563_3", "wnd_id": "16404563_3_1", "text": "Corticosteroids may be useful for therapy of some features of this syndrome , such as thrombocytopenia .", "tokens": ["Corticosteroids", "may", "be", "useful", "for", "therapy", "of", "some", "features", "of", "this", "syndrome", ",", "such", "as", "thrombocytopenia", "."], "event_mentions": [{"id": "16404563_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "be useful", "start": 2, "end": 4}, "arguments": [{"entity_id": "16404563_3_Ent0", "role": "Treatment", "text": "Corticosteroids", "start": 0, "end": 1}, {"entity_id": "16404563_3_Ent1", "role": "Treatment_Drug", "text": "Corticosteroids", "start": 0, "end": 1}, {"entity_id": "16404563_3_Ent2", "role": "Treatment_Disorder", "text": "thrombocytopenia", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "16404563_3_Ent0", "text": "Corticosteroids", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16404563_3_Ent1", "text": "Corticosteroids", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16404563_3_Ent2", "text": "thrombocytopenia", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "16405935_2", "wnd_id": "16405935_2_1", "text": "Ptosis occurring 24 h after chloroquine therapy , with full recovery 48 h after cessation of chloroquine , has not been described previously .", "tokens": ["Ptosis", "occurring", "24", "h", "after", "chloroquine", "therapy", ",", "with", "full", "recovery", "48", "h", "after", "cessation", "of", "chloroquine", ",", "has", "not", "been", "described", "previously", "."], "event_mentions": [{"id": "16405935_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 1, "end": 2}, "arguments": [{"entity_id": "16405935_2_Ent0", "role": "Effect", "text": "Ptosis", "start": 0, "end": 1}, {"entity_id": "16405935_2_Ent3", "role": "Treatment_Time_elapsed", "text": "24 h", "start": 2, "end": 4}, {"entity_id": "16405935_2_Ent4", "role": "Treatment_Drug", "text": "chloroquine", "start": 5, "end": 6}, {"entity_id": "16405935_2_Ent2", "role": "Treatment", "text": "chloroquine therapy", "start": 5, "end": 7}, {"entity_id": "16405935_2_Ent1", "role": "Effect", "text": "full recovery 48 h after cessation of chloroquine", "start": 9, "end": 17}]}], "entity_mentions": [{"id": "16405935_2_Ent0", "text": "Ptosis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16405935_2_Ent3", "text": "24 h", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16405935_2_Ent4", "text": "chloroquine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16405935_2_Ent2", "text": "chloroquine therapy", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16405935_2_Ent1", "text": "full recovery 48 h after cessation of chloroquine", "entity_type": "Entity", "start": 9, "end": 17}], "lang": "en"}
{"doc_id": "16411025_3", "wnd_id": "16411025_3_1", "text": "OBJECTIVES : A delayed stroke - like leukoencephalopathy has been observed in patients receiving methotrexate ( MTX ) for childhood leukemia .", "tokens": ["OBJECTIVES", ":", "A", "delayed", "stroke", "-", "like", "leukoencephalopathy", "has", "been", "observed", "in", "patients", "receiving", "methotrexate", "(", "MTX", ")", "for", "childhood", "leukemia", "."], "event_mentions": [{"id": "16411025_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "has been observed", "start": 8, "end": 11}, "arguments": [{"entity_id": "16411025_3_Ent3", "role": "Effect", "text": "delayed stroke - like leukoencephalopathy", "start": 3, "end": 8}, {"entity_id": "16411025_3_Ent0", "role": "Subject", "text": "patients", "start": 12, "end": 13}, {"entity_id": "16411025_3_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 14, "end": 15}, {"entity_id": "16411025_3_Ent4", "role": "Treatment", "text": "methotrexate ( MTX )", "start": 14, "end": 18}, {"entity_id": "16411025_3_Ent2", "role": "Subject_Age", "text": "childhood", "start": 19, "end": 20}, {"entity_id": "16411025_3_Ent1", "role": "Subject", "text": "childhood leukemia", "start": 19, "end": 21}, {"entity_id": "16411025_3_Ent6", "role": "Treatment_Disorder", "text": "childhood leukemia", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "16411025_3_Ent3", "text": "delayed stroke - like leukoencephalopathy", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "16411025_3_Ent0", "text": "patients", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16411025_3_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16411025_3_Ent4", "text": "methotrexate ( MTX )", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "16411025_3_Ent2", "text": "childhood", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16411025_3_Ent1", "text": "childhood leukemia", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "16411025_3_Ent6", "text": "childhood leukemia", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "16411025_4", "wnd_id": "16411025_4_1", "text": "Our objective is to present a retrospective analysis of the DWI findings in four patients who suffered subacute neurotoxicity after intrathecal MTX .", "tokens": ["Our", "objective", "is", "to", "present", "a", "retrospective", "analysis", "of", "the", "DWI", "findings", "in", "four", "patients", "who", "suffered", "subacute", "neurotoxicity", "after", "intrathecal", "MTX", "."], "event_mentions": [{"id": "16411025_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 19, "end": 20}, "arguments": [{"entity_id": "16411025_4_Ent1", "role": "Subject_Population", "text": "four", "start": 13, "end": 14}, {"entity_id": "16411025_4_Ent0", "role": "Subject", "text": "four patients", "start": 13, "end": 15}, {"entity_id": "16411025_4_Ent2", "role": "Effect", "text": "subacute neurotoxicity", "start": 17, "end": 19}, {"entity_id": "16411025_4_Ent3", "role": "Treatment", "text": "intrathecal MTX", "start": 20, "end": 22}, {"entity_id": "16411025_4_Ent4", "role": "Treatment_Drug", "text": "intrathecal MTX", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "16411025_4_Ent1", "text": "four", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16411025_4_Ent0", "text": "four patients", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "16411025_4_Ent2", "text": "subacute neurotoxicity", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "16411025_4_Ent3", "text": "intrathecal MTX", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "16411025_4_Ent4", "text": "intrathecal MTX", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "16421117_1", "wnd_id": "16421117_1_1", "text": "CONCLUSION : The present findings suggest that : ( i ) amantadine probably exerts its anti - dyskinetic effect by acting on the \" indirect \" pathway ; ( ii ) the pathophysiological mechanisms of subthalamotomy induced dyskinesias may differ from those involved in L - dopa induced dyskinesias ; ( iii ) dyskinesias induced by STN surgery resolve spontaneously as compensatory mechanisms develop .", "tokens": ["CONCLUSION", ":", "The", "present", "findings", "suggest", "that", ":", "(", "i", ")", "amantadine", "probably", "exerts", "its", "anti", "-", "dyskinetic", "effect", "by", "acting", "on", "the", "\"", "indirect", "\"", "pathway", ";", "(", "ii", ")", "the", "pathophysiological", "mechanisms", "of", "subthalamotomy", "induced", "dyskinesias", "may", "differ", "from", "those", "involved", "in", "L", "-", "dopa", "induced", "dyskinesias", ";", "(", "iii", ")", "dyskinesias", "induced", "by", "STN", "surgery", "resolve", "spontaneously", "as", "compensatory", "mechanisms", "develop", "."], "event_mentions": [{"id": "16421117_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "exerts", "start": 13, "end": 14}, "arguments": [{"entity_id": "16421117_1_Ent1", "role": "Treatment", "text": "amantadine", "start": 11, "end": 12}, {"entity_id": "16421117_1_Ent2", "role": "Treatment_Drug", "text": "amantadine", "start": 11, "end": 12}, {"entity_id": "16421117_1_Ent0", "role": "Effect", "text": "anti - dyskinetic effect", "start": 15, "end": 19}]}], "entity_mentions": [{"id": "16421117_1_Ent1", "text": "amantadine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16421117_1_Ent2", "text": "amantadine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16421117_1_Ent0", "text": "anti - dyskinetic effect", "entity_type": "Entity", "start": 15, "end": 19}], "lang": "en"}
{"doc_id": "16432996_3", "wnd_id": "16432996_3_1", "text": "Although interferon gamma has been implicated in the pathogenesis of sarcoidosis , only a few cases of sarcoidosis associated with interferon alpha therapy have been reported .", "tokens": ["Although", "interferon", "gamma", "has", "been", "implicated", "in", "the", "pathogenesis", "of", "sarcoidosis", ",", "only", "a", "few", "cases", "of", "sarcoidosis", "associated", "with", "interferon", "alpha", "therapy", "have", "been", "reported", "."], "event_mentions": [{"id": "16432996_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "pathogenesis", "start": 8, "end": 9}, "arguments": [{"entity_id": "16432996_3_Ent1", "role": "Treatment", "text": "interferon gamma", "start": 1, "end": 3}, {"entity_id": "16432996_3_Ent2", "role": "Treatment_Drug", "text": "interferon gamma", "start": 1, "end": 3}, {"entity_id": "16432996_3_Ent0", "role": "Effect", "text": "sarcoidosis", "start": 10, "end": 11}]}, {"id": "16432996_3_Evt1", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 18, "end": 19}, "arguments": [{"entity_id": "16432996_3_Ent3", "role": "Effect", "text": "sarcoidosis", "start": 17, "end": 18}, {"entity_id": "16432996_3_Ent4", "role": "Treatment", "text": "interferon alpha", "start": 20, "end": 22}, {"entity_id": "16432996_3_Ent5", "role": "Treatment_Drug", "text": "interferon alpha", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "16432996_3_Ent1", "text": "interferon gamma", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "16432996_3_Ent2", "text": "interferon gamma", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "16432996_3_Ent0", "text": "sarcoidosis", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16432996_3_Ent3", "text": "sarcoidosis", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16432996_3_Ent4", "text": "interferon alpha", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "16432996_3_Ent5", "text": "interferon alpha", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "16446228_1", "wnd_id": "16446228_1_1", "text": "Here , we present a case of sirolimus - associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids .", "tokens": ["Here", ",", "we", "present", "a", "case", "of", "sirolimus", "-", "associated", "interstitial", "pneumonitis", "in", "a", "cardiac", "transplant", "recipient", "that", "resolved", "completely", "with", "withdrawal", "of", "the", "drug", "and", "treatment", "with", "corticosteroids", "."], "event_mentions": [{"id": "16446228_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "16446228_1_Ent4", "role": "Treatment", "text": "sirolimus", "start": 7, "end": 8}, {"entity_id": "16446228_1_Ent5", "role": "Treatment_Drug", "text": "sirolimus", "start": 7, "end": 8}, {"entity_id": "16446228_1_Ent6", "role": "Treatment_Disorder", "text": "sirolimus - associated interstitial pneumonitis", "start": 7, "end": 12}, {"entity_id": "16446228_1_Ent3", "role": "Effect", "text": "interstitial pneumonitis", "start": 10, "end": 12}]}, {"id": "16446228_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 18, "end": 19}, "arguments": [{"entity_id": "16446228_1_Ent0", "role": "Subject", "text": "a case of sirolimus - associated interstitial pneumonitis in a cardiac transplant recipient", "start": 4, "end": 17}, {"entity_id": "16446228_1_Ent1", "role": "Treatment", "text": "withdrawal of the drug and treatment with corticosteroids", "start": 21, "end": 29}, {"entity_id": "16446228_1_Ent2", "role": "Treatment_Drug", "text": "corticosteroids", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "16446228_1_Ent0", "text": "a case of sirolimus - associated interstitial pneumonitis in a cardiac transplant recipient", "entity_type": "Entity", "start": 4, "end": 17}, {"id": "16446228_1_Ent4", "text": "sirolimus", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16446228_1_Ent5", "text": "sirolimus", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16446228_1_Ent6", "text": "sirolimus - associated interstitial pneumonitis", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "16446228_1_Ent3", "text": "interstitial pneumonitis", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16446228_1_Ent1", "text": "withdrawal of the drug and treatment with corticosteroids", "entity_type": "Entity", "start": 21, "end": 29}, {"id": "16446228_1_Ent2", "text": "corticosteroids", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "16449538_5", "wnd_id": "16449538_5_1", "text": "Nonconvulsive status epilepticus due to ifosfamide .", "tokens": ["Nonconvulsive", "status", "epilepticus", "due", "to", "ifosfamide", "."], "event_mentions": [{"id": "16449538_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 3, "end": 4}, "arguments": [{"entity_id": "16449538_5_Ent0", "role": "Effect", "text": "Nonconvulsive status epilepticus", "start": 0, "end": 3}, {"entity_id": "16449538_5_Ent1", "role": "Treatment", "text": "ifosfamide", "start": 5, "end": 6}, {"entity_id": "16449538_5_Ent2", "role": "Treatment_Drug", "text": "ifosfamide", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "16449538_5_Ent0", "text": "Nonconvulsive status epilepticus", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16449538_5_Ent1", "text": "ifosfamide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16449538_5_Ent2", "text": "ifosfamide", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "16459502_2", "wnd_id": "16459502_2_1", "text": "Disseminated tuberculous lesions post intravesical BCG therapy are rare but need to be identified and treated quickly .", "tokens": ["Disseminated", "tuberculous", "lesions", "post", "intravesical", "BCG", "therapy", "are", "rare", "but", "need", "to", "be", "identified", "and", "treated", "quickly", "."], "event_mentions": [{"id": "16459502_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "post", "start": 3, "end": 4}, "arguments": [{"entity_id": "16459502_2_Ent0", "role": "Effect", "text": "Disseminated tuberculous lesions", "start": 0, "end": 3}, {"entity_id": "16459502_2_Ent1", "role": "Treatment", "text": "BCG", "start": 5, "end": 6}, {"entity_id": "16459502_2_Ent2", "role": "Treatment_Drug", "text": "BCG", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "16459502_2_Ent0", "text": "Disseminated tuberculous lesions", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16459502_2_Ent1", "text": "BCG", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16459502_2_Ent2", "text": "BCG", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "16472339_1", "wnd_id": "16472339_1_1", "text": "Administration of sumatriptan in subarachnoid haemorrhage ( SAH ) patients , misdiagnosed as migraine patients , may induce symptomatic cerebral vasospasm with potentially dangerous consequences .", "tokens": ["Administration", "of", "sumatriptan", "in", "subarachnoid", "haemorrhage", "(", "SAH", ")", "patients", ",", "misdiagnosed", "as", "migraine", "patients", ",", "may", "induce", "symptomatic", "cerebral", "vasospasm", "with", "potentially", "dangerous", "consequences", "."], "event_mentions": [{"id": "16472339_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 17, "end": 18}, "arguments": [{"entity_id": "16472339_1_Ent2", "role": "Treatment", "text": "sumatriptan", "start": 2, "end": 3}, {"entity_id": "16472339_1_Ent4", "role": "Treatment_Drug", "text": "sumatriptan", "start": 2, "end": 3}, {"entity_id": "16472339_1_Ent3", "role": "Treatment_Disorder", "text": "subarachnoid haemorrhage", "start": 4, "end": 6}, {"entity_id": "16472339_1_Ent0", "role": "Subject", "text": "patients", "start": 9, "end": 10}, {"entity_id": "16472339_1_Ent1", "role": "Effect", "text": "symptomatic cerebral vasospasm", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "16472339_1_Ent2", "text": "sumatriptan", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16472339_1_Ent4", "text": "sumatriptan", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16472339_1_Ent3", "text": "subarachnoid haemorrhage", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "16472339_1_Ent0", "text": "patients", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16472339_1_Ent1", "text": "symptomatic cerebral vasospasm", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "16490518_2", "wnd_id": "16490518_2_1", "text": "RESULTS : A 34 - year - old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema .", "tokens": ["RESULTS", ":", "A", "34", "-", "year", "-", "old", "man", "acquired", "visual", "field", "defects", "and", "severe", "vision", "loss", "in", "both", "eyes", "after", "intravitreal", "injection", "of", "triamcinolone", "for", "diabetic", "macular", "edema", "."], "event_mentions": [{"id": "16490518_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 20, "end": 21}, "arguments": [{"entity_id": "16490518_2_Ent0", "role": "Subject", "text": "A 34 - year - old man", "start": 2, "end": 9}, {"entity_id": "16490518_2_Ent1", "role": "Subject_Age", "text": "34 - year - old", "start": 3, "end": 8}, {"entity_id": "16490518_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}, {"entity_id": "16490518_2_Ent3", "role": "Effect", "text": "visual field defects and severe vision loss in both eyes", "start": 10, "end": 20}, {"entity_id": "16490518_2_Ent6", "role": "Treatment_Route", "text": "intravitreal injection", "start": 21, "end": 23}, {"entity_id": "16490518_2_Ent4", "role": "Treatment", "text": "intravitreal injection of triamcinolone", "start": 21, "end": 25}, {"entity_id": "16490518_2_Ent7", "role": "Treatment_Drug", "text": "triamcinolone", "start": 24, "end": 25}, {"entity_id": "16490518_2_Ent5", "role": "Treatment_Disorder", "text": "diabetic macular edema", "start": 26, "end": 29}]}], "entity_mentions": [{"id": "16490518_2_Ent0", "text": "A 34 - year - old man", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "16490518_2_Ent1", "text": "34 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "16490518_2_Ent2", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16490518_2_Ent3", "text": "visual field defects and severe vision loss in both eyes", "entity_type": "Entity", "start": 10, "end": 20}, {"id": "16490518_2_Ent6", "text": "intravitreal injection", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "16490518_2_Ent4", "text": "intravitreal injection of triamcinolone", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "16490518_2_Ent7", "text": "triamcinolone", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "16490518_2_Ent5", "text": "diabetic macular edema", "entity_type": "Entity", "start": 26, "end": 29}], "lang": "en"}
{"doc_id": "16498048_3", "wnd_id": "16498048_3_1", "text": "Hence , hyperthyroidism induced by IFN - alpha could correspond to the first phase of silent thyroiditis , to Graves ' disease or to the succession of both .", "tokens": ["Hence", ",", "hyperthyroidism", "induced", "by", "IFN", "-", "alpha", "could", "correspond", "to", "the", "first", "phase", "of", "silent", "thyroiditis", ",", "to", "Graves", "'", "disease", "or", "to", "the", "succession", "of", "both", "."], "event_mentions": [{"id": "16498048_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "16498048_3_Ent0", "role": "Effect", "text": "hyperthyroidism", "start": 2, "end": 3}, {"entity_id": "16498048_3_Ent1", "role": "Treatment", "text": "IFN - alpha", "start": 5, "end": 8}, {"entity_id": "16498048_3_Ent2", "role": "Treatment_Drug", "text": "IFN - alpha", "start": 5, "end": 8}]}], "entity_mentions": [{"id": "16498048_3_Ent0", "text": "hyperthyroidism", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16498048_3_Ent1", "text": "IFN - alpha", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "16498048_3_Ent2", "text": "IFN - alpha", "entity_type": "Entity", "start": 5, "end": 8}], "lang": "en"}
{"doc_id": "16507380_13", "wnd_id": "16507380_13_1", "text": "A possible drug - drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN - induced hypertriglyceridemia .", "tokens": ["A", "possible", "drug", "-", "drug", "interaction", "between", "IFN", "alfa", "11", "MU", "TIW", "and", "gemfibrozil", "600", "mg", "BID", "was", "reported", "in", "a", "patient", "undergoing", "treatment", "for", "IFN", "-", "induced", "hypertriglyceridemia", "."], "event_mentions": [{"id": "16507380_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 18, "end": 19}, "arguments": [{"entity_id": "16507380_13_Ent2", "role": "Treatment", "text": "drug - drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID", "start": 2, "end": 17}, {"entity_id": "16507380_13_Ent3", "role": "Treatment_Drug", "text": "IFN alfa", "start": 7, "end": 9}, {"entity_id": "16507380_13_Ent9", "role": "Combination_Drug", "text": "IFN alfa", "start": 7, "end": 9}, {"entity_id": "16507380_13_Ent6", "role": "Treatment_Dosage", "text": "11 MU", "start": 9, "end": 11}, {"entity_id": "16507380_13_Ent8", "role": "Treatment_Freq", "text": "TIW", "start": 11, "end": 12}, {"entity_id": "16507380_13_Ent4", "role": "Treatment_Drug", "text": "gemfibrozil", "start": 13, "end": 14}, {"entity_id": "16507380_13_Ent10", "role": "Combination_Drug", "text": "gemfibrozil", "start": 13, "end": 14}, {"entity_id": "16507380_13_Ent5", "role": "Treatment_Dosage", "text": "600 mg", "start": 14, "end": 16}, {"entity_id": "16507380_13_Ent7", "role": "Treatment_Freq", "text": "BID", "start": 16, "end": 17}, {"entity_id": "16507380_13_Ent0", "role": "Subject", "text": "a patient", "start": 20, "end": 22}, {"entity_id": "16507380_13_Ent1", "role": "Effect", "text": "IFN - induced hypertriglyceridemia", "start": 25, "end": 29}]}], "entity_mentions": [{"id": "16507380_13_Ent2", "text": "drug - drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID", "entity_type": "Entity", "start": 2, "end": 17}, {"id": "16507380_13_Ent3", "text": "IFN alfa", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "16507380_13_Ent9", "text": "IFN alfa", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "16507380_13_Ent6", "text": "11 MU", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "16507380_13_Ent8", "text": "TIW", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16507380_13_Ent4", "text": "gemfibrozil", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16507380_13_Ent10", "text": "gemfibrozil", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16507380_13_Ent5", "text": "600 mg", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "16507380_13_Ent7", "text": "BID", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16507380_13_Ent0", "text": "a patient", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "16507380_13_Ent1", "text": "IFN - induced hypertriglyceridemia", "entity_type": "Entity", "start": 25, "end": 29}], "lang": "en"}
{"doc_id": "16511396_3", "wnd_id": "16511396_3_1", "text": "This case underscores problems in clinical management with sulfadiazine hypersensitivity , potential immunosuppression from corticosteroids and selection of medications for recurrences of toxoplasmic chorioretinitis .", "tokens": ["This", "case", "underscores", "problems", "in", "clinical", "management", "with", "sulfadiazine", "hypersensitivity", ",", "potential", "immunosuppression", "from", "corticosteroids", "and", "selection", "of", "medications", "for", "recurrences", "of", "toxoplasmic", "chorioretinitis", "."], "event_mentions": [{"id": "16511396_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "hypersensitivity", "start": 9, "end": 10}, "arguments": [{"entity_id": "16511396_3_Ent1", "role": "Treatment", "text": "sulfadiazine", "start": 8, "end": 9}, {"entity_id": "16511396_3_Ent2", "role": "Treatment_Drug", "text": "sulfadiazine", "start": 8, "end": 9}, {"entity_id": "16511396_3_Ent0", "role": "Effect", "text": "hypersensitivity", "start": 9, "end": 10}]}, {"id": "16511396_3_Evt1", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 13, "end": 14}, "arguments": [{"entity_id": "16511396_3_Ent3", "role": "Effect", "text": "immunosuppression", "start": 12, "end": 13}, {"entity_id": "16511396_3_Ent4", "role": "Treatment", "text": "corticosteroids", "start": 14, "end": 15}, {"entity_id": "16511396_3_Ent5", "role": "Treatment_Drug", "text": "corticosteroids", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "16511396_3_Ent1", "text": "sulfadiazine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16511396_3_Ent2", "text": "sulfadiazine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16511396_3_Ent0", "text": "hypersensitivity", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16511396_3_Ent3", "text": "immunosuppression", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16511396_3_Ent4", "text": "corticosteroids", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16511396_3_Ent5", "text": "corticosteroids", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "16521231_2", "wnd_id": "16521231_2_1", "text": "In this case report , we have described a patient with Crohn 's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs - antigen carrier state .", "tokens": ["In", "this", "case", "report", ",", "we", "have", "described", "a", "patient", "with", "Crohn", "'s", "disease", "who", "developed", "subfulminant", "hepatitis", "B", "after", "the", "fourth", "infusion", "of", "infliximab", "due", "to", "an", "unrecognized", "HBs", "-", "antigen", "carrier", "state", "."], "event_mentions": [{"id": "16521231_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "16521231_2_Ent0", "role": "Subject", "text": "a patient with Crohn 's disease", "start": 8, "end": 14}, {"entity_id": "16521231_2_Ent3", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 11, "end": 14}, {"entity_id": "16521231_2_Ent1", "role": "Effect", "text": "subfulminant hepatitis B", "start": 16, "end": 19}, {"entity_id": "16521231_2_Ent4", "role": "Treatment_Time_elapsed", "text": "fourth", "start": 21, "end": 22}, {"entity_id": "16521231_2_Ent2", "role": "Treatment", "text": "fourth infusion of infliximab", "start": 21, "end": 25}, {"entity_id": "16521231_2_Ent6", "role": "Treatment_Route", "text": "infusion", "start": 22, "end": 23}, {"entity_id": "16521231_2_Ent5", "role": "Treatment_Drug", "text": "infliximab", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "16521231_2_Ent0", "text": "a patient with Crohn 's disease", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "16521231_2_Ent3", "text": "Crohn 's disease", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "16521231_2_Ent1", "text": "subfulminant hepatitis B", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "16521231_2_Ent4", "text": "fourth", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16521231_2_Ent2", "text": "fourth infusion of infliximab", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "16521231_2_Ent6", "text": "infusion", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "16521231_2_Ent5", "text": "infliximab", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "16540070_2", "wnd_id": "16540070_2_1", "text": "Allergy to cloxacillin with normal tolerance to amoxicillin and cefuroxime .", "tokens": ["Allergy", "to", "cloxacillin", "with", "normal", "tolerance", "to", "amoxicillin", "and", "cefuroxime", "."], "event_mentions": [{"id": "16540070_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 1, "end": 2}, "arguments": [{"entity_id": "16540070_2_Ent0", "role": "Effect", "text": "Allergy", "start": 0, "end": 1}, {"entity_id": "16540070_2_Ent1", "role": "Treatment", "text": "cloxacillin", "start": 2, "end": 3}, {"entity_id": "16540070_2_Ent2", "role": "Treatment_Drug", "text": "cloxacillin", "start": 2, "end": 3}, {"entity_id": "16540070_2_Ent3", "role": "Treatment_Drug", "text": "amoxicillin", "start": 7, "end": 8}, {"entity_id": "16540070_2_Ent4", "role": "Treatment_Drug", "text": "cefuroxime", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "16540070_2_Ent0", "text": "Allergy", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16540070_2_Ent1", "text": "cloxacillin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16540070_2_Ent2", "text": "cloxacillin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16540070_2_Ent3", "text": "amoxicillin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16540070_2_Ent4", "text": "cefuroxime", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "16580907_5", "wnd_id": "16580907_5_1", "text": "The plasma concentrations of both drugs were significantly increased during the coadministration , and the cetirizine concentration decreased on cessation of pilsicainide despite the fact that treatment with cetirizine was continued , which suggested that the fainting was induced by the pharmacokinetic drug interaction .", "tokens": ["The", "plasma", "concentrations", "of", "both", "drugs", "were", "significantly", "increased", "during", "the", "coadministration", ",", "and", "the", "cetirizine", "concentration", "decreased", "on", "cessation", "of", "pilsicainide", "despite", "the", "fact", "that", "treatment", "with", "cetirizine", "was", "continued", ",", "which", "suggested", "that", "the", "fainting", "was", "induced", "by", "the", "pharmacokinetic", "drug", "interaction", "."], "event_mentions": [{"id": "16580907_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 38, "end": 39}, "arguments": [{"entity_id": "16580907_5_Ent1", "role": "Treatment", "text": "pilsicainide", "start": 21, "end": 22}, {"entity_id": "16580907_5_Ent3", "role": "Treatment_Drug", "text": "pilsicainide", "start": 21, "end": 22}, {"entity_id": "16580907_5_Ent5", "role": "Combination_Drug", "text": "pilsicainide", "start": 21, "end": 22}, {"entity_id": "16580907_5_Ent2", "role": "Treatment", "text": "cetirizine", "start": 28, "end": 29}, {"entity_id": "16580907_5_Ent4", "role": "Treatment_Drug", "text": "cetirizine", "start": 28, "end": 29}, {"entity_id": "16580907_5_Ent6", "role": "Combination_Drug", "text": "cetirizine", "start": 28, "end": 29}, {"entity_id": "16580907_5_Ent0", "role": "Effect", "text": "fainting", "start": 36, "end": 37}]}], "entity_mentions": [{"id": "16580907_5_Ent1", "text": "pilsicainide", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16580907_5_Ent3", "text": "pilsicainide", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16580907_5_Ent5", "text": "pilsicainide", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16580907_5_Ent2", "text": "cetirizine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "16580907_5_Ent4", "text": "cetirizine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "16580907_5_Ent6", "text": "cetirizine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "16580907_5_Ent0", "text": "fainting", "entity_type": "Entity", "start": 36, "end": 37}], "lang": "en"}
{"doc_id": "16580907_9", "wnd_id": "16580907_9_1", "text": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers , such an interaction should be considered , especially in patients with renal insufficiency who are receiving pilsicainide .", "tokens": ["Although", "cetirizine", "has", "less", "potential", "for", "causing", "arrhythmias", "than", "other", "histamine", "1", "blockers", ",", "such", "an", "interaction", "should", "be", "considered", ",", "especially", "in", "patients", "with", "renal", "insufficiency", "who", "are", "receiving", "pilsicainide", "."], "event_mentions": [{"id": "16580907_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causing", "start": 6, "end": 7}, "arguments": [{"entity_id": "16580907_9_Ent3", "role": "Treatment", "text": "cetirizine", "start": 1, "end": 2}, {"entity_id": "16580907_9_Ent4", "role": "Treatment_Drug", "text": "cetirizine", "start": 1, "end": 2}, {"entity_id": "16580907_9_Ent2", "role": "Effect", "text": "arrhythmias", "start": 7, "end": 8}, {"entity_id": "16580907_9_Ent0", "role": "Subject", "text": "patients with renal insufficiency", "start": 23, "end": 27}, {"entity_id": "16580907_9_Ent1", "role": "Subject_Disorder", "text": "renal insufficiency", "start": 25, "end": 27}]}], "entity_mentions": [{"id": "16580907_9_Ent3", "text": "cetirizine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16580907_9_Ent4", "text": "cetirizine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16580907_9_Ent2", "text": "arrhythmias", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16580907_9_Ent0", "text": "patients with renal insufficiency", "entity_type": "Entity", "start": 23, "end": 27}, {"id": "16580907_9_Ent1", "text": "renal insufficiency", "entity_type": "Entity", "start": 25, "end": 27}], "lang": "en"}
{"doc_id": "16620273_2", "wnd_id": "16620273_2_1", "text": "Severe acidosis in patients taking metformin -- rapid reversal and survival despite high APACHE score .", "tokens": ["Severe", "acidosis", "in", "patients", "taking", "metformin", "--", "rapid", "reversal", "and", "survival", "despite", "high", "APACHE", "score", "."], "event_mentions": [{"id": "16620273_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 4, "end": 5}, "arguments": [{"entity_id": "16620273_2_Ent1", "role": "Effect", "text": "Severe acidosis", "start": 0, "end": 2}, {"entity_id": "16620273_2_Ent0", "role": "Subject", "text": "patients", "start": 3, "end": 4}, {"entity_id": "16620273_2_Ent2", "role": "Treatment", "text": "metformin", "start": 5, "end": 6}, {"entity_id": "16620273_2_Ent3", "role": "Treatment_Drug", "text": "metformin", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "16620273_2_Ent1", "text": "Severe acidosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16620273_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16620273_2_Ent2", "text": "metformin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16620273_2_Ent3", "text": "metformin", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "16623611_2", "wnd_id": "16623611_2_1", "text": "The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of olanzapine to metabolic changes manifested as uncontrolled diabetes mellitus and weight gain .", "tokens": ["The", "following", "is", "a", "case", "report", "analysis", "intended", "to", "draw", "attention", "to", "the", "need", "for", "better", "care", "coordination", "by", "describing", "the", "observed", "relationship", "of", "olanzapine", "to", "metabolic", "changes", "manifested", "as", "uncontrolled", "diabetes", "mellitus", "and", "weight", "gain", "."], "event_mentions": [{"id": "16623611_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship", "start": 22, "end": 23}, "arguments": [{"entity_id": "16623611_2_Ent1", "role": "Treatment", "text": "olanzapine", "start": 24, "end": 25}, {"entity_id": "16623611_2_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 24, "end": 25}, {"entity_id": "16623611_2_Ent0", "role": "Effect", "text": "metabolic changes manifested as uncontrolled diabetes mellitus and weight gain", "start": 26, "end": 36}]}], "entity_mentions": [{"id": "16623611_2_Ent1", "text": "olanzapine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "16623611_2_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "16623611_2_Ent0", "text": "metabolic changes manifested as uncontrolled diabetes mellitus and weight gain", "entity_type": "Entity", "start": 26, "end": 36}], "lang": "en"}
{"doc_id": "16632429_1", "wnd_id": "16632429_1_1", "text": "We report the case of a lung cancer patient with bronquiloalveolar carcinoma ( BAC ) presenting with BOOP after chemotherapy with docetaxel and gemcitabine producing severe respiratory insufficiency , and simulating a progression of the tumor .", "tokens": ["We", "report", "the", "case", "of", "a", "lung", "cancer", "patient", "with", "bronquiloalveolar", "carcinoma", "(", "BAC", ")", "presenting", "with", "BOOP", "after", "chemotherapy", "with", "docetaxel", "and", "gemcitabine", "producing", "severe", "respiratory", "insufficiency", ",", "and", "simulating", "a", "progression", "of", "the", "tumor", "."], "event_mentions": [{"id": "16632429_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 18, "end": 19}, "arguments": [{"entity_id": "16632429_1_Ent4", "role": "Treatment_Disorder", "text": "lung cancer", "start": 6, "end": 8}, {"entity_id": "16632429_1_Ent0", "role": "Subject", "text": "lung cancer patient with bronquiloalveolar carcinoma ( BAC )", "start": 6, "end": 15}, {"entity_id": "16632429_1_Ent5", "role": "Treatment_Disorder", "text": "bronquiloalveolar carcinoma ( BAC )", "start": 10, "end": 15}, {"entity_id": "16632429_1_Ent2", "role": "Effect", "text": "BOOP", "start": 17, "end": 18}, {"entity_id": "16632429_1_Ent8", "role": "Treatment_Route", "text": "chemotherapy", "start": 19, "end": 20}, {"entity_id": "16632429_1_Ent3", "role": "Treatment", "text": "chemotherapy with docetaxel and gemcitabine", "start": 19, "end": 24}, {"entity_id": "16632429_1_Ent6", "role": "Treatment_Drug", "text": "docetaxel", "start": 21, "end": 22}, {"entity_id": "16632429_1_Ent9", "role": "Combination_Drug", "text": "docetaxel", "start": 21, "end": 22}, {"entity_id": "16632429_1_Ent7", "role": "Treatment_Drug", "text": "gemcitabine", "start": 23, "end": 24}, {"entity_id": "16632429_1_Ent10", "role": "Combination_Drug", "text": "gemcitabine", "start": 23, "end": 24}, {"entity_id": "16632429_1_Ent1", "role": "Effect", "text": "producing severe respiratory insufficiency , and simulating a progression of the tumor", "start": 24, "end": 36}]}], "entity_mentions": [{"id": "16632429_1_Ent4", "text": "lung cancer", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16632429_1_Ent0", "text": "lung cancer patient with bronquiloalveolar carcinoma ( BAC )", "entity_type": "Entity", "start": 6, "end": 15}, {"id": "16632429_1_Ent5", "text": "bronquiloalveolar carcinoma ( BAC )", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "16632429_1_Ent2", "text": "BOOP", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16632429_1_Ent8", "text": "chemotherapy", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16632429_1_Ent3", "text": "chemotherapy with docetaxel and gemcitabine", "entity_type": "Entity", "start": 19, "end": 24}, {"id": "16632429_1_Ent6", "text": "docetaxel", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16632429_1_Ent9", "text": "docetaxel", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16632429_1_Ent7", "text": "gemcitabine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16632429_1_Ent10", "text": "gemcitabine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16632429_1_Ent1", "text": "producing severe respiratory insufficiency , and simulating a progression of the tumor", "entity_type": "Entity", "start": 24, "end": 36}], "lang": "en"}
{"doc_id": "16637972_4", "wnd_id": "16637972_4_1", "text": "The sub - conjunctival haematoma in a patient receiving warfarin can pose a significant management challenge .", "tokens": ["The", "sub", "-", "conjunctival", "haematoma", "in", "a", "patient", "receiving", "warfarin", "can", "pose", "a", "significant", "management", "challenge", "."], "event_mentions": [{"id": "16637972_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 8, "end": 9}, "arguments": [{"entity_id": "16637972_4_Ent0", "role": "Effect", "text": "sub - conjunctival haematoma", "start": 1, "end": 5}, {"entity_id": "16637972_4_Ent1", "role": "Treatment", "text": "warfarin", "start": 9, "end": 10}, {"entity_id": "16637972_4_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "16637972_4_Ent0", "text": "sub - conjunctival haematoma", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "16637972_4_Ent1", "text": "warfarin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16637972_4_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "16685112_1", "wnd_id": "16685112_1_1", "text": "CASE REPORT : We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy , five months after completing chemoradiation for locally advanced pancreatic cancer .", "tokens": ["CASE", "REPORT", ":", "We", "hereby", "report", "a", "case", "of", "radiation", "recall", "dermatitis", "and", "myositis", "occurring", "on", "gemcitabine", "monotherapy", ",", "five", "months", "after", "completing", "chemoradiation", "for", "locally", "advanced", "pancreatic", "cancer", "."], "event_mentions": [{"id": "16685112_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 14, "end": 15}, "arguments": [{"entity_id": "16685112_1_Ent0", "role": "Effect", "text": "radiation recall dermatitis and myositis", "start": 9, "end": 14}, {"entity_id": "16685112_1_Ent2", "role": "Treatment_Drug", "text": "gemcitabine", "start": 16, "end": 17}, {"entity_id": "16685112_1_Ent1", "role": "Treatment", "text": "gemcitabine monotherapy , five months after completing chemoradiation", "start": 16, "end": 24}, {"entity_id": "16685112_1_Ent4", "role": "Treatment_Time_elapsed", "text": "five months after", "start": 19, "end": 22}, {"entity_id": "16685112_1_Ent3", "role": "Treatment_Disorder", "text": "locally advanced pancreatic cancer", "start": 25, "end": 29}]}], "entity_mentions": [{"id": "16685112_1_Ent0", "text": "radiation recall dermatitis and myositis", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "16685112_1_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16685112_1_Ent1", "text": "gemcitabine monotherapy , five months after completing chemoradiation", "entity_type": "Entity", "start": 16, "end": 24}, {"id": "16685112_1_Ent4", "text": "five months after", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "16685112_1_Ent3", "text": "locally advanced pancreatic cancer", "entity_type": "Entity", "start": 25, "end": 29}], "lang": "en"}
{"doc_id": "16685112_2", "wnd_id": "16685112_2_1", "text": "CONCLUSIONS : This is the second case report that describes gemcitabine - induced radiation recall in rectus abdominus muscles after gemcitabine - based radiation therapy .", "tokens": ["CONCLUSIONS", ":", "This", "is", "the", "second", "case", "report", "that", "describes", "gemcitabine", "-", "induced", "radiation", "recall", "in", "rectus", "abdominus", "muscles", "after", "gemcitabine", "-", "based", "radiation", "therapy", "."], "event_mentions": [{"id": "16685112_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "16685112_2_Ent1", "role": "Treatment", "text": "gemcitabine", "start": 10, "end": 11}, {"entity_id": "16685112_2_Ent2", "role": "Treatment_Drug", "text": "gemcitabine", "start": 10, "end": 11}, {"entity_id": "16685112_2_Ent0", "role": "Effect", "text": "radiation recall in rectus abdominus muscles", "start": 13, "end": 19}]}], "entity_mentions": [{"id": "16685112_2_Ent1", "text": "gemcitabine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16685112_2_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16685112_2_Ent0", "text": "radiation recall in rectus abdominus muscles", "entity_type": "Entity", "start": 13, "end": 19}], "lang": "en"}
{"doc_id": "16697705_1", "wnd_id": "16697705_1_1", "text": "Acute coronary syndrome induced by capecitabine therapy .", "tokens": ["Acute", "coronary", "syndrome", "induced", "by", "capecitabine", "therapy", "."], "event_mentions": [{"id": "16697705_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "16697705_1_Ent0", "role": "Effect", "text": "Acute coronary syndrome", "start": 0, "end": 3}, {"entity_id": "16697705_1_Ent2", "role": "Treatment_Drug", "text": "capecitabine", "start": 5, "end": 6}, {"entity_id": "16697705_1_Ent1", "role": "Treatment", "text": "capecitabine therapy", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "16697705_1_Ent0", "text": "Acute coronary syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16697705_1_Ent2", "text": "capecitabine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16697705_1_Ent1", "text": "capecitabine therapy", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "1673494_1", "wnd_id": "1673494_1_1", "text": "Amphotericin B ( AmB ) is effective , but its use is limited by toxicity : renal impairment , anaemia , fever , malaise , and hypokalaemia are common .", "tokens": ["Amphotericin", "B", "(", "AmB", ")", "is", "effective", ",", "but", "its", "use", "is", "limited", "by", "toxicity", ":", "renal", "impairment", ",", "anaemia", ",", "fever", ",", "malaise", ",", "and", "hypokalaemia", "are", "common", "."], "event_mentions": [{"id": "1673494_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 13, "end": 14}, "arguments": [{"entity_id": "1673494_1_Ent2", "role": "Treatment_Drug", "text": "Amphotericin B", "start": 0, "end": 2}, {"entity_id": "1673494_1_Ent1", "role": "Treatment", "text": "Amphotericin B ( AmB )", "start": 0, "end": 5}, {"entity_id": "1673494_1_Ent0", "role": "Effect", "text": "toxicity : renal impairment , anaemia , fever , malaise , and hypokalaemia", "start": 14, "end": 27}]}], "entity_mentions": [{"id": "1673494_1_Ent2", "text": "Amphotericin B", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1673494_1_Ent1", "text": "Amphotericin B ( AmB )", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "1673494_1_Ent0", "text": "toxicity : renal impairment , anaemia , fever , malaise , and hypokalaemia", "entity_type": "Entity", "start": 14, "end": 27}], "lang": "en"}
{"doc_id": "16816519_1", "wnd_id": "16816519_1_1", "text": "Vincristine induced cranial polyneuropathy .", "tokens": ["Vincristine", "induced", "cranial", "polyneuropathy", "."], "event_mentions": [{"id": "16816519_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "16816519_1_Ent1", "role": "Treatment", "text": "Vincristine", "start": 0, "end": 1}, {"entity_id": "16816519_1_Ent2", "role": "Treatment_Drug", "text": "Vincristine", "start": 0, "end": 1}, {"entity_id": "16816519_1_Ent0", "role": "Effect", "text": "cranial polyneuropathy", "start": 2, "end": 4}]}], "entity_mentions": [{"id": "16816519_1_Ent1", "text": "Vincristine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16816519_1_Ent2", "text": "Vincristine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16816519_1_Ent0", "text": "cranial polyneuropathy", "entity_type": "Entity", "start": 2, "end": 4}], "lang": "en"}
{"doc_id": "16882112_7", "wnd_id": "16882112_7_1", "text": "Use of the Naranjo adverse drug reaction probability algorithm indicated a probable relationship between serotonin syndrome and treatment with lithium and venlafaxine .", "tokens": ["Use", "of", "the", "Naranjo", "adverse", "drug", "reaction", "probability", "algorithm", "indicated", "a", "probable", "relationship", "between", "serotonin", "syndrome", "and", "treatment", "with", "lithium", "and", "venlafaxine", "."], "event_mentions": [{"id": "16882112_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "a probable relationship between", "start": 10, "end": 14}, "arguments": [{"entity_id": "16882112_7_Ent0", "role": "Effect", "text": "serotonin syndrome", "start": 14, "end": 16}, {"entity_id": "16882112_7_Ent1", "role": "Treatment", "text": "treatment with lithium and venlafaxine", "start": 17, "end": 22}, {"entity_id": "16882112_7_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 19, "end": 20}, {"entity_id": "16882112_7_Ent4", "role": "Combination_Drug", "text": "lithium", "start": 19, "end": 20}, {"entity_id": "16882112_7_Ent3", "role": "Treatment_Drug", "text": "venlafaxine", "start": 21, "end": 22}, {"entity_id": "16882112_7_Ent5", "role": "Combination_Drug", "text": "venlafaxine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "16882112_7_Ent0", "text": "serotonin syndrome", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "16882112_7_Ent1", "text": "treatment with lithium and venlafaxine", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "16882112_7_Ent2", "text": "lithium", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16882112_7_Ent4", "text": "lithium", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16882112_7_Ent3", "text": "venlafaxine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16882112_7_Ent5", "text": "venlafaxine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "1688693_5", "wnd_id": "1688693_5_1", "text": "We suggest the use of esmolol for treatment of dysrhythmias secondary to caffeine toxicity ; to the best of our knowledge , the use of esmolol has not been reported for this purpose .", "tokens": ["We", "suggest", "the", "use", "of", "esmolol", "for", "treatment", "of", "dysrhythmias", "secondary", "to", "caffeine", "toxicity", ";", "to", "the", "best", "of", "our", "knowledge", ",", "the", "use", "of", "esmolol", "has", "not", "been", "reported", "for", "this", "purpose", "."], "event_mentions": [{"id": "1688693_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 7, "end": 8}, "arguments": [{"entity_id": "1688693_5_Ent0", "role": "Treatment", "text": "esmolol", "start": 5, "end": 6}, {"entity_id": "1688693_5_Ent1", "role": "Treatment_Drug", "text": "esmolol", "start": 5, "end": 6}, {"entity_id": "1688693_5_Ent4", "role": "Treatment_Disorder", "text": "dysrhythmias", "start": 9, "end": 10}, {"entity_id": "1688693_5_Ent2", "role": "Treatment_Drug", "text": "caffeine", "start": 12, "end": 13}, {"entity_id": "1688693_5_Ent3", "role": "Treatment_Drug", "text": "esmolol", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "1688693_5_Ent0", "text": "esmolol", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1688693_5_Ent1", "text": "esmolol", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1688693_5_Ent4", "text": "dysrhythmias", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1688693_5_Ent2", "text": "caffeine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1688693_5_Ent3", "text": "esmolol", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "16889287_3", "wnd_id": "16889287_3_1", "text": "We report the case of a 21 - year - old female patient with dapsone hypersensitivity syndrome .", "tokens": ["We", "report", "the", "case", "of", "a", "21", "-", "year", "-", "old", "female", "patient", "with", "dapsone", "hypersensitivity", "syndrome", "."], "event_mentions": [{"id": "16889287_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 13, "end": 14}, "arguments": [{"entity_id": "16889287_3_Ent0", "role": "Subject", "text": "a 21 - year - old female patient", "start": 5, "end": 13}, {"entity_id": "16889287_3_Ent1", "role": "Subject_Age", "text": "21 - year - old", "start": 6, "end": 11}, {"entity_id": "16889287_3_Ent2", "role": "Subject_Gender", "text": "female", "start": 11, "end": 12}, {"entity_id": "16889287_3_Ent4", "role": "Treatment", "text": "dapsone", "start": 14, "end": 15}, {"entity_id": "16889287_3_Ent5", "role": "Treatment_Drug", "text": "dapsone", "start": 14, "end": 15}, {"entity_id": "16889287_3_Ent3", "role": "Effect", "text": "hypersensitivity syndrome", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "16889287_3_Ent0", "text": "a 21 - year - old female patient", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "16889287_3_Ent1", "text": "21 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "16889287_3_Ent2", "text": "female", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16889287_3_Ent4", "text": "dapsone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16889287_3_Ent5", "text": "dapsone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16889287_3_Ent3", "text": "hypersensitivity syndrome", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "16901609_2", "wnd_id": "16901609_2_1", "text": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis .", "tokens": ["We", "believe", "this", "is", "the", "first", "report", "of", "intrathecal", "diamorphine", "causing", "anaphylaxis", "."], "event_mentions": [{"id": "16901609_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causing", "start": 10, "end": 11}, "arguments": [{"entity_id": "16901609_2_Ent3", "role": "Treatment_Route", "text": "intrathecal", "start": 8, "end": 9}, {"entity_id": "16901609_2_Ent1", "role": "Treatment", "text": "intrathecal diamorphine", "start": 8, "end": 10}, {"entity_id": "16901609_2_Ent2", "role": "Treatment_Drug", "text": "diamorphine", "start": 9, "end": 10}, {"entity_id": "16901609_2_Ent0", "role": "Effect", "text": "anaphylaxis", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "16901609_2_Ent3", "text": "intrathecal", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16901609_2_Ent1", "text": "intrathecal diamorphine", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16901609_2_Ent2", "text": "diamorphine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16901609_2_Ent0", "text": "anaphylaxis", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "16914372_1", "wnd_id": "16914372_1_1", "text": "We highlight two instances of systemic allergic reaction , and discuss the potential side effects of local aprotinin injections in the orthopaedic setting as well as the evidence base for its use .", "tokens": ["We", "highlight", "two", "instances", "of", "systemic", "allergic", "reaction", ",", "and", "discuss", "the", "potential", "side", "effects", "of", "local", "aprotinin", "injections", "in", "the", "orthopaedic", "setting", "as", "well", "as", "the", "evidence", "base", "for", "its", "use", "."], "event_mentions": [{"id": "16914372_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 15, "end": 16}, "arguments": [{"entity_id": "16914372_1_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "16914372_1_Ent0", "role": "Subject", "text": "two instances", "start": 2, "end": 4}, {"entity_id": "16914372_1_Ent2", "role": "Effect", "text": "systemic allergic reaction", "start": 5, "end": 8}, {"entity_id": "16914372_1_Ent3", "role": "Effect", "text": "potential side effects", "start": 12, "end": 15}, {"entity_id": "16914372_1_Ent4", "role": "Treatment", "text": "aprotinin", "start": 17, "end": 18}, {"entity_id": "16914372_1_Ent5", "role": "Treatment_Drug", "text": "aprotinin", "start": 17, "end": 18}, {"entity_id": "16914372_1_Ent6", "role": "Treatment_Route", "text": "injections", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "16914372_1_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16914372_1_Ent0", "text": "two instances", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16914372_1_Ent2", "text": "systemic allergic reaction", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "16914372_1_Ent3", "text": "potential side effects", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "16914372_1_Ent4", "text": "aprotinin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16914372_1_Ent5", "text": "aprotinin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16914372_1_Ent6", "text": "injections", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "16968538_1", "wnd_id": "16968538_1_1", "text": "Hemolytic uremic syndrome following the infusion of oxaliplatin : case report .", "tokens": ["Hemolytic", "uremic", "syndrome", "following", "the", "infusion", "of", "oxaliplatin", ":", "case", "report", "."], "event_mentions": [{"id": "16968538_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "16968538_1_Ent0", "role": "Effect", "text": "Hemolytic uremic syndrome", "start": 0, "end": 3}, {"entity_id": "16968538_1_Ent1", "role": "Treatment", "text": "oxaliplatin", "start": 7, "end": 8}, {"entity_id": "16968538_1_Ent2", "role": "Treatment_Drug", "text": "oxaliplatin", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "16968538_1_Ent0", "text": "Hemolytic uremic syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16968538_1_Ent1", "text": "oxaliplatin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16968538_1_Ent2", "text": "oxaliplatin", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "16968538_6", "wnd_id": "16968538_6_1", "text": "Three cycles of chemotherapy had been administered without complications when , at the beginning of the fourth cycle , the patient developed clinical and laboratory abnormalities consistent with the development of the hemolytic - uremic syndrome .", "tokens": ["Three", "cycles", "of", "chemotherapy", "had", "been", "administered", "without", "complications", "when", ",", "at", "the", "beginning", "of", "the", "fourth", "cycle", ",", "the", "patient", "developed", "clinical", "and", "laboratory", "abnormalities", "consistent", "with", "the", "development", "of", "the", "hemolytic", "-", "uremic", "syndrome", "."], "event_mentions": [{"id": "16968538_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 21, "end": 22}, "arguments": [{"entity_id": "16968538_6_Ent2", "role": "Treatment", "text": "chemotherapy", "start": 3, "end": 4}, {"entity_id": "16968538_6_Ent4", "role": "Treatment_Drug", "text": "chemotherapy", "start": 3, "end": 4}, {"entity_id": "16968538_6_Ent3", "role": "Treatment", "text": "at the beginning of the fourth cycle", "start": 11, "end": 18}, {"entity_id": "16968538_6_Ent5", "role": "Treatment_Duration", "text": "fourth cycle", "start": 16, "end": 18}, {"entity_id": "16968538_6_Ent0", "role": "Subject", "text": "the patient", "start": 19, "end": 21}, {"entity_id": "16968538_6_Ent1", "role": "Effect", "text": "hemolytic - uremic syndrome .", "start": 32, "end": 37}]}], "entity_mentions": [{"id": "16968538_6_Ent2", "text": "chemotherapy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16968538_6_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16968538_6_Ent3", "text": "at the beginning of the fourth cycle", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "16968538_6_Ent5", "text": "fourth cycle", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "16968538_6_Ent0", "text": "the patient", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "16968538_6_Ent1", "text": "hemolytic - uremic syndrome .", "entity_type": "Entity", "start": 32, "end": 37}], "lang": "en"}
{"doc_id": "16978752_4", "wnd_id": "16978752_4_1", "text": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians .", "tokens": ["Thus", "any", "case", "of", "severe", "neutropenia", "occurring", "in", "a", "patient", "receiving", "olanzapine", "is", "alarming", "to", "clinicians", "."], "event_mentions": [{"id": "16978752_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 6, "end": 7}, "arguments": [{"entity_id": "16978752_4_Ent1", "role": "Effect", "text": "severe neutropenia", "start": 4, "end": 6}, {"entity_id": "16978752_4_Ent0", "role": "Subject", "text": "a patient", "start": 8, "end": 10}, {"entity_id": "16978752_4_Ent2", "role": "Treatment", "text": "olanzapine", "start": 11, "end": 12}, {"entity_id": "16978752_4_Ent3", "role": "Treatment_Drug", "text": "olanzapine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "16978752_4_Ent1", "text": "severe neutropenia", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "16978752_4_Ent0", "text": "a patient", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16978752_4_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16978752_4_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "16986159_1", "wnd_id": "16986159_1_1", "text": "We present a depressive patient who developed mild parkinsonian signs and camptocormia after the introduction of olanzapine .", "tokens": ["We", "present", "a", "depressive", "patient", "who", "developed", "mild", "parkinsonian", "signs", "and", "camptocormia", "after", "the", "introduction", "of", "olanzapine", "."], "event_mentions": [{"id": "16986159_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "16986159_1_Ent4", "role": "Treatment_Disorder", "text": "depressive", "start": 3, "end": 4}, {"entity_id": "16986159_1_Ent0", "role": "Subject", "text": "depressive patient", "start": 3, "end": 5}, {"entity_id": "16986159_1_Ent1", "role": "Effect", "text": "mild parkinsonian signs and camptocormia", "start": 7, "end": 12}, {"entity_id": "16986159_1_Ent2", "role": "Treatment", "text": "introduction of olanzapine", "start": 14, "end": 17}, {"entity_id": "16986159_1_Ent3", "role": "Treatment_Drug", "text": "olanzapine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "16986159_1_Ent4", "text": "depressive", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16986159_1_Ent0", "text": "depressive patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16986159_1_Ent1", "text": "mild parkinsonian signs and camptocormia", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "16986159_1_Ent2", "text": "introduction of olanzapine", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "16986159_1_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "17009081_3", "wnd_id": "17009081_3_1", "text": "Nephrotic syndrome associated with interferon - beta - 1b therapy for multiple sclerosis .", "tokens": ["Nephrotic", "syndrome", "associated", "with", "interferon", "-", "beta", "-", "1b", "therapy", "for", "multiple", "sclerosis", "."], "event_mentions": [{"id": "17009081_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 2, "end": 4}, "arguments": [{"entity_id": "17009081_3_Ent0", "role": "Effect", "text": "Nephrotic syndrome", "start": 0, "end": 2}, {"entity_id": "17009081_3_Ent2", "role": "Treatment_Drug", "text": "interferon - beta - 1b", "start": 4, "end": 9}, {"entity_id": "17009081_3_Ent1", "role": "Treatment", "text": "interferon - beta - 1b therapy", "start": 4, "end": 10}, {"entity_id": "17009081_3_Ent3", "role": "Treatment_Disorder", "text": "multiple sclerosis .", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "17009081_3_Ent0", "text": "Nephrotic syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17009081_3_Ent2", "text": "interferon - beta - 1b", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "17009081_3_Ent1", "text": "interferon - beta - 1b therapy", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "17009081_3_Ent3", "text": "multiple sclerosis .", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "17016002_2", "wnd_id": "17016002_2_1", "text": "Acute eosinophilic pneumonia caused by calcium stearate , an additive agent for an oral antihistaminic medication .", "tokens": ["Acute", "eosinophilic", "pneumonia", "caused", "by", "calcium", "stearate", ",", "an", "additive", "agent", "for", "an", "oral", "antihistaminic", "medication", "."], "event_mentions": [{"id": "17016002_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 3, "end": 4}, "arguments": [{"entity_id": "17016002_2_Ent0", "role": "Effect", "text": "Acute eosinophilic pneumonia", "start": 0, "end": 3}, {"entity_id": "17016002_2_Ent2", "role": "Treatment_Drug", "text": "calcium stearate", "start": 5, "end": 7}, {"entity_id": "17016002_2_Ent1", "role": "Treatment", "text": "calcium stearate , an additive agent for an oral antihistaminic medication", "start": 5, "end": 16}, {"entity_id": "17016002_2_Ent3", "role": "Treatment_Route", "text": "oral", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "17016002_2_Ent0", "text": "Acute eosinophilic pneumonia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17016002_2_Ent2", "text": "calcium stearate", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "17016002_2_Ent1", "text": "calcium stearate , an additive agent for an oral antihistaminic medication", "entity_type": "Entity", "start": 5, "end": 16}, {"id": "17016002_2_Ent3", "text": "oral", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "17016002_3", "wnd_id": "17016002_3_1", "text": "Therefore , we concluded that this patient 's pulmonary disease was caused by calcium stearate , an additive for an antihistaminic drug .", "tokens": ["Therefore", ",", "we", "concluded", "that", "this", "patient", "'s", "pulmonary", "disease", "was", "caused", "by", "calcium", "stearate", ",", "an", "additive", "for", "an", "antihistaminic", "drug", "."], "event_mentions": [{"id": "17016002_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 11, "end": 12}, "arguments": [{"entity_id": "17016002_3_Ent0", "role": "Subject", "text": "this patient 's", "start": 5, "end": 8}, {"entity_id": "17016002_3_Ent1", "role": "Effect", "text": "pulmonary disease", "start": 8, "end": 10}, {"entity_id": "17016002_3_Ent2", "role": "Treatment", "text": "calcium stearate", "start": 13, "end": 15}, {"entity_id": "17016002_3_Ent4", "role": "Treatment_Drug", "text": "calcium stearate", "start": 13, "end": 15}, {"entity_id": "17016002_3_Ent3", "role": "Treatment", "text": "an additive for an antihistaminic drug", "start": 16, "end": 22}]}], "entity_mentions": [{"id": "17016002_3_Ent0", "text": "this patient 's", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "17016002_3_Ent1", "text": "pulmonary disease", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "17016002_3_Ent2", "text": "calcium stearate", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "17016002_3_Ent4", "text": "calcium stearate", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "17016002_3_Ent3", "text": "an additive for an antihistaminic drug", "entity_type": "Entity", "start": 16, "end": 22}], "lang": "en"}
{"doc_id": "17034541_3", "wnd_id": "17034541_3_1", "text": "This is the first case of HBV reactivation occurring during the year following rituximab monotherapy in the absence of any other immunosuppressive factor .", "tokens": ["This", "is", "the", "first", "case", "of", "HBV", "reactivation", "occurring", "during", "the", "year", "following", "rituximab", "monotherapy", "in", "the", "absence", "of", "any", "other", "immunosuppressive", "factor", "."], "event_mentions": [{"id": "17034541_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 8, "end": 9}, "arguments": [{"entity_id": "17034541_3_Ent0", "role": "Effect", "text": "HBV reactivation", "start": 6, "end": 8}, {"entity_id": "17034541_3_Ent1", "role": "Treatment", "text": "the year following rituximab monotherapy in the absence of any other immunosuppressive factor", "start": 10, "end": 23}, {"entity_id": "17034541_3_Ent3", "role": "Treatment_Time_elapsed", "text": "year following", "start": 11, "end": 13}, {"entity_id": "17034541_3_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "17034541_3_Ent0", "text": "HBV reactivation", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17034541_3_Ent1", "text": "the year following rituximab monotherapy in the absence of any other immunosuppressive factor", "entity_type": "Entity", "start": 10, "end": 23}, {"id": "17034541_3_Ent3", "text": "year following", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "17034541_3_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "17068466_3", "wnd_id": "17068466_3_1", "text": "Severe corneal toxicity after topical fluoroquinolone therapy : report of two cases .", "tokens": ["Severe", "corneal", "toxicity", "after", "topical", "fluoroquinolone", "therapy", ":", "report", "of", "two", "cases", "."], "event_mentions": [{"id": "17068466_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "17068466_3_Ent0", "role": "Effect", "text": "corneal toxicity", "start": 1, "end": 3}, {"entity_id": "17068466_3_Ent1", "role": "Treatment", "text": "topical fluoroquinolone therapy", "start": 4, "end": 7}, {"entity_id": "17068466_3_Ent2", "role": "Treatment_Drug", "text": "fluoroquinolone", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "17068466_3_Ent0", "text": "corneal toxicity", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "17068466_3_Ent1", "text": "topical fluoroquinolone therapy", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "17068466_3_Ent2", "text": "fluoroquinolone", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "17083890_4", "wnd_id": "17083890_4_1", "text": "We describe a 52 - year - old male diagnosed with stage III multiple myeloma , who was treated with 5 - monthly cycles of VAD ( vincristine , adriamycin and dexamathasone ) .", "tokens": ["We", "describe", "a", "52", "-", "year", "-", "old", "male", "diagnosed", "with", "stage", "III", "multiple", "myeloma", ",", "who", "was", "treated", "with", "5", "-", "monthly", "cycles", "of", "VAD", "(", "vincristine", ",", "adriamycin", "and", "dexamathasone", ")", "."], "event_mentions": [{"id": "17083890_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 18, "end": 19}, "arguments": [{"entity_id": "17083890_4_Ent0", "role": "Subject", "text": "a 52 - year - old male", "start": 2, "end": 9}, {"entity_id": "17083890_4_Ent1", "role": "Subject_Age", "text": "52 - year - old", "start": 3, "end": 8}, {"entity_id": "17083890_4_Ent2", "role": "Subject_Gender", "text": "male", "start": 8, "end": 9}, {"entity_id": "17083890_4_Ent4", "role": "Treatment_Disorder", "text": "stage III multiple myeloma", "start": 11, "end": 15}, {"entity_id": "17083890_4_Ent5", "role": "Treatment_Duration", "text": "5 - monthly", "start": 20, "end": 23}, {"entity_id": "17083890_4_Ent3", "role": "Treatment", "text": "5 - monthly cycles of VAD ( vincristine , adriamycin and dexamathasone )", "start": 20, "end": 33}, {"entity_id": "17083890_4_Ent6", "role": "Treatment_Drug", "text": "vincristine", "start": 27, "end": 28}, {"entity_id": "17083890_4_Ent9", "role": "Combination_Drug", "text": "vincristine", "start": 27, "end": 28}, {"entity_id": "17083890_4_Ent7", "role": "Treatment_Drug", "text": "adriamycin", "start": 29, "end": 30}, {"entity_id": "17083890_4_Ent10", "role": "Combination_Drug", "text": "adriamycin", "start": 29, "end": 30}, {"entity_id": "17083890_4_Ent8", "role": "Treatment_Drug", "text": "dexamathasone", "start": 31, "end": 32}, {"entity_id": "17083890_4_Ent11", "role": "Combination_Drug", "text": "dexamathasone", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "17083890_4_Ent0", "text": "a 52 - year - old male", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "17083890_4_Ent1", "text": "52 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "17083890_4_Ent2", "text": "male", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17083890_4_Ent4", "text": "stage III multiple myeloma", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "17083890_4_Ent5", "text": "5 - monthly", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "17083890_4_Ent3", "text": "5 - monthly cycles of VAD ( vincristine , adriamycin and dexamathasone )", "entity_type": "Entity", "start": 20, "end": 33}, {"id": "17083890_4_Ent6", "text": "vincristine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17083890_4_Ent9", "text": "vincristine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17083890_4_Ent7", "text": "adriamycin", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "17083890_4_Ent10", "text": "adriamycin", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "17083890_4_Ent8", "text": "dexamathasone", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "17083890_4_Ent11", "text": "dexamathasone", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "17083890_5", "wnd_id": "17083890_5_1", "text": "During administration of chemotherapy , the patient progressively developed a complex association of Beau 's lines , transverse melanonychia , Muehrcke 's lines , and diffuse hyperpigmentation of the skin .", "tokens": ["During", "administration", "of", "chemotherapy", ",", "the", "patient", "progressively", "developed", "a", "complex", "association", "of", "Beau", "'s", "lines", ",", "transverse", "melanonychia", ",", "Muehrcke", "'s", "lines", ",", "and", "diffuse", "hyperpigmentation", "of", "the", "skin", "."], "event_mentions": [{"id": "17083890_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "17083890_5_Ent2", "role": "Treatment", "text": "chemotherapy", "start": 3, "end": 4}, {"entity_id": "17083890_5_Ent3", "role": "Treatment_Route", "text": "chemotherapy", "start": 3, "end": 4}, {"entity_id": "17083890_5_Ent0", "role": "Subject", "text": "patient", "start": 6, "end": 7}, {"entity_id": "17083890_5_Ent1", "role": "Effect", "text": "a complex association of Beau 's lines , transverse melanonychia , Muehrcke 's lines , and diffuse hyperpigmentation of the skin", "start": 9, "end": 30}]}], "entity_mentions": [{"id": "17083890_5_Ent2", "text": "chemotherapy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17083890_5_Ent3", "text": "chemotherapy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17083890_5_Ent0", "text": "patient", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17083890_5_Ent1", "text": "a complex association of Beau 's lines , transverse melanonychia , Muehrcke 's lines , and diffuse hyperpigmentation of the skin", "entity_type": "Entity", "start": 9, "end": 30}], "lang": "en"}
{"doc_id": "17090724_1", "wnd_id": "17090724_1_1", "text": "DISCUSSION : Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity , with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease , even when administered in conventional dosages and infusion rates .", "tokens": ["DISCUSSION", ":", "Amphotericin", "B", "deoxycholate", "has", "been", "reported", "to", "produce", "significant", "cardiac", "toxicity", ",", "with", "ventricular", "arrhythmias", "and", "bradycardia", "reported", "in", "overdoses", "in", "children", "and", "in", "adults", "with", "preexisting", "cardiac", "disease", ",", "even", "when", "administered", "in", "conventional", "dosages", "and", "infusion", "rates", "."], "event_mentions": [{"id": "17090724_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "produce", "start": 9, "end": 10}, "arguments": [{"entity_id": "17090724_1_Ent4", "role": "Treatment", "text": "Amphotericin B deoxycholate", "start": 2, "end": 5}, {"entity_id": "17090724_1_Ent6", "role": "Treatment_Drug", "text": "Amphotericin B deoxycholate", "start": 2, "end": 5}, {"entity_id": "17090724_1_Ent3", "role": "Effect", "text": "cardiac toxicity , with ventricular arrhythmias and bradycardia", "start": 11, "end": 19}, {"entity_id": "17090724_1_Ent1", "role": "Subject_Age", "text": "in children and in adults", "start": 22, "end": 27}, {"entity_id": "17090724_1_Ent0", "role": "Subject", "text": "in children and in adults with preexisting cardiac disease", "start": 22, "end": 31}, {"entity_id": "17090724_1_Ent2", "role": "Subject_Disorder", "text": "preexisting cardiac disease", "start": 28, "end": 31}, {"entity_id": "17090724_1_Ent7", "role": "Treatment_Dosage", "text": "conventional dosages", "start": 36, "end": 38}, {"entity_id": "17090724_1_Ent5", "role": "Treatment", "text": "conventional dosages and infusion rates", "start": 36, "end": 41}, {"entity_id": "17090724_1_Ent8", "role": "Treatment_Route", "text": "infusion", "start": 39, "end": 40}]}], "entity_mentions": [{"id": "17090724_1_Ent4", "text": "Amphotericin B deoxycholate", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "17090724_1_Ent6", "text": "Amphotericin B deoxycholate", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "17090724_1_Ent3", "text": "cardiac toxicity , with ventricular arrhythmias and bradycardia", "entity_type": "Entity", "start": 11, "end": 19}, {"id": "17090724_1_Ent1", "text": "in children and in adults", "entity_type": "Entity", "start": 22, "end": 27}, {"id": "17090724_1_Ent0", "text": "in children and in adults with preexisting cardiac disease", "entity_type": "Entity", "start": 22, "end": 31}, {"id": "17090724_1_Ent2", "text": "preexisting cardiac disease", "entity_type": "Entity", "start": 28, "end": 31}, {"id": "17090724_1_Ent7", "text": "conventional dosages", "entity_type": "Entity", "start": 36, "end": 38}, {"id": "17090724_1_Ent5", "text": "conventional dosages and infusion rates", "entity_type": "Entity", "start": 36, "end": 41}, {"id": "17090724_1_Ent8", "text": "infusion", "entity_type": "Entity", "start": 39, "end": 40}], "lang": "en"}
{"doc_id": "17109650_2", "wnd_id": "17109650_2_1", "text": "Valvular heart disease in a patient taking benfluorex .", "tokens": ["Valvular", "heart", "disease", "in", "a", "patient", "taking", "benfluorex", "."], "event_mentions": [{"id": "17109650_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 6, "end": 7}, "arguments": [{"entity_id": "17109650_2_Ent1", "role": "Effect", "text": "Valvular heart disease", "start": 0, "end": 3}, {"entity_id": "17109650_2_Ent0", "role": "Subject", "text": "a patient", "start": 4, "end": 6}, {"entity_id": "17109650_2_Ent2", "role": "Treatment", "text": "benfluorex", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "17109650_2_Ent1", "text": "Valvular heart disease", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17109650_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "17109650_2_Ent2", "text": "benfluorex", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "1711090_1", "wnd_id": "1711090_1_1", "text": "Trans - catheter hepatic arterial injection of lipiodol soluble anti - cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma .", "tokens": ["Trans", "-", "catheter", "hepatic", "arterial", "injection", "of", "lipiodol", "soluble", "anti", "-", "cancer", "agent", "SMANCS", "and", "ADR", "suspension", "in", "lipiodol", "combined", "with", "arterial", "embolization", "and", "local", "hyperthermia", "for", "treatment", "of", "hepatocellular", "carcinoma", "."], "event_mentions": [{"id": "1711090_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 27, "end": 28}, "arguments": [{"entity_id": "1711090_1_Ent0", "role": "Treatment", "text": "Trans - catheter hepatic arterial injection of lipiodol soluble anti - cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia", "start": 0, "end": 26}, {"entity_id": "1711090_1_Ent2", "role": "Treatment_Route", "text": "arterial injection", "start": 4, "end": 6}, {"entity_id": "1711090_1_Ent3", "role": "Treatment_Drug", "text": "SMANCS", "start": 13, "end": 14}, {"entity_id": "1711090_1_Ent6", "role": "Combination_Drug", "text": "SMANCS", "start": 13, "end": 14}, {"entity_id": "1711090_1_Ent4", "role": "Treatment_Drug", "text": "ADR", "start": 15, "end": 16}, {"entity_id": "1711090_1_Ent5", "role": "Combination_Drug", "text": "ADR", "start": 15, "end": 16}, {"entity_id": "1711090_1_Ent1", "role": "Treatment_Disorder", "text": "hepatocellular carcinoma", "start": 29, "end": 31}]}], "entity_mentions": [{"id": "1711090_1_Ent0", "text": "Trans - catheter hepatic arterial injection of lipiodol soluble anti - cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia", "entity_type": "Entity", "start": 0, "end": 26}, {"id": "1711090_1_Ent2", "text": "arterial injection", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "1711090_1_Ent3", "text": "SMANCS", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "1711090_1_Ent6", "text": "SMANCS", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "1711090_1_Ent4", "text": "ADR", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "1711090_1_Ent5", "text": "ADR", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "1711090_1_Ent1", "text": "hepatocellular carcinoma", "entity_type": "Entity", "start": 29, "end": 31}], "lang": "en"}
{"doc_id": "1711090_2", "wnd_id": "1711090_2_1", "text": "The clinical effect and safety of Lp - TAE alone and combined with radiofrequency ( RF ) capacitive hyperthermia ( HT ) were evaluated in 20 patients with hepatocellular carcinoma ( HCC ) associated with cirrhosis of the liver .", "tokens": ["The", "clinical", "effect", "and", "safety", "of", "Lp", "-", "TAE", "alone", "and", "combined", "with", "radiofrequency", "(", "RF", ")", "capacitive", "hyperthermia", "(", "HT", ")", "were", "evaluated", "in", "20", "patients", "with", "hepatocellular", "carcinoma", "(", "HCC", ")", "associated", "with", "cirrhosis", "of", "the", "liver", "."], "event_mentions": [{"id": "1711090_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "effect and safety", "start": 2, "end": 5}, "arguments": [{"entity_id": "1711090_2_Ent4", "role": "Treatment_Drug", "text": "Lp - TAE", "start": 6, "end": 9}, {"entity_id": "1711090_2_Ent7", "role": "Combination_Drug", "text": "Lp - TAE", "start": 6, "end": 9}, {"entity_id": "1711090_2_Ent3", "role": "Treatment", "text": "Lp - TAE alone and combined with radiofrequency ( RF ) capacitive hyperthermia ( HT )", "start": 6, "end": 22}, {"entity_id": "1711090_2_Ent5", "role": "Treatment_Drug", "text": "radiofrequency ( RF ) capacitive hyperthermia", "start": 13, "end": 19}, {"entity_id": "1711090_2_Ent8", "role": "Combination_Drug", "text": "radiofrequency ( RF ) capacitive hyperthermia", "start": 13, "end": 19}, {"entity_id": "1711090_2_Ent1", "role": "Subject_Population", "text": "20", "start": 25, "end": 26}, {"entity_id": "1711090_2_Ent0", "role": "Subject", "text": "20 patients with hepatocellular carcinoma ( HCC )", "start": 25, "end": 33}, {"entity_id": "1711090_2_Ent2", "role": "Subject_Disorder", "text": "hepatocellular carcinoma", "start": 28, "end": 30}, {"entity_id": "1711090_2_Ent6", "role": "Treatment_Disorder", "text": "cirrhosis of the liver", "start": 35, "end": 39}]}], "entity_mentions": [{"id": "1711090_2_Ent4", "text": "Lp - TAE", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "1711090_2_Ent7", "text": "Lp - TAE", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "1711090_2_Ent3", "text": "Lp - TAE alone and combined with radiofrequency ( RF ) capacitive hyperthermia ( HT )", "entity_type": "Entity", "start": 6, "end": 22}, {"id": "1711090_2_Ent5", "text": "radiofrequency ( RF ) capacitive hyperthermia", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "1711090_2_Ent8", "text": "radiofrequency ( RF ) capacitive hyperthermia", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "1711090_2_Ent1", "text": "20", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "1711090_2_Ent0", "text": "20 patients with hepatocellular carcinoma ( HCC )", "entity_type": "Entity", "start": 25, "end": 33}, {"id": "1711090_2_Ent2", "text": "hepatocellular carcinoma", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "1711090_2_Ent6", "text": "cirrhosis of the liver", "entity_type": "Entity", "start": 35, "end": 39}], "lang": "en"}
{"doc_id": "17133571_2", "wnd_id": "17133571_2_1", "text": "We describe a detailed case of fulminant hepatitis induced by nevirapine ( Viramune ) and treated by liver transplantation .", "tokens": ["We", "describe", "a", "detailed", "case", "of", "fulminant", "hepatitis", "induced", "by", "nevirapine", "(", "Viramune", ")", "and", "treated", "by", "liver", "transplantation", "."], "event_mentions": [{"id": "17133571_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "17133571_2_Ent0", "role": "Effect", "text": "fulminant hepatitis", "start": 6, "end": 8}, {"entity_id": "17133571_2_Ent1", "role": "Treatment", "text": "nevirapine", "start": 10, "end": 11}, {"entity_id": "17133571_2_Ent2", "role": "Treatment_Drug", "text": "nevirapine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "17133571_2_Ent0", "text": "fulminant hepatitis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17133571_2_Ent1", "text": "nevirapine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17133571_2_Ent2", "text": "nevirapine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "17167851_2", "wnd_id": "17167851_2_1", "text": "Three male patients aged 78 - 83 years are presented , in whom severe hepatotoxic reactions emerged after CPA administration .", "tokens": ["Three", "male", "patients", "aged", "78", "-", "83", "years", "are", "presented", ",", "in", "whom", "severe", "hepatotoxic", "reactions", "emerged", "after", "CPA", "administration", "."], "event_mentions": [{"id": "17167851_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 17, "end": 18}, "arguments": [{"entity_id": "17167851_2_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "17167851_2_Ent0", "role": "Subject", "text": "Three male patients aged 78 - 83 years", "start": 0, "end": 8}, {"entity_id": "17167851_2_Ent2", "role": "Subject_Gender", "text": "male", "start": 1, "end": 2}, {"entity_id": "17167851_2_Ent3", "role": "Subject_Age", "text": "78 - 83 years", "start": 4, "end": 8}, {"entity_id": "17167851_2_Ent4", "role": "Effect", "text": "severe hepatotoxic reactions", "start": 13, "end": 16}, {"entity_id": "17167851_2_Ent5", "role": "Treatment", "text": "CPA", "start": 18, "end": 19}, {"entity_id": "17167851_2_Ent6", "role": "Treatment_Drug", "text": "CPA", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "17167851_2_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17167851_2_Ent0", "text": "Three male patients aged 78 - 83 years", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "17167851_2_Ent2", "text": "male", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17167851_2_Ent3", "text": "78 - 83 years", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "17167851_2_Ent4", "text": "severe hepatotoxic reactions", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "17167851_2_Ent5", "text": "CPA", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17167851_2_Ent6", "text": "CPA", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "17182354_3", "wnd_id": "17182354_3_1", "text": "Methylphenidate ( Ritalin) - associated cataract and glaucoma .", "tokens": ["Methylphenidate", "(", "Ritalin)", "-", "associated", "cataract", "and", "glaucoma", "."], "event_mentions": [{"id": "17182354_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "17182354_3_Ent2", "role": "Treatment_Drug", "text": "Methylphenidate", "start": 0, "end": 1}, {"entity_id": "17182354_3_Ent1", "role": "Treatment", "text": "Methylphenidate ( Ritalin)", "start": 0, "end": 3}, {"entity_id": "17182354_3_Ent0", "role": "Effect", "text": "cataract and glaucoma", "start": 5, "end": 8}]}], "entity_mentions": [{"id": "17182354_3_Ent2", "text": "Methylphenidate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17182354_3_Ent1", "text": "Methylphenidate ( Ritalin)", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17182354_3_Ent0", "text": "cataract and glaucoma", "entity_type": "Entity", "start": 5, "end": 8}], "lang": "en"}
{"doc_id": "17188061_1", "wnd_id": "17188061_1_1", "text": "CONCLUSIONS : We report a typical symptoms of Charles - Bonnet syndrome ( CBS ) in patients with severe AMD after intravitreal Avastin - injections .", "tokens": ["CONCLUSIONS", ":", "We", "report", "a", "typical", "symptoms", "of", "Charles", "-", "Bonnet", "syndrome", "(", "CBS", ")", "in", "patients", "with", "severe", "AMD", "after", "intravitreal", "Avastin", "-", "injections", "."], "event_mentions": [{"id": "17188061_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 20, "end": 21}, "arguments": [{"entity_id": "17188061_1_Ent1", "role": "Effect", "text": "typical symptoms of Charles - Bonnet syndrome ( CBS )", "start": 5, "end": 15}, {"entity_id": "17188061_1_Ent0", "role": "Subject", "text": "patients with severe AMD", "start": 16, "end": 20}, {"entity_id": "17188061_1_Ent6", "role": "Treatment_Disorder", "text": "AMD", "start": 19, "end": 20}, {"entity_id": "17188061_1_Ent4", "role": "Treatment_Route", "text": "intravitreal", "start": 21, "end": 22}, {"entity_id": "17188061_1_Ent2", "role": "Treatment", "text": "intravitreal Avastin - injections", "start": 21, "end": 25}, {"entity_id": "17188061_1_Ent3", "role": "Treatment_Drug", "text": "Avastin", "start": 22, "end": 23}, {"entity_id": "17188061_1_Ent5", "role": "Treatment_Route", "text": "injections", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "17188061_1_Ent1", "text": "typical symptoms of Charles - Bonnet syndrome ( CBS )", "entity_type": "Entity", "start": 5, "end": 15}, {"id": "17188061_1_Ent0", "text": "patients with severe AMD", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "17188061_1_Ent6", "text": "AMD", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17188061_1_Ent4", "text": "intravitreal", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "17188061_1_Ent2", "text": "intravitreal Avastin - injections", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "17188061_1_Ent3", "text": "Avastin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "17188061_1_Ent5", "text": "injections", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "17189581_11", "wnd_id": "17189581_11_1", "text": "After a total of four doses of linezolid , the patient reported further discomfort .", "tokens": ["After", "a", "total", "of", "four", "doses", "of", "linezolid", ",", "the", "patient", "reported", "further", "discomfort", "."], "event_mentions": [{"id": "17189581_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 11, "end": 12}, "arguments": [{"entity_id": "17189581_11_Ent2", "role": "Treatment", "text": "a total of four doses of linezolid", "start": 1, "end": 8}, {"entity_id": "17189581_11_Ent4", "role": "Treatment_Dosage", "text": "four doses", "start": 4, "end": 6}, {"entity_id": "17189581_11_Ent3", "role": "Treatment_Drug", "text": "linezolid", "start": 7, "end": 8}, {"entity_id": "17189581_11_Ent0", "role": "Subject", "text": "the patient", "start": 9, "end": 11}, {"entity_id": "17189581_11_Ent1", "role": "Effect", "text": "further discomfort", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "17189581_11_Ent2", "text": "a total of four doses of linezolid", "entity_type": "Entity", "start": 1, "end": 8}, {"id": "17189581_11_Ent4", "text": "four doses", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "17189581_11_Ent3", "text": "linezolid", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17189581_11_Ent0", "text": "the patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "17189581_11_Ent1", "text": "further discomfort", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "17199845_1", "wnd_id": "17199845_1_1", "text": "However , cyclosporine dependency is associated with the risk of nephrotoxicity .", "tokens": ["However", ",", "cyclosporine", "dependency", "is", "associated", "with", "the", "risk", "of", "nephrotoxicity", "."], "event_mentions": [{"id": "17199845_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "17199845_1_Ent2", "role": "Treatment_Drug", "text": "cyclosporine", "start": 2, "end": 3}, {"entity_id": "17199845_1_Ent1", "role": "Treatment", "text": "cyclosporine dependency", "start": 2, "end": 4}, {"entity_id": "17199845_1_Ent0", "role": "Effect", "text": "nephrotoxicity", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "17199845_1_Ent2", "text": "cyclosporine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17199845_1_Ent1", "text": "cyclosporine dependency", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "17199845_1_Ent0", "text": "nephrotoxicity", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "17228132_2", "wnd_id": "17228132_2_1", "text": "CONTEXT : Acute drug induced hepatitis has not been commonly associated with epidermal growth factor receptor ( EGFR ) inhibitors .", "tokens": ["CONTEXT", ":", "Acute", "drug", "induced", "hepatitis", "has", "not", "been", "commonly", "associated", "with", "epidermal", "growth", "factor", "receptor", "(", "EGFR", ")", "inhibitors", "."], "event_mentions": [{"id": "17228132_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 10, "end": 11}, "arguments": [{"entity_id": "17228132_2_Ent0", "role": "Effect", "text": "Acute drug induced hepatitis", "start": 2, "end": 6}, {"entity_id": "17228132_2_Ent2", "role": "Treatment_Drug", "text": "epidermal growth factor receptor", "start": 12, "end": 16}, {"entity_id": "17228132_2_Ent1", "role": "Treatment", "text": "epidermal growth factor receptor ( EGFR ) inhibitors", "start": 12, "end": 20}, {"entity_id": "17228132_2_Ent3", "role": "Treatment_Drug", "text": "inhibitors", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "17228132_2_Ent0", "text": "Acute drug induced hepatitis", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "17228132_2_Ent2", "text": "epidermal growth factor receptor", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "17228132_2_Ent1", "text": "epidermal growth factor receptor ( EGFR ) inhibitors", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "17228132_2_Ent3", "text": "inhibitors", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "17228132_8", "wnd_id": "17228132_8_1", "text": "Hepatotoxicity resolved once erlotinib was discontinued and serum transaminases returned to baseline normal values .", "tokens": ["Hepatotoxicity", "resolved", "once", "erlotinib", "was", "discontinued", "and", "serum", "transaminases", "returned", "to", "baseline", "normal", "values", "."], "event_mentions": [{"id": "17228132_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "discontinued", "start": 5, "end": 6}, "arguments": [{"entity_id": "17228132_8_Ent0", "role": "Effect", "text": "Hepatotoxicity", "start": 0, "end": 1}, {"entity_id": "17228132_8_Ent2", "role": "Treatment_Disorder", "text": "Hepatotoxicity", "start": 0, "end": 1}, {"entity_id": "17228132_8_Ent1", "role": "Treatment", "text": "erlotinib", "start": 3, "end": 4}, {"entity_id": "17228132_8_Ent3", "role": "Treatment_Drug", "text": "erlotinib", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "17228132_8_Ent0", "text": "Hepatotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17228132_8_Ent2", "text": "Hepatotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17228132_8_Ent1", "text": "erlotinib", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17228132_8_Ent3", "text": "erlotinib", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "1722991_6", "wnd_id": "1722991_6_1", "text": "In the two cases , a combination of iloprost , a stable prostacyclin analogue ( 1 to 2 ng / kg / mn ) with aspirin and dipyridamole was shown to inhibit ex vivo the heparin - induced platelet aggregation .", "tokens": ["In", "the", "two", "cases", ",", "a", "combination", "of", "iloprost", ",", "a", "stable", "prostacyclin", "analogue", "(", "1", "to", "2", "ng", "/", "kg", "/", "mn", ")", "with", "aspirin", "and", "dipyridamole", "was", "shown", "to", "inhibit", "ex", "vivo", "the", "heparin", "-", "induced", "platelet", "aggregation", "."], "event_mentions": [{"id": "1722991_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "inhibit ex vivo", "start": 31, "end": 34}, "arguments": [{"entity_id": "1722991_6_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "1722991_6_Ent0", "role": "Subject", "text": "two cases", "start": 2, "end": 4}, {"entity_id": "1722991_6_Ent5", "role": "Treatment_Drug", "text": "iloprost", "start": 8, "end": 9}, {"entity_id": "1722991_6_Ent8", "role": "Combination_Drug", "text": "iloprost", "start": 8, "end": 9}, {"entity_id": "1722991_6_Ent2", "role": "Treatment", "text": "iloprost , a stable prostacyclin analogue ( 1 to 2 ng / kg / mn ) with aspirin and dipyridamole", "start": 8, "end": 28}, {"entity_id": "1722991_6_Ent4", "role": "Treatment_Dosage", "text": "1 to 2 ng / kg / mn", "start": 15, "end": 23}, {"entity_id": "1722991_6_Ent6", "role": "Treatment_Drug", "text": "aspirin", "start": 25, "end": 26}, {"entity_id": "1722991_6_Ent9", "role": "Combination_Drug", "text": "aspirin", "start": 25, "end": 26}, {"entity_id": "1722991_6_Ent7", "role": "Treatment_Drug", "text": "dipyridamole", "start": 27, "end": 28}, {"entity_id": "1722991_6_Ent10", "role": "Combination_Drug", "text": "dipyridamole", "start": 27, "end": 28}, {"entity_id": "1722991_6_Ent3", "role": "Treatment_Disorder", "text": "heparin - induced platelet aggregation", "start": 35, "end": 40}]}, {"id": "1722991_6_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 37, "end": 38}, "arguments": [{"entity_id": "1722991_6_Ent12", "role": "Treatment", "text": "heparin", "start": 35, "end": 36}, {"entity_id": "1722991_6_Ent13", "role": "Treatment_Drug", "text": "heparin", "start": 35, "end": 36}, {"entity_id": "1722991_6_Ent11", "role": "Effect", "text": "platelet aggregation", "start": 38, "end": 40}]}], "entity_mentions": [{"id": "1722991_6_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "1722991_6_Ent0", "text": "two cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1722991_6_Ent5", "text": "iloprost", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1722991_6_Ent8", "text": "iloprost", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1722991_6_Ent2", "text": "iloprost , a stable prostacyclin analogue ( 1 to 2 ng / kg / mn ) with aspirin and dipyridamole", "entity_type": "Entity", "start": 8, "end": 28}, {"id": "1722991_6_Ent4", "text": "1 to 2 ng / kg / mn", "entity_type": "Entity", "start": 15, "end": 23}, {"id": "1722991_6_Ent6", "text": "aspirin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "1722991_6_Ent9", "text": "aspirin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "1722991_6_Ent7", "text": "dipyridamole", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "1722991_6_Ent10", "text": "dipyridamole", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "1722991_6_Ent12", "text": "heparin", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "1722991_6_Ent13", "text": "heparin", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "1722991_6_Ent3", "text": "heparin - induced platelet aggregation", "entity_type": "Entity", "start": 35, "end": 40}, {"id": "1722991_6_Ent11", "text": "platelet aggregation", "entity_type": "Entity", "start": 38, "end": 40}], "lang": "en"}
{"doc_id": "17260498_1", "wnd_id": "17260498_1_1", "text": "Fatal interstitial pneumonitis associated with docetaxel administration in a patient with hormone - refractory prostate cancer .", "tokens": ["Fatal", "interstitial", "pneumonitis", "associated", "with", "docetaxel", "administration", "in", "a", "patient", "with", "hormone", "-", "refractory", "prostate", "cancer", "."], "event_mentions": [{"id": "17260498_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "17260498_1_Ent1", "role": "Effect", "text": "Fatal interstitial pneumonitis", "start": 0, "end": 3}, {"entity_id": "17260498_1_Ent2", "role": "Treatment", "text": "docetaxel", "start": 5, "end": 6}, {"entity_id": "17260498_1_Ent3", "role": "Treatment_Drug", "text": "docetaxel", "start": 5, "end": 6}, {"entity_id": "17260498_1_Ent0", "role": "Subject", "text": "a patient with hormone - refractory prostate cancer", "start": 8, "end": 16}, {"entity_id": "17260498_1_Ent4", "role": "Treatment_Disorder", "text": "hormone - refractory prostate cancer", "start": 11, "end": 16}]}], "entity_mentions": [{"id": "17260498_1_Ent1", "text": "Fatal interstitial pneumonitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17260498_1_Ent2", "text": "docetaxel", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17260498_1_Ent3", "text": "docetaxel", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17260498_1_Ent0", "text": "a patient with hormone - refractory prostate cancer", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "17260498_1_Ent4", "text": "hormone - refractory prostate cancer", "entity_type": "Entity", "start": 11, "end": 16}], "lang": "en"}
{"doc_id": "17260498_2", "wnd_id": "17260498_2_1", "text": "Taxanes are widely used chemotherapeutic agents with the potential to induce pulmonary injury through a variety of mechanisms .", "tokens": ["Taxanes", "are", "widely", "used", "chemotherapeutic", "agents", "with", "the", "potential", "to", "induce", "pulmonary", "injury", "through", "a", "variety", "of", "mechanisms", "."], "event_mentions": [{"id": "17260498_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 10, "end": 11}, "arguments": [{"entity_id": "17260498_2_Ent1", "role": "Treatment", "text": "Taxanes", "start": 0, "end": 1}, {"entity_id": "17260498_2_Ent2", "role": "Treatment_Drug", "text": "Taxanes", "start": 0, "end": 1}, {"entity_id": "17260498_2_Ent0", "role": "Effect", "text": "pulmonary injury", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "17260498_2_Ent1", "text": "Taxanes", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17260498_2_Ent2", "text": "Taxanes", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17260498_2_Ent0", "text": "pulmonary injury", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "17266059_1", "wnd_id": "17266059_1_1", "text": "The patient presented with fulminant microangiopathic hemolytic anemia and thrombocytopenia within 48 hr of initiating therapy with trimethoprim - sulfamethoxazole .", "tokens": ["The", "patient", "presented", "with", "fulminant", "microangiopathic", "hemolytic", "anemia", "and", "thrombocytopenia", "within", "48", "hr", "of", "initiating", "therapy", "with", "trimethoprim", "-", "sulfamethoxazole", "."], "event_mentions": [{"id": "17266059_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 2, "end": 3}, "arguments": [{"entity_id": "17266059_1_Ent0", "role": "Subject", "text": "The patient", "start": 0, "end": 2}, {"entity_id": "17266059_1_Ent1", "role": "Effect", "text": "fulminant microangiopathic hemolytic anemia and thrombocytopenia", "start": 4, "end": 10}, {"entity_id": "17266059_1_Ent2", "role": "Treatment", "text": "within 48 hr of initiating therapy with trimethoprim - sulfamethoxazole", "start": 10, "end": 20}, {"entity_id": "17266059_1_Ent3", "role": "Treatment_Time_elapsed", "text": "48 hr", "start": 11, "end": 13}, {"entity_id": "17266059_1_Ent4", "role": "Treatment_Drug", "text": "trimethoprim", "start": 17, "end": 18}, {"entity_id": "17266059_1_Ent6", "role": "Combination_Drug", "text": "trimethoprim", "start": 17, "end": 18}, {"entity_id": "17266059_1_Ent5", "role": "Treatment_Drug", "text": "sulfamethoxazole", "start": 19, "end": 20}, {"entity_id": "17266059_1_Ent7", "role": "Combination_Drug", "text": "sulfamethoxazole", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "17266059_1_Ent0", "text": "The patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17266059_1_Ent1", "text": "fulminant microangiopathic hemolytic anemia and thrombocytopenia", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "17266059_1_Ent2", "text": "within 48 hr of initiating therapy with trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 10, "end": 20}, {"id": "17266059_1_Ent3", "text": "48 hr", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "17266059_1_Ent4", "text": "trimethoprim", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "17266059_1_Ent6", "text": "trimethoprim", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "17266059_1_Ent5", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17266059_1_Ent7", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "17275666_2", "wnd_id": "17275666_2_1", "text": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies , including juvenile absence epilepsy .", "tokens": ["Valproic", "acid", "is", "commonly", "and", "effectively", "used", "in", "the", "treatment", "of", "idiopathic", "generalized", "epilepsies", ",", "including", "juvenile", "absence", "epilepsy", "."], "event_mentions": [{"id": "17275666_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used", "start": 6, "end": 7}, "arguments": [{"entity_id": "17275666_2_Ent0", "role": "Treatment", "text": "Valproic acid", "start": 0, "end": 2}, {"entity_id": "17275666_2_Ent1", "role": "Treatment_Drug", "text": "Valproic acid", "start": 0, "end": 2}, {"entity_id": "17275666_2_Ent2", "role": "Treatment_Disorder", "text": "idiopathic generalized epilepsies", "start": 11, "end": 14}, {"entity_id": "17275666_2_Ent3", "role": "Treatment_Disorder", "text": "juvenile absence epilepsy", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "17275666_2_Ent0", "text": "Valproic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17275666_2_Ent1", "text": "Valproic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17275666_2_Ent2", "text": "idiopathic generalized epilepsies", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "17275666_2_Ent3", "text": "juvenile absence epilepsy", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "17275666_6", "wnd_id": "17275666_6_1", "text": "This report describes a case of paradoxical , intravenous valproic acid - induced seizure exacerbation in a child with juvenile absence epilepsy , documented by video - electroencephalography .", "tokens": ["This", "report", "describes", "a", "case", "of", "paradoxical", ",", "intravenous", "valproic", "acid", "-", "induced", "seizure", "exacerbation", "in", "a", "child", "with", "juvenile", "absence", "epilepsy", ",", "documented", "by", "video", "-", "electroencephalography", "."], "event_mentions": [{"id": "17275666_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "17275666_6_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 8, "end": 9}, {"entity_id": "17275666_6_Ent3", "role": "Treatment", "text": "intravenous valproic acid", "start": 8, "end": 11}, {"entity_id": "17275666_6_Ent4", "role": "Treatment_Drug", "text": "valproic acid", "start": 9, "end": 11}, {"entity_id": "17275666_6_Ent2", "role": "Effect", "text": "seizure exacerbation", "start": 13, "end": 15}, {"entity_id": "17275666_6_Ent0", "role": "Subject", "text": "a child with juvenile absence epilepsy", "start": 16, "end": 22}, {"entity_id": "17275666_6_Ent1", "role": "Subject_Age", "text": "child", "start": 17, "end": 18}, {"entity_id": "17275666_6_Ent6", "role": "Treatment_Disorder", "text": "juvenile absence epilepsy", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "17275666_6_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17275666_6_Ent3", "text": "intravenous valproic acid", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "17275666_6_Ent4", "text": "valproic acid", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "17275666_6_Ent2", "text": "seizure exacerbation", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "17275666_6_Ent0", "text": "a child with juvenile absence epilepsy", "entity_type": "Entity", "start": 16, "end": 22}, {"id": "17275666_6_Ent1", "text": "child", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "17275666_6_Ent6", "text": "juvenile absence epilepsy", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "17277758_1", "wnd_id": "17277758_1_1", "text": "Acute endophthalmitis following intravitreal bevacizumab ( Avastin ) injection .", "tokens": ["Acute", "endophthalmitis", "following", "intravitreal", "bevacizumab", "(", "Avastin", ")", "injection", "."], "event_mentions": [{"id": "17277758_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "17277758_1_Ent0", "role": "Effect", "text": "Acute endophthalmitis", "start": 0, "end": 2}, {"entity_id": "17277758_1_Ent2", "role": "Treatment_Route", "text": "intravitreal", "start": 3, "end": 4}, {"entity_id": "17277758_1_Ent1", "role": "Treatment", "text": "intravitreal bevacizumab ( Avastin ) injection", "start": 3, "end": 9}, {"entity_id": "17277758_1_Ent4", "role": "Treatment_Drug", "text": "bevacizumab", "start": 4, "end": 5}, {"entity_id": "17277758_1_Ent3", "role": "Treatment_Route", "text": "injection", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "17277758_1_Ent0", "text": "Acute endophthalmitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17277758_1_Ent2", "text": "intravitreal", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17277758_1_Ent1", "text": "intravitreal bevacizumab ( Avastin ) injection", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "17277758_1_Ent4", "text": "bevacizumab", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17277758_1_Ent3", "text": "injection", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "17285101_1", "wnd_id": "17285101_1_1", "text": "Pulmonary hypertension during lithium therapy : clinical case study .", "tokens": ["Pulmonary", "hypertension", "during", "lithium", "therapy", ":", "clinical", "case", "study", "."], "event_mentions": [{"id": "17285101_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 2, "end": 3}, "arguments": [{"entity_id": "17285101_1_Ent0", "role": "Effect", "text": "Pulmonary hypertension", "start": 0, "end": 2}, {"entity_id": "17285101_1_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 3, "end": 4}, {"entity_id": "17285101_1_Ent1", "role": "Treatment", "text": "lithium therapy", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "17285101_1_Ent0", "text": "Pulmonary hypertension", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17285101_1_Ent2", "text": "lithium", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17285101_1_Ent1", "text": "lithium therapy", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "17324248_1", "wnd_id": "17324248_1_1", "text": "AIMS : To present a case of piloerection after replacing fluvoxamine maleate with milnacipran hydrochloride , and to analyse this effect based on receptor occupancy theory .", "tokens": ["AIMS", ":", "To", "present", "a", "case", "of", "piloerection", "after", "replacing", "fluvoxamine", "maleate", "with", "milnacipran", "hydrochloride", ",", "and", "to", "analyse", "this", "effect", "based", "on", "receptor", "occupancy", "theory", "."], "event_mentions": [{"id": "17324248_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 8, "end": 9}, "arguments": [{"entity_id": "17324248_1_Ent0", "role": "Effect", "text": "piloerection", "start": 7, "end": 8}, {"entity_id": "17324248_1_Ent1", "role": "Treatment", "text": "fluvoxamine maleate", "start": 10, "end": 12}, {"entity_id": "17324248_1_Ent2", "role": "Treatment_Drug", "text": "fluvoxamine maleate", "start": 10, "end": 12}, {"entity_id": "17324248_1_Ent3", "role": "Treatment_Drug", "text": "milnacipran hydrochloride", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "17324248_1_Ent0", "text": "piloerection", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17324248_1_Ent1", "text": "fluvoxamine maleate", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "17324248_1_Ent2", "text": "fluvoxamine maleate", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "17324248_1_Ent3", "text": "milnacipran hydrochloride", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "17329303_2", "wnd_id": "17329303_2_1", "text": "As atypical antipsychotics are increasingly used in the treatment of childhood behavioural disorders either as monotherapy or in combination with other medications , there is a need to know more about their safety , in particular during switching to and from methylphenidate treatment , as antipsychotics and methylphenidate have opposing effects on dopaminergic neurotransmission .", "tokens": ["As", "atypical", "antipsychotics", "are", "increasingly", "used", "in", "the", "treatment", "of", "childhood", "behavioural", "disorders", "either", "as", "monotherapy", "or", "in", "combination", "with", "other", "medications", ",", "there", "is", "a", "need", "to", "know", "more", "about", "their", "safety", ",", "in", "particular", "during", "switching", "to", "and", "from", "methylphenidate", "treatment", ",", "as", "antipsychotics", "and", "methylphenidate", "have", "opposing", "effects", "on", "dopaminergic", "neurotransmission", "."], "event_mentions": [{"id": "17329303_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 8, "end": 9}, "arguments": [{"entity_id": "17329303_2_Ent0", "role": "Treatment", "text": "atypical antipsychotics", "start": 1, "end": 3}, {"entity_id": "17329303_2_Ent3", "role": "Treatment_Drug", "text": "atypical antipsychotics", "start": 1, "end": 3}, {"entity_id": "17329303_2_Ent2", "role": "Treatment_Disorder", "text": "childhood behavioural disorders", "start": 10, "end": 13}, {"entity_id": "17329303_2_Ent1", "role": "Treatment", "text": "as monotherapy or in combination with other medications", "start": 14, "end": 22}]}], "entity_mentions": [{"id": "17329303_2_Ent0", "text": "atypical antipsychotics", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "17329303_2_Ent3", "text": "atypical antipsychotics", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "17329303_2_Ent2", "text": "childhood behavioural disorders", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "17329303_2_Ent1", "text": "as monotherapy or in combination with other medications", "entity_type": "Entity", "start": 14, "end": 22}], "lang": "en"}
{"doc_id": "17329303_3", "wnd_id": "17329303_3_1", "text": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate .", "tokens": ["This", "report", "is", "about", "three", "cases", "of", "children", "who", "developed", "severe", "adverse", "reactions", "during", "switching", "from", "risperidone", "to", "methylphenidate", "."], "event_mentions": [{"id": "17329303_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "17329303_3_Ent1", "role": "Subject_Population", "text": "three", "start": 4, "end": 5}, {"entity_id": "17329303_3_Ent0", "role": "Subject", "text": "three cases of children", "start": 4, "end": 8}, {"entity_id": "17329303_3_Ent2", "role": "Subject_Age", "text": "children", "start": 7, "end": 8}, {"entity_id": "17329303_3_Ent3", "role": "Effect", "text": "adverse reactions", "start": 11, "end": 13}, {"entity_id": "17329303_3_Ent4", "role": "Treatment", "text": "during switching from risperidone to methylphenidate", "start": 13, "end": 19}, {"entity_id": "17329303_3_Ent5", "role": "Treatment_Drug", "text": "risperidone", "start": 16, "end": 17}, {"entity_id": "17329303_3_Ent6", "role": "Treatment_Drug", "text": "methylphenidate", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "17329303_3_Ent1", "text": "three", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17329303_3_Ent0", "text": "three cases of children", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "17329303_3_Ent2", "text": "children", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17329303_3_Ent3", "text": "adverse reactions", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "17329303_3_Ent4", "text": "during switching from risperidone to methylphenidate", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "17329303_3_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17329303_3_Ent6", "text": "methylphenidate", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "17352036_3", "wnd_id": "17352036_3_1", "text": "Under the suspicion of amiodarone - induced acute pancreatitis , amiodarone was substituted by propafenone .", "tokens": ["Under", "the", "suspicion", "of", "amiodarone", "-", "induced", "acute", "pancreatitis", ",", "amiodarone", "was", "substituted", "by", "propafenone", "."], "event_mentions": [{"id": "17352036_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "17352036_3_Ent1", "role": "Treatment", "text": "amiodarone", "start": 4, "end": 5}, {"entity_id": "17352036_3_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 4, "end": 5}, {"entity_id": "17352036_3_Ent0", "role": "Effect", "text": "acute pancreatitis", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "17352036_3_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17352036_3_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17352036_3_Ent0", "text": "acute pancreatitis", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "17364199_1", "wnd_id": "17364199_1_1", "text": "Tuberculous uveitis after treatment with etanercept .", "tokens": ["Tuberculous", "uveitis", "after", "treatment", "with", "etanercept", "."], "event_mentions": [{"id": "17364199_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "17364199_1_Ent0", "role": "Effect", "text": "Tuberculous uveitis", "start": 0, "end": 2}, {"entity_id": "17364199_1_Ent1", "role": "Treatment", "text": "etanercept", "start": 5, "end": 6}, {"entity_id": "17364199_1_Ent2", "role": "Treatment_Drug", "text": "etanercept", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "17364199_1_Ent0", "text": "Tuberculous uveitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17364199_1_Ent1", "text": "etanercept", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17364199_1_Ent2", "text": "etanercept", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "17364199_7", "wnd_id": "17364199_7_1", "text": "She was on etanercept and methotrexate for rheumatoid arthritis .", "tokens": ["She", "was", "on", "etanercept", "and", "methotrexate", "for", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "17364199_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 6, "end": 7}, "arguments": [{"entity_id": "17364199_7_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "17364199_7_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "17364199_7_Ent4", "role": "Treatment_Drug", "text": "etanercept", "start": 3, "end": 4}, {"entity_id": "17364199_7_Ent6", "role": "Combination_Drug", "text": "etanercept", "start": 3, "end": 4}, {"entity_id": "17364199_7_Ent2", "role": "Treatment", "text": "etanercept and methotrexate", "start": 3, "end": 6}, {"entity_id": "17364199_7_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 5, "end": 6}, {"entity_id": "17364199_7_Ent7", "role": "Combination_Drug", "text": "methotrexate", "start": 5, "end": 6}, {"entity_id": "17364199_7_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "17364199_7_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17364199_7_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17364199_7_Ent4", "text": "etanercept", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17364199_7_Ent6", "text": "etanercept", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17364199_7_Ent2", "text": "etanercept and methotrexate", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "17364199_7_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17364199_7_Ent7", "text": "methotrexate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17364199_7_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "17381671_2", "wnd_id": "17381671_2_1", "text": "To report a case of serotonin syndrome associated with interaction between fentanyl and citalopram , as evidenced by medication history , clinical features and reversal following discontinuation of fentanyl .", "tokens": ["To", "report", "a", "case", "of", "serotonin", "syndrome", "associated", "with", "interaction", "between", "fentanyl", "and", "citalopram", ",", "as", "evidenced", "by", "medication", "history", ",", "clinical", "features", "and", "reversal", "following", "discontinuation", "of", "fentanyl", "."], "event_mentions": [{"id": "17381671_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "17381671_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "17381671_2_Ent1", "role": "Effect", "text": "serotonin syndrome", "start": 5, "end": 7}, {"entity_id": "17381671_2_Ent2", "role": "Treatment", "text": "interaction between fentanyl and citalopram", "start": 9, "end": 14}, {"entity_id": "17381671_2_Ent3", "role": "Treatment_Drug", "text": "fentanyl", "start": 11, "end": 12}, {"entity_id": "17381671_2_Ent5", "role": "Combination_Drug", "text": "fentanyl", "start": 11, "end": 12}, {"entity_id": "17381671_2_Ent4", "role": "Treatment_Drug", "text": "citalopram", "start": 13, "end": 14}, {"entity_id": "17381671_2_Ent6", "role": "Combination_Drug", "text": "citalopram", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "17381671_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "17381671_2_Ent1", "text": "serotonin syndrome", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "17381671_2_Ent2", "text": "interaction between fentanyl and citalopram", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "17381671_2_Ent3", "text": "fentanyl", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17381671_2_Ent5", "text": "fentanyl", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17381671_2_Ent4", "text": "citalopram", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17381671_2_Ent6", "text": "citalopram", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "17383767_4", "wnd_id": "17383767_4_1", "text": "We report a case in which a potential drug interaction resulted in elevated phenytoin levels after initiation of erlotinib therapy in a patient who was receiving phenytoin .", "tokens": ["We", "report", "a", "case", "in", "which", "a", "potential", "drug", "interaction", "resulted", "in", "elevated", "phenytoin", "levels", "after", "initiation", "of", "erlotinib", "therapy", "in", "a", "patient", "who", "was", "receiving", "phenytoin", "."], "event_mentions": [{"id": "17383767_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted in", "start": 10, "end": 12}, "arguments": [{"entity_id": "17383767_4_Ent2", "role": "Treatment", "text": "a potential drug interaction", "start": 6, "end": 10}, {"entity_id": "17383767_4_Ent1", "role": "Effect", "text": "elevated phenytoin levels", "start": 12, "end": 15}, {"entity_id": "17383767_4_Ent3", "role": "Treatment", "text": "initiation of erlotinib therapy", "start": 16, "end": 20}, {"entity_id": "17383767_4_Ent6", "role": "Treatment_Drug", "text": "erlotinib", "start": 18, "end": 19}, {"entity_id": "17383767_4_Ent7", "role": "Combination_Drug", "text": "erlotinib", "start": 18, "end": 19}, {"entity_id": "17383767_4_Ent0", "role": "Subject", "text": "a patient", "start": 21, "end": 23}, {"entity_id": "17383767_4_Ent4", "role": "Treatment", "text": "receiving phenytoin", "start": 25, "end": 27}, {"entity_id": "17383767_4_Ent5", "role": "Treatment_Drug", "text": "phenytoin", "start": 26, "end": 27}, {"entity_id": "17383767_4_Ent8", "role": "Combination_Drug", "text": "phenytoin", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "17383767_4_Ent2", "text": "a potential drug interaction", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "17383767_4_Ent1", "text": "elevated phenytoin levels", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "17383767_4_Ent3", "text": "initiation of erlotinib therapy", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "17383767_4_Ent6", "text": "erlotinib", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17383767_4_Ent7", "text": "erlotinib", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17383767_4_Ent0", "text": "a patient", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "17383767_4_Ent4", "text": "receiving phenytoin", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "17383767_4_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "17383767_4_Ent8", "text": "phenytoin", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "17404582_3", "wnd_id": "17404582_3_1", "text": "We report a 71 - year male with castration - resistant metastatic prostate cancer who was treated with weekly docetaxel for 12 weeks and developed significant eye irritation and dryness during treatment .", "tokens": ["We", "report", "a", "71", "-", "year", "male", "with", "castration", "-", "resistant", "metastatic", "prostate", "cancer", "who", "was", "treated", "with", "weekly", "docetaxel", "for", "12", "weeks", "and", "developed", "significant", "eye", "irritation", "and", "dryness", "during", "treatment", "."], "event_mentions": [{"id": "17404582_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 24, "end": 25}, "arguments": [{"entity_id": "17404582_3_Ent0", "role": "Subject", "text": "a 71 - year male with castration - resistant metastatic prostate cancer", "start": 2, "end": 14}, {"entity_id": "17404582_3_Ent1", "role": "Subject_Age", "text": "71 - year", "start": 3, "end": 6}, {"entity_id": "17404582_3_Ent2", "role": "Subject_Gender", "text": "male", "start": 6, "end": 7}, {"entity_id": "17404582_3_Ent5", "role": "Treatment_Disorder", "text": "castration - resistant metastatic prostate cancer", "start": 8, "end": 14}, {"entity_id": "17404582_3_Ent7", "role": "Treatment_Freq", "text": "weekly", "start": 18, "end": 19}, {"entity_id": "17404582_3_Ent4", "role": "Treatment", "text": "weekly docetaxel for 12 weeks", "start": 18, "end": 23}, {"entity_id": "17404582_3_Ent6", "role": "Treatment_Drug", "text": "docetaxel", "start": 19, "end": 20}, {"entity_id": "17404582_3_Ent8", "role": "Treatment_Duration", "text": "12 weeks", "start": 21, "end": 23}, {"entity_id": "17404582_3_Ent3", "role": "Effect", "text": "significant eye irritation and dryness", "start": 25, "end": 30}]}], "entity_mentions": [{"id": "17404582_3_Ent0", "text": "a 71 - year male with castration - resistant metastatic prostate cancer", "entity_type": "Entity", "start": 2, "end": 14}, {"id": "17404582_3_Ent1", "text": "71 - year", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "17404582_3_Ent2", "text": "male", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17404582_3_Ent5", "text": "castration - resistant metastatic prostate cancer", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "17404582_3_Ent7", "text": "weekly", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17404582_3_Ent4", "text": "weekly docetaxel for 12 weeks", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "17404582_3_Ent6", "text": "docetaxel", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17404582_3_Ent8", "text": "12 weeks", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "17404582_3_Ent3", "text": "significant eye irritation and dryness", "entity_type": "Entity", "start": 25, "end": 30}], "lang": "en"}
{"doc_id": "17406804_4", "wnd_id": "17406804_4_1", "text": "Radiation recall pneumonitis induced by gemcitabine .", "tokens": ["Radiation", "recall", "pneumonitis", "induced", "by", "gemcitabine", "."], "event_mentions": [{"id": "17406804_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "17406804_4_Ent0", "role": "Effect", "text": "Radiation recall pneumonitis", "start": 0, "end": 3}, {"entity_id": "17406804_4_Ent1", "role": "Treatment", "text": "gemcitabine", "start": 5, "end": 6}, {"entity_id": "17406804_4_Ent2", "role": "Treatment_Drug", "text": "gemcitabine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "17406804_4_Ent0", "text": "Radiation recall pneumonitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17406804_4_Ent1", "text": "gemcitabine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17406804_4_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "17420198_1", "wnd_id": "17420198_1_1", "text": "Potential aripiprazole - mediated extrapyramidal symptoms in an adult with developmental disabilities .", "tokens": ["Potential", "aripiprazole", "-", "mediated", "extrapyramidal", "symptoms", "in", "an", "adult", "with", "developmental", "disabilities", "."], "event_mentions": [{"id": "17420198_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "mediated", "start": 3, "end": 4}, "arguments": [{"entity_id": "17420198_1_Ent3", "role": "Treatment", "text": "aripiprazole", "start": 1, "end": 2}, {"entity_id": "17420198_1_Ent4", "role": "Treatment_Drug", "text": "aripiprazole", "start": 1, "end": 2}, {"entity_id": "17420198_1_Ent2", "role": "Effect", "text": "extrapyramidal symptoms", "start": 4, "end": 6}, {"entity_id": "17420198_1_Ent0", "role": "Subject", "text": "an adult with developmental disabilities", "start": 7, "end": 12}, {"entity_id": "17420198_1_Ent1", "role": "Subject_Age", "text": "adult", "start": 8, "end": 9}, {"entity_id": "17420198_1_Ent5", "role": "Treatment_Disorder", "text": "developmental disabilities", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "17420198_1_Ent3", "text": "aripiprazole", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17420198_1_Ent4", "text": "aripiprazole", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17420198_1_Ent2", "text": "extrapyramidal symptoms", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "17420198_1_Ent0", "text": "an adult with developmental disabilities", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "17420198_1_Ent1", "text": "adult", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17420198_1_Ent5", "text": "developmental disabilities", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "17420198_10", "wnd_id": "17420198_10_1", "text": "Facial , tongue , and arm movements were first reported approximately five weeks after the initiation of aripiprazole .", "tokens": ["Facial", ",", "tongue", ",", "and", "arm", "movements", "were", "first", "reported", "approximately", "five", "weeks", "after", "the", "initiation", "of", "aripiprazole", "."], "event_mentions": [{"id": "17420198_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "17420198_10_Ent0", "role": "Effect", "text": "Facial , tongue , and arm movements", "start": 0, "end": 7}, {"entity_id": "17420198_10_Ent2", "role": "Treatment_Time_elapsed", "text": "five weeks", "start": 11, "end": 13}, {"entity_id": "17420198_10_Ent1", "role": "Treatment", "text": "initiation of aripiprazole", "start": 15, "end": 18}, {"entity_id": "17420198_10_Ent3", "role": "Treatment_Drug", "text": "aripiprazole", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "17420198_10_Ent0", "text": "Facial , tongue , and arm movements", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "17420198_10_Ent2", "text": "five weeks", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "17420198_10_Ent1", "text": "initiation of aripiprazole", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "17420198_10_Ent3", "text": "aripiprazole", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "17420198_18", "wnd_id": "17420198_18_1", "text": "Aripiprazole was subsequently discontinued secondary to its lack of efficacy for OCD and the development of a movement disorder .", "tokens": ["Aripiprazole", "was", "subsequently", "discontinued", "secondary", "to", "its", "lack", "of", "efficacy", "for", "OCD", "and", "the", "development", "of", "a", "movement", "disorder", "."], "event_mentions": [{"id": "17420198_18_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 14, "end": 15}, "arguments": [{"entity_id": "17420198_18_Ent1", "role": "Treatment", "text": "Aripiprazole", "start": 0, "end": 1}, {"entity_id": "17420198_18_Ent3", "role": "Treatment_Drug", "text": "Aripiprazole", "start": 0, "end": 1}, {"entity_id": "17420198_18_Ent2", "role": "Treatment_Disorder", "text": "OCD", "start": 11, "end": 12}, {"entity_id": "17420198_18_Ent0", "role": "Effect", "text": "a movement disorder", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "17420198_18_Ent1", "text": "Aripiprazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17420198_18_Ent3", "text": "Aripiprazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17420198_18_Ent2", "text": "OCD", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17420198_18_Ent0", "text": "a movement disorder", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "17420198_2", "wnd_id": "17420198_2_1", "text": "A case of extrapyramidal symptoms ( EPS ) following administration of aripiprazole to a man with developmental disabilities who had never received antipsychotic medications and had no history of movement disorders is presented .", "tokens": ["A", "case", "of", "extrapyramidal", "symptoms", "(", "EPS", ")", "following", "administration", "of", "aripiprazole", "to", "a", "man", "with", "developmental", "disabilities", "who", "had", "never", "received", "antipsychotic", "medications", "and", "had", "no", "history", "of", "movement", "disorders", "is", "presented", "."], "event_mentions": [{"id": "17420198_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "17420198_2_Ent3", "role": "Effect", "text": "extrapyramidal symptoms ( EPS )", "start": 3, "end": 8}, {"entity_id": "17420198_2_Ent4", "role": "Treatment", "text": "aripiprazole", "start": 11, "end": 12}, {"entity_id": "17420198_2_Ent5", "role": "Treatment_Drug", "text": "aripiprazole", "start": 11, "end": 12}, {"entity_id": "17420198_2_Ent0", "role": "Subject", "text": "a man with developmental disabilities who had never received antipsychotic medications and had no history of movement disorders is presented", "start": 13, "end": 33}, {"entity_id": "17420198_2_Ent1", "role": "Subject_Gender", "text": "man", "start": 14, "end": 15}, {"entity_id": "17420198_2_Ent2", "role": "Subject_Disorder", "text": "developmental disabilities", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "17420198_2_Ent3", "text": "extrapyramidal symptoms ( EPS )", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "17420198_2_Ent4", "text": "aripiprazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17420198_2_Ent5", "text": "aripiprazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17420198_2_Ent0", "text": "a man with developmental disabilities who had never received antipsychotic medications and had no history of movement disorders is presented", "entity_type": "Entity", "start": 13, "end": 33}, {"id": "17420198_2_Ent1", "text": "man", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17420198_2_Ent2", "text": "developmental disabilities", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "17420198_5", "wnd_id": "17420198_5_1", "text": "He developed episodic movements possibly consistent with EPS secondary to aripiprazole usage .", "tokens": ["He", "developed", "episodic", "movements", "possibly", "consistent", "with", "EPS", "secondary", "to", "aripiprazole", "usage", "."], "event_mentions": [{"id": "17420198_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 1, "end": 2}, "arguments": [{"entity_id": "17420198_5_Ent0", "role": "Effect", "text": "episodic movements possibly consistent with EPS", "start": 2, "end": 8}, {"entity_id": "17420198_5_Ent1", "role": "Treatment", "text": "secondary to aripiprazole usage", "start": 8, "end": 12}, {"entity_id": "17420198_5_Ent2", "role": "Treatment_Drug", "text": "aripiprazole", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "17420198_5_Ent0", "text": "episodic movements possibly consistent with EPS", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "17420198_5_Ent1", "text": "secondary to aripiprazole usage", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "17420198_5_Ent2", "text": "aripiprazole", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "17473493_2", "wnd_id": "17473493_2_1", "text": "This is the first histologically confirmed case of NASH that was aggravated by raloxifene .", "tokens": ["This", "is", "the", "first", "histologically", "confirmed", "case", "of", "NASH", "that", "was", "aggravated", "by", "raloxifene", "."], "event_mentions": [{"id": "17473493_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "aggravated", "start": 11, "end": 12}, "arguments": [{"entity_id": "17473493_2_Ent0", "role": "Subject", "text": "the first histologically confirmed case", "start": 2, "end": 7}, {"entity_id": "17473493_2_Ent1", "role": "Effect", "text": "NASH", "start": 8, "end": 9}, {"entity_id": "17473493_2_Ent2", "role": "Treatment", "text": "raloxifene", "start": 13, "end": 14}, {"entity_id": "17473493_2_Ent3", "role": "Treatment_Drug", "text": "raloxifene", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "17473493_2_Ent0", "text": "the first histologically confirmed case", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "17473493_2_Ent1", "text": "NASH", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17473493_2_Ent2", "text": "raloxifene", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17473493_2_Ent3", "text": "raloxifene", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "17473920_1", "wnd_id": "17473920_1_1", "text": "Pharmacokinetics of methadone in human - immunodeficiency - virus - infected patients receiving nevirapine once daily .", "tokens": ["Pharmacokinetics", "of", "methadone", "in", "human", "-", "immunodeficiency", "-", "virus", "-", "infected", "patients", "receiving", "nevirapine", "once", "daily", "."], "event_mentions": [{"id": "17473920_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 12, "end": 13}, "arguments": [{"entity_id": "17473920_1_Ent1", "role": "Treatment", "text": "methadone", "start": 2, "end": 3}, {"entity_id": "17473920_1_Ent6", "role": "Treatment_Drug", "text": "methadone", "start": 2, "end": 3}, {"entity_id": "17473920_1_Ent8", "role": "Combination_Drug", "text": "methadone", "start": 2, "end": 3}, {"entity_id": "17473920_1_Ent3", "role": "Treatment_Disorder", "text": "human - immunodeficiency - virus", "start": 4, "end": 9}, {"entity_id": "17473920_1_Ent0", "role": "Subject", "text": "human - immunodeficiency - virus - infected patients", "start": 4, "end": 12}, {"entity_id": "17473920_1_Ent5", "role": "Treatment_Drug", "text": "nevirapine", "start": 13, "end": 14}, {"entity_id": "17473920_1_Ent7", "role": "Combination_Drug", "text": "nevirapine", "start": 13, "end": 14}, {"entity_id": "17473920_1_Ent2", "role": "Treatment", "text": "nevirapine once daily", "start": 13, "end": 16}, {"entity_id": "17473920_1_Ent4", "role": "Treatment_Freq", "text": "once daily", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "17473920_1_Ent1", "text": "methadone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17473920_1_Ent6", "text": "methadone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17473920_1_Ent8", "text": "methadone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17473920_1_Ent3", "text": "human - immunodeficiency - virus", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "17473920_1_Ent0", "text": "human - immunodeficiency - virus - infected patients", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "17473920_1_Ent5", "text": "nevirapine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17473920_1_Ent7", "text": "nevirapine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17473920_1_Ent2", "text": "nevirapine once daily", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "17473920_1_Ent4", "text": "once daily", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "1747495_2", "wnd_id": "1747495_2_1", "text": "A case of liver damage following treatment with Danazol for fibrocystic breast disease is reported .", "tokens": ["A", "case", "of", "liver", "damage", "following", "treatment", "with", "Danazol", "for", "fibrocystic", "breast", "disease", "is", "reported", "."], "event_mentions": [{"id": "1747495_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 5, "end": 6}, "arguments": [{"entity_id": "1747495_2_Ent0", "role": "Effect", "text": "liver damage", "start": 3, "end": 5}, {"entity_id": "1747495_2_Ent1", "role": "Treatment", "text": "Danazol", "start": 8, "end": 9}, {"entity_id": "1747495_2_Ent2", "role": "Treatment_Drug", "text": "Danazol", "start": 8, "end": 9}, {"entity_id": "1747495_2_Ent3", "role": "Treatment_Disorder", "text": "fibrocystic breast disease", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "1747495_2_Ent0", "text": "liver damage", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "1747495_2_Ent1", "text": "Danazol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1747495_2_Ent2", "text": "Danazol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1747495_2_Ent3", "text": "fibrocystic breast disease", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "17509184_2", "wnd_id": "17509184_2_1", "text": "Ethambutol toxicity manifesting as acute onset psychosis .", "tokens": ["Ethambutol", "toxicity", "manifesting", "as", "acute", "onset", "psychosis", "."], "event_mentions": [{"id": "17509184_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 1, "end": 2}, "arguments": [{"entity_id": "17509184_2_Ent1", "role": "Treatment", "text": "Ethambutol", "start": 0, "end": 1}, {"entity_id": "17509184_2_Ent2", "role": "Treatment_Drug", "text": "Ethambutol", "start": 0, "end": 1}, {"entity_id": "17509184_2_Ent0", "role": "Effect", "text": "acute onset psychosis", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "17509184_2_Ent1", "text": "Ethambutol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17509184_2_Ent2", "text": "Ethambutol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17509184_2_Ent0", "text": "acute onset psychosis", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "17536204_2", "wnd_id": "17536204_2_1", "text": "BACKGROUND : Headaches have been reported as a potential side effect of capecitabine therapy .", "tokens": ["BACKGROUND", ":", "Headaches", "have", "been", "reported", "as", "a", "potential", "side", "effect", "of", "capecitabine", "therapy", "."], "event_mentions": [{"id": "17536204_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 11, "end": 12}, "arguments": [{"entity_id": "17536204_2_Ent0", "role": "Effect", "text": "Headaches", "start": 2, "end": 3}, {"entity_id": "17536204_2_Ent1", "role": "Treatment", "text": "capecitabine", "start": 12, "end": 13}, {"entity_id": "17536204_2_Ent2", "role": "Treatment_Drug", "text": "capecitabine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "17536204_2_Ent0", "text": "Headaches", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17536204_2_Ent1", "text": "capecitabine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "17536204_2_Ent2", "text": "capecitabine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "17547624_2", "wnd_id": "17547624_2_1", "text": "We report a case of ST elevation in right precordial leads compatible with type 1 Brugada syndrome following administration of propafenone in a patient with Wolff - Parkinson - White syndrome who was receiving lithium at concentrations within therapeutic levels .", "tokens": ["We", "report", "a", "case", "of", "ST", "elevation", "in", "right", "precordial", "leads", "compatible", "with", "type", "1", "Brugada", "syndrome", "following", "administration", "of", "propafenone", "in", "a", "patient", "with", "Wolff", "-", "Parkinson", "-", "White", "syndrome", "who", "was", "receiving", "lithium", "at", "concentrations", "within", "therapeutic", "levels", "."], "event_mentions": [{"id": "17547624_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 17, "end": 18}, "arguments": [{"entity_id": "17547624_2_Ent1", "role": "Effect", "text": "ST elevation in right precordial leads compatible with type 1 Brugada syndrome", "start": 5, "end": 17}, {"entity_id": "17547624_2_Ent2", "role": "Treatment", "text": "administration of propafenone", "start": 18, "end": 21}, {"entity_id": "17547624_2_Ent4", "role": "Treatment_Drug", "text": "propafenone", "start": 20, "end": 21}, {"entity_id": "17547624_2_Ent7", "role": "Combination_Drug", "text": "propafenone", "start": 20, "end": 21}, {"entity_id": "17547624_2_Ent0", "role": "Subject", "text": "a patient with Wolff - Parkinson - White syndrome", "start": 22, "end": 31}, {"entity_id": "17547624_2_Ent6", "role": "Treatment_Disorder", "text": "Wolff - Parkinson - White syndrome", "start": 25, "end": 31}, {"entity_id": "17547624_2_Ent3", "role": "Treatment", "text": "receiving lithium at concentrations within therapeutic levels", "start": 33, "end": 40}, {"entity_id": "17547624_2_Ent5", "role": "Treatment_Drug", "text": "lithium", "start": 34, "end": 35}, {"entity_id": "17547624_2_Ent8", "role": "Combination_Drug", "text": "lithium", "start": 34, "end": 35}]}], "entity_mentions": [{"id": "17547624_2_Ent1", "text": "ST elevation in right precordial leads compatible with type 1 Brugada syndrome", "entity_type": "Entity", "start": 5, "end": 17}, {"id": "17547624_2_Ent2", "text": "administration of propafenone", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "17547624_2_Ent4", "text": "propafenone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17547624_2_Ent7", "text": "propafenone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17547624_2_Ent0", "text": "a patient with Wolff - Parkinson - White syndrome", "entity_type": "Entity", "start": 22, "end": 31}, {"id": "17547624_2_Ent6", "text": "Wolff - Parkinson - White syndrome", "entity_type": "Entity", "start": 25, "end": 31}, {"id": "17547624_2_Ent3", "text": "receiving lithium at concentrations within therapeutic levels", "entity_type": "Entity", "start": 33, "end": 40}, {"id": "17547624_2_Ent5", "text": "lithium", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "17547624_2_Ent8", "text": "lithium", "entity_type": "Entity", "start": 34, "end": 35}], "lang": "en"}
{"doc_id": "17551408_1", "wnd_id": "17551408_1_1", "text": "We postulate that gastritis caused by dexamethasone , mucositis caused by doxorubicin , and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event .", "tokens": ["We", "postulate", "that", "gastritis", "caused", "by", "dexamethasone", ",", "mucositis", "caused", "by", "doxorubicin", ",", "and", "the", "unique", "anatomic", "nature", "of", "a", "Meckel", "diverticulum", "may", "have", "contributed", "to", "this", "extremely", "unlikely", "and", "previously", "unreported", "event", "."], "event_mentions": [{"id": "17551408_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 4, "end": 5}, "arguments": [{"entity_id": "17551408_1_Ent0", "role": "Effect", "text": "gastritis", "start": 3, "end": 4}, {"entity_id": "17551408_1_Ent1", "role": "Treatment", "text": "dexamethasone", "start": 6, "end": 7}, {"entity_id": "17551408_1_Ent2", "role": "Treatment_Drug", "text": "dexamethasone", "start": 6, "end": 7}]}, {"id": "17551408_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 9, "end": 10}, "arguments": [{"entity_id": "17551408_1_Ent3", "role": "Effect", "text": "mucositis", "start": 8, "end": 9}, {"entity_id": "17551408_1_Ent4", "role": "Treatment", "text": "doxorubicin", "start": 11, "end": 12}, {"entity_id": "17551408_1_Ent5", "role": "Treatment_Drug", "text": "doxorubicin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "17551408_1_Ent0", "text": "gastritis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17551408_1_Ent1", "text": "dexamethasone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17551408_1_Ent2", "text": "dexamethasone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17551408_1_Ent3", "text": "mucositis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17551408_1_Ent4", "text": "doxorubicin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17551408_1_Ent5", "text": "doxorubicin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "1756352_2", "wnd_id": "1756352_2_1", "text": "Delusional parasitosis associated with phenelzine .", "tokens": ["Delusional", "parasitosis", "associated", "with", "phenelzine", "."], "event_mentions": [{"id": "1756352_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "1756352_2_Ent0", "role": "Effect", "text": "Delusional parasitosis", "start": 0, "end": 2}, {"entity_id": "1756352_2_Ent1", "role": "Treatment", "text": "phenelzine", "start": 4, "end": 5}, {"entity_id": "1756352_2_Ent2", "role": "Treatment_Drug", "text": "phenelzine", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "1756352_2_Ent0", "text": "Delusional parasitosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1756352_2_Ent1", "text": "phenelzine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1756352_2_Ent2", "text": "phenelzine", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "17596682_2", "wnd_id": "17596682_2_1", "text": "The use of rituximab has been uncommonly associated with delayed pulmonary toxicity .", "tokens": ["The", "use", "of", "rituximab", "has", "been", "uncommonly", "associated", "with", "delayed", "pulmonary", "toxicity", "."], "event_mentions": [{"id": "17596682_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "17596682_2_Ent1", "role": "Treatment", "text": "rituximab", "start": 3, "end": 4}, {"entity_id": "17596682_2_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 3, "end": 4}, {"entity_id": "17596682_2_Ent0", "role": "Effect", "text": "delayed pulmonary toxicity", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "17596682_2_Ent1", "text": "rituximab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17596682_2_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17596682_2_Ent0", "text": "delayed pulmonary toxicity", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "17619811_2", "wnd_id": "17619811_2_1", "text": "A case of colchicine - induced rhabdomyolysis is reported .", "tokens": ["A", "case", "of", "colchicine", "-", "induced", "rhabdomyolysis", "is", "reported", "."], "event_mentions": [{"id": "17619811_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "17619811_2_Ent1", "role": "Treatment", "text": "colchicine", "start": 3, "end": 4}, {"entity_id": "17619811_2_Ent2", "role": "Treatment_Drug", "text": "colchicine", "start": 3, "end": 4}, {"entity_id": "17619811_2_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "17619811_2_Ent1", "text": "colchicine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17619811_2_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17619811_2_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "17619811_5", "wnd_id": "17619811_5_1", "text": "Investigation confirmed the diagnosis of rhabdomyolysis , and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis .", "tokens": ["Investigation", "confirmed", "the", "diagnosis", "of", "rhabdomyolysis", ",", "and", "discontinuation", "of", "colchicine", "resulted", "in", "resolution", "of", "clinical", "and", "biochemical", "features", "of", "rhabdomylysis", "."], "event_mentions": [{"id": "17619811_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 11, "end": 12}, "arguments": [{"entity_id": "17619811_5_Ent1", "role": "Treatment", "text": "colchicine", "start": 10, "end": 11}, {"entity_id": "17619811_5_Ent2", "role": "Treatment_Drug", "text": "colchicine", "start": 10, "end": 11}, {"entity_id": "17619811_5_Ent0", "role": "Effect", "text": "rhabdomylysis", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "17619811_5_Ent1", "text": "colchicine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17619811_5_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17619811_5_Ent0", "text": "rhabdomylysis", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "17624096_1", "wnd_id": "17624096_1_1", "text": "5 - Fluorouracil cardiotoxicity complicating treatment of stage IIB cervical cancer -- case report .", "tokens": ["5", "-", "Fluorouracil", "cardiotoxicity", "complicating", "treatment", "of", "stage", "IIB", "cervical", "cancer", "--", "case", "report", "."], "event_mentions": [{"id": "17624096_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complicating", "start": 4, "end": 5}, "arguments": [{"entity_id": "17624096_1_Ent1", "role": "Treatment", "text": "5 - Fluorouracil", "start": 0, "end": 3}, {"entity_id": "17624096_1_Ent2", "role": "Treatment_Drug", "text": "5 - Fluorouracil", "start": 0, "end": 3}, {"entity_id": "17624096_1_Ent0", "role": "Effect", "text": "cardiotoxicity", "start": 3, "end": 4}, {"entity_id": "17624096_1_Ent3", "role": "Treatment_Disorder", "text": "cervical cancer", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "17624096_1_Ent1", "text": "5 - Fluorouracil", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17624096_1_Ent2", "text": "5 - Fluorouracil", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17624096_1_Ent0", "text": "cardiotoxicity", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17624096_1_Ent3", "text": "cervical cancer", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "17627694_1", "wnd_id": "17627694_1_1", "text": "CONCLUSION : Acetic acid is corrosive and may cause vagina bleeding .", "tokens": ["CONCLUSION", ":", "Acetic", "acid", "is", "corrosive", "and", "may", "cause", "vagina", "bleeding", "."], "event_mentions": [{"id": "17627694_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 8, "end": 9}, "arguments": [{"entity_id": "17627694_1_Ent1", "role": "Treatment", "text": "Acetic acid", "start": 2, "end": 4}, {"entity_id": "17627694_1_Ent2", "role": "Treatment_Drug", "text": "Acetic acid", "start": 2, "end": 4}, {"entity_id": "17627694_1_Ent0", "role": "Effect", "text": "vagina bleeding", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "17627694_1_Ent1", "text": "Acetic acid", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "17627694_1_Ent2", "text": "Acetic acid", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "17627694_1_Ent0", "text": "vagina bleeding", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "17655517_2", "wnd_id": "17655517_2_1", "text": "Linezolid is an oxazolidinone antibacterial agent indicated for serious gram - positive infections .", "tokens": ["Linezolid", "is", "an", "oxazolidinone", "antibacterial", "agent", "indicated", "for", "serious", "gram", "-", "positive", "infections", "."], "event_mentions": [{"id": "17655517_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "indicated", "start": 6, "end": 7}, "arguments": [{"entity_id": "17655517_2_Ent0", "role": "Treatment", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "17655517_2_Ent2", "role": "Treatment_Drug", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "17655517_2_Ent1", "role": "Treatment_Disorder", "text": "serious gram - positive infections", "start": 8, "end": 13}]}], "entity_mentions": [{"id": "17655517_2_Ent0", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17655517_2_Ent2", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17655517_2_Ent1", "text": "serious gram - positive infections", "entity_type": "Entity", "start": 8, "end": 13}], "lang": "en"}
{"doc_id": "17655517_5", "wnd_id": "17655517_5_1", "text": "Peripheral and optic neuropathy was usually seen after several months of linezolid therapy ( median 5 mo ) , lactic acidosis after several weeks ( median 6 wks ) , and serotonin syndrome after several days ( median 4 days ) .", "tokens": ["Peripheral", "and", "optic", "neuropathy", "was", "usually", "seen", "after", "several", "months", "of", "linezolid", "therapy", "(", "median", "5", "mo", ")", ",", "lactic", "acidosis", "after", "several", "weeks", "(", "median", "6", "wks", ")", ",", "and", "serotonin", "syndrome", "after", "several", "days", "(", "median", "4", "days", ")", "."], "event_mentions": [{"id": "17655517_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "17655517_5_Ent0", "role": "Effect", "text": "Peripheral and optic neuropathy", "start": 0, "end": 4}, {"entity_id": "17655517_5_Ent4", "role": "Treatment_Time_elapsed", "text": "several months", "start": 8, "end": 10}, {"entity_id": "17655517_5_Ent2", "role": "Treatment", "text": "several months of linezolid therapy ( median 5 mo )", "start": 8, "end": 18}, {"entity_id": "17655517_5_Ent3", "role": "Treatment_Drug", "text": "linezolid", "start": 11, "end": 12}, {"entity_id": "17655517_5_Ent1", "role": "Effect", "text": "lactic acidosis after several weeks ( median 6 wks ) , and serotonin syndrome after several days ( median 4 days )", "start": 19, "end": 41}]}], "entity_mentions": [{"id": "17655517_5_Ent0", "text": "Peripheral and optic neuropathy", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "17655517_5_Ent4", "text": "several months", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "17655517_5_Ent2", "text": "several months of linezolid therapy ( median 5 mo )", "entity_type": "Entity", "start": 8, "end": 18}, {"id": "17655517_5_Ent3", "text": "linezolid", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17655517_5_Ent1", "text": "lactic acidosis after several weeks ( median 6 wks ) , and serotonin syndrome after several days ( median 4 days )", "entity_type": "Entity", "start": 19, "end": 41}], "lang": "en"}
{"doc_id": "17655517_9", "wnd_id": "17655517_9_1", "text": "Patients receiving linezolid for more than 28 days should be monitored for signs of peripheral and optic neuropathy .", "tokens": ["Patients", "receiving", "linezolid", "for", "more", "than", "28", "days", "should", "be", "monitored", "for", "signs", "of", "peripheral", "and", "optic", "neuropathy", "."], "event_mentions": [{"id": "17655517_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "monitored", "start": 10, "end": 11}, "arguments": [{"entity_id": "17655517_9_Ent0", "role": "Subject", "text": "Patients", "start": 0, "end": 1}, {"entity_id": "17655517_9_Ent3", "role": "Treatment_Drug", "text": "linezolid", "start": 2, "end": 3}, {"entity_id": "17655517_9_Ent2", "role": "Treatment", "text": "linezolid for more than 28 days", "start": 2, "end": 8}, {"entity_id": "17655517_9_Ent4", "role": "Treatment_Duration", "text": "28 days", "start": 6, "end": 8}, {"entity_id": "17655517_9_Ent1", "role": "Effect", "text": "peripheral and optic neuropathy", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "17655517_9_Ent0", "text": "Patients", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17655517_9_Ent3", "text": "linezolid", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17655517_9_Ent2", "text": "linezolid for more than 28 days", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "17655517_9_Ent4", "text": "28 days", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17655517_9_Ent1", "text": "peripheral and optic neuropathy", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "17675030_1", "wnd_id": "17675030_1_1", "text": "A search of the United States Food and Drug Administration 's Adverse Event Reporting System identified nine cases of oxcarbazepine - associated angioedema in pediatric patients aged 16 years and younger .", "tokens": ["A", "search", "of", "the", "United", "States", "Food", "and", "Drug", "Administration", "'s", "Adverse", "Event", "Reporting", "System", "identified", "nine", "cases", "of", "oxcarbazepine", "-", "associated", "angioedema", "in", "pediatric", "patients", "aged", "16", "years", "and", "younger", "."], "event_mentions": [{"id": "17675030_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 21, "end": 22}, "arguments": [{"entity_id": "17675030_1_Ent4", "role": "Treatment", "text": "oxcarbazepine", "start": 19, "end": 20}, {"entity_id": "17675030_1_Ent5", "role": "Treatment_Drug", "text": "oxcarbazepine", "start": 19, "end": 20}, {"entity_id": "17675030_1_Ent3", "role": "Effect", "text": "angioedema", "start": 22, "end": 23}, {"entity_id": "17675030_1_Ent2", "role": "Subject_Disorder", "text": "pediatric", "start": 24, "end": 25}, {"entity_id": "17675030_1_Ent0", "role": "Subject", "text": "pediatric patients aged 16 years and younger", "start": 24, "end": 31}, {"entity_id": "17675030_1_Ent1", "role": "Subject_Age", "text": "16 years and younger", "start": 27, "end": 31}]}], "entity_mentions": [{"id": "17675030_1_Ent4", "text": "oxcarbazepine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17675030_1_Ent5", "text": "oxcarbazepine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17675030_1_Ent3", "text": "angioedema", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "17675030_1_Ent2", "text": "pediatric", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "17675030_1_Ent0", "text": "pediatric patients aged 16 years and younger", "entity_type": "Entity", "start": 24, "end": 31}, {"id": "17675030_1_Ent1", "text": "16 years and younger", "entity_type": "Entity", "start": 27, "end": 31}], "lang": "en"}
{"doc_id": "17675030_3", "wnd_id": "17675030_3_1", "text": "Oxcarbazepine - associated angioedema manifested by swelling of the face , eyes , lips , or tongue or difficulty swallowing or breathing ( or both ) is a rare but potentially life - threatening reaction for which early recognition and management are vital .", "tokens": ["Oxcarbazepine", "-", "associated", "angioedema", "manifested", "by", "swelling", "of", "the", "face", ",", "eyes", ",", "lips", ",", "or", "tongue", "or", "difficulty", "swallowing", "or", "breathing", "(", "or", "both", ")", "is", "a", "rare", "but", "potentially", "life", "-", "threatening", "reaction", "for", "which", "early", "recognition", "and", "management", "are", "vital", "."], "event_mentions": [{"id": "17675030_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "17675030_3_Ent1", "role": "Treatment", "text": "Oxcarbazepine", "start": 0, "end": 1}, {"entity_id": "17675030_3_Ent2", "role": "Treatment_Drug", "text": "Oxcarbazepine", "start": 0, "end": 1}, {"entity_id": "17675030_3_Ent0", "role": "Effect", "text": "angioedema manifested by swelling of the face , eyes , lips , or tongue or difficulty swallowing or breathing ( or both )", "start": 3, "end": 26}]}], "entity_mentions": [{"id": "17675030_3_Ent1", "text": "Oxcarbazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17675030_3_Ent2", "text": "Oxcarbazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17675030_3_Ent0", "text": "angioedema manifested by swelling of the face , eyes , lips , or tongue or difficulty swallowing or breathing ( or both )", "entity_type": "Entity", "start": 3, "end": 26}], "lang": "en"}
{"doc_id": "17697264_1", "wnd_id": "17697264_1_1", "text": "Here we describe another case of VOD occurring after LT , but in which the causative role was played by azathioprine .", "tokens": ["Here", "we", "describe", "another", "case", "of", "VOD", "occurring", "after", "LT", ",", "but", "in", "which", "the", "causative", "role", "was", "played", "by", "azathioprine", "."], "event_mentions": [{"id": "17697264_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 7, "end": 8}, "arguments": [{"entity_id": "17697264_1_Ent0", "role": "Effect", "text": "VOD", "start": 6, "end": 7}, {"entity_id": "17697264_1_Ent1", "role": "Treatment", "text": "azathioprine", "start": 20, "end": 21}, {"entity_id": "17697264_1_Ent2", "role": "Treatment_Drug", "text": "azathioprine", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "17697264_1_Ent0", "text": "VOD", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17697264_1_Ent1", "text": "azathioprine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17697264_1_Ent2", "text": "azathioprine", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "17697264_2", "wnd_id": "17697264_2_1", "text": "One case of tacrolimus - induced hepatic VOD developing after lung transplantation ( LT ) has been recently reported .", "tokens": ["One", "case", "of", "tacrolimus", "-", "induced", "hepatic", "VOD", "developing", "after", "lung", "transplantation", "(", "LT", ")", "has", "been", "recently", "reported", "."], "event_mentions": [{"id": "17697264_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "17697264_2_Ent1", "role": "Treatment", "text": "tacrolimus", "start": 3, "end": 4}, {"entity_id": "17697264_2_Ent3", "role": "Treatment_Drug", "text": "tacrolimus", "start": 3, "end": 4}, {"entity_id": "17697264_2_Ent0", "role": "Effect", "text": "hepatic VOD", "start": 6, "end": 8}, {"entity_id": "17697264_2_Ent2", "role": "Treatment", "text": "after lung transplantation ( LT )", "start": 9, "end": 15}]}], "entity_mentions": [{"id": "17697264_2_Ent1", "text": "tacrolimus", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17697264_2_Ent3", "text": "tacrolimus", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17697264_2_Ent0", "text": "hepatic VOD", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17697264_2_Ent2", "text": "after lung transplantation ( LT )", "entity_type": "Entity", "start": 9, "end": 15}], "lang": "en"}
{"doc_id": "1775411_1", "wnd_id": "1775411_1_1", "text": "A patient is described who developed a rapid onset of pulmonary fibrosis following treatment with a new non - steroidal anti - inflammatory drug , nabumetone .", "tokens": ["A", "patient", "is", "described", "who", "developed", "a", "rapid", "onset", "of", "pulmonary", "fibrosis", "following", "treatment", "with", "a", "new", "non", "-", "steroidal", "anti", "-", "inflammatory", "drug", ",", "nabumetone", "."], "event_mentions": [{"id": "1775411_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "1775411_1_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "1775411_1_Ent1", "role": "Effect", "text": "pulmonary fibrosis", "start": 10, "end": 12}, {"entity_id": "1775411_1_Ent2", "role": "Treatment", "text": "nabumetone", "start": 25, "end": 26}, {"entity_id": "1775411_1_Ent3", "role": "Treatment_Drug", "text": "nabumetone", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "1775411_1_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1775411_1_Ent1", "text": "pulmonary fibrosis", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "1775411_1_Ent2", "text": "nabumetone", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "1775411_1_Ent3", "text": "nabumetone", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "1775411_2", "wnd_id": "1775411_2_1", "text": "Pulmonary fibrosis associated with nabumetone .", "tokens": ["Pulmonary", "fibrosis", "associated", "with", "nabumetone", "."], "event_mentions": [{"id": "1775411_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "1775411_2_Ent0", "role": "Effect", "text": "Pulmonary fibrosis", "start": 0, "end": 2}, {"entity_id": "1775411_2_Ent1", "role": "Treatment", "text": "nabumetone", "start": 4, "end": 5}, {"entity_id": "1775411_2_Ent2", "role": "Treatment_Drug", "text": "nabumetone", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "1775411_2_Ent0", "text": "Pulmonary fibrosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1775411_2_Ent1", "text": "nabumetone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1775411_2_Ent2", "text": "nabumetone", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "17873198_1", "wnd_id": "17873198_1_1", "text": "Interstitial lung disease ( ILD ) related to therapy with the drug gefitinib has been well reported .", "tokens": ["Interstitial", "lung", "disease", "(", "ILD", ")", "related", "to", "therapy", "with", "the", "drug", "gefitinib", "has", "been", "well", "reported", "."], "event_mentions": [{"id": "17873198_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 6, "end": 7}, "arguments": [{"entity_id": "17873198_1_Ent0", "role": "Effect", "text": "Interstitial lung disease ( ILD )", "start": 0, "end": 6}, {"entity_id": "17873198_1_Ent1", "role": "Treatment", "text": "therapy with the drug gefitinib", "start": 8, "end": 13}, {"entity_id": "17873198_1_Ent2", "role": "Treatment_Drug", "text": "gefitinib", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "17873198_1_Ent0", "text": "Interstitial lung disease ( ILD )", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "17873198_1_Ent1", "text": "therapy with the drug gefitinib", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "17873198_1_Ent2", "text": "gefitinib", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "17873198_3", "wnd_id": "17873198_3_1", "text": "Similar to reports in patients receiving gefitinib , those with pathologic findings of UIP on resected lung specimens or known pulmonary fibrosis may be at particular risk for erlotinib pulmonary toxicity .", "tokens": ["Similar", "to", "reports", "in", "patients", "receiving", "gefitinib", ",", "those", "with", "pathologic", "findings", "of", "UIP", "on", "resected", "lung", "specimens", "or", "known", "pulmonary", "fibrosis", "may", "be", "at", "particular", "risk", "for", "erlotinib", "pulmonary", "toxicity", "."], "event_mentions": [{"id": "17873198_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 5, "end": 6}, "arguments": [{"entity_id": "17873198_3_Ent0", "role": "Subject", "text": "patients", "start": 4, "end": 5}, {"entity_id": "17873198_3_Ent2", "role": "Treatment", "text": "gefitinib", "start": 6, "end": 7}, {"entity_id": "17873198_3_Ent3", "role": "Treatment_Drug", "text": "gefitinib", "start": 6, "end": 7}, {"entity_id": "17873198_3_Ent1", "role": "Effect", "text": "erlotinib pulmonary toxicity .", "start": 28, "end": 32}]}], "entity_mentions": [{"id": "17873198_3_Ent0", "text": "patients", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17873198_3_Ent2", "text": "gefitinib", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17873198_3_Ent3", "text": "gefitinib", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17873198_3_Ent1", "text": "erlotinib pulmonary toxicity .", "entity_type": "Entity", "start": 28, "end": 32}], "lang": "en"}
{"doc_id": "17876386_2", "wnd_id": "17876386_2_1", "text": "Torsade de pointes associated with moxifloxacin : a rare but potentially fatal adverse event .", "tokens": ["Torsade", "de", "pointes", "associated", "with", "moxifloxacin", ":", "a", "rare", "but", "potentially", "fatal", "adverse", "event", "."], "event_mentions": [{"id": "17876386_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "17876386_2_Ent0", "role": "Effect", "text": "Torsade de pointes", "start": 0, "end": 3}, {"entity_id": "17876386_2_Ent1", "role": "Treatment", "text": "moxifloxacin", "start": 5, "end": 6}, {"entity_id": "17876386_2_Ent2", "role": "Treatment_Drug", "text": "moxifloxacin", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "17876386_2_Ent0", "text": "Torsade de pointes", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17876386_2_Ent1", "text": "moxifloxacin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17876386_2_Ent2", "text": "moxifloxacin", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "17921794_4", "wnd_id": "17921794_4_1", "text": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis .", "tokens": ["We", "report", "a", "case", "of", "a", "patient", "with", "mild", "chronic", "renal", "insufficiency", "who", "had", "been", "taking", "simvastatin", "for", "over", "a", "year", "and", "developed", "acute", "weakness", "within", "3", "weeks", "after", "the", "start", "of", "treatment", "with", "colchicine", "for", "acute", "gouty", "bursitis", "."], "event_mentions": [{"id": "17921794_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 22, "end": 23}, "arguments": [{"entity_id": "17921794_4_Ent0", "role": "Subject", "text": "a patient with mild chronic renal insufficiency", "start": 5, "end": 12}, {"entity_id": "17921794_4_Ent1", "role": "Subject_Disorder", "text": "mild chronic renal insufficiency", "start": 8, "end": 12}, {"entity_id": "17921794_4_Ent3", "role": "Treatment", "text": "taking simvastatin for over a year", "start": 15, "end": 21}, {"entity_id": "17921794_4_Ent6", "role": "Treatment_Drug", "text": "simvastatin", "start": 16, "end": 17}, {"entity_id": "17921794_4_Ent10", "role": "Combination_Drug", "text": "simvastatin", "start": 16, "end": 17}, {"entity_id": "17921794_4_Ent8", "role": "Treatment_Time_elapsed", "text": "over a year", "start": 18, "end": 21}, {"entity_id": "17921794_4_Ent2", "role": "Effect", "text": "acute weakness", "start": 23, "end": 25}, {"entity_id": "17921794_4_Ent9", "role": "Treatment_Time_elapsed", "text": "3 weeks", "start": 26, "end": 28}, {"entity_id": "17921794_4_Ent4", "role": "Treatment", "text": "3 weeks after the start of treatment with colchicine for acute gouty bursitis", "start": 26, "end": 39}, {"entity_id": "17921794_4_Ent7", "role": "Treatment_Drug", "text": "colchicine", "start": 34, "end": 35}, {"entity_id": "17921794_4_Ent11", "role": "Combination_Drug", "text": "colchicine", "start": 34, "end": 35}, {"entity_id": "17921794_4_Ent5", "role": "Treatment_Disorder", "text": "acute gouty bursitis", "start": 36, "end": 39}]}], "entity_mentions": [{"id": "17921794_4_Ent0", "text": "a patient with mild chronic renal insufficiency", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "17921794_4_Ent1", "text": "mild chronic renal insufficiency", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "17921794_4_Ent3", "text": "taking simvastatin for over a year", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "17921794_4_Ent6", "text": "simvastatin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17921794_4_Ent10", "text": "simvastatin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17921794_4_Ent8", "text": "over a year", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "17921794_4_Ent2", "text": "acute weakness", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "17921794_4_Ent9", "text": "3 weeks", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "17921794_4_Ent4", "text": "3 weeks after the start of treatment with colchicine for acute gouty bursitis", "entity_type": "Entity", "start": 26, "end": 39}, {"id": "17921794_4_Ent7", "text": "colchicine", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "17921794_4_Ent11", "text": "colchicine", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "17921794_4_Ent5", "text": "acute gouty bursitis", "entity_type": "Entity", "start": 36, "end": 39}], "lang": "en"}
{"doc_id": "1792646_1", "wnd_id": "1792646_1_1", "text": "Pneumocystis carinii pneumonia as a complication of methotrexate treatment of asthma .", "tokens": ["Pneumocystis", "carinii", "pneumonia", "as", "a", "complication", "of", "methotrexate", "treatment", "of", "asthma", "."], "event_mentions": [{"id": "1792646_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 5, "end": 6}, "arguments": [{"entity_id": "1792646_1_Ent0", "role": "Effect", "text": "Pneumocystis carinii pneumonia", "start": 0, "end": 3}, {"entity_id": "1792646_1_Ent1", "role": "Treatment", "text": "methotrexate", "start": 7, "end": 8}, {"entity_id": "1792646_1_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 7, "end": 8}, {"entity_id": "1792646_1_Ent3", "role": "Treatment_Disorder", "text": "asthma", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "1792646_1_Ent0", "text": "Pneumocystis carinii pneumonia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "1792646_1_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1792646_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1792646_1_Ent3", "text": "asthma", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "17937473_1", "wnd_id": "17937473_1_1", "text": "Eleven patients developed infection requiring hospitalization while taking leflunomide including : lower respiratory tract infections ( 3 ) , cellulitis ( 2 ) , disseminated herpes zoster ( 2 ) , probable TB liver ( 1 ) , abdominal sepsis ( 1 ) , mycotic aneurysm ( 1 ) and gastroenteritis ( 1 ) .", "tokens": ["Eleven", "patients", "developed", "infection", "requiring", "hospitalization", "while", "taking", "leflunomide", "including", ":", "lower", "respiratory", "tract", "infections", "(", "3", ")", ",", "cellulitis", "(", "2", ")", ",", "disseminated", "herpes", "zoster", "(", "2", ")", ",", "probable", "TB", "liver", "(", "1", ")", ",", "abdominal", "sepsis", "(", "1", ")", ",", "mycotic", "aneurysm", "(", "1", ")", "and", "gastroenteritis", "(", "1", ")", "."], "event_mentions": [{"id": "17937473_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "17937473_1_Ent1", "role": "Subject_Population", "text": "Eleven", "start": 0, "end": 1}, {"entity_id": "17937473_1_Ent0", "role": "Subject", "text": "Eleven patients", "start": 0, "end": 2}, {"entity_id": "17937473_1_Ent2", "role": "Effect", "text": "infection", "start": 3, "end": 4}, {"entity_id": "17937473_1_Ent4", "role": "Treatment", "text": "leflunomide", "start": 8, "end": 9}, {"entity_id": "17937473_1_Ent5", "role": "Treatment_Drug", "text": "leflunomide", "start": 8, "end": 9}, {"entity_id": "17937473_1_Ent3", "role": "Effect", "text": "lower respiratory tract infections ( 3 ) , cellulitis ( 2 ) , disseminated herpes zoster ( 2 ) , probable TB liver ( 1 ) , abdominal sepsis ( 1 ) , mycotic aneurysm ( 1 ) and gastroenteritis ( 1 )", "start": 11, "end": 54}]}], "entity_mentions": [{"id": "17937473_1_Ent1", "text": "Eleven", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17937473_1_Ent0", "text": "Eleven patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17937473_1_Ent2", "text": "infection", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17937473_1_Ent4", "text": "leflunomide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17937473_1_Ent5", "text": "leflunomide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17937473_1_Ent3", "text": "lower respiratory tract infections ( 3 ) , cellulitis ( 2 ) , disseminated herpes zoster ( 2 ) , probable TB liver ( 1 ) , abdominal sepsis ( 1 ) , mycotic aneurysm ( 1 ) and gastroenteritis ( 1 )", "entity_type": "Entity", "start": 11, "end": 54}], "lang": "en"}
{"doc_id": "17937473_3", "wnd_id": "17937473_3_1", "text": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide .", "tokens": ["The", "NZ", "Pharmacovigilance", "Centre", "has", "received", "7", "additional", "reports", "of", "severe", "infections", "in", "patients", "with", "RA", "taking", "leflunomide", "."], "event_mentions": [{"id": "17937473_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 16, "end": 17}, "arguments": [{"entity_id": "17937473_3_Ent1", "role": "Effect", "text": "severe infections", "start": 10, "end": 12}, {"entity_id": "17937473_3_Ent0", "role": "Subject", "text": "patients with RA", "start": 13, "end": 16}, {"entity_id": "17937473_3_Ent3", "role": "Treatment_Disorder", "text": "RA", "start": 15, "end": 16}, {"entity_id": "17937473_3_Ent2", "role": "Treatment", "text": "leflunomide", "start": 17, "end": 18}, {"entity_id": "17937473_3_Ent4", "role": "Treatment_Drug", "text": "leflunomide", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "17937473_3_Ent1", "text": "severe infections", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "17937473_3_Ent0", "text": "patients with RA", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "17937473_3_Ent3", "text": "RA", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17937473_3_Ent2", "text": "leflunomide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "17937473_3_Ent4", "text": "leflunomide", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "17955169_2", "wnd_id": "17955169_2_1", "text": "Uncontrolled headache induced by oxcarbazepine .", "tokens": ["Uncontrolled", "headache", "induced", "by", "oxcarbazepine", "."], "event_mentions": [{"id": "17955169_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17955169_2_Ent0", "role": "Effect", "text": "Uncontrolled headache", "start": 0, "end": 2}, {"entity_id": "17955169_2_Ent1", "role": "Treatment", "text": "oxcarbazepine", "start": 4, "end": 5}, {"entity_id": "17955169_2_Ent2", "role": "Treatment_Drug", "text": "oxcarbazepine", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "17955169_2_Ent0", "text": "Uncontrolled headache", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17955169_2_Ent1", "text": "oxcarbazepine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17955169_2_Ent2", "text": "oxcarbazepine", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "18037876_2", "wnd_id": "18037876_2_1", "text": "Multiple syncopal episodes started to occur during thalidomide treatment , and a Holter electrocardiogram showed multiple abnormalities , with an episode of sustained ventricular tachycardia .", "tokens": ["Multiple", "syncopal", "episodes", "started", "to", "occur", "during", "thalidomide", "treatment", ",", "and", "a", "Holter", "electrocardiogram", "showed", "multiple", "abnormalities", ",", "with", "an", "episode", "of", "sustained", "ventricular", "tachycardia", "."], "event_mentions": [{"id": "18037876_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 5, "end": 6}, "arguments": [{"entity_id": "18037876_2_Ent0", "role": "Effect", "text": "Multiple syncopal episodes", "start": 0, "end": 3}, {"entity_id": "18037876_2_Ent4", "role": "Treatment_Duration", "text": "during", "start": 6, "end": 7}, {"entity_id": "18037876_2_Ent2", "role": "Treatment", "text": "during thalidomide treatment", "start": 6, "end": 9}, {"entity_id": "18037876_2_Ent3", "role": "Treatment_Drug", "text": "thalidomide", "start": 7, "end": 8}, {"entity_id": "18037876_2_Ent1", "role": "Effect", "text": "and a Holter electrocardiogram showed multiple abnormalities , with an episode of sustained ventricular tachycardia", "start": 10, "end": 25}]}], "entity_mentions": [{"id": "18037876_2_Ent0", "text": "Multiple syncopal episodes", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18037876_2_Ent4", "text": "during", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18037876_2_Ent2", "text": "during thalidomide treatment", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "18037876_2_Ent3", "text": "thalidomide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18037876_2_Ent1", "text": "and a Holter electrocardiogram showed multiple abnormalities , with an episode of sustained ventricular tachycardia", "entity_type": "Entity", "start": 10, "end": 25}], "lang": "en"}
{"doc_id": "18071101_1", "wnd_id": "18071101_1_1", "text": "Although adverse effects are usually mild , the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation .", "tokens": ["Although", "adverse", "effects", "are", "usually", "mild", ",", "the", "author", "reports", "here", "a", "case", "of", "leucocytopenia", "and", "thrombocytopenia", "with", "quetiapine", "treatment", "that", "required", "its", "discontinuation", "."], "event_mentions": [{"id": "18071101_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 17, "end": 18}, "arguments": [{"entity_id": "18071101_1_Ent0", "role": "Subject", "text": "a case", "start": 11, "end": 13}, {"entity_id": "18071101_1_Ent1", "role": "Effect", "text": "leucocytopenia and thrombocytopenia", "start": 14, "end": 17}, {"entity_id": "18071101_1_Ent2", "role": "Treatment", "text": "quetiapine", "start": 18, "end": 19}, {"entity_id": "18071101_1_Ent3", "role": "Treatment_Drug", "text": "quetiapine", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "18071101_1_Ent0", "text": "a case", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18071101_1_Ent1", "text": "leucocytopenia and thrombocytopenia", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "18071101_1_Ent2", "text": "quetiapine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "18071101_1_Ent3", "text": "quetiapine", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "18076602_2", "wnd_id": "18076602_2_1", "text": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment .", "tokens": ["Palpable", "purpuric", "skin", "lesions", "on", "the", "anterior", "surface", "of", "both", "legs", "appeared", "on", "the", "55th", "day", "of", "amphotericin", "B", "treatment", "."], "event_mentions": [{"id": "18076602_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appeared", "start": 11, "end": 12}, "arguments": [{"entity_id": "18076602_2_Ent0", "role": "Effect", "text": "Palpable purpuric skin lesions on the anterior surface of both legs", "start": 0, "end": 11}, {"entity_id": "18076602_2_Ent2", "role": "Treatment_Duration", "text": "55th day", "start": 14, "end": 16}, {"entity_id": "18076602_2_Ent1", "role": "Treatment", "text": "55th day of amphotericin B treatment", "start": 14, "end": 20}, {"entity_id": "18076602_2_Ent3", "role": "Treatment_Drug", "text": "amphotericin B", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "18076602_2_Ent0", "text": "Palpable purpuric skin lesions on the anterior surface of both legs", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "18076602_2_Ent2", "text": "55th day", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "18076602_2_Ent1", "text": "55th day of amphotericin B treatment", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "18076602_2_Ent3", "text": "amphotericin B", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "18076602_3", "wnd_id": "18076602_3_1", "text": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor .", "tokens": ["We", "present", "a", "case", "of", "cutaneous", "leucocytoclastic", "vasculitis", "in", "which", "amphotericin", "B", "might", "presumably", "be", "the", "aetiological", "factor", "."], "event_mentions": [{"id": "18076602_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "be", "start": 14, "end": 15}, "arguments": [{"entity_id": "18076602_3_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "18076602_3_Ent1", "role": "Effect", "text": "cutaneous leucocytoclastic vasculitis", "start": 5, "end": 8}, {"entity_id": "18076602_3_Ent2", "role": "Treatment", "text": "amphotericin B", "start": 10, "end": 12}, {"entity_id": "18076602_3_Ent3", "role": "Treatment_Drug", "text": "amphotericin B", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "18076602_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "18076602_3_Ent1", "text": "cutaneous leucocytoclastic vasculitis", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "18076602_3_Ent2", "text": "amphotericin B", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "18076602_3_Ent3", "text": "amphotericin B", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "18079582_1", "wnd_id": "18079582_1_1", "text": "The incidence of 5 - fluorouracil ( 5 - FU) - related cardiotoxicity seems to be dosage and schedule dependent .", "tokens": ["The", "incidence", "of", "5", "-", "fluorouracil", "(", "5", "-", "FU)", "-", "related", "cardiotoxicity", "seems", "to", "be", "dosage", "and", "schedule", "dependent", "."], "event_mentions": [{"id": "18079582_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 11, "end": 12}, "arguments": [{"entity_id": "18079582_1_Ent1", "role": "Treatment", "text": "5 - fluorouracil", "start": 3, "end": 6}, {"entity_id": "18079582_1_Ent4", "role": "Treatment_Drug", "text": "5 - fluorouracil ( 5 - FU)", "start": 3, "end": 10}, {"entity_id": "18079582_1_Ent0", "role": "Effect", "text": "cardiotoxicity", "start": 12, "end": 13}, {"entity_id": "18079582_1_Ent2", "role": "Treatment", "text": "dosage", "start": 16, "end": 17}, {"entity_id": "18079582_1_Ent3", "role": "Treatment", "text": "schedule", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "18079582_1_Ent1", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "18079582_1_Ent4", "text": "5 - fluorouracil ( 5 - FU)", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "18079582_1_Ent0", "text": "cardiotoxicity", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18079582_1_Ent2", "text": "dosage", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18079582_1_Ent3", "text": "schedule", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "1814986_1", "wnd_id": "1814986_1_1", "text": "Metabolic acidosis induced by acetazolamide .", "tokens": ["Metabolic", "acidosis", "induced", "by", "acetazolamide", "."], "event_mentions": [{"id": "1814986_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "1814986_1_Ent0", "role": "Effect", "text": "Metabolic acidosis", "start": 0, "end": 2}, {"entity_id": "1814986_1_Ent1", "role": "Treatment", "text": "acetazolamide", "start": 4, "end": 5}, {"entity_id": "1814986_1_Ent2", "role": "Treatment_Drug", "text": "acetazolamide", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "1814986_1_Ent0", "text": "Metabolic acidosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1814986_1_Ent1", "text": "acetazolamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1814986_1_Ent2", "text": "acetazolamide", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "18159131_4", "wnd_id": "18159131_4_1", "text": "We present a Japanese male patient who underwent a living - donor kidney transplantation having received tacrolimus , mycophenolate mofetil , and prednisolone for immunosuppression .", "tokens": ["We", "present", "a", "Japanese", "male", "patient", "who", "underwent", "a", "living", "-", "donor", "kidney", "transplantation", "having", "received", "tacrolimus", ",", "mycophenolate", "mofetil", ",", "and", "prednisolone", "for", "immunosuppression", "."], "event_mentions": [{"id": "18159131_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 15, "end": 16}, "arguments": [{"entity_id": "18159131_4_Ent0", "role": "Subject", "text": "a Japanese male patient who underwent a living - donor kidney transplantation", "start": 2, "end": 14}, {"entity_id": "18159131_4_Ent2", "role": "Subject_Race", "text": "Japanese", "start": 3, "end": 4}, {"entity_id": "18159131_4_Ent3", "role": "Subject_Gender", "text": "male", "start": 4, "end": 5}, {"entity_id": "18159131_4_Ent4", "role": "Subject_Disorder", "text": "kidney transplantation", "start": 12, "end": 14}, {"entity_id": "18159131_4_Ent7", "role": "Treatment_Drug", "text": "tacrolimus", "start": 16, "end": 17}, {"entity_id": "18159131_4_Ent10", "role": "Combination_Drug", "text": "tacrolimus", "start": 16, "end": 17}, {"entity_id": "18159131_4_Ent5", "role": "Treatment", "text": "tacrolimus , mycophenolate mofetil , and prednisolone", "start": 16, "end": 23}, {"entity_id": "18159131_4_Ent8", "role": "Treatment_Drug", "text": "mycophenolate mofetil", "start": 18, "end": 20}, {"entity_id": "18159131_4_Ent11", "role": "Combination_Drug", "text": "mycophenolate mofetil", "start": 18, "end": 20}, {"entity_id": "18159131_4_Ent9", "role": "Treatment_Drug", "text": "prednisolone", "start": 22, "end": 23}, {"entity_id": "18159131_4_Ent12", "role": "Combination_Drug", "text": "prednisolone", "start": 22, "end": 23}, {"entity_id": "18159131_4_Ent1", "role": "Subject", "text": "immunosuppression", "start": 24, "end": 25}, {"entity_id": "18159131_4_Ent6", "role": "Treatment_Disorder", "text": "immunosuppression", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "18159131_4_Ent0", "text": "a Japanese male patient who underwent a living - donor kidney transplantation", "entity_type": "Entity", "start": 2, "end": 14}, {"id": "18159131_4_Ent2", "text": "Japanese", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18159131_4_Ent3", "text": "male", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18159131_4_Ent4", "text": "kidney transplantation", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "18159131_4_Ent7", "text": "tacrolimus", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18159131_4_Ent10", "text": "tacrolimus", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18159131_4_Ent5", "text": "tacrolimus , mycophenolate mofetil , and prednisolone", "entity_type": "Entity", "start": 16, "end": 23}, {"id": "18159131_4_Ent8", "text": "mycophenolate mofetil", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "18159131_4_Ent11", "text": "mycophenolate mofetil", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "18159131_4_Ent9", "text": "prednisolone", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "18159131_4_Ent12", "text": "prednisolone", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "18159131_4_Ent1", "text": "immunosuppression", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "18159131_4_Ent6", "text": "immunosuppression", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "18171260_5", "wnd_id": "18171260_5_1", "text": "We describe serotonin syndrome after concomitant use of linezolid and meperidine in a 27 - year - old man with acute leukemia .", "tokens": ["We", "describe", "serotonin", "syndrome", "after", "concomitant", "use", "of", "linezolid", "and", "meperidine", "in", "a", "27", "-", "year", "-", "old", "man", "with", "acute", "leukemia", "."], "event_mentions": [{"id": "18171260_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "18171260_5_Ent4", "role": "Effect", "text": "serotonin syndrome", "start": 2, "end": 4}, {"entity_id": "18171260_5_Ent5", "role": "Treatment", "text": "concomitant use of linezolid and meperidine", "start": 5, "end": 11}, {"entity_id": "18171260_5_Ent6", "role": "Treatment_Drug", "text": "linezolid", "start": 8, "end": 9}, {"entity_id": "18171260_5_Ent8", "role": "Combination_Drug", "text": "linezolid", "start": 8, "end": 9}, {"entity_id": "18171260_5_Ent7", "role": "Treatment_Drug", "text": "meperidine", "start": 10, "end": 11}, {"entity_id": "18171260_5_Ent9", "role": "Combination_Drug", "text": "meperidine", "start": 10, "end": 11}, {"entity_id": "18171260_5_Ent0", "role": "Subject", "text": "a 27 - year - old man with acute leukemia", "start": 12, "end": 22}, {"entity_id": "18171260_5_Ent2", "role": "Subject_Age", "text": "27 - year - old", "start": 13, "end": 18}, {"entity_id": "18171260_5_Ent3", "role": "Subject_Gender", "text": "man", "start": 18, "end": 19}, {"entity_id": "18171260_5_Ent1", "role": "Subject_Disorder", "text": "acute leukemia", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "18171260_5_Ent4", "text": "serotonin syndrome", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "18171260_5_Ent5", "text": "concomitant use of linezolid and meperidine", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "18171260_5_Ent6", "text": "linezolid", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18171260_5_Ent8", "text": "linezolid", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18171260_5_Ent7", "text": "meperidine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18171260_5_Ent9", "text": "meperidine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18171260_5_Ent0", "text": "a 27 - year - old man with acute leukemia", "entity_type": "Entity", "start": 12, "end": 22}, {"id": "18171260_5_Ent2", "text": "27 - year - old", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "18171260_5_Ent3", "text": "man", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "18171260_5_Ent1", "text": "acute leukemia", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "18176653_3", "wnd_id": "18176653_3_1", "text": "BACKGROUND : NVP is a non - nucleoside reverse transcriptase inhibitor used in the treatment of Human Immunodeficiency Virus ( HIV ) infection .", "tokens": ["BACKGROUND", ":", "NVP", "is", "a", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitor", "used", "in", "the", "treatment", "of", "Human", "Immunodeficiency", "Virus", "(", "HIV", ")", "infection", "."], "event_mentions": [{"id": "18176653_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used", "start": 11, "end": 12}, "arguments": [{"entity_id": "18176653_3_Ent0", "role": "Treatment", "text": "NVP", "start": 2, "end": 3}, {"entity_id": "18176653_3_Ent2", "role": "Treatment_Drug", "text": "NVP", "start": 2, "end": 3}, {"entity_id": "18176653_3_Ent1", "role": "Treatment_Disorder", "text": "Human Immunodeficiency Virus ( HIV ) infection", "start": 16, "end": 23}]}], "entity_mentions": [{"id": "18176653_3_Ent0", "text": "NVP", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18176653_3_Ent2", "text": "NVP", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18176653_3_Ent1", "text": "Human Immunodeficiency Virus ( HIV ) infection", "entity_type": "Entity", "start": 16, "end": 23}], "lang": "en"}
{"doc_id": "18191947_1", "wnd_id": "18191947_1_1", "text": "Conventional and diffusion - weighted MRI findings of methotrexate related sub - acute neurotoxicity .", "tokens": ["Conventional", "and", "diffusion", "-", "weighted", "MRI", "findings", "of", "methotrexate", "related", "sub", "-", "acute", "neurotoxicity", "."], "event_mentions": [{"id": "18191947_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 9, "end": 10}, "arguments": [{"entity_id": "18191947_1_Ent1", "role": "Treatment", "text": "methotrexate", "start": 8, "end": 9}, {"entity_id": "18191947_1_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 8, "end": 9}, {"entity_id": "18191947_1_Ent0", "role": "Effect", "text": "sub - acute neurotoxicity", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "18191947_1_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18191947_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18191947_1_Ent0", "text": "sub - acute neurotoxicity", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "18191947_2", "wnd_id": "18191947_2_1", "text": "This case demonstrates the value of DWI in evaluation and diagnosis of sub - acute toxic leukoencephalopathy in patients being treated with methotrexate .", "tokens": ["This", "case", "demonstrates", "the", "value", "of", "DWI", "in", "evaluation", "and", "diagnosis", "of", "sub", "-", "acute", "toxic", "leukoencephalopathy", "in", "patients", "being", "treated", "with", "methotrexate", "."], "event_mentions": [{"id": "18191947_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 17, "end": 18}, "arguments": [{"entity_id": "18191947_2_Ent1", "role": "Effect", "text": "sub - acute toxic leukoencephalopathy", "start": 12, "end": 17}, {"entity_id": "18191947_2_Ent0", "role": "Subject", "text": "patients", "start": 18, "end": 19}, {"entity_id": "18191947_2_Ent2", "role": "Treatment", "text": "methotrexate", "start": 22, "end": 23}, {"entity_id": "18191947_2_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "18191947_2_Ent1", "text": "sub - acute toxic leukoencephalopathy", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "18191947_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "18191947_2_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "18191947_2_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "18203308_3", "wnd_id": "18203308_3_1", "text": "Typical symptoms of active CD occurred 11 , 12 , and 26 months after start of etanercept therapy , respectively .", "tokens": ["Typical", "symptoms", "of", "active", "CD", "occurred", "11", ",", "12", ",", "and", "26", "months", "after", "start", "of", "etanercept", "therapy", ",", "respectively", "."], "event_mentions": [{"id": "18203308_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 5, "end": 6}, "arguments": [{"entity_id": "18203308_3_Ent0", "role": "Effect", "text": "Typical symptoms of active CD", "start": 0, "end": 5}, {"entity_id": "18203308_3_Ent3", "role": "Treatment_Time_elapsed", "text": "11 , 12 , and 26 months after start", "start": 6, "end": 15}, {"entity_id": "18203308_3_Ent2", "role": "Treatment_Drug", "text": "etanercept", "start": 16, "end": 17}, {"entity_id": "18203308_3_Ent1", "role": "Treatment", "text": "etanercept therapy", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "18203308_3_Ent0", "text": "Typical symptoms of active CD", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "18203308_3_Ent3", "text": "11 , 12 , and 26 months after start", "entity_type": "Entity", "start": 6, "end": 15}, {"id": "18203308_3_Ent2", "text": "etanercept", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18203308_3_Ent1", "text": "etanercept therapy", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "18262450_8", "wnd_id": "18262450_8_1", "text": "Oxycodone - gabapentin reduced pain score by 33 % from baseline to end of treatment .", "tokens": ["Oxycodone", "-", "gabapentin", "reduced", "pain", "score", "by", "33", "%", "from", "baseline", "to", "end", "of", "treatment", "."], "event_mentions": [{"id": "18262450_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reduced", "start": 3, "end": 4}, "arguments": [{"entity_id": "18262450_8_Ent3", "role": "Treatment_Drug", "text": "Oxycodone", "start": 0, "end": 1}, {"entity_id": "18262450_8_Ent5", "role": "Combination_Drug", "text": "Oxycodone", "start": 0, "end": 1}, {"entity_id": "18262450_8_Ent1", "role": "Treatment", "text": "Oxycodone - gabapentin", "start": 0, "end": 3}, {"entity_id": "18262450_8_Ent4", "role": "Treatment_Drug", "text": "gabapentin", "start": 2, "end": 3}, {"entity_id": "18262450_8_Ent6", "role": "Combination_Drug", "text": "gabapentin", "start": 2, "end": 3}, {"entity_id": "18262450_8_Ent0", "role": "Effect", "text": "reduced pain score by 33 % from baseline", "start": 3, "end": 11}, {"entity_id": "18262450_8_Ent2", "role": "Treatment_Disorder", "text": "pain", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "18262450_8_Ent3", "text": "Oxycodone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18262450_8_Ent5", "text": "Oxycodone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18262450_8_Ent1", "text": "Oxycodone - gabapentin", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18262450_8_Ent4", "text": "gabapentin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18262450_8_Ent6", "text": "gabapentin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18262450_8_Ent0", "text": "reduced pain score by 33 % from baseline", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "18262450_8_Ent2", "text": "pain", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "18277922_1", "wnd_id": "18277922_1_1", "text": "She was treated with acyclovir and subsequently developed VZV antigen - positive zoster .", "tokens": ["She", "was", "treated", "with", "acyclovir", "and", "subsequently", "developed", "VZV", "antigen", "-", "positive", "zoster", "."], "event_mentions": [{"id": "18277922_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "18277922_1_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "18277922_1_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "18277922_1_Ent3", "role": "Treatment", "text": "acyclovir", "start": 4, "end": 5}, {"entity_id": "18277922_1_Ent4", "role": "Treatment_Drug", "text": "acyclovir", "start": 4, "end": 5}, {"entity_id": "18277922_1_Ent2", "role": "Effect", "text": "VZV antigen - positive zoster", "start": 8, "end": 13}]}], "entity_mentions": [{"id": "18277922_1_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18277922_1_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18277922_1_Ent3", "text": "acyclovir", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18277922_1_Ent4", "text": "acyclovir", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18277922_1_Ent2", "text": "VZV antigen - positive zoster", "entity_type": "Entity", "start": 8, "end": 13}], "lang": "en"}
{"doc_id": "18294121_2", "wnd_id": "18294121_2_1", "text": "Clinicians should be aware that an erythematous and exfoliative rash may be induced by temozolomide , and be familiar with the pharmacologic and supportive measures necessary for its treatment .", "tokens": ["Clinicians", "should", "be", "aware", "that", "an", "erythematous", "and", "exfoliative", "rash", "may", "be", "induced", "by", "temozolomide", ",", "and", "be", "familiar", "with", "the", "pharmacologic", "and", "supportive", "measures", "necessary", "for", "its", "treatment", "."], "event_mentions": [{"id": "18294121_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "18294121_2_Ent0", "role": "Effect", "text": "an erythematous and exfoliative rash", "start": 5, "end": 10}, {"entity_id": "18294121_2_Ent1", "role": "Treatment", "text": "temozolomide", "start": 14, "end": 15}, {"entity_id": "18294121_2_Ent2", "role": "Treatment_Drug", "text": "temozolomide", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "18294121_2_Ent0", "text": "an erythematous and exfoliative rash", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "18294121_2_Ent1", "text": "temozolomide", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18294121_2_Ent2", "text": "temozolomide", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "18315788_1", "wnd_id": "18315788_1_1", "text": "Phenytoin toxicity : an easily missed cause of cerebellar syndrome .", "tokens": ["Phenytoin", "toxicity", ":", "an", "easily", "missed", "cause", "of", "cerebellar", "syndrome", "."], "event_mentions": [{"id": "18315788_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 6, "end": 7}, "arguments": [{"entity_id": "18315788_1_Ent1", "role": "Treatment", "text": "Phenytoin", "start": 0, "end": 1}, {"entity_id": "18315788_1_Ent2", "role": "Treatment_Drug", "text": "Phenytoin", "start": 0, "end": 1}, {"entity_id": "18315788_1_Ent0", "role": "Effect", "text": "cerebellar syndrome", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "18315788_1_Ent1", "text": "Phenytoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18315788_1_Ent2", "text": "Phenytoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18315788_1_Ent0", "text": "cerebellar syndrome", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "18343993_1", "wnd_id": "18343993_1_1", "text": "A diagnosis of trastuzumab - induced pneumonitis was made .", "tokens": ["A", "diagnosis", "of", "trastuzumab", "-", "induced", "pneumonitis", "was", "made", "."], "event_mentions": [{"id": "18343993_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "18343993_1_Ent1", "role": "Treatment", "text": "trastuzumab", "start": 3, "end": 4}, {"entity_id": "18343993_1_Ent2", "role": "Treatment_Drug", "text": "trastuzumab", "start": 3, "end": 4}, {"entity_id": "18343993_1_Ent0", "role": "Effect", "text": "pneumonitis", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "18343993_1_Ent1", "text": "trastuzumab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18343993_1_Ent2", "text": "trastuzumab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18343993_1_Ent0", "text": "pneumonitis", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "18343993_3", "wnd_id": "18343993_3_1", "text": "Life - threatening interstitial lung disease associated with trastuzumab : case report .", "tokens": ["Life", "-", "threatening", "interstitial", "lung", "disease", "associated", "with", "trastuzumab", ":", "case", "report", "."], "event_mentions": [{"id": "18343993_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "18343993_3_Ent1", "role": "Effect", "text": "Life - threatening interstitial lung disease", "start": 0, "end": 6}, {"entity_id": "18343993_3_Ent2", "role": "Treatment", "text": "trastuzumab", "start": 8, "end": 9}, {"entity_id": "18343993_3_Ent3", "role": "Treatment_Drug", "text": "trastuzumab", "start": 8, "end": 9}, {"entity_id": "18343993_3_Ent0", "role": "Subject", "text": "case", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "18343993_3_Ent1", "text": "Life - threatening interstitial lung disease", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "18343993_3_Ent2", "text": "trastuzumab", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18343993_3_Ent3", "text": "trastuzumab", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18343993_3_Ent0", "text": "case", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "1834424_2", "wnd_id": "1834424_2_1", "text": "Allergic contact dermatitis from 4 - chloro - 7 - nitrobenzofurazan .", "tokens": ["Allergic", "contact", "dermatitis", "from", "4", "-", "chloro", "-", "7", "-", "nitrobenzofurazan", "."], "event_mentions": [{"id": "1834424_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 3, "end": 4}, "arguments": [{"entity_id": "1834424_2_Ent0", "role": "Effect", "text": "Allergic contact dermatitis", "start": 0, "end": 3}, {"entity_id": "1834424_2_Ent1", "role": "Treatment", "text": "4 - chloro - 7 - nitrobenzofurazan", "start": 4, "end": 11}, {"entity_id": "1834424_2_Ent2", "role": "Treatment_Drug", "text": "4 - chloro - 7 - nitrobenzofurazan", "start": 4, "end": 11}]}], "entity_mentions": [{"id": "1834424_2_Ent0", "text": "Allergic contact dermatitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "1834424_2_Ent1", "text": "4 - chloro - 7 - nitrobenzofurazan", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "1834424_2_Ent2", "text": "4 - chloro - 7 - nitrobenzofurazan", "entity_type": "Entity", "start": 4, "end": 11}], "lang": "en"}
{"doc_id": "18347524_1", "wnd_id": "18347524_1_1", "text": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis .", "tokens": ["Diffuse", "alveolar", "hemorrhage", "after", "leflunomide", "therapy", "in", "a", "patient", "with", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "18347524_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "18347524_1_Ent1", "role": "Effect", "text": "Diffuse alveolar hemorrhage", "start": 0, "end": 3}, {"entity_id": "18347524_1_Ent2", "role": "Treatment", "text": "leflunomide", "start": 4, "end": 5}, {"entity_id": "18347524_1_Ent4", "role": "Treatment_Drug", "text": "leflunomide", "start": 4, "end": 5}, {"entity_id": "18347524_1_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 7, "end": 12}, {"entity_id": "18347524_1_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "18347524_1_Ent1", "text": "Diffuse alveolar hemorrhage", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18347524_1_Ent2", "text": "leflunomide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18347524_1_Ent4", "text": "leflunomide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18347524_1_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18347524_1_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "18362995_3", "wnd_id": "18362995_3_1", "text": "Up to four percent of patients treated with imatinib may develop hepatotoxicity , which usually resolves with discontinuation of the drug .", "tokens": ["Up", "to", "four", "percent", "of", "patients", "treated", "with", "imatinib", "may", "develop", "hepatotoxicity", ",", "which", "usually", "resolves", "with", "discontinuation", "of", "the", "drug", "."], "event_mentions": [{"id": "18362995_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 10, "end": 11}, "arguments": [{"entity_id": "18362995_3_Ent1", "role": "Subject_Population", "text": "Up to four percent", "start": 0, "end": 4}, {"entity_id": "18362995_3_Ent0", "role": "Subject", "text": "Up to four percent of patients", "start": 0, "end": 6}, {"entity_id": "18362995_3_Ent3", "role": "Treatment", "text": "imatinib", "start": 8, "end": 9}, {"entity_id": "18362995_3_Ent4", "role": "Treatment_Drug", "text": "imatinib", "start": 8, "end": 9}, {"entity_id": "18362995_3_Ent2", "role": "Effect", "text": "hepatotoxicity", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "18362995_3_Ent1", "text": "Up to four percent", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "18362995_3_Ent0", "text": "Up to four percent of patients", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "18362995_3_Ent3", "text": "imatinib", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18362995_3_Ent4", "text": "imatinib", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18362995_3_Ent2", "text": "hepatotoxicity", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "18364401_2", "wnd_id": "18364401_2_1", "text": "OBJECTIVE : To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "rapidly", "occurring", "hyperglycemia", "that", "occurred", "in", "a", "geriatric", "patient", "3", "days", "after", "treatment", "with", "olanzapine", "."], "event_mentions": [{"id": "18364401_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 8, "end": 9}, "arguments": [{"entity_id": "18364401_2_Ent2", "role": "Effect", "text": "hyperglycemia", "start": 9, "end": 10}, {"entity_id": "18364401_2_Ent0", "role": "Subject", "text": "a geriatric patient", "start": 13, "end": 16}, {"entity_id": "18364401_2_Ent1", "role": "Subject_Age", "text": "geriatric", "start": 14, "end": 15}, {"entity_id": "18364401_2_Ent5", "role": "Treatment_Time_elapsed", "text": "3 days", "start": 16, "end": 18}, {"entity_id": "18364401_2_Ent3", "role": "Treatment", "text": "olanzapine", "start": 21, "end": 22}, {"entity_id": "18364401_2_Ent4", "role": "Treatment_Drug", "text": "olanzapine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "18364401_2_Ent2", "text": "hyperglycemia", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18364401_2_Ent0", "text": "a geriatric patient", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "18364401_2_Ent1", "text": "geriatric", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18364401_2_Ent5", "text": "3 days", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "18364401_2_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "18364401_2_Ent4", "text": "olanzapine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "18396749_4", "wnd_id": "18396749_4_1", "text": "In the absence of evidence of a potential role for concomitant medication i.e. hydroxychloroquine sulfate to play a role in the clinical , biochemical and morphological picture , an interaction between the herbal preparation and tibolone was suspected as the likely cause of liver damage .", "tokens": ["In", "the", "absence", "of", "evidence", "of", "a", "potential", "role", "for", "concomitant", "medication", "i.e.", "hydroxychloroquine", "sulfate", "to", "play", "a", "role", "in", "the", "clinical", ",", "biochemical", "and", "morphological", "picture", ",", "an", "interaction", "between", "the", "herbal", "preparation", "and", "tibolone", "was", "suspected", "as", "the", "likely", "cause", "of", "liver", "damage", "."], "event_mentions": [{"id": "18396749_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suspected", "start": 37, "end": 38}, "arguments": [{"entity_id": "18396749_4_Ent1", "role": "Treatment", "text": "an interaction between the herbal preparation and tibolone", "start": 28, "end": 36}, {"entity_id": "18396749_4_Ent2", "role": "Treatment_Drug", "text": "herbal preparation", "start": 32, "end": 34}, {"entity_id": "18396749_4_Ent4", "role": "Combination_Drug", "text": "herbal preparation", "start": 32, "end": 34}, {"entity_id": "18396749_4_Ent3", "role": "Treatment_Drug", "text": "tibolone", "start": 35, "end": 36}, {"entity_id": "18396749_4_Ent5", "role": "Combination_Drug", "text": "tibolone", "start": 35, "end": 36}, {"entity_id": "18396749_4_Ent0", "role": "Effect", "text": "liver damage", "start": 43, "end": 45}]}], "entity_mentions": [{"id": "18396749_4_Ent1", "text": "an interaction between the herbal preparation and tibolone", "entity_type": "Entity", "start": 28, "end": 36}, {"id": "18396749_4_Ent2", "text": "herbal preparation", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "18396749_4_Ent4", "text": "herbal preparation", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "18396749_4_Ent3", "text": "tibolone", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "18396749_4_Ent5", "text": "tibolone", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "18396749_4_Ent0", "text": "liver damage", "entity_type": "Entity", "start": 43, "end": 45}], "lang": "en"}
{"doc_id": "18425523_1", "wnd_id": "18425523_1_1", "text": "BACKGROUND : To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally .", "tokens": ["BACKGROUND", ":", "To", "describe", "the", "occurrence", "of", "ocular", "hypertension", "in", "four", "patients", "following", "injection", "of", "ranibizumab", "intravitreally", "."], "event_mentions": [{"id": "18425523_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurrence", "start": 5, "end": 6}, "arguments": [{"entity_id": "18425523_1_Ent2", "role": "Effect", "text": "ocular hypertension", "start": 7, "end": 9}, {"entity_id": "18425523_1_Ent1", "role": "Subject_Population", "text": "four", "start": 10, "end": 11}, {"entity_id": "18425523_1_Ent0", "role": "Subject", "text": "four patients", "start": 10, "end": 12}, {"entity_id": "18425523_1_Ent3", "role": "Treatment", "text": "ranibizumab", "start": 15, "end": 16}, {"entity_id": "18425523_1_Ent4", "role": "Treatment_Drug", "text": "ranibizumab", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "18425523_1_Ent2", "text": "ocular hypertension", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "18425523_1_Ent1", "text": "four", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18425523_1_Ent0", "text": "four patients", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "18425523_1_Ent3", "text": "ranibizumab", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18425523_1_Ent4", "text": "ranibizumab", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "18446030_2", "wnd_id": "18446030_2_1", "text": "We report a 45 - year - old psoriasis patient who developed eruptive mollusca contagiosa during an antipsoriatic treatment with efalizumab .", "tokens": ["We", "report", "a", "45", "-", "year", "-", "old", "psoriasis", "patient", "who", "developed", "eruptive", "mollusca", "contagiosa", "during", "an", "antipsoriatic", "treatment", "with", "efalizumab", "."], "event_mentions": [{"id": "18446030_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "18446030_2_Ent1", "role": "Subject_Age", "text": "45 - year - old", "start": 3, "end": 8}, {"entity_id": "18446030_2_Ent0", "role": "Subject", "text": "45 - year - old psoriasis patient", "start": 3, "end": 10}, {"entity_id": "18446030_2_Ent4", "role": "Treatment_Disorder", "text": "psoriasis", "start": 8, "end": 9}, {"entity_id": "18446030_2_Ent2", "role": "Effect", "text": "eruptive mollusca contagiosa", "start": 12, "end": 15}, {"entity_id": "18446030_2_Ent3", "role": "Treatment", "text": "antipsoriatic treatment with efalizumab", "start": 17, "end": 21}, {"entity_id": "18446030_2_Ent5", "role": "Treatment_Drug", "text": "efalizumab", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "18446030_2_Ent1", "text": "45 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "18446030_2_Ent0", "text": "45 - year - old psoriasis patient", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "18446030_2_Ent4", "text": "psoriasis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18446030_2_Ent2", "text": "eruptive mollusca contagiosa", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "18446030_2_Ent3", "text": "antipsoriatic treatment with efalizumab", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "18446030_2_Ent5", "text": "efalizumab", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "18465737_2", "wnd_id": "18465737_2_1", "text": "The authors report one case of incomplete posterior hyaloid detachment ( PHD ) following intravitreal pegaptanib to treat DME .", "tokens": ["The", "authors", "report", "one", "case", "of", "incomplete", "posterior", "hyaloid", "detachment", "(", "PHD", ")", "following", "intravitreal", "pegaptanib", "to", "treat", "DME", "."], "event_mentions": [{"id": "18465737_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 13, "end": 14}, "arguments": [{"entity_id": "18465737_2_Ent0", "role": "Subject", "text": "one case", "start": 3, "end": 5}, {"entity_id": "18465737_2_Ent1", "role": "Effect", "text": "incomplete posterior hyaloid detachment ( PHD )", "start": 6, "end": 13}, {"entity_id": "18465737_2_Ent3", "role": "Treatment_Route", "text": "intravitreal", "start": 14, "end": 15}, {"entity_id": "18465737_2_Ent2", "role": "Treatment", "text": "intravitreal pegaptanib", "start": 14, "end": 16}, {"entity_id": "18465737_2_Ent4", "role": "Treatment_Drug", "text": "pegaptanib", "start": 15, "end": 16}, {"entity_id": "18465737_2_Ent5", "role": "Treatment_Disorder", "text": "DME", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "18465737_2_Ent0", "text": "one case", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "18465737_2_Ent1", "text": "incomplete posterior hyaloid detachment ( PHD )", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "18465737_2_Ent3", "text": "intravitreal", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18465737_2_Ent2", "text": "intravitreal pegaptanib", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "18465737_2_Ent4", "text": "pegaptanib", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18465737_2_Ent5", "text": "DME", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "18487000_2", "wnd_id": "18487000_2_1", "text": "The known side effects of sibutramine , ie , hypertension and tachycardia , depend on its adrenergic and serotoninergic effects .", "tokens": ["The", "known", "side", "effects", "of", "sibutramine", ",", "ie", ",", "hypertension", "and", "tachycardia", ",", "depend", "on", "its", "adrenergic", "and", "serotoninergic", "effects", "."], "event_mentions": [{"id": "18487000_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 4, "end": 5}, "arguments": [{"entity_id": "18487000_2_Ent1", "role": "Treatment", "text": "sibutramine", "start": 5, "end": 6}, {"entity_id": "18487000_2_Ent2", "role": "Treatment_Dosage", "text": "sibutramine", "start": 5, "end": 6}, {"entity_id": "18487000_2_Ent0", "role": "Effect", "text": "hypertension and tachycardia", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "18487000_2_Ent1", "text": "sibutramine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18487000_2_Ent2", "text": "sibutramine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18487000_2_Ent0", "text": "hypertension and tachycardia", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "1849334_2", "wnd_id": "1849334_2_1", "text": "We report on 7 patients ( 2 women , 5 men ) with chronic renal failure , who developed under a high dosage of the new diuretic muzolimine ( range 240 to 1440 mg per day ) fatal neuromyeloencephalopathy .", "tokens": ["We", "report", "on", "7", "patients", "(", "2", "women", ",", "5", "men", ")", "with", "chronic", "renal", "failure", ",", "who", "developed", "under", "a", "high", "dosage", "of", "the", "new", "diuretic", "muzolimine", "(", "range", "240", "to", "1440", "mg", "per", "day", ")", "fatal", "neuromyeloencephalopathy", "."], "event_mentions": [{"id": "1849334_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "1849334_2_Ent2", "role": "Subject_Population", "text": "7", "start": 3, "end": 4}, {"entity_id": "1849334_2_Ent0", "role": "Subject", "text": "7 patients ( 2 women , 5 men ) with chronic renal failure", "start": 3, "end": 16}, {"entity_id": "1849334_2_Ent1", "role": "Subject_Disorder", "text": "chronic renal failure", "start": 13, "end": 16}, {"entity_id": "1849334_2_Ent4", "role": "Treatment", "text": "a high dosage of the new diuretic muzolimine ( range 240 to 1440 mg per day )", "start": 20, "end": 37}, {"entity_id": "1849334_2_Ent5", "role": "Treatment_Drug", "text": "diuretic muzolimine", "start": 26, "end": 28}, {"entity_id": "1849334_2_Ent7", "role": "Treatment_Dosage", "text": "range 240 to 1440 mg", "start": 29, "end": 34}, {"entity_id": "1849334_2_Ent6", "role": "Treatment_Freq", "text": "per day", "start": 34, "end": 36}, {"entity_id": "1849334_2_Ent3", "role": "Effect", "text": "fatal neuromyeloencephalopathy", "start": 37, "end": 39}]}], "entity_mentions": [{"id": "1849334_2_Ent2", "text": "7", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1849334_2_Ent0", "text": "7 patients ( 2 women , 5 men ) with chronic renal failure", "entity_type": "Entity", "start": 3, "end": 16}, {"id": "1849334_2_Ent1", "text": "chronic renal failure", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "1849334_2_Ent4", "text": "a high dosage of the new diuretic muzolimine ( range 240 to 1440 mg per day )", "entity_type": "Entity", "start": 20, "end": 37}, {"id": "1849334_2_Ent5", "text": "diuretic muzolimine", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "1849334_2_Ent7", "text": "range 240 to 1440 mg", "entity_type": "Entity", "start": 29, "end": 34}, {"id": "1849334_2_Ent6", "text": "per day", "entity_type": "Entity", "start": 34, "end": 36}, {"id": "1849334_2_Ent3", "text": "fatal neuromyeloencephalopathy", "entity_type": "Entity", "start": 37, "end": 39}], "lang": "en"}
{"doc_id": "18505911_1", "wnd_id": "18505911_1_1", "text": "Azathioprine - induced warfarin resistance .", "tokens": ["Azathioprine", "-", "induced", "warfarin", "resistance", "."], "event_mentions": [{"id": "18505911_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18505911_1_Ent1", "role": "Treatment", "text": "Azathioprine", "start": 0, "end": 1}, {"entity_id": "18505911_1_Ent2", "role": "Treatment_Drug", "text": "Azathioprine", "start": 0, "end": 1}, {"entity_id": "18505911_1_Ent0", "role": "Effect", "text": "warfarin resistance .", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "18505911_1_Ent1", "text": "Azathioprine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18505911_1_Ent2", "text": "Azathioprine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18505911_1_Ent0", "text": "warfarin resistance .", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "18505911_9", "wnd_id": "18505911_9_1", "text": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale , and a possible causative agent according to the Drug Interaction Probability Scale .", "tokens": ["Azathioprine", "was", "the", "probable", "causative", "agent", "of", "warfarin", "resistance", "according", "to", "the", "Naranjo", "probability", "scale", ",", "and", "a", "possible", "causative", "agent", "according", "to", "the", "Drug", "Interaction", "Probability", "Scale", "."], "event_mentions": [{"id": "18505911_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causative agent", "start": 4, "end": 6}, "arguments": [{"entity_id": "18505911_9_Ent1", "role": "Treatment", "text": "Azathioprine", "start": 0, "end": 1}, {"entity_id": "18505911_9_Ent2", "role": "Treatment_Drug", "text": "Azathioprine", "start": 0, "end": 1}, {"entity_id": "18505911_9_Ent0", "role": "Effect", "text": "warfarin resistance", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "18505911_9_Ent1", "text": "Azathioprine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18505911_9_Ent2", "text": "Azathioprine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18505911_9_Ent0", "text": "warfarin resistance", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "18515982_3", "wnd_id": "18515982_3_1", "text": "Diagnosis of sclerosing glomerulonephritis occurred in this patient during anastrozole use , suggesting a newly defined side effect of anastrozole .", "tokens": ["Diagnosis", "of", "sclerosing", "glomerulonephritis", "occurred", "in", "this", "patient", "during", "anastrozole", "use", ",", "suggesting", "a", "newly", "defined", "side", "effect", "of", "anastrozole", "."], "event_mentions": [{"id": "18515982_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 8, "end": 9}, "arguments": [{"entity_id": "18515982_3_Ent1", "role": "Effect", "text": "sclerosing glomerulonephritis", "start": 2, "end": 4}, {"entity_id": "18515982_3_Ent0", "role": "Subject", "text": "patient", "start": 7, "end": 8}, {"entity_id": "18515982_3_Ent2", "role": "Treatment", "text": "anastrozole", "start": 9, "end": 10}, {"entity_id": "18515982_3_Ent3", "role": "Treatment_Drug", "text": "anastrozole", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "18515982_3_Ent1", "text": "sclerosing glomerulonephritis", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "18515982_3_Ent0", "text": "patient", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18515982_3_Ent2", "text": "anastrozole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18515982_3_Ent3", "text": "anastrozole", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "18523232_5", "wnd_id": "18523232_5_1", "text": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously .", "tokens": ["Only", "one", "case", "of", "severe", "symptomatic", "hepatitis", "occurring", "after", "pulse", "therapy", "with", "itraconazole", "for", "onychomycosis", "and", "requiring", "transplantation", "has", "been", "reported", "previously", "."], "event_mentions": [{"id": "18523232_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 7, "end": 8}, "arguments": [{"entity_id": "18523232_5_Ent1", "role": "Subject_Population", "text": "one", "start": 1, "end": 2}, {"entity_id": "18523232_5_Ent0", "role": "Subject", "text": "one case", "start": 1, "end": 3}, {"entity_id": "18523232_5_Ent2", "role": "Effect", "text": "severe symptomatic hepatitis", "start": 4, "end": 7}, {"entity_id": "18523232_5_Ent3", "role": "Treatment", "text": "pulse therapy with itraconazole", "start": 9, "end": 13}, {"entity_id": "18523232_5_Ent5", "role": "Treatment_Drug", "text": "itraconazole", "start": 12, "end": 13}, {"entity_id": "18523232_5_Ent4", "role": "Treatment_Disorder", "text": "onychomycosis", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "18523232_5_Ent1", "text": "one", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18523232_5_Ent0", "text": "one case", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "18523232_5_Ent2", "text": "severe symptomatic hepatitis", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "18523232_5_Ent3", "text": "pulse therapy with itraconazole", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "18523232_5_Ent5", "text": "itraconazole", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18523232_5_Ent4", "text": "onychomycosis", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "18533420_2", "wnd_id": "18533420_2_1", "text": "RESULTS : A male and a female patient with spasticity treated with intrathecal baclofen were recognized to have sexual dysfunction side effects from treatment .", "tokens": ["RESULTS", ":", "A", "male", "and", "a", "female", "patient", "with", "spasticity", "treated", "with", "intrathecal", "baclofen", "were", "recognized", "to", "have", "sexual", "dysfunction", "side", "effects", "from", "treatment", "."], "event_mentions": [{"id": "18533420_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 10, "end": 11}, "arguments": [{"entity_id": "18533420_2_Ent0", "role": "Subject", "text": "A male and a female patient with spasticity", "start": 2, "end": 10}, {"entity_id": "18533420_2_Ent1", "role": "Subject_Gender", "text": "male", "start": 3, "end": 4}, {"entity_id": "18533420_2_Ent2", "role": "Subject_Gender", "text": "female", "start": 6, "end": 7}, {"entity_id": "18533420_2_Ent5", "role": "Treatment_Disorder", "text": "spasticity", "start": 9, "end": 10}, {"entity_id": "18533420_2_Ent7", "role": "Treatment_Route", "text": "intrathecal", "start": 12, "end": 13}, {"entity_id": "18533420_2_Ent4", "role": "Treatment", "text": "intrathecal baclofen", "start": 12, "end": 14}, {"entity_id": "18533420_2_Ent6", "role": "Treatment_Drug", "text": "baclofen", "start": 13, "end": 14}, {"entity_id": "18533420_2_Ent3", "role": "Effect", "text": "sexual dysfunction", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "18533420_2_Ent0", "text": "A male and a female patient with spasticity", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "18533420_2_Ent1", "text": "male", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18533420_2_Ent2", "text": "female", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18533420_2_Ent5", "text": "spasticity", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18533420_2_Ent7", "text": "intrathecal", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18533420_2_Ent4", "text": "intrathecal baclofen", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "18533420_2_Ent6", "text": "baclofen", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18533420_2_Ent3", "text": "sexual dysfunction", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "18562412_6", "wnd_id": "18562412_6_1", "text": "The third patient had been suffering from serious akathisia while on risperidone , and was cured after switching to olanzapine , but thereafter the patient suffered from RLS at nighttime .", "tokens": ["The", "third", "patient", "had", "been", "suffering", "from", "serious", "akathisia", "while", "on", "risperidone", ",", "and", "was", "cured", "after", "switching", "to", "olanzapine", ",", "but", "thereafter", "the", "patient", "suffered", "from", "RLS", "at", "nighttime", "."], "event_mentions": [{"id": "18562412_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffering", "start": 5, "end": 6}, "arguments": [{"entity_id": "18562412_6_Ent0", "role": "Subject", "text": "The third patient", "start": 0, "end": 3}, {"entity_id": "18562412_6_Ent1", "role": "Effect", "text": "akathisia", "start": 8, "end": 9}, {"entity_id": "18562412_6_Ent2", "role": "Treatment", "text": "risperidone", "start": 11, "end": 12}, {"entity_id": "18562412_6_Ent3", "role": "Treatment_Drug", "text": "risperidone", "start": 11, "end": 12}]}, {"id": "18562412_6_Evt1", "event_type": "Adverse_event", "trigger": {"text": "suffered", "start": 25, "end": 26}, "arguments": [{"entity_id": "18562412_6_Ent4", "role": "Subject", "text": "The third patient", "start": 0, "end": 3}, {"entity_id": "18562412_6_Ent7", "role": "Treatment_Disorder", "text": "akathisia", "start": 8, "end": 9}, {"entity_id": "18562412_6_Ent6", "role": "Treatment", "text": "switching to olanzapine", "start": 17, "end": 20}, {"entity_id": "18562412_6_Ent8", "role": "Treatment_Drug", "text": "olanzapine", "start": 19, "end": 20}, {"entity_id": "18562412_6_Ent5", "role": "Effect", "text": "RLS at nighttime", "start": 27, "end": 30}]}], "entity_mentions": [{"id": "18562412_6_Ent0", "text": "The third patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18562412_6_Ent4", "text": "The third patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18562412_6_Ent1", "text": "akathisia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18562412_6_Ent7", "text": "akathisia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18562412_6_Ent2", "text": "risperidone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18562412_6_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18562412_6_Ent6", "text": "switching to olanzapine", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "18562412_6_Ent8", "text": "olanzapine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "18562412_6_Ent5", "text": "RLS at nighttime", "entity_type": "Entity", "start": 27, "end": 30}], "lang": "en"}
{"doc_id": "18585545_5", "wnd_id": "18585545_5_1", "text": "RESULTS : A previously healthy 42 - year - old woman presented with acute - onset delirium with psychotic features as a consequence of levofloxacin therapy .", "tokens": ["RESULTS", ":", "A", "previously", "healthy", "42", "-", "year", "-", "old", "woman", "presented", "with", "acute", "-", "onset", "delirium", "with", "psychotic", "features", "as", "a", "consequence", "of", "levofloxacin", "therapy", "."], "event_mentions": [{"id": "18585545_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "as a consequence of", "start": 20, "end": 24}, "arguments": [{"entity_id": "18585545_5_Ent0", "role": "Subject", "text": "A previously healthy 42 - year - old woman", "start": 2, "end": 11}, {"entity_id": "18585545_5_Ent1", "role": "Subject_Age", "text": "42 - year - old", "start": 5, "end": 10}, {"entity_id": "18585545_5_Ent2", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "18585545_5_Ent3", "role": "Effect", "text": "acute - onset delirium with psychotic features", "start": 13, "end": 20}, {"entity_id": "18585545_5_Ent5", "role": "Treatment_Drug", "text": "levofloxacin", "start": 24, "end": 25}, {"entity_id": "18585545_5_Ent4", "role": "Treatment", "text": "levofloxacin therapy", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "18585545_5_Ent0", "text": "A previously healthy 42 - year - old woman", "entity_type": "Entity", "start": 2, "end": 11}, {"id": "18585545_5_Ent1", "text": "42 - year - old", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "18585545_5_Ent2", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18585545_5_Ent3", "text": "acute - onset delirium with psychotic features", "entity_type": "Entity", "start": 13, "end": 20}, {"id": "18585545_5_Ent5", "text": "levofloxacin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "18585545_5_Ent4", "text": "levofloxacin therapy", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "18607107_1", "wnd_id": "18607107_1_1", "text": "CONCLUSIONS : Clinicians should be aware that Crohn 's disease is a potential novel adverse drug effect of Copaxone .", "tokens": ["CONCLUSIONS", ":", "Clinicians", "should", "be", "aware", "that", "Crohn", "'s", "disease", "is", "a", "potential", "novel", "adverse", "drug", "effect", "of", "Copaxone", "."], "event_mentions": [{"id": "18607107_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "effect", "start": 16, "end": 17}, "arguments": [{"entity_id": "18607107_1_Ent0", "role": "Effect", "text": "Crohn 's disease", "start": 7, "end": 10}, {"entity_id": "18607107_1_Ent1", "role": "Treatment", "text": "Copaxone", "start": 18, "end": 19}, {"entity_id": "18607107_1_Ent2", "role": "Treatment_Drug", "text": "Copaxone", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "18607107_1_Ent0", "text": "Crohn 's disease", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "18607107_1_Ent1", "text": "Copaxone", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "18607107_1_Ent2", "text": "Copaxone", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "18607107_3", "wnd_id": "18607107_3_1", "text": "RESULTS : Our patient developed Crohn 's disease while on Copaxone treatment as a consequence of long - term immunosuppression .", "tokens": ["RESULTS", ":", "Our", "patient", "developed", "Crohn", "'s", "disease", "while", "on", "Copaxone", "treatment", "as", "a", "consequence", "of", "long", "-", "term", "immunosuppression", "."], "event_mentions": [{"id": "18607107_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 4, "end": 5}, "arguments": [{"entity_id": "18607107_3_Ent0", "role": "Subject", "text": "patient", "start": 3, "end": 4}, {"entity_id": "18607107_3_Ent1", "role": "Effect", "text": "Crohn 's disease", "start": 5, "end": 8}, {"entity_id": "18607107_3_Ent3", "role": "Treatment", "text": "Copaxone", "start": 10, "end": 11}, {"entity_id": "18607107_3_Ent4", "role": "Treatment_Drug", "text": "Copaxone", "start": 10, "end": 11}, {"entity_id": "18607107_3_Ent2", "role": "Effect", "text": "long - term immunosuppression", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "18607107_3_Ent0", "text": "patient", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18607107_3_Ent1", "text": "Crohn 's disease", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "18607107_3_Ent3", "text": "Copaxone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18607107_3_Ent4", "text": "Copaxone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18607107_3_Ent2", "text": "long - term immunosuppression", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "1860779_1", "wnd_id": "1860779_1_1", "text": "The authors present a case study of a mentally healthy man who repeatedly experienced short - lived , obsessional - like suicidal ideas and images after ingestion of the anti - fungal drug ketoconazole .", "tokens": ["The", "authors", "present", "a", "case", "study", "of", "a", "mentally", "healthy", "man", "who", "repeatedly", "experienced", "short", "-", "lived", ",", "obsessional", "-", "like", "suicidal", "ideas", "and", "images", "after", "ingestion", "of", "the", "anti", "-", "fungal", "drug", "ketoconazole", "."], "event_mentions": [{"id": "1860779_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 13, "end": 14}, "arguments": [{"entity_id": "1860779_1_Ent0", "role": "Subject", "text": "a mentally healthy man", "start": 7, "end": 11}, {"entity_id": "1860779_1_Ent1", "role": "Subject_Gender", "text": "man", "start": 10, "end": 11}, {"entity_id": "1860779_1_Ent2", "role": "Effect", "text": "short - lived , obsessional - like suicidal ideas and images", "start": 14, "end": 25}, {"entity_id": "1860779_1_Ent4", "role": "Treatment_Route", "text": "ingestion", "start": 26, "end": 27}, {"entity_id": "1860779_1_Ent3", "role": "Treatment", "text": "ingestion of the anti - fungal drug ketoconazole", "start": 26, "end": 34}, {"entity_id": "1860779_1_Ent5", "role": "Treatment_Drug", "text": "ketoconazole", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "1860779_1_Ent0", "text": "a mentally healthy man", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "1860779_1_Ent1", "text": "man", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1860779_1_Ent2", "text": "short - lived , obsessional - like suicidal ideas and images", "entity_type": "Entity", "start": 14, "end": 25}, {"id": "1860779_1_Ent4", "text": "ingestion", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "1860779_1_Ent3", "text": "ingestion of the anti - fungal drug ketoconazole", "entity_type": "Entity", "start": 26, "end": 34}, {"id": "1860779_1_Ent5", "text": "ketoconazole", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "18622319_3", "wnd_id": "18622319_3_1", "text": "This case describes a 52 - year - old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug , bevacizumab , for metastatic ovarian cancer treatment .", "tokens": ["This", "case", "describes", "a", "52", "-", "year", "-", "old", "white", "woman", "who", "developed", "a", "spontaneous", "nasal", "septal", "perforation", "after", "given", "the", "antiangiogenic", "drug", ",", "bevacizumab", ",", "for", "metastatic", "ovarian", "cancer", "treatment", "."], "event_mentions": [{"id": "18622319_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "18622319_3_Ent0", "role": "Subject", "text": "a 52 - year - old white woman", "start": 3, "end": 11}, {"entity_id": "18622319_3_Ent1", "role": "Subject_Age", "text": "52 - year - old", "start": 4, "end": 9}, {"entity_id": "18622319_3_Ent2", "role": "Subject_Race", "text": "white", "start": 9, "end": 10}, {"entity_id": "18622319_3_Ent3", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "18622319_3_Ent4", "role": "Effect", "text": "a spontaneous nasal septal perforation", "start": 13, "end": 18}, {"entity_id": "18622319_3_Ent5", "role": "Treatment", "text": "antiangiogenic drug , bevacizumab", "start": 21, "end": 25}, {"entity_id": "18622319_3_Ent6", "role": "Treatment_Drug", "text": "bevacizumab", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "18622319_3_Ent0", "text": "a 52 - year - old white woman", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "18622319_3_Ent1", "text": "52 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "18622319_3_Ent2", "text": "white", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18622319_3_Ent3", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18622319_3_Ent4", "text": "a spontaneous nasal septal perforation", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "18622319_3_Ent5", "text": "antiangiogenic drug , bevacizumab", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "18622319_3_Ent6", "text": "bevacizumab", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "18622319_4", "wnd_id": "18622319_4_1", "text": "Bevacizumab is a recently developed monoclonal antibody against vascular endothelial growth factor receptor used to inhibit angiogenesis .", "tokens": ["Bevacizumab", "is", "a", "recently", "developed", "monoclonal", "antibody", "against", "vascular", "endothelial", "growth", "factor", "receptor", "used", "to", "inhibit", "angiogenesis", "."], "event_mentions": [{"id": "18622319_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "inhibit", "start": 15, "end": 16}, "arguments": [{"entity_id": "18622319_4_Ent2", "role": "Treatment_Drug", "text": "Bevacizumab", "start": 0, "end": 1}, {"entity_id": "18622319_4_Ent0", "role": "Treatment", "text": "Bevacizumab is a recently developed monoclonal antibody", "start": 0, "end": 7}, {"entity_id": "18622319_4_Ent1", "role": "Treatment_Disorder", "text": "angiogenesis", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "18622319_4_Ent2", "text": "Bevacizumab", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18622319_4_Ent0", "text": "Bevacizumab is a recently developed monoclonal antibody", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "18622319_4_Ent1", "text": "angiogenesis", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "18676387_4", "wnd_id": "18676387_4_1", "text": "A 60 - yr - old woman , established on paroxetine for depression , underwent excision of a chest wall myxofibrosarcoma and chest wall reconstruction .", "tokens": ["A", "60", "-", "yr", "-", "old", "woman", ",", "established", "on", "paroxetine", "for", "depression", ",", "underwent", "excision", "of", "a", "chest", "wall", "myxofibrosarcoma", "and", "chest", "wall", "reconstruction", "."], "event_mentions": [{"id": "18676387_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "established", "start": 8, "end": 9}, "arguments": [{"entity_id": "18676387_4_Ent0", "role": "Subject", "text": "A 60 - yr - old woman", "start": 0, "end": 7}, {"entity_id": "18676387_4_Ent2", "role": "Subject_Age", "text": "60 - yr - old", "start": 1, "end": 6}, {"entity_id": "18676387_4_Ent3", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "18676387_4_Ent4", "role": "Treatment", "text": "paroxetine", "start": 10, "end": 11}, {"entity_id": "18676387_4_Ent6", "role": "Treatment_Drug", "text": "paroxetine", "start": 10, "end": 11}, {"entity_id": "18676387_4_Ent1", "role": "Subject", "text": "depression", "start": 12, "end": 13}, {"entity_id": "18676387_4_Ent7", "role": "Treatment_Disorder", "text": "depression", "start": 12, "end": 13}, {"entity_id": "18676387_4_Ent5", "role": "Treatment", "text": "underwent excision of a chest wall myxofibrosarcoma and chest wall reconstruction", "start": 14, "end": 25}, {"entity_id": "18676387_4_Ent8", "role": "Treatment_Disorder", "text": "myxofibrosarcoma", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "18676387_4_Ent0", "text": "A 60 - yr - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "18676387_4_Ent2", "text": "60 - yr - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "18676387_4_Ent3", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18676387_4_Ent4", "text": "paroxetine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18676387_4_Ent6", "text": "paroxetine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18676387_4_Ent1", "text": "depression", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18676387_4_Ent7", "text": "depression", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18676387_4_Ent5", "text": "underwent excision of a chest wall myxofibrosarcoma and chest wall reconstruction", "entity_type": "Entity", "start": 14, "end": 25}, {"id": "18676387_4_Ent8", "text": "myxofibrosarcoma", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "18682542_1", "wnd_id": "18682542_1_1", "text": "CONCLUSIONS : Clinicians should be aware of this adverse reaction when facing similar complex neurologic symptoms in patients who are receiving the antibiotic treatment described here , especially vancomycin .", "tokens": ["CONCLUSIONS", ":", "Clinicians", "should", "be", "aware", "of", "this", "adverse", "reaction", "when", "facing", "similar", "complex", "neurologic", "symptoms", "in", "patients", "who", "are", "receiving", "the", "antibiotic", "treatment", "described", "here", ",", "especially", "vancomycin", "."], "event_mentions": [{"id": "18682542_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse reaction", "start": 8, "end": 10}, "arguments": [{"entity_id": "18682542_1_Ent1", "role": "Effect", "text": "neurologic symptoms", "start": 14, "end": 16}, {"entity_id": "18682542_1_Ent0", "role": "Subject", "text": "patients", "start": 17, "end": 18}, {"entity_id": "18682542_1_Ent2", "role": "Treatment", "text": "vancomycin", "start": 28, "end": 29}, {"entity_id": "18682542_1_Ent3", "role": "Treatment_Drug", "text": "vancomycin", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "18682542_1_Ent1", "text": "neurologic symptoms", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "18682542_1_Ent0", "text": "patients", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18682542_1_Ent2", "text": "vancomycin", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "18682542_1_Ent3", "text": "vancomycin", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "18682542_2", "wnd_id": "18682542_2_1", "text": "DISCUSSION : To our knowledge , this is the first case report illustrating neuralgic amyotrophy triggered by exposure to the antibiotics vancomycin , tobramycin , and piperacillin / tazobactam .", "tokens": ["DISCUSSION", ":", "To", "our", "knowledge", ",", "this", "is", "the", "first", "case", "report", "illustrating", "neuralgic", "amyotrophy", "triggered", "by", "exposure", "to", "the", "antibiotics", "vancomycin", ",", "tobramycin", ",", "and", "piperacillin", "/", "tazobactam", "."], "event_mentions": [{"id": "18682542_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "triggered", "start": 15, "end": 16}, "arguments": [{"entity_id": "18682542_2_Ent0", "role": "Effect", "text": "neuralgic amyotrophy", "start": 13, "end": 15}, {"entity_id": "18682542_2_Ent1", "role": "Treatment", "text": "antibiotics vancomycin , tobramycin , and piperacillin / tazobactam", "start": 20, "end": 29}, {"entity_id": "18682542_2_Ent2", "role": "Treatment_Drug", "text": "vancomycin", "start": 21, "end": 22}, {"entity_id": "18682542_2_Ent6", "role": "Combination_Drug", "text": "vancomycin", "start": 21, "end": 22}, {"entity_id": "18682542_2_Ent3", "role": "Treatment_Drug", "text": "tobramycin", "start": 23, "end": 24}, {"entity_id": "18682542_2_Ent7", "role": "Combination_Drug", "text": "tobramycin", "start": 23, "end": 24}, {"entity_id": "18682542_2_Ent4", "role": "Treatment_Drug", "text": "piperacillin", "start": 26, "end": 27}, {"entity_id": "18682542_2_Ent8", "role": "Combination_Drug", "text": "piperacillin", "start": 26, "end": 27}, {"entity_id": "18682542_2_Ent5", "role": "Treatment_Drug", "text": "tazobactam", "start": 28, "end": 29}, {"entity_id": "18682542_2_Ent9", "role": "Combination_Drug", "text": "tazobactam", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "18682542_2_Ent0", "text": "neuralgic amyotrophy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "18682542_2_Ent1", "text": "antibiotics vancomycin , tobramycin , and piperacillin / tazobactam", "entity_type": "Entity", "start": 20, "end": 29}, {"id": "18682542_2_Ent2", "text": "vancomycin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "18682542_2_Ent6", "text": "vancomycin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "18682542_2_Ent3", "text": "tobramycin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "18682542_2_Ent7", "text": "tobramycin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "18682542_2_Ent4", "text": "piperacillin", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "18682542_2_Ent8", "text": "piperacillin", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "18682542_2_Ent5", "text": "tazobactam", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "18682542_2_Ent9", "text": "tazobactam", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "1868481_1", "wnd_id": "1868481_1_1", "text": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis .", "tokens": ["Seizures", "and", "transient", "blindness", "following", "intravenous", "pulse", "methylprednisolone", "in", "children", "with", "primary", "glomerulonephritis", "."], "event_mentions": [{"id": "1868481_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 4, "end": 5}, "arguments": [{"entity_id": "1868481_1_Ent2", "role": "Effect", "text": "Seizures and transient blindness", "start": 0, "end": 4}, {"entity_id": "1868481_1_Ent4", "role": "Treatment_Route", "text": "intravenous", "start": 5, "end": 6}, {"entity_id": "1868481_1_Ent3", "role": "Treatment", "text": "intravenous pulse methylprednisolone", "start": 5, "end": 8}, {"entity_id": "1868481_1_Ent5", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 7, "end": 8}, {"entity_id": "1868481_1_Ent1", "role": "Subject_Age", "text": "children", "start": 9, "end": 10}, {"entity_id": "1868481_1_Ent0", "role": "Subject", "text": "children with primary glomerulonephritis", "start": 9, "end": 13}, {"entity_id": "1868481_1_Ent6", "role": "Treatment_Disorder", "text": "primary glomerulonephritis", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "1868481_1_Ent2", "text": "Seizures and transient blindness", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "1868481_1_Ent4", "text": "intravenous", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1868481_1_Ent3", "text": "intravenous pulse methylprednisolone", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "1868481_1_Ent5", "text": "methylprednisolone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1868481_1_Ent1", "text": "children", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1868481_1_Ent0", "text": "children with primary glomerulonephritis", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "1868481_1_Ent6", "text": "primary glomerulonephritis", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "1868481_2", "wnd_id": "1868481_2_1", "text": "Two children , 1 with idiopathic nephrotic syndrome and 1 with endo - extracapillary glomerulonephritis , presented an episode of seizures and transient blindness at different times after i.v . pulse methylprednisolone ( IVPMP ) treatment .", "tokens": ["Two", "children", ",", "1", "with", "idiopathic", "nephrotic", "syndrome", "and", "1", "with", "endo", "-", "extracapillary", "glomerulonephritis", ",", "presented", "an", "episode", "of", "seizures", "and", "transient", "blindness", "at", "different", "times", "after", "i.v", ".", "pulse", "methylprednisolone", "(", "IVPMP", ")", "treatment", "."], "event_mentions": [{"id": "1868481_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 27, "end": 28}, "arguments": [{"entity_id": "1868481_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "1868481_2_Ent0", "role": "Subject", "text": "Two children , 1 with idiopathic nephrotic syndrome and 1 with endo - extracapillary glomerulonephritis", "start": 0, "end": 15}, {"entity_id": "1868481_2_Ent4", "role": "Treatment_Disorder", "text": "idiopathic nephrotic syndrome", "start": 5, "end": 8}, {"entity_id": "1868481_2_Ent5", "role": "Treatment_Disorder", "text": "endo - extracapillary glomerulonephritis ,", "start": 11, "end": 16}, {"entity_id": "1868481_2_Ent2", "role": "Effect", "text": "seizures and transient blindness", "start": 20, "end": 24}, {"entity_id": "1868481_2_Ent7", "role": "Treatment_Route", "text": "i.v . pulse", "start": 28, "end": 31}, {"entity_id": "1868481_2_Ent3", "role": "Treatment", "text": "i.v . pulse methylprednisolone ( IVPMP ) treatment", "start": 28, "end": 36}, {"entity_id": "1868481_2_Ent6", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "1868481_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1868481_2_Ent0", "text": "Two children , 1 with idiopathic nephrotic syndrome and 1 with endo - extracapillary glomerulonephritis", "entity_type": "Entity", "start": 0, "end": 15}, {"id": "1868481_2_Ent4", "text": "idiopathic nephrotic syndrome", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "1868481_2_Ent5", "text": "endo - extracapillary glomerulonephritis ,", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "1868481_2_Ent2", "text": "seizures and transient blindness", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "1868481_2_Ent7", "text": "i.v . pulse", "entity_type": "Entity", "start": 28, "end": 31}, {"id": "1868481_2_Ent3", "text": "i.v . pulse methylprednisolone ( IVPMP ) treatment", "entity_type": "Entity", "start": 28, "end": 36}, {"id": "1868481_2_Ent6", "text": "methylprednisolone", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "18691992_3", "wnd_id": "18691992_3_1", "text": "Both the longitudinal melanonychia and the multiple skin cancers first appeared after approximately 6 months of hydroxyurea treatment .", "tokens": ["Both", "the", "longitudinal", "melanonychia", "and", "the", "multiple", "skin", "cancers", "first", "appeared", "after", "approximately", "6", "months", "of", "hydroxyurea", "treatment", "."], "event_mentions": [{"id": "18691992_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appeared", "start": 10, "end": 11}, "arguments": [{"entity_id": "18691992_3_Ent0", "role": "Effect", "text": "longitudinal melanonychia and the multiple skin cancers", "start": 2, "end": 9}, {"entity_id": "18691992_3_Ent1", "role": "Treatment", "text": "approximately 6 months of hydroxyurea treatment", "start": 12, "end": 18}, {"entity_id": "18691992_3_Ent2", "role": "Treatment_Duration", "text": "6 months", "start": 13, "end": 15}, {"entity_id": "18691992_3_Ent3", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "18691992_3_Ent0", "text": "longitudinal melanonychia and the multiple skin cancers", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "18691992_3_Ent1", "text": "approximately 6 months of hydroxyurea treatment", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "18691992_3_Ent2", "text": "6 months", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "18691992_3_Ent3", "text": "hydroxyurea", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "18715650_1", "wnd_id": "18715650_1_1", "text": "Disseminated salmonellosis in a patient treated with temozolomide .", "tokens": ["Disseminated", "salmonellosis", "in", "a", "patient", "treated", "with", "temozolomide", "."], "event_mentions": [{"id": "18715650_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 2, "end": 3}, "arguments": [{"entity_id": "18715650_1_Ent1", "role": "Effect", "text": "Disseminated salmonellosis", "start": 0, "end": 2}, {"entity_id": "18715650_1_Ent0", "role": "Subject", "text": "a patient", "start": 3, "end": 5}, {"entity_id": "18715650_1_Ent2", "role": "Treatment", "text": "temozolomide", "start": 7, "end": 8}, {"entity_id": "18715650_1_Ent3", "role": "Treatment_Drug", "text": "temozolomide", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "18715650_1_Ent1", "text": "Disseminated salmonellosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18715650_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "18715650_1_Ent2", "text": "temozolomide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18715650_1_Ent3", "text": "temozolomide", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "18717612_3", "wnd_id": "18717612_3_1", "text": "We report the first case of a 54 - year - old Turkish woman who presented with ceftriaxone - induced FDE .", "tokens": ["We", "report", "the", "first", "case", "of", "a", "54", "-", "year", "-", "old", "Turkish", "woman", "who", "presented", "with", "ceftriaxone", "-", "induced", "FDE", "."], "event_mentions": [{"id": "18717612_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 19, "end": 20}, "arguments": [{"entity_id": "18717612_3_Ent0", "role": "Subject", "text": "a 54 - year - old Turkish woman", "start": 6, "end": 14}, {"entity_id": "18717612_3_Ent1", "role": "Subject_Age", "text": "54 - year - old", "start": 7, "end": 12}, {"entity_id": "18717612_3_Ent2", "role": "Subject_Race", "text": "Turkish", "start": 12, "end": 13}, {"entity_id": "18717612_3_Ent3", "role": "Subject_Gender", "text": "woman", "start": 13, "end": 14}, {"entity_id": "18717612_3_Ent5", "role": "Treatment", "text": "ceftriaxone", "start": 17, "end": 18}, {"entity_id": "18717612_3_Ent6", "role": "Treatment_Drug", "text": "ceftriaxone", "start": 17, "end": 18}, {"entity_id": "18717612_3_Ent4", "role": "Effect", "text": "FDE", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "18717612_3_Ent0", "text": "a 54 - year - old Turkish woman", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "18717612_3_Ent1", "text": "54 - year - old", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18717612_3_Ent2", "text": "Turkish", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18717612_3_Ent3", "text": "woman", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18717612_3_Ent5", "text": "ceftriaxone", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18717612_3_Ent6", "text": "ceftriaxone", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18717612_3_Ent4", "text": "FDE", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "18721173_1", "wnd_id": "18721173_1_1", "text": "CONCLUSION : All doctors need to be aware of the need to review the indications for gabapentin use during periods of acute illness , especially with regard to renal impairment .", "tokens": ["CONCLUSION", ":", "All", "doctors", "need", "to", "be", "aware", "of", "the", "need", "to", "review", "the", "indications", "for", "gabapentin", "use", "during", "periods", "of", "acute", "illness", ",", "especially", "with", "regard", "to", "renal", "impairment", "."], "event_mentions": [{"id": "18721173_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "regard", "start": 26, "end": 27}, "arguments": [{"entity_id": "18721173_1_Ent1", "role": "Treatment", "text": "gabapentin", "start": 16, "end": 17}, {"entity_id": "18721173_1_Ent3", "role": "Treatment_Drug", "text": "gabapentin", "start": 16, "end": 17}, {"entity_id": "18721173_1_Ent2", "role": "Treatment_Disorder", "text": "acute illness", "start": 21, "end": 23}, {"entity_id": "18721173_1_Ent0", "role": "Effect", "text": "renal impairment", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "18721173_1_Ent1", "text": "gabapentin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18721173_1_Ent3", "text": "gabapentin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18721173_1_Ent2", "text": "acute illness", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "18721173_1_Ent0", "text": "renal impairment", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "18755414_3", "wnd_id": "18755414_3_1", "text": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis .", "tokens": ["Our", "case", "is", "the", "second", "one", "in", "which", "hemorrhage", "from", "a", "meningioma", "may", "have", "been", "induced", "by", "aspirin", "prophylaxis", "."], "event_mentions": [{"id": "18755414_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 15, "end": 16}, "arguments": [{"entity_id": "18755414_3_Ent0", "role": "Subject", "text": "Our case is the second one", "start": 0, "end": 6}, {"entity_id": "18755414_3_Ent1", "role": "Subject_Population", "text": "second", "start": 4, "end": 5}, {"entity_id": "18755414_3_Ent2", "role": "Effect", "text": "hemorrhage from a meningioma", "start": 8, "end": 12}, {"entity_id": "18755414_3_Ent4", "role": "Treatment_Drug", "text": "aspirin", "start": 17, "end": 18}, {"entity_id": "18755414_3_Ent3", "role": "Treatment", "text": "aspirin prophylaxis", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "18755414_3_Ent0", "text": "Our case is the second one", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "18755414_3_Ent1", "text": "second", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18755414_3_Ent2", "text": "hemorrhage from a meningioma", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "18755414_3_Ent4", "text": "aspirin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18755414_3_Ent3", "text": "aspirin prophylaxis", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "18765315_3", "wnd_id": "18765315_3_1", "text": "The aim of this study was to describe the occurrence of acute coronary syndromes in 3 cases of rituximab infusions .", "tokens": ["The", "aim", "of", "this", "study", "was", "to", "describe", "the", "occurrence", "of", "acute", "coronary", "syndromes", "in", "3", "cases", "of", "rituximab", "infusions", "."], "event_mentions": [{"id": "18765315_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurrence", "start": 9, "end": 10}, "arguments": [{"entity_id": "18765315_3_Ent0", "role": "Effect", "text": "acute coronary syndromes", "start": 11, "end": 14}, {"entity_id": "18765315_3_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 18, "end": 19}, {"entity_id": "18765315_3_Ent1", "role": "Treatment", "text": "rituximab infusions", "start": 18, "end": 20}, {"entity_id": "18765315_3_Ent3", "role": "Treatment_Route", "text": "infusions", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "18765315_3_Ent0", "text": "acute coronary syndromes", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "18765315_3_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "18765315_3_Ent1", "text": "rituximab infusions", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "18765315_3_Ent3", "text": "infusions", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "18765315_4", "wnd_id": "18765315_4_1", "text": "The occurrence of symptoms that could be ascribed to an acute coronary syndrome should always be taken seriously during the first rituximab infusion and investigated aggressively .", "tokens": ["The", "occurrence", "of", "symptoms", "that", "could", "be", "ascribed", "to", "an", "acute", "coronary", "syndrome", "should", "always", "be", "taken", "seriously", "during", "the", "first", "rituximab", "infusion", "and", "investigated", "aggressively", "."], "event_mentions": [{"id": "18765315_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 18, "end": 19}, "arguments": [{"entity_id": "18765315_4_Ent0", "role": "Effect", "text": "acute coronary syndrome", "start": 10, "end": 13}, {"entity_id": "18765315_4_Ent2", "role": "Treatment_Duration", "text": "first", "start": 20, "end": 21}, {"entity_id": "18765315_4_Ent1", "role": "Treatment", "text": "first rituximab infusion", "start": 20, "end": 23}, {"entity_id": "18765315_4_Ent3", "role": "Treatment_Drug", "text": "rituximab", "start": 21, "end": 22}, {"entity_id": "18765315_4_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "18765315_4_Ent0", "text": "acute coronary syndrome", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "18765315_4_Ent2", "text": "first", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "18765315_4_Ent1", "text": "first rituximab infusion", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "18765315_4_Ent3", "text": "rituximab", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "18765315_4_Ent4", "text": "infusion", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "18836269_1", "wnd_id": "18836269_1_1", "text": "After treatment with a beta - sympathomimetic drug ( Partusisten ) one fetus developed supraventricular tachycardia .", "tokens": ["After", "treatment", "with", "a", "beta", "-", "sympathomimetic", "drug", "(", "Partusisten", ")", "one", "fetus", "developed", "supraventricular", "tachycardia", "."], "event_mentions": [{"id": "18836269_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "18836269_1_Ent3", "role": "Treatment", "text": "a beta - sympathomimetic drug ( Partusisten )", "start": 3, "end": 11}, {"entity_id": "18836269_1_Ent4", "role": "Treatment_Drug", "text": "Partusisten", "start": 9, "end": 10}, {"entity_id": "18836269_1_Ent0", "role": "Subject", "text": "one fetus", "start": 11, "end": 13}, {"entity_id": "18836269_1_Ent1", "role": "Subject_Age", "text": "fetus", "start": 12, "end": 13}, {"entity_id": "18836269_1_Ent2", "role": "Effect", "text": "supraventricular tachycardia .", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "18836269_1_Ent3", "text": "a beta - sympathomimetic drug ( Partusisten )", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "18836269_1_Ent4", "text": "Partusisten", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18836269_1_Ent0", "text": "one fetus", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18836269_1_Ent1", "text": "fetus", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18836269_1_Ent2", "text": "supraventricular tachycardia .", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "18837734_1", "wnd_id": "18837734_1_1", "text": "Rosaceiform eruption induced by erlotinib .", "tokens": ["Rosaceiform", "eruption", "induced", "by", "erlotinib", "."], "event_mentions": [{"id": "18837734_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18837734_1_Ent0", "role": "Effect", "text": "Rosaceiform eruption", "start": 0, "end": 2}, {"entity_id": "18837734_1_Ent2", "role": "Treatment_Drug", "text": "erlotinib", "start": 4, "end": 5}, {"entity_id": "18837734_1_Ent1", "role": "Treatment", "text": "erlotinib .", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "18837734_1_Ent0", "text": "Rosaceiform eruption", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18837734_1_Ent2", "text": "erlotinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18837734_1_Ent1", "text": "erlotinib .", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "18855892_2", "wnd_id": "18855892_2_1", "text": "Anaphylactic / anaphylactoid reactions to methotrexate are rare .", "tokens": ["Anaphylactic", "/", "anaphylactoid", "reactions", "to", "methotrexate", "are", "rare", "."], "event_mentions": [{"id": "18855892_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 4, "end": 5}, "arguments": [{"entity_id": "18855892_2_Ent0", "role": "Effect", "text": "Anaphylactic / anaphylactoid reactions", "start": 0, "end": 4}, {"entity_id": "18855892_2_Ent1", "role": "Treatment", "text": "methotrexate", "start": 5, "end": 6}, {"entity_id": "18855892_2_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "18855892_2_Ent0", "text": "Anaphylactic / anaphylactoid reactions", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "18855892_2_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18855892_2_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "18957000_1", "wnd_id": "18957000_1_1", "text": "Although heparin - dependent antibodies ( HDAs ) typically manifest with thrombocytopenia as in heparin - induced thrombocytopenia ( HIT ) , they may also manifest with preserved platelet counts .", "tokens": ["Although", "heparin", "-", "dependent", "antibodies", "(", "HDAs", ")", "typically", "manifest", "with", "thrombocytopenia", "as", "in", "heparin", "-", "induced", "thrombocytopenia", "(", "HIT", ")", ",", "they", "may", "also", "manifest", "with", "preserved", "platelet", "counts", "."], "event_mentions": [{"id": "18957000_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "manifest", "start": 9, "end": 10}, "arguments": [{"entity_id": "18957000_1_Ent2", "role": "Treatment_Drug", "text": "heparin", "start": 1, "end": 2}, {"entity_id": "18957000_1_Ent1", "role": "Treatment", "text": "heparin - dependent antibodies ( HDAs )", "start": 1, "end": 8}, {"entity_id": "18957000_1_Ent0", "role": "Effect", "text": "thrombocytopenia", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "18957000_1_Ent2", "text": "heparin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18957000_1_Ent1", "text": "heparin - dependent antibodies ( HDAs )", "entity_type": "Entity", "start": 1, "end": 8}, {"id": "18957000_1_Ent0", "text": "thrombocytopenia", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "18957000_2", "wnd_id": "18957000_2_1", "text": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy .", "tokens": ["Clinicians", "should", "be", "cognizant", "of", "this", "possibility", "and", "consider", "a", "diagnosis", "of", "HDAs", "in", "patients", "with", "ongoing", "thrombosis", "who", "are", "receiving", "heparin", "therapy", "."], "event_mentions": [{"id": "18957000_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 20, "end": 21}, "arguments": [{"entity_id": "18957000_2_Ent1", "role": "Effect", "text": "HDAs", "start": 12, "end": 13}, {"entity_id": "18957000_2_Ent0", "role": "Subject", "text": "patients", "start": 14, "end": 15}, {"entity_id": "18957000_2_Ent2", "role": "Effect", "text": "thrombosis", "start": 17, "end": 18}, {"entity_id": "18957000_2_Ent3", "role": "Treatment", "text": "heparin", "start": 21, "end": 22}, {"entity_id": "18957000_2_Ent4", "role": "Treatment_Drug", "text": "heparin", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "18957000_2_Ent1", "text": "HDAs", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18957000_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18957000_2_Ent2", "text": "thrombosis", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18957000_2_Ent3", "text": "heparin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "18957000_2_Ent4", "text": "heparin", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "18957000_3", "wnd_id": "18957000_3_1", "text": "Heparin - dependent antibodies and thrombosis without heparin - induced thrombocytopenia .", "tokens": ["Heparin", "-", "dependent", "antibodies", "and", "thrombosis", "without", "heparin", "-", "induced", "thrombocytopenia", "."], "event_mentions": [{"id": "18957000_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "18957000_3_Ent1", "role": "Treatment", "text": "heparin", "start": 7, "end": 8}, {"entity_id": "18957000_3_Ent2", "role": "Treatment_Drug", "text": "heparin", "start": 7, "end": 8}, {"entity_id": "18957000_3_Ent0", "role": "Effect", "text": "thrombocytopenia", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "18957000_3_Ent1", "text": "heparin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18957000_3_Ent2", "text": "heparin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18957000_3_Ent0", "text": "thrombocytopenia", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "18977778_1", "wnd_id": "18977778_1_1", "text": "Despite these antithrombotic effects , the patient developed repeated venous thromboembolism during treatment with low - molecular - weight heparin .", "tokens": ["Despite", "these", "antithrombotic", "effects", ",", "the", "patient", "developed", "repeated", "venous", "thromboembolism", "during", "treatment", "with", "low", "-", "molecular", "-", "weight", "heparin", "."], "event_mentions": [{"id": "18977778_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 11, "end": 12}, "arguments": [{"entity_id": "18977778_1_Ent0", "role": "Effect", "text": "repeated venous thromboembolism", "start": 8, "end": 11}, {"entity_id": "18977778_1_Ent1", "role": "Treatment", "text": "treatment with low - molecular - weight heparin", "start": 12, "end": 20}, {"entity_id": "18977778_1_Ent2", "role": "Treatment_Drug", "text": "low - molecular - weight heparin", "start": 14, "end": 20}]}], "entity_mentions": [{"id": "18977778_1_Ent0", "text": "repeated venous thromboembolism", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "18977778_1_Ent1", "text": "treatment with low - molecular - weight heparin", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "18977778_1_Ent2", "text": "low - molecular - weight heparin", "entity_type": "Entity", "start": 14, "end": 20}], "lang": "en"}
{"doc_id": "18991509_2", "wnd_id": "18991509_2_1", "text": "We report the first case of a human immunodeficiency virus type 1 ( HIV - 1) - infected individual receiving combination antiretroviral therapy , which included ritonavir , who developed Cushing syndrome with profound complications after epidural triamcinolone injections .", "tokens": ["We", "report", "the", "first", "case", "of", "a", "human", "immunodeficiency", "virus", "type", "1", "(", "HIV", "-", "1)", "-", "infected", "individual", "receiving", "combination", "antiretroviral", "therapy", ",", "which", "included", "ritonavir", ",", "who", "developed", "Cushing", "syndrome", "with", "profound", "complications", "after", "epidural", "triamcinolone", "injections", "."], "event_mentions": [{"id": "18991509_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 29, "end": 30}, "arguments": [{"entity_id": "18991509_2_Ent0", "role": "Subject", "text": "a human immunodeficiency virus type 1 ( HIV - 1) - infected individual", "start": 6, "end": 19}, {"entity_id": "18991509_2_Ent4", "role": "Treatment_Disorder", "text": "human immunodeficiency virus type 1", "start": 7, "end": 12}, {"entity_id": "18991509_2_Ent2", "role": "Treatment", "text": "combination antiretroviral therapy , which included ritonavir", "start": 20, "end": 27}, {"entity_id": "18991509_2_Ent6", "role": "Treatment_Drug", "text": "ritonavir", "start": 26, "end": 27}, {"entity_id": "18991509_2_Ent9", "role": "Combination_Drug", "text": "ritonavir", "start": 26, "end": 27}, {"entity_id": "18991509_2_Ent1", "role": "Effect", "text": "Cushing syndrome", "start": 30, "end": 32}, {"entity_id": "18991509_2_Ent7", "role": "Treatment_Route", "text": "epidural", "start": 36, "end": 37}, {"entity_id": "18991509_2_Ent3", "role": "Treatment", "text": "epidural triamcinolone injections", "start": 36, "end": 39}, {"entity_id": "18991509_2_Ent5", "role": "Treatment_Drug", "text": "triamcinolone", "start": 37, "end": 38}, {"entity_id": "18991509_2_Ent10", "role": "Combination_Drug", "text": "triamcinolone", "start": 37, "end": 38}, {"entity_id": "18991509_2_Ent8", "role": "Treatment_Route", "text": "injections", "start": 38, "end": 39}]}], "entity_mentions": [{"id": "18991509_2_Ent0", "text": "a human immunodeficiency virus type 1 ( HIV - 1) - infected individual", "entity_type": "Entity", "start": 6, "end": 19}, {"id": "18991509_2_Ent4", "text": "human immunodeficiency virus type 1", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18991509_2_Ent2", "text": "combination antiretroviral therapy , which included ritonavir", "entity_type": "Entity", "start": 20, "end": 27}, {"id": "18991509_2_Ent6", "text": "ritonavir", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "18991509_2_Ent9", "text": "ritonavir", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "18991509_2_Ent1", "text": "Cushing syndrome", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "18991509_2_Ent7", "text": "epidural", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "18991509_2_Ent3", "text": "epidural triamcinolone injections", "entity_type": "Entity", "start": 36, "end": 39}, {"id": "18991509_2_Ent5", "text": "triamcinolone", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "18991509_2_Ent10", "text": "triamcinolone", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "18991509_2_Ent8", "text": "injections", "entity_type": "Entity", "start": 38, "end": 39}], "lang": "en"}
{"doc_id": "19003750_1", "wnd_id": "19003750_1_1", "text": "A 22 - year - old drug - abuser injected flunitrazepam tablets dissolved in tap water into her left femoral artery and presented with clinical signs of acute ischaemia of the left leg .", "tokens": ["A", "22", "-", "year", "-", "old", "drug", "-", "abuser", "injected", "flunitrazepam", "tablets", "dissolved", "in", "tap", "water", "into", "her", "left", "femoral", "artery", "and", "presented", "with", "clinical", "signs", "of", "acute", "ischaemia", "of", "the", "left", "leg", "."], "event_mentions": [{"id": "19003750_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 22, "end": 23}, "arguments": [{"entity_id": "19003750_1_Ent0", "role": "Subject", "text": "A 22 - year - old drug - abuser", "start": 0, "end": 9}, {"entity_id": "19003750_1_Ent1", "role": "Subject_Age", "text": "22 - year - old", "start": 1, "end": 6}, {"entity_id": "19003750_1_Ent2", "role": "Subject_Disorder", "text": "drug - abuser", "start": 6, "end": 9}, {"entity_id": "19003750_1_Ent6", "role": "Treatment_Route", "text": "injected", "start": 9, "end": 10}, {"entity_id": "19003750_1_Ent4", "role": "Treatment", "text": "injected flunitrazepam tablets dissolved in tap water into her left femoral artery", "start": 9, "end": 21}, {"entity_id": "19003750_1_Ent5", "role": "Treatment_Drug", "text": "flunitrazepam", "start": 10, "end": 11}, {"entity_id": "19003750_1_Ent7", "role": "Treatment_Route", "text": "tablets dissolved in tap water", "start": 11, "end": 16}, {"entity_id": "19003750_1_Ent3", "role": "Effect", "text": "acute ischaemia of the left leg", "start": 27, "end": 33}]}], "entity_mentions": [{"id": "19003750_1_Ent0", "text": "A 22 - year - old drug - abuser", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "19003750_1_Ent1", "text": "22 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "19003750_1_Ent2", "text": "drug - abuser", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19003750_1_Ent6", "text": "injected", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19003750_1_Ent4", "text": "injected flunitrazepam tablets dissolved in tap water into her left femoral artery", "entity_type": "Entity", "start": 9, "end": 21}, {"id": "19003750_1_Ent5", "text": "flunitrazepam", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19003750_1_Ent7", "text": "tablets dissolved in tap water", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "19003750_1_Ent3", "text": "acute ischaemia of the left leg", "entity_type": "Entity", "start": 27, "end": 33}], "lang": "en"}
{"doc_id": "19017039_2", "wnd_id": "19017039_2_1", "text": "Syringotropic hypersensitivity reaction associated with infliximab and leflunomide combination therapy in a child with psoriatic arthritis .", "tokens": ["Syringotropic", "hypersensitivity", "reaction", "associated", "with", "infliximab", "and", "leflunomide", "combination", "therapy", "in", "a", "child", "with", "psoriatic", "arthritis", "."], "event_mentions": [{"id": "19017039_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "19017039_2_Ent2", "role": "Effect", "text": "Syringotropic hypersensitivity reaction", "start": 0, "end": 3}, {"entity_id": "19017039_2_Ent4", "role": "Treatment_Drug", "text": "infliximab", "start": 5, "end": 6}, {"entity_id": "19017039_2_Ent8", "role": "Combination_Drug", "text": "infliximab", "start": 5, "end": 6}, {"entity_id": "19017039_2_Ent3", "role": "Treatment", "text": "infliximab and leflunomide combination therapy", "start": 5, "end": 10}, {"entity_id": "19017039_2_Ent5", "role": "Treatment_Drug", "text": "leflunomide", "start": 7, "end": 8}, {"entity_id": "19017039_2_Ent7", "role": "Combination_Drug", "text": "leflunomide", "start": 7, "end": 8}, {"entity_id": "19017039_2_Ent0", "role": "Subject", "text": "a child with psoriatic arthritis", "start": 11, "end": 16}, {"entity_id": "19017039_2_Ent1", "role": "Subject_Age", "text": "child", "start": 12, "end": 13}, {"entity_id": "19017039_2_Ent6", "role": "Treatment_Disorder", "text": "psoriatic arthritis", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "19017039_2_Ent2", "text": "Syringotropic hypersensitivity reaction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19017039_2_Ent4", "text": "infliximab", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19017039_2_Ent8", "text": "infliximab", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19017039_2_Ent3", "text": "infliximab and leflunomide combination therapy", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "19017039_2_Ent5", "text": "leflunomide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19017039_2_Ent7", "text": "leflunomide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19017039_2_Ent0", "text": "a child with psoriatic arthritis", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "19017039_2_Ent1", "text": "child", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19017039_2_Ent6", "text": "psoriatic arthritis", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "19018868_1", "wnd_id": "19018868_1_1", "text": "A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma .", "tokens": ["A", "case", "of", "severe", "aplastic", "anemia", "secondary", "to", "treatment", "with", "lenalidomide", "for", "multiple", "myeloma", "."], "event_mentions": [{"id": "19018868_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 6, "end": 7}, "arguments": [{"entity_id": "19018868_1_Ent0", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "19018868_1_Ent1", "role": "Effect", "text": "severe aplastic anemia", "start": 3, "end": 6}, {"entity_id": "19018868_1_Ent4", "role": "Treatment_Drug", "text": "lenalidomide", "start": 10, "end": 11}, {"entity_id": "19018868_1_Ent2", "role": "Treatment", "text": "lenalidomide for multiple myeloma", "start": 10, "end": 14}, {"entity_id": "19018868_1_Ent3", "role": "Treatment_Disorder", "text": "multiple myeloma", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "19018868_1_Ent0", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19018868_1_Ent1", "text": "severe aplastic anemia", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "19018868_1_Ent4", "text": "lenalidomide", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19018868_1_Ent2", "text": "lenalidomide for multiple myeloma", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "19018868_1_Ent3", "text": "multiple myeloma", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "19034138_7", "wnd_id": "19034138_7_1", "text": "Therefore , amantadine was permanently discontinued and the cornea cleared again .", "tokens": ["Therefore", ",", "amantadine", "was", "permanently", "discontinued", "and", "the", "cornea", "cleared", "again", "."], "event_mentions": [{"id": "19034138_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "was", "start": 3, "end": 4}, "arguments": [{"entity_id": "19034138_7_Ent1", "role": "Treatment", "text": "amantadine", "start": 2, "end": 3}, {"entity_id": "19034138_7_Ent2", "role": "Treatment_Drug", "text": "amantadine", "start": 2, "end": 3}, {"entity_id": "19034138_7_Ent0", "role": "Effect", "text": "cornea cleared", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "19034138_7_Ent1", "text": "amantadine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19034138_7_Ent2", "text": "amantadine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19034138_7_Ent0", "text": "cornea cleared", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "19097599_2", "wnd_id": "19097599_2_1", "text": "We herein described an additional patient with BCR - ABL ( ela2 ) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10 - day treatment with imatinib .", "tokens": ["We", "herein", "described", "an", "additional", "patient", "with", "BCR", "-", "ABL", "(", "ela2", ")", "positive", "acute", "lymphoblastic", "leukemia", "who", "developed", "tumor", "lysis", "syndrome", "after", "10", "-", "day", "treatment", "with", "imatinib", "."], "event_mentions": [{"id": "19097599_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "19097599_2_Ent0", "role": "Subject", "text": "patient with BCR - ABL ( ela2 ) positive acute lymphoblastic leukemia", "start": 5, "end": 17}, {"entity_id": "19097599_2_Ent5", "role": "Treatment_Disorder", "text": "BCR - ABL ( ela2 ) positive acute lymphoblastic leukemia", "start": 7, "end": 17}, {"entity_id": "19097599_2_Ent1", "role": "Effect", "text": "tumor lysis syndrome", "start": 19, "end": 22}, {"entity_id": "19097599_2_Ent4", "role": "Treatment_Time_elapsed", "text": "10 - day", "start": 23, "end": 26}, {"entity_id": "19097599_2_Ent2", "role": "Treatment", "text": "10 - day treatment with imatinib", "start": 23, "end": 29}, {"entity_id": "19097599_2_Ent3", "role": "Treatment_Drug", "text": "imatinib", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "19097599_2_Ent0", "text": "patient with BCR - ABL ( ela2 ) positive acute lymphoblastic leukemia", "entity_type": "Entity", "start": 5, "end": 17}, {"id": "19097599_2_Ent5", "text": "BCR - ABL ( ela2 ) positive acute lymphoblastic leukemia", "entity_type": "Entity", "start": 7, "end": 17}, {"id": "19097599_2_Ent1", "text": "tumor lysis syndrome", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "19097599_2_Ent4", "text": "10 - day", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "19097599_2_Ent2", "text": "10 - day treatment with imatinib", "entity_type": "Entity", "start": 23, "end": 29}, {"id": "19097599_2_Ent3", "text": "imatinib", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "19122478_5", "wnd_id": "19122478_5_1", "text": "We report the first case of chlorambucil - induced DRESS syndrome in a 70 - year - old man recently diagnosed with chronic lymphocytic leukaemia .", "tokens": ["We", "report", "the", "first", "case", "of", "chlorambucil", "-", "induced", "DRESS", "syndrome", "in", "a", "70", "-", "year", "-", "old", "man", "recently", "diagnosed", "with", "chronic", "lymphocytic", "leukaemia", "."], "event_mentions": [{"id": "19122478_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "19122478_5_Ent4", "role": "Treatment", "text": "chlorambucil", "start": 6, "end": 7}, {"entity_id": "19122478_5_Ent5", "role": "Treatment_Drug", "text": "chlorambucil", "start": 6, "end": 7}, {"entity_id": "19122478_5_Ent3", "role": "Effect", "text": "DRESS syndrome", "start": 9, "end": 11}, {"entity_id": "19122478_5_Ent0", "role": "Subject", "text": "a 70 - year - old man", "start": 12, "end": 19}, {"entity_id": "19122478_5_Ent1", "role": "Subject_Age", "text": "70 - year - old", "start": 13, "end": 18}, {"entity_id": "19122478_5_Ent2", "role": "Subject_Gender", "text": "man", "start": 18, "end": 19}, {"entity_id": "19122478_5_Ent6", "role": "Treatment_Disorder", "text": "chronic lymphocytic leukaemia", "start": 22, "end": 25}]}], "entity_mentions": [{"id": "19122478_5_Ent4", "text": "chlorambucil", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19122478_5_Ent5", "text": "chlorambucil", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19122478_5_Ent3", "text": "DRESS syndrome", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "19122478_5_Ent0", "text": "a 70 - year - old man", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "19122478_5_Ent1", "text": "70 - year - old", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "19122478_5_Ent2", "text": "man", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "19122478_5_Ent6", "text": "chronic lymphocytic leukaemia", "entity_type": "Entity", "start": 22, "end": 25}], "lang": "en"}
{"doc_id": "19131789_3", "wnd_id": "19131789_3_1", "text": "Early recognition of renal toxicity of high - dose methotrexate therapy : a case report .", "tokens": ["Early", "recognition", "of", "renal", "toxicity", "of", "high", "-", "dose", "methotrexate", "therapy", ":", "a", "case", "report", "."], "event_mentions": [{"id": "19131789_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "recognition", "start": 1, "end": 2}, "arguments": [{"entity_id": "19131789_3_Ent0", "role": "Effect", "text": "renal toxicity", "start": 3, "end": 5}, {"entity_id": "19131789_3_Ent2", "role": "Treatment_Dosage", "text": "high - dose", "start": 6, "end": 9}, {"entity_id": "19131789_3_Ent1", "role": "Treatment", "text": "high - dose methotrexate therapy", "start": 6, "end": 11}, {"entity_id": "19131789_3_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "19131789_3_Ent0", "text": "renal toxicity", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "19131789_3_Ent2", "text": "high - dose", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19131789_3_Ent1", "text": "high - dose methotrexate therapy", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "19131789_3_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "19212144_1", "wnd_id": "19212144_1_1", "text": "A 58 - year - old man with advanced renal cell carcinoma developed grade 3 proteinuria ( 8.5 g/24 h ) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion .", "tokens": ["A", "58", "-", "year", "-", "old", "man", "with", "advanced", "renal", "cell", "carcinoma", "developed", "grade", "3", "proteinuria", "(", "8.5", "g/24", "h", ")", "without", "microscopic", "hematuria", "or", "renal", "insufficiency", "five", "days", "after", "temsirolimus", "infusion", "."], "event_mentions": [{"id": "19212144_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "19212144_1_Ent0", "role": "Subject", "text": "A 58 - year - old man with advanced renal cell carcinoma", "start": 0, "end": 12}, {"entity_id": "19212144_1_Ent1", "role": "Subject_Age", "text": "58 - year - old", "start": 1, "end": 6}, {"entity_id": "19212144_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "19212144_1_Ent5", "role": "Treatment_Disorder", "text": "renal cell carcinoma", "start": 9, "end": 12}, {"entity_id": "19212144_1_Ent3", "role": "Effect", "text": "grade 3 proteinuria ( 8.5 g/24 h ) without microscopic hematuria or renal insufficiency", "start": 13, "end": 27}, {"entity_id": "19212144_1_Ent6", "role": "Treatment_Time_elapsed", "text": "five days", "start": 27, "end": 29}, {"entity_id": "19212144_1_Ent4", "role": "Treatment", "text": "five days after temsirolimus infusion", "start": 27, "end": 32}, {"entity_id": "19212144_1_Ent7", "role": "Treatment_Drug", "text": "temsirolimus", "start": 30, "end": 31}, {"entity_id": "19212144_1_Ent8", "role": "Treatment_Route", "text": "infusion", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "19212144_1_Ent0", "text": "A 58 - year - old man with advanced renal cell carcinoma", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "19212144_1_Ent1", "text": "58 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "19212144_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19212144_1_Ent5", "text": "renal cell carcinoma", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "19212144_1_Ent3", "text": "grade 3 proteinuria ( 8.5 g/24 h ) without microscopic hematuria or renal insufficiency", "entity_type": "Entity", "start": 13, "end": 27}, {"id": "19212144_1_Ent6", "text": "five days", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "19212144_1_Ent4", "text": "five days after temsirolimus infusion", "entity_type": "Entity", "start": 27, "end": 32}, {"id": "19212144_1_Ent7", "text": "temsirolimus", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "19212144_1_Ent8", "text": "infusion", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "19224802_3", "wnd_id": "19224802_3_1", "text": "dexmedetomidine is used to provide sedation for pediatric patients undergoing nonpainful radiological imaging studies .", "tokens": ["dexmedetomidine", "is", "used", "to", "provide", "sedation", "for", "pediatric", "patients", "undergoing", "nonpainful", "radiological", "imaging", "studies", "."], "event_mentions": [{"id": "19224802_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used to", "start": 2, "end": 4}, "arguments": [{"entity_id": "19224802_3_Ent3", "role": "Treatment", "text": "dexmedetomidine", "start": 0, "end": 1}, {"entity_id": "19224802_3_Ent4", "role": "Treatment_Drug", "text": "dexmedetomidine", "start": 0, "end": 1}, {"entity_id": "19224802_3_Ent2", "role": "Effect", "text": "provide sedation", "start": 4, "end": 6}, {"entity_id": "19224802_3_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 7, "end": 8}, {"entity_id": "19224802_3_Ent0", "role": "Subject", "text": "pediatric patients undergoing nonpainful radiological imaging studies", "start": 7, "end": 14}]}], "entity_mentions": [{"id": "19224802_3_Ent3", "text": "dexmedetomidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19224802_3_Ent4", "text": "dexmedetomidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19224802_3_Ent2", "text": "provide sedation", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "19224802_3_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19224802_3_Ent0", "text": "pediatric patients undergoing nonpainful radiological imaging studies", "entity_type": "Entity", "start": 7, "end": 14}], "lang": "en"}
{"doc_id": "19224802_5", "wnd_id": "19224802_5_1", "text": "We report on three cases wherein treatment of dexmedetomidine - induced bradycardia with i.v .", "tokens": ["We", "report", "on", "three", "cases", "wherein", "treatment", "of", "dexmedetomidine", "-", "induced", "bradycardia", "with", "i.v", "."], "event_mentions": [{"id": "19224802_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "19224802_5_Ent1", "role": "Treatment", "text": "treatment of dexmedetomidine", "start": 6, "end": 9}, {"entity_id": "19224802_5_Ent2", "role": "Treatment_Drug", "text": "dexmedetomidine", "start": 8, "end": 9}, {"entity_id": "19224802_5_Ent0", "role": "Effect", "text": "bradycardia with i.v", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "19224802_5_Ent1", "text": "treatment of dexmedetomidine", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19224802_5_Ent2", "text": "dexmedetomidine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19224802_5_Ent0", "text": "bradycardia with i.v", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "19226083_16", "wnd_id": "19226083_16_1", "text": "Linezolid is a popular choice of antibiotic , especially for the treatment of orthopedic - related MRSA infections .", "tokens": ["Linezolid", "is", "a", "popular", "choice", "of", "antibiotic", ",", "especially", "for", "the", "treatment", "of", "orthopedic", "-", "related", "MRSA", "infections", "."], "event_mentions": [{"id": "19226083_16_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 11, "end": 12}, "arguments": [{"entity_id": "19226083_16_Ent0", "role": "Treatment", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "19226083_16_Ent2", "role": "Treatment_Drug", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "19226083_16_Ent1", "role": "Treatment_Disorder", "text": "orthopedic - related MRSA infections", "start": 13, "end": 18}]}], "entity_mentions": [{"id": "19226083_16_Ent0", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19226083_16_Ent2", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19226083_16_Ent1", "text": "orthopedic - related MRSA infections", "entity_type": "Entity", "start": 13, "end": 18}], "lang": "en"}
{"doc_id": "19226083_4", "wnd_id": "19226083_4_1", "text": "There are several documented case reports of serotonin toxicity when used with selective serotonin reuptake inhibitors .", "tokens": ["There", "are", "several", "documented", "case", "reports", "of", "serotonin", "toxicity", "when", "used", "with", "selective", "serotonin", "reuptake", "inhibitors", "."], "event_mentions": [{"id": "19226083_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reports", "start": 5, "end": 6}, "arguments": [{"entity_id": "19226083_4_Ent1", "role": "Subject_Population", "text": "several", "start": 2, "end": 3}, {"entity_id": "19226083_4_Ent0", "role": "Subject", "text": "several documented case", "start": 2, "end": 5}, {"entity_id": "19226083_4_Ent5", "role": "Treatment_Drug", "text": "serotonin", "start": 7, "end": 8}, {"entity_id": "19226083_4_Ent7", "role": "Combination_Drug", "text": "serotonin", "start": 7, "end": 8}, {"entity_id": "19226083_4_Ent2", "role": "Effect", "text": "serotonin toxicity", "start": 7, "end": 9}, {"entity_id": "19226083_4_Ent3", "role": "Treatment", "text": "selective serotonin reuptake inhibitors", "start": 12, "end": 16}, {"entity_id": "19226083_4_Ent4", "role": "Treatment_Drug", "text": "selective serotonin reuptake inhibitors", "start": 12, "end": 16}, {"entity_id": "19226083_4_Ent6", "role": "Combination_Drug", "text": "selective serotonin reuptake inhibitors", "start": 12, "end": 16}]}], "entity_mentions": [{"id": "19226083_4_Ent1", "text": "several", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19226083_4_Ent0", "text": "several documented case", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "19226083_4_Ent5", "text": "serotonin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19226083_4_Ent7", "text": "serotonin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19226083_4_Ent2", "text": "serotonin toxicity", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "19226083_4_Ent3", "text": "selective serotonin reuptake inhibitors", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "19226083_4_Ent4", "text": "selective serotonin reuptake inhibitors", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "19226083_4_Ent6", "text": "selective serotonin reuptake inhibitors", "entity_type": "Entity", "start": 12, "end": 16}], "lang": "en"}
{"doc_id": "19235747_1", "wnd_id": "19235747_1_1", "text": "Bisphosphonate - related osteonecrosis of the jaw ( BRONJ ) is reported in up to 18.6 % of patients treated with intravenous bisphosphonates and can result in significant morbidity .", "tokens": ["Bisphosphonate", "-", "related", "osteonecrosis", "of", "the", "jaw", "(", "BRONJ", ")", "is", "reported", "in", "up", "to", "18.6", "%", "of", "patients", "treated", "with", "intravenous", "bisphosphonates", "and", "can", "result", "in", "significant", "morbidity", "."], "event_mentions": [{"id": "19235747_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 2, "end": 3}, "arguments": [{"entity_id": "19235747_1_Ent4", "role": "Treatment_Drug", "text": "Bisphosphonate", "start": 0, "end": 1}, {"entity_id": "19235747_1_Ent2", "role": "Effect", "text": "osteonecrosis of the jaw ( BRONJ )", "start": 3, "end": 10}, {"entity_id": "19235747_1_Ent1", "role": "Subject_Population", "text": "18.6 %", "start": 15, "end": 17}, {"entity_id": "19235747_1_Ent0", "role": "Subject", "text": "18.6 % of patients", "start": 15, "end": 19}, {"entity_id": "19235747_1_Ent6", "role": "Treatment_Route", "text": "intravenous", "start": 21, "end": 22}, {"entity_id": "19235747_1_Ent3", "role": "Treatment", "text": "intravenous bisphosphonates", "start": 21, "end": 23}, {"entity_id": "19235747_1_Ent5", "role": "Treatment_Drug", "text": "bisphosphonates", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "19235747_1_Ent4", "text": "Bisphosphonate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19235747_1_Ent2", "text": "osteonecrosis of the jaw ( BRONJ )", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "19235747_1_Ent1", "text": "18.6 %", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "19235747_1_Ent0", "text": "18.6 % of patients", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "19235747_1_Ent6", "text": "intravenous", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "19235747_1_Ent3", "text": "intravenous bisphosphonates", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "19235747_1_Ent5", "text": "bisphosphonates", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "19249953_7", "wnd_id": "19249953_7_1", "text": "As it had been 10 months since her last dosage adjustment of diltiazem , it was unlikely that the statin - induced rhabdomyolysis was precipitated by diltiazem .", "tokens": ["As", "it", "had", "been", "10", "months", "since", "her", "last", "dosage", "adjustment", "of", "diltiazem", ",", "it", "was", "unlikely", "that", "the", "statin", "-", "induced", "rhabdomyolysis", "was", "precipitated", "by", "diltiazem", "."], "event_mentions": [{"id": "19249953_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitated", "start": 24, "end": 25}, "arguments": [{"entity_id": "19249953_7_Ent0", "role": "Effect", "text": "statin - induced rhabdomyolysis", "start": 19, "end": 23}, {"entity_id": "19249953_7_Ent1", "role": "Treatment", "text": "diltiazem", "start": 26, "end": 27}, {"entity_id": "19249953_7_Ent2", "role": "Treatment_Drug", "text": "diltiazem", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "19249953_7_Ent0", "text": "statin - induced rhabdomyolysis", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "19249953_7_Ent1", "text": "diltiazem", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "19249953_7_Ent2", "text": "diltiazem", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "19260037_2", "wnd_id": "19260037_2_1", "text": "A retrospective review of TTP patients with quinine - associated thrombotic microangiopathy ( TMA ) for whom ADAMTS13 was measured before plasma exchange was performed .", "tokens": ["A", "retrospective", "review", "of", "TTP", "patients", "with", "quinine", "-", "associated", "thrombotic", "microangiopathy", "(", "TMA", ")", "for", "whom", "ADAMTS13", "was", "measured", "before", "plasma", "exchange", "was", "performed", "."], "event_mentions": [{"id": "19260037_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "19260037_2_Ent1", "role": "Subject_Disorder", "text": "TTP", "start": 4, "end": 5}, {"entity_id": "19260037_2_Ent0", "role": "Subject", "text": "TTP patients", "start": 4, "end": 6}, {"entity_id": "19260037_2_Ent3", "role": "Treatment", "text": "quinine", "start": 7, "end": 8}, {"entity_id": "19260037_2_Ent4", "role": "Treatment_Drug", "text": "quinine", "start": 7, "end": 8}, {"entity_id": "19260037_2_Ent2", "role": "Effect", "text": "thrombotic microangiopathy ( TMA )", "start": 10, "end": 15}]}], "entity_mentions": [{"id": "19260037_2_Ent1", "text": "TTP", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19260037_2_Ent0", "text": "TTP patients", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "19260037_2_Ent3", "text": "quinine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19260037_2_Ent4", "text": "quinine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19260037_2_Ent2", "text": "thrombotic microangiopathy ( TMA )", "entity_type": "Entity", "start": 10, "end": 15}], "lang": "en"}
{"doc_id": "19296063_2", "wnd_id": "19296063_2_1", "text": "However , acute cardiomyopathy and pericarditis secondary to methylphenidate use has been rarely reported .", "tokens": ["However", ",", "acute", "cardiomyopathy", "and", "pericarditis", "secondary", "to", "methylphenidate", "use", "has", "been", "rarely", "reported", "."], "event_mentions": [{"id": "19296063_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "use", "start": 9, "end": 10}, "arguments": [{"entity_id": "19296063_2_Ent0", "role": "Effect", "text": "acute cardiomyopathy and pericarditis", "start": 2, "end": 6}, {"entity_id": "19296063_2_Ent1", "role": "Treatment", "text": "methylphenidate", "start": 8, "end": 9}, {"entity_id": "19296063_2_Ent2", "role": "Treatment_Drug", "text": "methylphenidate", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "19296063_2_Ent0", "text": "acute cardiomyopathy and pericarditis", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "19296063_2_Ent1", "text": "methylphenidate", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19296063_2_Ent2", "text": "methylphenidate", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "19299370_1", "wnd_id": "19299370_1_1", "text": "According to the Naranjo et al . adverse - reaction probability scale , enoxaparin was the probable cause of hepatotoxicity in this patient .", "tokens": ["According", "to", "the", "Naranjo", "et", "al", ".", "adverse", "-", "reaction", "probability", "scale", ",", "enoxaparin", "was", "the", "probable", "cause", "of", "hepatotoxicity", "in", "this", "patient", "."], "event_mentions": [{"id": "19299370_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 17, "end": 18}, "arguments": [{"entity_id": "19299370_1_Ent2", "role": "Treatment", "text": "enoxaparin", "start": 13, "end": 14}, {"entity_id": "19299370_1_Ent3", "role": "Treatment_Drug", "text": "enoxaparin", "start": 13, "end": 14}, {"entity_id": "19299370_1_Ent1", "role": "Effect", "text": "hepatotoxicity", "start": 19, "end": 20}, {"entity_id": "19299370_1_Ent0", "role": "Subject", "text": "this patient", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "19299370_1_Ent2", "text": "enoxaparin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19299370_1_Ent3", "text": "enoxaparin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19299370_1_Ent1", "text": "hepatotoxicity", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "19299370_1_Ent0", "text": "this patient", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "19336028_1", "wnd_id": "19336028_1_1", "text": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis .", "tokens": ["A", "case", "of", "tuberculosis", "in", "a", "patient", "on", "Efalizumab", "and", "Etanercept", "for", "treatment", "of", "refractory", "palmopustular", "psoriasis", "and", "psoriatic", "arthritis", "."], "event_mentions": [{"id": "19336028_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 12, "end": 13}, "arguments": [{"entity_id": "19336028_1_Ent1", "role": "Effect", "text": "tuberculosis", "start": 3, "end": 4}, {"entity_id": "19336028_1_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "19336028_1_Ent4", "role": "Treatment_Drug", "text": "Efalizumab", "start": 8, "end": 9}, {"entity_id": "19336028_1_Ent6", "role": "Combination_Drug", "text": "Efalizumab", "start": 8, "end": 9}, {"entity_id": "19336028_1_Ent2", "role": "Treatment", "text": "Efalizumab and Etanercept", "start": 8, "end": 11}, {"entity_id": "19336028_1_Ent5", "role": "Treatment_Drug", "text": "Etanercept", "start": 10, "end": 11}, {"entity_id": "19336028_1_Ent7", "role": "Combination_Drug", "text": "Etanercept", "start": 10, "end": 11}, {"entity_id": "19336028_1_Ent3", "role": "Treatment_Disorder", "text": "refractory palmopustular psoriasis and psoriatic arthritis", "start": 14, "end": 20}]}], "entity_mentions": [{"id": "19336028_1_Ent1", "text": "tuberculosis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19336028_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "19336028_1_Ent4", "text": "Efalizumab", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19336028_1_Ent6", "text": "Efalizumab", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19336028_1_Ent2", "text": "Efalizumab and Etanercept", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "19336028_1_Ent5", "text": "Etanercept", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19336028_1_Ent7", "text": "Etanercept", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19336028_1_Ent3", "text": "refractory palmopustular psoriasis and psoriatic arthritis", "entity_type": "Entity", "start": 14, "end": 20}], "lang": "en"}
{"doc_id": "19354059_1", "wnd_id": "19354059_1_1", "text": "The most common complication of warfarin use is adverse bleeding .", "tokens": ["The", "most", "common", "complication", "of", "warfarin", "use", "is", "adverse", "bleeding", "."], "event_mentions": [{"id": "19354059_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "use", "start": 6, "end": 7}, "arguments": [{"entity_id": "19354059_1_Ent1", "role": "Treatment", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "19354059_1_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "19354059_1_Ent0", "role": "Effect", "text": "adverse bleeding", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "19354059_1_Ent1", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19354059_1_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19354059_1_Ent0", "text": "adverse bleeding", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "19390192_2", "wnd_id": "19390192_2_1", "text": "The uncomplicated long - term use of adequately - dosed AZA and stable non - toxic metabolite levels could not acknowledge TPMT deficiency as a primary cause of the leukopenia .", "tokens": ["The", "uncomplicated", "long", "-", "term", "use", "of", "adequately", "-", "dosed", "AZA", "and", "stable", "non", "-", "toxic", "metabolite", "levels", "could", "not", "acknowledge", "TPMT", "deficiency", "as", "a", "primary", "cause", "of", "the", "leukopenia", "."], "event_mentions": [{"id": "19390192_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 26, "end": 27}, "arguments": [{"entity_id": "19390192_2_Ent2", "role": "Treatment_Duration", "text": "long - term", "start": 2, "end": 5}, {"entity_id": "19390192_2_Ent1", "role": "Treatment", "text": "long - term use of adequately - dosed AZA and stable non - toxic metabolite levels could not acknowledge TPMT deficiency", "start": 2, "end": 23}, {"entity_id": "19390192_2_Ent3", "role": "Treatment_Dosage", "text": "adequately - dosed", "start": 7, "end": 10}, {"entity_id": "19390192_2_Ent4", "role": "Treatment_Drug", "text": "AZA", "start": 10, "end": 11}, {"entity_id": "19390192_2_Ent0", "role": "Effect", "text": "leukopenia", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "19390192_2_Ent2", "text": "long - term", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "19390192_2_Ent1", "text": "long - term use of adequately - dosed AZA and stable non - toxic metabolite levels could not acknowledge TPMT deficiency", "entity_type": "Entity", "start": 2, "end": 23}, {"id": "19390192_2_Ent3", "text": "adequately - dosed", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "19390192_2_Ent4", "text": "AZA", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19390192_2_Ent0", "text": "leukopenia", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "19434733_3", "wnd_id": "19434733_3_1", "text": "Two patients with HLH developed etoposide - related secondary acute myeloid leukemia ( sAML ) following therapy for HLH .", "tokens": ["Two", "patients", "with", "HLH", "developed", "etoposide", "-", "related", "secondary", "acute", "myeloid", "leukemia", "(", "sAML", ")", "following", "therapy", "for", "HLH", "."], "event_mentions": [{"id": "19434733_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 7, "end": 8}, "arguments": [{"entity_id": "19434733_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "19434733_3_Ent0", "role": "Subject", "text": "Two patients with HLH", "start": 0, "end": 4}, {"entity_id": "19434733_3_Ent4", "role": "Treatment_Disorder", "text": "HLH", "start": 3, "end": 4}, {"entity_id": "19434733_3_Ent3", "role": "Treatment", "text": "etoposide", "start": 5, "end": 6}, {"entity_id": "19434733_3_Ent5", "role": "Treatment_Drug", "text": "etoposide", "start": 5, "end": 6}, {"entity_id": "19434733_3_Ent2", "role": "Effect", "text": "secondary acute myeloid leukemia ( sAML )", "start": 8, "end": 15}]}], "entity_mentions": [{"id": "19434733_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19434733_3_Ent0", "text": "Two patients with HLH", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "19434733_3_Ent4", "text": "HLH", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19434733_3_Ent3", "text": "etoposide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19434733_3_Ent5", "text": "etoposide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19434733_3_Ent2", "text": "secondary acute myeloid leukemia ( sAML )", "entity_type": "Entity", "start": 8, "end": 15}], "lang": "en"}
{"doc_id": "19499966_1", "wnd_id": "19499966_1_1", "text": "At the end of his fifth cycle of sunitinib therapy , the patient complained of the development of abnormally large mammary glands associated with pain and peri - areolar erythema .", "tokens": ["At", "the", "end", "of", "his", "fifth", "cycle", "of", "sunitinib", "therapy", ",", "the", "patient", "complained", "of", "the", "development", "of", "abnormally", "large", "mammary", "glands", "associated", "with", "pain", "and", "peri", "-", "areolar", "erythema", "."], "event_mentions": [{"id": "19499966_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 16, "end": 17}, "arguments": [{"entity_id": "19499966_1_Ent4", "role": "Treatment_Freq", "text": "fifth cycle", "start": 5, "end": 7}, {"entity_id": "19499966_1_Ent2", "role": "Treatment", "text": "fifth cycle of sunitinib therapy", "start": 5, "end": 10}, {"entity_id": "19499966_1_Ent3", "role": "Treatment_Drug", "text": "sunitinib", "start": 8, "end": 9}, {"entity_id": "19499966_1_Ent0", "role": "Subject", "text": "the patient", "start": 11, "end": 13}, {"entity_id": "19499966_1_Ent1", "role": "Effect", "text": "abnormally large mammary glands associated with pain and peri - areolar erythema", "start": 18, "end": 30}]}], "entity_mentions": [{"id": "19499966_1_Ent4", "text": "fifth cycle", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "19499966_1_Ent2", "text": "fifth cycle of sunitinib therapy", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "19499966_1_Ent3", "text": "sunitinib", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19499966_1_Ent0", "text": "the patient", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "19499966_1_Ent1", "text": "abnormally large mammary glands associated with pain and peri - areolar erythema", "entity_type": "Entity", "start": 18, "end": 30}], "lang": "en"}
{"doc_id": "19499966_3", "wnd_id": "19499966_3_1", "text": "Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma .", "tokens": ["Onset", "of", "male", "gynaecomastia", "in", "a", "patient", "treated", "with", "sunitinib", "for", "metastatic", "renal", "cell", "carcinoma", "."], "event_mentions": [{"id": "19499966_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Onset", "start": 0, "end": 1}, "arguments": [{"entity_id": "19499966_3_Ent0", "role": "Subject", "text": "male", "start": 2, "end": 3}, {"entity_id": "19499966_3_Ent2", "role": "Subject_Gender", "text": "male", "start": 2, "end": 3}, {"entity_id": "19499966_3_Ent3", "role": "Effect", "text": "gynaecomastia", "start": 3, "end": 4}, {"entity_id": "19499966_3_Ent1", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "19499966_3_Ent6", "role": "Treatment_Drug", "text": "sunitinib", "start": 9, "end": 10}, {"entity_id": "19499966_3_Ent4", "role": "Treatment", "text": "sunitinib for metastatic renal cell carcinoma", "start": 9, "end": 15}, {"entity_id": "19499966_3_Ent5", "role": "Treatment_Disorder", "text": "metastatic renal cell carcinoma", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "19499966_3_Ent0", "text": "male", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19499966_3_Ent2", "text": "male", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19499966_3_Ent3", "text": "gynaecomastia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19499966_3_Ent1", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "19499966_3_Ent6", "text": "sunitinib", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19499966_3_Ent4", "text": "sunitinib for metastatic renal cell carcinoma", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "19499966_3_Ent5", "text": "metastatic renal cell carcinoma", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "19531695_11", "wnd_id": "19531695_11_1", "text": "A MEDLINE search ( 1966 - January 2009 ) revealed one in vivo pharmacokinetic study on the interaction between flecainide , a CYP2D6 substrate , and paroxetine , a CYP2D6 inhibitor , as well as 3 case reports of flecainide - induced delirium .", "tokens": ["A", "MEDLINE", "search", "(", "1966", "-", "January", "2009", ")", "revealed", "one", "in", "vivo", "pharmacokinetic", "study", "on", "the", "interaction", "between", "flecainide", ",", "a", "CYP2D6", "substrate", ",", "and", "paroxetine", ",", "a", "CYP2D6", "inhibitor", ",", "as", "well", "as", "3", "case", "reports", "of", "flecainide", "-", "induced", "delirium", "."], "event_mentions": [{"id": "19531695_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 41, "end": 42}, "arguments": [{"entity_id": "19531695_11_Ent1", "role": "Subject_Population", "text": "3", "start": 35, "end": 36}, {"entity_id": "19531695_11_Ent0", "role": "Subject", "text": "3 case reports", "start": 35, "end": 38}, {"entity_id": "19531695_11_Ent3", "role": "Treatment", "text": "flecainide", "start": 39, "end": 40}, {"entity_id": "19531695_11_Ent4", "role": "Treatment_Drug", "text": "flecainide", "start": 39, "end": 40}, {"entity_id": "19531695_11_Ent2", "role": "Effect", "text": "delirium", "start": 42, "end": 43}]}], "entity_mentions": [{"id": "19531695_11_Ent1", "text": "3", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "19531695_11_Ent0", "text": "3 case reports", "entity_type": "Entity", "start": 35, "end": 38}, {"id": "19531695_11_Ent3", "text": "flecainide", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "19531695_11_Ent4", "text": "flecainide", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "19531695_11_Ent2", "text": "delirium", "entity_type": "Entity", "start": 42, "end": 43}], "lang": "en"}
{"doc_id": "19531695_2", "wnd_id": "19531695_2_1", "text": "To describe a case of flecainide - induced delirium associated with a pharmacokinetic drug interaction with paroxetine .", "tokens": ["To", "describe", "a", "case", "of", "flecainide", "-", "induced", "delirium", "associated", "with", "a", "pharmacokinetic", "drug", "interaction", "with", "paroxetine", "."], "event_mentions": [{"id": "19531695_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "19531695_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "19531695_2_Ent2", "role": "Treatment", "text": "flecainide", "start": 5, "end": 6}, {"entity_id": "19531695_2_Ent4", "role": "Treatment_Drug", "text": "flecainide", "start": 5, "end": 6}, {"entity_id": "19531695_2_Ent7", "role": "Combination_Drug", "text": "flecainide", "start": 5, "end": 6}, {"entity_id": "19531695_2_Ent1", "role": "Effect", "text": "delirium", "start": 8, "end": 9}, {"entity_id": "19531695_2_Ent3", "role": "Treatment", "text": "interaction with paroxetine", "start": 14, "end": 17}, {"entity_id": "19531695_2_Ent5", "role": "Treatment_Drug", "text": "paroxetine", "start": 16, "end": 17}, {"entity_id": "19531695_2_Ent6", "role": "Combination_Drug", "text": "paroxetine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "19531695_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "19531695_2_Ent2", "text": "flecainide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19531695_2_Ent4", "text": "flecainide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19531695_2_Ent7", "text": "flecainide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19531695_2_Ent1", "text": "delirium", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19531695_2_Ent3", "text": "interaction with paroxetine", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "19531695_2_Ent5", "text": "paroxetine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19531695_2_Ent6", "text": "paroxetine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "19531696_2", "wnd_id": "19531696_2_1", "text": "To report a probable interaction between warfarin and marijuana smoking , resulting in increased international normalized ratio ( INR ) values and bleeding complications .", "tokens": ["To", "report", "a", "probable", "interaction", "between", "warfarin", "and", "marijuana", "smoking", ",", "resulting", "in", "increased", "international", "normalized", "ratio", "(", "INR", ")", "values", "and", "bleeding", "complications", "."], "event_mentions": [{"id": "19531696_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 11, "end": 12}, "arguments": [{"entity_id": "19531696_2_Ent1", "role": "Treatment", "text": "interaction between warfarin and marijuana smoking", "start": 4, "end": 10}, {"entity_id": "19531696_2_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 6, "end": 7}, {"entity_id": "19531696_2_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 6, "end": 7}, {"entity_id": "19531696_2_Ent3", "role": "Treatment_Drug", "text": "marijuana", "start": 8, "end": 9}, {"entity_id": "19531696_2_Ent6", "role": "Combination_Drug", "text": "marijuana", "start": 8, "end": 9}, {"entity_id": "19531696_2_Ent4", "role": "Treatment_Route", "text": "smoking", "start": 9, "end": 10}, {"entity_id": "19531696_2_Ent0", "role": "Effect", "text": "increased international normalized ratio ( INR ) values and bleeding complications", "start": 13, "end": 24}]}], "entity_mentions": [{"id": "19531696_2_Ent1", "text": "interaction between warfarin and marijuana smoking", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "19531696_2_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19531696_2_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19531696_2_Ent3", "text": "marijuana", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19531696_2_Ent6", "text": "marijuana", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19531696_2_Ent4", "text": "smoking", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19531696_2_Ent0", "text": "increased international normalized ratio ( INR ) values and bleeding complications", "entity_type": "Entity", "start": 13, "end": 24}], "lang": "en"}
{"doc_id": "19537383_4", "wnd_id": "19537383_4_1", "text": "This article presents a case of an atypical localized cutaneous eruption with an unusual course and protracted resolution time associated with sorafenib therapy .", "tokens": ["This", "article", "presents", "a", "case", "of", "an", "atypical", "localized", "cutaneous", "eruption", "with", "an", "unusual", "course", "and", "protracted", "resolution", "time", "associated", "with", "sorafenib", "therapy", "."], "event_mentions": [{"id": "19537383_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 19, "end": 21}, "arguments": [{"entity_id": "19537383_4_Ent0", "role": "Effect", "text": "an atypical localized cutaneous eruption with an unusual course and protracted resolution time", "start": 6, "end": 19}, {"entity_id": "19537383_4_Ent2", "role": "Treatment_Drug", "text": "sorafenib", "start": 21, "end": 22}, {"entity_id": "19537383_4_Ent1", "role": "Treatment", "text": "sorafenib therapy", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "19537383_4_Ent0", "text": "an atypical localized cutaneous eruption with an unusual course and protracted resolution time", "entity_type": "Entity", "start": 6, "end": 19}, {"id": "19537383_4_Ent2", "text": "sorafenib", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "19537383_4_Ent1", "text": "sorafenib therapy", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "19540093_3", "wnd_id": "19540093_3_1", "text": "Pancreatitis has been associated with the tetracycline class of antibiotics and concerns about tigecycline - induced acute pancreatitis have recently been raised .", "tokens": ["Pancreatitis", "has", "been", "associated", "with", "the", "tetracycline", "class", "of", "antibiotics", "and", "concerns", "about", "tigecycline", "-", "induced", "acute", "pancreatitis", "have", "recently", "been", "raised", "."], "event_mentions": [{"id": "19540093_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 15, "end": 16}, "arguments": [{"entity_id": "19540093_3_Ent1", "role": "Treatment", "text": "tigecycline", "start": 13, "end": 14}, {"entity_id": "19540093_3_Ent2", "role": "Treatment_Drug", "text": "tigecycline", "start": 13, "end": 14}, {"entity_id": "19540093_3_Ent0", "role": "Effect", "text": "acute pancreatitis", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "19540093_3_Ent1", "text": "tigecycline", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19540093_3_Ent2", "text": "tigecycline", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19540093_3_Ent0", "text": "acute pancreatitis", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "1954704_1", "wnd_id": "1954704_1_1", "text": "Drug induced polymyositis secondary to leuprolide acetate ( Lupron ) therapy for prostate carcinoma .", "tokens": ["Drug", "induced", "polymyositis", "secondary", "to", "leuprolide", "acetate", "(", "Lupron", ")", "therapy", "for", "prostate", "carcinoma", "."], "event_mentions": [{"id": "1954704_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary to", "start": 3, "end": 5}, "arguments": [{"entity_id": "1954704_1_Ent0", "role": "Effect", "text": "Drug induced polymyositis", "start": 0, "end": 3}, {"entity_id": "1954704_1_Ent3", "role": "Treatment_Drug", "text": "leuprolide acetate ( Lupron )", "start": 5, "end": 10}, {"entity_id": "1954704_1_Ent1", "role": "Treatment", "text": "leuprolide acetate ( Lupron ) therapy", "start": 5, "end": 11}, {"entity_id": "1954704_1_Ent2", "role": "Treatment_Disorder", "text": "prostate carcinoma", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "1954704_1_Ent0", "text": "Drug induced polymyositis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "1954704_1_Ent3", "text": "leuprolide acetate ( Lupron )", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "1954704_1_Ent1", "text": "leuprolide acetate ( Lupron ) therapy", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "1954704_1_Ent2", "text": "prostate carcinoma", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "19567656_3", "wnd_id": "19567656_3_1", "text": "OBJECTIVE : To describe a case of sertraline - induced rhabdomyolysis in an elderly patient with dementia and comorbidities .", "tokens": ["OBJECTIVE", ":", "To", "describe", "a", "case", "of", "sertraline", "-", "induced", "rhabdomyolysis", "in", "an", "elderly", "patient", "with", "dementia", "and", "comorbidities", "."], "event_mentions": [{"id": "19567656_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "19567656_3_Ent3", "role": "Treatment", "text": "sertraline", "start": 7, "end": 8}, {"entity_id": "19567656_3_Ent6", "role": "Treatment_Drug", "text": "sertraline", "start": 7, "end": 8}, {"entity_id": "19567656_3_Ent2", "role": "Effect", "text": "rhabdomyolysis", "start": 10, "end": 11}, {"entity_id": "19567656_3_Ent0", "role": "Subject", "text": "an elderly patient with dementia and comorbidities", "start": 12, "end": 19}, {"entity_id": "19567656_3_Ent1", "role": "Subject_Age", "text": "elderly", "start": 13, "end": 14}, {"entity_id": "19567656_3_Ent5", "role": "Treatment_Disorder", "text": "dementia", "start": 16, "end": 17}, {"entity_id": "19567656_3_Ent4", "role": "Treatment_Disorder", "text": "comorbidities", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "19567656_3_Ent3", "text": "sertraline", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19567656_3_Ent6", "text": "sertraline", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19567656_3_Ent2", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19567656_3_Ent0", "text": "an elderly patient with dementia and comorbidities", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "19567656_3_Ent1", "text": "elderly", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19567656_3_Ent5", "text": "dementia", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19567656_3_Ent4", "text": "comorbidities", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "19579947_1", "wnd_id": "19579947_1_1", "text": "He had priapism following the use of olanzapine .", "tokens": ["He", "had", "priapism", "following", "the", "use", "of", "olanzapine", "."], "event_mentions": [{"id": "19579947_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "19579947_1_Ent0", "role": "Effect", "text": "priapism", "start": 2, "end": 3}, {"entity_id": "19579947_1_Ent1", "role": "Treatment", "text": "olanzapine", "start": 7, "end": 8}, {"entity_id": "19579947_1_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "19579947_1_Ent0", "text": "priapism", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19579947_1_Ent1", "text": "olanzapine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19579947_1_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "19653965_1", "wnd_id": "19653965_1_1", "text": "These two cases highlight the importance of considering lopinavir / ritonavir induced arrhythmias when dealing with HIV - positive individuals .", "tokens": ["These", "two", "cases", "highlight", "the", "importance", "of", "considering", "lopinavir", "/", "ritonavir", "induced", "arrhythmias", "when", "dealing", "with", "HIV", "-", "positive", "individuals", "."], "event_mentions": [{"id": "19653965_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "19653965_1_Ent3", "role": "Treatment_Drug", "text": "lopinavir", "start": 8, "end": 9}, {"entity_id": "19653965_1_Ent6", "role": "Combination_Drug", "text": "lopinavir", "start": 8, "end": 9}, {"entity_id": "19653965_1_Ent2", "role": "Treatment", "text": "lopinavir / ritonavir", "start": 8, "end": 11}, {"entity_id": "19653965_1_Ent4", "role": "Treatment_Drug", "text": "ritonavir", "start": 10, "end": 11}, {"entity_id": "19653965_1_Ent7", "role": "Combination_Drug", "text": "ritonavir", "start": 10, "end": 11}, {"entity_id": "19653965_1_Ent1", "role": "Effect", "text": "arrhythmias", "start": 12, "end": 13}, {"entity_id": "19653965_1_Ent5", "role": "Treatment_Disorder", "text": "HIV", "start": 16, "end": 17}, {"entity_id": "19653965_1_Ent0", "role": "Subject", "text": "HIV - positive individuals", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "19653965_1_Ent3", "text": "lopinavir", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19653965_1_Ent6", "text": "lopinavir", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19653965_1_Ent2", "text": "lopinavir / ritonavir", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "19653965_1_Ent4", "text": "ritonavir", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19653965_1_Ent7", "text": "ritonavir", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19653965_1_Ent1", "text": "arrhythmias", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19653965_1_Ent5", "text": "HIV", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19653965_1_Ent0", "text": "HIV - positive individuals", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "19667003_15", "wnd_id": "19667003_15_1", "text": "He had also developed elevated serum ammonia levels while on valproic acid .", "tokens": ["He", "had", "also", "developed", "elevated", "serum", "ammonia", "levels", "while", "on", "valproic", "acid", "."], "event_mentions": [{"id": "19667003_15_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 3, "end": 4}, "arguments": [{"entity_id": "19667003_15_Ent0", "role": "Subject", "text": "He", "start": 0, "end": 1}, {"entity_id": "19667003_15_Ent1", "role": "Subject_Gender", "text": "He", "start": 0, "end": 1}, {"entity_id": "19667003_15_Ent2", "role": "Effect", "text": "elevated serum ammonia levels", "start": 4, "end": 8}, {"entity_id": "19667003_15_Ent3", "role": "Treatment", "text": "valproic acid", "start": 10, "end": 12}, {"entity_id": "19667003_15_Ent4", "role": "Treatment_Drug", "text": "valproic acid", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "19667003_15_Ent0", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19667003_15_Ent1", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19667003_15_Ent2", "text": "elevated serum ammonia levels", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "19667003_15_Ent3", "text": "valproic acid", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "19667003_15_Ent4", "text": "valproic acid", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "19667003_4", "wnd_id": "19667003_4_1", "text": "After three weeks of carbamazepine therapy , the patient arrived at the emergency department ( ED ) with severe agitation and aggressive behavior .", "tokens": ["After", "three", "weeks", "of", "carbamazepine", "therapy", ",", "the", "patient", "arrived", "at", "the", "emergency", "department", "(", "ED", ")", "with", "severe", "agitation", "and", "aggressive", "behavior", "."], "event_mentions": [{"id": "19667003_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "19667003_4_Ent2", "role": "Treatment", "text": "After three weeks of carbamazepine therapy", "start": 0, "end": 6}, {"entity_id": "19667003_4_Ent3", "role": "Treatment_Duration", "text": "three weeks", "start": 1, "end": 3}, {"entity_id": "19667003_4_Ent4", "role": "Treatment_Drug", "text": "carbamazepine", "start": 4, "end": 5}, {"entity_id": "19667003_4_Ent0", "role": "Subject", "text": "patient", "start": 8, "end": 9}, {"entity_id": "19667003_4_Ent1", "role": "Effect", "text": "severe agitation and aggressive behavior", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "19667003_4_Ent2", "text": "After three weeks of carbamazepine therapy", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "19667003_4_Ent3", "text": "three weeks", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "19667003_4_Ent4", "text": "carbamazepine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19667003_4_Ent0", "text": "patient", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19667003_4_Ent1", "text": "severe agitation and aggressive behavior", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "19687711_6", "wnd_id": "19687711_6_1", "text": "The potential development of SJS / TEN , a severe life - threatening illness , emphasizes the need for judicious use of TMP - Sx and close monitoring and follow - up for patients who were given TMP - Sx for SSTIs .", "tokens": ["The", "potential", "development", "of", "SJS", "/", "TEN", ",", "a", "severe", "life", "-", "threatening", "illness", ",", "emphasizes", "the", "need", "for", "judicious", "use", "of", "TMP", "-", "Sx", "and", "close", "monitoring", "and", "follow", "-", "up", "for", "patients", "who", "were", "given", "TMP", "-", "Sx", "for", "SSTIs", "."], "event_mentions": [{"id": "19687711_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 2, "end": 3}, "arguments": [{"entity_id": "19687711_6_Ent1", "role": "Effect", "text": "SJS / TEN , a severe life - threatening illness", "start": 4, "end": 14}, {"entity_id": "19687711_6_Ent0", "role": "Subject", "text": "patients", "start": 33, "end": 34}, {"entity_id": "19687711_6_Ent4", "role": "Treatment_Drug", "text": "TMP", "start": 37, "end": 38}, {"entity_id": "19687711_6_Ent6", "role": "Combination_Drug", "text": "TMP", "start": 37, "end": 38}, {"entity_id": "19687711_6_Ent2", "role": "Treatment", "text": "TMP - Sx", "start": 37, "end": 40}, {"entity_id": "19687711_6_Ent5", "role": "Treatment_Drug", "text": "Sx", "start": 39, "end": 40}, {"entity_id": "19687711_6_Ent7", "role": "Combination_Drug", "text": "Sx", "start": 39, "end": 40}, {"entity_id": "19687711_6_Ent3", "role": "Treatment_Disorder", "text": "SSTIs", "start": 41, "end": 42}]}], "entity_mentions": [{"id": "19687711_6_Ent1", "text": "SJS / TEN , a severe life - threatening illness", "entity_type": "Entity", "start": 4, "end": 14}, {"id": "19687711_6_Ent0", "text": "patients", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "19687711_6_Ent4", "text": "TMP", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "19687711_6_Ent6", "text": "TMP", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "19687711_6_Ent2", "text": "TMP - Sx", "entity_type": "Entity", "start": 37, "end": 40}, {"id": "19687711_6_Ent5", "text": "Sx", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "19687711_6_Ent7", "text": "Sx", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "19687711_6_Ent3", "text": "SSTIs", "entity_type": "Entity", "start": 41, "end": 42}], "lang": "en"}
{"doc_id": "19690222_1", "wnd_id": "19690222_1_1", "text": "CONCLUSIONS : Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of LMWH .", "tokens": ["CONCLUSIONS", ":", "Spontaneous", "hemothorax", "is", "a", "rare", "phenomenon", "in", "conjunction", "with", "LMWH", "but", "should", "be", "considered", "in", "cases", "of", "acute", "respiratory", "distress", "following", "commencement", "of", "LMWH", "."], "event_mentions": [{"id": "19690222_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "considered", "start": 15, "end": 16}, "arguments": [{"entity_id": "19690222_1_Ent0", "role": "Effect", "text": "Spontaneous hemothorax", "start": 2, "end": 4}, {"entity_id": "19690222_1_Ent2", "role": "Treatment", "text": "LMWH", "start": 11, "end": 12}, {"entity_id": "19690222_1_Ent3", "role": "Treatment_Drug", "text": "LMWH", "start": 11, "end": 12}, {"entity_id": "19690222_1_Ent1", "role": "Effect", "text": "acute respiratory distress", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "19690222_1_Ent0", "text": "Spontaneous hemothorax", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "19690222_1_Ent2", "text": "LMWH", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19690222_1_Ent3", "text": "LMWH", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19690222_1_Ent1", "text": "acute respiratory distress", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "19697589_3", "wnd_id": "19697589_3_1", "text": "While serotonin syndrome has become more frequent in an overdose situation and when an interacting drug is given , the toxicity of SSIRs is less than that of most other psychiatric drugs .", "tokens": ["While", "serotonin", "syndrome", "has", "become", "more", "frequent", "in", "an", "overdose", "situation", "and", "when", "an", "interacting", "drug", "is", "given", ",", "the", "toxicity", "of", "SSIRs", "is", "less", "than", "that", "of", "most", "other", "psychiatric", "drugs", "."], "event_mentions": [{"id": "19697589_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 20, "end": 21}, "arguments": [{"entity_id": "19697589_3_Ent0", "role": "Effect", "text": "serotonin syndrome", "start": 1, "end": 3}, {"entity_id": "19697589_3_Ent1", "role": "Treatment", "text": "SSIRs", "start": 22, "end": 23}, {"entity_id": "19697589_3_Ent2", "role": "Treatment_Drug", "text": "SSIRs", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "19697589_3_Ent0", "text": "serotonin syndrome", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "19697589_3_Ent1", "text": "SSIRs", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "19697589_3_Ent2", "text": "SSIRs", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "19707032_3", "wnd_id": "19707032_3_1", "text": "AIM : To report a patient with diabetic rubeosis who suffered from acute retinal ischemic change and stroke after intravitreal injection of bevacizumab .", "tokens": ["AIM", ":", "To", "report", "a", "patient", "with", "diabetic", "rubeosis", "who", "suffered", "from", "acute", "retinal", "ischemic", "change", "and", "stroke", "after", "intravitreal", "injection", "of", "bevacizumab", "."], "event_mentions": [{"id": "19707032_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffered", "start": 10, "end": 11}, "arguments": [{"entity_id": "19707032_3_Ent0", "role": "Subject", "text": "patient with diabetic rubeosis", "start": 5, "end": 9}, {"entity_id": "19707032_3_Ent3", "role": "Treatment_Disorder", "text": "diabetic rubeosis", "start": 7, "end": 9}, {"entity_id": "19707032_3_Ent1", "role": "Effect", "text": "acute retinal ischemic change and stroke", "start": 12, "end": 18}, {"entity_id": "19707032_3_Ent5", "role": "Treatment_Route", "text": "intravitreal injection", "start": 19, "end": 21}, {"entity_id": "19707032_3_Ent2", "role": "Treatment", "text": "intravitreal injection of bevacizumab", "start": 19, "end": 23}, {"entity_id": "19707032_3_Ent4", "role": "Treatment_Drug", "text": "bevacizumab", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "19707032_3_Ent0", "text": "patient with diabetic rubeosis", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "19707032_3_Ent3", "text": "diabetic rubeosis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "19707032_3_Ent1", "text": "acute retinal ischemic change and stroke", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "19707032_3_Ent5", "text": "intravitreal injection", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "19707032_3_Ent2", "text": "intravitreal injection of bevacizumab", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "19707032_3_Ent4", "text": "bevacizumab", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "19707032_5", "wnd_id": "19707032_5_1", "text": "Three days after intravitreal injection of bevacizumab , acute ocular ischemic syndrome occurred .", "tokens": ["Three", "days", "after", "intravitreal", "injection", "of", "bevacizumab", ",", "acute", "ocular", "ischemic", "syndrome", "occurred", "."], "event_mentions": [{"id": "19707032_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 12, "end": 13}, "arguments": [{"entity_id": "19707032_5_Ent4", "role": "Treatment_Time_elapsed", "text": "Three days", "start": 0, "end": 2}, {"entity_id": "19707032_5_Ent1", "role": "Treatment", "text": "Three days after intravitreal injection of bevacizumab", "start": 0, "end": 7}, {"entity_id": "19707032_5_Ent3", "role": "Treatment_Route", "text": "intravitreal injection", "start": 3, "end": 5}, {"entity_id": "19707032_5_Ent2", "role": "Treatment_Drug", "text": "bevacizumab", "start": 6, "end": 7}, {"entity_id": "19707032_5_Ent0", "role": "Effect", "text": "acute ocular ischemic syndrome", "start": 8, "end": 12}]}], "entity_mentions": [{"id": "19707032_5_Ent4", "text": "Three days", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19707032_5_Ent1", "text": "Three days after intravitreal injection of bevacizumab", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "19707032_5_Ent3", "text": "intravitreal injection", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "19707032_5_Ent2", "text": "bevacizumab", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19707032_5_Ent0", "text": "acute ocular ischemic syndrome", "entity_type": "Entity", "start": 8, "end": 12}], "lang": "en"}
{"doc_id": "19717383_1", "wnd_id": "19717383_1_1", "text": "Herein , we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide , prednisone , vincristine , cyclophosphamide , doxorubicin , and rituximab ( R - EPOCH ) for diffuse large B - cell lymphoma .", "tokens": ["Herein", ",", "we", "describe", "a", "patient", "with", "AIDS", "who", "presented", "to", "medical", "attention", "with", "pancytopenia", "48", "months", "postchemotherapy", "with", "etoposide", ",", "prednisone", ",", "vincristine", ",", "cyclophosphamide", ",", "doxorubicin", ",", "and", "rituximab", "(", "R", "-", "EPOCH", ")", "for", "diffuse", "large", "B", "-", "cell", "lymphoma", "."], "event_mentions": [{"id": "19717383_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 9, "end": 10}, "arguments": [{"entity_id": "19717383_1_Ent0", "role": "Subject", "text": "a patient with AIDS", "start": 4, "end": 8}, {"entity_id": "19717383_1_Ent1", "role": "Subject_Disorder", "text": "AIDS", "start": 7, "end": 8}, {"entity_id": "19717383_1_Ent2", "role": "Effect", "text": "medical attention with pancytopenia", "start": 11, "end": 15}, {"entity_id": "19717383_1_Ent5", "role": "Treatment_Duration", "text": "48 months", "start": 15, "end": 17}, {"entity_id": "19717383_1_Ent3", "role": "Treatment", "text": "48 months postchemotherapy with etoposide , prednisone , vincristine , cyclophosphamide , doxorubicin , and rituximab ( R - EPOCH )", "start": 15, "end": 36}, {"entity_id": "19717383_1_Ent6", "role": "Treatment_Drug", "text": "etoposide", "start": 19, "end": 20}, {"entity_id": "19717383_1_Ent12", "role": "Combination_Drug", "text": "etoposide", "start": 19, "end": 20}, {"entity_id": "19717383_1_Ent7", "role": "Treatment_Drug", "text": "prednisone", "start": 21, "end": 22}, {"entity_id": "19717383_1_Ent13", "role": "Combination_Drug", "text": "prednisone", "start": 21, "end": 22}, {"entity_id": "19717383_1_Ent8", "role": "Treatment_Drug", "text": "vincristine", "start": 23, "end": 24}, {"entity_id": "19717383_1_Ent14", "role": "Combination_Drug", "text": "vincristine", "start": 23, "end": 24}, {"entity_id": "19717383_1_Ent9", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 25, "end": 26}, {"entity_id": "19717383_1_Ent15", "role": "Combination_Drug", "text": "cyclophosphamide", "start": 25, "end": 26}, {"entity_id": "19717383_1_Ent10", "role": "Treatment_Drug", "text": "doxorubicin", "start": 27, "end": 28}, {"entity_id": "19717383_1_Ent16", "role": "Combination_Drug", "text": "doxorubicin", "start": 27, "end": 28}, {"entity_id": "19717383_1_Ent11", "role": "Treatment_Drug", "text": "rituximab", "start": 30, "end": 31}, {"entity_id": "19717383_1_Ent17", "role": "Combination_Drug", "text": "rituximab", "start": 30, "end": 31}, {"entity_id": "19717383_1_Ent4", "role": "Treatment_Disorder", "text": "diffuse large B - cell lymphoma", "start": 37, "end": 43}]}], "entity_mentions": [{"id": "19717383_1_Ent0", "text": "a patient with AIDS", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "19717383_1_Ent1", "text": "AIDS", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19717383_1_Ent2", "text": "medical attention with pancytopenia", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "19717383_1_Ent5", "text": "48 months", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "19717383_1_Ent3", "text": "48 months postchemotherapy with etoposide , prednisone , vincristine , cyclophosphamide , doxorubicin , and rituximab ( R - EPOCH )", "entity_type": "Entity", "start": 15, "end": 36}, {"id": "19717383_1_Ent6", "text": "etoposide", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "19717383_1_Ent12", "text": "etoposide", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "19717383_1_Ent7", "text": "prednisone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "19717383_1_Ent13", "text": "prednisone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "19717383_1_Ent8", "text": "vincristine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "19717383_1_Ent14", "text": "vincristine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "19717383_1_Ent9", "text": "cyclophosphamide", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "19717383_1_Ent15", "text": "cyclophosphamide", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "19717383_1_Ent10", "text": "doxorubicin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "19717383_1_Ent16", "text": "doxorubicin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "19717383_1_Ent11", "text": "rituximab", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "19717383_1_Ent17", "text": "rituximab", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "19717383_1_Ent4", "text": "diffuse large B - cell lymphoma", "entity_type": "Entity", "start": 37, "end": 43}], "lang": "en"}
{"doc_id": "19745701_1", "wnd_id": "19745701_1_1", "text": "Increased awareness is needed on the possible occurrence of LPD resembling gastric cancer in rheumatoid arthritis patients treated with MTX .", "tokens": ["Increased", "awareness", "is", "needed", "on", "the", "possible", "occurrence", "of", "LPD", "resembling", "gastric", "cancer", "in", "rheumatoid", "arthritis", "patients", "treated", "with", "MTX", "."], "event_mentions": [{"id": "19745701_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurrence", "start": 7, "end": 8}, "arguments": [{"entity_id": "19745701_1_Ent1", "role": "Effect", "text": "LPD", "start": 9, "end": 10}, {"entity_id": "19745701_1_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 14, "end": 16}, {"entity_id": "19745701_1_Ent0", "role": "Subject", "text": "rheumatoid arthritis patients", "start": 14, "end": 17}, {"entity_id": "19745701_1_Ent2", "role": "Treatment", "text": "MTX", "start": 19, "end": 20}, {"entity_id": "19745701_1_Ent4", "role": "Treatment_Drug", "text": "MTX", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "19745701_1_Ent1", "text": "LPD", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19745701_1_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "19745701_1_Ent0", "text": "rheumatoid arthritis patients", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "19745701_1_Ent2", "text": "MTX", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "19745701_1_Ent4", "text": "MTX", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "19745701_3", "wnd_id": "19745701_3_1", "text": "She was diagnosed with Epstein - Barr virus - associated polymorphic lymphoproliferative disorder ( LPD ) due to immunodeficiency caused by MTX administration .", "tokens": ["She", "was", "diagnosed", "with", "Epstein", "-", "Barr", "virus", "-", "associated", "polymorphic", "lymphoproliferative", "disorder", "(", "LPD", ")", "due", "to", "immunodeficiency", "caused", "by", "MTX", "administration", "."], "event_mentions": [{"id": "19745701_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 16, "end": 17}, "arguments": [{"entity_id": "19745701_3_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "19745701_3_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "19745701_3_Ent2", "role": "Effect", "text": "Epstein - Barr virus - associated polymorphic lymphoproliferative disorder ( LPD )", "start": 4, "end": 16}, {"entity_id": "19745701_3_Ent3", "role": "Treatment", "text": "immunodeficiency caused by MTX administration", "start": 18, "end": 23}, {"entity_id": "19745701_3_Ent4", "role": "Treatment_Drug", "text": "MTX", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "19745701_3_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19745701_3_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19745701_3_Ent2", "text": "Epstein - Barr virus - associated polymorphic lymphoproliferative disorder ( LPD )", "entity_type": "Entity", "start": 4, "end": 16}, {"id": "19745701_3_Ent3", "text": "immunodeficiency caused by MTX administration", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "19745701_3_Ent4", "text": "MTX", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "19754002_1", "wnd_id": "19754002_1_1", "text": "Mood stabilizer therapy and pravastatin : higher risk for adverse skin reactions ?", "tokens": ["Mood", "stabilizer", "therapy", "and", "pravastatin", ":", "higher", "risk", "for", "adverse", "skin", "reactions", "?"], "event_mentions": [{"id": "19754002_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 7, "end": 8}, "arguments": [{"entity_id": "19754002_1_Ent2", "role": "Treatment_Drug", "text": "Mood stabilizer", "start": 0, "end": 2}, {"entity_id": "19754002_1_Ent4", "role": "Combination_Drug", "text": "Mood stabilizer", "start": 0, "end": 2}, {"entity_id": "19754002_1_Ent1", "role": "Treatment", "text": "Mood stabilizer therapy and pravastatin", "start": 0, "end": 5}, {"entity_id": "19754002_1_Ent3", "role": "Treatment_Drug", "text": "pravastatin", "start": 4, "end": 5}, {"entity_id": "19754002_1_Ent5", "role": "Combination_Drug", "text": "pravastatin", "start": 4, "end": 5}, {"entity_id": "19754002_1_Ent0", "role": "Effect", "text": "adverse skin reactions", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "19754002_1_Ent2", "text": "Mood stabilizer", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19754002_1_Ent4", "text": "Mood stabilizer", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19754002_1_Ent1", "text": "Mood stabilizer therapy and pravastatin", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "19754002_1_Ent3", "text": "pravastatin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19754002_1_Ent5", "text": "pravastatin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19754002_1_Ent0", "text": "adverse skin reactions", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "19838099_2", "wnd_id": "19838099_2_1", "text": "Dasatinib - induced pleural effusions : a lymphatic network disorder ?", "tokens": ["Dasatinib", "-", "induced", "pleural", "effusions", ":", "a", "lymphatic", "network", "disorder", "?"], "event_mentions": [{"id": "19838099_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19838099_2_Ent1", "role": "Treatment", "text": "Dasatinib", "start": 0, "end": 1}, {"entity_id": "19838099_2_Ent2", "role": "Treatment_Drug", "text": "Dasatinib", "start": 0, "end": 1}, {"entity_id": "19838099_2_Ent0", "role": "Effect", "text": "pleural effusions", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "19838099_2_Ent1", "text": "Dasatinib", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19838099_2_Ent2", "text": "Dasatinib", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19838099_2_Ent0", "text": "pleural effusions", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "19844714_1", "wnd_id": "19844714_1_1", "text": "RESULTS : One case of recurrent primary peritoneal carcinoma previously treated with a carboplatin - based regimen , developed a platinum hypersensitivity .", "tokens": ["RESULTS", ":", "One", "case", "of", "recurrent", "primary", "peritoneal", "carcinoma", "previously", "treated", "with", "a", "carboplatin", "-", "based", "regimen", ",", "developed", "a", "platinum", "hypersensitivity", "."], "event_mentions": [{"id": "19844714_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "19844714_1_Ent3", "role": "Treatment_Disorder", "text": "recurrent primary peritoneal carcinoma", "start": 5, "end": 9}, {"entity_id": "19844714_1_Ent1", "role": "Treatment", "text": "a carboplatin - based regimen", "start": 12, "end": 17}, {"entity_id": "19844714_1_Ent2", "role": "Treatment_Drug", "text": "carboplatin", "start": 13, "end": 14}, {"entity_id": "19844714_1_Ent0", "role": "Effect", "text": "a platinum hypersensitivity", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "19844714_1_Ent3", "text": "recurrent primary peritoneal carcinoma", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "19844714_1_Ent1", "text": "a carboplatin - based regimen", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "19844714_1_Ent2", "text": "carboplatin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19844714_1_Ent0", "text": "a platinum hypersensitivity", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "19884751_2", "wnd_id": "19884751_2_1", "text": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug , Amikacin .", "tokens": ["Recovery", "of", "the", "tubular", "dysfunction", "took", "15", "days", "following", "cessation", "of", "the", "offending", "drug", ",", "Amikacin", "."], "event_mentions": [{"id": "19884751_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Recovery", "start": 0, "end": 1}, "arguments": [{"entity_id": "19884751_2_Ent1", "role": "Treatment_Disorder", "text": "tubular dysfunction", "start": 3, "end": 5}, {"entity_id": "19884751_2_Ent3", "role": "Treatment_Time_elapsed", "text": "15 days", "start": 6, "end": 8}, {"entity_id": "19884751_2_Ent0", "role": "Treatment", "text": "15 days following cessation of the offending drug , Amikacin", "start": 6, "end": 16}, {"entity_id": "19884751_2_Ent4", "role": "Treatment_Dosage", "text": "cessation", "start": 9, "end": 10}, {"entity_id": "19884751_2_Ent2", "role": "Treatment_Drug", "text": "Amikacin", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "19884751_2_Ent1", "text": "tubular dysfunction", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "19884751_2_Ent3", "text": "15 days", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "19884751_2_Ent0", "text": "15 days following cessation of the offending drug , Amikacin", "entity_type": "Entity", "start": 6, "end": 16}, {"id": "19884751_2_Ent4", "text": "cessation", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19884751_2_Ent2", "text": "Amikacin", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "19897274_1", "wnd_id": "19897274_1_1", "text": "However , a recent post - marketing survey in Japan revealed that interstitial pneumonia occurred in 4 among approximately 2 000 Japanese patients treated with sorafenib .", "tokens": ["However", ",", "a", "recent", "post", "-", "marketing", "survey", "in", "Japan", "revealed", "that", "interstitial", "pneumonia", "occurred", "in", "4", "among", "approximately", "2", "000", "Japanese", "patients", "treated", "with", "sorafenib", "."], "event_mentions": [{"id": "19897274_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 14, "end": 15}, "arguments": [{"entity_id": "19897274_1_Ent3", "role": "Effect", "text": "interstitial pneumonia", "start": 12, "end": 14}, {"entity_id": "19897274_1_Ent2", "role": "Subject_Population", "text": "4 among approximately 2 000", "start": 16, "end": 21}, {"entity_id": "19897274_1_Ent0", "role": "Subject", "text": "4 among approximately 2 000 Japanese patients", "start": 16, "end": 23}, {"entity_id": "19897274_1_Ent1", "role": "Subject_Race", "text": "Japanese", "start": 21, "end": 22}, {"entity_id": "19897274_1_Ent4", "role": "Treatment", "text": "sorafenib", "start": 25, "end": 26}, {"entity_id": "19897274_1_Ent5", "role": "Treatment_Drug", "text": "sorafenib", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "19897274_1_Ent3", "text": "interstitial pneumonia", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "19897274_1_Ent2", "text": "4 among approximately 2 000", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "19897274_1_Ent0", "text": "4 among approximately 2 000 Japanese patients", "entity_type": "Entity", "start": 16, "end": 23}, {"id": "19897274_1_Ent1", "text": "Japanese", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "19897274_1_Ent4", "text": "sorafenib", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "19897274_1_Ent5", "text": "sorafenib", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "19904536_13", "wnd_id": "19904536_13_1", "text": "Gemcitabine - induced pulmonary toxicity is usually a dramatic condition .", "tokens": ["Gemcitabine", "-", "induced", "pulmonary", "toxicity", "is", "usually", "a", "dramatic", "condition", "."], "event_mentions": [{"id": "19904536_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19904536_13_Ent1", "role": "Treatment", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "19904536_13_Ent2", "role": "Treatment_Drug", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "19904536_13_Ent0", "role": "Effect", "text": "pulmonary toxicity", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "19904536_13_Ent1", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19904536_13_Ent2", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19904536_13_Ent0", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "19915794_2", "wnd_id": "19915794_2_1", "text": "Therefore , although garenoxacin reportedly causes fewer adverse reactions for cardiac rhythms than third - generation quinolone antibiotics , one must be cautious of the interference of other drugs during hypokalemia in order to prevent TdP.", "tokens": ["Therefore", ",", "although", "garenoxacin", "reportedly", "causes", "fewer", "adverse", "reactions", "for", "cardiac", "rhythms", "than", "third", "-", "generation", "quinolone", "antibiotics", ",", "one", "must", "be", "cautious", "of", "the", "interference", "of", "other", "drugs", "during", "hypokalemia", "in", "order", "to", "prevent", "TdP."], "event_mentions": [{"id": "19915794_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 5, "end": 6}, "arguments": [{"entity_id": "19915794_2_Ent1", "role": "Treatment", "text": "garenoxacin", "start": 3, "end": 4}, {"entity_id": "19915794_2_Ent2", "role": "Treatment_Drug", "text": "garenoxacin", "start": 3, "end": 4}, {"entity_id": "19915794_2_Ent0", "role": "Effect", "text": "adverse reactions for cardiac rhythms", "start": 7, "end": 12}]}, {"id": "19915794_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "prevent", "start": 34, "end": 35}, "arguments": [{"entity_id": "19915794_2_Ent6", "role": "Treatment", "text": "garenoxacin", "start": 3, "end": 4}, {"entity_id": "19915794_2_Ent7", "role": "Treatment_Drug", "text": "garenoxacin", "start": 3, "end": 4}, {"entity_id": "19915794_2_Ent3", "role": "Subject", "text": "hypokalemia", "start": 30, "end": 31}, {"entity_id": "19915794_2_Ent4", "role": "Subject_Disorder", "text": "hypokalemia", "start": 30, "end": 31}, {"entity_id": "19915794_2_Ent5", "role": "Effect", "text": "TdP.", "start": 35, "end": 36}]}], "entity_mentions": [{"id": "19915794_2_Ent1", "text": "garenoxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19915794_2_Ent2", "text": "garenoxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19915794_2_Ent6", "text": "garenoxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19915794_2_Ent7", "text": "garenoxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19915794_2_Ent0", "text": "adverse reactions for cardiac rhythms", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "19915794_2_Ent3", "text": "hypokalemia", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "19915794_2_Ent4", "text": "hypokalemia", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "19915794_2_Ent5", "text": "TdP.", "entity_type": "Entity", "start": 35, "end": 36}], "lang": "en"}
{"doc_id": "19934385_2", "wnd_id": "19934385_2_1", "text": "To report the results of therapeutic drug monitoring of lopinavir / ritonavir and itraconazole concentrations in an HIV - infected male who was treated for histoplasmosis .", "tokens": ["To", "report", "the", "results", "of", "therapeutic", "drug", "monitoring", "of", "lopinavir", "/", "ritonavir", "and", "itraconazole", "concentrations", "in", "an", "HIV", "-", "infected", "male", "who", "was", "treated", "for", "histoplasmosis", "."], "event_mentions": [{"id": "19934385_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 23, "end": 24}, "arguments": [{"entity_id": "19934385_2_Ent7", "role": "Treatment_Drug", "text": "lopinavir", "start": 9, "end": 10}, {"entity_id": "19934385_2_Ent8", "role": "Combination_Drug", "text": "lopinavir", "start": 9, "end": 10}, {"entity_id": "19934385_2_Ent2", "role": "Treatment", "text": "lopinavir / ritonavir and itraconazole concentrations", "start": 9, "end": 15}, {"entity_id": "19934385_2_Ent6", "role": "Treatment_Drug", "text": "ritonavir", "start": 11, "end": 12}, {"entity_id": "19934385_2_Ent9", "role": "Combination_Drug", "text": "ritonavir", "start": 11, "end": 12}, {"entity_id": "19934385_2_Ent5", "role": "Treatment_Drug", "text": "itraconazole", "start": 13, "end": 14}, {"entity_id": "19934385_2_Ent10", "role": "Combination_Drug", "text": "itraconazole", "start": 13, "end": 14}, {"entity_id": "19934385_2_Ent0", "role": "Subject", "text": "an HIV - infected male", "start": 16, "end": 21}, {"entity_id": "19934385_2_Ent4", "role": "Treatment_Disorder", "text": "HIV", "start": 17, "end": 18}, {"entity_id": "19934385_2_Ent1", "role": "Subject_Gender", "text": "male", "start": 20, "end": 21}, {"entity_id": "19934385_2_Ent3", "role": "Treatment_Disorder", "text": "histoplasmosis", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "19934385_2_Ent7", "text": "lopinavir", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19934385_2_Ent8", "text": "lopinavir", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19934385_2_Ent2", "text": "lopinavir / ritonavir and itraconazole concentrations", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "19934385_2_Ent6", "text": "ritonavir", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19934385_2_Ent9", "text": "ritonavir", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19934385_2_Ent5", "text": "itraconazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19934385_2_Ent10", "text": "itraconazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19934385_2_Ent0", "text": "an HIV - infected male", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "19934385_2_Ent4", "text": "HIV", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "19934385_2_Ent1", "text": "male", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "19934385_2_Ent3", "text": "histoplasmosis", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "19949685_2", "wnd_id": "19949685_2_1", "text": "Colonic necrosis is known as a rare complication following the administration of Kayexalate ( sodium polystryrene sulfonate ) in sorbitol .", "tokens": ["Colonic", "necrosis", "is", "known", "as", "a", "rare", "complication", "following", "the", "administration", "of", "Kayexalate", "(", "sodium", "polystryrene", "sulfonate", ")", "in", "sorbitol", "."], "event_mentions": [{"id": "19949685_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "19949685_2_Ent0", "role": "Effect", "text": "Colonic necrosis", "start": 0, "end": 2}, {"entity_id": "19949685_2_Ent2", "role": "Treatment_Drug", "text": "Kayexalate", "start": 12, "end": 13}, {"entity_id": "19949685_2_Ent5", "role": "Combination_Drug", "text": "Kayexalate", "start": 12, "end": 13}, {"entity_id": "19949685_2_Ent1", "role": "Treatment", "text": "Kayexalate ( sodium polystryrene sulfonate ) in sorbitol", "start": 12, "end": 20}, {"entity_id": "19949685_2_Ent3", "role": "Treatment_Drug", "text": "sorbitol", "start": 19, "end": 20}, {"entity_id": "19949685_2_Ent4", "role": "Combination_Drug", "text": "sorbitol", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "19949685_2_Ent0", "text": "Colonic necrosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19949685_2_Ent2", "text": "Kayexalate", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19949685_2_Ent5", "text": "Kayexalate", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19949685_2_Ent1", "text": "Kayexalate ( sodium polystryrene sulfonate ) in sorbitol", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "19949685_2_Ent3", "text": "sorbitol", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "19949685_2_Ent4", "text": "sorbitol", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "19995690_4", "wnd_id": "19995690_4_1", "text": "We report a case of a 34 - year - old man on carbamazepine for complex partial seizures who developed acute liver and renal failure on less than 2.5 grams a day of acetaminophen .", "tokens": ["We", "report", "a", "case", "of", "a", "34", "-", "year", "-", "old", "man", "on", "carbamazepine", "for", "complex", "partial", "seizures", "who", "developed", "acute", "liver", "and", "renal", "failure", "on", "less", "than", "2.5", "grams", "a", "day", "of", "acetaminophen", "."], "event_mentions": [{"id": "19995690_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "on", "start": 12, "end": 13}, "arguments": [{"entity_id": "19995690_4_Ent0", "role": "Subject", "text": "a 34 - year - old man", "start": 5, "end": 12}, {"entity_id": "19995690_4_Ent1", "role": "Subject_Age", "text": "34 - year - old", "start": 6, "end": 11}, {"entity_id": "19995690_4_Ent2", "role": "Subject_Gender", "text": "man", "start": 11, "end": 12}, {"entity_id": "19995690_4_Ent4", "role": "Treatment", "text": "carbamazepine", "start": 13, "end": 14}, {"entity_id": "19995690_4_Ent6", "role": "Treatment_Drug", "text": "carbamazepine", "start": 13, "end": 14}, {"entity_id": "19995690_4_Ent12", "role": "Combination_Drug", "text": "carbamazepine", "start": 13, "end": 14}, {"entity_id": "19995690_4_Ent8", "role": "Treatment_Disorder", "text": "complex partial seizures", "start": 15, "end": 18}, {"entity_id": "19995690_4_Ent3", "role": "Effect", "text": "acute liver and renal failure", "start": 20, "end": 25}, {"entity_id": "19995690_4_Ent9", "role": "Treatment_Dosage", "text": "less than 2.5 grams", "start": 26, "end": 30}, {"entity_id": "19995690_4_Ent5", "role": "Treatment", "text": "less than 2.5 grams a day of acetaminophen", "start": 26, "end": 34}, {"entity_id": "19995690_4_Ent10", "role": "Treatment_Freq", "text": "a day", "start": 30, "end": 32}, {"entity_id": "19995690_4_Ent7", "role": "Treatment_Drug", "text": "acetaminophen", "start": 33, "end": 34}, {"entity_id": "19995690_4_Ent11", "role": "Combination_Drug", "text": "acetaminophen", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "19995690_4_Ent0", "text": "a 34 - year - old man", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "19995690_4_Ent1", "text": "34 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "19995690_4_Ent2", "text": "man", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19995690_4_Ent4", "text": "carbamazepine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19995690_4_Ent6", "text": "carbamazepine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19995690_4_Ent12", "text": "carbamazepine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19995690_4_Ent8", "text": "complex partial seizures", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "19995690_4_Ent3", "text": "acute liver and renal failure", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "19995690_4_Ent9", "text": "less than 2.5 grams", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "19995690_4_Ent5", "text": "less than 2.5 grams a day of acetaminophen", "entity_type": "Entity", "start": 26, "end": 34}, {"id": "19995690_4_Ent10", "text": "a day", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "19995690_4_Ent7", "text": "acetaminophen", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "19995690_4_Ent11", "text": "acetaminophen", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "20009973_2", "wnd_id": "20009973_2_1", "text": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis , synovitis , and possible vasculitis , after receiving all - trans retinoic acid therapy .", "tokens": ["Here", "we", "report", "a", "patient", "with", "newly", "diagnosed", "acute", "promyelocytic", "leukemia", "who", "developed", "acute", "focal", "myositis", ",", "synovitis", ",", "and", "possible", "vasculitis", ",", "after", "receiving", "all", "-", "trans", "retinoic", "acid", "therapy", "."], "event_mentions": [{"id": "20009973_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "20009973_2_Ent0", "role": "Subject", "text": "a patient with newly diagnosed acute promyelocytic leukemia", "start": 3, "end": 11}, {"entity_id": "20009973_2_Ent3", "role": "Treatment_Disorder", "text": "acute promyelocytic leukemia", "start": 8, "end": 11}, {"entity_id": "20009973_2_Ent1", "role": "Effect", "text": "acute focal myositis , synovitis , and possible vasculitis", "start": 13, "end": 22}, {"entity_id": "20009973_2_Ent2", "role": "Treatment", "text": "all - trans retinoic acid", "start": 25, "end": 30}, {"entity_id": "20009973_2_Ent4", "role": "Treatment_Drug", "text": "all - trans retinoic acid", "start": 25, "end": 30}]}], "entity_mentions": [{"id": "20009973_2_Ent0", "text": "a patient with newly diagnosed acute promyelocytic leukemia", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "20009973_2_Ent3", "text": "acute promyelocytic leukemia", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "20009973_2_Ent1", "text": "acute focal myositis , synovitis , and possible vasculitis", "entity_type": "Entity", "start": 13, "end": 22}, {"id": "20009973_2_Ent2", "text": "all - trans retinoic acid", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "20009973_2_Ent4", "text": "all - trans retinoic acid", "entity_type": "Entity", "start": 25, "end": 30}], "lang": "en"}
{"doc_id": "20065266_2", "wnd_id": "20065266_2_1", "text": "CONCLUSION : A 37 - year - old African - American man with G6PD deficiency developed hemolytic anemia , hepatitis , orthostatic hypotension , and aseptic meningitis simultaneously after using trimethoprim - sulfamethoxazole .", "tokens": ["CONCLUSION", ":", "A", "37", "-", "year", "-", "old", "African", "-", "American", "man", "with", "G6PD", "deficiency", "developed", "hemolytic", "anemia", ",", "hepatitis", ",", "orthostatic", "hypotension", ",", "and", "aseptic", "meningitis", "simultaneously", "after", "using", "trimethoprim", "-", "sulfamethoxazole", "."], "event_mentions": [{"id": "20065266_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "20065266_2_Ent0", "role": "Subject", "text": "A 37 - year - old African - American man with G6PD deficiency", "start": 2, "end": 15}, {"entity_id": "20065266_2_Ent2", "role": "Subject_Age", "text": "37 - year - old", "start": 3, "end": 8}, {"entity_id": "20065266_2_Ent3", "role": "Subject_Race", "text": "African - American", "start": 8, "end": 11}, {"entity_id": "20065266_2_Ent4", "role": "Subject_Gender", "text": "man", "start": 11, "end": 12}, {"entity_id": "20065266_2_Ent1", "role": "Subject_Disorder", "text": "G6PD deficiency", "start": 13, "end": 15}, {"entity_id": "20065266_2_Ent5", "role": "Effect", "text": "hemolytic anemia , hepatitis , orthostatic hypotension , and aseptic meningitis", "start": 16, "end": 27}, {"entity_id": "20065266_2_Ent6", "role": "Treatment", "text": "trimethoprim - sulfamethoxazole", "start": 30, "end": 33}, {"entity_id": "20065266_2_Ent7", "role": "Treatment_Drug", "text": "trimethoprim - sulfamethoxazole", "start": 30, "end": 33}]}], "entity_mentions": [{"id": "20065266_2_Ent0", "text": "A 37 - year - old African - American man with G6PD deficiency", "entity_type": "Entity", "start": 2, "end": 15}, {"id": "20065266_2_Ent2", "text": "37 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "20065266_2_Ent3", "text": "African - American", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "20065266_2_Ent4", "text": "man", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20065266_2_Ent1", "text": "G6PD deficiency", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "20065266_2_Ent5", "text": "hemolytic anemia , hepatitis , orthostatic hypotension , and aseptic meningitis", "entity_type": "Entity", "start": 16, "end": 27}, {"id": "20065266_2_Ent6", "text": "trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 30, "end": 33}, {"id": "20065266_2_Ent7", "text": "trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 30, "end": 33}], "lang": "en"}
{"doc_id": "2006943_1", "wnd_id": "2006943_1_1", "text": "Type I second - degree AV block ( Mobitz type I , Wenckebach AV block ) during ritodrine therapy for preterm labor .", "tokens": ["Type", "I", "second", "-", "degree", "AV", "block", "(", "Mobitz", "type", "I", ",", "Wenckebach", "AV", "block", ")", "during", "ritodrine", "therapy", "for", "preterm", "labor", "."], "event_mentions": [{"id": "2006943_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 16, "end": 17}, "arguments": [{"entity_id": "2006943_1_Ent0", "role": "Effect", "text": "Type I second - degree AV block ( Mobitz type I , Wenckebach AV block )", "start": 0, "end": 16}, {"entity_id": "2006943_1_Ent1", "role": "Treatment", "text": "ritodrine", "start": 17, "end": 18}, {"entity_id": "2006943_1_Ent3", "role": "Treatment_Drug", "text": "ritodrine", "start": 17, "end": 18}, {"entity_id": "2006943_1_Ent2", "role": "Treatment_Disorder", "text": "preterm labor", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "2006943_1_Ent0", "text": "Type I second - degree AV block ( Mobitz type I , Wenckebach AV block )", "entity_type": "Entity", "start": 0, "end": 16}, {"id": "2006943_1_Ent1", "text": "ritodrine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "2006943_1_Ent3", "text": "ritodrine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "2006943_1_Ent2", "text": "preterm labor", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "2011096_2", "wnd_id": "2011096_2_1", "text": "Three of 38 children given high - dose cytosine arabinoside therapy developed a previously undescribed complication .", "tokens": ["Three", "of", "38", "children", "given", "high", "-", "dose", "cytosine", "arabinoside", "therapy", "developed", "a", "previously", "undescribed", "complication", "."], "event_mentions": [{"id": "2011096_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "2011096_2_Ent1", "role": "Subject_Population", "text": "38", "start": 2, "end": 3}, {"entity_id": "2011096_2_Ent0", "role": "Subject", "text": "38 children", "start": 2, "end": 4}, {"entity_id": "2011096_2_Ent2", "role": "Subject_Age", "text": "children", "start": 3, "end": 4}, {"entity_id": "2011096_2_Ent5", "role": "Treatment_Dosage", "text": "high - dose", "start": 5, "end": 8}, {"entity_id": "2011096_2_Ent4", "role": "Treatment", "text": "high - dose cytosine arabinoside", "start": 5, "end": 10}, {"entity_id": "2011096_2_Ent6", "role": "Treatment_Drug", "text": "cytosine arabinoside", "start": 8, "end": 10}, {"entity_id": "2011096_2_Ent3", "role": "Effect", "text": "complication", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "2011096_2_Ent1", "text": "38", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "2011096_2_Ent0", "text": "38 children", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "2011096_2_Ent2", "text": "children", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2011096_2_Ent5", "text": "high - dose", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "2011096_2_Ent4", "text": "high - dose cytosine arabinoside", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "2011096_2_Ent6", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "2011096_2_Ent3", "text": "complication", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "20178709_1", "wnd_id": "20178709_1_1", "text": "A case of aseptic pleuropericarditis in a patient with chronic plaque psoriasis under methotrexate therapy .", "tokens": ["A", "case", "of", "aseptic", "pleuropericarditis", "in", "a", "patient", "with", "chronic", "plaque", "psoriasis", "under", "methotrexate", "therapy", "."], "event_mentions": [{"id": "20178709_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 5, "end": 6}, "arguments": [{"entity_id": "20178709_1_Ent1", "role": "Effect", "text": "aseptic pleuropericarditis", "start": 3, "end": 5}, {"entity_id": "20178709_1_Ent0", "role": "Subject", "text": "a patient with chronic plaque psoriasis", "start": 6, "end": 12}, {"entity_id": "20178709_1_Ent4", "role": "Treatment_Disorder", "text": "chronic plaque psoriasis", "start": 9, "end": 12}, {"entity_id": "20178709_1_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 13, "end": 14}, {"entity_id": "20178709_1_Ent2", "role": "Treatment", "text": "methotrexate therapy", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "20178709_1_Ent1", "text": "aseptic pleuropericarditis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "20178709_1_Ent0", "text": "a patient with chronic plaque psoriasis", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "20178709_1_Ent4", "text": "chronic plaque psoriasis", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "20178709_1_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "20178709_1_Ent2", "text": "methotrexate therapy", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "20190474_1", "wnd_id": "20190474_1_1", "text": "Acute kidney injury caused by zonisamide - induced hypersensitivity syndrome .", "tokens": ["Acute", "kidney", "injury", "caused", "by", "zonisamide", "-", "induced", "hypersensitivity", "syndrome", "."], "event_mentions": [{"id": "20190474_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "20190474_1_Ent1", "role": "Treatment", "text": "zonisamide", "start": 5, "end": 6}, {"entity_id": "20190474_1_Ent2", "role": "Treatment_Drug", "text": "zonisamide", "start": 5, "end": 6}, {"entity_id": "20190474_1_Ent0", "role": "Effect", "text": "hypersensitivity syndrome", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "20190474_1_Ent1", "text": "zonisamide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "20190474_1_Ent2", "text": "zonisamide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "20190474_1_Ent0", "text": "hypersensitivity syndrome", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "20190474_4", "wnd_id": "20190474_4_1", "text": "This is the first report of acute kidney injury due to zonisamide - induced DRESS / DIHS .", "tokens": ["This", "is", "the", "first", "report", "of", "acute", "kidney", "injury", "due", "to", "zonisamide", "-", "induced", "DRESS", "/", "DIHS", "."], "event_mentions": [{"id": "20190474_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "20190474_4_Ent0", "role": "Effect", "text": "acute kidney injury due to", "start": 6, "end": 11}, {"entity_id": "20190474_4_Ent2", "role": "Treatment", "text": "zonisamide", "start": 11, "end": 12}, {"entity_id": "20190474_4_Ent3", "role": "Treatment_Drug", "text": "zonisamide", "start": 11, "end": 12}, {"entity_id": "20190474_4_Ent1", "role": "Effect", "text": "DRESS / DIHS", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "20190474_4_Ent0", "text": "acute kidney injury due to", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "20190474_4_Ent2", "text": "zonisamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20190474_4_Ent3", "text": "zonisamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20190474_4_Ent1", "text": "DRESS / DIHS", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "20298401_5", "wnd_id": "20298401_5_1", "text": "RESULTS : We recently experienced a case of fatal erlotinib - induced ILD , diagnosed based on clinical and radiologic findings , which occurred in a patient with radiation fibrosis .", "tokens": ["RESULTS", ":", "We", "recently", "experienced", "a", "case", "of", "fatal", "erlotinib", "-", "induced", "ILD", ",", "diagnosed", "based", "on", "clinical", "and", "radiologic", "findings", ",", "which", "occurred", "in", "a", "patient", "with", "radiation", "fibrosis", "."], "event_mentions": [{"id": "20298401_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "20298401_5_Ent3", "role": "Treatment", "text": "erlotinib", "start": 9, "end": 10}, {"entity_id": "20298401_5_Ent4", "role": "Treatment_Drug", "text": "erlotinib", "start": 9, "end": 10}, {"entity_id": "20298401_5_Ent2", "role": "Effect", "text": "ILD", "start": 12, "end": 13}, {"entity_id": "20298401_5_Ent0", "role": "Subject", "text": "a patient with radiation fibrosis", "start": 25, "end": 30}, {"entity_id": "20298401_5_Ent1", "role": "Subject_Disorder", "text": "radiation fibrosis", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "20298401_5_Ent3", "text": "erlotinib", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "20298401_5_Ent4", "text": "erlotinib", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "20298401_5_Ent2", "text": "ILD", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "20298401_5_Ent0", "text": "a patient with radiation fibrosis", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "20298401_5_Ent1", "text": "radiation fibrosis", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "20338114_2", "wnd_id": "20338114_2_1", "text": "The other patient developed transient intraoperative hypertension immediately after inadvertent submucosal injection of concentrated epinephrine .", "tokens": ["The", "other", "patient", "developed", "transient", "intraoperative", "hypertension", "immediately", "after", "inadvertent", "submucosal", "injection", "of", "concentrated", "epinephrine", "."], "event_mentions": [{"id": "20338114_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 3, "end": 4}, "arguments": [{"entity_id": "20338114_2_Ent0", "role": "Subject", "text": "The other patient", "start": 0, "end": 3}, {"entity_id": "20338114_2_Ent1", "role": "Effect", "text": "transient intraoperative hypertension immediately", "start": 4, "end": 8}, {"entity_id": "20338114_2_Ent2", "role": "Treatment", "text": "inadvertent submucosal injection of concentrated epinephrine", "start": 9, "end": 15}, {"entity_id": "20338114_2_Ent4", "role": "Treatment_Route", "text": "injection", "start": 11, "end": 12}, {"entity_id": "20338114_2_Ent3", "role": "Treatment_Drug", "text": "epinephrine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "20338114_2_Ent0", "text": "The other patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "20338114_2_Ent1", "text": "transient intraoperative hypertension immediately", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "20338114_2_Ent2", "text": "inadvertent submucosal injection of concentrated epinephrine", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "20338114_2_Ent4", "text": "injection", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20338114_2_Ent3", "text": "epinephrine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "20349794_4", "wnd_id": "20349794_4_1", "text": "Carboplatin was substituted for cisplatin , and there were no further episodes of SIADH .", "tokens": ["Carboplatin", "was", "substituted", "for", "cisplatin", ",", "and", "there", "were", "no", "further", "episodes", "of", "SIADH", "."], "event_mentions": [{"id": "20349794_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "substituted", "start": 2, "end": 3}, "arguments": [{"entity_id": "20349794_4_Ent0", "role": "Treatment", "text": "Carboplatin was substituted for cisplatin", "start": 0, "end": 5}, {"entity_id": "20349794_4_Ent2", "role": "Treatment_Drug", "text": "cisplatin", "start": 4, "end": 5}, {"entity_id": "20349794_4_Ent1", "role": "Treatment_Disorder", "text": "SIADH", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "20349794_4_Ent0", "text": "Carboplatin was substituted for cisplatin", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "20349794_4_Ent2", "text": "cisplatin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20349794_4_Ent1", "text": "SIADH", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "20367573_2", "wnd_id": "20367573_2_1", "text": "Thrombocytosis associated with enoxaparin : A very rare cause in newborns .", "tokens": ["Thrombocytosis", "associated", "with", "enoxaparin", ":", "A", "very", "rare", "cause", "in", "newborns", "."], "event_mentions": [{"id": "20367573_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "20367573_2_Ent2", "role": "Effect", "text": "Thrombocytosis", "start": 0, "end": 1}, {"entity_id": "20367573_2_Ent3", "role": "Treatment", "text": "enoxaparin", "start": 3, "end": 4}, {"entity_id": "20367573_2_Ent4", "role": "Treatment_Drug", "text": "enoxaparin", "start": 3, "end": 4}, {"entity_id": "20367573_2_Ent0", "role": "Subject", "text": "newborns", "start": 10, "end": 11}, {"entity_id": "20367573_2_Ent1", "role": "Subject_Age", "text": "newborns", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "20367573_2_Ent2", "text": "Thrombocytosis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20367573_2_Ent3", "text": "enoxaparin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "20367573_2_Ent4", "text": "enoxaparin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "20367573_2_Ent0", "text": "newborns", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "20367573_2_Ent1", "text": "newborns", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "20397038_1", "wnd_id": "20397038_1_1", "text": "Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow - up .", "tokens": ["Normalization", "of", "generalized", "retinal", "function", "and", "progression", "of", "maculopathy", "after", "cessation", "of", "therapy", "in", "a", "case", "of", "severe", "hydroxychloroquine", "retinopathy", "with", "19", "years", "follow", "-", "up", "."], "event_mentions": [{"id": "20397038_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "after", "start": 9, "end": 10}, "arguments": [{"entity_id": "20397038_1_Ent1", "role": "Effect", "text": "Normalization of generalized retinal function and progression of maculopathy", "start": 0, "end": 9}, {"entity_id": "20397038_1_Ent2", "role": "Treatment", "text": "cessation of therapy", "start": 10, "end": 13}, {"entity_id": "20397038_1_Ent0", "role": "Subject", "text": "a case of severe hydroxychloroquine retinopathy", "start": 14, "end": 20}, {"entity_id": "20397038_1_Ent3", "role": "Treatment", "text": "hydroxychloroquine", "start": 18, "end": 19}, {"entity_id": "20397038_1_Ent4", "role": "Treatment_Drug", "text": "hydroxychloroquine", "start": 18, "end": 19}, {"entity_id": "20397038_1_Ent5", "role": "Treatment_Disorder", "text": "hydroxychloroquine retinopathy", "start": 18, "end": 20}, {"entity_id": "20397038_1_Ent6", "role": "Treatment_Time_elapsed", "text": "19 years", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "20397038_1_Ent1", "text": "Normalization of generalized retinal function and progression of maculopathy", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "20397038_1_Ent2", "text": "cessation of therapy", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "20397038_1_Ent0", "text": "a case of severe hydroxychloroquine retinopathy", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "20397038_1_Ent3", "text": "hydroxychloroquine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "20397038_1_Ent4", "text": "hydroxychloroquine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "20397038_1_Ent5", "text": "hydroxychloroquine retinopathy", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "20397038_1_Ent6", "text": "19 years", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "20412003_1", "wnd_id": "20412003_1_1", "text": "After other potential causes of liver toxicity were excluded , TMP - SMX was determined to be the cause of his acute liver toxicity .", "tokens": ["After", "other", "potential", "causes", "of", "liver", "toxicity", "were", "excluded", ",", "TMP", "-", "SMX", "was", "determined", "to", "be", "the", "cause", "of", "his", "acute", "liver", "toxicity", "."], "event_mentions": [{"id": "20412003_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "determined", "start": 14, "end": 15}, "arguments": [{"entity_id": "20412003_1_Ent2", "role": "Treatment_Drug", "text": "TMP", "start": 10, "end": 11}, {"entity_id": "20412003_1_Ent4", "role": "Combination_Drug", "text": "TMP", "start": 10, "end": 11}, {"entity_id": "20412003_1_Ent1", "role": "Treatment", "text": "TMP - SMX", "start": 10, "end": 13}, {"entity_id": "20412003_1_Ent3", "role": "Treatment_Drug", "text": "SMX", "start": 12, "end": 13}, {"entity_id": "20412003_1_Ent5", "role": "Combination_Drug", "text": "SMX", "start": 12, "end": 13}, {"entity_id": "20412003_1_Ent0", "role": "Effect", "text": "acute liver toxicity", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "20412003_1_Ent2", "text": "TMP", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "20412003_1_Ent4", "text": "TMP", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "20412003_1_Ent1", "text": "TMP - SMX", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "20412003_1_Ent3", "text": "SMX", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "20412003_1_Ent5", "text": "SMX", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "20412003_1_Ent0", "text": "acute liver toxicity", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "20465622_4", "wnd_id": "20465622_4_1", "text": "CASE : We present an 11 - year old male with Budd - Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus .", "tokens": ["CASE", ":", "We", "present", "an", "11", "-", "year", "old", "male", "with", "Budd", "-", "Chiari", "syndrome", "who", "experienced", "profound", "worsening", "of", "chronic", "aphthous", "ulcers", "after", "immunosuppressive", "therapy", "was", "changed", "from", "tacrolimus", "to", "sirolimus", "."], "event_mentions": [{"id": "20465622_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 16, "end": 17}, "arguments": [{"entity_id": "20465622_4_Ent0", "role": "Subject", "text": "an 11 - year old male with Budd - Chiari syndrome", "start": 4, "end": 15}, {"entity_id": "20465622_4_Ent1", "role": "Subject_Age", "text": "11 - year old", "start": 5, "end": 9}, {"entity_id": "20465622_4_Ent2", "role": "Subject_Gender", "text": "male", "start": 9, "end": 10}, {"entity_id": "20465622_4_Ent3", "role": "Subject_Disorder", "text": "Budd - Chiari syndrome", "start": 11, "end": 15}, {"entity_id": "20465622_4_Ent4", "role": "Effect", "text": "profound worsening of chronic aphthous ulcers", "start": 17, "end": 23}, {"entity_id": "20465622_4_Ent5", "role": "Treatment", "text": "immunosuppressive therapy was changed from tacrolimus to sirolimus", "start": 24, "end": 32}, {"entity_id": "20465622_4_Ent6", "role": "Treatment_Drug", "text": "tacrolimus", "start": 29, "end": 30}, {"entity_id": "20465622_4_Ent7", "role": "Treatment_Drug", "text": "sirolimus", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "20465622_4_Ent0", "text": "an 11 - year old male with Budd - Chiari syndrome", "entity_type": "Entity", "start": 4, "end": 15}, {"id": "20465622_4_Ent1", "text": "11 - year old", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "20465622_4_Ent2", "text": "male", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "20465622_4_Ent3", "text": "Budd - Chiari syndrome", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "20465622_4_Ent4", "text": "profound worsening of chronic aphthous ulcers", "entity_type": "Entity", "start": 17, "end": 23}, {"id": "20465622_4_Ent5", "text": "immunosuppressive therapy was changed from tacrolimus to sirolimus", "entity_type": "Entity", "start": 24, "end": 32}, {"id": "20465622_4_Ent6", "text": "tacrolimus", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "20465622_4_Ent7", "text": "sirolimus", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "2051906_1", "wnd_id": "2051906_1_1", "text": "A 67 - year - old patient , with primary polymyositis and without previous evidence of liver disease , developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy .", "tokens": ["A", "67", "-", "year", "-", "old", "patient", ",", "with", "primary", "polymyositis", "and", "without", "previous", "evidence", "of", "liver", "disease", ",", "developed", "clinical", "and", "biochemical", "features", "of", "severe", "cholestasis", "3", "months", "after", "initiation", "of", "azathioprine", "therapy", "."], "event_mentions": [{"id": "2051906_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "2051906_1_Ent0", "role": "Subject", "text": "A 67 - year - old patient , with primary polymyositis and without previous evidence of liver disease", "start": 0, "end": 18}, {"entity_id": "2051906_1_Ent1", "role": "Subject_Age", "text": "67 - year - old", "start": 1, "end": 6}, {"entity_id": "2051906_1_Ent6", "role": "Treatment_Disorder", "text": "primary polymyositis", "start": 9, "end": 11}, {"entity_id": "2051906_1_Ent2", "role": "Effect", "text": "cholestasis", "start": 26, "end": 27}, {"entity_id": "2051906_1_Ent5", "role": "Treatment_Time_elapsed", "text": "3 months", "start": 27, "end": 29}, {"entity_id": "2051906_1_Ent3", "role": "Treatment", "text": "3 months after initiation of azathioprine", "start": 27, "end": 33}, {"entity_id": "2051906_1_Ent4", "role": "Treatment_Drug", "text": "azathioprine", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "2051906_1_Ent0", "text": "A 67 - year - old patient , with primary polymyositis and without previous evidence of liver disease", "entity_type": "Entity", "start": 0, "end": 18}, {"id": "2051906_1_Ent1", "text": "67 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "2051906_1_Ent6", "text": "primary polymyositis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "2051906_1_Ent2", "text": "cholestasis", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "2051906_1_Ent5", "text": "3 months", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "2051906_1_Ent3", "text": "3 months after initiation of azathioprine", "entity_type": "Entity", "start": 27, "end": 33}, {"id": "2051906_1_Ent4", "text": "azathioprine", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "20628041_1", "wnd_id": "20628041_1_1", "text": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant - like syndrome and prolonged ICU stay .", "tokens": ["An", "interaction", "between", "levodopa", "and", "enteral", "nutrition", "resulting", "in", "neuroleptic", "malignant", "-", "like", "syndrome", "and", "prolonged", "ICU", "stay", "."], "event_mentions": [{"id": "20628041_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 7, "end": 8}, "arguments": [{"entity_id": "20628041_1_Ent2", "role": "Treatment_Drug", "text": "levodopa", "start": 3, "end": 4}, {"entity_id": "20628041_1_Ent1", "role": "Treatment", "text": "levodopa and enteral nutrition", "start": 3, "end": 7}, {"entity_id": "20628041_1_Ent0", "role": "Effect", "text": "neuroleptic malignant - like syndrome and prolonged ICU stay", "start": 9, "end": 18}]}], "entity_mentions": [{"id": "20628041_1_Ent2", "text": "levodopa", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "20628041_1_Ent1", "text": "levodopa and enteral nutrition", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "20628041_1_Ent0", "text": "neuroleptic malignant - like syndrome and prolonged ICU stay", "entity_type": "Entity", "start": 9, "end": 18}], "lang": "en"}
{"doc_id": "20628041_2", "wnd_id": "20628041_2_1", "text": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant - like syndrome ( NMLS ) in a polytrauma patient with Parkinson 's disease ( PD ) .", "tokens": ["To", "describe", "a", "probable", "interaction", "between", "enteral", "feeds", "and", "levodopa", "leading", "to", "neuroleptic", "malignant", "-", "like", "syndrome", "(", "NMLS", ")", "in", "a", "polytrauma", "patient", "with", "Parkinson", "'s", "disease", "(", "PD", ")", "."], "event_mentions": [{"id": "20628041_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "leading", "start": 10, "end": 11}, "arguments": [{"entity_id": "20628041_2_Ent3", "role": "Treatment", "text": "interaction between enteral feeds and levodopa", "start": 4, "end": 10}, {"entity_id": "20628041_2_Ent5", "role": "Treatment_Drug", "text": "enteral feeds", "start": 6, "end": 8}, {"entity_id": "20628041_2_Ent7", "role": "Combination_Drug", "text": "enteral feeds", "start": 6, "end": 8}, {"entity_id": "20628041_2_Ent4", "role": "Treatment_Drug", "text": "levodopa", "start": 9, "end": 10}, {"entity_id": "20628041_2_Ent8", "role": "Combination_Drug", "text": "levodopa", "start": 9, "end": 10}, {"entity_id": "20628041_2_Ent2", "role": "Effect", "text": "neuroleptic malignant - like syndrome ( NMLS )", "start": 12, "end": 20}, {"entity_id": "20628041_2_Ent0", "role": "Subject", "text": "a polytrauma patient with Parkinson 's disease ( PD )", "start": 21, "end": 31}, {"entity_id": "20628041_2_Ent1", "role": "Subject_Disorder", "text": "polytrauma", "start": 22, "end": 23}, {"entity_id": "20628041_2_Ent6", "role": "Treatment_Disorder", "text": "Parkinson 's disease ( PD )", "start": 25, "end": 31}]}], "entity_mentions": [{"id": "20628041_2_Ent3", "text": "interaction between enteral feeds and levodopa", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "20628041_2_Ent5", "text": "enteral feeds", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "20628041_2_Ent7", "text": "enteral feeds", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "20628041_2_Ent4", "text": "levodopa", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "20628041_2_Ent8", "text": "levodopa", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "20628041_2_Ent2", "text": "neuroleptic malignant - like syndrome ( NMLS )", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "20628041_2_Ent0", "text": "a polytrauma patient with Parkinson 's disease ( PD )", "entity_type": "Entity", "start": 21, "end": 31}, {"id": "20628041_2_Ent1", "text": "polytrauma", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "20628041_2_Ent6", "text": "Parkinson 's disease ( PD )", "entity_type": "Entity", "start": 25, "end": 31}], "lang": "en"}
{"doc_id": "2063999_2", "wnd_id": "2063999_2_1", "text": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate ( HOPA ) .", "tokens": ["We", "report", "a", "girl", "with", "the", "Rett", "syndrome", "who", "had", "acute", "encephalopathy", "probably", "induced", "by", "calcium", "hopantenate", "(", "HOPA", ")", "."], "event_mentions": [{"id": "2063999_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "2063999_2_Ent0", "role": "Subject", "text": "a girl", "start": 2, "end": 4}, {"entity_id": "2063999_2_Ent1", "role": "Subject_Gender", "text": "girl", "start": 3, "end": 4}, {"entity_id": "2063999_2_Ent2", "role": "Effect", "text": "Rett syndrome", "start": 6, "end": 8}, {"entity_id": "2063999_2_Ent3", "role": "Effect", "text": "acute encephalopathy", "start": 10, "end": 12}, {"entity_id": "2063999_2_Ent5", "role": "Treatment_Drug", "text": "calcium hopantenate", "start": 15, "end": 17}, {"entity_id": "2063999_2_Ent4", "role": "Treatment", "text": "calcium hopantenate ( HOPA )", "start": 15, "end": 20}]}], "entity_mentions": [{"id": "2063999_2_Ent0", "text": "a girl", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "2063999_2_Ent1", "text": "girl", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2063999_2_Ent2", "text": "Rett syndrome", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "2063999_2_Ent3", "text": "acute encephalopathy", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "2063999_2_Ent5", "text": "calcium hopantenate", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "2063999_2_Ent4", "text": "calcium hopantenate ( HOPA )", "entity_type": "Entity", "start": 15, "end": 20}], "lang": "en"}
{"doc_id": "20666169_9", "wnd_id": "20666169_9_1", "text": "We presume the cause for multiple organ failure could be the result of drug - drug interaction , atorvastatin and verapamil , as verapamil is known to increase the serum concentration of atorvastatin significantly .", "tokens": ["We", "presume", "the", "cause", "for", "multiple", "organ", "failure", "could", "be", "the", "result", "of", "drug", "-", "drug", "interaction", ",", "atorvastatin", "and", "verapamil", ",", "as", "verapamil", "is", "known", "to", "increase", "the", "serum", "concentration", "of", "atorvastatin", "significantly", "."], "event_mentions": [{"id": "20666169_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 3, "end": 4}, "arguments": [{"entity_id": "20666169_9_Ent0", "role": "Effect", "text": "multiple organ failure", "start": 5, "end": 8}, {"entity_id": "20666169_9_Ent1", "role": "Treatment", "text": "interaction , atorvastatin and verapamil", "start": 16, "end": 21}, {"entity_id": "20666169_9_Ent2", "role": "Treatment_Drug", "text": "atorvastatin", "start": 18, "end": 19}, {"entity_id": "20666169_9_Ent4", "role": "Combination_Drug", "text": "atorvastatin", "start": 18, "end": 19}, {"entity_id": "20666169_9_Ent3", "role": "Treatment_Drug", "text": "verapamil", "start": 20, "end": 21}, {"entity_id": "20666169_9_Ent5", "role": "Combination_Drug", "text": "verapamil", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "20666169_9_Ent0", "text": "multiple organ failure", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "20666169_9_Ent1", "text": "interaction , atorvastatin and verapamil", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "20666169_9_Ent2", "text": "atorvastatin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "20666169_9_Ent4", "text": "atorvastatin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "20666169_9_Ent3", "text": "verapamil", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "20666169_9_Ent5", "text": "verapamil", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "21045170_11", "wnd_id": "21045170_11_1", "text": "Caution should be used when coadministering enfuvirtide and niacin to HIV - infected patients .", "tokens": ["Caution", "should", "be", "used", "when", "coadministering", "enfuvirtide", "and", "niacin", "to", "HIV", "-", "infected", "patients", "."], "event_mentions": [{"id": "21045170_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "used", "start": 3, "end": 4}, "arguments": [{"entity_id": "21045170_11_Ent1", "role": "Effect", "text": "Caution", "start": 0, "end": 1}, {"entity_id": "21045170_11_Ent2", "role": "Treatment", "text": "coadministering enfuvirtide and niacin", "start": 5, "end": 9}, {"entity_id": "21045170_11_Ent3", "role": "Treatment_Drug", "text": "enfuvirtide", "start": 6, "end": 7}, {"entity_id": "21045170_11_Ent6", "role": "Combination_Drug", "text": "enfuvirtide", "start": 6, "end": 7}, {"entity_id": "21045170_11_Ent4", "role": "Treatment_Drug", "text": "niacin", "start": 8, "end": 9}, {"entity_id": "21045170_11_Ent7", "role": "Combination_Drug", "text": "niacin", "start": 8, "end": 9}, {"entity_id": "21045170_11_Ent5", "role": "Treatment_Disorder", "text": "HIV", "start": 10, "end": 11}, {"entity_id": "21045170_11_Ent0", "role": "Subject", "text": "HIV - infected patients", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "21045170_11_Ent1", "text": "Caution", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21045170_11_Ent2", "text": "coadministering enfuvirtide and niacin", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "21045170_11_Ent3", "text": "enfuvirtide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21045170_11_Ent6", "text": "enfuvirtide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21045170_11_Ent4", "text": "niacin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "21045170_11_Ent7", "text": "niacin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "21045170_11_Ent5", "text": "HIV", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "21045170_11_Ent0", "text": "HIV - infected patients", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "2104570_4", "wnd_id": "2104570_4_1", "text": "Intravesical chemotherapy may be associated with a risk of secondary malignancy .", "tokens": ["Intravesical", "chemotherapy", "may", "be", "associated", "with", "a", "risk", "of", "secondary", "malignancy", "."], "event_mentions": [{"id": "2104570_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "2104570_4_Ent2", "role": "Treatment_Route", "text": "Intravesical", "start": 0, "end": 1}, {"entity_id": "2104570_4_Ent1", "role": "Treatment", "text": "Intravesical chemotherapy", "start": 0, "end": 2}, {"entity_id": "2104570_4_Ent3", "role": "Treatment_Drug", "text": "chemotherapy", "start": 1, "end": 2}, {"entity_id": "2104570_4_Ent0", "role": "Effect", "text": "secondary malignancy", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "2104570_4_Ent2", "text": "Intravesical", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2104570_4_Ent1", "text": "Intravesical chemotherapy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2104570_4_Ent3", "text": "chemotherapy", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2104570_4_Ent0", "text": "secondary malignancy", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "2113320_2", "wnd_id": "2113320_2_1", "text": "Subglottic stenosis in Wegener 's granulomatosis : development during cyclophosphamide treatment with response to carbon dioxide laser therapy .", "tokens": ["Subglottic", "stenosis", "in", "Wegener", "'s", "granulomatosis", ":", "development", "during", "cyclophosphamide", "treatment", "with", "response", "to", "carbon", "dioxide", "laser", "therapy", "."], "event_mentions": [{"id": "2113320_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 8, "end": 9}, "arguments": [{"entity_id": "2113320_2_Ent0", "role": "Effect", "text": "Subglottic stenosis in Wegener 's granulomatosis", "start": 0, "end": 6}, {"entity_id": "2113320_2_Ent3", "role": "Treatment_Disorder", "text": "Wegener 's granulomatosis", "start": 3, "end": 6}, {"entity_id": "2113320_2_Ent2", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 9, "end": 10}, {"entity_id": "2113320_2_Ent1", "role": "Treatment", "text": "cyclophosphamide treatment with response to carbon dioxide laser therapy", "start": 9, "end": 18}]}], "entity_mentions": [{"id": "2113320_2_Ent0", "text": "Subglottic stenosis in Wegener 's granulomatosis", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "2113320_2_Ent3", "text": "Wegener 's granulomatosis", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "2113320_2_Ent2", "text": "cyclophosphamide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2113320_2_Ent1", "text": "cyclophosphamide treatment with response to carbon dioxide laser therapy", "entity_type": "Entity", "start": 9, "end": 18}], "lang": "en"}
{"doc_id": "2140997_3", "wnd_id": "2140997_3_1", "text": "Severe hepatitis caused by cyproterone acetate .", "tokens": ["Severe", "hepatitis", "caused", "by", "cyproterone", "acetate", "."], "event_mentions": [{"id": "2140997_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 2, "end": 3}, "arguments": [{"entity_id": "2140997_3_Ent0", "role": "Effect", "text": "Severe hepatitis", "start": 0, "end": 2}, {"entity_id": "2140997_3_Ent1", "role": "Treatment", "text": "cyproterone acetate", "start": 4, "end": 6}, {"entity_id": "2140997_3_Ent2", "role": "Treatment_Drug", "text": "cyproterone acetate", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "2140997_3_Ent0", "text": "Severe hepatitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2140997_3_Ent1", "text": "cyproterone acetate", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "2140997_3_Ent2", "text": "cyproterone acetate", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "21416219_1", "wnd_id": "21416219_1_1", "text": "Long - term efficacy of adding fenofibric acid to moderate - dose statin therapy in patients with persistent elevated triglycerides .", "tokens": ["Long", "-", "term", "efficacy", "of", "adding", "fenofibric", "acid", "to", "moderate", "-", "dose", "statin", "therapy", "in", "patients", "with", "persistent", "elevated", "triglycerides", "."], "event_mentions": [{"id": "21416219_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "efficacy", "start": 3, "end": 4}, "arguments": [{"entity_id": "21416219_1_Ent1", "role": "Treatment", "text": "adding fenofibric acid to moderate - dose statin therapy", "start": 5, "end": 14}, {"entity_id": "21416219_1_Ent3", "role": "Treatment_Drug", "text": "fenofibric acid", "start": 6, "end": 8}, {"entity_id": "21416219_1_Ent6", "role": "Combination_Drug", "text": "fenofibric acid", "start": 6, "end": 8}, {"entity_id": "21416219_1_Ent5", "role": "Treatment_Dosage", "text": "moderate - dose", "start": 9, "end": 12}, {"entity_id": "21416219_1_Ent4", "role": "Treatment_Drug", "text": "statin", "start": 12, "end": 13}, {"entity_id": "21416219_1_Ent7", "role": "Combination_Drug", "text": "statin", "start": 12, "end": 13}, {"entity_id": "21416219_1_Ent0", "role": "Subject", "text": "patients with persistent elevated triglycerides", "start": 15, "end": 20}, {"entity_id": "21416219_1_Ent2", "role": "Treatment_Disorder", "text": "persistent elevated triglycerides", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "21416219_1_Ent1", "text": "adding fenofibric acid to moderate - dose statin therapy", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "21416219_1_Ent3", "text": "fenofibric acid", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "21416219_1_Ent6", "text": "fenofibric acid", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "21416219_1_Ent5", "text": "moderate - dose", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "21416219_1_Ent4", "text": "statin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "21416219_1_Ent7", "text": "statin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "21416219_1_Ent0", "text": "patients with persistent elevated triglycerides", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "21416219_1_Ent2", "text": "persistent elevated triglycerides", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "21448111_3", "wnd_id": "21448111_3_1", "text": "Many types of medicaments can cause akathisia as an adverse event of their use and they include : antipsychotics , antidepressants , antiemetics , antihistamines , and psychoactive substances .", "tokens": ["Many", "types", "of", "medicaments", "can", "cause", "akathisia", "as", "an", "adverse", "event", "of", "their", "use", "and", "they", "include", ":", "antipsychotics", ",", "antidepressants", ",", "antiemetics", ",", "antihistamines", ",", "and", "psychoactive", "substances", "."], "event_mentions": [{"id": "21448111_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse event", "start": 9, "end": 11}, "arguments": [{"entity_id": "21448111_3_Ent0", "role": "Effect", "text": "akathisia", "start": 6, "end": 7}, {"entity_id": "21448111_3_Ent2", "role": "Treatment_Drug", "text": "antipsychotics", "start": 18, "end": 19}, {"entity_id": "21448111_3_Ent7", "role": "Combination_Drug", "text": "antipsychotics", "start": 18, "end": 19}, {"entity_id": "21448111_3_Ent1", "role": "Treatment", "text": "antipsychotics , antidepressants , antiemetics , antihistamines , and psychoactive substances", "start": 18, "end": 29}, {"entity_id": "21448111_3_Ent3", "role": "Treatment_Drug", "text": "antidepressants", "start": 20, "end": 21}, {"entity_id": "21448111_3_Ent8", "role": "Combination_Drug", "text": "antidepressants", "start": 20, "end": 21}, {"entity_id": "21448111_3_Ent4", "role": "Treatment_Drug", "text": "antiemetics", "start": 22, "end": 23}, {"entity_id": "21448111_3_Ent9", "role": "Combination_Drug", "text": "antiemetics", "start": 22, "end": 23}, {"entity_id": "21448111_3_Ent5", "role": "Treatment_Drug", "text": "antihistamines", "start": 24, "end": 25}, {"entity_id": "21448111_3_Ent10", "role": "Combination_Drug", "text": "antihistamines", "start": 24, "end": 25}, {"entity_id": "21448111_3_Ent6", "role": "Treatment_Drug", "text": "psychoactive substances .", "start": 27, "end": 30}, {"entity_id": "21448111_3_Ent11", "role": "Combination_Drug", "text": "psychoactive substances .", "start": 27, "end": 30}]}], "entity_mentions": [{"id": "21448111_3_Ent0", "text": "akathisia", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21448111_3_Ent2", "text": "antipsychotics", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "21448111_3_Ent7", "text": "antipsychotics", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "21448111_3_Ent1", "text": "antipsychotics , antidepressants , antiemetics , antihistamines , and psychoactive substances", "entity_type": "Entity", "start": 18, "end": 29}, {"id": "21448111_3_Ent3", "text": "antidepressants", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "21448111_3_Ent8", "text": "antidepressants", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "21448111_3_Ent4", "text": "antiemetics", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "21448111_3_Ent9", "text": "antiemetics", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "21448111_3_Ent5", "text": "antihistamines", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "21448111_3_Ent10", "text": "antihistamines", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "21448111_3_Ent6", "text": "psychoactive substances .", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "21448111_3_Ent11", "text": "psychoactive substances .", "entity_type": "Entity", "start": 27, "end": 30}], "lang": "en"}
{"doc_id": "2147700_1", "wnd_id": "2147700_1_1", "text": "One patient with systemic lupus erythematosus developed erythema multiforme after taking griseofulvin .", "tokens": ["One", "patient", "with", "systemic", "lupus", "erythematosus", "developed", "erythema", "multiforme", "after", "taking", "griseofulvin", "."], "event_mentions": [{"id": "2147700_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 9, "end": 10}, "arguments": [{"entity_id": "2147700_1_Ent1", "role": "Subject_Population", "text": "One", "start": 0, "end": 1}, {"entity_id": "2147700_1_Ent0", "role": "Subject", "text": "One patient with systemic lupus erythematosus", "start": 0, "end": 6}, {"entity_id": "2147700_1_Ent2", "role": "Subject_Disorder", "text": "systemic lupus erythematosus", "start": 3, "end": 6}, {"entity_id": "2147700_1_Ent3", "role": "Effect", "text": "erythema multiforme", "start": 7, "end": 9}, {"entity_id": "2147700_1_Ent4", "role": "Treatment", "text": "griseofulvin", "start": 11, "end": 12}, {"entity_id": "2147700_1_Ent5", "role": "Treatment_Drug", "text": "griseofulvin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "2147700_1_Ent1", "text": "One", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2147700_1_Ent0", "text": "One patient with systemic lupus erythematosus", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "2147700_1_Ent2", "text": "systemic lupus erythematosus", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "2147700_1_Ent3", "text": "erythema multiforme", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "2147700_1_Ent4", "text": "griseofulvin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "2147700_1_Ent5", "text": "griseofulvin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "21515865_3", "wnd_id": "21515865_3_1", "text": "An 89 - year - old man receiving long - term anticoagulation with warfarin sodium ( total weekly dosage of 19 mg ) arrived at the anticoagulation clinic for his monthly visit .", "tokens": ["An", "89", "-", "year", "-", "old", "man", "receiving", "long", "-", "term", "anticoagulation", "with", "warfarin", "sodium", "(", "total", "weekly", "dosage", "of", "19", "mg", ")", "arrived", "at", "the", "anticoagulation", "clinic", "for", "his", "monthly", "visit", "."], "event_mentions": [{"id": "21515865_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 7, "end": 8}, "arguments": [{"entity_id": "21515865_3_Ent0", "role": "Subject", "text": "An 89 - year - old man", "start": 0, "end": 7}, {"entity_id": "21515865_3_Ent1", "role": "Subject_Age", "text": "89 - year - old", "start": 1, "end": 6}, {"entity_id": "21515865_3_Ent6", "role": "Treatment_Duration", "text": "long - term", "start": 8, "end": 11}, {"entity_id": "21515865_3_Ent2", "role": "Treatment", "text": "long - term anticoagulation with warfarin sodium ( total weekly dosage of 19 mg )", "start": 8, "end": 23}, {"entity_id": "21515865_3_Ent3", "role": "Treatment_Drug", "text": "warfarin sodium", "start": 13, "end": 15}, {"entity_id": "21515865_3_Ent4", "role": "Treatment_Freq", "text": "weekly", "start": 17, "end": 18}, {"entity_id": "21515865_3_Ent5", "role": "Treatment_Dosage", "text": "19 mg", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "21515865_3_Ent0", "text": "An 89 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "21515865_3_Ent1", "text": "89 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "21515865_3_Ent6", "text": "long - term", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "21515865_3_Ent2", "text": "long - term anticoagulation with warfarin sodium ( total weekly dosage of 19 mg )", "entity_type": "Entity", "start": 8, "end": 23}, {"id": "21515865_3_Ent3", "text": "warfarin sodium", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "21515865_3_Ent4", "text": "weekly", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "21515865_3_Ent5", "text": "19 mg", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "2154663_3", "wnd_id": "2154663_3_1", "text": "We report a case of radiotherapy - enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer .", "tokens": ["We", "report", "a", "case", "of", "radiotherapy", "-", "enhanced", "aminoglutethimide", "skin", "toxicity", "in", "a", "patient", "with", "metastatic", "breast", "cancer", "."], "event_mentions": [{"id": "2154663_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 10, "end": 11}, "arguments": [{"entity_id": "2154663_3_Ent2", "role": "Treatment", "text": "radiotherapy - enhanced aminoglutethimide", "start": 5, "end": 9}, {"entity_id": "2154663_3_Ent4", "role": "Treatment_Drug", "text": "aminoglutethimide", "start": 8, "end": 9}, {"entity_id": "2154663_3_Ent1", "role": "Effect", "text": "skin toxicity", "start": 9, "end": 11}, {"entity_id": "2154663_3_Ent0", "role": "Subject", "text": "a patient with metastatic breast cancer", "start": 12, "end": 18}, {"entity_id": "2154663_3_Ent3", "role": "Treatment_Disorder", "text": "metastatic breast cancer", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "2154663_3_Ent2", "text": "radiotherapy - enhanced aminoglutethimide", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "2154663_3_Ent4", "text": "aminoglutethimide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2154663_3_Ent1", "text": "skin toxicity", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "2154663_3_Ent0", "text": "a patient with metastatic breast cancer", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "2154663_3_Ent3", "text": "metastatic breast cancer", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "21597286_4", "wnd_id": "21597286_4_1", "text": "A methotrexate overdosage was shown at 36 h after infusion associated with a severe renal failure .", "tokens": ["A", "methotrexate", "overdosage", "was", "shown", "at", "36", "h", "after", "infusion", "associated", "with", "a", "severe", "renal", "failure", "."], "event_mentions": [{"id": "21597286_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 10, "end": 11}, "arguments": [{"entity_id": "21597286_4_Ent2", "role": "Treatment", "text": "methotrexate", "start": 1, "end": 2}, {"entity_id": "21597286_4_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 1, "end": 2}, {"entity_id": "21597286_4_Ent0", "role": "Effect", "text": "methotrexate overdosage was shown at 36 h after infusion", "start": 1, "end": 10}, {"entity_id": "21597286_4_Ent1", "role": "Effect", "text": "severe renal failure", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "21597286_4_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "21597286_4_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "21597286_4_Ent0", "text": "methotrexate overdosage was shown at 36 h after infusion", "entity_type": "Entity", "start": 1, "end": 10}, {"id": "21597286_4_Ent1", "text": "severe renal failure", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "21751666_1", "wnd_id": "21751666_1_1", "text": "Post - exposure prophylaxis for H1N1 with oseltamivir in renal allograft recipient -- safe and effective without any immunosuppresive drug interaction .", "tokens": ["Post", "-", "exposure", "prophylaxis", "for", "H1N1", "with", "oseltamivir", "in", "renal", "allograft", "recipient", "--", "safe", "and", "effective", "without", "any", "immunosuppresive", "drug", "interaction", "."], "event_mentions": [{"id": "21751666_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Post - exposure prophylaxis", "start": 0, "end": 4}, "arguments": [{"entity_id": "21751666_1_Ent4", "role": "Treatment_Disorder", "text": "H1N1", "start": 5, "end": 6}, {"entity_id": "21751666_1_Ent3", "role": "Treatment", "text": "oseltamivir", "start": 7, "end": 8}, {"entity_id": "21751666_1_Ent5", "role": "Treatment_Drug", "text": "oseltamivir", "start": 7, "end": 8}, {"entity_id": "21751666_1_Ent1", "role": "Subject_Disorder", "text": "renal allograft", "start": 9, "end": 11}, {"entity_id": "21751666_1_Ent0", "role": "Subject", "text": "renal allograft recipient", "start": 9, "end": 12}, {"entity_id": "21751666_1_Ent2", "role": "Effect", "text": "safe and effective without any immunosuppresive drug interaction", "start": 13, "end": 21}]}], "entity_mentions": [{"id": "21751666_1_Ent4", "text": "H1N1", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "21751666_1_Ent3", "text": "oseltamivir", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21751666_1_Ent5", "text": "oseltamivir", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21751666_1_Ent1", "text": "renal allograft", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "21751666_1_Ent0", "text": "renal allograft recipient", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "21751666_1_Ent2", "text": "safe and effective without any immunosuppresive drug interaction", "entity_type": "Entity", "start": 13, "end": 21}], "lang": "en"}
{"doc_id": "21751666_3", "wnd_id": "21751666_3_1", "text": "Prevention of infection by immunization , together with early recognition and prompt antiviral treatment are critical .", "tokens": ["Prevention", "of", "infection", "by", "immunization", ",", "together", "with", "early", "recognition", "and", "prompt", "antiviral", "treatment", "are", "critical", "."], "event_mentions": [{"id": "21751666_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Prevention", "start": 0, "end": 1}, "arguments": [{"entity_id": "21751666_3_Ent1", "role": "Treatment_Disorder", "text": "infection", "start": 2, "end": 3}, {"entity_id": "21751666_3_Ent0", "role": "Treatment", "text": "immunization , together with early recognition and prompt antiviral treatment", "start": 4, "end": 14}]}], "entity_mentions": [{"id": "21751666_3_Ent1", "text": "infection", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "21751666_3_Ent0", "text": "immunization , together with early recognition and prompt antiviral treatment", "entity_type": "Entity", "start": 4, "end": 14}], "lang": "en"}
{"doc_id": "21762153_9", "wnd_id": "21762153_9_1", "text": "The zinc / o - cymen - 5 - ol system has direct antimicrobial effects and inhibits oral disease - related processes .", "tokens": ["The", "zinc", "/", "o", "-", "cymen", "-", "5", "-", "ol", "system", "has", "direct", "antimicrobial", "effects", "and", "inhibits", "oral", "disease", "-", "related", "processes", "."], "event_mentions": [{"id": "21762153_9_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "inhibits", "start": 16, "end": 17}, "arguments": [{"entity_id": "21762153_9_Ent3", "role": "Treatment_Drug", "text": "zinc", "start": 1, "end": 2}, {"entity_id": "21762153_9_Ent5", "role": "Combination_Drug", "text": "zinc", "start": 1, "end": 2}, {"entity_id": "21762153_9_Ent2", "role": "Treatment", "text": "zinc / o - cymen - 5 - ol system", "start": 1, "end": 11}, {"entity_id": "21762153_9_Ent4", "role": "Treatment_Drug", "text": "o - cymen - 5 - ol", "start": 3, "end": 10}, {"entity_id": "21762153_9_Ent6", "role": "Combination_Drug", "text": "o - cymen - 5 - ol", "start": 3, "end": 10}, {"entity_id": "21762153_9_Ent0", "role": "Effect", "text": "antimicrobial effects", "start": 13, "end": 15}, {"entity_id": "21762153_9_Ent1", "role": "Effect", "text": "inhibits oral disease - related processes", "start": 16, "end": 22}]}], "entity_mentions": [{"id": "21762153_9_Ent3", "text": "zinc", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "21762153_9_Ent5", "text": "zinc", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "21762153_9_Ent2", "text": "zinc / o - cymen - 5 - ol system", "entity_type": "Entity", "start": 1, "end": 11}, {"id": "21762153_9_Ent4", "text": "o - cymen - 5 - ol", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "21762153_9_Ent6", "text": "o - cymen - 5 - ol", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "21762153_9_Ent0", "text": "antimicrobial effects", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "21762153_9_Ent1", "text": "inhibits oral disease - related processes", "entity_type": "Entity", "start": 16, "end": 22}], "lang": "en"}
{"doc_id": "21887897_1", "wnd_id": "21887897_1_1", "text": "An autopsy case of multiple psychotropic drug poisoning .", "tokens": ["An", "autopsy", "case", "of", "multiple", "psychotropic", "drug", "poisoning", "."], "event_mentions": [{"id": "21887897_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "poisoning", "start": 7, "end": 8}, "arguments": [{"entity_id": "21887897_1_Ent0", "role": "Subject", "text": "An autopsy case", "start": 0, "end": 3}, {"entity_id": "21887897_1_Ent2", "role": "Treatment", "text": "multiple psychotropic drug", "start": 4, "end": 7}, {"entity_id": "21887897_1_Ent3", "role": "Treatment_Drug", "text": "psychotropic", "start": 5, "end": 6}, {"entity_id": "21887897_1_Ent1", "role": "Effect", "text": "poisoning", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "21887897_1_Ent0", "text": "An autopsy case", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "21887897_1_Ent2", "text": "multiple psychotropic drug", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "21887897_1_Ent3", "text": "psychotropic", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "21887897_1_Ent1", "text": "poisoning", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "22010004_1", "wnd_id": "22010004_1_1", "text": "Critically elevated INR in a patient on warfarin after increase in extended - release niacin dose .", "tokens": ["Critically", "elevated", "INR", "in", "a", "patient", "on", "warfarin", "after", "increase", "in", "extended", "-", "release", "niacin", "dose", "."], "event_mentions": [{"id": "22010004_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 8, "end": 9}, "arguments": [{"entity_id": "22010004_1_Ent1", "role": "Effect", "text": "elevated INR", "start": 1, "end": 3}, {"entity_id": "22010004_1_Ent0", "role": "Subject", "text": "a patient", "start": 4, "end": 6}, {"entity_id": "22010004_1_Ent2", "role": "Treatment", "text": "warfarin", "start": 7, "end": 8}, {"entity_id": "22010004_1_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 7, "end": 8}, {"entity_id": "22010004_1_Ent6", "role": "Treatment_Dosage", "text": "increase in", "start": 9, "end": 11}, {"entity_id": "22010004_1_Ent3", "role": "Treatment", "text": "increase in extended - release niacin dose", "start": 9, "end": 16}, {"entity_id": "22010004_1_Ent5", "role": "Treatment_Drug", "text": "niacin", "start": 14, "end": 15}, {"entity_id": "22010004_1_Ent7", "role": "Treatment_Dosage", "text": "dose", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "22010004_1_Ent1", "text": "elevated INR", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "22010004_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "22010004_1_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "22010004_1_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "22010004_1_Ent6", "text": "increase in", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "22010004_1_Ent3", "text": "increase in extended - release niacin dose", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "22010004_1_Ent5", "text": "niacin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "22010004_1_Ent7", "text": "dose", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "22010004_8", "wnd_id": "22010004_8_1", "text": "The mechanism of niacin - induced coagulopathy is theorized to be related to diminished coagulation factors , and limited data suggest that this may be more pronounced with extended - release niacin .", "tokens": ["The", "mechanism", "of", "niacin", "-", "induced", "coagulopathy", "is", "theorized", "to", "be", "related", "to", "diminished", "coagulation", "factors", ",", "and", "limited", "data", "suggest", "that", "this", "may", "be", "more", "pronounced", "with", "extended", "-", "release", "niacin", "."], "event_mentions": [{"id": "22010004_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "22010004_8_Ent1", "role": "Treatment", "text": "niacin", "start": 3, "end": 4}, {"entity_id": "22010004_8_Ent2", "role": "Treatment_Drug", "text": "niacin", "start": 3, "end": 4}, {"entity_id": "22010004_8_Ent0", "role": "Effect", "text": "coagulopathy", "start": 6, "end": 7}, {"entity_id": "22010004_8_Ent3", "role": "Treatment_Drug", "text": "extended - release niacin", "start": 28, "end": 32}]}], "entity_mentions": [{"id": "22010004_8_Ent1", "text": "niacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "22010004_8_Ent2", "text": "niacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "22010004_8_Ent0", "text": "coagulopathy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "22010004_8_Ent3", "text": "extended - release niacin", "entity_type": "Entity", "start": 28, "end": 32}], "lang": "en"}
{"doc_id": "2204409_2", "wnd_id": "2204409_2_1", "text": "Methotrexate - induced leukoencephalopathy is treatable with high - dose folinic acid : a case report and analysis of the literature .", "tokens": ["Methotrexate", "-", "induced", "leukoencephalopathy", "is", "treatable", "with", "high", "-", "dose", "folinic", "acid", ":", "a", "case", "report", "and", "analysis", "of", "the", "literature", "."], "event_mentions": [{"id": "2204409_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2204409_2_Ent5", "role": "Treatment", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "2204409_2_Ent6", "role": "Treatment_Drug", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "2204409_2_Ent4", "role": "Effect", "text": "leukoencephalopathy", "start": 3, "end": 4}]}, {"id": "2204409_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatable", "start": 5, "end": 6}, "arguments": [{"entity_id": "2204409_2_Ent1", "role": "Treatment_Disorder", "text": "Methotrexate - induced leukoencephalopathy", "start": 0, "end": 4}, {"entity_id": "2204409_2_Ent2", "role": "Treatment_Dosage", "text": "high - dose", "start": 7, "end": 10}, {"entity_id": "2204409_2_Ent0", "role": "Treatment", "text": "high - dose folinic acid", "start": 7, "end": 12}, {"entity_id": "2204409_2_Ent3", "role": "Treatment_Drug", "text": "folinic acid", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "2204409_2_Ent5", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2204409_2_Ent6", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2204409_2_Ent1", "text": "Methotrexate - induced leukoencephalopathy", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "2204409_2_Ent4", "text": "leukoencephalopathy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2204409_2_Ent2", "text": "high - dose", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "2204409_2_Ent0", "text": "high - dose folinic acid", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "2204409_2_Ent3", "text": "folinic acid", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "2212262_1", "wnd_id": "2212262_1_1", "text": "Severe heparin associated thrombocytopenia is a rare complication of heparin therapy .", "tokens": ["Severe", "heparin", "associated", "thrombocytopenia", "is", "a", "rare", "complication", "of", "heparin", "therapy", "."], "event_mentions": [{"id": "2212262_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "2212262_1_Ent1", "role": "Treatment", "text": "heparin", "start": 1, "end": 2}, {"entity_id": "2212262_1_Ent2", "role": "Treatment_Drug", "text": "heparin", "start": 1, "end": 2}, {"entity_id": "2212262_1_Ent0", "role": "Effect", "text": "thrombocytopenia", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "2212262_1_Ent1", "text": "heparin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2212262_1_Ent2", "text": "heparin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2212262_1_Ent0", "text": "thrombocytopenia", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "2212262_2", "wnd_id": "2212262_2_1", "text": "We report a patient who developed heparin associated thrombocytopenia during continuous arteriovenous haemofiltration and discuss its implications and alternative anticoagulant treatment .", "tokens": ["We", "report", "a", "patient", "who", "developed", "heparin", "associated", "thrombocytopenia", "during", "continuous", "arteriovenous", "haemofiltration", "and", "discuss", "its", "implications", "and", "alternative", "anticoagulant", "treatment", "."], "event_mentions": [{"id": "2212262_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 9, "end": 10}, "arguments": [{"entity_id": "2212262_2_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "2212262_2_Ent2", "role": "Treatment", "text": "heparin", "start": 6, "end": 7}, {"entity_id": "2212262_2_Ent4", "role": "Treatment_Drug", "text": "heparin", "start": 6, "end": 7}, {"entity_id": "2212262_2_Ent1", "role": "Effect", "text": "heparin associated thrombocytopenia", "start": 6, "end": 9}, {"entity_id": "2212262_2_Ent3", "role": "Treatment", "text": "continuous arteriovenous haemofiltration", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "2212262_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "2212262_2_Ent2", "text": "heparin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2212262_2_Ent4", "text": "heparin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2212262_2_Ent1", "text": "heparin associated thrombocytopenia", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "2212262_2_Ent3", "text": "continuous arteriovenous haemofiltration", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "2219619_1", "wnd_id": "2219619_1_1", "text": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis .", "tokens": ["Acute", "aluminum", "toxicity", "after", "continuous", "intravesical", "alum", "irrigation", "for", "hemorrhagic", "cystitis", "."], "event_mentions": [{"id": "2219619_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "2219619_1_Ent0", "role": "Effect", "text": "Acute aluminum toxicity", "start": 0, "end": 3}, {"entity_id": "2219619_1_Ent1", "role": "Treatment", "text": "continuous intravesical alum irrigation", "start": 4, "end": 8}, {"entity_id": "2219619_1_Ent3", "role": "Treatment_Route", "text": "intravesical", "start": 5, "end": 6}, {"entity_id": "2219619_1_Ent5", "role": "Treatment_Drug", "text": "alum", "start": 6, "end": 7}, {"entity_id": "2219619_1_Ent4", "role": "Treatment_Route", "text": "irrigation", "start": 7, "end": 8}, {"entity_id": "2219619_1_Ent2", "role": "Treatment_Disorder", "text": "hemorrhagic cystitis", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "2219619_1_Ent0", "text": "Acute aluminum toxicity", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2219619_1_Ent1", "text": "continuous intravesical alum irrigation", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "2219619_1_Ent3", "text": "intravesical", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2219619_1_Ent5", "text": "alum", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2219619_1_Ent4", "text": "irrigation", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2219619_1_Ent2", "text": "hemorrhagic cystitis", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "2224786_1", "wnd_id": "2224786_1_1", "text": "A 62 - year - old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy - related hemolytic - uremic syndrome during the second cycle of neoadjuvant chemotherapy consisting of cisplatin , bleomycin , and methotrexate .", "tokens": ["A", "62", "-", "year", "-", "old", "woman", "who", "was", "being", "treated", "for", "squamous", "cell", "carcinoma", "of", "the", "head", "and", "neck", "developed", "a", "chemotherapy", "-", "related", "hemolytic", "-", "uremic", "syndrome", "during", "the", "second", "cycle", "of", "neoadjuvant", "chemotherapy", "consisting", "of", "cisplatin", ",", "bleomycin", ",", "and", "methotrexate", "."], "event_mentions": [{"id": "2224786_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "2224786_1_Ent0", "role": "Subject", "text": "A 62 - year - old woman who was being treated for squamous cell carcinoma of the head and neck", "start": 0, "end": 20}, {"entity_id": "2224786_1_Ent1", "role": "Subject_Age", "text": "62 - year - old", "start": 1, "end": 6}, {"entity_id": "2224786_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "2224786_1_Ent5", "role": "Treatment_Disorder", "text": "squamous cell carcinoma of the head and neck", "start": 12, "end": 20}, {"entity_id": "2224786_1_Ent3", "role": "Effect", "text": "a chemotherapy - related hemolytic - uremic syndrome", "start": 21, "end": 29}, {"entity_id": "2224786_1_Ent4", "role": "Treatment", "text": "the second cycle of neoadjuvant chemotherapy consisting of cisplatin , bleomycin , and methotrexate", "start": 30, "end": 44}, {"entity_id": "2224786_1_Ent6", "role": "Treatment_Dosage", "text": "second cycle", "start": 31, "end": 33}, {"entity_id": "2224786_1_Ent7", "role": "Treatment_Drug", "text": "cisplatin", "start": 38, "end": 39}, {"entity_id": "2224786_1_Ent10", "role": "Combination_Drug", "text": "cisplatin", "start": 38, "end": 39}, {"entity_id": "2224786_1_Ent8", "role": "Treatment_Drug", "text": "bleomycin", "start": 40, "end": 41}, {"entity_id": "2224786_1_Ent11", "role": "Combination_Drug", "text": "bleomycin", "start": 40, "end": 41}, {"entity_id": "2224786_1_Ent9", "role": "Treatment_Drug", "text": "methotrexate", "start": 43, "end": 44}, {"entity_id": "2224786_1_Ent12", "role": "Combination_Drug", "text": "methotrexate", "start": 43, "end": 44}]}], "entity_mentions": [{"id": "2224786_1_Ent0", "text": "A 62 - year - old woman who was being treated for squamous cell carcinoma of the head and neck", "entity_type": "Entity", "start": 0, "end": 20}, {"id": "2224786_1_Ent1", "text": "62 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "2224786_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2224786_1_Ent5", "text": "squamous cell carcinoma of the head and neck", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "2224786_1_Ent3", "text": "a chemotherapy - related hemolytic - uremic syndrome", "entity_type": "Entity", "start": 21, "end": 29}, {"id": "2224786_1_Ent4", "text": "the second cycle of neoadjuvant chemotherapy consisting of cisplatin , bleomycin , and methotrexate", "entity_type": "Entity", "start": 30, "end": 44}, {"id": "2224786_1_Ent6", "text": "second cycle", "entity_type": "Entity", "start": 31, "end": 33}, {"id": "2224786_1_Ent7", "text": "cisplatin", "entity_type": "Entity", "start": 38, "end": 39}, {"id": "2224786_1_Ent10", "text": "cisplatin", "entity_type": "Entity", "start": 38, "end": 39}, {"id": "2224786_1_Ent8", "text": "bleomycin", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "2224786_1_Ent11", "text": "bleomycin", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "2224786_1_Ent9", "text": "methotrexate", "entity_type": "Entity", "start": 43, "end": 44}, {"id": "2224786_1_Ent12", "text": "methotrexate", "entity_type": "Entity", "start": 43, "end": 44}], "lang": "en"}
{"doc_id": "2234880_2", "wnd_id": "2234880_2_1", "text": "Nitrendipine is an experimental calcium channel blocking agent that also appears to cause the side effect of drug - induced gingival hyperplasia .", "tokens": ["Nitrendipine", "is", "an", "experimental", "calcium", "channel", "blocking", "agent", "that", "also", "appears", "to", "cause", "the", "side", "effect", "of", "drug", "-", "induced", "gingival", "hyperplasia", "."], "event_mentions": [{"id": "2234880_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 12, "end": 13}, "arguments": [{"entity_id": "2234880_2_Ent2", "role": "Treatment_Drug", "text": "Nitrendipine", "start": 0, "end": 1}, {"entity_id": "2234880_2_Ent1", "role": "Treatment", "text": "Nitrendipine is an experimental calcium channel blocking agent", "start": 0, "end": 8}, {"entity_id": "2234880_2_Ent0", "role": "Effect", "text": "gingival hyperplasia", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "2234880_2_Ent2", "text": "Nitrendipine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2234880_2_Ent1", "text": "Nitrendipine is an experimental calcium channel blocking agent", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "2234880_2_Ent0", "text": "gingival hyperplasia", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "22372628_1", "wnd_id": "22372628_1_1", "text": "Long - term safety and efficacy in patients with uncontrolled partial - onset seizures treated with adjunctive lacosamide : results from a Phase III open - label extension trial .", "tokens": ["Long", "-", "term", "safety", "and", "efficacy", "in", "patients", "with", "uncontrolled", "partial", "-", "onset", "seizures", "treated", "with", "adjunctive", "lacosamide", ":", "results", "from", "a", "Phase", "III", "open", "-", "label", "extension", "trial", "."], "event_mentions": [{"id": "22372628_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 14, "end": 15}, "arguments": [{"entity_id": "22372628_1_Ent0", "role": "Subject", "text": "patients with uncontrolled partial - onset seizures", "start": 7, "end": 14}, {"entity_id": "22372628_1_Ent3", "role": "Treatment_Disorder", "text": "uncontrolled partial - onset seizures", "start": 9, "end": 14}, {"entity_id": "22372628_1_Ent1", "role": "Treatment", "text": "adjunctive lacosamide", "start": 16, "end": 18}, {"entity_id": "22372628_1_Ent2", "role": "Treatment_Drug", "text": "lacosamide", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "22372628_1_Ent0", "text": "patients with uncontrolled partial - onset seizures", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "22372628_1_Ent3", "text": "uncontrolled partial - onset seizures", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "22372628_1_Ent1", "text": "adjunctive lacosamide", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "22372628_1_Ent2", "text": "lacosamide", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "228648_1", "wnd_id": "228648_1_1", "text": "Prenatal cytomegalovirus ( CMV ) infection associated with severe brain damage was detected in an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus ( SLE ) .", "tokens": ["Prenatal", "cytomegalovirus", "(", "CMV", ")", "infection", "associated", "with", "severe", "brain", "damage", "was", "detected", "in", "an", "infant", "whose", "mother", "had", "been", "treated", "with", "prednisolone", "and", "azathioprine", "for", "systemic", "lupus", "erythematosus", "(", "SLE", ")", "."], "event_mentions": [{"id": "228648_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 20, "end": 21}, "arguments": [{"entity_id": "228648_1_Ent2", "role": "Effect", "text": "Prenatal cytomegalovirus ( CMV ) infection associated with severe brain damage", "start": 0, "end": 11}, {"entity_id": "228648_1_Ent0", "role": "Subject", "text": "an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus ( SLE )", "start": 14, "end": 32}, {"entity_id": "228648_1_Ent1", "role": "Subject_Age", "text": "infant", "start": 15, "end": 16}, {"entity_id": "228648_1_Ent4", "role": "Treatment_Drug", "text": "prednisolone", "start": 22, "end": 23}, {"entity_id": "228648_1_Ent6", "role": "Combination_Drug", "text": "prednisolone", "start": 22, "end": 23}, {"entity_id": "228648_1_Ent3", "role": "Treatment", "text": "prednisolone and azathioprine", "start": 22, "end": 25}, {"entity_id": "228648_1_Ent5", "role": "Treatment_Drug", "text": "azathioprine", "start": 24, "end": 25}, {"entity_id": "228648_1_Ent7", "role": "Combination_Drug", "text": "azathioprine", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "228648_1_Ent2", "text": "Prenatal cytomegalovirus ( CMV ) infection associated with severe brain damage", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "228648_1_Ent0", "text": "an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus ( SLE )", "entity_type": "Entity", "start": 14, "end": 32}, {"id": "228648_1_Ent1", "text": "infant", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "228648_1_Ent4", "text": "prednisolone", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "228648_1_Ent6", "text": "prednisolone", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "228648_1_Ent3", "text": "prednisolone and azathioprine", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "228648_1_Ent5", "text": "azathioprine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "228648_1_Ent7", "text": "azathioprine", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "2299784_2", "wnd_id": "2299784_2_1", "text": "Bromide intoxication secondary to pyridostigmine bromide therapy .", "tokens": ["Bromide", "intoxication", "secondary", "to", "pyridostigmine", "bromide", "therapy", "."], "event_mentions": [{"id": "2299784_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 2, "end": 3}, "arguments": [{"entity_id": "2299784_2_Ent0", "role": "Effect", "text": "Bromide intoxication", "start": 0, "end": 2}, {"entity_id": "2299784_2_Ent1", "role": "Treatment", "text": "pyridostigmine bromide", "start": 4, "end": 6}, {"entity_id": "2299784_2_Ent2", "role": "Treatment_Drug", "text": "pyridostigmine bromide", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "2299784_2_Ent0", "text": "Bromide intoxication", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2299784_2_Ent1", "text": "pyridostigmine bromide", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "2299784_2_Ent2", "text": "pyridostigmine bromide", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "23042259_3", "wnd_id": "23042259_3_1", "text": "The determinant role of individual pharmacogenetic profile in the occurrence of tacrolimus nephrotoxicity is presented and discussed .", "tokens": ["The", "determinant", "role", "of", "individual", "pharmacogenetic", "profile", "in", "the", "occurrence", "of", "tacrolimus", "nephrotoxicity", "is", "presented", "and", "discussed", "."], "event_mentions": [{"id": "23042259_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurrence", "start": 9, "end": 10}, "arguments": [{"entity_id": "23042259_3_Ent1", "role": "Treatment", "text": "tacrolimus", "start": 11, "end": 12}, {"entity_id": "23042259_3_Ent2", "role": "Treatment_Drug", "text": "tacrolimus", "start": 11, "end": 12}, {"entity_id": "23042259_3_Ent0", "role": "Effect", "text": "tacrolimus nephrotoxicity", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "23042259_3_Ent1", "text": "tacrolimus", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "23042259_3_Ent2", "text": "tacrolimus", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "23042259_3_Ent0", "text": "tacrolimus nephrotoxicity", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "2309833_1", "wnd_id": "2309833_1_1", "text": "After discontinuation of danazol the diabetes completely resolved .", "tokens": ["After", "discontinuation", "of", "danazol", "the", "diabetes", "completely", "resolved", "."], "event_mentions": [{"id": "2309833_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 7, "end": 8}, "arguments": [{"entity_id": "2309833_1_Ent0", "role": "Treatment", "text": "discontinuation of danazol", "start": 1, "end": 4}, {"entity_id": "2309833_1_Ent2", "role": "Treatment_Drug", "text": "danazol", "start": 3, "end": 4}, {"entity_id": "2309833_1_Ent1", "role": "Treatment_Disorder", "text": "diabetes", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "2309833_1_Ent0", "text": "discontinuation of danazol", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "2309833_1_Ent2", "text": "danazol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2309833_1_Ent1", "text": "diabetes", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "23115227_6", "wnd_id": "23115227_6_1", "text": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg ( 95 % CI 12.7 to 13.8 ) , with a mean international normalized ratio ( INR ) of 2.8 ( 95 % CI 2.5 to 3.1 ) .", "tokens": ["The", "mean", "weekly", "warfarin", "dose", "while", "the", "patient", "was", "receiving", "emtricitabine", "monotherapy", "was", "13.3", "mg", "(", "95", "%", "CI", "12.7", "to", "13.8", ")", ",", "with", "a", "mean", "international", "normalized", "ratio", "(", "INR", ")", "of", "2.8", "(", "95", "%", "CI", "2.5", "to", "3.1", ")", "."], "event_mentions": [{"id": "23115227_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 9, "end": 10}, "arguments": [{"entity_id": "23115227_6_Ent1", "role": "Treatment", "text": "The mean weekly warfarin dose", "start": 0, "end": 5}, {"entity_id": "23115227_6_Ent3", "role": "Treatment_Freq", "text": "weekly", "start": 2, "end": 3}, {"entity_id": "23115227_6_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "23115227_6_Ent0", "role": "Subject", "text": "the patient", "start": 6, "end": 8}, {"entity_id": "23115227_6_Ent5", "role": "Treatment_Drug", "text": "emtricitabine", "start": 10, "end": 11}, {"entity_id": "23115227_6_Ent2", "role": "Treatment", "text": "emtricitabine monotherapy was 13.3 mg ( 95 % CI 12.7 to 13.8 )", "start": 10, "end": 23}, {"entity_id": "23115227_6_Ent6", "role": "Treatment_Dosage", "text": "13.3 mg", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "23115227_6_Ent1", "text": "The mean weekly warfarin dose", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "23115227_6_Ent3", "text": "weekly", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "23115227_6_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "23115227_6_Ent0", "text": "the patient", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "23115227_6_Ent5", "text": "emtricitabine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "23115227_6_Ent2", "text": "emtricitabine monotherapy was 13.3 mg ( 95 % CI 12.7 to 13.8 )", "entity_type": "Entity", "start": 10, "end": 23}, {"id": "23115227_6_Ent6", "text": "13.3 mg", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "2316232_2", "wnd_id": "2316232_2_1", "text": "Symptomatic hypoglycemia secondary to a glipizide - trimethoprim / sulfamethoxazole drug interaction .", "tokens": ["Symptomatic", "hypoglycemia", "secondary", "to", "a", "glipizide", "-", "trimethoprim", "/", "sulfamethoxazole", "drug", "interaction", "."], "event_mentions": [{"id": "2316232_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary to", "start": 2, "end": 4}, "arguments": [{"entity_id": "2316232_2_Ent0", "role": "Effect", "text": "Symptomatic hypoglycemia", "start": 0, "end": 2}, {"entity_id": "2316232_2_Ent2", "role": "Treatment_Drug", "text": "glipizide", "start": 5, "end": 6}, {"entity_id": "2316232_2_Ent5", "role": "Combination_Drug", "text": "glipizide", "start": 5, "end": 6}, {"entity_id": "2316232_2_Ent1", "role": "Treatment", "text": "glipizide - trimethoprim / sulfamethoxazole drug interaction", "start": 5, "end": 12}, {"entity_id": "2316232_2_Ent3", "role": "Treatment_Drug", "text": "trimethoprim", "start": 7, "end": 8}, {"entity_id": "2316232_2_Ent6", "role": "Combination_Drug", "text": "trimethoprim", "start": 7, "end": 8}, {"entity_id": "2316232_2_Ent4", "role": "Treatment_Drug", "text": "sulfamethoxazole", "start": 9, "end": 10}, {"entity_id": "2316232_2_Ent7", "role": "Combination_Drug", "text": "sulfamethoxazole", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "2316232_2_Ent0", "text": "Symptomatic hypoglycemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2316232_2_Ent2", "text": "glipizide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2316232_2_Ent5", "text": "glipizide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2316232_2_Ent1", "text": "glipizide - trimethoprim / sulfamethoxazole drug interaction", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "2316232_2_Ent3", "text": "trimethoprim", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2316232_2_Ent6", "text": "trimethoprim", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2316232_2_Ent4", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2316232_2_Ent7", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "2320800_1", "wnd_id": "2320800_1_1", "text": "Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function .", "tokens": ["Lethal", "anuria", "complicating", "high", "dose", "ifosfamide", "chemotherapy", "in", "a", "breast", "cancer", "patient", "with", "an", "impaired", "renal", "function", "."], "event_mentions": [{"id": "2320800_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complicating", "start": 2, "end": 3}, "arguments": [{"entity_id": "2320800_1_Ent2", "role": "Effect", "text": "anuria", "start": 1, "end": 2}, {"entity_id": "2320800_1_Ent7", "role": "Treatment_Dosage", "text": "high dose", "start": 3, "end": 5}, {"entity_id": "2320800_1_Ent3", "role": "Treatment", "text": "high dose ifosfamide chemotherapy", "start": 3, "end": 7}, {"entity_id": "2320800_1_Ent5", "role": "Treatment_Drug", "text": "ifosfamide", "start": 5, "end": 6}, {"entity_id": "2320800_1_Ent6", "role": "Treatment_Route", "text": "chemotherapy", "start": 6, "end": 7}, {"entity_id": "2320800_1_Ent0", "role": "Subject", "text": "a breast cancer patient with an impaired renal function", "start": 8, "end": 17}, {"entity_id": "2320800_1_Ent4", "role": "Treatment_Disorder", "text": "breast cancer", "start": 9, "end": 11}, {"entity_id": "2320800_1_Ent1", "role": "Subject_Disorder", "text": "an impaired renal function", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "2320800_1_Ent2", "text": "anuria", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2320800_1_Ent7", "text": "high dose", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "2320800_1_Ent3", "text": "high dose ifosfamide chemotherapy", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "2320800_1_Ent5", "text": "ifosfamide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2320800_1_Ent6", "text": "chemotherapy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2320800_1_Ent0", "text": "a breast cancer patient with an impaired renal function", "entity_type": "Entity", "start": 8, "end": 17}, {"id": "2320800_1_Ent4", "text": "breast cancer", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "2320800_1_Ent1", "text": "an impaired renal function", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "2327115_3", "wnd_id": "2327115_3_1", "text": "Suspected ciprofloxacin - induced interstitial nephritis .", "tokens": ["Suspected", "ciprofloxacin", "-", "induced", "interstitial", "nephritis", "."], "event_mentions": [{"id": "2327115_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "2327115_3_Ent1", "role": "Treatment", "text": "ciprofloxacin", "start": 1, "end": 2}, {"entity_id": "2327115_3_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 1, "end": 2}, {"entity_id": "2327115_3_Ent0", "role": "Effect", "text": "interstitial nephritis", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "2327115_3_Ent1", "text": "ciprofloxacin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2327115_3_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2327115_3_Ent0", "text": "interstitial nephritis", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "2332596_3", "wnd_id": "2332596_3_1", "text": "Skin rash began after 2 weeks of treatment , and signs of hepatocellular failure developed 3 weeks after phenobarbital had been started .", "tokens": ["Skin", "rash", "began", "after", "2", "weeks", "of", "treatment", ",", "and", "signs", "of", "hepatocellular", "failure", "developed", "3", "weeks", "after", "phenobarbital", "had", "been", "started", "."], "event_mentions": [{"id": "2332596_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "2332596_3_Ent0", "role": "Effect", "text": "Skin rash", "start": 0, "end": 2}, {"entity_id": "2332596_3_Ent4", "role": "Treatment_Time_elapsed", "text": "2 weeks", "start": 4, "end": 6}, {"entity_id": "2332596_3_Ent1", "role": "Effect", "text": "hepatocellular failure", "start": 12, "end": 14}, {"entity_id": "2332596_3_Ent3", "role": "Treatment_Time_elapsed", "text": "3 weeks", "start": 15, "end": 17}, {"entity_id": "2332596_3_Ent2", "role": "Treatment", "text": "phenobarbital", "start": 18, "end": 19}, {"entity_id": "2332596_3_Ent5", "role": "Treatment_Drug", "text": "phenobarbital", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "2332596_3_Ent0", "text": "Skin rash", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2332596_3_Ent4", "text": "2 weeks", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "2332596_3_Ent1", "text": "hepatocellular failure", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "2332596_3_Ent3", "text": "3 weeks", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "2332596_3_Ent2", "text": "phenobarbital", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "2332596_3_Ent5", "text": "phenobarbital", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "2357706_1", "wnd_id": "2357706_1_1", "text": "Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents , it was only rarely reported in association with sulpiride , a selective D2 - receptor antagonist .", "tokens": ["Although", "tardive", "dyskinesia", "is", "a", "known", "adverse", "reaction", "of", "sustained", "treatment", "with", "traditional", "neuroleptic", "agents", ",", "it", "was", "only", "rarely", "reported", "in", "association", "with", "sulpiride", ",", "a", "selective", "D2", "-", "receptor", "antagonist", "."], "event_mentions": [{"id": "2357706_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 22, "end": 23}, "arguments": [{"entity_id": "2357706_1_Ent0", "role": "Effect", "text": "tardive dyskinesia", "start": 1, "end": 3}, {"entity_id": "2357706_1_Ent1", "role": "Treatment", "text": "sulpiride", "start": 24, "end": 25}, {"entity_id": "2357706_1_Ent2", "role": "Treatment_Drug", "text": "sulpiride", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "2357706_1_Ent0", "text": "tardive dyskinesia", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "2357706_1_Ent1", "text": "sulpiride", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "2357706_1_Ent2", "text": "sulpiride", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "23624139_1", "wnd_id": "23624139_1_1", "text": "Severe water intoxication secondary to the concomitant intake of non - steroidal anti - inflammatory drugs and desmopressin : a case report and review of the literature .", "tokens": ["Severe", "water", "intoxication", "secondary", "to", "the", "concomitant", "intake", "of", "non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", "and", "desmopressin", ":", "a", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "23624139_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary to", "start": 3, "end": 5}, "arguments": [{"entity_id": "23624139_1_Ent0", "role": "Effect", "text": "Severe water intoxication", "start": 0, "end": 3}, {"entity_id": "23624139_1_Ent1", "role": "Treatment", "text": "the concomitant intake of non - steroidal anti - inflammatory drugs and desmopressin", "start": 5, "end": 18}, {"entity_id": "23624139_1_Ent2", "role": "Treatment_Drug", "text": "non - steroidal anti - inflammatory drugs", "start": 9, "end": 16}, {"entity_id": "23624139_1_Ent4", "role": "Combination_Drug", "text": "non - steroidal anti - inflammatory drugs", "start": 9, "end": 16}, {"entity_id": "23624139_1_Ent3", "role": "Treatment_Drug", "text": "desmopressin", "start": 17, "end": 18}, {"entity_id": "23624139_1_Ent5", "role": "Combination_Drug", "text": "desmopressin", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "23624139_1_Ent0", "text": "Severe water intoxication", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "23624139_1_Ent1", "text": "the concomitant intake of non - steroidal anti - inflammatory drugs and desmopressin", "entity_type": "Entity", "start": 5, "end": 18}, {"id": "23624139_1_Ent2", "text": "non - steroidal anti - inflammatory drugs", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "23624139_1_Ent4", "text": "non - steroidal anti - inflammatory drugs", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "23624139_1_Ent3", "text": "desmopressin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "23624139_1_Ent5", "text": "desmopressin", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "2369419_3", "wnd_id": "2369419_3_1", "text": "This is the third report of reversible hepatic decompensation associated with prolonged MTX therapy in patients with rheumatoid arthritis .", "tokens": ["This", "is", "the", "third", "report", "of", "reversible", "hepatic", "decompensation", "associated", "with", "prolonged", "MTX", "therapy", "in", "patients", "with", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "2369419_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "2369419_3_Ent1", "role": "Effect", "text": "reversible hepatic decompensation", "start": 6, "end": 9}, {"entity_id": "2369419_3_Ent2", "role": "Treatment", "text": "MTX", "start": 12, "end": 13}, {"entity_id": "2369419_3_Ent4", "role": "Treatment_Drug", "text": "MTX", "start": 12, "end": 13}, {"entity_id": "2369419_3_Ent0", "role": "Subject", "text": "patients with rheumatoid arthritis", "start": 15, "end": 19}, {"entity_id": "2369419_3_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "2369419_3_Ent1", "text": "reversible hepatic decompensation", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "2369419_3_Ent2", "text": "MTX", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2369419_3_Ent4", "text": "MTX", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2369419_3_Ent0", "text": "patients with rheumatoid arthritis", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "2369419_3_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "24163322_8", "wnd_id": "24163322_8_1", "text": "Within 3 days after starting bismuth subsalicylate therapy , the patient 's INR increased from 2.56 to 3.54 and minor bleeding was noted from the patient 's tracheostomy site .", "tokens": ["Within", "3", "days", "after", "starting", "bismuth", "subsalicylate", "therapy", ",", "the", "patient", "'s", "INR", "increased", "from", "2.56", "to", "3.54", "and", "minor", "bleeding", "was", "noted", "from", "the", "patient", "'s", "tracheostomy", "site", "."], "event_mentions": [{"id": "24163322_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "noted", "start": 22, "end": 23}, "arguments": [{"entity_id": "24163322_8_Ent2", "role": "Treatment", "text": "Within 3 days after starting bismuth subsalicylate therapy", "start": 0, "end": 8}, {"entity_id": "24163322_8_Ent3", "role": "Treatment_Duration", "text": "3 days", "start": 1, "end": 3}, {"entity_id": "24163322_8_Ent4", "role": "Treatment_Drug", "text": "bismuth subsalicylate", "start": 5, "end": 7}, {"entity_id": "24163322_8_Ent0", "role": "Subject", "text": "the patient", "start": 9, "end": 11}, {"entity_id": "24163322_8_Ent1", "role": "Effect", "text": "INR increased from 2.56 to 3.54 and minor bleeding was noted from the patient 's tracheostomy site", "start": 12, "end": 29}]}], "entity_mentions": [{"id": "24163322_8_Ent2", "text": "Within 3 days after starting bismuth subsalicylate therapy", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "24163322_8_Ent3", "text": "3 days", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "24163322_8_Ent4", "text": "bismuth subsalicylate", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "24163322_8_Ent0", "text": "the patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "24163322_8_Ent1", "text": "INR increased from 2.56 to 3.54 and minor bleeding was noted from the patient 's tracheostomy site", "entity_type": "Entity", "start": 12, "end": 29}], "lang": "en"}
{"doc_id": "24318743_3", "wnd_id": "24318743_3_1", "text": "Based on prior data suggesting that scheduling alterations of platinum would increase activity , the aim of the present study was to assess the potential therapeutic benefit of phenoxodiol ( PXD ) , a novel biomodulator shown to have chemoresistance reversing potential , when combined with weekly AUC2 - carboplatin in PROC patients .", "tokens": ["Based", "on", "prior", "data", "suggesting", "that", "scheduling", "alterations", "of", "platinum", "would", "increase", "activity", ",", "the", "aim", "of", "the", "present", "study", "was", "to", "assess", "the", "potential", "therapeutic", "benefit", "of", "phenoxodiol", "(", "PXD", ")", ",", "a", "novel", "biomodulator", "shown", "to", "have", "chemoresistance", "reversing", "potential", ",", "when", "combined", "with", "weekly", "AUC2", "-", "carboplatin", "in", "PROC", "patients", "."], "event_mentions": [{"id": "24318743_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "assess", "start": 22, "end": 23}, "arguments": [{"entity_id": "24318743_3_Ent1", "role": "Effect", "text": "potential therapeutic benefit", "start": 24, "end": 27}, {"entity_id": "24318743_3_Ent3", "role": "Treatment_Drug", "text": "phenoxodiol", "start": 28, "end": 29}, {"entity_id": "24318743_3_Ent8", "role": "Combination_Drug", "text": "phenoxodiol", "start": 28, "end": 29}, {"entity_id": "24318743_3_Ent2", "role": "Treatment", "text": "phenoxodiol ( PXD ) , a novel biomodulator shown to have chemoresistance reversing potential , when combined with weekly AUC2 - carboplatin", "start": 28, "end": 50}, {"entity_id": "24318743_3_Ent6", "role": "Treatment_Freq", "text": "weekly", "start": 46, "end": 47}, {"entity_id": "24318743_3_Ent4", "role": "Treatment_Drug", "text": "carboplatin", "start": 49, "end": 50}, {"entity_id": "24318743_3_Ent7", "role": "Combination_Drug", "text": "carboplatin", "start": 49, "end": 50}, {"entity_id": "24318743_3_Ent5", "role": "Treatment_Disorder", "text": "PROC", "start": 51, "end": 52}, {"entity_id": "24318743_3_Ent0", "role": "Subject", "text": "PROC patients", "start": 51, "end": 53}]}], "entity_mentions": [{"id": "24318743_3_Ent1", "text": "potential therapeutic benefit", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "24318743_3_Ent3", "text": "phenoxodiol", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "24318743_3_Ent8", "text": "phenoxodiol", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "24318743_3_Ent2", "text": "phenoxodiol ( PXD ) , a novel biomodulator shown to have chemoresistance reversing potential , when combined with weekly AUC2 - carboplatin", "entity_type": "Entity", "start": 28, "end": 50}, {"id": "24318743_3_Ent6", "text": "weekly", "entity_type": "Entity", "start": 46, "end": 47}, {"id": "24318743_3_Ent4", "text": "carboplatin", "entity_type": "Entity", "start": 49, "end": 50}, {"id": "24318743_3_Ent7", "text": "carboplatin", "entity_type": "Entity", "start": 49, "end": 50}, {"id": "24318743_3_Ent5", "text": "PROC", "entity_type": "Entity", "start": 51, "end": 52}, {"id": "24318743_3_Ent0", "text": "PROC patients", "entity_type": "Entity", "start": 51, "end": 53}], "lang": "en"}
{"doc_id": "24429012_1", "wnd_id": "24429012_1_1", "text": "Elevated International Normalized Ratio in a patient concurrently using warfarin and vismodegib .", "tokens": ["Elevated", "International", "Normalized", "Ratio", "in", "a", "patient", "concurrently", "using", "warfarin", "and", "vismodegib", "."], "event_mentions": [{"id": "24429012_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "using", "start": 8, "end": 9}, "arguments": [{"entity_id": "24429012_1_Ent1", "role": "Effect", "text": "Elevated International Normalized Ratio", "start": 0, "end": 4}, {"entity_id": "24429012_1_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "24429012_1_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 9, "end": 10}, {"entity_id": "24429012_1_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 9, "end": 10}, {"entity_id": "24429012_1_Ent2", "role": "Treatment", "text": "warfarin and vismodegib", "start": 9, "end": 12}, {"entity_id": "24429012_1_Ent4", "role": "Treatment_Drug", "text": "vismodegib", "start": 11, "end": 12}, {"entity_id": "24429012_1_Ent6", "role": "Combination_Drug", "text": "vismodegib", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "24429012_1_Ent1", "text": "Elevated International Normalized Ratio", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "24429012_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "24429012_1_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "24429012_1_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "24429012_1_Ent2", "text": "warfarin and vismodegib", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "24429012_1_Ent4", "text": "vismodegib", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "24429012_1_Ent6", "text": "vismodegib", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "2442958_3", "wnd_id": "2442958_3_1", "text": "This paper reports an autopsy case of a 78 - year - old male with multiple nodules in the liver developed after long - termed administration of phosphate diethylstilbestrol ( PDES ) for prostatic cancer .", "tokens": ["This", "paper", "reports", "an", "autopsy", "case", "of", "a", "78", "-", "year", "-", "old", "male", "with", "multiple", "nodules", "in", "the", "liver", "developed", "after", "long", "-", "termed", "administration", "of", "phosphate", "diethylstilbestrol", "(", "PDES", ")", "for", "prostatic", "cancer", "."], "event_mentions": [{"id": "2442958_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "2442958_3_Ent0", "role": "Subject", "text": "an autopsy case of a 78 - year - old male", "start": 3, "end": 14}, {"entity_id": "2442958_3_Ent2", "role": "Subject_Age", "text": "78 - year - old", "start": 8, "end": 13}, {"entity_id": "2442958_3_Ent3", "role": "Subject_Gender", "text": "male", "start": 13, "end": 14}, {"entity_id": "2442958_3_Ent4", "role": "Effect", "text": "multiple nodules in the liver", "start": 15, "end": 20}, {"entity_id": "2442958_3_Ent7", "role": "Treatment_Drug", "text": "phosphate diethylstilbestrol", "start": 27, "end": 29}, {"entity_id": "2442958_3_Ent5", "role": "Treatment", "text": "phosphate diethylstilbestrol ( PDES )", "start": 27, "end": 32}, {"entity_id": "2442958_3_Ent1", "role": "Subject", "text": "prostatic cancer", "start": 33, "end": 35}, {"entity_id": "2442958_3_Ent6", "role": "Treatment_Disorder", "text": "prostatic cancer", "start": 33, "end": 35}]}], "entity_mentions": [{"id": "2442958_3_Ent0", "text": "an autopsy case of a 78 - year - old male", "entity_type": "Entity", "start": 3, "end": 14}, {"id": "2442958_3_Ent2", "text": "78 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "2442958_3_Ent3", "text": "male", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "2442958_3_Ent4", "text": "multiple nodules in the liver", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "2442958_3_Ent7", "text": "phosphate diethylstilbestrol", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "2442958_3_Ent5", "text": "phosphate diethylstilbestrol ( PDES )", "entity_type": "Entity", "start": 27, "end": 32}, {"id": "2442958_3_Ent1", "text": "prostatic cancer", "entity_type": "Entity", "start": 33, "end": 35}, {"id": "2442958_3_Ent6", "text": "prostatic cancer", "entity_type": "Entity", "start": 33, "end": 35}], "lang": "en"}
{"doc_id": "24477376_4", "wnd_id": "24477376_4_1", "text": "The patient was previously on phenytoin and was initiated on ticagrelor for antiplatelet therapy following stent placement .", "tokens": ["The", "patient", "was", "previously", "on", "phenytoin", "and", "was", "initiated", "on", "ticagrelor", "for", "antiplatelet", "therapy", "following", "stent", "placement", "."], "event_mentions": [{"id": "24477376_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 11, "end": 12}, "arguments": [{"entity_id": "24477376_4_Ent0", "role": "Subject", "text": "The patient", "start": 0, "end": 2}, {"entity_id": "24477376_4_Ent1", "role": "Treatment", "text": "previously on phenytoin", "start": 3, "end": 6}, {"entity_id": "24477376_4_Ent5", "role": "Treatment_Drug", "text": "phenytoin", "start": 5, "end": 6}, {"entity_id": "24477376_4_Ent2", "role": "Treatment", "text": "initiated on ticagrelor", "start": 8, "end": 11}, {"entity_id": "24477376_4_Ent6", "role": "Treatment_Drug", "text": "ticagrelor", "start": 10, "end": 11}, {"entity_id": "24477376_4_Ent4", "role": "Treatment_Disorder", "text": "antiplatelet therapy", "start": 12, "end": 14}, {"entity_id": "24477376_4_Ent3", "role": "Treatment", "text": "following stent placement", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "24477376_4_Ent0", "text": "The patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "24477376_4_Ent1", "text": "previously on phenytoin", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "24477376_4_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "24477376_4_Ent2", "text": "initiated on ticagrelor", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "24477376_4_Ent6", "text": "ticagrelor", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "24477376_4_Ent4", "text": "antiplatelet therapy", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "24477376_4_Ent3", "text": "following stent placement", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "24531907_1", "wnd_id": "24531907_1_1", "text": "Pharmacokinetics of etravirine in HIV - infected patients concomitantly treated with rifampin for tuberculosis .", "tokens": ["Pharmacokinetics", "of", "etravirine", "in", "HIV", "-", "infected", "patients", "concomitantly", "treated", "with", "rifampin", "for", "tuberculosis", "."], "event_mentions": [{"id": "24531907_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 12, "end": 13}, "arguments": [{"entity_id": "24531907_1_Ent1", "role": "Treatment", "text": "Pharmacokinetics of etravirine", "start": 0, "end": 3}, {"entity_id": "24531907_1_Ent3", "role": "Treatment_Drug", "text": "etravirine", "start": 2, "end": 3}, {"entity_id": "24531907_1_Ent7", "role": "Combination_Drug", "text": "etravirine", "start": 2, "end": 3}, {"entity_id": "24531907_1_Ent5", "role": "Treatment_Disorder", "text": "HIV", "start": 4, "end": 5}, {"entity_id": "24531907_1_Ent0", "role": "Subject", "text": "HIV - infected patients", "start": 4, "end": 8}, {"entity_id": "24531907_1_Ent2", "role": "Treatment", "text": "concomitantly treated with rifampin", "start": 8, "end": 12}, {"entity_id": "24531907_1_Ent4", "role": "Treatment_Drug", "text": "rifampin", "start": 11, "end": 12}, {"entity_id": "24531907_1_Ent8", "role": "Combination_Drug", "text": "rifampin", "start": 11, "end": 12}, {"entity_id": "24531907_1_Ent6", "role": "Treatment_Disorder", "text": "tuberculosis", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "24531907_1_Ent1", "text": "Pharmacokinetics of etravirine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "24531907_1_Ent3", "text": "etravirine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "24531907_1_Ent7", "text": "etravirine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "24531907_1_Ent5", "text": "HIV", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "24531907_1_Ent0", "text": "HIV - infected patients", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "24531907_1_Ent2", "text": "concomitantly treated with rifampin", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "24531907_1_Ent4", "text": "rifampin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "24531907_1_Ent8", "text": "rifampin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "24531907_1_Ent6", "text": "tuberculosis", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "24679099_4", "wnd_id": "24679099_4_1", "text": "We report the case of severe liver toxicity with jaundice during radiochemotherapy with temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma .", "tokens": ["We", "report", "the", "case", "of", "severe", "liver", "toxicity", "with", "jaundice", "during", "radiochemotherapy", "with", "temozolomide", "likely", "due", "to", "interaction", "with", "a", "popular", "Chinese", "herbal", "formula", "after", "surgery", "for", "glioblastoma", "."], "event_mentions": [{"id": "24679099_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 15, "end": 16}, "arguments": [{"entity_id": "24679099_4_Ent0", "role": "Effect", "text": "severe liver toxicity with jaundice", "start": 5, "end": 10}, {"entity_id": "24679099_4_Ent1", "role": "Treatment", "text": "temozolomide", "start": 13, "end": 14}, {"entity_id": "24679099_4_Ent4", "role": "Treatment_Drug", "text": "temozolomide", "start": 13, "end": 14}, {"entity_id": "24679099_4_Ent6", "role": "Combination_Drug", "text": "temozolomide", "start": 13, "end": 14}, {"entity_id": "24679099_4_Ent2", "role": "Treatment", "text": "a popular Chinese herbal formula", "start": 19, "end": 24}, {"entity_id": "24679099_4_Ent5", "role": "Treatment_Drug", "text": "Chinese herbal formula", "start": 21, "end": 24}, {"entity_id": "24679099_4_Ent7", "role": "Combination_Drug", "text": "Chinese herbal formula", "start": 21, "end": 24}, {"entity_id": "24679099_4_Ent3", "role": "Treatment_Disorder", "text": "glioblastoma", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "24679099_4_Ent0", "text": "severe liver toxicity with jaundice", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "24679099_4_Ent1", "text": "temozolomide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "24679099_4_Ent4", "text": "temozolomide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "24679099_4_Ent6", "text": "temozolomide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "24679099_4_Ent2", "text": "a popular Chinese herbal formula", "entity_type": "Entity", "start": 19, "end": 24}, {"id": "24679099_4_Ent5", "text": "Chinese herbal formula", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "24679099_4_Ent7", "text": "Chinese herbal formula", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "24679099_4_Ent3", "text": "glioblastoma", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "24679099_7", "wnd_id": "24679099_7_1", "text": "Because of further progression combination treatment of bevacizumab and irinotecan was started and again no liver toxicity was observed .", "tokens": ["Because", "of", "further", "progression", "combination", "treatment", "of", "bevacizumab", "and", "irinotecan", "was", "started", "and", "again", "no", "liver", "toxicity", "was", "observed", "."], "event_mentions": [{"id": "24679099_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 18, "end": 19}, "arguments": [{"entity_id": "24679099_7_Ent2", "role": "Treatment_Drug", "text": "bevacizumab", "start": 7, "end": 8}, {"entity_id": "24679099_7_Ent4", "role": "Combination_Drug", "text": "bevacizumab", "start": 7, "end": 8}, {"entity_id": "24679099_7_Ent1", "role": "Treatment", "text": "bevacizumab and irinotecan", "start": 7, "end": 10}, {"entity_id": "24679099_7_Ent3", "role": "Treatment_Drug", "text": "irinotecan", "start": 9, "end": 10}, {"entity_id": "24679099_7_Ent5", "role": "Combination_Drug", "text": "irinotecan", "start": 9, "end": 10}, {"entity_id": "24679099_7_Ent0", "role": "Effect", "text": "liver toxicity", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "24679099_7_Ent2", "text": "bevacizumab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "24679099_7_Ent4", "text": "bevacizumab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "24679099_7_Ent1", "text": "bevacizumab and irinotecan", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "24679099_7_Ent3", "text": "irinotecan", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "24679099_7_Ent5", "text": "irinotecan", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "24679099_7_Ent0", "text": "liver toxicity", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "2483959_1", "wnd_id": "2483959_1_1", "text": "A typical case of dextran - 40 associated acute renal failure is presented .", "tokens": ["A", "typical", "case", "of", "dextran", "-", "40", "associated", "acute", "renal", "failure", "is", "presented", "."], "event_mentions": [{"id": "2483959_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "2483959_1_Ent1", "role": "Treatment", "text": "dextran - 40", "start": 4, "end": 7}, {"entity_id": "2483959_1_Ent2", "role": "Treatment_Drug", "text": "dextran - 40", "start": 4, "end": 7}, {"entity_id": "2483959_1_Ent0", "role": "Effect", "text": "acute renal failure", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "2483959_1_Ent1", "text": "dextran - 40", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "2483959_1_Ent2", "text": "dextran - 40", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "2483959_1_Ent0", "text": "acute renal failure", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "24846936_2", "wnd_id": "24846936_2_1", "text": "This is the first report of a fatal outcome from serotonin toxicity , precipitated by an interaction between methylene blue and venlafaxine .", "tokens": ["This", "is", "the", "first", "report", "of", "a", "fatal", "outcome", "from", "serotonin", "toxicity", ",", "precipitated", "by", "an", "interaction", "between", "methylene", "blue", "and", "venlafaxine", "."], "event_mentions": [{"id": "24846936_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitated", "start": 13, "end": 14}, "arguments": [{"entity_id": "24846936_2_Ent0", "role": "Effect", "text": "serotonin toxicity", "start": 10, "end": 12}, {"entity_id": "24846936_2_Ent1", "role": "Treatment", "text": "methylene blue", "start": 18, "end": 20}, {"entity_id": "24846936_2_Ent3", "role": "Treatment_Drug", "text": "methylene blue", "start": 18, "end": 20}, {"entity_id": "24846936_2_Ent5", "role": "Combination_Drug", "text": "methylene blue", "start": 18, "end": 20}, {"entity_id": "24846936_2_Ent2", "role": "Treatment", "text": "venlafaxine", "start": 21, "end": 22}, {"entity_id": "24846936_2_Ent4", "role": "Treatment_Drug", "text": "venlafaxine", "start": 21, "end": 22}, {"entity_id": "24846936_2_Ent6", "role": "Combination_Drug", "text": "venlafaxine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "24846936_2_Ent0", "text": "serotonin toxicity", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "24846936_2_Ent1", "text": "methylene blue", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "24846936_2_Ent3", "text": "methylene blue", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "24846936_2_Ent5", "text": "methylene blue", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "24846936_2_Ent2", "text": "venlafaxine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "24846936_2_Ent4", "text": "venlafaxine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "24846936_2_Ent6", "text": "venlafaxine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "24927617_1", "wnd_id": "24927617_1_1", "text": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin .", "tokens": ["Rhabdomyolysis", "in", "a", "hepatitis", "C", "virus", "infected", "patient", "treated", "with", "telaprevir", "and", "simvastatin", "."], "event_mentions": [{"id": "24927617_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 8, "end": 9}, "arguments": [{"entity_id": "24927617_1_Ent1", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "24927617_1_Ent5", "role": "Treatment_Disorder", "text": "hepatitis C virus", "start": 3, "end": 6}, {"entity_id": "24927617_1_Ent0", "role": "Subject", "text": "hepatitis C virus infected patient", "start": 3, "end": 8}, {"entity_id": "24927617_1_Ent3", "role": "Treatment_Drug", "text": "telaprevir", "start": 10, "end": 11}, {"entity_id": "24927617_1_Ent6", "role": "Combination_Drug", "text": "telaprevir", "start": 10, "end": 11}, {"entity_id": "24927617_1_Ent2", "role": "Treatment", "text": "telaprevir and simvastatin", "start": 10, "end": 13}, {"entity_id": "24927617_1_Ent4", "role": "Treatment_Drug", "text": "simvastatin", "start": 12, "end": 13}, {"entity_id": "24927617_1_Ent7", "role": "Combination_Drug", "text": "simvastatin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "24927617_1_Ent1", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "24927617_1_Ent5", "text": "hepatitis C virus", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "24927617_1_Ent0", "text": "hepatitis C virus infected patient", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "24927617_1_Ent3", "text": "telaprevir", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "24927617_1_Ent6", "text": "telaprevir", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "24927617_1_Ent2", "text": "telaprevir and simvastatin", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "24927617_1_Ent4", "text": "simvastatin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "24927617_1_Ent7", "text": "simvastatin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "2523364_2", "wnd_id": "2523364_2_1", "text": "A 57 - year - old man developed morphea while taking bromocriptine .", "tokens": ["A", "57", "-", "year", "-", "old", "man", "developed", "morphea", "while", "taking", "bromocriptine", "."], "event_mentions": [{"id": "2523364_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 10, "end": 11}, "arguments": [{"entity_id": "2523364_2_Ent0", "role": "Subject", "text": "A 57 - year - old man", "start": 0, "end": 7}, {"entity_id": "2523364_2_Ent1", "role": "Subject_Age", "text": "57 - year - old", "start": 1, "end": 6}, {"entity_id": "2523364_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "2523364_2_Ent3", "role": "Effect", "text": "morphea", "start": 8, "end": 9}, {"entity_id": "2523364_2_Ent4", "role": "Treatment", "text": "bromocriptine", "start": 11, "end": 12}, {"entity_id": "2523364_2_Ent5", "role": "Treatment_Drug", "text": "bromocriptine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "2523364_2_Ent0", "text": "A 57 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "2523364_2_Ent1", "text": "57 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "2523364_2_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2523364_2_Ent3", "text": "morphea", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2523364_2_Ent4", "text": "bromocriptine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "2523364_2_Ent5", "text": "bromocriptine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "25407257_1", "wnd_id": "25407257_1_1", "text": "First case report of suspected onset of convulsive seizures due to co - administration of valproic acid and tebipenem .", "tokens": ["First", "case", "report", "of", "suspected", "onset", "of", "convulsive", "seizures", "due", "to", "co", "-", "administration", "of", "valproic", "acid", "and", "tebipenem", "."], "event_mentions": [{"id": "25407257_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 9, "end": 10}, "arguments": [{"entity_id": "25407257_1_Ent0", "role": "Effect", "text": "convulsive seizures", "start": 7, "end": 9}, {"entity_id": "25407257_1_Ent1", "role": "Treatment", "text": "co - administration of valproic acid and tebipenem", "start": 11, "end": 19}, {"entity_id": "25407257_1_Ent2", "role": "Treatment_Drug", "text": "valproic acid", "start": 15, "end": 17}, {"entity_id": "25407257_1_Ent4", "role": "Combination_Drug", "text": "valproic acid", "start": 15, "end": 17}, {"entity_id": "25407257_1_Ent3", "role": "Treatment_Drug", "text": "tebipenem", "start": 18, "end": 19}, {"entity_id": "25407257_1_Ent5", "role": "Combination_Drug", "text": "tebipenem", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "25407257_1_Ent0", "text": "convulsive seizures", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "25407257_1_Ent1", "text": "co - administration of valproic acid and tebipenem", "entity_type": "Entity", "start": 11, "end": 19}, {"id": "25407257_1_Ent2", "text": "valproic acid", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "25407257_1_Ent4", "text": "valproic acid", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "25407257_1_Ent3", "text": "tebipenem", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "25407257_1_Ent5", "text": "tebipenem", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "25417855_3", "wnd_id": "25417855_3_1", "text": "We report serious adverse effects due to interaction between orally administered voriconazole and everolimus in a renal transplant recipient .", "tokens": ["We", "report", "serious", "adverse", "effects", "due", "to", "interaction", "between", "orally", "administered", "voriconazole", "and", "everolimus", "in", "a", "renal", "transplant", "recipient", "."], "event_mentions": [{"id": "25417855_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 5, "end": 7}, "arguments": [{"entity_id": "25417855_3_Ent2", "role": "Effect", "text": "serious adverse effects", "start": 2, "end": 5}, {"entity_id": "25417855_3_Ent3", "role": "Treatment", "text": "interaction between orally administered voriconazole and everolimus", "start": 7, "end": 14}, {"entity_id": "25417855_3_Ent6", "role": "Treatment_Route", "text": "orally", "start": 9, "end": 10}, {"entity_id": "25417855_3_Ent4", "role": "Treatment_Drug", "text": "voriconazole", "start": 11, "end": 12}, {"entity_id": "25417855_3_Ent7", "role": "Combination_Drug", "text": "voriconazole", "start": 11, "end": 12}, {"entity_id": "25417855_3_Ent5", "role": "Treatment_Drug", "text": "everolimus", "start": 13, "end": 14}, {"entity_id": "25417855_3_Ent8", "role": "Combination_Drug", "text": "everolimus", "start": 13, "end": 14}, {"entity_id": "25417855_3_Ent0", "role": "Subject", "text": "a renal transplant recipient", "start": 15, "end": 19}, {"entity_id": "25417855_3_Ent1", "role": "Subject_Disorder", "text": "renal transplant", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "25417855_3_Ent2", "text": "serious adverse effects", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "25417855_3_Ent3", "text": "interaction between orally administered voriconazole and everolimus", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "25417855_3_Ent6", "text": "orally", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "25417855_3_Ent4", "text": "voriconazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "25417855_3_Ent7", "text": "voriconazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "25417855_3_Ent5", "text": "everolimus", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "25417855_3_Ent8", "text": "everolimus", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "25417855_3_Ent0", "text": "a renal transplant recipient", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "25417855_3_Ent1", "text": "renal transplant", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "25515435_8", "wnd_id": "25515435_8_1", "text": "A liver biopsy in 2012 revealed marked fibrosis , leading the patient to start hepatitis C treatment with peginterferon alfa - 2a , ribavirin and boceprevir .", "tokens": ["A", "liver", "biopsy", "in", "2012", "revealed", "marked", "fibrosis", ",", "leading", "the", "patient", "to", "start", "hepatitis", "C", "treatment", "with", "peginterferon", "alfa", "-", "2a", ",", "ribavirin", "and", "boceprevir", "."], "event_mentions": [{"id": "25515435_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 16, "end": 17}, "arguments": [{"entity_id": "25515435_8_Ent2", "role": "Treatment_Disorder", "text": "fibrosis", "start": 7, "end": 8}, {"entity_id": "25515435_8_Ent0", "role": "Subject", "text": "fibrosis , leading the patient", "start": 7, "end": 12}, {"entity_id": "25515435_8_Ent3", "role": "Treatment_Drug", "text": "peginterferon alfa - 2a", "start": 18, "end": 22}, {"entity_id": "25515435_8_Ent8", "role": "Combination_Drug", "text": "peginterferon alfa - 2a", "start": 18, "end": 22}, {"entity_id": "25515435_8_Ent1", "role": "Treatment", "text": "peginterferon alfa - 2a , ribavirin and boceprevir", "start": 18, "end": 26}, {"entity_id": "25515435_8_Ent4", "role": "Treatment_Drug", "text": "ribavirin", "start": 23, "end": 24}, {"entity_id": "25515435_8_Ent6", "role": "Combination_Drug", "text": "ribavirin", "start": 23, "end": 24}, {"entity_id": "25515435_8_Ent5", "role": "Treatment_Drug", "text": "boceprevir", "start": 25, "end": 26}, {"entity_id": "25515435_8_Ent7", "role": "Combination_Drug", "text": "boceprevir", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "25515435_8_Ent2", "text": "fibrosis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "25515435_8_Ent0", "text": "fibrosis , leading the patient", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "25515435_8_Ent3", "text": "peginterferon alfa - 2a", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "25515435_8_Ent8", "text": "peginterferon alfa - 2a", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "25515435_8_Ent1", "text": "peginterferon alfa - 2a , ribavirin and boceprevir", "entity_type": "Entity", "start": 18, "end": 26}, {"id": "25515435_8_Ent4", "text": "ribavirin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "25515435_8_Ent6", "text": "ribavirin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "25515435_8_Ent5", "text": "boceprevir", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "25515435_8_Ent7", "text": "boceprevir", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "25540831_1", "wnd_id": "25540831_1_1", "text": "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor .", "tokens": ["Transient", "serotonin", "syndrome", "caused", "by", "concurrent", "use", "of", "tramadol", "and", "selective", "serotonin", "reuptake", "inhibitor", "."], "event_mentions": [{"id": "25540831_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 3, "end": 4}, "arguments": [{"entity_id": "25540831_1_Ent0", "role": "Effect", "text": "Transient serotonin syndrome", "start": 0, "end": 3}, {"entity_id": "25540831_1_Ent1", "role": "Treatment", "text": "concurrent use of tramadol and selective serotonin reuptake inhibitor", "start": 5, "end": 14}, {"entity_id": "25540831_1_Ent2", "role": "Treatment_Drug", "text": "tramadol", "start": 8, "end": 9}, {"entity_id": "25540831_1_Ent4", "role": "Combination_Drug", "text": "tramadol", "start": 8, "end": 9}, {"entity_id": "25540831_1_Ent3", "role": "Treatment_Drug", "text": "selective serotonin reuptake inhibitor", "start": 10, "end": 14}, {"entity_id": "25540831_1_Ent5", "role": "Combination_Drug", "text": "selective serotonin reuptake inhibitor", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "25540831_1_Ent0", "text": "Transient serotonin syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "25540831_1_Ent1", "text": "concurrent use of tramadol and selective serotonin reuptake inhibitor", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "25540831_1_Ent2", "text": "tramadol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "25540831_1_Ent4", "text": "tramadol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "25540831_1_Ent3", "text": "selective serotonin reuptake inhibitor", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "25540831_1_Ent5", "text": "selective serotonin reuptake inhibitor", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "25540831_4", "wnd_id": "25540831_4_1", "text": "We report a typical case of transient serotonin syndrome secondary to tramadol - Citalopram combination .", "tokens": ["We", "report", "a", "typical", "case", "of", "transient", "serotonin", "syndrome", "secondary", "to", "tramadol", "-", "Citalopram", "combination", "."], "event_mentions": [{"id": "25540831_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 9, "end": 10}, "arguments": [{"entity_id": "25540831_4_Ent0", "role": "Subject", "text": "a typical case", "start": 2, "end": 5}, {"entity_id": "25540831_4_Ent1", "role": "Effect", "text": "transient serotonin syndrome", "start": 6, "end": 9}, {"entity_id": "25540831_4_Ent3", "role": "Treatment_Drug", "text": "tramadol", "start": 11, "end": 12}, {"entity_id": "25540831_4_Ent5", "role": "Combination_Drug", "text": "tramadol", "start": 11, "end": 12}, {"entity_id": "25540831_4_Ent2", "role": "Treatment", "text": "tramadol - Citalopram combination", "start": 11, "end": 15}, {"entity_id": "25540831_4_Ent4", "role": "Treatment_Drug", "text": "Citalopram", "start": 13, "end": 14}, {"entity_id": "25540831_4_Ent6", "role": "Combination_Drug", "text": "Citalopram", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "25540831_4_Ent0", "text": "a typical case", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "25540831_4_Ent1", "text": "transient serotonin syndrome", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "25540831_4_Ent3", "text": "tramadol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "25540831_4_Ent5", "text": "tramadol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "25540831_4_Ent2", "text": "tramadol - Citalopram combination", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "25540831_4_Ent4", "text": "Citalopram", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "25540831_4_Ent6", "text": "Citalopram", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "2554727_1", "wnd_id": "2554727_1_1", "text": "Horner 's syndrome and demyelinating peripheral neuropathy caused by high - dose cytosine arabinoside .", "tokens": ["Horner", "'s", "syndrome", "and", "demyelinating", "peripheral", "neuropathy", "caused", "by", "high", "-", "dose", "cytosine", "arabinoside", "."], "event_mentions": [{"id": "2554727_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 7, "end": 8}, "arguments": [{"entity_id": "2554727_1_Ent0", "role": "Effect", "text": "Horner 's syndrome and demyelinating peripheral neuropathy", "start": 0, "end": 7}, {"entity_id": "2554727_1_Ent2", "role": "Treatment_Dosage", "text": "high - dose", "start": 9, "end": 12}, {"entity_id": "2554727_1_Ent1", "role": "Treatment", "text": "high - dose cytosine arabinoside", "start": 9, "end": 14}, {"entity_id": "2554727_1_Ent3", "role": "Treatment_Drug", "text": "cytosine arabinoside", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "2554727_1_Ent0", "text": "Horner 's syndrome and demyelinating peripheral neuropathy", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "2554727_1_Ent2", "text": "high - dose", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "2554727_1_Ent1", "text": "high - dose cytosine arabinoside", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "2554727_1_Ent3", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "2554727_5", "wnd_id": "2554727_5_1", "text": "Peripheral nerve dysfunction is a potentially serious complication of high - dose cytosine arabinoside .", "tokens": ["Peripheral", "nerve", "dysfunction", "is", "a", "potentially", "serious", "complication", "of", "high", "-", "dose", "cytosine", "arabinoside", "."], "event_mentions": [{"id": "2554727_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 8, "end": 9}, "arguments": [{"entity_id": "2554727_5_Ent0", "role": "Effect", "text": "Peripheral nerve dysfunction", "start": 0, "end": 3}, {"entity_id": "2554727_5_Ent3", "role": "Treatment_Dosage", "text": "high - dose", "start": 9, "end": 12}, {"entity_id": "2554727_5_Ent1", "role": "Treatment", "text": "cytosine arabinoside", "start": 12, "end": 14}, {"entity_id": "2554727_5_Ent2", "role": "Treatment_Drug", "text": "cytosine arabinoside", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "2554727_5_Ent0", "text": "Peripheral nerve dysfunction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2554727_5_Ent3", "text": "high - dose", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "2554727_5_Ent1", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "2554727_5_Ent2", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "25671244_3", "wnd_id": "25671244_3_1", "text": "The mechanism of action of this centrally acting muscle relaxant is unknown ; however , the observation of serotonin syndrome in patients with metaxalone overdose suggests a role in the serotonergic pathway .", "tokens": ["The", "mechanism", "of", "action", "of", "this", "centrally", "acting", "muscle", "relaxant", "is", "unknown", ";", "however", ",", "the", "observation", "of", "serotonin", "syndrome", "in", "patients", "with", "metaxalone", "overdose", "suggests", "a", "role", "in", "the", "serotonergic", "pathway", "."], "event_mentions": [{"id": "25671244_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 20, "end": 21}, "arguments": [{"entity_id": "25671244_3_Ent2", "role": "Treatment", "text": "centrally acting muscle relaxant", "start": 6, "end": 10}, {"entity_id": "25671244_3_Ent4", "role": "Treatment_Drug", "text": "centrally acting muscle relaxant", "start": 6, "end": 10}, {"entity_id": "25671244_3_Ent1", "role": "Effect", "text": "serotonin syndrome", "start": 18, "end": 20}, {"entity_id": "25671244_3_Ent0", "role": "Subject", "text": "patients", "start": 21, "end": 22}, {"entity_id": "25671244_3_Ent5", "role": "Treatment_Drug", "text": "metaxalone", "start": 23, "end": 24}, {"entity_id": "25671244_3_Ent3", "role": "Treatment", "text": "metaxalone overdose", "start": 23, "end": 25}, {"entity_id": "25671244_3_Ent6", "role": "Treatment_Dosage", "text": "overdose", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "25671244_3_Ent2", "text": "centrally acting muscle relaxant", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "25671244_3_Ent4", "text": "centrally acting muscle relaxant", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "25671244_3_Ent1", "text": "serotonin syndrome", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "25671244_3_Ent0", "text": "patients", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "25671244_3_Ent5", "text": "metaxalone", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "25671244_3_Ent3", "text": "metaxalone overdose", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "25671244_3_Ent6", "text": "overdose", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "25671244_4", "wnd_id": "25671244_4_1", "text": "( Case 1 ) A 29 - year - old woman with overdose of metaxalone presented to the emergency department with altered mental status , seizure - like activity , hyperthermia , rigidity in the lower extremities , myoclonus , and hyperreflexia .", "tokens": ["(", "Case", "1", ")", "A", "29", "-", "year", "-", "old", "woman", "with", "overdose", "of", "metaxalone", "presented", "to", "the", "emergency", "department", "with", "altered", "mental", "status", ",", "seizure", "-", "like", "activity", ",", "hyperthermia", ",", "rigidity", "in", "the", "lower", "extremities", ",", "myoclonus", ",", "and", "hyperreflexia", "."], "event_mentions": [{"id": "25671244_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 15, "end": 16}, "arguments": [{"entity_id": "25671244_4_Ent0", "role": "Subject", "text": "A 29 - year - old woman", "start": 4, "end": 11}, {"entity_id": "25671244_4_Ent1", "role": "Subject_Age", "text": "29 - year - old", "start": 5, "end": 10}, {"entity_id": "25671244_4_Ent2", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "25671244_4_Ent6", "role": "Treatment_Dosage", "text": "overdose", "start": 12, "end": 13}, {"entity_id": "25671244_4_Ent4", "role": "Treatment", "text": "metaxalone", "start": 14, "end": 15}, {"entity_id": "25671244_4_Ent5", "role": "Treatment_Drug", "text": "metaxalone", "start": 14, "end": 15}, {"entity_id": "25671244_4_Ent3", "role": "Effect", "text": "altered mental status , seizure - like activity , hyperthermia , rigidity in the lower extremities , myoclonus , and hyperreflexia", "start": 21, "end": 42}]}], "entity_mentions": [{"id": "25671244_4_Ent0", "text": "A 29 - year - old woman", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "25671244_4_Ent1", "text": "29 - year - old", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "25671244_4_Ent2", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "25671244_4_Ent6", "text": "overdose", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "25671244_4_Ent4", "text": "metaxalone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "25671244_4_Ent5", "text": "metaxalone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "25671244_4_Ent3", "text": "altered mental status , seizure - like activity , hyperthermia , rigidity in the lower extremities , myoclonus , and hyperreflexia", "entity_type": "Entity", "start": 21, "end": 42}], "lang": "en"}
{"doc_id": "2572964_2", "wnd_id": "2572964_2_1", "text": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics , who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption .", "tokens": ["Two", "cases", "are", "described", "of", "chronic", "schizophrenic", "patients", "maintained", "on", "depot", "neuroleptics", ",", "who", "developed", "severe", "extrapyramidal", "symptoms", "following", "a", "period", "of", "heavy", "betel", "nut", "consumption", "."], "event_mentions": [{"id": "2572964_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "2572964_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "2572964_2_Ent0", "role": "Subject", "text": "Two cases", "start": 0, "end": 2}, {"entity_id": "2572964_2_Ent5", "role": "Treatment_Disorder", "text": "chronic schizophrenic", "start": 5, "end": 7}, {"entity_id": "2572964_2_Ent4", "role": "Treatment", "text": "depot neuroleptics", "start": 10, "end": 12}, {"entity_id": "2572964_2_Ent6", "role": "Treatment_Drug", "text": "depot neuroleptics", "start": 10, "end": 12}, {"entity_id": "2572964_2_Ent2", "role": "Effect", "text": "severe extrapyramidal symptoms", "start": 15, "end": 18}, {"entity_id": "2572964_2_Ent3", "role": "Treatment", "text": "heavy betel nut consumption", "start": 22, "end": 26}, {"entity_id": "2572964_2_Ent7", "role": "Treatment_Drug", "text": "betel nut", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "2572964_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2572964_2_Ent0", "text": "Two cases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2572964_2_Ent5", "text": "chronic schizophrenic", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "2572964_2_Ent4", "text": "depot neuroleptics", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "2572964_2_Ent6", "text": "depot neuroleptics", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "2572964_2_Ent2", "text": "severe extrapyramidal symptoms", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "2572964_2_Ent3", "text": "heavy betel nut consumption", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "2572964_2_Ent7", "text": "betel nut", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "25842648_7", "wnd_id": "25842648_7_1", "text": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl , a commonly used opioid in anesthesia practice .", "tokens": ["This", "article", "discusses", "the", "clinical", "manifestations", "of", "the", "serotonin", "syndrome", "and", "highlights", "reported", "cases", "of", "serotonin", "syndrome", "specifically", "related", "to", "an", "interaction", "between", "SSRIs", "and", "fentanyl", ",", "a", "commonly", "used", "opioid", "in", "anesthesia", "practice", "."], "event_mentions": [{"id": "25842648_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 18, "end": 19}, "arguments": [{"entity_id": "25842648_7_Ent0", "role": "Subject", "text": "cases", "start": 13, "end": 14}, {"entity_id": "25842648_7_Ent1", "role": "Effect", "text": "serotonin syndrome", "start": 15, "end": 17}, {"entity_id": "25842648_7_Ent3", "role": "Treatment_Drug", "text": "SSRIs", "start": 23, "end": 24}, {"entity_id": "25842648_7_Ent5", "role": "Combination_Drug", "text": "SSRIs", "start": 23, "end": 24}, {"entity_id": "25842648_7_Ent2", "role": "Treatment", "text": "SSRIs and fentanyl", "start": 23, "end": 26}, {"entity_id": "25842648_7_Ent4", "role": "Treatment_Drug", "text": "fentanyl", "start": 25, "end": 26}, {"entity_id": "25842648_7_Ent6", "role": "Combination_Drug", "text": "fentanyl", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "25842648_7_Ent0", "text": "cases", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "25842648_7_Ent1", "text": "serotonin syndrome", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "25842648_7_Ent3", "text": "SSRIs", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "25842648_7_Ent5", "text": "SSRIs", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "25842648_7_Ent2", "text": "SSRIs and fentanyl", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "25842648_7_Ent4", "text": "fentanyl", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "25842648_7_Ent6", "text": "fentanyl", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "2616440_2", "wnd_id": "2616440_2_1", "text": "We report the case of a patient with multiple myeloma who developed acute life - threatening water intoxication following treatment with oral indomethacin and low dose intravenous cyclophosphamide .", "tokens": ["We", "report", "the", "case", "of", "a", "patient", "with", "multiple", "myeloma", "who", "developed", "acute", "life", "-", "threatening", "water", "intoxication", "following", "treatment", "with", "oral", "indomethacin", "and", "low", "dose", "intravenous", "cyclophosphamide", "."], "event_mentions": [{"id": "2616440_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "2616440_2_Ent0", "role": "Subject", "text": "a patient with multiple myeloma", "start": 5, "end": 10}, {"entity_id": "2616440_2_Ent3", "role": "Treatment_Disorder", "text": "multiple myeloma", "start": 8, "end": 10}, {"entity_id": "2616440_2_Ent1", "role": "Effect", "text": "acute life - threatening water intoxication", "start": 12, "end": 18}, {"entity_id": "2616440_2_Ent4", "role": "Treatment_Route", "text": "oral", "start": 21, "end": 22}, {"entity_id": "2616440_2_Ent2", "role": "Treatment", "text": "oral indomethacin and low dose intravenous cyclophosphamide", "start": 21, "end": 28}, {"entity_id": "2616440_2_Ent6", "role": "Treatment_Drug", "text": "indomethacin", "start": 22, "end": 23}, {"entity_id": "2616440_2_Ent9", "role": "Combination_Drug", "text": "indomethacin", "start": 22, "end": 23}, {"entity_id": "2616440_2_Ent8", "role": "Treatment_Dosage", "text": "low dose", "start": 24, "end": 26}, {"entity_id": "2616440_2_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 26, "end": 27}, {"entity_id": "2616440_2_Ent7", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 27, "end": 28}, {"entity_id": "2616440_2_Ent10", "role": "Combination_Drug", "text": "cyclophosphamide", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "2616440_2_Ent0", "text": "a patient with multiple myeloma", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "2616440_2_Ent3", "text": "multiple myeloma", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "2616440_2_Ent1", "text": "acute life - threatening water intoxication", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "2616440_2_Ent4", "text": "oral", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "2616440_2_Ent2", "text": "oral indomethacin and low dose intravenous cyclophosphamide", "entity_type": "Entity", "start": 21, "end": 28}, {"id": "2616440_2_Ent6", "text": "indomethacin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "2616440_2_Ent9", "text": "indomethacin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "2616440_2_Ent8", "text": "low dose", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "2616440_2_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "2616440_2_Ent7", "text": "cyclophosphamide", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "2616440_2_Ent10", "text": "cyclophosphamide", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "2728526_1", "wnd_id": "2728526_1_1", "text": "Rifampin - associated thrombocytopenia secondary to poor compliance .", "tokens": ["Rifampin", "-", "associated", "thrombocytopenia", "secondary", "to", "poor", "compliance", "."], "event_mentions": [{"id": "2728526_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "2728526_1_Ent1", "role": "Treatment", "text": "Rifampin", "start": 0, "end": 1}, {"entity_id": "2728526_1_Ent2", "role": "Treatment_Drug", "text": "Rifampin", "start": 0, "end": 1}, {"entity_id": "2728526_1_Ent0", "role": "Effect", "text": "thrombocytopenia secondary to poor compliance", "start": 3, "end": 8}]}], "entity_mentions": [{"id": "2728526_1_Ent1", "text": "Rifampin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2728526_1_Ent2", "text": "Rifampin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2728526_1_Ent0", "text": "thrombocytopenia secondary to poor compliance", "entity_type": "Entity", "start": 3, "end": 8}], "lang": "en"}
{"doc_id": "2746565_2", "wnd_id": "2746565_2_1", "text": "Ulcerative proctitis in juvenile systemic lupus erythematosus after ibuprofen treatment .", "tokens": ["Ulcerative", "proctitis", "in", "juvenile", "systemic", "lupus", "erythematosus", "after", "ibuprofen", "treatment", "."], "event_mentions": [{"id": "2746565_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "2746565_2_Ent0", "role": "Effect", "text": "Ulcerative proctitis in juvenile systemic lupus erythematosus", "start": 0, "end": 7}, {"entity_id": "2746565_2_Ent1", "role": "Treatment", "text": "ibuprofen", "start": 8, "end": 9}, {"entity_id": "2746565_2_Ent2", "role": "Treatment_Drug", "text": "ibuprofen", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "2746565_2_Ent0", "text": "Ulcerative proctitis in juvenile systemic lupus erythematosus", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "2746565_2_Ent1", "text": "ibuprofen", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2746565_2_Ent2", "text": "ibuprofen", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "2746565_3", "wnd_id": "2746565_3_1", "text": "We describe a case of ulcerative proctitis after ibuprofen treatment in a girl with juvenile systemic lupus erythematosus .", "tokens": ["We", "describe", "a", "case", "of", "ulcerative", "proctitis", "after", "ibuprofen", "treatment", "in", "a", "girl", "with", "juvenile", "systemic", "lupus", "erythematosus", "."], "event_mentions": [{"id": "2746565_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "2746565_3_Ent2", "role": "Effect", "text": "ulcerative proctitis", "start": 5, "end": 7}, {"entity_id": "2746565_3_Ent4", "role": "Treatment_Drug", "text": "ibuprofen", "start": 8, "end": 9}, {"entity_id": "2746565_3_Ent3", "role": "Treatment", "text": "ibuprofen treatment", "start": 8, "end": 10}, {"entity_id": "2746565_3_Ent0", "role": "Subject", "text": "a girl with juvenile systemic lupus erythematosus", "start": 11, "end": 18}, {"entity_id": "2746565_3_Ent1", "role": "Subject_Gender", "text": "girl", "start": 12, "end": 13}, {"entity_id": "2746565_3_Ent5", "role": "Treatment_Disorder", "text": "juvenile systemic lupus erythematosus", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "2746565_3_Ent2", "text": "ulcerative proctitis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "2746565_3_Ent4", "text": "ibuprofen", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2746565_3_Ent3", "text": "ibuprofen treatment", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "2746565_3_Ent0", "text": "a girl with juvenile systemic lupus erythematosus", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "2746565_3_Ent1", "text": "girl", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2746565_3_Ent5", "text": "juvenile systemic lupus erythematosus", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "2857534_2", "wnd_id": "2857534_2_1", "text": "The authors caution that treatment with alprazolam may be complicated by the induction of mania .", "tokens": ["The", "authors", "caution", "that", "treatment", "with", "alprazolam", "may", "be", "complicated", "by", "the", "induction", "of", "mania", "."], "event_mentions": [{"id": "2857534_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induction of", "start": 12, "end": 14}, "arguments": [{"entity_id": "2857534_2_Ent1", "role": "Treatment", "text": "treatment with alprazolam", "start": 4, "end": 7}, {"entity_id": "2857534_2_Ent2", "role": "Treatment_Drug", "text": "alprazolam", "start": 6, "end": 7}, {"entity_id": "2857534_2_Ent0", "role": "Effect", "text": "mania", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "2857534_2_Ent1", "text": "treatment with alprazolam", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "2857534_2_Ent2", "text": "alprazolam", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2857534_2_Ent0", "text": "mania", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "2857534_3", "wnd_id": "2857534_3_1", "text": "Two patients treated with alprazolam had histories suggestive of a bipolar disorder and developed lithium - responsive manic episodes .", "tokens": ["Two", "patients", "treated", "with", "alprazolam", "had", "histories", "suggestive", "of", "a", "bipolar", "disorder", "and", "developed", "lithium", "-", "responsive", "manic", "episodes", "."], "event_mentions": [{"id": "2857534_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "2857534_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "2857534_3_Ent0", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "2857534_3_Ent4", "role": "Treatment", "text": "alprazolam", "start": 4, "end": 5}, {"entity_id": "2857534_3_Ent5", "role": "Treatment_Drug", "text": "alprazolam", "start": 4, "end": 5}, {"entity_id": "2857534_3_Ent2", "role": "Subject_Disorder", "text": "a bipolar disorder", "start": 9, "end": 12}, {"entity_id": "2857534_3_Ent3", "role": "Effect", "text": "lithium - responsive manic episodes", "start": 14, "end": 19}]}], "entity_mentions": [{"id": "2857534_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2857534_3_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2857534_3_Ent4", "text": "alprazolam", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "2857534_3_Ent5", "text": "alprazolam", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "2857534_3_Ent2", "text": "a bipolar disorder", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "2857534_3_Ent3", "text": "lithium - responsive manic episodes", "entity_type": "Entity", "start": 14, "end": 19}], "lang": "en"}
{"doc_id": "2863342_2", "wnd_id": "2863342_2_1", "text": "We discuss a variety of bronchopulmonary complications of IBD and their association with sulfasalazine .", "tokens": ["We", "discuss", "a", "variety", "of", "bronchopulmonary", "complications", "of", "IBD", "and", "their", "association", "with", "sulfasalazine", "."], "event_mentions": [{"id": "2863342_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 11, "end": 12}, "arguments": [{"entity_id": "2863342_2_Ent0", "role": "Effect", "text": "a variety of bronchopulmonary complications of IBD", "start": 2, "end": 9}, {"entity_id": "2863342_2_Ent1", "role": "Treatment", "text": "sulfasalazine", "start": 13, "end": 14}, {"entity_id": "2863342_2_Ent2", "role": "Treatment_Drug", "text": "sulfasalazine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "2863342_2_Ent0", "text": "a variety of bronchopulmonary complications of IBD", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "2863342_2_Ent1", "text": "sulfasalazine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "2863342_2_Ent2", "text": "sulfasalazine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "2887555_1", "wnd_id": "2887555_1_1", "text": "Soon after its introduction in 1952 , chlorpromazine was noted to induce symptoms resembling Parkinson 's disease .", "tokens": ["Soon", "after", "its", "introduction", "in", "1952", ",", "chlorpromazine", "was", "noted", "to", "induce", "symptoms", "resembling", "Parkinson", "'s", "disease", "."], "event_mentions": [{"id": "2887555_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 11, "end": 12}, "arguments": [{"entity_id": "2887555_1_Ent1", "role": "Treatment", "text": "chlorpromazine", "start": 7, "end": 8}, {"entity_id": "2887555_1_Ent2", "role": "Treatment_Drug", "text": "chlorpromazine", "start": 7, "end": 8}, {"entity_id": "2887555_1_Ent0", "role": "Effect", "text": "symptoms resembling Parkinson 's disease", "start": 12, "end": 17}]}], "entity_mentions": [{"id": "2887555_1_Ent1", "text": "chlorpromazine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2887555_1_Ent2", "text": "chlorpromazine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2887555_1_Ent0", "text": "symptoms resembling Parkinson 's disease", "entity_type": "Entity", "start": 12, "end": 17}], "lang": "en"}
{"doc_id": "2894766_1", "wnd_id": "2894766_1_1", "text": "It is suggested that the patient had sulfasalazine - induced lupus , which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms .", "tokens": ["It", "is", "suggested", "that", "the", "patient", "had", "sulfasalazine", "-", "induced", "lupus", ",", "which", "manifested", "with", "serositis", "and", "pulmonary", "parenchymal", "involvement", "in", "the", "absence", "of", "joint", "symptoms", "."], "event_mentions": [{"id": "2894766_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "2894766_1_Ent1", "role": "Treatment", "text": "sulfasalazine", "start": 7, "end": 8}, {"entity_id": "2894766_1_Ent2", "role": "Treatment_Drug", "text": "sulfasalazine", "start": 7, "end": 8}, {"entity_id": "2894766_1_Ent0", "role": "Effect", "text": "lupus , which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms", "start": 10, "end": 26}]}], "entity_mentions": [{"id": "2894766_1_Ent1", "text": "sulfasalazine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2894766_1_Ent2", "text": "sulfasalazine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2894766_1_Ent0", "text": "lupus , which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms", "entity_type": "Entity", "start": 10, "end": 26}], "lang": "en"}
{"doc_id": "2894766_4", "wnd_id": "2894766_4_1", "text": "Sulfasalazine - induced lupus erythematosus .", "tokens": ["Sulfasalazine", "-", "induced", "lupus", "erythematosus", "."], "event_mentions": [{"id": "2894766_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2894766_4_Ent1", "role": "Treatment", "text": "Sulfasalazine", "start": 0, "end": 1}, {"entity_id": "2894766_4_Ent2", "role": "Treatment_Drug", "text": "Sulfasalazine", "start": 0, "end": 1}, {"entity_id": "2894766_4_Ent0", "role": "Effect", "text": "lupus erythematosus", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "2894766_4_Ent1", "text": "Sulfasalazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2894766_4_Ent2", "text": "Sulfasalazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2894766_4_Ent0", "text": "lupus erythematosus", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "2924444_5", "wnd_id": "2924444_5_1", "text": "Electrocardiographic findings and laboratory data indicated a diagnosis of acute myocardial infarction due to the L - thyroxine therapy .", "tokens": ["Electrocardiographic", "findings", "and", "laboratory", "data", "indicated", "a", "diagnosis", "of", "acute", "myocardial", "infarction", "due", "to", "the", "L", "-", "thyroxine", "therapy", "."], "event_mentions": [{"id": "2924444_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 12, "end": 14}, "arguments": [{"entity_id": "2924444_5_Ent0", "role": "Effect", "text": "acute myocardial infarction", "start": 9, "end": 12}, {"entity_id": "2924444_5_Ent1", "role": "Treatment", "text": "the L - thyroxine therapy .", "start": 14, "end": 20}, {"entity_id": "2924444_5_Ent2", "role": "Treatment_Drug", "text": "L - thyroxine", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "2924444_5_Ent0", "text": "acute myocardial infarction", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "2924444_5_Ent1", "text": "the L - thyroxine therapy .", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "2924444_5_Ent2", "text": "L - thyroxine", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "2924444_8", "wnd_id": "2924444_8_1", "text": "We believe this is the first report of myocardial infarction due to coronary spasm , demonstrated by angiography associated with L - thyroxine therapy .", "tokens": ["We", "believe", "this", "is", "the", "first", "report", "of", "myocardial", "infarction", "due", "to", "coronary", "spasm", ",", "demonstrated", "by", "angiography", "associated", "with", "L", "-", "thyroxine", "therapy", "."], "event_mentions": [{"id": "2924444_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 18, "end": 19}, "arguments": [{"entity_id": "2924444_8_Ent0", "role": "Effect", "text": "myocardial infarction", "start": 8, "end": 10}, {"entity_id": "2924444_8_Ent1", "role": "Effect", "text": "coronary spasm", "start": 12, "end": 14}, {"entity_id": "2924444_8_Ent2", "role": "Treatment", "text": "L - thyroxine", "start": 20, "end": 23}, {"entity_id": "2924444_8_Ent3", "role": "Treatment_Drug", "text": "L - thyroxine", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "2924444_8_Ent0", "text": "myocardial infarction", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "2924444_8_Ent1", "text": "coronary spasm", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "2924444_8_Ent2", "text": "L - thyroxine", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "2924444_8_Ent3", "text": "L - thyroxine", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "2931445_2", "wnd_id": "2931445_2_1", "text": "A study of in vitro reactivity to L - T4 , as assessed by peripheral blood lymphocyte transformation , was carried out in a patient with Hashimoto 's disease who developed leukopenia during treatment with L - T4 .", "tokens": ["A", "study", "of", "in", "vitro", "reactivity", "to", "L", "-", "T4", ",", "as", "assessed", "by", "peripheral", "blood", "lymphocyte", "transformation", ",", "was", "carried", "out", "in", "a", "patient", "with", "Hashimoto", "'s", "disease", "who", "developed", "leukopenia", "during", "treatment", "with", "L", "-", "T4", "."], "event_mentions": [{"id": "2931445_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 30, "end": 31}, "arguments": [{"entity_id": "2931445_2_Ent0", "role": "Subject", "text": "a patient with Hashimoto 's disease", "start": 23, "end": 29}, {"entity_id": "2931445_2_Ent3", "role": "Treatment_Disorder", "text": "Hashimoto 's disease", "start": 26, "end": 29}, {"entity_id": "2931445_2_Ent1", "role": "Effect", "text": "leukopenia", "start": 31, "end": 32}, {"entity_id": "2931445_2_Ent2", "role": "Treatment", "text": "L - T4", "start": 35, "end": 38}, {"entity_id": "2931445_2_Ent4", "role": "Treatment_Drug", "text": "L - T4", "start": 35, "end": 38}]}], "entity_mentions": [{"id": "2931445_2_Ent0", "text": "a patient with Hashimoto 's disease", "entity_type": "Entity", "start": 23, "end": 29}, {"id": "2931445_2_Ent3", "text": "Hashimoto 's disease", "entity_type": "Entity", "start": 26, "end": 29}, {"id": "2931445_2_Ent1", "text": "leukopenia", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "2931445_2_Ent2", "text": "L - T4", "entity_type": "Entity", "start": 35, "end": 38}, {"id": "2931445_2_Ent4", "text": "L - T4", "entity_type": "Entity", "start": 35, "end": 38}], "lang": "en"}
{"doc_id": "2935070_2", "wnd_id": "2935070_2_1", "text": "However , there are few reports in the literature of ampicillin as a cause of acute interstitial nephritis .", "tokens": ["However", ",", "there", "are", "few", "reports", "in", "the", "literature", "of", "ampicillin", "as", "a", "cause", "of", "acute", "interstitial", "nephritis", "."], "event_mentions": [{"id": "2935070_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 13, "end": 14}, "arguments": [{"entity_id": "2935070_2_Ent1", "role": "Treatment", "text": "ampicillin", "start": 10, "end": 11}, {"entity_id": "2935070_2_Ent2", "role": "Treatment_Drug", "text": "ampicillin", "start": 10, "end": 11}, {"entity_id": "2935070_2_Ent0", "role": "Effect", "text": "acute interstitial nephritis", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "2935070_2_Ent1", "text": "ampicillin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "2935070_2_Ent2", "text": "ampicillin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "2935070_2_Ent0", "text": "acute interstitial nephritis", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "2935070_4", "wnd_id": "2935070_4_1", "text": "The diagnosis was based on the rapid onset of renal failure , presence of eosinophilia , skin rash , and characteristic renal biopsy finding , following the administration of ampicillin .", "tokens": ["The", "diagnosis", "was", "based", "on", "the", "rapid", "onset", "of", "renal", "failure", ",", "presence", "of", "eosinophilia", ",", "skin", "rash", ",", "and", "characteristic", "renal", "biopsy", "finding", ",", "following", "the", "administration", "of", "ampicillin", "."], "event_mentions": [{"id": "2935070_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 25, "end": 26}, "arguments": [{"entity_id": "2935070_4_Ent0", "role": "Effect", "text": "rapid onset of renal failure , presence of eosinophilia , skin rash , and characteristic renal biopsy", "start": 6, "end": 23}, {"entity_id": "2935070_4_Ent1", "role": "Treatment", "text": "ampicillin", "start": 29, "end": 30}, {"entity_id": "2935070_4_Ent2", "role": "Treatment_Drug", "text": "ampicillin", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "2935070_4_Ent0", "text": "rapid onset of renal failure , presence of eosinophilia , skin rash , and characteristic renal biopsy", "entity_type": "Entity", "start": 6, "end": 23}, {"id": "2935070_4_Ent1", "text": "ampicillin", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "2935070_4_Ent2", "text": "ampicillin", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "3003260_2", "wnd_id": "3003260_2_1", "text": "Cataracts induced by intermittent Decadron used as an antiemetic .", "tokens": ["Cataracts", "induced", "by", "intermittent", "Decadron", "used", "as", "an", "antiemetic", "."], "event_mentions": [{"id": "3003260_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "3003260_2_Ent0", "role": "Effect", "text": "Cataracts", "start": 0, "end": 1}, {"entity_id": "3003260_2_Ent1", "role": "Treatment", "text": "Decadron", "start": 4, "end": 5}, {"entity_id": "3003260_2_Ent2", "role": "Treatment_Drug", "text": "Decadron", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "3003260_2_Ent0", "text": "Cataracts", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3003260_2_Ent1", "text": "Decadron", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3003260_2_Ent2", "text": "Decadron", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "3030084_1", "wnd_id": "3030084_1_1", "text": "Transient phenytoin induced IgA deficiency and permanent IgE increase .", "tokens": ["Transient", "phenytoin", "induced", "IgA", "deficiency", "and", "permanent", "IgE", "increase", "."], "event_mentions": [{"id": "3030084_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "3030084_1_Ent1", "role": "Treatment", "text": "phenytoin", "start": 1, "end": 2}, {"entity_id": "3030084_1_Ent2", "role": "Treatment_Drug", "text": "phenytoin", "start": 1, "end": 2}, {"entity_id": "3030084_1_Ent0", "role": "Effect", "text": "IgA deficiency and permanent IgE increase", "start": 3, "end": 9}]}], "entity_mentions": [{"id": "3030084_1_Ent1", "text": "phenytoin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3030084_1_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3030084_1_Ent0", "text": "IgA deficiency and permanent IgE increase", "entity_type": "Entity", "start": 3, "end": 9}], "lang": "en"}
{"doc_id": "3084231_2", "wnd_id": "3084231_2_1", "text": "Reversible valproic acid - induced dementia : a case report .", "tokens": ["Reversible", "valproic", "acid", "-", "induced", "dementia", ":", "a", "case", "report", "."], "event_mentions": [{"id": "3084231_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "3084231_2_Ent1", "role": "Treatment", "text": "valproic acid", "start": 1, "end": 3}, {"entity_id": "3084231_2_Ent2", "role": "Treatment_Drug", "text": "valproic acid", "start": 1, "end": 3}, {"entity_id": "3084231_2_Ent0", "role": "Effect", "text": "dementia", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "3084231_2_Ent1", "text": "valproic acid", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "3084231_2_Ent2", "text": "valproic acid", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "3084231_2_Ent0", "text": "dementia", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "3124393_2", "wnd_id": "3124393_2_1", "text": "Calcification and ossification of the spinal arachnoid after intrathecal administration of Depo - Medrol .", "tokens": ["Calcification", "and", "ossification", "of", "the", "spinal", "arachnoid", "after", "intrathecal", "administration", "of", "Depo", "-", "Medrol", "."], "event_mentions": [{"id": "3124393_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "3124393_2_Ent0", "role": "Effect", "text": "Calcification and ossification of the spinal arachnoid", "start": 0, "end": 7}, {"entity_id": "3124393_2_Ent2", "role": "Treatment_Route", "text": "intrathecal", "start": 8, "end": 9}, {"entity_id": "3124393_2_Ent1", "role": "Treatment", "text": "intrathecal administration of Depo - Medrol", "start": 8, "end": 14}, {"entity_id": "3124393_2_Ent3", "role": "Treatment_Drug", "text": "Depo - Medrol", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "3124393_2_Ent0", "text": "Calcification and ossification of the spinal arachnoid", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "3124393_2_Ent2", "text": "intrathecal", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3124393_2_Ent1", "text": "intrathecal administration of Depo - Medrol", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "3124393_2_Ent3", "text": "Depo - Medrol", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "3143551_1", "wnd_id": "3143551_1_1", "text": "Accordingly , camptocormia is a dose - dependent side effect of valproate .", "tokens": ["Accordingly", ",", "camptocormia", "is", "a", "dose", "-", "dependent", "side", "effect", "of", "valproate", "."], "event_mentions": [{"id": "3143551_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "effect", "start": 9, "end": 10}, "arguments": [{"entity_id": "3143551_1_Ent0", "role": "Effect", "text": "camptocormia", "start": 2, "end": 3}, {"entity_id": "3143551_1_Ent1", "role": "Treatment", "text": "valproate", "start": 11, "end": 12}, {"entity_id": "3143551_1_Ent2", "role": "Treatment_Drug", "text": "valproate", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "3143551_1_Ent0", "text": "camptocormia", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "3143551_1_Ent1", "text": "valproate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "3143551_1_Ent2", "text": "valproate", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "3143551_2", "wnd_id": "3143551_2_1", "text": "A mentally retarded 23 - year - old woman with myoclonic astatic epilepsy developed an abnormal posture of extreme forward flexion , called camptocormia , during valproate monotherapy .", "tokens": ["A", "mentally", "retarded", "23", "-", "year", "-", "old", "woman", "with", "myoclonic", "astatic", "epilepsy", "developed", "an", "abnormal", "posture", "of", "extreme", "forward", "flexion", ",", "called", "camptocormia", ",", "during", "valproate", "monotherapy", "."], "event_mentions": [{"id": "3143551_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 25, "end": 26}, "arguments": [{"entity_id": "3143551_2_Ent0", "role": "Subject", "text": "A mentally retarded 23 - year - old woman with myoclonic astatic epilepsy", "start": 0, "end": 13}, {"entity_id": "3143551_2_Ent1", "role": "Subject_Disorder", "text": "mentally retarded", "start": 1, "end": 3}, {"entity_id": "3143551_2_Ent2", "role": "Subject_Age", "text": "23 - year - old", "start": 3, "end": 8}, {"entity_id": "3143551_2_Ent6", "role": "Treatment_Disorder", "text": "myoclonic astatic epilepsy", "start": 10, "end": 13}, {"entity_id": "3143551_2_Ent3", "role": "Effect", "text": "abnormal posture of extreme forward flexion , called camptocormia ,", "start": 15, "end": 25}, {"entity_id": "3143551_2_Ent4", "role": "Treatment", "text": "valproate", "start": 26, "end": 27}, {"entity_id": "3143551_2_Ent5", "role": "Treatment_Drug", "text": "valproate", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "3143551_2_Ent0", "text": "A mentally retarded 23 - year - old woman with myoclonic astatic epilepsy", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "3143551_2_Ent1", "text": "mentally retarded", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "3143551_2_Ent2", "text": "23 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "3143551_2_Ent6", "text": "myoclonic astatic epilepsy", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "3143551_2_Ent3", "text": "abnormal posture of extreme forward flexion , called camptocormia ,", "entity_type": "Entity", "start": 15, "end": 25}, {"id": "3143551_2_Ent4", "text": "valproate", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "3143551_2_Ent5", "text": "valproate", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "3156465_1", "wnd_id": "3156465_1_1", "text": "Isotretinoin , a drug used for the treatment of acne , has been shown to have teratogenic effects .", "tokens": ["Isotretinoin", ",", "a", "drug", "used", "for", "the", "treatment", "of", "acne", ",", "has", "been", "shown", "to", "have", "teratogenic", "effects", "."], "event_mentions": [{"id": "3156465_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "have", "start": 15, "end": 16}, "arguments": [{"entity_id": "3156465_1_Ent1", "role": "Treatment", "text": "Isotretinoin", "start": 0, "end": 1}, {"entity_id": "3156465_1_Ent2", "role": "Treatment_Drug", "text": "Isotretinoin", "start": 0, "end": 1}, {"entity_id": "3156465_1_Ent3", "role": "Treatment_Disorder", "text": "acne", "start": 9, "end": 10}, {"entity_id": "3156465_1_Ent0", "role": "Effect", "text": "teratogenic effects", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "3156465_1_Ent1", "text": "Isotretinoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3156465_1_Ent2", "text": "Isotretinoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3156465_1_Ent3", "text": "acne", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3156465_1_Ent0", "text": "teratogenic effects", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "3195622_2", "wnd_id": "3195622_2_1", "text": "A dapsone hypersensitivity syndrome , consisting of fever , headache , nausea , vomiting , lymphadenopathy , hepatitis , hemolysis , leukopenia , and mononucleosis , has been described in patients treated with the drug for leprosy .", "tokens": ["A", "dapsone", "hypersensitivity", "syndrome", ",", "consisting", "of", "fever", ",", "headache", ",", "nausea", ",", "vomiting", ",", "lymphadenopathy", ",", "hepatitis", ",", "hemolysis", ",", "leukopenia", ",", "and", "mononucleosis", ",", "has", "been", "described", "in", "patients", "treated", "with", "the", "drug", "for", "leprosy", "."], "event_mentions": [{"id": "3195622_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 31, "end": 32}, "arguments": [{"entity_id": "3195622_2_Ent2", "role": "Treatment", "text": "dapsone", "start": 1, "end": 2}, {"entity_id": "3195622_2_Ent3", "role": "Treatment_Drug", "text": "dapsone", "start": 1, "end": 2}, {"entity_id": "3195622_2_Ent1", "role": "Effect", "text": "hypersensitivity syndrome , consisting of fever , headache , nausea , vomiting , lymphadenopathy , hepatitis , hemolysis , leukopenia , and mononucleosis", "start": 2, "end": 25}, {"entity_id": "3195622_2_Ent0", "role": "Subject", "text": "patients", "start": 30, "end": 31}, {"entity_id": "3195622_2_Ent4", "role": "Treatment_Disorder", "text": "leprosy", "start": 36, "end": 37}]}], "entity_mentions": [{"id": "3195622_2_Ent2", "text": "dapsone", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3195622_2_Ent3", "text": "dapsone", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3195622_2_Ent1", "text": "hypersensitivity syndrome , consisting of fever , headache , nausea , vomiting , lymphadenopathy , hepatitis , hemolysis , leukopenia , and mononucleosis", "entity_type": "Entity", "start": 2, "end": 25}, {"id": "3195622_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "3195622_2_Ent4", "text": "leprosy", "entity_type": "Entity", "start": 36, "end": 37}], "lang": "en"}
{"doc_id": "3290702_1", "wnd_id": "3290702_1_1", "text": "A clinically atypical , neuropathologically verified case of Creutzfeldt - Jakob disease is described in a 32 - year - old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence ( 1970 to 1973 ) with human growth hormone processed from pooled cadaveric pituitary glands .", "tokens": ["A", "clinically", "atypical", ",", "neuropathologically", "verified", "case", "of", "Creutzfeldt", "-", "Jakob", "disease", "is", "described", "in", "a", "32", "-", "year", "-", "old", "New", "Zealand", "woman", "with", "idiopathic", "hypopituitarism", "who", "had", "been", "treated", "in", "late", "adolescence", "(", "1970", "to", "1973", ")", "with", "human", "growth", "hormone", "processed", "from", "pooled", "cadaveric", "pituitary", "glands", "."], "event_mentions": [{"id": "3290702_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "described", "start": 13, "end": 14}, "arguments": [{"entity_id": "3290702_1_Ent4", "role": "Effect", "text": "Creutzfeldt - Jakob disease", "start": 8, "end": 12}, {"entity_id": "3290702_1_Ent0", "role": "Subject", "text": "a 32 - year - old New Zealand woman with idiopathic hypopituitarism", "start": 15, "end": 27}, {"entity_id": "3290702_1_Ent1", "role": "Subject_Age", "text": "32 - year - old", "start": 16, "end": 21}, {"entity_id": "3290702_1_Ent2", "role": "Subject_Race", "text": "New Zealand", "start": 21, "end": 23}, {"entity_id": "3290702_1_Ent3", "role": "Subject_Gender", "text": "woman", "start": 23, "end": 24}, {"entity_id": "3290702_1_Ent6", "role": "Treatment_Disorder", "text": "idiopathic hypopituitarism", "start": 25, "end": 27}, {"entity_id": "3290702_1_Ent5", "role": "Treatment", "text": "human growth hormone", "start": 40, "end": 43}, {"entity_id": "3290702_1_Ent7", "role": "Treatment_Drug", "text": "human growth hormone", "start": 40, "end": 43}]}], "entity_mentions": [{"id": "3290702_1_Ent4", "text": "Creutzfeldt - Jakob disease", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "3290702_1_Ent0", "text": "a 32 - year - old New Zealand woman with idiopathic hypopituitarism", "entity_type": "Entity", "start": 15, "end": 27}, {"id": "3290702_1_Ent1", "text": "32 - year - old", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "3290702_1_Ent2", "text": "New Zealand", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "3290702_1_Ent3", "text": "woman", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "3290702_1_Ent6", "text": "idiopathic hypopituitarism", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "3290702_1_Ent5", "text": "human growth hormone", "entity_type": "Entity", "start": 40, "end": 43}, {"id": "3290702_1_Ent7", "text": "human growth hormone", "entity_type": "Entity", "start": 40, "end": 43}], "lang": "en"}
{"doc_id": "3301251_4", "wnd_id": "3301251_4_1", "text": "They continued to rise for five more days before salicylate hepatotoxicity was suspected .", "tokens": ["They", "continued", "to", "rise", "for", "five", "more", "days", "before", "salicylate", "hepatotoxicity", "was", "suspected", "."], "event_mentions": [{"id": "3301251_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suspected", "start": 12, "end": 13}, "arguments": [{"entity_id": "3301251_4_Ent1", "role": "Treatment", "text": "salicylate", "start": 9, "end": 10}, {"entity_id": "3301251_4_Ent2", "role": "Treatment_Drug", "text": "salicylate", "start": 9, "end": 10}, {"entity_id": "3301251_4_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "3301251_4_Ent1", "text": "salicylate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3301251_4_Ent2", "text": "salicylate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3301251_4_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "3310776_2", "wnd_id": "3310776_2_1", "text": "Captopril - related ( and -induced ? ) asthma .", "tokens": ["Captopril", "-", "related", "(", "and", "-induced", "?", ")", "asthma", "."], "event_mentions": [{"id": "3310776_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 2, "end": 3}, "arguments": [{"entity_id": "3310776_2_Ent1", "role": "Treatment", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "3310776_2_Ent2", "role": "Treatment_Drug", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "3310776_2_Ent0", "role": "Effect", "text": "asthma", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "3310776_2_Ent1", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3310776_2_Ent2", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3310776_2_Ent0", "text": "asthma", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "3310776_3", "wnd_id": "3310776_3_1", "text": "This confirmed the history of captopril - related asthma .", "tokens": ["This", "confirmed", "the", "history", "of", "captopril", "-", "related", "asthma", "."], "event_mentions": [{"id": "3310776_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 7, "end": 8}, "arguments": [{"entity_id": "3310776_3_Ent1", "role": "Treatment", "text": "captopril", "start": 5, "end": 6}, {"entity_id": "3310776_3_Ent2", "role": "Treatment_Drug", "text": "captopril", "start": 5, "end": 6}, {"entity_id": "3310776_3_Ent0", "role": "Effect", "text": "asthma", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "3310776_3_Ent1", "text": "captopril", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3310776_3_Ent2", "text": "captopril", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3310776_3_Ent0", "text": "asthma", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "3335488_1", "wnd_id": "3335488_1_1", "text": "The observations suggest that testicular swelling and pain are side effects of desipramine .", "tokens": ["The", "observations", "suggest", "that", "testicular", "swelling", "and", "pain", "are", "side", "effects", "of", "desipramine", "."], "event_mentions": [{"id": "3335488_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 9, "end": 11}, "arguments": [{"entity_id": "3335488_1_Ent0", "role": "Effect", "text": "testicular swelling and pain", "start": 4, "end": 8}, {"entity_id": "3335488_1_Ent1", "role": "Treatment", "text": "desipramine", "start": 12, "end": 13}, {"entity_id": "3335488_1_Ent2", "role": "Treatment_Drug", "text": "desipramine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "3335488_1_Ent0", "text": "testicular swelling and pain", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "3335488_1_Ent1", "text": "desipramine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "3335488_1_Ent2", "text": "desipramine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "3346128_1", "wnd_id": "3346128_1_1", "text": "A 43 - year - old white man developed a shallow erosion of a psoriatic plaque after chronic administration of methotrexate .", "tokens": ["A", "43", "-", "year", "-", "old", "white", "man", "developed", "a", "shallow", "erosion", "of", "a", "psoriatic", "plaque", "after", "chronic", "administration", "of", "methotrexate", "."], "event_mentions": [{"id": "3346128_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "3346128_1_Ent0", "role": "Subject", "text": "A 43 - year - old white man", "start": 0, "end": 8}, {"entity_id": "3346128_1_Ent1", "role": "Subject_Age", "text": "43 - year - old", "start": 1, "end": 6}, {"entity_id": "3346128_1_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "3346128_1_Ent3", "role": "Subject_Gender", "text": "man", "start": 7, "end": 8}, {"entity_id": "3346128_1_Ent4", "role": "Effect", "text": "shallow erosion of a psoriatic plaque", "start": 10, "end": 16}, {"entity_id": "3346128_1_Ent7", "role": "Treatment_Disorder", "text": "psoriatic plaque", "start": 14, "end": 16}, {"entity_id": "3346128_1_Ent8", "role": "Treatment_Duration", "text": "chronic", "start": 17, "end": 18}, {"entity_id": "3346128_1_Ent5", "role": "Treatment", "text": "chronic administration of methotrexate", "start": 17, "end": 21}, {"entity_id": "3346128_1_Ent6", "role": "Treatment_Drug", "text": "methotrexate", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "3346128_1_Ent0", "text": "A 43 - year - old white man", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "3346128_1_Ent1", "text": "43 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "3346128_1_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3346128_1_Ent3", "text": "man", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3346128_1_Ent4", "text": "shallow erosion of a psoriatic plaque", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "3346128_1_Ent7", "text": "psoriatic plaque", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "3346128_1_Ent8", "text": "chronic", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "3346128_1_Ent5", "text": "chronic administration of methotrexate", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "3346128_1_Ent6", "text": "methotrexate", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "3346128_2", "wnd_id": "3346128_2_1", "text": "Erosion of psoriatic plaques after chronic methotrexate administration .", "tokens": ["Erosion", "of", "psoriatic", "plaques", "after", "chronic", "methotrexate", "administration", "."], "event_mentions": [{"id": "3346128_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "3346128_2_Ent0", "role": "Effect", "text": "Erosion of psoriatic plaques", "start": 0, "end": 4}, {"entity_id": "3346128_2_Ent1", "role": "Treatment", "text": "methotrexate", "start": 6, "end": 7}, {"entity_id": "3346128_2_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "3346128_2_Ent0", "text": "Erosion of psoriatic plaques", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3346128_2_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3346128_2_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "3365032_1", "wnd_id": "3365032_1_1", "text": "A patient is presented with typical hyperthyroidism , who developed a severe proximal muscle weakness and a raised creatine phosphokinase after treatment for hyperthyroidism with propylthiouracil ( 100 mg orally , three times a day ) .", "tokens": ["A", "patient", "is", "presented", "with", "typical", "hyperthyroidism", ",", "who", "developed", "a", "severe", "proximal", "muscle", "weakness", "and", "a", "raised", "creatine", "phosphokinase", "after", "treatment", "for", "hyperthyroidism", "with", "propylthiouracil", "(", "100", "mg", "orally", ",", "three", "times", "a", "day", ")", "."], "event_mentions": [{"id": "3365032_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 20, "end": 21}, "arguments": [{"entity_id": "3365032_1_Ent0", "role": "Subject", "text": "A patient is presented with typical hyperthyroidism", "start": 0, "end": 7}, {"entity_id": "3365032_1_Ent4", "role": "Treatment_Disorder", "text": "typical hyperthyroidism", "start": 5, "end": 7}, {"entity_id": "3365032_1_Ent1", "role": "Effect", "text": "severe proximal muscle weakness and a raised creatine phosphokinase", "start": 11, "end": 20}, {"entity_id": "3365032_1_Ent2", "role": "Treatment", "text": "treatment for hyperthyroidism with propylthiouracil ( 100 mg orally , three times a day )", "start": 21, "end": 36}, {"entity_id": "3365032_1_Ent3", "role": "Treatment_Disorder", "text": "hyperthyroidism", "start": 23, "end": 24}, {"entity_id": "3365032_1_Ent5", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 25, "end": 26}, {"entity_id": "3365032_1_Ent6", "role": "Treatment_Dosage", "text": "100 mg", "start": 27, "end": 29}, {"entity_id": "3365032_1_Ent7", "role": "Treatment_Route", "text": "orally", "start": 29, "end": 30}, {"entity_id": "3365032_1_Ent8", "role": "Treatment_Freq", "text": "three times a day", "start": 31, "end": 35}]}], "entity_mentions": [{"id": "3365032_1_Ent0", "text": "A patient is presented with typical hyperthyroidism", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "3365032_1_Ent4", "text": "typical hyperthyroidism", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "3365032_1_Ent1", "text": "severe proximal muscle weakness and a raised creatine phosphokinase", "entity_type": "Entity", "start": 11, "end": 20}, {"id": "3365032_1_Ent2", "text": "treatment for hyperthyroidism with propylthiouracil ( 100 mg orally , three times a day )", "entity_type": "Entity", "start": 21, "end": 36}, {"id": "3365032_1_Ent3", "text": "hyperthyroidism", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "3365032_1_Ent5", "text": "propylthiouracil", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "3365032_1_Ent6", "text": "100 mg", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "3365032_1_Ent7", "text": "orally", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "3365032_1_Ent8", "text": "three times a day", "entity_type": "Entity", "start": 31, "end": 35}], "lang": "en"}
{"doc_id": "3370103_1", "wnd_id": "3370103_1_1", "text": "Cardiopulmonary arrest following intravenous phenytoin loading .", "tokens": ["Cardiopulmonary", "arrest", "following", "intravenous", "phenytoin", "loading", "."], "event_mentions": [{"id": "3370103_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "3370103_1_Ent0", "role": "Effect", "text": "Cardiopulmonary arrest", "start": 0, "end": 2}, {"entity_id": "3370103_1_Ent2", "role": "Treatment_Route", "text": "intravenous", "start": 3, "end": 4}, {"entity_id": "3370103_1_Ent1", "role": "Treatment", "text": "intravenous phenytoin loading", "start": 3, "end": 6}, {"entity_id": "3370103_1_Ent3", "role": "Treatment_Drug", "text": "phenytoin", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "3370103_1_Ent0", "text": "Cardiopulmonary arrest", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3370103_1_Ent2", "text": "intravenous", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3370103_1_Ent1", "text": "intravenous phenytoin loading", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "3370103_1_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "3379435_2", "wnd_id": "3379435_2_1", "text": "Reye - like syndrome following treatment with the pantothenic acid antagonist , calcium hopantenate .", "tokens": ["Reye", "-", "like", "syndrome", "following", "treatment", "with", "the", "pantothenic", "acid", "antagonist", ",", "calcium", "hopantenate", "."], "event_mentions": [{"id": "3379435_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 4, "end": 5}, "arguments": [{"entity_id": "3379435_2_Ent0", "role": "Effect", "text": "Reye - like syndrome", "start": 0, "end": 4}, {"entity_id": "3379435_2_Ent1", "role": "Treatment", "text": "calcium hopantenate", "start": 12, "end": 14}, {"entity_id": "3379435_2_Ent2", "role": "Treatment_Drug", "text": "calcium hopantenate", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "3379435_2_Ent0", "text": "Reye - like syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3379435_2_Ent1", "text": "calcium hopantenate", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "3379435_2_Ent2", "text": "calcium hopantenate", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "3397227_1", "wnd_id": "3397227_1_1", "text": "Anhedonic ejaculation with desipramine .", "tokens": ["Anhedonic", "ejaculation", "with", "desipramine", "."], "event_mentions": [{"id": "3397227_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 2, "end": 3}, "arguments": [{"entity_id": "3397227_1_Ent0", "role": "Effect", "text": "Anhedonic ejaculation", "start": 0, "end": 2}, {"entity_id": "3397227_1_Ent1", "role": "Treatment", "text": "desipramine", "start": 3, "end": 4}, {"entity_id": "3397227_1_Ent2", "role": "Treatment_Drug", "text": "desipramine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "3397227_1_Ent0", "text": "Anhedonic ejaculation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3397227_1_Ent1", "text": "desipramine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3397227_1_Ent2", "text": "desipramine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "3410226_2", "wnd_id": "3410226_2_1", "text": "We report a 46 - yr - old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide .", "tokens": ["We", "report", "a", "46", "-", "yr", "-", "old", "woman", "with", "ovarian", "carcinoma", "who", "developed", "porphyria", "cutanea", "tarda", "while", "undergoing", "treatment", "with", "cisplatin", "and", "cyclophosphamide", "."], "event_mentions": [{"id": "3410226_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "3410226_2_Ent0", "role": "Subject", "text": "a 46 - yr - old woman with ovarian carcinoma", "start": 2, "end": 12}, {"entity_id": "3410226_2_Ent1", "role": "Subject_Age", "text": "46 - yr - old", "start": 3, "end": 8}, {"entity_id": "3410226_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "3410226_2_Ent7", "role": "Treatment_Disorder", "text": "ovarian carcinoma", "start": 10, "end": 12}, {"entity_id": "3410226_2_Ent3", "role": "Effect", "text": "porphyria cutanea tarda", "start": 14, "end": 17}, {"entity_id": "3410226_2_Ent5", "role": "Treatment_Drug", "text": "cisplatin", "start": 21, "end": 22}, {"entity_id": "3410226_2_Ent8", "role": "Combination_Drug", "text": "cisplatin", "start": 21, "end": 22}, {"entity_id": "3410226_2_Ent4", "role": "Treatment", "text": "cisplatin and cyclophosphamide", "start": 21, "end": 24}, {"entity_id": "3410226_2_Ent6", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 23, "end": 24}, {"entity_id": "3410226_2_Ent9", "role": "Combination_Drug", "text": "cyclophosphamide", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "3410226_2_Ent0", "text": "a 46 - yr - old woman with ovarian carcinoma", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "3410226_2_Ent1", "text": "46 - yr - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "3410226_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3410226_2_Ent7", "text": "ovarian carcinoma", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "3410226_2_Ent3", "text": "porphyria cutanea tarda", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "3410226_2_Ent5", "text": "cisplatin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "3410226_2_Ent8", "text": "cisplatin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "3410226_2_Ent4", "text": "cisplatin and cyclophosphamide", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "3410226_2_Ent6", "text": "cyclophosphamide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "3410226_2_Ent9", "text": "cyclophosphamide", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "3430507_4", "wnd_id": "3430507_4_1", "text": "The 9 other reported cases of D - penicillamine induced rapidly progressive glomerulonephritis have been reviewed .", "tokens": ["The", "9", "other", "reported", "cases", "of", "D", "-", "penicillamine", "induced", "rapidly", "progressive", "glomerulonephritis", "have", "been", "reviewed", "."], "event_mentions": [{"id": "3430507_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "3430507_4_Ent1", "role": "Treatment", "text": "D - penicillamine", "start": 6, "end": 9}, {"entity_id": "3430507_4_Ent2", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 6, "end": 9}, {"entity_id": "3430507_4_Ent0", "role": "Effect", "text": "rapidly progressive glomerulonephritis", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "3430507_4_Ent1", "text": "D - penicillamine", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "3430507_4_Ent2", "text": "D - penicillamine", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "3430507_4_Ent0", "text": "rapidly progressive glomerulonephritis", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "3470173_3", "wnd_id": "3470173_3_1", "text": "During the first treatment , dysarthria and ataxia were seen after completion of the patient 's eighth and final dose of HDARAC .", "tokens": ["During", "the", "first", "treatment", ",", "dysarthria", "and", "ataxia", "were", "seen", "after", "completion", "of", "the", "patient", "'s", "eighth", "and", "final", "dose", "of", "HDARAC", "."], "event_mentions": [{"id": "3470173_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "seen", "start": 9, "end": 10}, "arguments": [{"entity_id": "3470173_3_Ent1", "role": "Effect", "text": "dysarthria and ataxia", "start": 5, "end": 8}, {"entity_id": "3470173_3_Ent0", "role": "Subject", "text": "the patient 's", "start": 13, "end": 16}, {"entity_id": "3470173_3_Ent2", "role": "Treatment", "text": "HDARAC", "start": 21, "end": 22}, {"entity_id": "3470173_3_Ent3", "role": "Treatment_Drug", "text": "HDARAC", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "3470173_3_Ent1", "text": "dysarthria and ataxia", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "3470173_3_Ent0", "text": "the patient 's", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "3470173_3_Ent2", "text": "HDARAC", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "3470173_3_Ent3", "text": "HDARAC", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "3501467_1", "wnd_id": "3501467_1_1", "text": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy .", "tokens": ["Extensive", "immunological", "investigations", "were", "performed", "in", "a", "patient", "with", "definite", "seronegative", "rheumatoid", "arthritis", "who", "developed", "hypogammaglobulinemia", "in", "the", "course", "of", "gold", "therapy", "."], "event_mentions": [{"id": "3501467_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "3501467_1_Ent0", "role": "Subject", "text": "a patient with definite seronegative rheumatoid arthritis", "start": 6, "end": 13}, {"entity_id": "3501467_1_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 11, "end": 13}, {"entity_id": "3501467_1_Ent1", "role": "Effect", "text": "hypogammaglobulinemia", "start": 15, "end": 16}, {"entity_id": "3501467_1_Ent4", "role": "Treatment_Drug", "text": "gold", "start": 20, "end": 21}, {"entity_id": "3501467_1_Ent2", "role": "Treatment", "text": "gold therapy", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "3501467_1_Ent0", "text": "a patient with definite seronegative rheumatoid arthritis", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "3501467_1_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "3501467_1_Ent1", "text": "hypogammaglobulinemia", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "3501467_1_Ent4", "text": "gold", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "3501467_1_Ent2", "text": "gold therapy", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "3508194_1", "wnd_id": "3508194_1_1", "text": "Transient leucopenia and thrombocytopenia associated with sodium nitroprusside infusion .", "tokens": ["Transient", "leucopenia", "and", "thrombocytopenia", "associated", "with", "sodium", "nitroprusside", "infusion", "."], "event_mentions": [{"id": "3508194_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "3508194_1_Ent0", "role": "Effect", "text": "Transient leucopenia and thrombocytopenia", "start": 0, "end": 4}, {"entity_id": "3508194_1_Ent3", "role": "Treatment_Drug", "text": "sodium nitroprusside", "start": 6, "end": 8}, {"entity_id": "3508194_1_Ent1", "role": "Treatment", "text": "sodium nitroprusside infusion", "start": 6, "end": 9}, {"entity_id": "3508194_1_Ent2", "role": "Treatment_Route", "text": "infusion", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "3508194_1_Ent0", "text": "Transient leucopenia and thrombocytopenia", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3508194_1_Ent3", "text": "sodium nitroprusside", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "3508194_1_Ent1", "text": "sodium nitroprusside infusion", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "3508194_1_Ent2", "text": "infusion", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "3513544_2", "wnd_id": "3513544_2_1", "text": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy .", "tokens": ["We", "report", "the", "first", "case", "of", "herpes", "esophagitis", "in", "a", "renal", "transplant", "patient", "treated", "with", "Cyclosporine", "A", "while", "on", "chronic", "steroid", "therapy", "."], "event_mentions": [{"id": "3513544_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 8, "end": 9}, "arguments": [{"entity_id": "3513544_2_Ent1", "role": "Effect", "text": "herpes esophagitis", "start": 6, "end": 8}, {"entity_id": "3513544_2_Ent0", "role": "Subject", "text": "a renal transplant patient", "start": 9, "end": 13}, {"entity_id": "3513544_2_Ent5", "role": "Treatment_Disorder", "text": "renal transplant", "start": 10, "end": 12}, {"entity_id": "3513544_2_Ent3", "role": "Treatment_Drug", "text": "Cyclosporine A", "start": 15, "end": 17}, {"entity_id": "3513544_2_Ent6", "role": "Combination_Drug", "text": "Cyclosporine A", "start": 15, "end": 17}, {"entity_id": "3513544_2_Ent2", "role": "Treatment", "text": "Cyclosporine A while on chronic steroid therapy", "start": 15, "end": 22}, {"entity_id": "3513544_2_Ent4", "role": "Treatment_Drug", "text": "chronic steroid", "start": 19, "end": 21}, {"entity_id": "3513544_2_Ent7", "role": "Combination_Drug", "text": "chronic steroid", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "3513544_2_Ent1", "text": "herpes esophagitis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "3513544_2_Ent0", "text": "a renal transplant patient", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "3513544_2_Ent5", "text": "renal transplant", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "3513544_2_Ent3", "text": "Cyclosporine A", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "3513544_2_Ent6", "text": "Cyclosporine A", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "3513544_2_Ent2", "text": "Cyclosporine A while on chronic steroid therapy", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "3513544_2_Ent4", "text": "chronic steroid", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "3513544_2_Ent7", "text": "chronic steroid", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "3569037_4", "wnd_id": "3569037_4_1", "text": "We present a case report of a patient with typhoid fever who experienced a hypersensitivity reaction subsequent to the infusion of chloramphenicol sodium succinate .", "tokens": ["We", "present", "a", "case", "report", "of", "a", "patient", "with", "typhoid", "fever", "who", "experienced", "a", "hypersensitivity", "reaction", "subsequent", "to", "the", "infusion", "of", "chloramphenicol", "sodium", "succinate", "."], "event_mentions": [{"id": "3569037_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "subsequent to", "start": 16, "end": 18}, "arguments": [{"entity_id": "3569037_4_Ent0", "role": "Subject", "text": "a patient with typhoid fever", "start": 6, "end": 11}, {"entity_id": "3569037_4_Ent3", "role": "Treatment_Disorder", "text": "typhoid fever", "start": 9, "end": 11}, {"entity_id": "3569037_4_Ent1", "role": "Effect", "text": "hypersensitivity reaction", "start": 14, "end": 16}, {"entity_id": "3569037_4_Ent2", "role": "Treatment", "text": "the infusion of chloramphenicol sodium succinate", "start": 18, "end": 24}, {"entity_id": "3569037_4_Ent5", "role": "Treatment_Route", "text": "infusion", "start": 19, "end": 20}, {"entity_id": "3569037_4_Ent4", "role": "Treatment_Drug", "text": "chloramphenicol sodium succinate", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "3569037_4_Ent0", "text": "a patient with typhoid fever", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "3569037_4_Ent3", "text": "typhoid fever", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "3569037_4_Ent1", "text": "hypersensitivity reaction", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "3569037_4_Ent2", "text": "the infusion of chloramphenicol sodium succinate", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "3569037_4_Ent5", "text": "infusion", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "3569037_4_Ent4", "text": "chloramphenicol sodium succinate", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "3579660_3", "wnd_id": "3579660_3_1", "text": "We describe a patient with Wilson 's disease who presented with neurologic disease , was treated with D - penicillamine , and suffered sudden neurologic deterioration coincident with therapy .", "tokens": ["We", "describe", "a", "patient", "with", "Wilson", "'s", "disease", "who", "presented", "with", "neurologic", "disease", ",", "was", "treated", "with", "D", "-", "penicillamine", ",", "and", "suffered", "sudden", "neurologic", "deterioration", "coincident", "with", "therapy", "."], "event_mentions": [{"id": "3579660_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffered", "start": 22, "end": 23}, "arguments": [{"entity_id": "3579660_3_Ent0", "role": "Subject", "text": "a patient with Wilson 's disease who presented with neurologic disease", "start": 2, "end": 13}, {"entity_id": "3579660_3_Ent4", "role": "Treatment_Disorder", "text": "Wilson 's disease", "start": 5, "end": 8}, {"entity_id": "3579660_3_Ent1", "role": "Subject_Disorder", "text": "neurologic disease", "start": 11, "end": 13}, {"entity_id": "3579660_3_Ent3", "role": "Treatment", "text": "D - penicillamine", "start": 17, "end": 20}, {"entity_id": "3579660_3_Ent5", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 17, "end": 20}, {"entity_id": "3579660_3_Ent2", "role": "Effect", "text": "sudden neurologic deterioration", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "3579660_3_Ent0", "text": "a patient with Wilson 's disease who presented with neurologic disease", "entity_type": "Entity", "start": 2, "end": 13}, {"id": "3579660_3_Ent4", "text": "Wilson 's disease", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "3579660_3_Ent1", "text": "neurologic disease", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "3579660_3_Ent3", "text": "D - penicillamine", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "3579660_3_Ent5", "text": "D - penicillamine", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "3579660_3_Ent2", "text": "sudden neurologic deterioration", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "3620420_4", "wnd_id": "3620420_4_1", "text": "We report here such a case with bilateral Mooren 's ulcer that failed to respond to local therapy with topical corticosteroids , silver nitrate , and conjunctival resection , as well as systemic immunosuppression with corticosteroids , cyclophosphamide , and azathioprine .", "tokens": ["We", "report", "here", "such", "a", "case", "with", "bilateral", "Mooren", "'s", "ulcer", "that", "failed", "to", "respond", "to", "local", "therapy", "with", "topical", "corticosteroids", ",", "silver", "nitrate", ",", "and", "conjunctival", "resection", ",", "as", "well", "as", "systemic", "immunosuppression", "with", "corticosteroids", ",", "cyclophosphamide", ",", "and", "azathioprine", "."], "event_mentions": [{"id": "3620420_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "respond", "start": 14, "end": 15}, "arguments": [{"entity_id": "3620420_4_Ent0", "role": "Subject", "text": "a case with bilateral Mooren 's ulcer", "start": 4, "end": 11}, {"entity_id": "3620420_4_Ent7", "role": "Treatment_Disorder", "text": "bilateral Mooren 's ulcer", "start": 7, "end": 11}, {"entity_id": "3620420_4_Ent1", "role": "Treatment", "text": "local therapy with topical corticosteroids , silver nitrate , and conjunctival resection , as well as systemic immunosuppression with corticosteroids , cyclophosphamide , and azathioprine", "start": 16, "end": 41}, {"entity_id": "3620420_4_Ent8", "role": "Treatment_Route", "text": "topical", "start": 19, "end": 20}, {"entity_id": "3620420_4_Ent2", "role": "Treatment_Drug", "text": "corticosteroids", "start": 20, "end": 21}, {"entity_id": "3620420_4_Ent9", "role": "Combination_Drug", "text": "corticosteroids", "start": 20, "end": 21}, {"entity_id": "3620420_4_Ent3", "role": "Treatment_Drug", "text": "silver nitrate", "start": 22, "end": 24}, {"entity_id": "3620420_4_Ent10", "role": "Combination_Drug", "text": "silver nitrate", "start": 22, "end": 24}, {"entity_id": "3620420_4_Ent4", "role": "Treatment_Drug", "text": "corticosteroids", "start": 35, "end": 36}, {"entity_id": "3620420_4_Ent11", "role": "Combination_Drug", "text": "corticosteroids", "start": 35, "end": 36}, {"entity_id": "3620420_4_Ent5", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 37, "end": 38}, {"entity_id": "3620420_4_Ent12", "role": "Combination_Drug", "text": "cyclophosphamide", "start": 37, "end": 38}, {"entity_id": "3620420_4_Ent6", "role": "Treatment_Drug", "text": "azathioprine", "start": 40, "end": 41}, {"entity_id": "3620420_4_Ent13", "role": "Combination_Drug", "text": "azathioprine", "start": 40, "end": 41}]}], "entity_mentions": [{"id": "3620420_4_Ent0", "text": "a case with bilateral Mooren 's ulcer", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "3620420_4_Ent7", "text": "bilateral Mooren 's ulcer", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "3620420_4_Ent1", "text": "local therapy with topical corticosteroids , silver nitrate , and conjunctival resection , as well as systemic immunosuppression with corticosteroids , cyclophosphamide , and azathioprine", "entity_type": "Entity", "start": 16, "end": 41}, {"id": "3620420_4_Ent8", "text": "topical", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "3620420_4_Ent2", "text": "corticosteroids", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "3620420_4_Ent9", "text": "corticosteroids", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "3620420_4_Ent3", "text": "silver nitrate", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "3620420_4_Ent10", "text": "silver nitrate", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "3620420_4_Ent4", "text": "corticosteroids", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "3620420_4_Ent11", "text": "corticosteroids", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "3620420_4_Ent5", "text": "cyclophosphamide", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "3620420_4_Ent12", "text": "cyclophosphamide", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "3620420_4_Ent6", "text": "azathioprine", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "3620420_4_Ent13", "text": "azathioprine", "entity_type": "Entity", "start": 40, "end": 41}], "lang": "en"}
{"doc_id": "3677571_1", "wnd_id": "3677571_1_1", "text": "Phenytoin - induced hypersensitivity reactions .", "tokens": ["Phenytoin", "-", "induced", "hypersensitivity", "reactions", "."], "event_mentions": [{"id": "3677571_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "3677571_1_Ent1", "role": "Treatment", "text": "Phenytoin", "start": 0, "end": 1}, {"entity_id": "3677571_1_Ent2", "role": "Treatment_Drug", "text": "Phenytoin", "start": 0, "end": 1}, {"entity_id": "3677571_1_Ent0", "role": "Effect", "text": "hypersensitivity reactions .", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "3677571_1_Ent1", "text": "Phenytoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3677571_1_Ent2", "text": "Phenytoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3677571_1_Ent0", "text": "hypersensitivity reactions .", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "3677571_16", "wnd_id": "3677571_16_1", "text": "Phenytoin was discontinued after admission ; however , phenytoin 1 g i.v . was given for a tonic - clonic seizure two days after admission , after which swelling of the face and legs and pruritus developed .", "tokens": ["Phenytoin", "was", "discontinued", "after", "admission", ";", "however", ",", "phenytoin", "1", "g", "i.v", ".", "was", "given", "for", "a", "tonic", "-", "clonic", "seizure", "two", "days", "after", "admission", ",", "after", "which", "swelling", "of", "the", "face", "and", "legs", "and", "pruritus", "developed", "."], "event_mentions": [{"id": "3677571_16_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 36, "end": 37}, "arguments": [{"entity_id": "3677571_16_Ent3", "role": "Treatment_Drug", "text": "phenytoin", "start": 8, "end": 9}, {"entity_id": "3677571_16_Ent1", "role": "Treatment", "text": "phenytoin 1 g i.v .", "start": 8, "end": 13}, {"entity_id": "3677571_16_Ent4", "role": "Treatment_Dosage", "text": "1 g", "start": 9, "end": 11}, {"entity_id": "3677571_16_Ent5", "role": "Treatment_Route", "text": "i.v .", "start": 11, "end": 13}, {"entity_id": "3677571_16_Ent2", "role": "Treatment_Disorder", "text": "a tonic - clonic seizure", "start": 16, "end": 21}, {"entity_id": "3677571_16_Ent0", "role": "Effect", "text": "swelling of the face and legs and pruritus", "start": 28, "end": 36}]}], "entity_mentions": [{"id": "3677571_16_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3677571_16_Ent1", "text": "phenytoin 1 g i.v .", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "3677571_16_Ent4", "text": "1 g", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "3677571_16_Ent5", "text": "i.v .", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "3677571_16_Ent2", "text": "a tonic - clonic seizure", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "3677571_16_Ent0", "text": "swelling of the face and legs and pruritus", "entity_type": "Entity", "start": 28, "end": 36}], "lang": "en"}
{"doc_id": "3677571_4", "wnd_id": "3677571_4_1", "text": "She was receiving phenytoin sodium 300 mg / day ; carbamazepine 200 mg four times daily had been discontinued four days before admission because of leukopenia .", "tokens": ["She", "was", "receiving", "phenytoin", "sodium", "300", "mg", "/", "day", ";", "carbamazepine", "200", "mg", "four", "times", "daily", "had", "been", "discontinued", "four", "days", "before", "admission", "because", "of", "leukopenia", "."], "event_mentions": [{"id": "3677571_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "because", "start": 23, "end": 24}, "arguments": [{"entity_id": "3677571_4_Ent2", "role": "Treatment_Drug", "text": "carbamazepine", "start": 10, "end": 11}, {"entity_id": "3677571_4_Ent1", "role": "Treatment", "text": "carbamazepine 200 mg four times daily", "start": 10, "end": 16}, {"entity_id": "3677571_4_Ent3", "role": "Treatment_Dosage", "text": "200 mg", "start": 11, "end": 13}, {"entity_id": "3677571_4_Ent4", "role": "Treatment_Freq", "text": "four times daily", "start": 13, "end": 16}, {"entity_id": "3677571_4_Ent0", "role": "Effect", "text": "leukopenia", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "3677571_4_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3677571_4_Ent1", "text": "carbamazepine 200 mg four times daily", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "3677571_4_Ent3", "text": "200 mg", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "3677571_4_Ent4", "text": "four times daily", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "3677571_4_Ent0", "text": "leukopenia", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "3677571_8", "wnd_id": "3677571_8_1", "text": "Seizures were treated with diazepam .", "tokens": ["Seizures", "were", "treated", "with", "diazepam", "."], "event_mentions": [{"id": "3677571_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 2, "end": 3}, "arguments": [{"entity_id": "3677571_8_Ent1", "role": "Treatment_Disorder", "text": "Seizures", "start": 0, "end": 1}, {"entity_id": "3677571_8_Ent0", "role": "Treatment", "text": "diazepam", "start": 4, "end": 5}, {"entity_id": "3677571_8_Ent2", "role": "Treatment_Drug", "text": "diazepam", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "3677571_8_Ent1", "text": "Seizures", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3677571_8_Ent0", "text": "diazepam", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3677571_8_Ent2", "text": "diazepam", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "3680913_2", "wnd_id": "3680913_2_1", "text": "Nicotinic acid - induced fulminant hepatic failure .", "tokens": ["Nicotinic", "acid", "-", "induced", "fulminant", "hepatic", "failure", "."], "event_mentions": [{"id": "3680913_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "3680913_2_Ent1", "role": "Treatment", "text": "Nicotinic acid", "start": 0, "end": 2}, {"entity_id": "3680913_2_Ent2", "role": "Treatment_Drug", "text": "Nicotinic acid", "start": 0, "end": 2}, {"entity_id": "3680913_2_Ent0", "role": "Effect", "text": "fulminant hepatic failure", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "3680913_2_Ent1", "text": "Nicotinic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3680913_2_Ent2", "text": "Nicotinic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3680913_2_Ent0", "text": "fulminant hepatic failure", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "3744305_1", "wnd_id": "3744305_1_1", "text": "Idiosyncratic pulmonary reactions to nitrofurantoin are not unusual , often presenting as eosinophilic pneumonia .", "tokens": ["Idiosyncratic", "pulmonary", "reactions", "to", "nitrofurantoin", "are", "not", "unusual", ",", "often", "presenting", "as", "eosinophilic", "pneumonia", "."], "event_mentions": [{"id": "3744305_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 3, "end": 4}, "arguments": [{"entity_id": "3744305_1_Ent0", "role": "Effect", "text": "Idiosyncratic pulmonary reactions", "start": 0, "end": 3}, {"entity_id": "3744305_1_Ent2", "role": "Treatment", "text": "nitrofurantoin", "start": 4, "end": 5}, {"entity_id": "3744305_1_Ent3", "role": "Treatment_Drug", "text": "nitrofurantoin", "start": 4, "end": 5}, {"entity_id": "3744305_1_Ent1", "role": "Effect", "text": "eosinophilic pneumonia", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "3744305_1_Ent0", "text": "Idiosyncratic pulmonary reactions", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3744305_1_Ent2", "text": "nitrofurantoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3744305_1_Ent3", "text": "nitrofurantoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3744305_1_Ent1", "text": "eosinophilic pneumonia", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "3763264_1", "wnd_id": "3763264_1_1", "text": "Graft versus host - like illness in a child with phenobarbital hypersensitivity .", "tokens": ["Graft", "versus", "host", "-", "like", "illness", "in", "a", "child", "with", "phenobarbital", "hypersensitivity", "."], "event_mentions": [{"id": "3763264_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "hypersensitivity", "start": 11, "end": 12}, "arguments": [{"entity_id": "3763264_1_Ent2", "role": "Effect", "text": "Graft versus host - like illness", "start": 0, "end": 6}, {"entity_id": "3763264_1_Ent0", "role": "Subject", "text": "a child", "start": 7, "end": 9}, {"entity_id": "3763264_1_Ent1", "role": "Subject_Age", "text": "child", "start": 8, "end": 9}, {"entity_id": "3763264_1_Ent4", "role": "Treatment", "text": "phenobarbital", "start": 10, "end": 11}, {"entity_id": "3763264_1_Ent5", "role": "Treatment_Drug", "text": "phenobarbital", "start": 10, "end": 11}, {"entity_id": "3763264_1_Ent3", "role": "Effect", "text": "hypersensitivity", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "3763264_1_Ent2", "text": "Graft versus host - like illness", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "3763264_1_Ent0", "text": "a child", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "3763264_1_Ent1", "text": "child", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3763264_1_Ent4", "text": "phenobarbital", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3763264_1_Ent5", "text": "phenobarbital", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3763264_1_Ent3", "text": "hypersensitivity", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "3773837_1", "wnd_id": "3773837_1_1", "text": "The latter form ( Macrodantin ) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form -- liver damage , acute and chronic pulmonary reactions , peripheral neuropathy , blood dyscrasias and allergic reactions -- and does so just as rapidly and floridly ; one such case is reported here .", "tokens": ["The", "latter", "form", "(", "Macrodantin", ")", "is", "reported", "to", "engender", "less", "gastrointestinal", "intolerance", "but", "it", "can", "produce", "the", "same", "adverse", "effects", "as", "the", "conventional", "form", "--", "liver", "damage", ",", "acute", "and", "chronic", "pulmonary", "reactions", ",", "peripheral", "neuropathy", ",", "blood", "dyscrasias", "and", "allergic", "reactions", "--", "and", "does", "so", "just", "as", "rapidly", "and", "floridly", ";", "one", "such", "case", "is", "reported", "here", "."], "event_mentions": [{"id": "3773837_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse effects", "start": 19, "end": 21}, "arguments": [{"entity_id": "3773837_1_Ent4", "role": "Treatment", "text": "Macrodantin", "start": 4, "end": 5}, {"entity_id": "3773837_1_Ent5", "role": "Treatment_Drug", "text": "Macrodantin", "start": 4, "end": 5}, {"entity_id": "3773837_1_Ent2", "role": "Effect", "text": "less gastrointestinal intolerance", "start": 10, "end": 13}, {"entity_id": "3773837_1_Ent3", "role": "Effect", "text": "liver damage , acute and chronic pulmonary reactions , peripheral neuropathy , blood dyscrasias and allergic reactions", "start": 26, "end": 43}, {"entity_id": "3773837_1_Ent1", "role": "Subject_Population", "text": "one", "start": 53, "end": 54}, {"entity_id": "3773837_1_Ent0", "role": "Subject", "text": "one such case", "start": 53, "end": 56}]}], "entity_mentions": [{"id": "3773837_1_Ent4", "text": "Macrodantin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3773837_1_Ent5", "text": "Macrodantin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3773837_1_Ent2", "text": "less gastrointestinal intolerance", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "3773837_1_Ent3", "text": "liver damage , acute and chronic pulmonary reactions , peripheral neuropathy , blood dyscrasias and allergic reactions", "entity_type": "Entity", "start": 26, "end": 43}, {"id": "3773837_1_Ent1", "text": "one", "entity_type": "Entity", "start": 53, "end": 54}, {"id": "3773837_1_Ent0", "text": "one such case", "entity_type": "Entity", "start": 53, "end": 56}], "lang": "en"}
{"doc_id": "3824704_1", "wnd_id": "3824704_1_1", "text": "Fatal outcome of intravesical formalin instillation , with changes mimicking renal tuberculosis .", "tokens": ["Fatal", "outcome", "of", "intravesical", "formalin", "instillation", ",", "with", "changes", "mimicking", "renal", "tuberculosis", "."], "event_mentions": [{"id": "3824704_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 2, "end": 3}, "arguments": [{"entity_id": "3824704_1_Ent1", "role": "Effect", "text": "Fatal outcome", "start": 0, "end": 2}, {"entity_id": "3824704_1_Ent4", "role": "Treatment_Route", "text": "intravesical", "start": 3, "end": 4}, {"entity_id": "3824704_1_Ent2", "role": "Treatment", "text": "intravesical formalin instillation", "start": 3, "end": 6}, {"entity_id": "3824704_1_Ent3", "role": "Treatment_Drug", "text": "formalin", "start": 4, "end": 5}, {"entity_id": "3824704_1_Ent5", "role": "Treatment_Route", "text": "instillation", "start": 5, "end": 6}, {"entity_id": "3824704_1_Ent0", "role": "Effect", "text": "with changes mimicking renal tuberculosis", "start": 7, "end": 12}]}], "entity_mentions": [{"id": "3824704_1_Ent1", "text": "Fatal outcome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3824704_1_Ent4", "text": "intravesical", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3824704_1_Ent2", "text": "intravesical formalin instillation", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "3824704_1_Ent3", "text": "formalin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3824704_1_Ent5", "text": "instillation", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3824704_1_Ent0", "text": "with changes mimicking renal tuberculosis", "entity_type": "Entity", "start": 7, "end": 12}], "lang": "en"}
{"doc_id": "3878320_2", "wnd_id": "3878320_2_1", "text": "The condition should be suspected in patients who develop unexplained abdominal pain or collapse following vasopressin treatment .", "tokens": ["The", "condition", "should", "be", "suspected", "in", "patients", "who", "develop", "unexplained", "abdominal", "pain", "or", "collapse", "following", "vasopressin", "treatment", "."], "event_mentions": [{"id": "3878320_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 8, "end": 9}, "arguments": [{"entity_id": "3878320_2_Ent0", "role": "Subject", "text": "patients", "start": 6, "end": 7}, {"entity_id": "3878320_2_Ent1", "role": "Effect", "text": "unexplained abdominal pain or collapse", "start": 9, "end": 14}, {"entity_id": "3878320_2_Ent2", "role": "Treatment", "text": "vasopressin", "start": 15, "end": 16}, {"entity_id": "3878320_2_Ent3", "role": "Treatment_Drug", "text": "vasopressin", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "3878320_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3878320_2_Ent1", "text": "unexplained abdominal pain or collapse", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "3878320_2_Ent2", "text": "vasopressin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "3878320_2_Ent3", "text": "vasopressin", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "3926849_1", "wnd_id": "3926849_1_1", "text": "Administration of intravenous nitroglycerin in a patient with idiopathic pulmonary hypertension resulted in an increase in pulmonary artery pressure associated with a decrease in blood flow that is best explained by an increase in pulmonary vascular resistance .", "tokens": ["Administration", "of", "intravenous", "nitroglycerin", "in", "a", "patient", "with", "idiopathic", "pulmonary", "hypertension", "resulted", "in", "an", "increase", "in", "pulmonary", "artery", "pressure", "associated", "with", "a", "decrease", "in", "blood", "flow", "that", "is", "best", "explained", "by", "an", "increase", "in", "pulmonary", "vascular", "resistance", "."], "event_mentions": [{"id": "3926849_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Administration", "start": 0, "end": 1}, "arguments": [{"entity_id": "3926849_1_Ent4", "role": "Treatment_Route", "text": "intravenous", "start": 2, "end": 3}, {"entity_id": "3926849_1_Ent2", "role": "Treatment", "text": "intravenous nitroglycerin", "start": 2, "end": 4}, {"entity_id": "3926849_1_Ent5", "role": "Treatment_Drug", "text": "nitroglycerin", "start": 3, "end": 4}, {"entity_id": "3926849_1_Ent0", "role": "Subject", "text": "a patient with idiopathic pulmonary hypertension", "start": 5, "end": 11}, {"entity_id": "3926849_1_Ent3", "role": "Treatment_Disorder", "text": "idiopathic pulmonary hypertension", "start": 8, "end": 11}, {"entity_id": "3926849_1_Ent1", "role": "Effect", "text": "increase in pulmonary artery pressure associated with a decrease in blood flow that is best explained by an increase in pulmonary vascular resistance", "start": 14, "end": 37}]}], "entity_mentions": [{"id": "3926849_1_Ent4", "text": "intravenous", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "3926849_1_Ent2", "text": "intravenous nitroglycerin", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "3926849_1_Ent5", "text": "nitroglycerin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3926849_1_Ent0", "text": "a patient with idiopathic pulmonary hypertension", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "3926849_1_Ent3", "text": "idiopathic pulmonary hypertension", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "3926849_1_Ent1", "text": "increase in pulmonary artery pressure associated with a decrease in blood flow that is best explained by an increase in pulmonary vascular resistance", "entity_type": "Entity", "start": 14, "end": 37}], "lang": "en"}
{"doc_id": "3941210_2", "wnd_id": "3941210_2_1", "text": "Such a case induced by hypothyroidism complicating long - term therapy with amiodarone in a 45 year old woman with pre - excitation is presented .", "tokens": ["Such", "a", "case", "induced", "by", "hypothyroidism", "complicating", "long", "-", "term", "therapy", "with", "amiodarone", "in", "a", "45", "year", "old", "woman", "with", "pre", "-", "excitation", "is", "presented", "."], "event_mentions": [{"id": "3941210_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complicating", "start": 6, "end": 7}, "arguments": [{"entity_id": "3941210_2_Ent3", "role": "Effect", "text": "hypothyroidism", "start": 5, "end": 6}, {"entity_id": "3941210_2_Ent6", "role": "Treatment_Duration", "text": "long - term", "start": 7, "end": 10}, {"entity_id": "3941210_2_Ent4", "role": "Treatment", "text": "long - term therapy with amiodarone", "start": 7, "end": 13}, {"entity_id": "3941210_2_Ent5", "role": "Treatment_Drug", "text": "amiodarone", "start": 12, "end": 13}, {"entity_id": "3941210_2_Ent0", "role": "Subject", "text": "a 45 year old woman with pre - excitation", "start": 14, "end": 23}, {"entity_id": "3941210_2_Ent1", "role": "Subject_Age", "text": "45 year old", "start": 15, "end": 18}, {"entity_id": "3941210_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 18, "end": 19}, {"entity_id": "3941210_2_Ent7", "role": "Treatment_Disorder", "text": "pre - excitation", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "3941210_2_Ent3", "text": "hypothyroidism", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3941210_2_Ent6", "text": "long - term", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "3941210_2_Ent4", "text": "long - term therapy with amiodarone", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "3941210_2_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "3941210_2_Ent0", "text": "a 45 year old woman with pre - excitation", "entity_type": "Entity", "start": 14, "end": 23}, {"id": "3941210_2_Ent1", "text": "45 year old", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "3941210_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "3941210_2_Ent7", "text": "pre - excitation", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "3947272_3", "wnd_id": "3947272_3_1", "text": "Myasthenic patients receiving ampicillin should be closely monitored for possible acute exacerbations .", "tokens": ["Myasthenic", "patients", "receiving", "ampicillin", "should", "be", "closely", "monitored", "for", "possible", "acute", "exacerbations", "."], "event_mentions": [{"id": "3947272_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 2, "end": 3}, "arguments": [{"entity_id": "3947272_3_Ent3", "role": "Treatment_Disorder", "text": "Myasthenic", "start": 0, "end": 1}, {"entity_id": "3947272_3_Ent0", "role": "Subject", "text": "Myasthenic patients", "start": 0, "end": 2}, {"entity_id": "3947272_3_Ent2", "role": "Treatment", "text": "ampicillin", "start": 3, "end": 4}, {"entity_id": "3947272_3_Ent4", "role": "Treatment_Drug", "text": "ampicillin", "start": 3, "end": 4}, {"entity_id": "3947272_3_Ent1", "role": "Effect", "text": "acute exacerbations", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "3947272_3_Ent3", "text": "Myasthenic", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3947272_3_Ent0", "text": "Myasthenic patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3947272_3_Ent2", "text": "ampicillin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3947272_3_Ent4", "text": "ampicillin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3947272_3_Ent1", "text": "acute exacerbations", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "3964363_1", "wnd_id": "3964363_1_1", "text": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented .", "tokens": ["A", "case", "of", "propranolol", "overdose", "complicated", "by", "esophageal", "spasm", "preventing", "extrication", "of", "an", "orogastric", "lavage", "tube", "and", "relieved", "by", "intravenous", "glucagon", "is", "presented", "."], "event_mentions": [{"id": "3964363_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complicated", "start": 5, "end": 6}, "arguments": [{"entity_id": "3964363_1_Ent2", "role": "Treatment_Drug", "text": "propranolol", "start": 3, "end": 4}, {"entity_id": "3964363_1_Ent1", "role": "Treatment", "text": "propranolol overdose", "start": 3, "end": 5}, {"entity_id": "3964363_1_Ent3", "role": "Treatment_Dosage", "text": "overdose", "start": 4, "end": 5}, {"entity_id": "3964363_1_Ent0", "role": "Effect", "text": "esophageal spasm preventing extrication of an orogastric lavage tube", "start": 7, "end": 16}]}, {"id": "3964363_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "relieved", "start": 17, "end": 18}, "arguments": [{"entity_id": "3964363_1_Ent5", "role": "Treatment_Disorder", "text": "esophageal spasm preventing extrication of an orogastric lavage tube", "start": 7, "end": 16}, {"entity_id": "3964363_1_Ent6", "role": "Treatment_Route", "text": "intravenous", "start": 19, "end": 20}, {"entity_id": "3964363_1_Ent4", "role": "Treatment", "text": "intravenous glucagon", "start": 19, "end": 21}, {"entity_id": "3964363_1_Ent7", "role": "Treatment_Drug", "text": "glucagon", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "3964363_1_Ent2", "text": "propranolol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3964363_1_Ent1", "text": "propranolol overdose", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3964363_1_Ent3", "text": "overdose", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3964363_1_Ent0", "text": "esophageal spasm preventing extrication of an orogastric lavage tube", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "3964363_1_Ent5", "text": "esophageal spasm preventing extrication of an orogastric lavage tube", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "3964363_1_Ent6", "text": "intravenous", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "3964363_1_Ent4", "text": "intravenous glucagon", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "3964363_1_Ent7", "text": "glucagon", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "3970339_1", "wnd_id": "3970339_1_1", "text": "A patient presented with a painful , oedematous , cyanosed hand having injected a solution of diamorphine and methylphenidate into his radial artery .", "tokens": ["A", "patient", "presented", "with", "a", "painful", ",", "oedematous", ",", "cyanosed", "hand", "having", "injected", "a", "solution", "of", "diamorphine", "and", "methylphenidate", "into", "his", "radial", "artery", "."], "event_mentions": [{"id": "3970339_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 2, "end": 3}, "arguments": [{"entity_id": "3970339_1_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "3970339_1_Ent1", "role": "Effect", "text": "painful , oedematous , cyanosed hand", "start": 5, "end": 11}, {"entity_id": "3970339_1_Ent3", "role": "Treatment_Route", "text": "injected", "start": 12, "end": 13}, {"entity_id": "3970339_1_Ent2", "role": "Treatment", "text": "injected a solution of diamorphine and methylphenidate into his radial artery", "start": 12, "end": 23}, {"entity_id": "3970339_1_Ent5", "role": "Treatment_Drug", "text": "diamorphine", "start": 16, "end": 17}, {"entity_id": "3970339_1_Ent7", "role": "Combination_Drug", "text": "diamorphine", "start": 16, "end": 17}, {"entity_id": "3970339_1_Ent6", "role": "Treatment_Drug", "text": "methylphenidate", "start": 18, "end": 19}, {"entity_id": "3970339_1_Ent8", "role": "Combination_Drug", "text": "methylphenidate", "start": 18, "end": 19}, {"entity_id": "3970339_1_Ent4", "role": "Treatment_Route", "text": "into his radial artery", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "3970339_1_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3970339_1_Ent1", "text": "painful , oedematous , cyanosed hand", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "3970339_1_Ent3", "text": "injected", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "3970339_1_Ent2", "text": "injected a solution of diamorphine and methylphenidate into his radial artery", "entity_type": "Entity", "start": 12, "end": 23}, {"id": "3970339_1_Ent5", "text": "diamorphine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "3970339_1_Ent7", "text": "diamorphine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "3970339_1_Ent6", "text": "methylphenidate", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "3970339_1_Ent8", "text": "methylphenidate", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "3970339_1_Ent4", "text": "into his radial artery", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "3970339_2", "wnd_id": "3970339_2_1", "text": "Ischaemia following selfadministered intra - arterial injection of methylphenidate and diamorphine .", "tokens": ["Ischaemia", "following", "selfadministered", "intra", "-", "arterial", "injection", "of", "methylphenidate", "and", "diamorphine", "."], "event_mentions": [{"id": "3970339_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 1, "end": 2}, "arguments": [{"entity_id": "3970339_2_Ent0", "role": "Effect", "text": "Ischaemia", "start": 0, "end": 1}, {"entity_id": "3970339_2_Ent1", "role": "Treatment", "text": "selfadministered intra - arterial injection of methylphenidate and diamorphine", "start": 2, "end": 11}, {"entity_id": "3970339_2_Ent4", "role": "Treatment_Route", "text": "intra - arterial injection", "start": 3, "end": 7}, {"entity_id": "3970339_2_Ent2", "role": "Treatment_Drug", "text": "methylphenidate", "start": 8, "end": 9}, {"entity_id": "3970339_2_Ent5", "role": "Combination_Drug", "text": "methylphenidate", "start": 8, "end": 9}, {"entity_id": "3970339_2_Ent3", "role": "Treatment_Drug", "text": "diamorphine", "start": 10, "end": 11}, {"entity_id": "3970339_2_Ent6", "role": "Combination_Drug", "text": "diamorphine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "3970339_2_Ent0", "text": "Ischaemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3970339_2_Ent1", "text": "selfadministered intra - arterial injection of methylphenidate and diamorphine", "entity_type": "Entity", "start": 2, "end": 11}, {"id": "3970339_2_Ent4", "text": "intra - arterial injection", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "3970339_2_Ent2", "text": "methylphenidate", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3970339_2_Ent5", "text": "methylphenidate", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3970339_2_Ent3", "text": "diamorphine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3970339_2_Ent6", "text": "diamorphine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "4004433_2", "wnd_id": "4004433_2_1", "text": "Our findings suggest that hyperkalemia can develop with the use of low - dose heparin , within seven days of initiating heparin therapy , and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication .", "tokens": ["Our", "findings", "suggest", "that", "hyperkalemia", "can", "develop", "with", "the", "use", "of", "low", "-", "dose", "heparin", ",", "within", "seven", "days", "of", "initiating", "heparin", "therapy", ",", "and", "that", "patients", "with", "diabetes", "mellitus", "or", "chronic", "renal", "insufficiency", "are", "especially", "predisposed", "to", "this", "complication", "."], "event_mentions": [{"id": "4004433_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 6, "end": 7}, "arguments": [{"entity_id": "4004433_2_Ent3", "role": "Effect", "text": "hyperkalemia", "start": 4, "end": 5}, {"entity_id": "4004433_2_Ent5", "role": "Treatment_Dosage", "text": "low - dose", "start": 11, "end": 14}, {"entity_id": "4004433_2_Ent4", "role": "Treatment", "text": "low - dose heparin , within seven days of initiating heparin therapy", "start": 11, "end": 23}, {"entity_id": "4004433_2_Ent6", "role": "Treatment_Drug", "text": "heparin", "start": 14, "end": 15}, {"entity_id": "4004433_2_Ent7", "role": "Treatment_Time_elapsed", "text": "within seven days", "start": 16, "end": 19}, {"entity_id": "4004433_2_Ent0", "role": "Subject", "text": "patients with diabetes mellitus or chronic renal insufficiency", "start": 26, "end": 34}, {"entity_id": "4004433_2_Ent1", "role": "Subject_Disorder", "text": "diabetes mellitus", "start": 28, "end": 30}, {"entity_id": "4004433_2_Ent2", "role": "Subject_Disorder", "text": "chronic renal insufficiency", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "4004433_2_Ent3", "text": "hyperkalemia", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "4004433_2_Ent5", "text": "low - dose", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "4004433_2_Ent4", "text": "low - dose heparin , within seven days of initiating heparin therapy", "entity_type": "Entity", "start": 11, "end": 23}, {"id": "4004433_2_Ent6", "text": "heparin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "4004433_2_Ent7", "text": "within seven days", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "4004433_2_Ent0", "text": "patients with diabetes mellitus or chronic renal insufficiency", "entity_type": "Entity", "start": 26, "end": 34}, {"id": "4004433_2_Ent1", "text": "diabetes mellitus", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "4004433_2_Ent2", "text": "chronic renal insufficiency", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "4004433_3", "wnd_id": "4004433_3_1", "text": "We present four cases in which the use of heparin was associated with hyperkalemia and discuss the pathophysiology .", "tokens": ["We", "present", "four", "cases", "in", "which", "the", "use", "of", "heparin", "was", "associated", "with", "hyperkalemia", "and", "discuss", "the", "pathophysiology", "."], "event_mentions": [{"id": "4004433_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 11, "end": 12}, "arguments": [{"entity_id": "4004433_3_Ent1", "role": "Subject_Population", "text": "four", "start": 2, "end": 3}, {"entity_id": "4004433_3_Ent0", "role": "Subject", "text": "four cases", "start": 2, "end": 4}, {"entity_id": "4004433_3_Ent3", "role": "Treatment", "text": "heparin", "start": 9, "end": 10}, {"entity_id": "4004433_3_Ent4", "role": "Treatment_Drug", "text": "heparin", "start": 9, "end": 10}, {"entity_id": "4004433_3_Ent2", "role": "Effect", "text": "hyperkalemia", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "4004433_3_Ent1", "text": "four", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "4004433_3_Ent0", "text": "four cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "4004433_3_Ent3", "text": "heparin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "4004433_3_Ent4", "text": "heparin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "4004433_3_Ent2", "text": "hyperkalemia", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "4014301_4", "wnd_id": "4014301_4_1", "text": "This report describes the first case of insulin - induced cardiac failure in a patient without underlying heart disease .", "tokens": ["This", "report", "describes", "the", "first", "case", "of", "insulin", "-", "induced", "cardiac", "failure", "in", "a", "patient", "without", "underlying", "heart", "disease", "."], "event_mentions": [{"id": "4014301_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "4014301_4_Ent2", "role": "Treatment", "text": "insulin", "start": 7, "end": 8}, {"entity_id": "4014301_4_Ent3", "role": "Treatment_Drug", "text": "insulin", "start": 7, "end": 8}, {"entity_id": "4014301_4_Ent1", "role": "Effect", "text": "cardiac failure", "start": 10, "end": 12}, {"entity_id": "4014301_4_Ent0", "role": "Subject", "text": "a patient without underlying heart disease", "start": 13, "end": 19}]}], "entity_mentions": [{"id": "4014301_4_Ent2", "text": "insulin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "4014301_4_Ent3", "text": "insulin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "4014301_4_Ent1", "text": "cardiac failure", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "4014301_4_Ent0", "text": "a patient without underlying heart disease", "entity_type": "Entity", "start": 13, "end": 19}], "lang": "en"}
{"doc_id": "4025011_2", "wnd_id": "4025011_2_1", "text": "Two patients with osteomyelitis who developed reversible cholestatic jaundice during treatment with oxacillin derivatives are described .", "tokens": ["Two", "patients", "with", "osteomyelitis", "who", "developed", "reversible", "cholestatic", "jaundice", "during", "treatment", "with", "oxacillin", "derivatives", "are", "described", "."], "event_mentions": [{"id": "4025011_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "4025011_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "4025011_2_Ent0", "role": "Subject", "text": "Two patients with osteomyelitis", "start": 0, "end": 4}, {"entity_id": "4025011_2_Ent4", "role": "Treatment_Disorder", "text": "osteomyelitis", "start": 3, "end": 4}, {"entity_id": "4025011_2_Ent2", "role": "Effect", "text": "reversible cholestatic jaundice", "start": 6, "end": 9}, {"entity_id": "4025011_2_Ent3", "role": "Treatment", "text": "oxacillin", "start": 12, "end": 13}, {"entity_id": "4025011_2_Ent5", "role": "Treatment_Drug", "text": "oxacillin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "4025011_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4025011_2_Ent0", "text": "Two patients with osteomyelitis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "4025011_2_Ent4", "text": "osteomyelitis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "4025011_2_Ent2", "text": "reversible cholestatic jaundice", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "4025011_2_Ent3", "text": "oxacillin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "4025011_2_Ent5", "text": "oxacillin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "4038927_1", "wnd_id": "4038927_1_1", "text": "Atrial fibrillation was induced by diltiazem in two patients and verapamil induced syncope in one patient .", "tokens": ["Atrial", "fibrillation", "was", "induced", "by", "diltiazem", "in", "two", "patients", "and", "verapamil", "induced", "syncope", "in", "one", "patient", "."], "event_mentions": [{"id": "4038927_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "4038927_1_Ent2", "role": "Effect", "text": "Atrial fibrillation", "start": 0, "end": 2}, {"entity_id": "4038927_1_Ent3", "role": "Treatment", "text": "diltiazem", "start": 5, "end": 6}, {"entity_id": "4038927_1_Ent4", "role": "Treatment_Drug", "text": "diltiazem", "start": 5, "end": 6}, {"entity_id": "4038927_1_Ent1", "role": "Subject_Population", "text": "two", "start": 7, "end": 8}, {"entity_id": "4038927_1_Ent0", "role": "Subject", "text": "two patients", "start": 7, "end": 9}]}, {"id": "4038927_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "4038927_1_Ent8", "role": "Treatment", "text": "verapamil", "start": 10, "end": 11}, {"entity_id": "4038927_1_Ent9", "role": "Treatment_Drug", "text": "verapamil", "start": 10, "end": 11}, {"entity_id": "4038927_1_Ent7", "role": "Effect", "text": "syncope", "start": 12, "end": 13}, {"entity_id": "4038927_1_Ent6", "role": "Subject_Population", "text": "one", "start": 14, "end": 15}, {"entity_id": "4038927_1_Ent5", "role": "Subject", "text": "one patient", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "4038927_1_Ent2", "text": "Atrial fibrillation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "4038927_1_Ent3", "text": "diltiazem", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "4038927_1_Ent4", "text": "diltiazem", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "4038927_1_Ent1", "text": "two", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "4038927_1_Ent0", "text": "two patients", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "4038927_1_Ent8", "text": "verapamil", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "4038927_1_Ent9", "text": "verapamil", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "4038927_1_Ent7", "text": "syncope", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "4038927_1_Ent6", "text": "one", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "4038927_1_Ent5", "text": "one patient", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "4044222_1", "wnd_id": "4044222_1_1", "text": "A 54 - year - old man , treated with amiodarone , developed thyrotoxicosis .", "tokens": ["A", "54", "-", "year", "-", "old", "man", ",", "treated", "with", "amiodarone", ",", "developed", "thyrotoxicosis", "."], "event_mentions": [{"id": "4044222_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "4044222_1_Ent0", "role": "Subject", "text": "A 54 - year - old man", "start": 0, "end": 7}, {"entity_id": "4044222_1_Ent1", "role": "Subject_Age", "text": "54 - year - old", "start": 1, "end": 6}, {"entity_id": "4044222_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "4044222_1_Ent4", "role": "Treatment", "text": "amiodarone", "start": 10, "end": 11}, {"entity_id": "4044222_1_Ent5", "role": "Treatment_Drug", "text": "amiodarone", "start": 10, "end": 11}, {"entity_id": "4044222_1_Ent3", "role": "Effect", "text": "thyrotoxicosis", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "4044222_1_Ent0", "text": "A 54 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "4044222_1_Ent1", "text": "54 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "4044222_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "4044222_1_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "4044222_1_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "4044222_1_Ent3", "text": "thyrotoxicosis", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "4044222_2", "wnd_id": "4044222_2_1", "text": "Amiodarone - induced dysthyroidism .", "tokens": ["Amiodarone", "-", "induced", "dysthyroidism", "."], "event_mentions": [{"id": "4044222_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "4044222_2_Ent1", "role": "Treatment", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "4044222_2_Ent2", "role": "Treatment_Drug", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "4044222_2_Ent0", "role": "Effect", "text": "dysthyroidism", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "4044222_2_Ent1", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4044222_2_Ent2", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4044222_2_Ent0", "text": "dysthyroidism", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "4054170_2", "wnd_id": "4054170_2_1", "text": "Chlorambucil central nervous toxicity : a significant side effect of chlorambucil therapy in childhood nephrotic syndrome .", "tokens": ["Chlorambucil", "central", "nervous", "toxicity", ":", "a", "significant", "side", "effect", "of", "chlorambucil", "therapy", "in", "childhood", "nephrotic", "syndrome", "."], "event_mentions": [{"id": "4054170_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effect", "start": 7, "end": 9}, "arguments": [{"entity_id": "4054170_2_Ent1", "role": "Treatment", "text": "Chlorambucil", "start": 0, "end": 1}, {"entity_id": "4054170_2_Ent2", "role": "Treatment_Drug", "text": "Chlorambucil", "start": 0, "end": 1}, {"entity_id": "4054170_2_Ent0", "role": "Effect", "text": "central nervous toxicity", "start": 1, "end": 4}, {"entity_id": "4054170_2_Ent3", "role": "Treatment_Disorder", "text": "childhood nephrotic syndrome", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "4054170_2_Ent1", "text": "Chlorambucil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4054170_2_Ent2", "text": "Chlorambucil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4054170_2_Ent0", "text": "central nervous toxicity", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "4054170_2_Ent3", "text": "childhood nephrotic syndrome", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "4063627_2", "wnd_id": "4063627_2_1", "text": "Fenclofenac - induced selective IgA deficiency in rheumatoid arthritis .", "tokens": ["Fenclofenac", "-", "induced", "selective", "IgA", "deficiency", "in", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "4063627_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "4063627_2_Ent1", "role": "Treatment", "text": "Fenclofenac", "start": 0, "end": 1}, {"entity_id": "4063627_2_Ent2", "role": "Treatment_Drug", "text": "Fenclofenac", "start": 0, "end": 1}, {"entity_id": "4063627_2_Ent0", "role": "Effect", "text": "selective IgA deficiency in rheumatoid arthritis", "start": 3, "end": 9}]}], "entity_mentions": [{"id": "4063627_2_Ent1", "text": "Fenclofenac", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4063627_2_Ent2", "text": "Fenclofenac", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4063627_2_Ent0", "text": "selective IgA deficiency in rheumatoid arthritis", "entity_type": "Entity", "start": 3, "end": 9}], "lang": "en"}
{"doc_id": "4063627_3", "wnd_id": "4063627_3_1", "text": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine .", "tokens": ["This", "case", "demonstrates", "the", "association", "of", "selective", "IgA", "deficiency", "with", "remission", "in", "rheumatoid", "arthritis", "induced", "by", "fenclofenac", "as", "well", "as", "aurothiomalate", "and", "sulphasalazine", "."], "event_mentions": [{"id": "4063627_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "4063627_3_Ent0", "role": "Subject", "text": "This case", "start": 0, "end": 2}, {"entity_id": "4063627_3_Ent1", "role": "Subject_Disorder", "text": "selective IgA deficiency", "start": 6, "end": 9}, {"entity_id": "4063627_3_Ent2", "role": "Effect", "text": "remission in rheumatoid arthritis", "start": 10, "end": 14}, {"entity_id": "4063627_3_Ent3", "role": "Treatment", "text": "fenclofenac", "start": 16, "end": 17}, {"entity_id": "4063627_3_Ent6", "role": "Treatment_Drug", "text": "fenclofenac", "start": 16, "end": 17}, {"entity_id": "4063627_3_Ent4", "role": "Treatment", "text": "aurothiomalate", "start": 20, "end": 21}, {"entity_id": "4063627_3_Ent7", "role": "Treatment_Drug", "text": "aurothiomalate", "start": 20, "end": 21}, {"entity_id": "4063627_3_Ent5", "role": "Treatment", "text": "sulphasalazine", "start": 22, "end": 23}, {"entity_id": "4063627_3_Ent8", "role": "Treatment_Drug", "text": "sulphasalazine", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "4063627_3_Ent0", "text": "This case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "4063627_3_Ent1", "text": "selective IgA deficiency", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "4063627_3_Ent2", "text": "remission in rheumatoid arthritis", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "4063627_3_Ent3", "text": "fenclofenac", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "4063627_3_Ent6", "text": "fenclofenac", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "4063627_3_Ent4", "text": "aurothiomalate", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "4063627_3_Ent7", "text": "aurothiomalate", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "4063627_3_Ent5", "text": "sulphasalazine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "4063627_3_Ent8", "text": "sulphasalazine", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "4066620_2", "wnd_id": "4066620_2_1", "text": "Although the movement disorder could not with certainty be attributed to trazodone alone , the drug at least acted as an eliciting agent .", "tokens": ["Although", "the", "movement", "disorder", "could", "not", "with", "certainty", "be", "attributed", "to", "trazodone", "alone", ",", "the", "drug", "at", "least", "acted", "as", "an", "eliciting", "agent", "."], "event_mentions": [{"id": "4066620_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "attributed", "start": 9, "end": 10}, "arguments": [{"entity_id": "4066620_2_Ent0", "role": "Effect", "text": "movement disorder", "start": 2, "end": 4}, {"entity_id": "4066620_2_Ent1", "role": "Treatment", "text": "trazodone", "start": 11, "end": 12}, {"entity_id": "4066620_2_Ent2", "role": "Treatment_Drug", "text": "trazodone", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "4066620_2_Ent0", "text": "movement disorder", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "4066620_2_Ent1", "text": "trazodone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "4066620_2_Ent2", "text": "trazodone", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "4082283_2", "wnd_id": "4082283_2_1", "text": "Renal failure is a rare complication associated with the use of rifampicin for the treatment of tuberculosis , usually occurring well into the course of therapy .", "tokens": ["Renal", "failure", "is", "a", "rare", "complication", "associated", "with", "the", "use", "of", "rifampicin", "for", "the", "treatment", "of", "tuberculosis", ",", "usually", "occurring", "well", "into", "the", "course", "of", "therapy", "."], "event_mentions": [{"id": "4082283_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "4082283_2_Ent0", "role": "Effect", "text": "Renal failure", "start": 0, "end": 2}, {"entity_id": "4082283_2_Ent1", "role": "Treatment", "text": "rifampicin", "start": 11, "end": 12}, {"entity_id": "4082283_2_Ent2", "role": "Treatment_Drug", "text": "rifampicin", "start": 11, "end": 12}, {"entity_id": "4082283_2_Ent3", "role": "Treatment_Disorder", "text": "tuberculosis", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "4082283_2_Ent0", "text": "Renal failure", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "4082283_2_Ent1", "text": "rifampicin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "4082283_2_Ent2", "text": "rifampicin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "4082283_2_Ent3", "text": "tuberculosis", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "412488_2", "wnd_id": "412488_2_1", "text": "Three patients developed proteinuria following gold therapy for rheumatoid arthritis .", "tokens": ["Three", "patients", "developed", "proteinuria", "following", "gold", "therapy", "for", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "412488_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 4, "end": 5}, "arguments": [{"entity_id": "412488_2_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "412488_2_Ent0", "role": "Subject", "text": "Three patients", "start": 0, "end": 2}, {"entity_id": "412488_2_Ent2", "role": "Effect", "text": "proteinuria", "start": 3, "end": 4}, {"entity_id": "412488_2_Ent3", "role": "Treatment", "text": "gold", "start": 5, "end": 6}, {"entity_id": "412488_2_Ent5", "role": "Treatment_Drug", "text": "gold", "start": 5, "end": 6}, {"entity_id": "412488_2_Ent4", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "412488_2_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "412488_2_Ent0", "text": "Three patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "412488_2_Ent2", "text": "proteinuria", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "412488_2_Ent3", "text": "gold", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "412488_2_Ent5", "text": "gold", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "412488_2_Ent4", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "412488_7", "wnd_id": "412488_7_1", "text": "These findings are consistent with an immune - complex form of glomerulopathy in which gold is neither the antigen nor a hapten in the glomerular deposits , and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by gold therapy may be a causative factor in the renal disease associated with gold therapy in rheumatoid arthritis .", "tokens": ["These", "findings", "are", "consistent", "with", "an", "immune", "-", "complex", "form", "of", "glomerulopathy", "in", "which", "gold", "is", "neither", "the", "antigen", "nor", "a", "hapten", "in", "the", "glomerular", "deposits", ",", "and", "they", "suggest", "the", "hypothesis", "that", "antibodies", "to", "tubular", "epithelial", "antigens", "induced", "by", "gold", "therapy", "may", "be", "a", "causative", "factor", "in", "the", "renal", "disease", "associated", "with", "gold", "therapy", "in", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "412488_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 51, "end": 52}, "arguments": [{"entity_id": "412488_7_Ent0", "role": "Effect", "text": "renal disease", "start": 49, "end": 51}, {"entity_id": "412488_7_Ent2", "role": "Treatment_Drug", "text": "gold", "start": 53, "end": 54}, {"entity_id": "412488_7_Ent1", "role": "Treatment", "text": "gold therapy in rheumatoid arthritis", "start": 53, "end": 58}, {"entity_id": "412488_7_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 56, "end": 58}]}], "entity_mentions": [{"id": "412488_7_Ent0", "text": "renal disease", "entity_type": "Entity", "start": 49, "end": 51}, {"id": "412488_7_Ent2", "text": "gold", "entity_type": "Entity", "start": 53, "end": 54}, {"id": "412488_7_Ent1", "text": "gold therapy in rheumatoid arthritis", "entity_type": "Entity", "start": 53, "end": 58}, {"id": "412488_7_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 56, "end": 58}], "lang": "en"}
{"doc_id": "448845_1", "wnd_id": "448845_1_1", "text": "Aplastic anemia and agranulocytosis in patients using methazolamide for glaucoma .", "tokens": ["Aplastic", "anemia", "and", "agranulocytosis", "in", "patients", "using", "methazolamide", "for", "glaucoma", "."], "event_mentions": [{"id": "448845_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 4, "end": 5}, "arguments": [{"entity_id": "448845_1_Ent2", "role": "Effect", "text": "Aplastic anemia and agranulocytosis", "start": 0, "end": 4}, {"entity_id": "448845_1_Ent0", "role": "Subject", "text": "patients", "start": 5, "end": 6}, {"entity_id": "448845_1_Ent3", "role": "Treatment", "text": "methazolamide", "start": 7, "end": 8}, {"entity_id": "448845_1_Ent4", "role": "Treatment_Drug", "text": "methazolamide", "start": 7, "end": 8}, {"entity_id": "448845_1_Ent1", "role": "Subject", "text": "glaucoma", "start": 9, "end": 10}, {"entity_id": "448845_1_Ent5", "role": "Treatment_Disorder", "text": "glaucoma", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "448845_1_Ent2", "text": "Aplastic anemia and agranulocytosis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "448845_1_Ent0", "text": "patients", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "448845_1_Ent3", "text": "methazolamide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "448845_1_Ent4", "text": "methazolamide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "448845_1_Ent1", "text": "glaucoma", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "448845_1_Ent5", "text": "glaucoma", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "458006_2", "wnd_id": "458006_2_1", "text": "We report the development of squamous - cell carcinoma within a basal - cell epithelioma that was treated with intralesional injections of 5 - FU .", "tokens": ["We", "report", "the", "development", "of", "squamous", "-", "cell", "carcinoma", "within", "a", "basal", "-", "cell", "epithelioma", "that", "was", "treated", "with", "intralesional", "injections", "of", "5", "-", "FU", "."], "event_mentions": [{"id": "458006_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 17, "end": 18}, "arguments": [{"entity_id": "458006_2_Ent0", "role": "Effect", "text": "squamous - cell carcinoma within a basal - cell epithelioma", "start": 5, "end": 15}, {"entity_id": "458006_2_Ent2", "role": "Treatment_Route", "text": "intralesional injections", "start": 19, "end": 21}, {"entity_id": "458006_2_Ent1", "role": "Treatment", "text": "intralesional injections of 5 - FU", "start": 19, "end": 25}, {"entity_id": "458006_2_Ent3", "role": "Treatment_Drug", "text": "5 - FU", "start": 22, "end": 25}]}], "entity_mentions": [{"id": "458006_2_Ent0", "text": "squamous - cell carcinoma within a basal - cell epithelioma", "entity_type": "Entity", "start": 5, "end": 15}, {"id": "458006_2_Ent2", "text": "intralesional injections", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "458006_2_Ent1", "text": "intralesional injections of 5 - FU", "entity_type": "Entity", "start": 19, "end": 25}, {"id": "458006_2_Ent3", "text": "5 - FU", "entity_type": "Entity", "start": 22, "end": 25}], "lang": "en"}
{"doc_id": "527355_2", "wnd_id": "527355_2_1", "text": "Severe acidosis from acetazolamide in a diabetic patient .", "tokens": ["Severe", "acidosis", "from", "acetazolamide", "in", "a", "diabetic", "patient", "."], "event_mentions": [{"id": "527355_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 2, "end": 3}, "arguments": [{"entity_id": "527355_2_Ent2", "role": "Effect", "text": "Severe acidosis", "start": 0, "end": 2}, {"entity_id": "527355_2_Ent3", "role": "Treatment", "text": "acetazolamide", "start": 3, "end": 4}, {"entity_id": "527355_2_Ent4", "role": "Treatment_Drug", "text": "acetazolamide", "start": 3, "end": 4}, {"entity_id": "527355_2_Ent0", "role": "Subject", "text": "a diabetic patient", "start": 5, "end": 8}, {"entity_id": "527355_2_Ent1", "role": "Subject_Disorder", "text": "diabetic", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "527355_2_Ent2", "text": "Severe acidosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "527355_2_Ent3", "text": "acetazolamide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "527355_2_Ent4", "text": "acetazolamide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "527355_2_Ent0", "text": "a diabetic patient", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "527355_2_Ent1", "text": "diabetic", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "582099_1", "wnd_id": "582099_1_1", "text": "A patient with coccidioidal meningitis was treated with intrathecally administered amphotericin B , and an acute toxic delirium with EEG abnormalities developed .", "tokens": ["A", "patient", "with", "coccidioidal", "meningitis", "was", "treated", "with", "intrathecally", "administered", "amphotericin", "B", ",", "and", "an", "acute", "toxic", "delirium", "with", "EEG", "abnormalities", "developed", "."], "event_mentions": [{"id": "582099_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated with", "start": 6, "end": 8}, "arguments": [{"entity_id": "582099_1_Ent0", "role": "Subject", "text": "A patient with coccidioidal meningitis", "start": 0, "end": 5}, {"entity_id": "582099_1_Ent3", "role": "Treatment_Disorder", "text": "coccidioidal meningitis", "start": 3, "end": 5}, {"entity_id": "582099_1_Ent5", "role": "Treatment_Route", "text": "intrathecally", "start": 8, "end": 9}, {"entity_id": "582099_1_Ent2", "role": "Treatment", "text": "intrathecally administered amphotericin B", "start": 8, "end": 12}, {"entity_id": "582099_1_Ent4", "role": "Treatment_Drug", "text": "amphotericin B", "start": 10, "end": 12}, {"entity_id": "582099_1_Ent1", "role": "Effect", "text": "an acute toxic delirium with EEG abnormalities", "start": 14, "end": 21}]}], "entity_mentions": [{"id": "582099_1_Ent0", "text": "A patient with coccidioidal meningitis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "582099_1_Ent3", "text": "coccidioidal meningitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "582099_1_Ent5", "text": "intrathecally", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "582099_1_Ent2", "text": "intrathecally administered amphotericin B", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "582099_1_Ent4", "text": "amphotericin B", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "582099_1_Ent1", "text": "an acute toxic delirium with EEG abnormalities", "entity_type": "Entity", "start": 14, "end": 21}], "lang": "en"}
{"doc_id": "6159523_2", "wnd_id": "6159523_2_1", "text": "Two patients with extrinsic asthma and coexistent insulin - dependent diabetes mellitus sustained an anaphylactoid reaction after the intravenous administration of 50 % solution of dextrose .", "tokens": ["Two", "patients", "with", "extrinsic", "asthma", "and", "coexistent", "insulin", "-", "dependent", "diabetes", "mellitus", "sustained", "an", "anaphylactoid", "reaction", "after", "the", "intravenous", "administration", "of", "50", "%", "solution", "of", "dextrose", "."], "event_mentions": [{"id": "6159523_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "6159523_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "6159523_2_Ent0", "role": "Subject", "text": "Two patients with extrinsic asthma and coexistent insulin - dependent diabetes mellitus", "start": 0, "end": 12}, {"entity_id": "6159523_2_Ent2", "role": "Subject_Disorder", "text": "extrinsic asthma", "start": 3, "end": 5}, {"entity_id": "6159523_2_Ent3", "role": "Subject_Disorder", "text": "insulin - dependent diabetes mellitus", "start": 7, "end": 12}, {"entity_id": "6159523_2_Ent4", "role": "Effect", "text": "anaphylactoid reaction", "start": 14, "end": 16}, {"entity_id": "6159523_2_Ent6", "role": "Treatment_Route", "text": "intravenous", "start": 18, "end": 19}, {"entity_id": "6159523_2_Ent5", "role": "Treatment", "text": "intravenous administration of 50 % solution of dextrose", "start": 18, "end": 26}, {"entity_id": "6159523_2_Ent7", "role": "Treatment_Drug", "text": "dextrose", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "6159523_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6159523_2_Ent0", "text": "Two patients with extrinsic asthma and coexistent insulin - dependent diabetes mellitus", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "6159523_2_Ent2", "text": "extrinsic asthma", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "6159523_2_Ent3", "text": "insulin - dependent diabetes mellitus", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "6159523_2_Ent4", "text": "anaphylactoid reaction", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "6159523_2_Ent6", "text": "intravenous", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "6159523_2_Ent5", "text": "intravenous administration of 50 % solution of dextrose", "entity_type": "Entity", "start": 18, "end": 26}, {"id": "6159523_2_Ent7", "text": "dextrose", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "623061_1", "wnd_id": "623061_1_1", "text": "A toxic encephalopathy characterized by depressed level of consciousness , marked irritability , and ataxia developed in seven children , 5 years of age and younger , following administration of an antiemetic combination of pentobarbital and pyrilamine maleate .", "tokens": ["A", "toxic", "encephalopathy", "characterized", "by", "depressed", "level", "of", "consciousness", ",", "marked", "irritability", ",", "and", "ataxia", "developed", "in", "seven", "children", ",", "5", "years", "of", "age", "and", "younger", ",", "following", "administration", "of", "an", "antiemetic", "combination", "of", "pentobarbital", "and", "pyrilamine", "maleate", "."], "event_mentions": [{"id": "623061_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "623061_1_Ent3", "role": "Effect", "text": "A toxic encephalopathy characterized by depressed level of consciousness , marked irritability , and ataxia", "start": 0, "end": 15}, {"entity_id": "623061_1_Ent1", "role": "Subject_Population", "text": "seven", "start": 17, "end": 18}, {"entity_id": "623061_1_Ent0", "role": "Subject", "text": "seven children , 5 years of age and younger", "start": 17, "end": 26}, {"entity_id": "623061_1_Ent2", "role": "Subject_Age", "text": "children , 5 years of age and younger", "start": 18, "end": 26}, {"entity_id": "623061_1_Ent4", "role": "Treatment", "text": "administration of an antiemetic combination of pentobarbital and pyrilamine maleate", "start": 28, "end": 38}, {"entity_id": "623061_1_Ent5", "role": "Treatment_Drug", "text": "pentobarbital", "start": 34, "end": 35}, {"entity_id": "623061_1_Ent7", "role": "Combination_Drug", "text": "pentobarbital", "start": 34, "end": 35}, {"entity_id": "623061_1_Ent6", "role": "Treatment_Drug", "text": "pyrilamine maleate", "start": 36, "end": 38}, {"entity_id": "623061_1_Ent8", "role": "Combination_Drug", "text": "pyrilamine maleate", "start": 36, "end": 38}]}], "entity_mentions": [{"id": "623061_1_Ent3", "text": "A toxic encephalopathy characterized by depressed level of consciousness , marked irritability , and ataxia", "entity_type": "Entity", "start": 0, "end": 15}, {"id": "623061_1_Ent1", "text": "seven", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "623061_1_Ent0", "text": "seven children , 5 years of age and younger", "entity_type": "Entity", "start": 17, "end": 26}, {"id": "623061_1_Ent2", "text": "children , 5 years of age and younger", "entity_type": "Entity", "start": 18, "end": 26}, {"id": "623061_1_Ent4", "text": "administration of an antiemetic combination of pentobarbital and pyrilamine maleate", "entity_type": "Entity", "start": 28, "end": 38}, {"id": "623061_1_Ent5", "text": "pentobarbital", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "623061_1_Ent7", "text": "pentobarbital", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "623061_1_Ent6", "text": "pyrilamine maleate", "entity_type": "Entity", "start": 36, "end": 38}, {"id": "623061_1_Ent8", "text": "pyrilamine maleate", "entity_type": "Entity", "start": 36, "end": 38}], "lang": "en"}
{"doc_id": "6233326_2", "wnd_id": "6233326_2_1", "text": "Optic neuropathy developed in a patient with rheumatoid arthritis who had been receiving D - penicillamine for about 1 year .", "tokens": ["Optic", "neuropathy", "developed", "in", "a", "patient", "with", "rheumatoid", "arthritis", "who", "had", "been", "receiving", "D", "-", "penicillamine", "for", "about", "1", "year", "."], "event_mentions": [{"id": "6233326_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "6233326_2_Ent1", "role": "Effect", "text": "Optic neuropathy", "start": 0, "end": 2}, {"entity_id": "6233326_2_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 4, "end": 9}, {"entity_id": "6233326_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 7, "end": 9}, {"entity_id": "6233326_2_Ent4", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 13, "end": 16}, {"entity_id": "6233326_2_Ent2", "role": "Treatment", "text": "D - penicillamine for about 1 year", "start": 13, "end": 20}, {"entity_id": "6233326_2_Ent5", "role": "Treatment_Duration", "text": "1 year", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "6233326_2_Ent1", "text": "Optic neuropathy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6233326_2_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "6233326_2_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6233326_2_Ent4", "text": "D - penicillamine", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "6233326_2_Ent2", "text": "D - penicillamine for about 1 year", "entity_type": "Entity", "start": 13, "end": 20}, {"id": "6233326_2_Ent5", "text": "1 year", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "6239881_2", "wnd_id": "6239881_2_1", "text": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described .", "tokens": ["Nineteen", "cases", "of", "allergic", "contact", "dermatitis", "to", "compound", "tincture", "of", "benzoin", "are", "described", "."], "event_mentions": [{"id": "6239881_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "described", "start": 12, "end": 13}, "arguments": [{"entity_id": "6239881_2_Ent1", "role": "Subject_Population", "text": "Nineteen", "start": 0, "end": 1}, {"entity_id": "6239881_2_Ent0", "role": "Subject", "text": "Nineteen cases", "start": 0, "end": 2}, {"entity_id": "6239881_2_Ent2", "role": "Effect", "text": "allergic contact dermatitis", "start": 3, "end": 6}, {"entity_id": "6239881_2_Ent3", "role": "Treatment", "text": "compound tincture of benzoin", "start": 7, "end": 11}, {"entity_id": "6239881_2_Ent4", "role": "Treatment_Drug", "text": "benzoin", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "6239881_2_Ent1", "text": "Nineteen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6239881_2_Ent0", "text": "Nineteen cases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6239881_2_Ent2", "text": "allergic contact dermatitis", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "6239881_2_Ent3", "text": "compound tincture of benzoin", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "6239881_2_Ent4", "text": "benzoin", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "6260900_2", "wnd_id": "6260900_2_1", "text": "One of these was clofazimine , an aniline aposafranine derivative known to produce a ceroid - like pigment in the tissues of patients treated with this drug or lepromatous leprosy .", "tokens": ["One", "of", "these", "was", "clofazimine", ",", "an", "aniline", "aposafranine", "derivative", "known", "to", "produce", "a", "ceroid", "-", "like", "pigment", "in", "the", "tissues", "of", "patients", "treated", "with", "this", "drug", "or", "lepromatous", "leprosy", "."], "event_mentions": [{"id": "6260900_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "produce", "start": 12, "end": 13}, "arguments": [{"entity_id": "6260900_2_Ent2", "role": "Treatment", "text": "clofazimine", "start": 4, "end": 5}, {"entity_id": "6260900_2_Ent4", "role": "Treatment_Drug", "text": "clofazimine", "start": 4, "end": 5}, {"entity_id": "6260900_2_Ent1", "role": "Effect", "text": "a ceroid - like pigment", "start": 13, "end": 18}, {"entity_id": "6260900_2_Ent0", "role": "Subject", "text": "patients treated with this drug or lepromatous leprosy", "start": 22, "end": 30}, {"entity_id": "6260900_2_Ent3", "role": "Treatment_Disorder", "text": "lepromatous leprosy", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "6260900_2_Ent2", "text": "clofazimine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6260900_2_Ent4", "text": "clofazimine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6260900_2_Ent1", "text": "a ceroid - like pigment", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "6260900_2_Ent0", "text": "patients treated with this drug or lepromatous leprosy", "entity_type": "Entity", "start": 22, "end": 30}, {"id": "6260900_2_Ent3", "text": "lepromatous leprosy", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "6303138_2", "wnd_id": "6303138_2_1", "text": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline .", "tokens": ["A", "young", "patient", "experienced", "marked", "sinus", "tachycardia", "while", "smoking", "marijuana", "and", "receiving", "therapeutic", "doses", "of", "nortriptyline", "."], "event_mentions": [{"id": "6303138_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 3, "end": 4}, "arguments": [{"entity_id": "6303138_2_Ent1", "role": "Subject_Age", "text": "young", "start": 1, "end": 2}, {"entity_id": "6303138_2_Ent0", "role": "Subject", "text": "young patient", "start": 1, "end": 3}, {"entity_id": "6303138_2_Ent2", "role": "Effect", "text": "sinus tachycardia", "start": 5, "end": 7}, {"entity_id": "6303138_2_Ent3", "role": "Treatment", "text": "nortriptyline", "start": 15, "end": 16}, {"entity_id": "6303138_2_Ent4", "role": "Treatment_Drug", "text": "nortriptyline", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "6303138_2_Ent1", "text": "young", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6303138_2_Ent0", "text": "young patient", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "6303138_2_Ent2", "text": "sinus tachycardia", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "6303138_2_Ent3", "text": "nortriptyline", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6303138_2_Ent4", "text": "nortriptyline", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "6311654_3", "wnd_id": "6311654_3_1", "text": "In six cases CT scans did not return to their original state after ACTH therapy .", "tokens": ["In", "six", "cases", "CT", "scans", "did", "not", "return", "to", "their", "original", "state", "after", "ACTH", "therapy", "."], "event_mentions": [{"id": "6311654_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "6311654_3_Ent1", "role": "Subject_Population", "text": "six", "start": 1, "end": 2}, {"entity_id": "6311654_3_Ent0", "role": "Subject", "text": "six cases", "start": 1, "end": 3}, {"entity_id": "6311654_3_Ent2", "role": "Effect", "text": "CT scans did not return to their original state", "start": 3, "end": 12}, {"entity_id": "6311654_3_Ent3", "role": "Treatment", "text": "ACTH", "start": 13, "end": 14}, {"entity_id": "6311654_3_Ent4", "role": "Treatment_Drug", "text": "ACTH", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "6311654_3_Ent1", "text": "six", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6311654_3_Ent0", "text": "six cases", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "6311654_3_Ent2", "text": "CT scans did not return to their original state", "entity_type": "Entity", "start": 3, "end": 12}, {"id": "6311654_3_Ent3", "text": "ACTH", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6311654_3_Ent4", "text": "ACTH", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "6324592_2", "wnd_id": "6324592_2_1", "text": "This is the first report of a disulfiram - like reaction with cefmenoxime .", "tokens": ["This", "is", "the", "first", "report", "of", "a", "disulfiram", "-", "like", "reaction", "with", "cefmenoxime", "."], "event_mentions": [{"id": "6324592_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 11, "end": 12}, "arguments": [{"entity_id": "6324592_2_Ent0", "role": "Effect", "text": "disulfiram - like reaction", "start": 7, "end": 11}, {"entity_id": "6324592_2_Ent1", "role": "Treatment", "text": "cefmenoxime", "start": 12, "end": 13}, {"entity_id": "6324592_2_Ent2", "role": "Treatment_Drug", "text": "cefmenoxime", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "6324592_2_Ent0", "text": "disulfiram - like reaction", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "6324592_2_Ent1", "text": "cefmenoxime", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6324592_2_Ent2", "text": "cefmenoxime", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "6353252_1", "wnd_id": "6353252_1_1", "text": "Captopril - induced acute reversible renal failure .", "tokens": ["Captopril", "-", "induced", "acute", "reversible", "renal", "failure", "."], "event_mentions": [{"id": "6353252_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "6353252_1_Ent1", "role": "Treatment", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "6353252_1_Ent2", "role": "Treatment_Drug", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "6353252_1_Ent0", "role": "Effect", "text": "acute reversible renal failure", "start": 3, "end": 7}]}], "entity_mentions": [{"id": "6353252_1_Ent1", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6353252_1_Ent2", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6353252_1_Ent0", "text": "acute reversible renal failure", "entity_type": "Entity", "start": 3, "end": 7}], "lang": "en"}
{"doc_id": "6362443_1", "wnd_id": "6362443_1_1", "text": "A case of mania associated with fluoxetine .", "tokens": ["A", "case", "of", "mania", "associated", "with", "fluoxetine", "."], "event_mentions": [{"id": "6362443_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "6362443_1_Ent0", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "6362443_1_Ent1", "role": "Effect", "text": "mania", "start": 3, "end": 4}, {"entity_id": "6362443_1_Ent2", "role": "Treatment", "text": "fluoxetine", "start": 6, "end": 7}, {"entity_id": "6362443_1_Ent3", "role": "Treatment_Drug", "text": "fluoxetine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6362443_1_Ent0", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6362443_1_Ent1", "text": "mania", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6362443_1_Ent2", "text": "fluoxetine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6362443_1_Ent3", "text": "fluoxetine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6362443_2", "wnd_id": "6362443_2_1", "text": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine .", "tokens": ["A", "depressed", "woman", "with", "no", "history", "of", "bipolar", "illness", "developed", "a", "manic", "episode", "during", "treatment", "with", "fluoxetine", "."], "event_mentions": [{"id": "6362443_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 13, "end": 14}, "arguments": [{"entity_id": "6362443_2_Ent0", "role": "Subject", "text": "A depressed woman with no history of bipolar illness", "start": 0, "end": 9}, {"entity_id": "6362443_2_Ent5", "role": "Treatment_Disorder", "text": "depressed", "start": 1, "end": 2}, {"entity_id": "6362443_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 2, "end": 3}, {"entity_id": "6362443_2_Ent2", "role": "Effect", "text": "manic episode", "start": 11, "end": 13}, {"entity_id": "6362443_2_Ent3", "role": "Treatment", "text": "fluoxetine", "start": 16, "end": 17}, {"entity_id": "6362443_2_Ent4", "role": "Treatment_Drug", "text": "fluoxetine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "6362443_2_Ent0", "text": "A depressed woman with no history of bipolar illness", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "6362443_2_Ent5", "text": "depressed", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6362443_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "6362443_2_Ent2", "text": "manic episode", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "6362443_2_Ent3", "text": "fluoxetine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "6362443_2_Ent4", "text": "fluoxetine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "6405633_1", "wnd_id": "6405633_1_1", "text": "Treatment of lithium tremor with metoprolol .", "tokens": ["Treatment", "of", "lithium", "tremor", "with", "metoprolol", "."], "event_mentions": [{"id": "6405633_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Treatment of", "start": 0, "end": 2}, "arguments": [{"entity_id": "6405633_1_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 2, "end": 3}, {"entity_id": "6405633_1_Ent1", "role": "Treatment_Disorder", "text": "lithium tremor", "start": 2, "end": 4}, {"entity_id": "6405633_1_Ent0", "role": "Treatment", "text": "metoprolol", "start": 5, "end": 6}, {"entity_id": "6405633_1_Ent3", "role": "Treatment_Drug", "text": "metoprolol", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "6405633_1_Ent2", "text": "lithium", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "6405633_1_Ent1", "text": "lithium tremor", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "6405633_1_Ent0", "text": "metoprolol", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "6405633_1_Ent3", "text": "metoprolol", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "6414095_1", "wnd_id": "6414095_1_1", "text": "Transient hemiparesis caused by phenytoin toxicity .", "tokens": ["Transient", "hemiparesis", "caused", "by", "phenytoin", "toxicity", "."], "event_mentions": [{"id": "6414095_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 2, "end": 3}, "arguments": [{"entity_id": "6414095_1_Ent0", "role": "Effect", "text": "Transient hemiparesis", "start": 0, "end": 2}, {"entity_id": "6414095_1_Ent2", "role": "Treatment_Drug", "text": "phenytoin", "start": 4, "end": 5}, {"entity_id": "6414095_1_Ent1", "role": "Treatment", "text": "phenytoin toxicity", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "6414095_1_Ent0", "text": "Transient hemiparesis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6414095_1_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6414095_1_Ent1", "text": "phenytoin toxicity", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "647693_1", "wnd_id": "647693_1_1", "text": "Four patients receiving high - dose tamoxifen for greater than 1 year have demonstrated similar retinal changes .", "tokens": ["Four", "patients", "receiving", "high", "-", "dose", "tamoxifen", "for", "greater", "than", "1", "year", "have", "demonstrated", "similar", "retinal", "changes", "."], "event_mentions": [{"id": "647693_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 2, "end": 3}, "arguments": [{"entity_id": "647693_1_Ent1", "role": "Subject_Population", "text": "Four", "start": 0, "end": 1}, {"entity_id": "647693_1_Ent0", "role": "Subject", "text": "Four patients", "start": 0, "end": 2}, {"entity_id": "647693_1_Ent5", "role": "Treatment_Dosage", "text": "high - dose", "start": 3, "end": 6}, {"entity_id": "647693_1_Ent3", "role": "Treatment", "text": "high - dose tamoxifen for greater than 1 year", "start": 3, "end": 12}, {"entity_id": "647693_1_Ent6", "role": "Treatment_Drug", "text": "tamoxifen", "start": 6, "end": 7}, {"entity_id": "647693_1_Ent4", "role": "Treatment_Duration", "text": "1 year", "start": 10, "end": 12}, {"entity_id": "647693_1_Ent2", "role": "Effect", "text": "retinal changes", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "647693_1_Ent1", "text": "Four", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "647693_1_Ent0", "text": "Four patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "647693_1_Ent5", "text": "high - dose", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "647693_1_Ent3", "text": "high - dose tamoxifen for greater than 1 year", "entity_type": "Entity", "start": 3, "end": 12}, {"id": "647693_1_Ent6", "text": "tamoxifen", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "647693_1_Ent4", "text": "1 year", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "647693_1_Ent2", "text": "retinal changes", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "6478628_1", "wnd_id": "6478628_1_1", "text": "Mammary gigantism is a rare complication of D - penicillamine treatment .", "tokens": ["Mammary", "gigantism", "is", "a", "rare", "complication", "of", "D", "-", "penicillamine", "treatment", "."], "event_mentions": [{"id": "6478628_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication of", "start": 5, "end": 7}, "arguments": [{"entity_id": "6478628_1_Ent0", "role": "Effect", "text": "Mammary gigantism", "start": 0, "end": 2}, {"entity_id": "6478628_1_Ent2", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 7, "end": 10}, {"entity_id": "6478628_1_Ent1", "role": "Treatment", "text": "D - penicillamine treatment", "start": 7, "end": 11}]}], "entity_mentions": [{"id": "6478628_1_Ent0", "text": "Mammary gigantism", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6478628_1_Ent2", "text": "D - penicillamine", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "6478628_1_Ent1", "text": "D - penicillamine treatment", "entity_type": "Entity", "start": 7, "end": 11}], "lang": "en"}
{"doc_id": "6498095_2", "wnd_id": "6498095_2_1", "text": "Pemphigus foliaceus induced by rifampicin .", "tokens": ["Pemphigus", "foliaceus", "induced", "by", "rifampicin", "."], "event_mentions": [{"id": "6498095_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "6498095_2_Ent0", "role": "Effect", "text": "Pemphigus foliaceus", "start": 0, "end": 2}, {"entity_id": "6498095_2_Ent1", "role": "Treatment", "text": "rifampicin", "start": 4, "end": 5}, {"entity_id": "6498095_2_Ent2", "role": "Treatment_Drug", "text": "rifampicin", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "6498095_2_Ent0", "text": "Pemphigus foliaceus", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6498095_2_Ent1", "text": "rifampicin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6498095_2_Ent2", "text": "rifampicin", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "6529939_4", "wnd_id": "6529939_4_1", "text": "This was accepted as evidence for propranolol being the cause of this conduction disorder .", "tokens": ["This", "was", "accepted", "as", "evidence", "for", "propranolol", "being", "the", "cause", "of", "this", "conduction", "disorder", "."], "event_mentions": [{"id": "6529939_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 9, "end": 10}, "arguments": [{"entity_id": "6529939_4_Ent1", "role": "Treatment", "text": "propranolol", "start": 6, "end": 7}, {"entity_id": "6529939_4_Ent2", "role": "Treatment_Drug", "text": "propranolol", "start": 6, "end": 7}, {"entity_id": "6529939_4_Ent0", "role": "Effect", "text": "conduction disorder", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "6529939_4_Ent1", "text": "propranolol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6529939_4_Ent2", "text": "propranolol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6529939_4_Ent0", "text": "conduction disorder", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "6572542_1", "wnd_id": "6572542_1_1", "text": "Although lung specimens were lacking from these three patients , it is suggested that the pulmonary toxicity of CCNU may be dose - related .", "tokens": ["Although", "lung", "specimens", "were", "lacking", "from", "these", "three", "patients", ",", "it", "is", "suggested", "that", "the", "pulmonary", "toxicity", "of", "CCNU", "may", "be", "dose", "-", "related", "."], "event_mentions": [{"id": "6572542_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 23, "end": 24}, "arguments": [{"entity_id": "6572542_1_Ent1", "role": "Subject_Population", "text": "three", "start": 7, "end": 8}, {"entity_id": "6572542_1_Ent0", "role": "Subject", "text": "three patients", "start": 7, "end": 9}, {"entity_id": "6572542_1_Ent2", "role": "Effect", "text": "pulmonary toxicity", "start": 15, "end": 17}, {"entity_id": "6572542_1_Ent3", "role": "Treatment", "text": "CCNU", "start": 18, "end": 19}, {"entity_id": "6572542_1_Ent4", "role": "Treatment_Drug", "text": "CCNU", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "6572542_1_Ent1", "text": "three", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6572542_1_Ent0", "text": "three patients", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6572542_1_Ent2", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "6572542_1_Ent3", "text": "CCNU", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "6572542_1_Ent4", "text": "CCNU", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "6597713_3", "wnd_id": "6597713_3_1", "text": "It is presumed that her hyperchloremic metabolic acidosis was secondary to cholestyramine because of the similarity to pediatric reports ; the rapid and lasting response to intravenous sodium bicarbonate ; the absence of another etiology ; normal serum potassium , chloride and bicarbonate despite continued spironolactone therapy after recovery .", "tokens": ["It", "is", "presumed", "that", "her", "hyperchloremic", "metabolic", "acidosis", "was", "secondary", "to", "cholestyramine", "because", "of", "the", "similarity", "to", "pediatric", "reports", ";", "the", "rapid", "and", "lasting", "response", "to", "intravenous", "sodium", "bicarbonate", ";", "the", "absence", "of", "another", "etiology", ";", "normal", "serum", "potassium", ",", "chloride", "and", "bicarbonate", "despite", "continued", "spironolactone", "therapy", "after", "recovery", "."], "event_mentions": [{"id": "6597713_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 9, "end": 10}, "arguments": [{"entity_id": "6597713_3_Ent0", "role": "Effect", "text": "hyperchloremic metabolic acidosis", "start": 5, "end": 8}, {"entity_id": "6597713_3_Ent1", "role": "Treatment", "text": "cholestyramine", "start": 11, "end": 12}, {"entity_id": "6597713_3_Ent2", "role": "Treatment_Drug", "text": "cholestyramine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "6597713_3_Ent0", "text": "hyperchloremic metabolic acidosis", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "6597713_3_Ent1", "text": "cholestyramine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "6597713_3_Ent2", "text": "cholestyramine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "6610943_1", "wnd_id": "6610943_1_1", "text": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion .", "tokens": ["Myoglobinuria", "and", "acute", "renal", "failure", "associated", "with", "intravenous", "vasopressin", "infusion", "."], "event_mentions": [{"id": "6610943_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "6610943_1_Ent0", "role": "Effect", "text": "Myoglobinuria and acute renal failure", "start": 0, "end": 5}, {"entity_id": "6610943_1_Ent2", "role": "Treatment_Route", "text": "intravenous", "start": 7, "end": 8}, {"entity_id": "6610943_1_Ent1", "role": "Treatment", "text": "intravenous vasopressin infusion", "start": 7, "end": 10}, {"entity_id": "6610943_1_Ent4", "role": "Treatment_Drug", "text": "vasopressin", "start": 8, "end": 9}, {"entity_id": "6610943_1_Ent3", "role": "Treatment_Route", "text": "infusion", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "6610943_1_Ent0", "text": "Myoglobinuria and acute renal failure", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "6610943_1_Ent2", "text": "intravenous", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6610943_1_Ent1", "text": "intravenous vasopressin infusion", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "6610943_1_Ent4", "text": "vasopressin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6610943_1_Ent3", "text": "infusion", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "6618859_1", "wnd_id": "6618859_1_1", "text": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered .", "tokens": ["Gynecomastia", "developed", "in", "two", "epileptic", "patients", "some", "months", "after", "the", "addition", "of", "oral", "fluoresone", "750", "mg", "daily", "to", "the", "phenobarbital", "and", "phenytoin", "already", "being", "administered", "."], "event_mentions": [{"id": "6618859_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 1, "end": 2}, "arguments": [{"entity_id": "6618859_1_Ent2", "role": "Effect", "text": "Gynecomastia", "start": 0, "end": 1}, {"entity_id": "6618859_1_Ent1", "role": "Subject_Population", "text": "two", "start": 3, "end": 4}, {"entity_id": "6618859_1_Ent0", "role": "Subject", "text": "two epileptic patients", "start": 3, "end": 6}, {"entity_id": "6618859_1_Ent10", "role": "Treatment_Disorder", "text": "epileptic", "start": 4, "end": 5}, {"entity_id": "6618859_1_Ent11", "role": "Treatment_Time_elapsed", "text": "some months after", "start": 6, "end": 9}, {"entity_id": "6618859_1_Ent3", "role": "Treatment", "text": "some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered", "start": 6, "end": 25}, {"entity_id": "6618859_1_Ent4", "role": "Treatment_Route", "text": "oral", "start": 12, "end": 13}, {"entity_id": "6618859_1_Ent5", "role": "Treatment_Drug", "text": "fluoresone", "start": 13, "end": 14}, {"entity_id": "6618859_1_Ent12", "role": "Combination_Drug", "text": "fluoresone", "start": 13, "end": 14}, {"entity_id": "6618859_1_Ent8", "role": "Treatment_Dosage", "text": "750 mg", "start": 14, "end": 16}, {"entity_id": "6618859_1_Ent9", "role": "Treatment_Freq", "text": "daily", "start": 16, "end": 17}, {"entity_id": "6618859_1_Ent6", "role": "Treatment_Drug", "text": "phenobarbital", "start": 19, "end": 20}, {"entity_id": "6618859_1_Ent13", "role": "Combination_Drug", "text": "phenobarbital", "start": 19, "end": 20}, {"entity_id": "6618859_1_Ent7", "role": "Treatment_Drug", "text": "phenytoin", "start": 21, "end": 22}, {"entity_id": "6618859_1_Ent14", "role": "Combination_Drug", "text": "phenytoin", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "6618859_1_Ent2", "text": "Gynecomastia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6618859_1_Ent1", "text": "two", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6618859_1_Ent0", "text": "two epileptic patients", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "6618859_1_Ent10", "text": "epileptic", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6618859_1_Ent11", "text": "some months after", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "6618859_1_Ent3", "text": "some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered", "entity_type": "Entity", "start": 6, "end": 25}, {"id": "6618859_1_Ent4", "text": "oral", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6618859_1_Ent5", "text": "fluoresone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6618859_1_Ent12", "text": "fluoresone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6618859_1_Ent8", "text": "750 mg", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "6618859_1_Ent9", "text": "daily", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "6618859_1_Ent6", "text": "phenobarbital", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "6618859_1_Ent13", "text": "phenobarbital", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "6618859_1_Ent7", "text": "phenytoin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "6618859_1_Ent14", "text": "phenytoin", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "6628806_1", "wnd_id": "6628806_1_1", "text": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47 - year - old woman .", "tokens": ["A", "case", "of", "toxic", "hepatitis", "caused", "by", "combination", "therapy", "with", "methotrexate", "and", "etretinate", "in", "the", "treatment", "of", "severe", "psoriasis", "is", "presented", "in", "a", "47", "-", "year", "-", "old", "woman", "."], "event_mentions": [{"id": "6628806_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 5, "end": 6}, "arguments": [{"entity_id": "6628806_1_Ent4", "role": "Effect", "text": "toxic hepatitis", "start": 3, "end": 5}, {"entity_id": "6628806_1_Ent5", "role": "Treatment", "text": "combination therapy with methotrexate and etretinate", "start": 7, "end": 13}, {"entity_id": "6628806_1_Ent7", "role": "Treatment_Drug", "text": "methotrexate", "start": 10, "end": 11}, {"entity_id": "6628806_1_Ent9", "role": "Combination_Drug", "text": "methotrexate", "start": 10, "end": 11}, {"entity_id": "6628806_1_Ent6", "role": "Treatment_Drug", "text": "etretinate", "start": 12, "end": 13}, {"entity_id": "6628806_1_Ent10", "role": "Combination_Drug", "text": "etretinate", "start": 12, "end": 13}, {"entity_id": "6628806_1_Ent8", "role": "Treatment_Disorder", "text": "severe psoriasis", "start": 17, "end": 19}, {"entity_id": "6628806_1_Ent0", "role": "Subject", "text": "psoriasis", "start": 18, "end": 19}, {"entity_id": "6628806_1_Ent1", "role": "Subject", "text": "a 47 - year - old woman", "start": 22, "end": 29}, {"entity_id": "6628806_1_Ent2", "role": "Subject_Age", "text": "47 - year - old", "start": 23, "end": 28}, {"entity_id": "6628806_1_Ent3", "role": "Subject_Gender", "text": "woman", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "6628806_1_Ent4", "text": "toxic hepatitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "6628806_1_Ent5", "text": "combination therapy with methotrexate and etretinate", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "6628806_1_Ent7", "text": "methotrexate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6628806_1_Ent9", "text": "methotrexate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6628806_1_Ent6", "text": "etretinate", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6628806_1_Ent10", "text": "etretinate", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6628806_1_Ent8", "text": "severe psoriasis", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "6628806_1_Ent0", "text": "psoriasis", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "6628806_1_Ent1", "text": "a 47 - year - old woman", "entity_type": "Entity", "start": 22, "end": 29}, {"id": "6628806_1_Ent2", "text": "47 - year - old", "entity_type": "Entity", "start": 23, "end": 28}, {"id": "6628806_1_Ent3", "text": "woman", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "6635723_1", "wnd_id": "6635723_1_1", "text": "Metabolic balance studies and rechallenge with hydrochlorothiazide were undertaken to investigate the mechanism of the thiazide - induced hyponatremia .", "tokens": ["Metabolic", "balance", "studies", "and", "rechallenge", "with", "hydrochlorothiazide", "were", "undertaken", "to", "investigate", "the", "mechanism", "of", "the", "thiazide", "-", "induced", "hyponatremia", "."], "event_mentions": [{"id": "6635723_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 17, "end": 18}, "arguments": [{"entity_id": "6635723_1_Ent2", "role": "Treatment_Drug", "text": "hydrochlorothiazide", "start": 6, "end": 7}, {"entity_id": "6635723_1_Ent1", "role": "Treatment", "text": "thiazide", "start": 15, "end": 16}, {"entity_id": "6635723_1_Ent3", "role": "Treatment_Drug", "text": "thiazide", "start": 15, "end": 16}, {"entity_id": "6635723_1_Ent0", "role": "Effect", "text": "hyponatremia", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "6635723_1_Ent2", "text": "hydrochlorothiazide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6635723_1_Ent1", "text": "thiazide", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6635723_1_Ent3", "text": "thiazide", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6635723_1_Ent0", "text": "hyponatremia", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "6671350_2", "wnd_id": "6671350_2_1", "text": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure .", "tokens": ["Coagulopathy", "associated", "with", "the", "use", "of", "cephalosporin", "or", "moxalactam", "antibiotics", "in", "acute", "and", "chronic", "renal", "failure", "."], "event_mentions": [{"id": "6671350_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "6671350_2_Ent0", "role": "Effect", "text": "Coagulopathy", "start": 0, "end": 1}, {"entity_id": "6671350_2_Ent3", "role": "Treatment_Drug", "text": "cephalosporin", "start": 6, "end": 7}, {"entity_id": "6671350_2_Ent1", "role": "Treatment", "text": "cephalosporin or moxalactam antibiotics", "start": 6, "end": 10}, {"entity_id": "6671350_2_Ent4", "role": "Treatment_Drug", "text": "moxalactam", "start": 8, "end": 9}, {"entity_id": "6671350_2_Ent2", "role": "Treatment_Disorder", "text": "acute and chronic renal failure", "start": 11, "end": 16}]}], "entity_mentions": [{"id": "6671350_2_Ent0", "text": "Coagulopathy", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6671350_2_Ent3", "text": "cephalosporin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6671350_2_Ent1", "text": "cephalosporin or moxalactam antibiotics", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "6671350_2_Ent4", "text": "moxalactam", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6671350_2_Ent2", "text": "acute and chronic renal failure", "entity_type": "Entity", "start": 11, "end": 16}], "lang": "en"}
{"doc_id": "6671350_4", "wnd_id": "6671350_4_1", "text": "Nevertheless , the coagulopathy seemed to be most closely associated with the administration of the cephalosporin .", "tokens": ["Nevertheless", ",", "the", "coagulopathy", "seemed", "to", "be", "most", "closely", "associated", "with", "the", "administration", "of", "the", "cephalosporin", "."], "event_mentions": [{"id": "6671350_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 9, "end": 11}, "arguments": [{"entity_id": "6671350_4_Ent0", "role": "Effect", "text": "coagulopathy", "start": 3, "end": 4}, {"entity_id": "6671350_4_Ent1", "role": "Treatment", "text": "cephalosporin", "start": 15, "end": 16}, {"entity_id": "6671350_4_Ent2", "role": "Treatment_Drug", "text": "cephalosporin", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "6671350_4_Ent0", "text": "coagulopathy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6671350_4_Ent1", "text": "cephalosporin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6671350_4_Ent2", "text": "cephalosporin", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "667809_2", "wnd_id": "667809_2_1", "text": "Fatal pulmonary fibrosis following 1,3 - bis(2 - chloroethyl) - 1 - nitrosourea ( BCNU ) therapy .", "tokens": ["Fatal", "pulmonary", "fibrosis", "following", "1,3", "-", "bis(2", "-", "chloroethyl)", "-", "1", "-", "nitrosourea", "(", "BCNU", ")", "therapy", "."], "event_mentions": [{"id": "667809_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "667809_2_Ent0", "role": "Effect", "text": "pulmonary fibrosis", "start": 1, "end": 3}, {"entity_id": "667809_2_Ent2", "role": "Treatment_Drug", "text": "1,3 - bis(2 - chloroethyl) - 1 - nitrosourea ( BCNU )", "start": 4, "end": 16}, {"entity_id": "667809_2_Ent1", "role": "Treatment", "text": "1,3 - bis(2 - chloroethyl) - 1 - nitrosourea ( BCNU ) therapy", "start": 4, "end": 17}]}], "entity_mentions": [{"id": "667809_2_Ent0", "text": "pulmonary fibrosis", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "667809_2_Ent2", "text": "1,3 - bis(2 - chloroethyl) - 1 - nitrosourea ( BCNU )", "entity_type": "Entity", "start": 4, "end": 16}, {"id": "667809_2_Ent1", "text": "1,3 - bis(2 - chloroethyl) - 1 - nitrosourea ( BCNU ) therapy", "entity_type": "Entity", "start": 4, "end": 17}], "lang": "en"}
{"doc_id": "6692713_2", "wnd_id": "6692713_2_1", "text": "Possible recurrence of amiodarone pulmonary toxicity following corticosteroid therapy .", "tokens": ["Possible", "recurrence", "of", "amiodarone", "pulmonary", "toxicity", "following", "corticosteroid", "therapy", "."], "event_mentions": [{"id": "6692713_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "6692713_2_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 3, "end": 4}, {"entity_id": "6692713_2_Ent0", "role": "Effect", "text": "amiodarone pulmonary toxicity", "start": 3, "end": 6}, {"entity_id": "6692713_2_Ent1", "role": "Treatment", "text": "corticosteroid", "start": 7, "end": 8}, {"entity_id": "6692713_2_Ent3", "role": "Treatment_Drug", "text": "corticosteroid", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "6692713_2_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6692713_2_Ent0", "text": "amiodarone pulmonary toxicity", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "6692713_2_Ent1", "text": "corticosteroid", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6692713_2_Ent3", "text": "corticosteroid", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "6693840_1", "wnd_id": "6693840_1_1", "text": "A 61 year - old male patient developed gynecomastia after starting theophylline .", "tokens": ["A", "61", "year", "-", "old", "male", "patient", "developed", "gynecomastia", "after", "starting", "theophylline", "."], "event_mentions": [{"id": "6693840_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "6693840_1_Ent0", "role": "Subject", "text": "A 61 year - old male patient", "start": 0, "end": 7}, {"entity_id": "6693840_1_Ent1", "role": "Subject_Age", "text": "61 year - old", "start": 1, "end": 5}, {"entity_id": "6693840_1_Ent2", "role": "Subject_Gender", "text": "male", "start": 5, "end": 6}, {"entity_id": "6693840_1_Ent3", "role": "Effect", "text": "gynecomastia", "start": 8, "end": 9}, {"entity_id": "6693840_1_Ent4", "role": "Treatment", "text": "theophylline", "start": 11, "end": 12}, {"entity_id": "6693840_1_Ent5", "role": "Treatment_Drug", "text": "theophylline", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "6693840_1_Ent0", "text": "A 61 year - old male patient", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "6693840_1_Ent1", "text": "61 year - old", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "6693840_1_Ent2", "text": "male", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "6693840_1_Ent3", "text": "gynecomastia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6693840_1_Ent4", "text": "theophylline", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "6693840_1_Ent5", "text": "theophylline", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "6693840_3", "wnd_id": "6693840_3_1", "text": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline .", "tokens": ["No", "other", "endogenous", "or", "exogenous", "cause", "for", "the", "gynecomastia", "could", "be", "found", "except", "for", "the", "theophylline", "."], "event_mentions": [{"id": "6693840_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 5, "end": 6}, "arguments": [{"entity_id": "6693840_3_Ent0", "role": "Effect", "text": "gynecomastia", "start": 8, "end": 9}, {"entity_id": "6693840_3_Ent1", "role": "Treatment", "text": "theophylline", "start": 15, "end": 16}, {"entity_id": "6693840_3_Ent2", "role": "Treatment_Drug", "text": "theophylline", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "6693840_3_Ent0", "text": "gynecomastia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6693840_3_Ent1", "text": "theophylline", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6693840_3_Ent2", "text": "theophylline", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "6731466_2", "wnd_id": "6731466_2_1", "text": "Anaphylactoid shock , disseminated intravascular coagulation , and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache .", "tokens": ["Anaphylactoid", "shock", ",", "disseminated", "intravascular", "coagulation", ",", "and", "anuric", "renal", "failure", "requiring", "dialysis", "occurred", "in", "a", "patient", "receiving", "zomepirac", "sodium", "for", "toothache", "."], "event_mentions": [{"id": "6731466_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 13, "end": 14}, "arguments": [{"entity_id": "6731466_2_Ent2", "role": "Effect", "text": "Anaphylactoid shock , disseminated intravascular coagulation , and anuric renal failure requiring dialysis", "start": 0, "end": 13}, {"entity_id": "6731466_2_Ent0", "role": "Subject", "text": "a patient", "start": 15, "end": 17}, {"entity_id": "6731466_2_Ent3", "role": "Treatment", "text": "zomepirac sodium", "start": 18, "end": 20}, {"entity_id": "6731466_2_Ent4", "role": "Treatment_Drug", "text": "zomepirac sodium", "start": 18, "end": 20}, {"entity_id": "6731466_2_Ent1", "role": "Subject", "text": "toothache", "start": 21, "end": 22}, {"entity_id": "6731466_2_Ent5", "role": "Treatment_Disorder", "text": "toothache", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "6731466_2_Ent2", "text": "Anaphylactoid shock , disseminated intravascular coagulation , and anuric renal failure requiring dialysis", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "6731466_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "6731466_2_Ent3", "text": "zomepirac sodium", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "6731466_2_Ent4", "text": "zomepirac sodium", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "6731466_2_Ent1", "text": "toothache", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "6731466_2_Ent5", "text": "toothache", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "6738830_2", "wnd_id": "6738830_2_1", "text": "Unique behavioral change with cinepazide in parkinsonism .", "tokens": ["Unique", "behavioral", "change", "with", "cinepazide", "in", "parkinsonism", "."], "event_mentions": [{"id": "6738830_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 3, "end": 4}, "arguments": [{"entity_id": "6738830_2_Ent0", "role": "Effect", "text": "Unique behavioral change", "start": 0, "end": 3}, {"entity_id": "6738830_2_Ent1", "role": "Treatment", "text": "cinepazide", "start": 4, "end": 5}, {"entity_id": "6738830_2_Ent3", "role": "Treatment_Drug", "text": "cinepazide", "start": 4, "end": 5}, {"entity_id": "6738830_2_Ent2", "role": "Treatment_Disorder", "text": "parkinsonism", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6738830_2_Ent0", "text": "Unique behavioral change", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6738830_2_Ent1", "text": "cinepazide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6738830_2_Ent3", "text": "cinepazide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6738830_2_Ent2", "text": "parkinsonism", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6744146_1", "wnd_id": "6744146_1_1", "text": "A 65 - year - old woman , in the intensive care unit because of septic shock and acute renal failure , had a small - bowel obstruction due to Amphojel concretions .", "tokens": ["A", "65", "-", "year", "-", "old", "woman", ",", "in", "the", "intensive", "care", "unit", "because", "of", "septic", "shock", "and", "acute", "renal", "failure", ",", "had", "a", "small", "-", "bowel", "obstruction", "due", "to", "Amphojel", "concretions", "."], "event_mentions": [{"id": "6744146_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 28, "end": 29}, "arguments": [{"entity_id": "6744146_1_Ent0", "role": "Subject", "text": "A 65 - year - old woman , in the intensive care unit because of septic shock and acute renal failure", "start": 0, "end": 21}, {"entity_id": "6744146_1_Ent3", "role": "Subject_Age", "text": "65 - year - old", "start": 1, "end": 6}, {"entity_id": "6744146_1_Ent4", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "6744146_1_Ent1", "role": "Subject_Disorder", "text": "septic shock", "start": 15, "end": 17}, {"entity_id": "6744146_1_Ent2", "role": "Subject_Disorder", "text": "acute renal failure", "start": 18, "end": 21}, {"entity_id": "6744146_1_Ent5", "role": "Effect", "text": "small - bowel obstruction", "start": 24, "end": 28}, {"entity_id": "6744146_1_Ent7", "role": "Treatment", "text": "Amphojel", "start": 30, "end": 31}, {"entity_id": "6744146_1_Ent8", "role": "Treatment_Drug", "text": "Amphojel", "start": 30, "end": 31}, {"entity_id": "6744146_1_Ent6", "role": "Effect", "text": "concretions", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "6744146_1_Ent0", "text": "A 65 - year - old woman , in the intensive care unit because of septic shock and acute renal failure", "entity_type": "Entity", "start": 0, "end": 21}, {"id": "6744146_1_Ent3", "text": "65 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "6744146_1_Ent4", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6744146_1_Ent1", "text": "septic shock", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "6744146_1_Ent2", "text": "acute renal failure", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "6744146_1_Ent5", "text": "small - bowel obstruction", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "6744146_1_Ent7", "text": "Amphojel", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "6744146_1_Ent8", "text": "Amphojel", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "6744146_1_Ent6", "text": "concretions", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "6794018_3", "wnd_id": "6794018_3_1", "text": "These features have not previously been reported as side effects of glibenclamide therapy , but intrahepatic cholestasis may occur with chlorpropamide , a similar sulphonylurea agent .", "tokens": ["These", "features", "have", "not", "previously", "been", "reported", "as", "side", "effects", "of", "glibenclamide", "therapy", ",", "but", "intrahepatic", "cholestasis", "may", "occur", "with", "chlorpropamide", ",", "a", "similar", "sulphonylurea", "agent", "."], "event_mentions": [{"id": "6794018_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 18, "end": 19}, "arguments": [{"entity_id": "6794018_3_Ent0", "role": "Effect", "text": "intrahepatic cholestasis", "start": 15, "end": 17}, {"entity_id": "6794018_3_Ent1", "role": "Treatment", "text": "chlorpropamide", "start": 20, "end": 21}, {"entity_id": "6794018_3_Ent2", "role": "Treatment_Drug", "text": "chlorpropamide", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "6794018_3_Ent0", "text": "intrahepatic cholestasis", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "6794018_3_Ent1", "text": "chlorpropamide", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "6794018_3_Ent2", "text": "chlorpropamide", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "6810714_1", "wnd_id": "6810714_1_1", "text": "The authors describe a woman with chronic schizophrenia who experienced delirium , grand mal seizure , and photosensitivity after the addition of propranolol to her neuroleptic regimen .", "tokens": ["The", "authors", "describe", "a", "woman", "with", "chronic", "schizophrenia", "who", "experienced", "delirium", ",", "grand", "mal", "seizure", ",", "and", "photosensitivity", "after", "the", "addition", "of", "propranolol", "to", "her", "neuroleptic", "regimen", "."], "event_mentions": [{"id": "6810714_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 18, "end": 19}, "arguments": [{"entity_id": "6810714_1_Ent0", "role": "Subject", "text": "a woman with chronic schizophrenia", "start": 3, "end": 8}, {"entity_id": "6810714_1_Ent1", "role": "Subject_Gender", "text": "woman", "start": 4, "end": 5}, {"entity_id": "6810714_1_Ent5", "role": "Treatment_Disorder", "text": "chronic schizophrenia", "start": 6, "end": 8}, {"entity_id": "6810714_1_Ent2", "role": "Effect", "text": "delirium , grand mal seizure , and photosensitivity", "start": 10, "end": 18}, {"entity_id": "6810714_1_Ent3", "role": "Treatment", "text": "propranolol", "start": 22, "end": 23}, {"entity_id": "6810714_1_Ent4", "role": "Treatment_Drug", "text": "propranolol", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "6810714_1_Ent0", "text": "a woman with chronic schizophrenia", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "6810714_1_Ent1", "text": "woman", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6810714_1_Ent5", "text": "chronic schizophrenia", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "6810714_1_Ent2", "text": "delirium , grand mal seizure , and photosensitivity", "entity_type": "Entity", "start": 10, "end": 18}, {"id": "6810714_1_Ent3", "text": "propranolol", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "6810714_1_Ent4", "text": "propranolol", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "681921_1", "wnd_id": "681921_1_1", "text": "Catatonia associated with disulfiram therapy .", "tokens": ["Catatonia", "associated", "with", "disulfiram", "therapy", "."], "event_mentions": [{"id": "681921_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "681921_1_Ent0", "role": "Effect", "text": "Catatonia", "start": 0, "end": 1}, {"entity_id": "681921_1_Ent2", "role": "Treatment_Drug", "text": "disulfiram", "start": 3, "end": 4}, {"entity_id": "681921_1_Ent1", "role": "Treatment", "text": "disulfiram therapy", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "681921_1_Ent0", "text": "Catatonia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "681921_1_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "681921_1_Ent1", "text": "disulfiram therapy", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "681921_3", "wnd_id": "681921_3_1", "text": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment .", "tokens": ["This", "is", "the", "first", "report", "of", "a", "catatonic", "syndrome", "occurring", "in", "a", "patient", "receiving", "disulfiram", "treatment", "."], "event_mentions": [{"id": "681921_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 9, "end": 10}, "arguments": [{"entity_id": "681921_3_Ent0", "role": "Effect", "text": "catatonic syndrome", "start": 7, "end": 9}, {"entity_id": "681921_3_Ent2", "role": "Treatment_Drug", "text": "disulfiram", "start": 14, "end": 15}, {"entity_id": "681921_3_Ent1", "role": "Treatment", "text": "disulfiram treatment", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "681921_3_Ent0", "text": "catatonic syndrome", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "681921_3_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "681921_3_Ent1", "text": "disulfiram treatment", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "6837655_3", "wnd_id": "6837655_3_1", "text": "Within 3 weeks of beginning continuous daily isoniazid and rifampin therapy for pulmonary tuberculosis , a patient developed acute renal failure .", "tokens": ["Within", "3", "weeks", "of", "beginning", "continuous", "daily", "isoniazid", "and", "rifampin", "therapy", "for", "pulmonary", "tuberculosis", ",", "a", "patient", "developed", "acute", "renal", "failure", "."], "event_mentions": [{"id": "6837655_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 17, "end": 18}, "arguments": [{"entity_id": "6837655_3_Ent4", "role": "Treatment_Time_elapsed", "text": "Within 3 weeks of beginning", "start": 0, "end": 5}, {"entity_id": "6837655_3_Ent2", "role": "Treatment", "text": "Within 3 weeks of beginning continuous daily isoniazid and rifampin", "start": 0, "end": 10}, {"entity_id": "6837655_3_Ent5", "role": "Treatment_Freq", "text": "daily", "start": 6, "end": 7}, {"entity_id": "6837655_3_Ent6", "role": "Treatment_Drug", "text": "isoniazid", "start": 7, "end": 8}, {"entity_id": "6837655_3_Ent8", "role": "Combination_Drug", "text": "isoniazid", "start": 7, "end": 8}, {"entity_id": "6837655_3_Ent7", "role": "Treatment_Drug", "text": "rifampin", "start": 9, "end": 10}, {"entity_id": "6837655_3_Ent9", "role": "Combination_Drug", "text": "rifampin", "start": 9, "end": 10}, {"entity_id": "6837655_3_Ent3", "role": "Treatment_Disorder", "text": "pulmonary tuberculosis", "start": 12, "end": 14}, {"entity_id": "6837655_3_Ent0", "role": "Subject", "text": "a patient", "start": 15, "end": 17}, {"entity_id": "6837655_3_Ent1", "role": "Effect", "text": "acute renal failure", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "6837655_3_Ent4", "text": "Within 3 weeks of beginning", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "6837655_3_Ent2", "text": "Within 3 weeks of beginning continuous daily isoniazid and rifampin", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "6837655_3_Ent5", "text": "daily", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6837655_3_Ent6", "text": "isoniazid", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6837655_3_Ent8", "text": "isoniazid", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6837655_3_Ent7", "text": "rifampin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6837655_3_Ent9", "text": "rifampin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6837655_3_Ent3", "text": "pulmonary tuberculosis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "6837655_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "6837655_3_Ent1", "text": "acute renal failure", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "6851259_1", "wnd_id": "6851259_1_1", "text": "Nephrotic range pseudoproteinuria in a tolmetin - treated patient .", "tokens": ["Nephrotic", "range", "pseudoproteinuria", "in", "a", "tolmetin", "-", "treated", "patient", "."], "event_mentions": [{"id": "6851259_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "6851259_1_Ent1", "role": "Effect", "text": "Nephrotic range pseudoproteinuria", "start": 0, "end": 3}, {"entity_id": "6851259_1_Ent2", "role": "Treatment", "text": "tolmetin", "start": 5, "end": 6}, {"entity_id": "6851259_1_Ent3", "role": "Treatment_Drug", "text": "tolmetin", "start": 5, "end": 6}, {"entity_id": "6851259_1_Ent0", "role": "Subject", "text": "patient", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "6851259_1_Ent1", "text": "Nephrotic range pseudoproteinuria", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6851259_1_Ent2", "text": "tolmetin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "6851259_1_Ent3", "text": "tolmetin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "6851259_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "6865827_2", "wnd_id": "6865827_2_1", "text": "The patient was given methimazole instead of propylthiouracil but , 10 weeks later , agranulocytosis again occurred .", "tokens": ["The", "patient", "was", "given", "methimazole", "instead", "of", "propylthiouracil", "but", ",", "10", "weeks", "later", ",", "agranulocytosis", "again", "occurred", "."], "event_mentions": [{"id": "6865827_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 16, "end": 17}, "arguments": [{"entity_id": "6865827_2_Ent0", "role": "Subject", "text": "The patient", "start": 0, "end": 2}, {"entity_id": "6865827_2_Ent2", "role": "Treatment", "text": "methimazole", "start": 4, "end": 5}, {"entity_id": "6865827_2_Ent3", "role": "Treatment_Drug", "text": "methimazole", "start": 4, "end": 5}, {"entity_id": "6865827_2_Ent4", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 7, "end": 8}, {"entity_id": "6865827_2_Ent5", "role": "Treatment_Time_elapsed", "text": "10 weeks later", "start": 10, "end": 13}, {"entity_id": "6865827_2_Ent1", "role": "Effect", "text": "agranulocytosis", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "6865827_2_Ent0", "text": "The patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6865827_2_Ent2", "text": "methimazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6865827_2_Ent3", "text": "methimazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6865827_2_Ent4", "text": "propylthiouracil", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6865827_2_Ent5", "text": "10 weeks later", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "6865827_2_Ent1", "text": "agranulocytosis", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "6873616_3", "wnd_id": "6873616_3_1", "text": "The literature on thiabendazole - induced cholestasis and its association with sicca complex is reviewed .", "tokens": ["The", "literature", "on", "thiabendazole", "-", "induced", "cholestasis", "and", "its", "association", "with", "sicca", "complex", "is", "reviewed", "."], "event_mentions": [{"id": "6873616_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "6873616_3_Ent1", "role": "Treatment", "text": "thiabendazole", "start": 3, "end": 4}, {"entity_id": "6873616_3_Ent2", "role": "Treatment_Drug", "text": "thiabendazole", "start": 3, "end": 4}, {"entity_id": "6873616_3_Ent0", "role": "Effect", "text": "cholestasis", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6873616_3_Ent1", "text": "thiabendazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6873616_3_Ent2", "text": "thiabendazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6873616_3_Ent0", "text": "cholestasis", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6933231_1", "wnd_id": "6933231_1_1", "text": "Intracranial hemorrhage and focal seizures secondary to use of L - asparaginase during induction therapy of acute lymphocytic leukemia .", "tokens": ["Intracranial", "hemorrhage", "and", "focal", "seizures", "secondary", "to", "use", "of", "L", "-", "asparaginase", "during", "induction", "therapy", "of", "acute", "lymphocytic", "leukemia", "."], "event_mentions": [{"id": "6933231_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary to", "start": 5, "end": 7}, "arguments": [{"entity_id": "6933231_1_Ent0", "role": "Effect", "text": "Intracranial hemorrhage and focal seizures", "start": 0, "end": 5}, {"entity_id": "6933231_1_Ent1", "role": "Treatment", "text": "L - asparaginase", "start": 9, "end": 12}, {"entity_id": "6933231_1_Ent2", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "6933231_1_Ent0", "text": "Intracranial hemorrhage and focal seizures", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "6933231_1_Ent1", "text": "L - asparaginase", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "6933231_1_Ent2", "text": "L - asparaginase", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "6998294_2", "wnd_id": "6998294_2_1", "text": "Disopyramide ( Norpace) - induced hypoglycemia .", "tokens": ["Disopyramide", "(", "Norpace)", "-", "induced", "hypoglycemia", "."], "event_mentions": [{"id": "6998294_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "6998294_2_Ent2", "role": "Treatment_Drug", "text": "Disopyramide", "start": 0, "end": 1}, {"entity_id": "6998294_2_Ent1", "role": "Treatment", "text": "Disopyramide ( Norpace)", "start": 0, "end": 3}, {"entity_id": "6998294_2_Ent0", "role": "Effect", "text": "hypoglycemia", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "6998294_2_Ent2", "text": "Disopyramide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6998294_2_Ent1", "text": "Disopyramide ( Norpace)", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6998294_2_Ent0", "text": "hypoglycemia", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "7035691_1", "wnd_id": "7035691_1_1", "text": "Transient anuria following administration of angiotensin I - converting enzyme inhibitor ( SQ 14225 ) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation .", "tokens": ["Transient", "anuria", "following", "administration", "of", "angiotensin", "I", "-", "converting", "enzyme", "inhibitor", "(", "SQ", "14225", ")", "in", "a", "patient", "with", "renal", "artery", "stenosis", "of", "the", "solitary", "kidney", "successfully", "treated", "with", "renal", "autotransplantation", "."], "event_mentions": [{"id": "7035691_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "7035691_1_Ent1", "role": "Effect", "text": "Transient anuria", "start": 0, "end": 2}, {"entity_id": "7035691_1_Ent4", "role": "Treatment_Drug", "text": "angiotensin I - converting enzyme inhibitor", "start": 5, "end": 11}, {"entity_id": "7035691_1_Ent2", "role": "Treatment", "text": "angiotensin I - converting enzyme inhibitor ( SQ 14225 )", "start": 5, "end": 15}, {"entity_id": "7035691_1_Ent0", "role": "Subject", "text": "a patient with renal artery stenosis of the solitary kidney", "start": 16, "end": 26}, {"entity_id": "7035691_1_Ent3", "role": "Treatment_Disorder", "text": "renal artery stenosis of the solitary kidney", "start": 19, "end": 26}]}, {"id": "7035691_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 27, "end": 28}, "arguments": [{"entity_id": "7035691_1_Ent7", "role": "Treatment_Disorder", "text": "Transient anuria", "start": 0, "end": 2}, {"entity_id": "7035691_1_Ent5", "role": "Subject", "text": "a patient with renal artery stenosis of the solitary kidney", "start": 16, "end": 26}, {"entity_id": "7035691_1_Ent6", "role": "Treatment", "text": "renal autotransplantation", "start": 29, "end": 31}]}], "entity_mentions": [{"id": "7035691_1_Ent1", "text": "Transient anuria", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7035691_1_Ent7", "text": "Transient anuria", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7035691_1_Ent4", "text": "angiotensin I - converting enzyme inhibitor", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "7035691_1_Ent2", "text": "angiotensin I - converting enzyme inhibitor ( SQ 14225 )", "entity_type": "Entity", "start": 5, "end": 15}, {"id": "7035691_1_Ent0", "text": "a patient with renal artery stenosis of the solitary kidney", "entity_type": "Entity", "start": 16, "end": 26}, {"id": "7035691_1_Ent5", "text": "a patient with renal artery stenosis of the solitary kidney", "entity_type": "Entity", "start": 16, "end": 26}, {"id": "7035691_1_Ent3", "text": "renal artery stenosis of the solitary kidney", "entity_type": "Entity", "start": 19, "end": 26}, {"id": "7035691_1_Ent6", "text": "renal autotransplantation", "entity_type": "Entity", "start": 29, "end": 31}], "lang": "en"}
{"doc_id": "7035691_2", "wnd_id": "7035691_2_1", "text": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril .", "tokens": ["We", "report", "on", "a", "patient", "with", "renal", "artery", "stenosis", "who", "had", "only", "1", "kidney", "and", "in", "whom", "acute", "renal", "impairment", "developed", "with", "transient", "anuria", "after", "the", "administration", "of", "captopril", "."], "event_mentions": [{"id": "7035691_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 24, "end": 25}, "arguments": [{"entity_id": "7035691_2_Ent0", "role": "Subject", "text": "a patient with renal artery stenosis who had only 1 kidney", "start": 3, "end": 14}, {"entity_id": "7035691_2_Ent1", "role": "Subject_Disorder", "text": "renal artery stenosis who had only 1 kidney", "start": 6, "end": 14}, {"entity_id": "7035691_2_Ent2", "role": "Effect", "text": "acute renal impairment developed with transient anuria", "start": 17, "end": 24}, {"entity_id": "7035691_2_Ent3", "role": "Treatment", "text": "the administration of captopril", "start": 25, "end": 29}, {"entity_id": "7035691_2_Ent4", "role": "Treatment_Drug", "text": "captopril", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "7035691_2_Ent0", "text": "a patient with renal artery stenosis who had only 1 kidney", "entity_type": "Entity", "start": 3, "end": 14}, {"id": "7035691_2_Ent1", "text": "renal artery stenosis who had only 1 kidney", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "7035691_2_Ent2", "text": "acute renal impairment developed with transient anuria", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "7035691_2_Ent3", "text": "the administration of captopril", "entity_type": "Entity", "start": 25, "end": 29}, {"id": "7035691_2_Ent4", "text": "captopril", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "7081289_3", "wnd_id": "7081289_3_1", "text": "There have been only two reports of cimetidine - induced hepatitis .", "tokens": ["There", "have", "been", "only", "two", "reports", "of", "cimetidine", "-", "induced", "hepatitis", "."], "event_mentions": [{"id": "7081289_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "7081289_3_Ent1", "role": "Treatment", "text": "cimetidine", "start": 7, "end": 8}, {"entity_id": "7081289_3_Ent2", "role": "Treatment_Drug", "text": "cimetidine", "start": 7, "end": 8}, {"entity_id": "7081289_3_Ent0", "role": "Effect", "text": "hepatitis", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "7081289_3_Ent1", "text": "cimetidine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7081289_3_Ent2", "text": "cimetidine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7081289_3_Ent0", "text": "hepatitis", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "7117795_1", "wnd_id": "7117795_1_1", "text": "Flucytosine - associated diarrhea has been previously described in 6% - 10 % of patients receiving the drug .", "tokens": ["Flucytosine", "-", "associated", "diarrhea", "has", "been", "previously", "described", "in", "6%", "-", "10", "%", "of", "patients", "receiving", "the", "drug", "."], "event_mentions": [{"id": "7117795_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "7117795_1_Ent3", "role": "Treatment", "text": "Flucytosine", "start": 0, "end": 1}, {"entity_id": "7117795_1_Ent4", "role": "Treatment_Drug", "text": "Flucytosine", "start": 0, "end": 1}, {"entity_id": "7117795_1_Ent2", "role": "Effect", "text": "diarrhea", "start": 3, "end": 4}, {"entity_id": "7117795_1_Ent1", "role": "Subject_Population", "text": "6% - 10 %", "start": 9, "end": 13}, {"entity_id": "7117795_1_Ent0", "role": "Subject", "text": "6% - 10 % of patients", "start": 9, "end": 15}]}], "entity_mentions": [{"id": "7117795_1_Ent3", "text": "Flucytosine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7117795_1_Ent4", "text": "Flucytosine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7117795_1_Ent2", "text": "diarrhea", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7117795_1_Ent1", "text": "6% - 10 %", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "7117795_1_Ent0", "text": "6% - 10 % of patients", "entity_type": "Entity", "start": 9, "end": 15}], "lang": "en"}
{"doc_id": "7117795_3", "wnd_id": "7117795_3_1", "text": "Ulcerating enteritis associated with flucytosine therapy .", "tokens": ["Ulcerating", "enteritis", "associated", "with", "flucytosine", "therapy", "."], "event_mentions": [{"id": "7117795_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 2, "end": 4}, "arguments": [{"entity_id": "7117795_3_Ent0", "role": "Effect", "text": "Ulcerating enteritis", "start": 0, "end": 2}, {"entity_id": "7117795_3_Ent2", "role": "Treatment_Drug", "text": "flucytosine", "start": 4, "end": 5}, {"entity_id": "7117795_3_Ent1", "role": "Treatment", "text": "flucytosine therapy", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "7117795_3_Ent0", "text": "Ulcerating enteritis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7117795_3_Ent2", "text": "flucytosine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7117795_3_Ent1", "text": "flucytosine therapy", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "7139589_2", "wnd_id": "7139589_2_1", "text": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L - asparaginase .", "tokens": ["Delayed", "pseudocyst", "of", "the", "pancreas", "can", "be", "a", "complication", "of", "intramuscular", "L", "-", "asparaginase", "."], "event_mentions": [{"id": "7139589_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "can", "start": 5, "end": 6}, "arguments": [{"entity_id": "7139589_2_Ent0", "role": "Effect", "text": "Delayed pseudocyst of the pancreas", "start": 0, "end": 5}, {"entity_id": "7139589_2_Ent3", "role": "Treatment_Route", "text": "intramuscular", "start": 10, "end": 11}, {"entity_id": "7139589_2_Ent1", "role": "Treatment", "text": "intramuscular L - asparaginase", "start": 10, "end": 14}, {"entity_id": "7139589_2_Ent2", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "7139589_2_Ent0", "text": "Delayed pseudocyst of the pancreas", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7139589_2_Ent3", "text": "intramuscular", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7139589_2_Ent1", "text": "intramuscular L - asparaginase", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "7139589_2_Ent2", "text": "L - asparaginase", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "7139589_4", "wnd_id": "7139589_4_1", "text": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L - asparaginase .", "tokens": ["Three", "cases", "of", "pseudocyst", "of", "the", "pancreas", "in", "two", "women", "and", "one", "man", "have", "previously", "been", "reported", "with", "the", "use", "of", "intravenous", "L", "-", "asparaginase", "."], "event_mentions": [{"id": "7139589_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 16, "end": 17}, "arguments": [{"entity_id": "7139589_4_Ent5", "role": "Effect", "text": "pseudocyst of the pancreas", "start": 3, "end": 7}, {"entity_id": "7139589_4_Ent1", "role": "Subject_Population", "text": "two", "start": 8, "end": 9}, {"entity_id": "7139589_4_Ent0", "role": "Subject", "text": "two women and one man", "start": 8, "end": 13}, {"entity_id": "7139589_4_Ent3", "role": "Subject_Gender", "text": "women", "start": 9, "end": 10}, {"entity_id": "7139589_4_Ent2", "role": "Subject_Population", "text": "one", "start": 11, "end": 12}, {"entity_id": "7139589_4_Ent4", "role": "Subject_Gender", "text": "man", "start": 12, "end": 13}, {"entity_id": "7139589_4_Ent8", "role": "Treatment_Route", "text": "intravenous", "start": 21, "end": 22}, {"entity_id": "7139589_4_Ent6", "role": "Treatment", "text": "intravenous L - asparaginase", "start": 21, "end": 25}, {"entity_id": "7139589_4_Ent7", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 22, "end": 25}]}], "entity_mentions": [{"id": "7139589_4_Ent5", "text": "pseudocyst of the pancreas", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "7139589_4_Ent1", "text": "two", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7139589_4_Ent0", "text": "two women and one man", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "7139589_4_Ent3", "text": "women", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7139589_4_Ent2", "text": "one", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7139589_4_Ent4", "text": "man", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7139589_4_Ent8", "text": "intravenous", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "7139589_4_Ent6", "text": "intravenous L - asparaginase", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "7139589_4_Ent7", "text": "L - asparaginase", "entity_type": "Entity", "start": 22, "end": 25}], "lang": "en"}
{"doc_id": "7174620_1", "wnd_id": "7174620_1_1", "text": "Nine delirious patients suffering from lithium intoxication were examined with the Mini - Mental State Exam ( MMS ) to describe the clinical course of the disorder .", "tokens": ["Nine", "delirious", "patients", "suffering", "from", "lithium", "intoxication", "were", "examined", "with", "the", "Mini", "-", "Mental", "State", "Exam", "(", "MMS", ")", "to", "describe", "the", "clinical", "course", "of", "the", "disorder", "."], "event_mentions": [{"id": "7174620_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffering from", "start": 3, "end": 5}, "arguments": [{"entity_id": "7174620_1_Ent1", "role": "Subject_Population", "text": "Nine", "start": 0, "end": 1}, {"entity_id": "7174620_1_Ent0", "role": "Subject", "text": "Nine delirious patients", "start": 0, "end": 3}, {"entity_id": "7174620_1_Ent2", "role": "Subject_Disorder", "text": "delirious", "start": 1, "end": 2}, {"entity_id": "7174620_1_Ent4", "role": "Treatment", "text": "lithium", "start": 5, "end": 6}, {"entity_id": "7174620_1_Ent5", "role": "Treatment_Drug", "text": "lithium", "start": 5, "end": 6}, {"entity_id": "7174620_1_Ent3", "role": "Effect", "text": "lithium intoxication", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "7174620_1_Ent1", "text": "Nine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7174620_1_Ent0", "text": "Nine delirious patients", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7174620_1_Ent2", "text": "delirious", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7174620_1_Ent4", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7174620_1_Ent5", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7174620_1_Ent3", "text": "lithium intoxication", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "7212107_2", "wnd_id": "7212107_2_1", "text": "These results indicate that lithium may cause biochemical hyperparathyroidism .", "tokens": ["These", "results", "indicate", "that", "lithium", "may", "cause", "biochemical", "hyperparathyroidism", "."], "event_mentions": [{"id": "7212107_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "may", "start": 5, "end": 6}, "arguments": [{"entity_id": "7212107_2_Ent1", "role": "Treatment", "text": "lithium", "start": 4, "end": 5}, {"entity_id": "7212107_2_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 4, "end": 5}, {"entity_id": "7212107_2_Ent0", "role": "Effect", "text": "biochemical hyperparathyroidism", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "7212107_2_Ent1", "text": "lithium", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7212107_2_Ent2", "text": "lithium", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7212107_2_Ent0", "text": "biochemical hyperparathyroidism", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "7235792_3", "wnd_id": "7235792_3_1", "text": "In the second case , five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy .", "tokens": ["In", "the", "second", "case", ",", "five", "cardiac", "arrests", "due", "to", "ventricular", "tachycardia", "and", "fibrillation", "occurred", "during", "several", "hours", "after", "beginning", "a", "trial", "of", "bretylium", "maintenance", "therapy", "for", "complex", "ventricular", "ectopy", "."], "event_mentions": [{"id": "7235792_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 14, "end": 15}, "arguments": [{"entity_id": "7235792_3_Ent0", "role": "Subject", "text": "In the second case", "start": 0, "end": 4}, {"entity_id": "7235792_3_Ent1", "role": "Effect", "text": "five cardiac arrests due to ventricular tachycardia and fibrillation", "start": 5, "end": 14}, {"entity_id": "7235792_3_Ent4", "role": "Treatment_Time_elapsed", "text": "several hours after", "start": 16, "end": 19}, {"entity_id": "7235792_3_Ent2", "role": "Treatment", "text": "several hours after beginning a trial of bretylium maintenance therapy", "start": 16, "end": 26}, {"entity_id": "7235792_3_Ent5", "role": "Treatment_Drug", "text": "bretylium", "start": 23, "end": 24}, {"entity_id": "7235792_3_Ent3", "role": "Treatment_Disorder", "text": "complex ventricular ectopy", "start": 27, "end": 30}]}], "entity_mentions": [{"id": "7235792_3_Ent0", "text": "In the second case", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "7235792_3_Ent1", "text": "five cardiac arrests due to ventricular tachycardia and fibrillation", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "7235792_3_Ent4", "text": "several hours after", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "7235792_3_Ent2", "text": "several hours after beginning a trial of bretylium maintenance therapy", "entity_type": "Entity", "start": 16, "end": 26}, {"id": "7235792_3_Ent5", "text": "bretylium", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "7235792_3_Ent3", "text": "complex ventricular ectopy", "entity_type": "Entity", "start": 27, "end": 30}], "lang": "en"}
{"doc_id": "7235792_4", "wnd_id": "7235792_4_1", "text": "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy .", "tokens": ["Paradoxical", "ventricular", "tachycardia", "and", "fibrillation", "after", "intravenous", "bretylium", "therapy", "."], "event_mentions": [{"id": "7235792_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "7235792_4_Ent0", "role": "Effect", "text": "Paradoxical ventricular tachycardia and fibrillation", "start": 0, "end": 5}, {"entity_id": "7235792_4_Ent2", "role": "Treatment_Route", "text": "intravenous", "start": 6, "end": 7}, {"entity_id": "7235792_4_Ent1", "role": "Treatment", "text": "intravenous bretylium", "start": 6, "end": 8}, {"entity_id": "7235792_4_Ent3", "role": "Treatment_Drug", "text": "bretylium", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "7235792_4_Ent0", "text": "Paradoxical ventricular tachycardia and fibrillation", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7235792_4_Ent2", "text": "intravenous", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7235792_4_Ent1", "text": "intravenous bretylium", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7235792_4_Ent3", "text": "bretylium", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "7272895_2", "wnd_id": "7272895_2_1", "text": "Acute acoustic nerve palsy associated with vincristine therapy .", "tokens": ["Acute", "acoustic", "nerve", "palsy", "associated", "with", "vincristine", "therapy", "."], "event_mentions": [{"id": "7272895_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "7272895_2_Ent0", "role": "Effect", "text": "Acute acoustic nerve palsy", "start": 0, "end": 4}, {"entity_id": "7272895_2_Ent2", "role": "Treatment_Drug", "text": "vincristine", "start": 6, "end": 7}, {"entity_id": "7272895_2_Ent1", "role": "Treatment", "text": "vincristine therapy", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "7272895_2_Ent0", "text": "Acute acoustic nerve palsy", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "7272895_2_Ent2", "text": "vincristine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7272895_2_Ent1", "text": "vincristine therapy", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "7282702_1", "wnd_id": "7282702_1_1", "text": "A case of timolol - associated heart failure in a 73 - year old white man is reported .", "tokens": ["A", "case", "of", "timolol", "-", "associated", "heart", "failure", "in", "a", "73", "-", "year", "old", "white", "man", "is", "reported", "."], "event_mentions": [{"id": "7282702_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "7282702_1_Ent5", "role": "Treatment", "text": "timolol", "start": 3, "end": 4}, {"entity_id": "7282702_1_Ent6", "role": "Treatment_Drug", "text": "timolol", "start": 3, "end": 4}, {"entity_id": "7282702_1_Ent4", "role": "Effect", "text": "heart failure", "start": 6, "end": 8}, {"entity_id": "7282702_1_Ent0", "role": "Subject", "text": "a 73 - year old white man", "start": 9, "end": 16}, {"entity_id": "7282702_1_Ent1", "role": "Subject_Age", "text": "73 - year old", "start": 10, "end": 14}, {"entity_id": "7282702_1_Ent2", "role": "Subject_Race", "text": "white", "start": 14, "end": 15}, {"entity_id": "7282702_1_Ent3", "role": "Subject_Gender", "text": "man", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "7282702_1_Ent5", "text": "timolol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7282702_1_Ent6", "text": "timolol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7282702_1_Ent4", "text": "heart failure", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7282702_1_Ent0", "text": "a 73 - year old white man", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "7282702_1_Ent1", "text": "73 - year old", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "7282702_1_Ent2", "text": "white", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "7282702_1_Ent3", "text": "man", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "7304798_2", "wnd_id": "7304798_2_1", "text": "The authors report a longitudinal case study of a woman with a history of bipolar affective disorder in which L - dopa shortened the manic - depressive cycle length when administered in a double - blind trial .", "tokens": ["The", "authors", "report", "a", "longitudinal", "case", "study", "of", "a", "woman", "with", "a", "history", "of", "bipolar", "affective", "disorder", "in", "which", "L", "-", "dopa", "shortened", "the", "manic", "-", "depressive", "cycle", "length", "when", "administered", "in", "a", "double", "-", "blind", "trial", "."], "event_mentions": [{"id": "7304798_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "shortened", "start": 22, "end": 23}, "arguments": [{"entity_id": "7304798_2_Ent0", "role": "Subject", "text": "a woman with a history of bipolar affective disorder", "start": 8, "end": 17}, {"entity_id": "7304798_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "7304798_2_Ent2", "role": "Subject_Disorder", "text": "bipolar affective disorder", "start": 14, "end": 17}, {"entity_id": "7304798_2_Ent4", "role": "Treatment", "text": "L - dopa", "start": 19, "end": 22}, {"entity_id": "7304798_2_Ent5", "role": "Treatment_Drug", "text": "L - dopa", "start": 19, "end": 22}, {"entity_id": "7304798_2_Ent3", "role": "Effect", "text": "shortened the manic - depressive cycle length", "start": 22, "end": 29}]}], "entity_mentions": [{"id": "7304798_2_Ent0", "text": "a woman with a history of bipolar affective disorder", "entity_type": "Entity", "start": 8, "end": 17}, {"id": "7304798_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7304798_2_Ent2", "text": "bipolar affective disorder", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "7304798_2_Ent4", "text": "L - dopa", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "7304798_2_Ent5", "text": "L - dopa", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "7304798_2_Ent3", "text": "shortened the manic - depressive cycle length", "entity_type": "Entity", "start": 22, "end": 29}], "lang": "en"}
{"doc_id": "7351000_1", "wnd_id": "7351000_1_1", "text": "Acute non - lymphocytic leukemia in patients with ovarian carcinoma following long - term treatment with Treosulfan (= dihydroxybusulfan ) .", "tokens": ["Acute", "non", "-", "lymphocytic", "leukemia", "in", "patients", "with", "ovarian", "carcinoma", "following", "long", "-", "term", "treatment", "with", "Treosulfan", "(=", "dihydroxybusulfan", ")", "."], "event_mentions": [{"id": "7351000_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 10, "end": 11}, "arguments": [{"entity_id": "7351000_1_Ent1", "role": "Effect", "text": "Acute non - lymphocytic leukemia", "start": 0, "end": 5}, {"entity_id": "7351000_1_Ent0", "role": "Subject", "text": "patients with ovarian carcinoma", "start": 6, "end": 10}, {"entity_id": "7351000_1_Ent4", "role": "Treatment_Disorder", "text": "ovarian carcinoma", "start": 8, "end": 10}, {"entity_id": "7351000_1_Ent2", "role": "Treatment", "text": "long - term treatment with Treosulfan (= dihydroxybusulfan )", "start": 11, "end": 20}, {"entity_id": "7351000_1_Ent3", "role": "Treatment_Drug", "text": "Treosulfan", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "7351000_1_Ent1", "text": "Acute non - lymphocytic leukemia", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7351000_1_Ent0", "text": "patients with ovarian carcinoma", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "7351000_1_Ent4", "text": "ovarian carcinoma", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "7351000_1_Ent2", "text": "long - term treatment with Treosulfan (= dihydroxybusulfan )", "entity_type": "Entity", "start": 11, "end": 20}, {"id": "7351000_1_Ent3", "text": "Treosulfan", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "7351000_3", "wnd_id": "7351000_3_1", "text": "Seven of the eight cases of acute leukemia occurred in a series of 553 patients treated with Treosulfan for ovarian cancer in the period from 1970 to 1977 and followed closely for a total of 1159 patient - years up to February 1978 .", "tokens": ["Seven", "of", "the", "eight", "cases", "of", "acute", "leukemia", "occurred", "in", "a", "series", "of", "553", "patients", "treated", "with", "Treosulfan", "for", "ovarian", "cancer", "in", "the", "period", "from", "1970", "to", "1977", "and", "followed", "closely", "for", "a", "total", "of", "1159", "patient", "-", "years", "up", "to", "February", "1978", "."], "event_mentions": [{"id": "7351000_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 8, "end": 9}, "arguments": [{"entity_id": "7351000_3_Ent0", "role": "Subject", "text": "Seven of the eight cases", "start": 0, "end": 5}, {"entity_id": "7351000_3_Ent1", "role": "Subject_Population", "text": "eight", "start": 3, "end": 4}, {"entity_id": "7351000_3_Ent2", "role": "Effect", "text": "acute leukemia", "start": 6, "end": 8}, {"entity_id": "7351000_3_Ent3", "role": "Treatment", "text": "Treosulfan", "start": 17, "end": 18}, {"entity_id": "7351000_3_Ent4", "role": "Treatment_Drug", "text": "Treosulfan", "start": 17, "end": 18}, {"entity_id": "7351000_3_Ent5", "role": "Treatment_Disorder", "text": "ovarian cancer", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "7351000_3_Ent0", "text": "Seven of the eight cases", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7351000_3_Ent1", "text": "eight", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7351000_3_Ent2", "text": "acute leukemia", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7351000_3_Ent3", "text": "Treosulfan", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "7351000_3_Ent4", "text": "Treosulfan", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "7351000_3_Ent5", "text": "ovarian cancer", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "7375145_1", "wnd_id": "7375145_1_1", "text": "Diagnosis : practolol induced sclerosing peritonitis .", "tokens": ["Diagnosis", ":", "practolol", "induced", "sclerosing", "peritonitis", "."], "event_mentions": [{"id": "7375145_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "7375145_1_Ent1", "role": "Treatment", "text": "practolol", "start": 2, "end": 3}, {"entity_id": "7375145_1_Ent2", "role": "Treatment_Drug", "text": "practolol", "start": 2, "end": 3}, {"entity_id": "7375145_1_Ent0", "role": "Effect", "text": "sclerosing peritonitis", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "7375145_1_Ent1", "text": "practolol", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7375145_1_Ent2", "text": "practolol", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7375145_1_Ent0", "text": "sclerosing peritonitis", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "7379406_3", "wnd_id": "7379406_3_1", "text": "The case report discussed is , to our knowledge , the third of its kind regarding bone fluorosis resulting from use of this nicotinic derivative .", "tokens": ["The", "case", "report", "discussed", "is", ",", "to", "our", "knowledge", ",", "the", "third", "of", "its", "kind", "regarding", "bone", "fluorosis", "resulting", "from", "use", "of", "this", "nicotinic", "derivative", "."], "event_mentions": [{"id": "7379406_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "use", "start": 20, "end": 21}, "arguments": [{"entity_id": "7379406_3_Ent0", "role": "Effect", "text": "bone fluorosis", "start": 16, "end": 18}, {"entity_id": "7379406_3_Ent1", "role": "Treatment", "text": "nicotinic derivative", "start": 23, "end": 25}, {"entity_id": "7379406_3_Ent2", "role": "Treatment_Drug", "text": "nicotinic derivative", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "7379406_3_Ent0", "text": "bone fluorosis", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "7379406_3_Ent1", "text": "nicotinic derivative", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "7379406_3_Ent2", "text": "nicotinic derivative", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "7393795_1", "wnd_id": "7393795_1_1", "text": "A 62 - year - old Indian with diabetic nephropathy controlled with metformin , developed miliary tuberculosis for which he was treated with rifampicin , isoniazid and ethambutol .", "tokens": ["A", "62", "-", "year", "-", "old", "Indian", "with", "diabetic", "nephropathy", "controlled", "with", "metformin", ",", "developed", "miliary", "tuberculosis", "for", "which", "he", "was", "treated", "with", "rifampicin", ",", "isoniazid", "and", "ethambutol", "."], "event_mentions": [{"id": "7393795_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "7393795_1_Ent0", "role": "Subject", "text": "A 62 - year - old Indian with diabetic nephropathy", "start": 0, "end": 10}, {"entity_id": "7393795_1_Ent1", "role": "Subject_Age", "text": "62 - year - old", "start": 1, "end": 6}, {"entity_id": "7393795_1_Ent2", "role": "Subject_Race", "text": "Indian", "start": 6, "end": 7}, {"entity_id": "7393795_1_Ent5", "role": "Treatment_Disorder", "text": "diabetic nephropathy", "start": 8, "end": 10}, {"entity_id": "7393795_1_Ent4", "role": "Treatment", "text": "metformin", "start": 12, "end": 13}, {"entity_id": "7393795_1_Ent6", "role": "Treatment_Drug", "text": "metformin", "start": 12, "end": 13}, {"entity_id": "7393795_1_Ent3", "role": "Effect", "text": "miliary tuberculosis", "start": 15, "end": 17}]}, {"id": "7393795_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 21, "end": 22}, "arguments": [{"entity_id": "7393795_1_Ent8", "role": "Treatment_Disorder", "text": "miliary tuberculosis", "start": 15, "end": 17}, {"entity_id": "7393795_1_Ent10", "role": "Treatment_Drug", "text": "rifampicin", "start": 23, "end": 24}, {"entity_id": "7393795_1_Ent14", "role": "Combination_Drug", "text": "rifampicin", "start": 23, "end": 24}, {"entity_id": "7393795_1_Ent7", "role": "Treatment", "text": "rifampicin , isoniazid and ethambutol", "start": 23, "end": 28}, {"entity_id": "7393795_1_Ent11", "role": "Treatment_Drug", "text": "isoniazid", "start": 25, "end": 26}, {"entity_id": "7393795_1_Ent13", "role": "Combination_Drug", "text": "isoniazid", "start": 25, "end": 26}, {"entity_id": "7393795_1_Ent9", "role": "Treatment_Drug", "text": "ethambutol", "start": 27, "end": 28}, {"entity_id": "7393795_1_Ent12", "role": "Combination_Drug", "text": "ethambutol", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "7393795_1_Ent0", "text": "A 62 - year - old Indian with diabetic nephropathy", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "7393795_1_Ent1", "text": "62 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "7393795_1_Ent2", "text": "Indian", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7393795_1_Ent5", "text": "diabetic nephropathy", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "7393795_1_Ent4", "text": "metformin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7393795_1_Ent6", "text": "metformin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7393795_1_Ent3", "text": "miliary tuberculosis", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "7393795_1_Ent8", "text": "miliary tuberculosis", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "7393795_1_Ent10", "text": "rifampicin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "7393795_1_Ent14", "text": "rifampicin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "7393795_1_Ent7", "text": "rifampicin , isoniazid and ethambutol", "entity_type": "Entity", "start": 23, "end": 28}, {"id": "7393795_1_Ent11", "text": "isoniazid", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "7393795_1_Ent13", "text": "isoniazid", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "7393795_1_Ent9", "text": "ethambutol", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "7393795_1_Ent12", "text": "ethambutol", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "7393795_2", "wnd_id": "7393795_2_1", "text": "Para - aminosalicylic acid - induced hypoglycaemia in a patient with diabetic nephropathy .", "tokens": ["Para", "-", "aminosalicylic", "acid", "-", "induced", "hypoglycaemia", "in", "a", "patient", "with", "diabetic", "nephropathy", "."], "event_mentions": [{"id": "7393795_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "7393795_2_Ent3", "role": "Treatment", "text": "Para - aminosalicylic acid", "start": 0, "end": 4}, {"entity_id": "7393795_2_Ent4", "role": "Treatment_Drug", "text": "Para - aminosalicylic acid", "start": 0, "end": 4}, {"entity_id": "7393795_2_Ent2", "role": "Effect", "text": "hypoglycaemia", "start": 6, "end": 7}, {"entity_id": "7393795_2_Ent0", "role": "Subject", "text": "a patient with diabetic nephropathy", "start": 8, "end": 13}, {"entity_id": "7393795_2_Ent1", "role": "Subject_Disorder", "text": "diabetic nephropathy", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "7393795_2_Ent3", "text": "Para - aminosalicylic acid", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "7393795_2_Ent4", "text": "Para - aminosalicylic acid", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "7393795_2_Ent2", "text": "hypoglycaemia", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7393795_2_Ent0", "text": "a patient with diabetic nephropathy", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "7393795_2_Ent1", "text": "diabetic nephropathy", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "7408538_1", "wnd_id": "7408538_1_1", "text": "Markedly increased pigmementation of skin immediately overlying veins used for multiple 5 - fluorouracil infusions was noted .", "tokens": ["Markedly", "increased", "pigmementation", "of", "skin", "immediately", "overlying", "veins", "used", "for", "multiple", "5", "-", "fluorouracil", "infusions", "was", "noted", "."], "event_mentions": [{"id": "7408538_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "noted", "start": 16, "end": 17}, "arguments": [{"entity_id": "7408538_1_Ent0", "role": "Effect", "text": "Markedly increased pigmementation of skin immediately overlying veins", "start": 0, "end": 8}, {"entity_id": "7408538_1_Ent1", "role": "Treatment", "text": "multiple 5 - fluorouracil infusions", "start": 10, "end": 15}, {"entity_id": "7408538_1_Ent2", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 11, "end": 14}, {"entity_id": "7408538_1_Ent3", "role": "Treatment_Route", "text": "infusions", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "7408538_1_Ent0", "text": "Markedly increased pigmementation of skin immediately overlying veins", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "7408538_1_Ent1", "text": "multiple 5 - fluorouracil infusions", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "7408538_1_Ent2", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "7408538_1_Ent3", "text": "infusions", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "7408538_2", "wnd_id": "7408538_2_1", "text": "Unusual pigmentary changes associated with 5 - fluorouracil therapy .", "tokens": ["Unusual", "pigmentary", "changes", "associated", "with", "5", "-", "fluorouracil", "therapy", "."], "event_mentions": [{"id": "7408538_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "7408538_2_Ent0", "role": "Effect", "text": "Unusual pigmentary changes", "start": 0, "end": 3}, {"entity_id": "7408538_2_Ent1", "role": "Treatment", "text": "5 - fluorouracil", "start": 5, "end": 8}, {"entity_id": "7408538_2_Ent2", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 5, "end": 8}]}], "entity_mentions": [{"id": "7408538_2_Ent0", "text": "Unusual pigmentary changes", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7408538_2_Ent1", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "7408538_2_Ent2", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 5, "end": 8}], "lang": "en"}
{"doc_id": "7416268_3", "wnd_id": "7416268_3_1", "text": "Although useful in the management of chronic alcoholism , disulfiram is being increasingly associated with a wide spectrum of side effects and untoward medical sequelae , which now include catatonia .", "tokens": ["Although", "useful", "in", "the", "management", "of", "chronic", "alcoholism", ",", "disulfiram", "is", "being", "increasingly", "associated", "with", "a", "wide", "spectrum", "of", "side", "effects", "and", "untoward", "medical", "sequelae", ",", "which", "now", "include", "catatonia", "."], "event_mentions": [{"id": "7416268_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 13, "end": 14}, "arguments": [{"entity_id": "7416268_3_Ent3", "role": "Treatment_Disorder", "text": "chronic alcoholism", "start": 6, "end": 8}, {"entity_id": "7416268_3_Ent1", "role": "Treatment", "text": "disulfiram", "start": 9, "end": 10}, {"entity_id": "7416268_3_Ent2", "role": "Treatment_Drug", "text": "disulfiram", "start": 9, "end": 10}, {"entity_id": "7416268_3_Ent0", "role": "Effect", "text": "a wide spectrum of side effects and untoward medical sequelae , which now include catatonia", "start": 15, "end": 30}]}], "entity_mentions": [{"id": "7416268_3_Ent3", "text": "chronic alcoholism", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7416268_3_Ent1", "text": "disulfiram", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7416268_3_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7416268_3_Ent0", "text": "a wide spectrum of side effects and untoward medical sequelae , which now include catatonia", "entity_type": "Entity", "start": 15, "end": 30}], "lang": "en"}
{"doc_id": "7436161_1", "wnd_id": "7436161_1_1", "text": "Cardiorespiratory toxicity due to miconazole .", "tokens": ["Cardiorespiratory", "toxicity", "due", "to", "miconazole", "."], "event_mentions": [{"id": "7436161_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 2, "end": 4}, "arguments": [{"entity_id": "7436161_1_Ent0", "role": "Effect", "text": "Cardiorespiratory toxicity", "start": 0, "end": 2}, {"entity_id": "7436161_1_Ent1", "role": "Treatment", "text": "miconazole", "start": 4, "end": 5}, {"entity_id": "7436161_1_Ent2", "role": "Treatment_Drug", "text": "miconazole", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "7436161_1_Ent0", "text": "Cardiorespiratory toxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7436161_1_Ent1", "text": "miconazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7436161_1_Ent2", "text": "miconazole", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "7436161_4", "wnd_id": "7436161_4_1", "text": "None of them had a history of cardiac disease , and with the possible exception of one case of cardiac arrest , where the patient received doxorubicin , no predisposing factors could be found .", "tokens": ["None", "of", "them", "had", "a", "history", "of", "cardiac", "disease", ",", "and", "with", "the", "possible", "exception", "of", "one", "case", "of", "cardiac", "arrest", ",", "where", "the", "patient", "received", "doxorubicin", ",", "no", "predisposing", "factors", "could", "be", "found", "."], "event_mentions": [{"id": "7436161_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "received", "start": 25, "end": 26}, "arguments": [{"entity_id": "7436161_4_Ent1", "role": "Effect", "text": "cardiac arrest", "start": 19, "end": 21}, {"entity_id": "7436161_4_Ent0", "role": "Subject", "text": "the patient", "start": 23, "end": 25}, {"entity_id": "7436161_4_Ent2", "role": "Treatment", "text": "doxorubicin", "start": 26, "end": 27}, {"entity_id": "7436161_4_Ent3", "role": "Treatment_Drug", "text": "doxorubicin", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "7436161_4_Ent1", "text": "cardiac arrest", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "7436161_4_Ent0", "text": "the patient", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "7436161_4_Ent2", "text": "doxorubicin", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "7436161_4_Ent3", "text": "doxorubicin", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "7495990_1", "wnd_id": "7495990_1_1", "text": "Used injudiciously , naloxone can lead to withdrawal syndrome , return of severe pain , and other adverse effects .", "tokens": ["Used", "injudiciously", ",", "naloxone", "can", "lead", "to", "withdrawal", "syndrome", ",", "return", "of", "severe", "pain", ",", "and", "other", "adverse", "effects", "."], "event_mentions": [{"id": "7495990_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead", "start": 5, "end": 6}, "arguments": [{"entity_id": "7495990_1_Ent1", "role": "Treatment", "text": "Used injudiciously , naloxone", "start": 0, "end": 4}, {"entity_id": "7495990_1_Ent2", "role": "Treatment_Drug", "text": "naloxone", "start": 3, "end": 4}, {"entity_id": "7495990_1_Ent0", "role": "Effect", "text": "withdrawal syndrome , return of severe pain , and other adverse effects", "start": 7, "end": 19}]}], "entity_mentions": [{"id": "7495990_1_Ent1", "text": "Used injudiciously , naloxone", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "7495990_1_Ent2", "text": "naloxone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7495990_1_Ent0", "text": "withdrawal syndrome , return of severe pain , and other adverse effects", "entity_type": "Entity", "start": 7, "end": 19}], "lang": "en"}
{"doc_id": "7526455_1", "wnd_id": "7526455_1_1", "text": "A 73 year - old patient with Wolff - Parkinson - White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide .", "tokens": ["A", "73", "year", "-", "old", "patient", "with", "Wolff", "-", "Parkinson", "-", "White", "syndrome", "and", "paroxysmic", "supraventricular", "tachycardia", "developed", "an", "acute", "reversible", "encephalopathy", "within", "15", "days", "of", "initiation", "of", "flecainide", "."], "event_mentions": [{"id": "7526455_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 17, "end": 18}, "arguments": [{"entity_id": "7526455_1_Ent1", "role": "Subject_Age", "text": "73 year - old", "start": 1, "end": 5}, {"entity_id": "7526455_1_Ent0", "role": "Subject", "text": "73 year - old patient with Wolff - Parkinson - White syndrome and paroxysmic supraventricular tachycardia", "start": 1, "end": 17}, {"entity_id": "7526455_1_Ent6", "role": "Treatment_Disorder", "text": "Wolff - Parkinson - White syndrome", "start": 7, "end": 13}, {"entity_id": "7526455_1_Ent7", "role": "Treatment_Disorder", "text": "paroxysmic supraventricular tachycardia", "start": 14, "end": 17}, {"entity_id": "7526455_1_Ent2", "role": "Effect", "text": "acute reversible encephalopathy", "start": 19, "end": 22}, {"entity_id": "7526455_1_Ent5", "role": "Treatment_Time_elapsed", "text": "within 15 days", "start": 22, "end": 25}, {"entity_id": "7526455_1_Ent3", "role": "Treatment", "text": "flecainide", "start": 28, "end": 29}, {"entity_id": "7526455_1_Ent4", "role": "Treatment_Drug", "text": "flecainide", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "7526455_1_Ent1", "text": "73 year - old", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "7526455_1_Ent0", "text": "73 year - old patient with Wolff - Parkinson - White syndrome and paroxysmic supraventricular tachycardia", "entity_type": "Entity", "start": 1, "end": 17}, {"id": "7526455_1_Ent6", "text": "Wolff - Parkinson - White syndrome", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "7526455_1_Ent7", "text": "paroxysmic supraventricular tachycardia", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "7526455_1_Ent2", "text": "acute reversible encephalopathy", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "7526455_1_Ent5", "text": "within 15 days", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "7526455_1_Ent3", "text": "flecainide", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "7526455_1_Ent4", "text": "flecainide", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "7549443_1", "wnd_id": "7549443_1_1", "text": "The second had acute cystitis and was treated by sulphonamide and the third developed myopia coincident with metronidazole treatment for trichomonas vaginalis .", "tokens": ["The", "second", "had", "acute", "cystitis", "and", "was", "treated", "by", "sulphonamide", "and", "the", "third", "developed", "myopia", "coincident", "with", "metronidazole", "treatment", "for", "trichomonas", "vaginalis", "."], "event_mentions": [{"id": "7549443_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 7, "end": 8}, "arguments": [{"entity_id": "7549443_1_Ent6", "role": "Treatment_Disorder", "text": "acute cystitis", "start": 3, "end": 5}, {"entity_id": "7549443_1_Ent5", "role": "Treatment", "text": "sulphonamide", "start": 9, "end": 10}, {"entity_id": "7549443_1_Ent7", "role": "Treatment_Drug", "text": "sulphonamide", "start": 9, "end": 10}]}, {"id": "7549443_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "7549443_1_Ent0", "role": "Subject", "text": "the third", "start": 11, "end": 13}, {"entity_id": "7549443_1_Ent1", "role": "Effect", "text": "myopia", "start": 14, "end": 15}, {"entity_id": "7549443_1_Ent3", "role": "Treatment_Drug", "text": "metronidazole", "start": 17, "end": 18}, {"entity_id": "7549443_1_Ent2", "role": "Treatment", "text": "metronidazole treatment", "start": 17, "end": 19}, {"entity_id": "7549443_1_Ent4", "role": "Treatment_Disorder", "text": "trichomonas vaginalis", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "7549443_1_Ent6", "text": "acute cystitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "7549443_1_Ent5", "text": "sulphonamide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7549443_1_Ent7", "text": "sulphonamide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7549443_1_Ent0", "text": "the third", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "7549443_1_Ent1", "text": "myopia", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "7549443_1_Ent3", "text": "metronidazole", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "7549443_1_Ent2", "text": "metronidazole treatment", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "7549443_1_Ent4", "text": "trichomonas vaginalis", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "7594371_1", "wnd_id": "7594371_1_1", "text": "Acute sensorineural hearing loss following intravenous ketoralac administration .", "tokens": ["Acute", "sensorineural", "hearing", "loss", "following", "intravenous", "ketoralac", "administration", "."], "event_mentions": [{"id": "7594371_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 4, "end": 5}, "arguments": [{"entity_id": "7594371_1_Ent0", "role": "Effect", "text": "Acute sensorineural hearing loss", "start": 0, "end": 4}, {"entity_id": "7594371_1_Ent3", "role": "Treatment_Route", "text": "intravenous", "start": 5, "end": 6}, {"entity_id": "7594371_1_Ent1", "role": "Treatment", "text": "intravenous ketoralac", "start": 5, "end": 7}, {"entity_id": "7594371_1_Ent2", "role": "Treatment_Drug", "text": "ketoralac", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "7594371_1_Ent0", "text": "Acute sensorineural hearing loss", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "7594371_1_Ent3", "text": "intravenous", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7594371_1_Ent1", "text": "intravenous ketoralac", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "7594371_1_Ent2", "text": "ketoralac", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "7606071_3", "wnd_id": "7606071_3_1", "text": "CONCLUSIONS : We conclude that a high dose combined with a short infusion time increases the risk of anaphylactoid reactions with the administration of intraperitoneal cisplatin .", "tokens": ["CONCLUSIONS", ":", "We", "conclude", "that", "a", "high", "dose", "combined", "with", "a", "short", "infusion", "time", "increases", "the", "risk", "of", "anaphylactoid", "reactions", "with", "the", "administration", "of", "intraperitoneal", "cisplatin", "."], "event_mentions": [{"id": "7606071_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 20, "end": 21}, "arguments": [{"entity_id": "7606071_3_Ent1", "role": "Treatment", "text": "a high dose combined with a short infusion time", "start": 5, "end": 14}, {"entity_id": "7606071_3_Ent3", "role": "Treatment_Dosage", "text": "high dose", "start": 6, "end": 8}, {"entity_id": "7606071_3_Ent0", "role": "Effect", "text": "anaphylactoid reactions", "start": 18, "end": 20}, {"entity_id": "7606071_3_Ent2", "role": "Treatment", "text": "administration of intraperitoneal cisplatin", "start": 22, "end": 26}, {"entity_id": "7606071_3_Ent5", "role": "Treatment_Route", "text": "intraperitoneal", "start": 24, "end": 25}, {"entity_id": "7606071_3_Ent4", "role": "Treatment_Drug", "text": "cisplatin", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "7606071_3_Ent1", "text": "a high dose combined with a short infusion time", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "7606071_3_Ent3", "text": "high dose", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7606071_3_Ent0", "text": "anaphylactoid reactions", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "7606071_3_Ent2", "text": "administration of intraperitoneal cisplatin", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "7606071_3_Ent5", "text": "intraperitoneal", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "7606071_3_Ent4", "text": "cisplatin", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "7606071_6", "wnd_id": "7606071_6_1", "text": "OBJECTIVE : To report the occurrence of anaphylactoid reactions to intraperitoneal cisplatin in 3 patients .", "tokens": ["OBJECTIVE", ":", "To", "report", "the", "occurrence", "of", "anaphylactoid", "reactions", "to", "intraperitoneal", "cisplatin", "in", "3", "patients", "."], "event_mentions": [{"id": "7606071_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 9, "end": 10}, "arguments": [{"entity_id": "7606071_6_Ent2", "role": "Effect", "text": "anaphylactoid reactions", "start": 7, "end": 9}, {"entity_id": "7606071_6_Ent5", "role": "Treatment_Route", "text": "intraperitoneal", "start": 10, "end": 11}, {"entity_id": "7606071_6_Ent3", "role": "Treatment", "text": "intraperitoneal cisplatin", "start": 10, "end": 12}, {"entity_id": "7606071_6_Ent4", "role": "Treatment_Drug", "text": "cisplatin", "start": 11, "end": 12}, {"entity_id": "7606071_6_Ent1", "role": "Subject_Population", "text": "3", "start": 13, "end": 14}, {"entity_id": "7606071_6_Ent0", "role": "Subject", "text": "3 patients .", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "7606071_6_Ent2", "text": "anaphylactoid reactions", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "7606071_6_Ent5", "text": "intraperitoneal", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7606071_6_Ent3", "text": "intraperitoneal cisplatin", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "7606071_6_Ent4", "text": "cisplatin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7606071_6_Ent1", "text": "3", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7606071_6_Ent0", "text": "3 patients .", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "7619765_2", "wnd_id": "7619765_2_1", "text": "The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide , in a man with no risk factors for coronary heart disease .", "tokens": ["The", "occurrence", "of", "a", "myocardial", "infarction", "is", "reported", "after", "chemotherapy", "containing", "etoposide", ",", "in", "a", "man", "with", "no", "risk", "factors", "for", "coronary", "heart", "disease", "."], "event_mentions": [{"id": "7619765_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 8, "end": 9}, "arguments": [{"entity_id": "7619765_2_Ent2", "role": "Effect", "text": "myocardial infarction", "start": 4, "end": 6}, {"entity_id": "7619765_2_Ent3", "role": "Treatment", "text": "chemotherapy containing etoposide", "start": 9, "end": 12}, {"entity_id": "7619765_2_Ent4", "role": "Treatment_Drug", "text": "etoposide", "start": 11, "end": 12}, {"entity_id": "7619765_2_Ent0", "role": "Subject", "text": "a man with no risk factors for coronary heart disease", "start": 14, "end": 24}, {"entity_id": "7619765_2_Ent1", "role": "Subject_Gender", "text": "man", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "7619765_2_Ent2", "text": "myocardial infarction", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7619765_2_Ent3", "text": "chemotherapy containing etoposide", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "7619765_2_Ent4", "text": "etoposide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7619765_2_Ent0", "text": "a man with no risk factors for coronary heart disease", "entity_type": "Entity", "start": 14, "end": 24}, {"id": "7619765_2_Ent1", "text": "man", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "7639655_2", "wnd_id": "7639655_2_1", "text": "CONCLUSION : Anterior ischemic optic neuropathy may complicate treatment with interferon alfa .", "tokens": ["CONCLUSION", ":", "Anterior", "ischemic", "optic", "neuropathy", "may", "complicate", "treatment", "with", "interferon", "alfa", "."], "event_mentions": [{"id": "7639655_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complicate", "start": 7, "end": 8}, "arguments": [{"entity_id": "7639655_2_Ent0", "role": "Effect", "text": "Anterior ischemic optic neuropathy", "start": 2, "end": 6}, {"entity_id": "7639655_2_Ent1", "role": "Treatment", "text": "interferon alfa", "start": 10, "end": 12}, {"entity_id": "7639655_2_Ent2", "role": "Treatment_Drug", "text": "interferon alfa", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "7639655_2_Ent0", "text": "Anterior ischemic optic neuropathy", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "7639655_2_Ent1", "text": "interferon alfa", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "7639655_2_Ent2", "text": "interferon alfa", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "7653281_2", "wnd_id": "7653281_2_1", "text": "Little has been studied of the adverse effects of the exposure of the liver to the interaction of ethanol with its congeners and acetaldehyde , coexisting in the contents of alcoholic beverages .", "tokens": ["Little", "has", "been", "studied", "of", "the", "adverse", "effects", "of", "the", "exposure", "of", "the", "liver", "to", "the", "interaction", "of", "ethanol", "with", "its", "congeners", "and", "acetaldehyde", ",", "coexisting", "in", "the", "contents", "of", "alcoholic", "beverages", "."], "event_mentions": [{"id": "7653281_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "interaction", "start": 16, "end": 17}, "arguments": [{"entity_id": "7653281_2_Ent0", "role": "Effect", "text": "adverse effects of the exposure of the liver", "start": 6, "end": 14}, {"entity_id": "7653281_2_Ent3", "role": "Treatment_Drug", "text": "ethanol", "start": 18, "end": 19}, {"entity_id": "7653281_2_Ent4", "role": "Combination_Drug", "text": "ethanol", "start": 18, "end": 19}, {"entity_id": "7653281_2_Ent1", "role": "Treatment", "text": "ethanol with its congeners and acetaldehyde", "start": 18, "end": 24}, {"entity_id": "7653281_2_Ent2", "role": "Treatment_Drug", "text": "acetaldehyde", "start": 23, "end": 24}, {"entity_id": "7653281_2_Ent5", "role": "Combination_Drug", "text": "acetaldehyde", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "7653281_2_Ent0", "text": "adverse effects of the exposure of the liver", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "7653281_2_Ent3", "text": "ethanol", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "7653281_2_Ent4", "text": "ethanol", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "7653281_2_Ent1", "text": "ethanol with its congeners and acetaldehyde", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "7653281_2_Ent2", "text": "acetaldehyde", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "7653281_2_Ent5", "text": "acetaldehyde", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "7663030_12", "wnd_id": "7663030_12_1", "text": "Propafenone 's distribution , clearance , and structural similarity to propranolol contribute to its central nervous system effects .", "tokens": ["Propafenone", "'s", "distribution", ",", "clearance", ",", "and", "structural", "similarity", "to", "propranolol", "contribute", "to", "its", "central", "nervous", "system", "effects", "."], "event_mentions": [{"id": "7663030_12_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "contribute", "start": 11, "end": 12}, "arguments": [{"entity_id": "7663030_12_Ent1", "role": "Treatment", "text": "Propafenone", "start": 0, "end": 1}, {"entity_id": "7663030_12_Ent3", "role": "Treatment_Drug", "text": "Propafenone", "start": 0, "end": 1}, {"entity_id": "7663030_12_Ent2", "role": "Treatment_Drug", "text": "propranolol", "start": 10, "end": 11}, {"entity_id": "7663030_12_Ent0", "role": "Effect", "text": "central nervous system effects", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "7663030_12_Ent1", "text": "Propafenone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7663030_12_Ent3", "text": "Propafenone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7663030_12_Ent2", "text": "propranolol", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7663030_12_Ent0", "text": "central nervous system effects", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "7663030_5", "wnd_id": "7663030_5_1", "text": "He began taking propafenone only 6 days prior to admission because of uncontrolled atrial fibrillation and symptoms of fatigue .", "tokens": ["He", "began", "taking", "propafenone", "only", "6", "days", "prior", "to", "admission", "because", "of", "uncontrolled", "atrial", "fibrillation", "and", "symptoms", "of", "fatigue", "."], "event_mentions": [{"id": "7663030_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "taking", "start": 2, "end": 3}, "arguments": [{"entity_id": "7663030_5_Ent0", "role": "Treatment", "text": "propafenone", "start": 3, "end": 4}, {"entity_id": "7663030_5_Ent1", "role": "Treatment_Drug", "text": "propafenone", "start": 3, "end": 4}, {"entity_id": "7663030_5_Ent2", "role": "Treatment_Disorder", "text": "atrial fibrillation", "start": 13, "end": 15}, {"entity_id": "7663030_5_Ent3", "role": "Treatment_Disorder", "text": "fatigue", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "7663030_5_Ent0", "text": "propafenone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7663030_5_Ent1", "text": "propafenone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7663030_5_Ent2", "text": "atrial fibrillation", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "7663030_5_Ent3", "text": "fatigue", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "7685228_2", "wnd_id": "7685228_2_1", "text": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts , using granulocyte colony - stimulating factor ( G - CSF ) , reducing the duration of neutropenia and risk of infection .", "tokens": ["We", "have", "successfully", "overcome", "severe", "neutropenia", "in", "an", "RA", "patient", "treated", "with", "gold", "salts", ",", "using", "granulocyte", "colony", "-", "stimulating", "factor", "(", "G", "-", "CSF", ")", ",", "reducing", "the", "duration", "of", "neutropenia", "and", "risk", "of", "infection", "."], "event_mentions": [{"id": "7685228_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "overcome", "start": 3, "end": 4}, "arguments": [{"entity_id": "7685228_2_Ent4", "role": "Treatment_Disorder", "text": "severe neutropenia", "start": 4, "end": 6}, {"entity_id": "7685228_2_Ent0", "role": "Subject", "text": "an RA patient treated with gold salts", "start": 7, "end": 14}, {"entity_id": "7685228_2_Ent1", "role": "Subject_Disorder", "text": "RA", "start": 8, "end": 9}, {"entity_id": "7685228_2_Ent5", "role": "Treatment_Drug", "text": "granulocyte colony - stimulating factor", "start": 16, "end": 21}, {"entity_id": "7685228_2_Ent3", "role": "Treatment", "text": "granulocyte colony - stimulating factor ( G - CSF )", "start": 16, "end": 26}, {"entity_id": "7685228_2_Ent2", "role": "Effect", "text": "reducing the duration of neutropenia and risk of infection", "start": 27, "end": 36}]}, {"id": "7685228_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 6, "end": 7}, "arguments": [{"entity_id": "7685228_2_Ent6", "role": "Effect", "text": "severe neutropenia", "start": 4, "end": 6}, {"entity_id": "7685228_2_Ent8", "role": "Treatment_Disorder", "text": "RA", "start": 8, "end": 9}, {"entity_id": "7685228_2_Ent7", "role": "Treatment", "text": "gold salts", "start": 12, "end": 14}, {"entity_id": "7685228_2_Ent9", "role": "Treatment_Drug", "text": "gold salts", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "7685228_2_Ent4", "text": "severe neutropenia", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7685228_2_Ent6", "text": "severe neutropenia", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7685228_2_Ent0", "text": "an RA patient treated with gold salts", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "7685228_2_Ent1", "text": "RA", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7685228_2_Ent8", "text": "RA", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7685228_2_Ent7", "text": "gold salts", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "7685228_2_Ent9", "text": "gold salts", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "7685228_2_Ent5", "text": "granulocyte colony - stimulating factor", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "7685228_2_Ent3", "text": "granulocyte colony - stimulating factor ( G - CSF )", "entity_type": "Entity", "start": 16, "end": 26}, {"id": "7685228_2_Ent2", "text": "reducing the duration of neutropenia and risk of infection", "entity_type": "Entity", "start": 27, "end": 36}], "lang": "en"}
{"doc_id": "7718983_1", "wnd_id": "7718983_1_1", "text": "Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C.", "tokens": ["Graves", "'", "hyperthyroidism", "following", "transient", "thyrotoxicosis", "during", "interferon", "therapy", "for", "chronic", "hepatitis", "type", "C."], "event_mentions": [{"id": "7718983_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 6, "end": 7}, "arguments": [{"entity_id": "7718983_1_Ent0", "role": "Effect", "text": "Graves ' hyperthyroidism following transient thyrotoxicosis", "start": 0, "end": 6}, {"entity_id": "7718983_1_Ent1", "role": "Treatment", "text": "interferon", "start": 7, "end": 8}, {"entity_id": "7718983_1_Ent2", "role": "Treatment_Drug", "text": "interferon", "start": 7, "end": 8}, {"entity_id": "7718983_1_Ent3", "role": "Treatment_Disorder", "text": "chronic hepatitis type C.", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "7718983_1_Ent0", "text": "Graves ' hyperthyroidism following transient thyrotoxicosis", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "7718983_1_Ent1", "text": "interferon", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7718983_1_Ent2", "text": "interferon", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7718983_1_Ent3", "text": "chronic hepatitis type C.", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "7748076_1", "wnd_id": "7748076_1_1", "text": "CONCLUSION : Squamous metaplasia in these cases appears to be a consequence of progestin therapy .", "tokens": ["CONCLUSION", ":", "Squamous", "metaplasia", "in", "these", "cases", "appears", "to", "be", "a", "consequence", "of", "progestin", "therapy", "."], "event_mentions": [{"id": "7748076_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "consequence", "start": 11, "end": 12}, "arguments": [{"entity_id": "7748076_1_Ent1", "role": "Effect", "text": "Squamous metaplasia", "start": 2, "end": 4}, {"entity_id": "7748076_1_Ent0", "role": "Subject", "text": "these cases", "start": 5, "end": 7}, {"entity_id": "7748076_1_Ent3", "role": "Treatment_Drug", "text": "progestin", "start": 13, "end": 14}, {"entity_id": "7748076_1_Ent2", "role": "Treatment", "text": "progestin therapy", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "7748076_1_Ent1", "text": "Squamous metaplasia", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "7748076_1_Ent0", "text": "these cases", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "7748076_1_Ent3", "text": "progestin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7748076_1_Ent2", "text": "progestin therapy", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "7752014_3", "wnd_id": "7752014_3_1", "text": "Fever caused by the use of furosemide was proved ; the fever resolved after discontinuation of this medication and recurred after its reintroduction .", "tokens": ["Fever", "caused", "by", "the", "use", "of", "furosemide", "was", "proved", ";", "the", "fever", "resolved", "after", "discontinuation", "of", "this", "medication", "and", "recurred", "after", "its", "reintroduction", "."], "event_mentions": [{"id": "7752014_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 1, "end": 2}, "arguments": [{"entity_id": "7752014_3_Ent0", "role": "Effect", "text": "Fever", "start": 0, "end": 1}, {"entity_id": "7752014_3_Ent1", "role": "Treatment", "text": "furosemide", "start": 6, "end": 7}, {"entity_id": "7752014_3_Ent2", "role": "Treatment_Drug", "text": "furosemide", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "7752014_3_Ent0", "text": "Fever", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7752014_3_Ent1", "text": "furosemide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7752014_3_Ent2", "text": "furosemide", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "7756684_1", "wnd_id": "7756684_1_1", "text": "The dose - limiting toxicity of KW - 2149 is pulmonary toxicity .", "tokens": ["The", "dose", "-", "limiting", "toxicity", "of", "KW", "-", "2149", "is", "pulmonary", "toxicity", "."], "event_mentions": [{"id": "7756684_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 11, "end": 12}, "arguments": [{"entity_id": "7756684_1_Ent1", "role": "Treatment", "text": "KW - 2149", "start": 6, "end": 9}, {"entity_id": "7756684_1_Ent2", "role": "Treatment_Drug", "text": "KW - 2149", "start": 6, "end": 9}, {"entity_id": "7756684_1_Ent0", "role": "Effect", "text": "pulmonary", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "7756684_1_Ent1", "text": "KW - 2149", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "7756684_1_Ent2", "text": "KW - 2149", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "7756684_1_Ent0", "text": "pulmonary", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "7776854_3", "wnd_id": "7776854_3_1", "text": "We report three cases of severe hepatotoxicity related to benzarone , a benzofuran derivative .", "tokens": ["We", "report", "three", "cases", "of", "severe", "hepatotoxicity", "related", "to", "benzarone", ",", "a", "benzofuran", "derivative", "."], "event_mentions": [{"id": "7776854_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 7, "end": 8}, "arguments": [{"entity_id": "7776854_3_Ent1", "role": "Subject_Population", "text": "three", "start": 2, "end": 3}, {"entity_id": "7776854_3_Ent0", "role": "Subject", "text": "three cases", "start": 2, "end": 4}, {"entity_id": "7776854_3_Ent2", "role": "Effect", "text": "severe hepatotoxicity", "start": 5, "end": 7}, {"entity_id": "7776854_3_Ent3", "role": "Treatment", "text": "benzarone", "start": 9, "end": 10}, {"entity_id": "7776854_3_Ent4", "role": "Treatment_Drug", "text": "benzarone", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "7776854_3_Ent1", "text": "three", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7776854_3_Ent0", "text": "three cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "7776854_3_Ent2", "text": "severe hepatotoxicity", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "7776854_3_Ent3", "text": "benzarone", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7776854_3_Ent4", "text": "benzarone", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "7776854_4", "wnd_id": "7776854_4_1", "text": "We stress the potential of benzarone to cause hepatotoxicity , which usually resembles severe chronic active hepatitis .", "tokens": ["We", "stress", "the", "potential", "of", "benzarone", "to", "cause", "hepatotoxicity", ",", "which", "usually", "resembles", "severe", "chronic", "active", "hepatitis", "."], "event_mentions": [{"id": "7776854_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 7, "end": 8}, "arguments": [{"entity_id": "7776854_4_Ent2", "role": "Treatment", "text": "benzarone", "start": 5, "end": 6}, {"entity_id": "7776854_4_Ent3", "role": "Treatment_Drug", "text": "benzarone", "start": 5, "end": 6}, {"entity_id": "7776854_4_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 8, "end": 9}, {"entity_id": "7776854_4_Ent1", "role": "Effect", "text": "severe chronic active hepatitis", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "7776854_4_Ent2", "text": "benzarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7776854_4_Ent3", "text": "benzarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7776854_4_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7776854_4_Ent1", "text": "severe chronic active hepatitis", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "7781845_11", "wnd_id": "7781845_11_1", "text": "Clinicians who manage cachectic patients , particularly those with protracted diarrhoea and/or receiving anti - malarial drugs including mefloquine , should be aware of the risk of severe hypoglycaemia .", "tokens": ["Clinicians", "who", "manage", "cachectic", "patients", ",", "particularly", "those", "with", "protracted", "diarrhoea", "and/or", "receiving", "anti", "-", "malarial", "drugs", "including", "mefloquine", ",", "should", "be", "aware", "of", "the", "risk", "of", "severe", "hypoglycaemia", "."], "event_mentions": [{"id": "7781845_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 25, "end": 26}, "arguments": [{"entity_id": "7781845_11_Ent5", "role": "Treatment_Disorder", "text": "cachectic", "start": 3, "end": 4}, {"entity_id": "7781845_11_Ent0", "role": "Subject", "text": "cachectic patients", "start": 3, "end": 5}, {"entity_id": "7781845_11_Ent1", "role": "Subject", "text": "with protracted diarrhoea", "start": 8, "end": 11}, {"entity_id": "7781845_11_Ent6", "role": "Treatment_Disorder", "text": "protracted diarrhoea", "start": 9, "end": 11}, {"entity_id": "7781845_11_Ent3", "role": "Treatment", "text": "anti - malarial drugs including mefloquine", "start": 13, "end": 19}, {"entity_id": "7781845_11_Ent4", "role": "Treatment_Drug", "text": "mefloquine", "start": 18, "end": 19}, {"entity_id": "7781845_11_Ent2", "role": "Effect", "text": "severe hypoglycaemia", "start": 27, "end": 29}]}], "entity_mentions": [{"id": "7781845_11_Ent5", "text": "cachectic", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7781845_11_Ent0", "text": "cachectic patients", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "7781845_11_Ent1", "text": "with protracted diarrhoea", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "7781845_11_Ent6", "text": "protracted diarrhoea", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "7781845_11_Ent3", "text": "anti - malarial drugs including mefloquine", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "7781845_11_Ent4", "text": "mefloquine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "7781845_11_Ent2", "text": "severe hypoglycaemia", "entity_type": "Entity", "start": 27, "end": 29}], "lang": "en"}
{"doc_id": "7781845_2", "wnd_id": "7781845_2_1", "text": "Quinine and its isomer quinidine are well - known causes of iatrogenic hypoglycaemia , due to excessive insulin secretion .", "tokens": ["Quinine", "and", "its", "isomer", "quinidine", "are", "well", "-", "known", "causes", "of", "iatrogenic", "hypoglycaemia", ",", "due", "to", "excessive", "insulin", "secretion", "."], "event_mentions": [{"id": "7781845_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 9, "end": 10}, "arguments": [{"entity_id": "7781845_2_Ent2", "role": "Treatment_Drug", "text": "Quinine", "start": 0, "end": 1}, {"entity_id": "7781845_2_Ent1", "role": "Treatment", "text": "Quinine and its isomer quinidine", "start": 0, "end": 5}, {"entity_id": "7781845_2_Ent0", "role": "Effect", "text": "iatrogenic hypoglycaemia , due to excessive insulin secretion", "start": 11, "end": 19}]}], "entity_mentions": [{"id": "7781845_2_Ent2", "text": "Quinine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7781845_2_Ent1", "text": "Quinine and its isomer quinidine", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7781845_2_Ent0", "text": "iatrogenic hypoglycaemia , due to excessive insulin secretion", "entity_type": "Entity", "start": 11, "end": 19}], "lang": "en"}
{"doc_id": "7783891_1", "wnd_id": "7783891_1_1", "text": "Because sumatriptan can cause coronary artery vasospasm , patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan .", "tokens": ["Because", "sumatriptan", "can", "cause", "coronary", "artery", "vasospasm", ",", "patients", "with", "significant", "risk", "factors", "for", "coronary", "artery", "disease", "should", "be", "carefully", "evaluated", "for", "cardiovascular", "disease", "prior", "to", "the", "use", "of", "sumatriptan", "."], "event_mentions": [{"id": "7783891_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 3, "end": 4}, "arguments": [{"entity_id": "7783891_1_Ent1", "role": "Treatment", "text": "sumatriptan", "start": 1, "end": 2}, {"entity_id": "7783891_1_Ent2", "role": "Treatment_Drug", "text": "sumatriptan", "start": 1, "end": 2}, {"entity_id": "7783891_1_Ent0", "role": "Effect", "text": "coronary artery vasospasm", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "7783891_1_Ent1", "text": "sumatriptan", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7783891_1_Ent2", "text": "sumatriptan", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7783891_1_Ent0", "text": "coronary artery vasospasm", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "7787496_2", "wnd_id": "7787496_2_1", "text": "We present a case of sotalol - induced bradycardia reversed by glucagon .", "tokens": ["We", "present", "a", "case", "of", "sotalol", "-", "induced", "bradycardia", "reversed", "by", "glucagon", "."], "event_mentions": [{"id": "7787496_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "7787496_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "7787496_2_Ent2", "role": "Treatment", "text": "sotalol", "start": 5, "end": 6}, {"entity_id": "7787496_2_Ent3", "role": "Treatment_Drug", "text": "sotalol", "start": 5, "end": 6}, {"entity_id": "7787496_2_Ent1", "role": "Effect", "text": "bradycardia", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "7787496_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "7787496_2_Ent2", "text": "sotalol", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7787496_2_Ent3", "text": "sotalol", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7787496_2_Ent1", "text": "bradycardia", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "7814182_1", "wnd_id": "7814182_1_1", "text": "High - grade atrioventricular block during dipyridamole stress testing .", "tokens": ["High", "-", "grade", "atrioventricular", "block", "during", "dipyridamole", "stress", "testing", "."], "event_mentions": [{"id": "7814182_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 5, "end": 6}, "arguments": [{"entity_id": "7814182_1_Ent0", "role": "Effect", "text": "High - grade atrioventricular block", "start": 0, "end": 5}, {"entity_id": "7814182_1_Ent2", "role": "Treatment_Drug", "text": "dipyridamole", "start": 6, "end": 7}, {"entity_id": "7814182_1_Ent1", "role": "Treatment", "text": "dipyridamole stress testing", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "7814182_1_Ent0", "text": "High - grade atrioventricular block", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7814182_1_Ent2", "text": "dipyridamole", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7814182_1_Ent1", "text": "dipyridamole stress testing", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "7814182_2", "wnd_id": "7814182_2_1", "text": "We present a case in which dipyridamole induced high - grade atrioventricular ( AV ) block that responded promptly to intravenous aminophylline but not to atropine .", "tokens": ["We", "present", "a", "case", "in", "which", "dipyridamole", "induced", "high", "-", "grade", "atrioventricular", "(", "AV", ")", "block", "that", "responded", "promptly", "to", "intravenous", "aminophylline", "but", "not", "to", "atropine", "."], "event_mentions": [{"id": "7814182_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "7814182_2_Ent1", "role": "Treatment", "text": "dipyridamole", "start": 6, "end": 7}, {"entity_id": "7814182_2_Ent2", "role": "Treatment_Drug", "text": "dipyridamole", "start": 6, "end": 7}, {"entity_id": "7814182_2_Ent0", "role": "Effect", "text": "high - grade atrioventricular ( AV ) block", "start": 8, "end": 16}]}, {"id": "7814182_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "responded", "start": 17, "end": 18}, "arguments": [{"entity_id": "7814182_2_Ent6", "role": "Treatment_Disorder", "text": "dipyridamole induced high - grade atrioventricular ( AV ) block", "start": 6, "end": 16}, {"entity_id": "7814182_2_Ent4", "role": "Treatment_Drug", "text": "intravenous aminophylline", "start": 20, "end": 22}, {"entity_id": "7814182_2_Ent3", "role": "Treatment", "text": "intravenous aminophylline but not to atropine", "start": 20, "end": 26}, {"entity_id": "7814182_2_Ent5", "role": "Treatment_Drug", "text": "atropine", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "7814182_2_Ent1", "text": "dipyridamole", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7814182_2_Ent2", "text": "dipyridamole", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7814182_2_Ent6", "text": "dipyridamole induced high - grade atrioventricular ( AV ) block", "entity_type": "Entity", "start": 6, "end": 16}, {"id": "7814182_2_Ent0", "text": "high - grade atrioventricular ( AV ) block", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "7814182_2_Ent4", "text": "intravenous aminophylline", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "7814182_2_Ent3", "text": "intravenous aminophylline but not to atropine", "entity_type": "Entity", "start": 20, "end": 26}, {"id": "7814182_2_Ent5", "text": "atropine", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "7835785_3", "wnd_id": "7835785_3_1", "text": "We present the first case of ovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with tamoxifen for breast cancer .", "tokens": ["We", "present", "the", "first", "case", "of", "ovarian", "endometrioid", "carcinoma", "and", "endometriosis", "in", "a", "postmenopausal", "patient", "who", "was", "treated", "with", "tamoxifen", "for", "breast", "cancer", "."], "event_mentions": [{"id": "7835785_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated with", "start": 17, "end": 19}, "arguments": [{"entity_id": "7835785_3_Ent2", "role": "Effect", "text": "ovarian endometrioid carcinoma and endometriosis", "start": 6, "end": 11}, {"entity_id": "7835785_3_Ent0", "role": "Subject", "text": "postmenopausal patient", "start": 13, "end": 15}, {"entity_id": "7835785_3_Ent3", "role": "Treatment", "text": "tamoxifen", "start": 19, "end": 20}, {"entity_id": "7835785_3_Ent4", "role": "Treatment_Drug", "text": "tamoxifen", "start": 19, "end": 20}, {"entity_id": "7835785_3_Ent5", "role": "Treatment_Disorder", "text": "breast cancer", "start": 21, "end": 23}, {"entity_id": "7835785_3_Ent1", "role": "Subject", "text": "breast cancer .", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "7835785_3_Ent2", "text": "ovarian endometrioid carcinoma and endometriosis", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "7835785_3_Ent0", "text": "postmenopausal patient", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "7835785_3_Ent3", "text": "tamoxifen", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "7835785_3_Ent4", "text": "tamoxifen", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "7835785_3_Ent5", "text": "breast cancer", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "7835785_3_Ent1", "text": "breast cancer .", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "7854541_3", "wnd_id": "7854541_3_1", "text": "Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5 - fluorouracil and levamisole may have been caused at least partly by levamisole .", "tokens": ["Observations", "in", "our", "patient", "suggest", "that", "the", "leukoencephalopathy", "that", "developed", "in", "previously", "reported", "patients", "who", "received", "5", "-", "fluorouracil", "and", "levamisole", "may", "have", "been", "caused", "at", "least", "partly", "by", "levamisole", "."], "event_mentions": [{"id": "7854541_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 24, "end": 25}, "arguments": [{"entity_id": "7854541_3_Ent1", "role": "Effect", "text": "leukoencephalopathy", "start": 7, "end": 8}, {"entity_id": "7854541_3_Ent0", "role": "Subject", "text": "patients", "start": 13, "end": 14}, {"entity_id": "7854541_3_Ent2", "role": "Treatment", "text": "levamisole", "start": 29, "end": 30}, {"entity_id": "7854541_3_Ent3", "role": "Treatment_Drug", "text": "levamisole", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "7854541_3_Ent1", "text": "leukoencephalopathy", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7854541_3_Ent0", "text": "patients", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7854541_3_Ent2", "text": "levamisole", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "7854541_3_Ent3", "text": "levamisole", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "788666_1", "wnd_id": "788666_1_1", "text": "Five patients are described in whom only gentamicin sulfate appeared responsible for acute renal failure .", "tokens": ["Five", "patients", "are", "described", "in", "whom", "only", "gentamicin", "sulfate", "appeared", "responsible", "for", "acute", "renal", "failure", "."], "event_mentions": [{"id": "788666_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "responsible", "start": 10, "end": 11}, "arguments": [{"entity_id": "788666_1_Ent1", "role": "Subject_Population", "text": "Five", "start": 0, "end": 1}, {"entity_id": "788666_1_Ent0", "role": "Subject", "text": "Five patients", "start": 0, "end": 2}, {"entity_id": "788666_1_Ent3", "role": "Treatment", "text": "gentamicin sulfate", "start": 7, "end": 9}, {"entity_id": "788666_1_Ent4", "role": "Treatment_Drug", "text": "gentamicin sulfate", "start": 7, "end": 9}, {"entity_id": "788666_1_Ent2", "role": "Effect", "text": "acute renal failure", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "788666_1_Ent1", "text": "Five", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "788666_1_Ent0", "text": "Five patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "788666_1_Ent3", "text": "gentamicin sulfate", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "788666_1_Ent4", "text": "gentamicin sulfate", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "788666_1_Ent2", "text": "acute renal failure", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "7887138_1", "wnd_id": "7887138_1_1", "text": "A 15 - year follow - up of phenytoin - induced unilateral gingival hyperplasia : a case report .", "tokens": ["A", "15", "-", "year", "follow", "-", "up", "of", "phenytoin", "-", "induced", "unilateral", "gingival", "hyperplasia", ":", "a", "case", "report", "."], "event_mentions": [{"id": "7887138_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "7887138_1_Ent3", "role": "Treatment_Time_elapsed", "text": "15 - year", "start": 1, "end": 4}, {"entity_id": "7887138_1_Ent1", "role": "Treatment", "text": "phenytoin", "start": 8, "end": 9}, {"entity_id": "7887138_1_Ent2", "role": "Treatment_Drug", "text": "phenytoin", "start": 8, "end": 9}, {"entity_id": "7887138_1_Ent0", "role": "Effect", "text": "unilateral gingival hyperplasia", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "7887138_1_Ent3", "text": "15 - year", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "7887138_1_Ent1", "text": "phenytoin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7887138_1_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7887138_1_Ent0", "text": "unilateral gingival hyperplasia", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "7897759_2", "wnd_id": "7897759_2_1", "text": "Propoxyphene - induced wide QRS complex dysrhythmia responsive to sodium bicarbonate -- a case report .", "tokens": ["Propoxyphene", "-", "induced", "wide", "QRS", "complex", "dysrhythmia", "responsive", "to", "sodium", "bicarbonate", "--", "a", "case", "report", "."], "event_mentions": [{"id": "7897759_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "7897759_2_Ent1", "role": "Treatment", "text": "Propoxyphene", "start": 0, "end": 1}, {"entity_id": "7897759_2_Ent2", "role": "Treatment_Drug", "text": "Propoxyphene", "start": 0, "end": 1}, {"entity_id": "7897759_2_Ent0", "role": "Effect", "text": "wide QRS complex dysrhythmia", "start": 3, "end": 7}]}], "entity_mentions": [{"id": "7897759_2_Ent1", "text": "Propoxyphene", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7897759_2_Ent2", "text": "Propoxyphene", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7897759_2_Ent0", "text": "wide QRS complex dysrhythmia", "entity_type": "Entity", "start": 3, "end": 7}], "lang": "en"}
{"doc_id": "7919557_3", "wnd_id": "7919557_3_1", "text": "OBJECTIVE : To report a case of chronic , nonproductive cough secondary to the angiotensin - converting enzyme ( ACE ) inhibitor quinapril , with complete resolution after switching to another ACE inhibitor , fosinopril .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "chronic", ",", "nonproductive", "cough", "secondary", "to", "the", "angiotensin", "-", "converting", "enzyme", "(", "ACE", ")", "inhibitor", "quinapril", ",", "with", "complete", "resolution", "after", "switching", "to", "another", "ACE", "inhibitor", ",", "fosinopril", "."], "event_mentions": [{"id": "7919557_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolution", "start": 26, "end": 27}, "arguments": [{"entity_id": "7919557_3_Ent0", "role": "Effect", "text": "chronic , nonproductive cough secondary to the angiotensin - converting enzyme ( ACE ) inhibitor quinapril", "start": 7, "end": 23}, {"entity_id": "7919557_3_Ent1", "role": "Treatment", "text": "switching to another ACE inhibitor , fosinopril", "start": 28, "end": 35}, {"entity_id": "7919557_3_Ent2", "role": "Treatment_Drug", "text": "fosinopril", "start": 34, "end": 35}]}], "entity_mentions": [{"id": "7919557_3_Ent0", "text": "chronic , nonproductive cough secondary to the angiotensin - converting enzyme ( ACE ) inhibitor quinapril", "entity_type": "Entity", "start": 7, "end": 23}, {"id": "7919557_3_Ent1", "text": "switching to another ACE inhibitor , fosinopril", "entity_type": "Entity", "start": 28, "end": 35}, {"id": "7919557_3_Ent2", "text": "fosinopril", "entity_type": "Entity", "start": 34, "end": 35}], "lang": "en"}
{"doc_id": "7933665_1", "wnd_id": "7933665_1_1", "text": "Fracture of the femoral neck occurred in one patient during PSL therapy , although the relationship between the fracture and PSL therapy was uncertain .", "tokens": ["Fracture", "of", "the", "femoral", "neck", "occurred", "in", "one", "patient", "during", "PSL", "therapy", ",", "although", "the", "relationship", "between", "the", "fracture", "and", "PSL", "therapy", "was", "uncertain", "."], "event_mentions": [{"id": "7933665_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 5, "end": 6}, "arguments": [{"entity_id": "7933665_1_Ent2", "role": "Effect", "text": "Fracture of the femoral neck", "start": 0, "end": 5}, {"entity_id": "7933665_1_Ent1", "role": "Subject_Population", "text": "one", "start": 7, "end": 8}, {"entity_id": "7933665_1_Ent0", "role": "Subject", "text": "one patient", "start": 7, "end": 9}, {"entity_id": "7933665_1_Ent4", "role": "Treatment_Drug", "text": "PSL", "start": 10, "end": 11}, {"entity_id": "7933665_1_Ent3", "role": "Treatment", "text": "PSL therapy", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "7933665_1_Ent2", "text": "Fracture of the femoral neck", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7933665_1_Ent1", "text": "one", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7933665_1_Ent0", "text": "one patient", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "7933665_1_Ent4", "text": "PSL", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7933665_1_Ent3", "text": "PSL therapy", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "7937287_1", "wnd_id": "7937287_1_1", "text": "Cefuroxime - induced acute renal failure .", "tokens": ["Cefuroxime", "-", "induced", "acute", "renal", "failure", "."], "event_mentions": [{"id": "7937287_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "7937287_1_Ent1", "role": "Treatment", "text": "Cefuroxime", "start": 0, "end": 1}, {"entity_id": "7937287_1_Ent2", "role": "Treatment_Drug", "text": "Cefuroxime", "start": 0, "end": 1}, {"entity_id": "7937287_1_Ent0", "role": "Effect", "text": "acute renal failure", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "7937287_1_Ent1", "text": "Cefuroxime", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7937287_1_Ent2", "text": "Cefuroxime", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7937287_1_Ent0", "text": "acute renal failure", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "7946029_2", "wnd_id": "7946029_2_1", "text": "A case of basilar invagination which is thought to have arisen from the patient 's intrauterine exposure to phenytoin is presented .", "tokens": ["A", "case", "of", "basilar", "invagination", "which", "is", "thought", "to", "have", "arisen", "from", "the", "patient", "'s", "intrauterine", "exposure", "to", "phenytoin", "is", "presented", "."], "event_mentions": [{"id": "7946029_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exposure", "start": 16, "end": 17}, "arguments": [{"entity_id": "7946029_2_Ent0", "role": "Effect", "text": "basilar invagination", "start": 3, "end": 5}, {"entity_id": "7946029_2_Ent3", "role": "Treatment_Route", "text": "intrauterine", "start": 15, "end": 16}, {"entity_id": "7946029_2_Ent1", "role": "Treatment", "text": "phenytoin", "start": 18, "end": 19}, {"entity_id": "7946029_2_Ent2", "role": "Treatment_Drug", "text": "phenytoin", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "7946029_2_Ent0", "text": "basilar invagination", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "7946029_2_Ent3", "text": "intrauterine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "7946029_2_Ent1", "text": "phenytoin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "7946029_2_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "7949255_1", "wnd_id": "7949255_1_1", "text": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high - dose methotrexate ( HD - MTX ) for osteogenic sarcoma .", "tokens": ["Temporary", "neurologic", "abnormalities", "were", "observed", "in", "one", "out", "of", "23", "patients", "undergoing", "chemotherapy", "with", "high", "-", "dose", "methotrexate", "(", "HD", "-", "MTX", ")", "for", "osteogenic", "sarcoma", "."], "event_mentions": [{"id": "7949255_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 4, "end": 5}, "arguments": [{"entity_id": "7949255_1_Ent2", "role": "Effect", "text": "Temporary neurologic abnormalities", "start": 0, "end": 3}, {"entity_id": "7949255_1_Ent1", "role": "Subject_Population", "text": "one out of 23", "start": 6, "end": 10}, {"entity_id": "7949255_1_Ent0", "role": "Subject", "text": "one out of 23 patients", "start": 6, "end": 11}, {"entity_id": "7949255_1_Ent5", "role": "Treatment_Route", "text": "chemotherapy", "start": 12, "end": 13}, {"entity_id": "7949255_1_Ent3", "role": "Treatment", "text": "chemotherapy with high - dose methotrexate ( HD - MTX )", "start": 12, "end": 23}, {"entity_id": "7949255_1_Ent6", "role": "Treatment_Dosage", "text": "high - dose", "start": 14, "end": 17}, {"entity_id": "7949255_1_Ent7", "role": "Treatment_Drug", "text": "methotrexate", "start": 17, "end": 18}, {"entity_id": "7949255_1_Ent4", "role": "Treatment_Disorder", "text": "osteogenic sarcoma", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "7949255_1_Ent2", "text": "Temporary neurologic abnormalities", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7949255_1_Ent1", "text": "one out of 23", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "7949255_1_Ent0", "text": "one out of 23 patients", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "7949255_1_Ent5", "text": "chemotherapy", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7949255_1_Ent3", "text": "chemotherapy with high - dose methotrexate ( HD - MTX )", "entity_type": "Entity", "start": 12, "end": 23}, {"id": "7949255_1_Ent6", "text": "high - dose", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "7949255_1_Ent7", "text": "methotrexate", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "7949255_1_Ent4", "text": "osteogenic sarcoma", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "7973922_3", "wnd_id": "7973922_3_1", "text": "Systemic disease , most commonly renal dysfunction , preceded all 30 reported cases of acyclovir neurotoxicity .", "tokens": ["Systemic", "disease", ",", "most", "commonly", "renal", "dysfunction", ",", "preceded", "all", "30", "reported", "cases", "of", "acyclovir", "neurotoxicity", "."], "event_mentions": [{"id": "7973922_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "preceded", "start": 8, "end": 9}, "arguments": [{"entity_id": "7973922_3_Ent2", "role": "Effect", "text": "Systemic disease , most commonly renal dysfunction", "start": 0, "end": 7}, {"entity_id": "7973922_3_Ent1", "role": "Subject_Population", "text": "30", "start": 10, "end": 11}, {"entity_id": "7973922_3_Ent0", "role": "Subject", "text": "30 reported cases", "start": 10, "end": 13}, {"entity_id": "7973922_3_Ent4", "role": "Treatment", "text": "acyclovir", "start": 14, "end": 15}, {"entity_id": "7973922_3_Ent5", "role": "Treatment_Drug", "text": "acyclovir", "start": 14, "end": 15}, {"entity_id": "7973922_3_Ent3", "role": "Effect", "text": "neurotoxicity", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "7973922_3_Ent2", "text": "Systemic disease , most commonly renal dysfunction", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "7973922_3_Ent1", "text": "30", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7973922_3_Ent0", "text": "30 reported cases", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "7973922_3_Ent4", "text": "acyclovir", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "7973922_3_Ent5", "text": "acyclovir", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "7973922_3_Ent3", "text": "neurotoxicity", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "7978578_2", "wnd_id": "7978578_2_1", "text": "We report the first case of a patient in a promethazine - induced coma responding to treatment with flumazenil .", "tokens": ["We", "report", "the", "first", "case", "of", "a", "patient", "in", "a", "promethazine", "-", "induced", "coma", "responding", "to", "treatment", "with", "flumazenil", "."], "event_mentions": [{"id": "7978578_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "responding to", "start": 14, "end": 16}, "arguments": [{"entity_id": "7978578_2_Ent0", "role": "Subject", "text": "a patient in a promethazine - induced coma", "start": 6, "end": 14}, {"entity_id": "7978578_2_Ent3", "role": "Treatment_Drug", "text": "promethazine", "start": 10, "end": 11}, {"entity_id": "7978578_2_Ent4", "role": "Treatment_Disorder", "text": "coma", "start": 13, "end": 14}, {"entity_id": "7978578_2_Ent1", "role": "Treatment", "text": "treatment with flumazenil", "start": 16, "end": 19}, {"entity_id": "7978578_2_Ent2", "role": "Treatment_Drug", "text": "flumazenil", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "7978578_2_Ent0", "text": "a patient in a promethazine - induced coma", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "7978578_2_Ent3", "text": "promethazine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7978578_2_Ent4", "text": "coma", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7978578_2_Ent1", "text": "treatment with flumazenil", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "7978578_2_Ent2", "text": "flumazenil", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "7986915_2", "wnd_id": "7986915_2_1", "text": "We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .", "tokens": ["We", "describe", "a", "patient", "with", "a", "liver", "abscess", "due", "to", "Entamoeba", "histolytica", ",", "in", "whom", "metronidazole", "therapy", "(", "total", "dose", ",", "21", "g", "over", "14", "days", ")", "was", "complicated", "by", "reversible", "deafness", ",", "tinnitus", ",", "and", "ataxia", "and", "who", "relapsed", "5", "months", "later", "with", "a", "splenic", "abscess", "."], "event_mentions": [{"id": "7986915_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complicated", "start": 28, "end": 29}, "arguments": [{"entity_id": "7986915_2_Ent0", "role": "Subject", "text": "a patient with a liver abscess due to Entamoeba histolytica", "start": 2, "end": 12}, {"entity_id": "7986915_2_Ent6", "role": "Treatment_Disorder", "text": "liver abscess", "start": 6, "end": 8}, {"entity_id": "7986915_2_Ent7", "role": "Treatment_Disorder", "text": "Entamoeba histolytica", "start": 10, "end": 12}, {"entity_id": "7986915_2_Ent3", "role": "Treatment_Drug", "text": "metronidazole", "start": 15, "end": 16}, {"entity_id": "7986915_2_Ent2", "role": "Treatment", "text": "metronidazole therapy ( total dose , 21 g over 14 days )", "start": 15, "end": 27}, {"entity_id": "7986915_2_Ent4", "role": "Treatment_Dosage", "text": "21 g", "start": 21, "end": 23}, {"entity_id": "7986915_2_Ent5", "role": "Treatment_Duration", "text": "14 days", "start": 24, "end": 26}, {"entity_id": "7986915_2_Ent1", "role": "Effect", "text": "reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess", "start": 30, "end": 47}]}], "entity_mentions": [{"id": "7986915_2_Ent0", "text": "a patient with a liver abscess due to Entamoeba histolytica", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "7986915_2_Ent6", "text": "liver abscess", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7986915_2_Ent7", "text": "Entamoeba histolytica", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "7986915_2_Ent3", "text": "metronidazole", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "7986915_2_Ent2", "text": "metronidazole therapy ( total dose , 21 g over 14 days )", "entity_type": "Entity", "start": 15, "end": 27}, {"id": "7986915_2_Ent4", "text": "21 g", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "7986915_2_Ent5", "text": "14 days", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "7986915_2_Ent1", "text": "reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess", "entity_type": "Entity", "start": 30, "end": 47}], "lang": "en"}
{"doc_id": "7991279_1", "wnd_id": "7991279_1_1", "text": "Actinomycin D associated hepatic veno - occlusive disease -- a report of 2 cases .", "tokens": ["Actinomycin", "D", "associated", "hepatic", "veno", "-", "occlusive", "disease", "--", "a", "report", "of", "2", "cases", "."], "event_mentions": [{"id": "7991279_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "7991279_1_Ent1", "role": "Treatment", "text": "Actinomycin D", "start": 0, "end": 2}, {"entity_id": "7991279_1_Ent2", "role": "Treatment_Drug", "text": "Actinomycin D", "start": 0, "end": 2}, {"entity_id": "7991279_1_Ent0", "role": "Effect", "text": "hepatic veno - occlusive disease", "start": 3, "end": 8}]}], "entity_mentions": [{"id": "7991279_1_Ent1", "text": "Actinomycin D", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7991279_1_Ent2", "text": "Actinomycin D", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7991279_1_Ent0", "text": "hepatic veno - occlusive disease", "entity_type": "Entity", "start": 3, "end": 8}], "lang": "en"}
{"doc_id": "8002140_4", "wnd_id": "8002140_4_1", "text": "RESULTS : Budesonide use can cause contact dermatitis .", "tokens": ["RESULTS", ":", "Budesonide", "use", "can", "cause", "contact", "dermatitis", "."], "event_mentions": [{"id": "8002140_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 5, "end": 6}, "arguments": [{"entity_id": "8002140_4_Ent1", "role": "Treatment", "text": "Budesonide", "start": 2, "end": 3}, {"entity_id": "8002140_4_Ent2", "role": "Treatment_Drug", "text": "Budesonide", "start": 2, "end": 3}, {"entity_id": "8002140_4_Ent0", "role": "Effect", "text": "contact dermatitis", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "8002140_4_Ent1", "text": "Budesonide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8002140_4_Ent2", "text": "Budesonide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8002140_4_Ent0", "text": "contact dermatitis", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "8007037_2", "wnd_id": "8007037_2_1", "text": "Methemoglobinemia : an occupational hazard of phenylpropanolamine production .", "tokens": ["Methemoglobinemia", ":", "an", "occupational", "hazard", "of", "phenylpropanolamine", "production", "."], "event_mentions": [{"id": "8007037_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "production", "start": 7, "end": 8}, "arguments": [{"entity_id": "8007037_2_Ent0", "role": "Effect", "text": "Methemoglobinemia", "start": 0, "end": 1}, {"entity_id": "8007037_2_Ent1", "role": "Treatment", "text": "phenylpropanolamine", "start": 6, "end": 7}, {"entity_id": "8007037_2_Ent2", "role": "Treatment_Drug", "text": "phenylpropanolamine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "8007037_2_Ent0", "text": "Methemoglobinemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8007037_2_Ent1", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8007037_2_Ent2", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "8013261_2", "wnd_id": "8013261_2_1", "text": "Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .", "tokens": ["Four", "years", "after", "the", "beginning", "of", "IFN", "therapy", ",", "he", "acutely", "developed", "moderate", "hyperglycemia", "and", "severe", "ketonuria", "with", "positive", "islet", "cell", "antibody", ",", "and", "then", "28", "units", "/", "day", "of", "insulin", "injection", "was", "started", "."], "event_mentions": [{"id": "8013261_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "8013261_2_Ent4", "role": "Treatment_Time_elapsed", "text": "Four years after", "start": 0, "end": 3}, {"entity_id": "8013261_2_Ent3", "role": "Treatment", "text": "Four years after the beginning of IFN therapy", "start": 0, "end": 8}, {"entity_id": "8013261_2_Ent5", "role": "Treatment_Drug", "text": "IFN", "start": 6, "end": 7}, {"entity_id": "8013261_2_Ent0", "role": "Subject", "text": "he", "start": 9, "end": 10}, {"entity_id": "8013261_2_Ent1", "role": "Subject_Gender", "text": "he", "start": 9, "end": 10}, {"entity_id": "8013261_2_Ent2", "role": "Effect", "text": "acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody", "start": 10, "end": 22}]}], "entity_mentions": [{"id": "8013261_2_Ent4", "text": "Four years after", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8013261_2_Ent3", "text": "Four years after the beginning of IFN therapy", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "8013261_2_Ent5", "text": "IFN", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8013261_2_Ent0", "text": "he", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8013261_2_Ent1", "text": "he", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8013261_2_Ent2", "text": "acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody", "entity_type": "Entity", "start": 10, "end": 22}], "lang": "en"}
{"doc_id": "8013261_4", "wnd_id": "8013261_4_1", "text": "We report a case of IDDM which occurred during interferon therapy for chronic hepatitis .", "tokens": ["We", "report", "a", "case", "of", "IDDM", "which", "occurred", "during", "interferon", "therapy", "for", "chronic", "hepatitis", "."], "event_mentions": [{"id": "8013261_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 7, "end": 8}, "arguments": [{"entity_id": "8013261_4_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "8013261_4_Ent1", "role": "Effect", "text": "IDDM", "start": 5, "end": 6}, {"entity_id": "8013261_4_Ent3", "role": "Treatment_Drug", "text": "interferon", "start": 9, "end": 10}, {"entity_id": "8013261_4_Ent2", "role": "Treatment", "text": "interferon therapy", "start": 9, "end": 11}, {"entity_id": "8013261_4_Ent4", "role": "Treatment_Disorder", "text": "chronic hepatitis .", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "8013261_4_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8013261_4_Ent1", "text": "IDDM", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8013261_4_Ent3", "text": "interferon", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8013261_4_Ent2", "text": "interferon therapy", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "8013261_4_Ent4", "text": "chronic hepatitis .", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "8034807_1", "wnd_id": "8034807_1_1", "text": "The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease .", "tokens": ["The", "use", "of", "methotrexate", "(", "MTX", ")", "has", "been", "contraindicated", "for", "treatment", "of", "severe", "psoriasis", "in", "HIV", "infection", "on", "the", "basis", "of", "six", "previously", "reported", "cases", "in", "which", "MTX", "appeared", "to", "potentiate", "opportunistic", "infections", "and", "accelerate", "HIV", "disease", "."], "event_mentions": [{"id": "8034807_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "accelerate", "start": 35, "end": 36}, "arguments": [{"entity_id": "8034807_1_Ent2", "role": "Treatment_Drug", "text": "methotrexate ( MTX )", "start": 3, "end": 7}, {"entity_id": "8034807_1_Ent1", "role": "Treatment", "text": "MTX", "start": 28, "end": 29}, {"entity_id": "8034807_1_Ent3", "role": "Treatment_Drug", "text": "MTX", "start": 28, "end": 29}, {"entity_id": "8034807_1_Ent0", "role": "Effect", "text": "HIV disease", "start": 36, "end": 38}]}], "entity_mentions": [{"id": "8034807_1_Ent2", "text": "methotrexate ( MTX )", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "8034807_1_Ent1", "text": "MTX", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "8034807_1_Ent3", "text": "MTX", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "8034807_1_Ent0", "text": "HIV disease", "entity_type": "Entity", "start": 36, "end": 38}], "lang": "en"}
{"doc_id": "8053440_2", "wnd_id": "8053440_2_1", "text": "One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .", "tokens": ["One", "patient", "who", "received", "clindamycin", "had", "liver", "biopsy", "findings", "of", "marked", "cholestasis", ",", "portal", "inflammation", ",", "bile", "duct", "injury", "and", "bile", "duct", "paucity", "(", "ductopenia", ")", "."], "event_mentions": [{"id": "8053440_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 5, "end": 6}, "arguments": [{"entity_id": "8053440_2_Ent1", "role": "Subject_Population", "text": "One", "start": 0, "end": 1}, {"entity_id": "8053440_2_Ent0", "role": "Subject", "text": "One patient", "start": 0, "end": 2}, {"entity_id": "8053440_2_Ent3", "role": "Treatment", "text": "clindamycin", "start": 4, "end": 5}, {"entity_id": "8053440_2_Ent4", "role": "Treatment_Drug", "text": "clindamycin", "start": 4, "end": 5}, {"entity_id": "8053440_2_Ent2", "role": "Effect", "text": "marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia )", "start": 10, "end": 26}]}], "entity_mentions": [{"id": "8053440_2_Ent1", "text": "One", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8053440_2_Ent0", "text": "One patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8053440_2_Ent3", "text": "clindamycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8053440_2_Ent4", "text": "clindamycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8053440_2_Ent2", "text": "marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia )", "entity_type": "Entity", "start": 10, "end": 26}], "lang": "en"}
{"doc_id": "8053440_5", "wnd_id": "8053440_5_1", "text": "Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .", "tokens": ["Three", "years", "later", ",", "treatment", "with", "ampicillin", "caused", "another", "episode", "of", "cholestatic", "hepatitis", "with", "cholestasis", "and", "duct", "paucity", "on", "rebiopsy", "."], "event_mentions": [{"id": "8053440_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 7, "end": 8}, "arguments": [{"entity_id": "8053440_5_Ent3", "role": "Treatment_Time_elapsed", "text": "Three years later", "start": 0, "end": 3}, {"entity_id": "8053440_5_Ent1", "role": "Treatment", "text": "ampicillin", "start": 6, "end": 7}, {"entity_id": "8053440_5_Ent2", "role": "Treatment_Drug", "text": "ampicillin", "start": 6, "end": 7}, {"entity_id": "8053440_5_Ent0", "role": "Effect", "text": "cholestatic hepatitis with cholestasis and duct paucity on rebiopsy", "start": 11, "end": 20}]}], "entity_mentions": [{"id": "8053440_5_Ent3", "text": "Three years later", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8053440_5_Ent1", "text": "ampicillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8053440_5_Ent2", "text": "ampicillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8053440_5_Ent0", "text": "cholestatic hepatitis with cholestasis and duct paucity on rebiopsy", "entity_type": "Entity", "start": 11, "end": 20}], "lang": "en"}
{"doc_id": "8149366_2", "wnd_id": "8149366_2_1", "text": "We report on three observations of parkinsonian patients with levo - dopa - induced diphasic dyskinesias , who received subcutaneous apomorphine to reduce the duration of abnormal movements .", "tokens": ["We", "report", "on", "three", "observations", "of", "parkinsonian", "patients", "with", "levo", "-", "dopa", "-", "induced", "diphasic", "dyskinesias", ",", "who", "received", "subcutaneous", "apomorphine", "to", "reduce", "the", "duration", "of", "abnormal", "movements", "."], "event_mentions": [{"id": "8149366_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "8149366_2_Ent1", "role": "Subject_Disorder", "text": "parkinsonian", "start": 6, "end": 7}, {"entity_id": "8149366_2_Ent0", "role": "Subject", "text": "parkinsonian patients", "start": 6, "end": 8}, {"entity_id": "8149366_2_Ent3", "role": "Treatment", "text": "levo - dopa", "start": 9, "end": 12}, {"entity_id": "8149366_2_Ent4", "role": "Treatment_Drug", "text": "levo - dopa", "start": 9, "end": 12}, {"entity_id": "8149366_2_Ent2", "role": "Effect", "text": "diphasic dyskinesias", "start": 14, "end": 16}]}, {"id": "8149366_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reduce", "start": 22, "end": 23}, "arguments": [{"entity_id": "8149366_2_Ent6", "role": "Subject_Disorder", "text": "parkinsonian", "start": 6, "end": 7}, {"entity_id": "8149366_2_Ent5", "role": "Subject", "text": "parkinsonian patients", "start": 6, "end": 8}, {"entity_id": "8149366_2_Ent9", "role": "Treatment_Route", "text": "subcutaneous", "start": 19, "end": 20}, {"entity_id": "8149366_2_Ent7", "role": "Treatment", "text": "subcutaneous apomorphine", "start": 19, "end": 21}, {"entity_id": "8149366_2_Ent10", "role": "Treatment_Drug", "text": "apomorphine", "start": 20, "end": 21}, {"entity_id": "8149366_2_Ent8", "role": "Treatment_Disorder", "text": "abnormal movements", "start": 26, "end": 28}]}], "entity_mentions": [{"id": "8149366_2_Ent1", "text": "parkinsonian", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8149366_2_Ent6", "text": "parkinsonian", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8149366_2_Ent0", "text": "parkinsonian patients", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8149366_2_Ent5", "text": "parkinsonian patients", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8149366_2_Ent3", "text": "levo - dopa", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "8149366_2_Ent4", "text": "levo - dopa", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "8149366_2_Ent2", "text": "diphasic dyskinesias", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "8149366_2_Ent9", "text": "subcutaneous", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "8149366_2_Ent7", "text": "subcutaneous apomorphine", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "8149366_2_Ent10", "text": "apomorphine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8149366_2_Ent8", "text": "abnormal movements", "entity_type": "Entity", "start": 26, "end": 28}], "lang": "en"}
{"doc_id": "8162401_3", "wnd_id": "8162401_3_1", "text": "Seizures associated with fluoxetine therapy .", "tokens": ["Seizures", "associated", "with", "fluoxetine", "therapy", "."], "event_mentions": [{"id": "8162401_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 1, "end": 3}, "arguments": [{"entity_id": "8162401_3_Ent0", "role": "Effect", "text": "Seizures", "start": 0, "end": 1}, {"entity_id": "8162401_3_Ent2", "role": "Treatment_Drug", "text": "fluoxetine", "start": 3, "end": 4}, {"entity_id": "8162401_3_Ent1", "role": "Treatment", "text": "fluoxetine therapy", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "8162401_3_Ent0", "text": "Seizures", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8162401_3_Ent2", "text": "fluoxetine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8162401_3_Ent1", "text": "fluoxetine therapy", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "8222875_1", "wnd_id": "8222875_1_1", "text": "Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .", "tokens": ["Mitomycin", "C", "(", "MMC", ")", "is", "an", "alkylating", "agent", "that", "has", "been", "recently", "associated", "with", "the", "hemolytic", "-", "uremic", "syndrome", "(", "HUS", ")", "."], "event_mentions": [{"id": "8222875_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 13, "end": 14}, "arguments": [{"entity_id": "8222875_1_Ent2", "role": "Treatment_Drug", "text": "Mitomycin C", "start": 0, "end": 2}, {"entity_id": "8222875_1_Ent1", "role": "Treatment", "text": "Mitomycin C ( MMC )", "start": 0, "end": 5}, {"entity_id": "8222875_1_Ent0", "role": "Effect", "text": "the hemolytic - uremic syndrome ( HUS )", "start": 15, "end": 23}]}], "entity_mentions": [{"id": "8222875_1_Ent2", "text": "Mitomycin C", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8222875_1_Ent1", "text": "Mitomycin C ( MMC )", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8222875_1_Ent0", "text": "the hemolytic - uremic syndrome ( HUS )", "entity_type": "Entity", "start": 15, "end": 23}], "lang": "en"}
{"doc_id": "8222875_2", "wnd_id": "8222875_2_1", "text": "Pulmonary hemorrhage as a clinical manifestation of hemolytic - uremic syndrome associated with mitomycin C therapy .", "tokens": ["Pulmonary", "hemorrhage", "as", "a", "clinical", "manifestation", "of", "hemolytic", "-", "uremic", "syndrome", "associated", "with", "mitomycin", "C", "therapy", "."], "event_mentions": [{"id": "8222875_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 11, "end": 12}, "arguments": [{"entity_id": "8222875_2_Ent0", "role": "Effect", "text": "Pulmonary hemorrhage", "start": 0, "end": 2}, {"entity_id": "8222875_2_Ent1", "role": "Effect", "text": "hemolytic - uremic syndrome", "start": 7, "end": 11}, {"entity_id": "8222875_2_Ent3", "role": "Treatment_Drug", "text": "mitomycin C", "start": 13, "end": 15}, {"entity_id": "8222875_2_Ent2", "role": "Treatment", "text": "mitomycin C therapy", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "8222875_2_Ent0", "text": "Pulmonary hemorrhage", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8222875_2_Ent1", "text": "hemolytic - uremic syndrome", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "8222875_2_Ent3", "text": "mitomycin C", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8222875_2_Ent2", "text": "mitomycin C therapy", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "8222875_3", "wnd_id": "8222875_3_1", "text": "Pulmonary hemorrhage is an uncommon feature in the HUS , and seems to appear especially in the HUS associated with MMC therapy .", "tokens": ["Pulmonary", "hemorrhage", "is", "an", "uncommon", "feature", "in", "the", "HUS", ",", "and", "seems", "to", "appear", "especially", "in", "the", "HUS", "associated", "with", "MMC", "therapy", "."], "event_mentions": [{"id": "8222875_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appear", "start": 13, "end": 14}, "arguments": [{"entity_id": "8222875_3_Ent0", "role": "Effect", "text": "Pulmonary hemorrhage", "start": 0, "end": 2}, {"entity_id": "8222875_3_Ent1", "role": "Treatment", "text": "MMC", "start": 20, "end": 21}, {"entity_id": "8222875_3_Ent2", "role": "Treatment_Drug", "text": "MMC", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "8222875_3_Ent0", "text": "Pulmonary hemorrhage", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8222875_3_Ent1", "text": "MMC", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8222875_3_Ent2", "text": "MMC", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "8222875_4", "wnd_id": "8222875_4_1", "text": "We describe two women who developed HUS after MMC therapy and presented massive pulmonary bleeding .", "tokens": ["We", "describe", "two", "women", "who", "developed", "HUS", "after", "MMC", "therapy", "and", "presented", "massive", "pulmonary", "bleeding", "."], "event_mentions": [{"id": "8222875_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "8222875_4_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "8222875_4_Ent0", "role": "Subject", "text": "two women", "start": 2, "end": 4}, {"entity_id": "8222875_4_Ent2", "role": "Subject_Gender", "text": "women", "start": 3, "end": 4}, {"entity_id": "8222875_4_Ent3", "role": "Effect", "text": "HUS", "start": 6, "end": 7}, {"entity_id": "8222875_4_Ent5", "role": "Treatment", "text": "MMC", "start": 8, "end": 9}, {"entity_id": "8222875_4_Ent6", "role": "Treatment_Drug", "text": "MMC", "start": 8, "end": 9}, {"entity_id": "8222875_4_Ent4", "role": "Effect", "text": "massive pulmonary bleeding", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "8222875_4_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8222875_4_Ent0", "text": "two women", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8222875_4_Ent2", "text": "women", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8222875_4_Ent3", "text": "HUS", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8222875_4_Ent5", "text": "MMC", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8222875_4_Ent6", "text": "MMC", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8222875_4_Ent4", "text": "massive pulmonary bleeding", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "8239963_1", "wnd_id": "8239963_1_1", "text": "Clonidine - induced bradycardia in patients with spinal cord injury .", "tokens": ["Clonidine", "-", "induced", "bradycardia", "in", "patients", "with", "spinal", "cord", "injury", "."], "event_mentions": [{"id": "8239963_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8239963_1_Ent2", "role": "Treatment", "text": "Clonidine", "start": 0, "end": 1}, {"entity_id": "8239963_1_Ent4", "role": "Treatment_Drug", "text": "Clonidine", "start": 0, "end": 1}, {"entity_id": "8239963_1_Ent1", "role": "Effect", "text": "bradycardia", "start": 3, "end": 4}, {"entity_id": "8239963_1_Ent0", "role": "Subject", "text": "patients with spinal cord injury", "start": 5, "end": 10}, {"entity_id": "8239963_1_Ent3", "role": "Treatment_Disorder", "text": "spinal cord injury", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "8239963_1_Ent2", "text": "Clonidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8239963_1_Ent4", "text": "Clonidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8239963_1_Ent1", "text": "bradycardia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8239963_1_Ent0", "text": "patients with spinal cord injury", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "8239963_1_Ent3", "text": "spinal cord injury", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "8239963_2", "wnd_id": "8239963_2_1", "text": "Possible mechanisms by which clonidine decreases spasticity are described , probable mechanisms of induced bradycardia are reviewed , and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented .", "tokens": ["Possible", "mechanisms", "by", "which", "clonidine", "decreases", "spasticity", "are", "described", ",", "probable", "mechanisms", "of", "induced", "bradycardia", "are", "reviewed", ",", "and", "specific", "treatment", "recommendations", "for", "the", "use", "of", "clonidine", "in", "spinal", "cord", "injured", "patients", "are", "presented", "."], "event_mentions": [{"id": "8239963_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "8239963_2_Ent1", "role": "Treatment", "text": "clonidine", "start": 4, "end": 5}, {"entity_id": "8239963_2_Ent2", "role": "Treatment_Drug", "text": "clonidine", "start": 4, "end": 5}, {"entity_id": "8239963_2_Ent0", "role": "Effect", "text": "bradycardia", "start": 14, "end": 15}, {"entity_id": "8239963_2_Ent3", "role": "Treatment_Disorder", "text": "spinal cord injured", "start": 28, "end": 31}]}], "entity_mentions": [{"id": "8239963_2_Ent1", "text": "clonidine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8239963_2_Ent2", "text": "clonidine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8239963_2_Ent0", "text": "bradycardia", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8239963_2_Ent3", "text": "spinal cord injured", "entity_type": "Entity", "start": 28, "end": 31}], "lang": "en"}
{"doc_id": "8250714_1", "wnd_id": "8250714_1_1", "text": "Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia .", "tokens": ["Five", "cases", "(", "four", "from", "the", "literature", "and", "one", "new", "case", ")", "are", "presented", "in", "which", "patients", "unsuspected", "of", "having", "vitamin", "B12", "deficiency", "developed", "subacute", "combined", "degeneration", "of", "the", "spinal", "cord", "following", "nitrous", "oxide", "anesthesia", "."], "event_mentions": [{"id": "8250714_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 23, "end": 24}, "arguments": [{"entity_id": "8250714_1_Ent1", "role": "Subject_Population", "text": "Five", "start": 0, "end": 1}, {"entity_id": "8250714_1_Ent0", "role": "Subject", "text": "Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency", "start": 0, "end": 23}, {"entity_id": "8250714_1_Ent5", "role": "Treatment_Disorder", "text": "vitamin B12 deficiency", "start": 20, "end": 23}, {"entity_id": "8250714_1_Ent2", "role": "Effect", "text": "subacute combined degeneration of the spinal cord", "start": 24, "end": 31}, {"entity_id": "8250714_1_Ent4", "role": "Treatment_Drug", "text": "nitrous oxide", "start": 32, "end": 34}, {"entity_id": "8250714_1_Ent3", "role": "Treatment", "text": "nitrous oxide anesthesia", "start": 32, "end": 35}]}], "entity_mentions": [{"id": "8250714_1_Ent1", "text": "Five", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8250714_1_Ent0", "text": "Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency", "entity_type": "Entity", "start": 0, "end": 23}, {"id": "8250714_1_Ent5", "text": "vitamin B12 deficiency", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "8250714_1_Ent2", "text": "subacute combined degeneration of the spinal cord", "entity_type": "Entity", "start": 24, "end": 31}, {"id": "8250714_1_Ent4", "text": "nitrous oxide", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "8250714_1_Ent3", "text": "nitrous oxide anesthesia", "entity_type": "Entity", "start": 32, "end": 35}], "lang": "en"}
{"doc_id": "8250714_2", "wnd_id": "8250714_2_1", "text": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency .", "tokens": ["Neurologic", "degeneration", "associated", "with", "nitrous", "oxide", "anesthesia", "in", "patients", "with", "vitamin", "B12", "deficiency", "."], "event_mentions": [{"id": "8250714_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "8250714_2_Ent2", "role": "Effect", "text": "Neurologic degeneration", "start": 0, "end": 2}, {"entity_id": "8250714_2_Ent4", "role": "Treatment_Drug", "text": "nitrous oxide", "start": 4, "end": 6}, {"entity_id": "8250714_2_Ent3", "role": "Treatment", "text": "nitrous oxide anesthesia", "start": 4, "end": 7}, {"entity_id": "8250714_2_Ent0", "role": "Subject", "text": "patients with vitamin B12 deficiency", "start": 8, "end": 13}, {"entity_id": "8250714_2_Ent1", "role": "Subject_Disorder", "text": "vitamin B12 deficiency", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "8250714_2_Ent2", "text": "Neurologic degeneration", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8250714_2_Ent4", "text": "nitrous oxide", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "8250714_2_Ent3", "text": "nitrous oxide anesthesia", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "8250714_2_Ent0", "text": "patients with vitamin B12 deficiency", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "8250714_2_Ent1", "text": "vitamin B12 deficiency", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "8250714_3", "wnd_id": "8250714_3_1", "text": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia .", "tokens": ["Patients", "with", "vitamin", "B12", "deficiency", "are", "exceedingly", "sensitive", "to", "neurologic", "deterioration", "following", "nitrous", "oxide", "anesthesia", "."], "event_mentions": [{"id": "8250714_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 11, "end": 12}, "arguments": [{"entity_id": "8250714_3_Ent0", "role": "Subject", "text": "Patients with vitamin B12 deficiency", "start": 0, "end": 5}, {"entity_id": "8250714_3_Ent1", "role": "Subject_Disorder", "text": "vitamin B12 deficiency", "start": 2, "end": 5}, {"entity_id": "8250714_3_Ent2", "role": "Effect", "text": "neurologic deterioration", "start": 9, "end": 11}, {"entity_id": "8250714_3_Ent4", "role": "Treatment_Drug", "text": "nitrous oxide", "start": 12, "end": 14}, {"entity_id": "8250714_3_Ent3", "role": "Treatment", "text": "nitrous oxide anesthesia", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "8250714_3_Ent0", "text": "Patients with vitamin B12 deficiency", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8250714_3_Ent1", "text": "vitamin B12 deficiency", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "8250714_3_Ent2", "text": "neurologic deterioration", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "8250714_3_Ent4", "text": "nitrous oxide", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "8250714_3_Ent3", "text": "nitrous oxide anesthesia", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "8255797_1", "wnd_id": "8255797_1_1", "text": "Captopril - induced bone marrow suppression in two cardiac patients with trisomy 21 .", "tokens": ["Captopril", "-", "induced", "bone", "marrow", "suppression", "in", "two", "cardiac", "patients", "with", "trisomy", "21", "."], "event_mentions": [{"id": "8255797_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8255797_1_Ent5", "role": "Treatment", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "8255797_1_Ent6", "role": "Treatment_Drug", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "8255797_1_Ent4", "role": "Effect", "text": "bone marrow suppression", "start": 3, "end": 6}, {"entity_id": "8255797_1_Ent1", "role": "Subject_Population", "text": "two", "start": 7, "end": 8}, {"entity_id": "8255797_1_Ent0", "role": "Subject", "text": "two cardiac patients with trisomy 21", "start": 7, "end": 13}, {"entity_id": "8255797_1_Ent2", "role": "Subject_Disorder", "text": "cardiac", "start": 8, "end": 9}, {"entity_id": "8255797_1_Ent3", "role": "Subject_Disorder", "text": "trisomy 21", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "8255797_1_Ent5", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8255797_1_Ent6", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8255797_1_Ent4", "text": "bone marrow suppression", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "8255797_1_Ent1", "text": "two", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8255797_1_Ent0", "text": "two cardiac patients with trisomy 21", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "8255797_1_Ent2", "text": "cardiac", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8255797_1_Ent3", "text": "trisomy 21", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "8260059_2", "wnd_id": "8260059_2_1", "text": "No explanation for this delay was found , other than the possibility that magnesium sulfate treatment impeded lactogenesis .", "tokens": ["No", "explanation", "for", "this", "delay", "was", "found", ",", "other", "than", "the", "possibility", "that", "magnesium", "sulfate", "treatment", "impeded", "lactogenesis", "."], "event_mentions": [{"id": "8260059_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "impeded", "start": 16, "end": 17}, "arguments": [{"entity_id": "8260059_2_Ent1", "role": "Treatment", "text": "magnesium sulfate", "start": 13, "end": 15}, {"entity_id": "8260059_2_Ent2", "role": "Treatment_Drug", "text": "magnesium sulfate", "start": 13, "end": 15}, {"entity_id": "8260059_2_Ent0", "role": "Effect", "text": "lactogenesis", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "8260059_2_Ent1", "text": "magnesium sulfate", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8260059_2_Ent2", "text": "magnesium sulfate", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8260059_2_Ent0", "text": "lactogenesis", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "8276031_5", "wnd_id": "8276031_5_1", "text": "The symptomatology of 18 other paediatric cases of naphthylimidazoline exposure reported to the Belgian National Poison Centre , is also discussed .", "tokens": ["The", "symptomatology", "of", "18", "other", "paediatric", "cases", "of", "naphthylimidazoline", "exposure", "reported", "to", "the", "Belgian", "National", "Poison", "Centre", ",", "is", "also", "discussed", "."], "event_mentions": [{"id": "8276031_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "symptomatology", "start": 1, "end": 2}, "arguments": [{"entity_id": "8276031_5_Ent1", "role": "Subject_Population", "text": "18", "start": 3, "end": 4}, {"entity_id": "8276031_5_Ent0", "role": "Subject", "text": "18 other paediatric cases", "start": 3, "end": 7}, {"entity_id": "8276031_5_Ent2", "role": "Subject_Age", "text": "paediatric", "start": 5, "end": 6}, {"entity_id": "8276031_5_Ent4", "role": "Treatment", "text": "naphthylimidazoline", "start": 8, "end": 9}, {"entity_id": "8276031_5_Ent5", "role": "Treatment_Drug", "text": "naphthylimidazoline", "start": 8, "end": 9}, {"entity_id": "8276031_5_Ent3", "role": "Effect", "text": "naphthylimidazoline exposure", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "8276031_5_Ent1", "text": "18", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8276031_5_Ent0", "text": "18 other paediatric cases", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "8276031_5_Ent2", "text": "paediatric", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8276031_5_Ent4", "text": "naphthylimidazoline", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8276031_5_Ent5", "text": "naphthylimidazoline", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8276031_5_Ent3", "text": "naphthylimidazoline exposure", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "8292513_2", "wnd_id": "8292513_2_1", "text": "Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .", "tokens": ["Children", "with", "acute", "lymphoblastic", "leukemia", "(", "ALL", ")", ",", "treated", "with", "L", "-", "asparaginase", "are", "at", "risk", "for", "cerebral", "thrombosis", "or", "hemorrhage", "because", "of", "coagulation", "protein", "deficiencies", "."], "event_mentions": [{"id": "8292513_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 16, "end": 17}, "arguments": [{"entity_id": "8292513_2_Ent1", "role": "Subject_Age", "text": "Children", "start": 0, "end": 1}, {"entity_id": "8292513_2_Ent0", "role": "Subject", "text": "Children with acute lymphoblastic leukemia ( ALL )", "start": 0, "end": 8}, {"entity_id": "8292513_2_Ent6", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia ( ALL )", "start": 2, "end": 8}, {"entity_id": "8292513_2_Ent4", "role": "Treatment", "text": "L - asparaginase", "start": 11, "end": 14}, {"entity_id": "8292513_2_Ent5", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 11, "end": 14}, {"entity_id": "8292513_2_Ent2", "role": "Effect", "text": "cerebral thrombosis or hemorrhage", "start": 18, "end": 22}, {"entity_id": "8292513_2_Ent3", "role": "Effect", "text": "coagulation protein deficiencies", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "8292513_2_Ent1", "text": "Children", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8292513_2_Ent0", "text": "Children with acute lymphoblastic leukemia ( ALL )", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "8292513_2_Ent6", "text": "acute lymphoblastic leukemia ( ALL )", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "8292513_2_Ent4", "text": "L - asparaginase", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "8292513_2_Ent5", "text": "L - asparaginase", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "8292513_2_Ent2", "text": "cerebral thrombosis or hemorrhage", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "8292513_2_Ent3", "text": "coagulation protein deficiencies", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "8301877_4", "wnd_id": "8301877_4_1", "text": "We described the occurrence of L - dopa - induced myoclonus and seizures in a case of parkinsonism with its SEPs findings .", "tokens": ["We", "described", "the", "occurrence", "of", "L", "-", "dopa", "-", "induced", "myoclonus", "and", "seizures", "in", "a", "case", "of", "parkinsonism", "with", "its", "SEPs", "findings", "."], "event_mentions": [{"id": "8301877_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "8301877_4_Ent2", "role": "Treatment", "text": "L - dopa", "start": 5, "end": 8}, {"entity_id": "8301877_4_Ent3", "role": "Treatment_Drug", "text": "L - dopa", "start": 5, "end": 8}, {"entity_id": "8301877_4_Ent1", "role": "Effect", "text": "myoclonus and seizures", "start": 10, "end": 13}, {"entity_id": "8301877_4_Ent0", "role": "Subject", "text": "case of parkinsonism", "start": 15, "end": 18}, {"entity_id": "8301877_4_Ent4", "role": "Treatment_Disorder", "text": "parkinsonism", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "8301877_4_Ent2", "text": "L - dopa", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "8301877_4_Ent3", "text": "L - dopa", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "8301877_4_Ent1", "text": "myoclonus and seizures", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "8301877_4_Ent0", "text": "case of parkinsonism", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "8301877_4_Ent4", "text": "parkinsonism", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "8305778_3", "wnd_id": "8305778_3_1", "text": "A 78 - year - old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia .", "tokens": ["A", "78", "-", "year", "-", "old", "man", "with", "a", "history", "of", "congestive", "heart", "failure", "and", "coronary", "artery", "disease", "began", "taking", "amiodarone", "to", "suppress", "sustained", "ventricular", "tachycardia", "."], "event_mentions": [{"id": "8305778_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "suppress", "start": 22, "end": 23}, "arguments": [{"entity_id": "8305778_3_Ent0", "role": "Subject", "text": "A 78 - year - old man with a history of congestive heart failure and coronary artery disease", "start": 0, "end": 18}, {"entity_id": "8305778_3_Ent1", "role": "Subject_Age", "text": "78 - year - old", "start": 1, "end": 6}, {"entity_id": "8305778_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "8305778_3_Ent3", "role": "Subject_Disorder", "text": "congestive heart failure", "start": 11, "end": 14}, {"entity_id": "8305778_3_Ent4", "role": "Subject_Disorder", "text": "coronary artery disease", "start": 15, "end": 18}, {"entity_id": "8305778_3_Ent5", "role": "Treatment", "text": "amiodarone", "start": 20, "end": 21}, {"entity_id": "8305778_3_Ent6", "role": "Treatment_Drug", "text": "amiodarone", "start": 20, "end": 21}, {"entity_id": "8305778_3_Ent7", "role": "Treatment_Disorder", "text": "sustained ventricular tachycardia", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "8305778_3_Ent0", "text": "A 78 - year - old man with a history of congestive heart failure and coronary artery disease", "entity_type": "Entity", "start": 0, "end": 18}, {"id": "8305778_3_Ent1", "text": "78 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "8305778_3_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8305778_3_Ent3", "text": "congestive heart failure", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "8305778_3_Ent4", "text": "coronary artery disease", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "8305778_3_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8305778_3_Ent6", "text": "amiodarone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8305778_3_Ent7", "text": "sustained ventricular tachycardia", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "8308511_1", "wnd_id": "8308511_1_1", "text": "Unintended exposure to acyclovir early in pregnancy , which is not uncommon , may cause excessive maternal and physician anxiety .", "tokens": ["Unintended", "exposure", "to", "acyclovir", "early", "in", "pregnancy", ",", "which", "is", "not", "uncommon", ",", "may", "cause", "excessive", "maternal", "and", "physician", "anxiety", "."], "event_mentions": [{"id": "8308511_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 14, "end": 15}, "arguments": [{"entity_id": "8308511_1_Ent1", "role": "Treatment", "text": "Unintended exposure to acyclovir", "start": 0, "end": 4}, {"entity_id": "8308511_1_Ent2", "role": "Treatment_Drug", "text": "acyclovir", "start": 3, "end": 4}, {"entity_id": "8308511_1_Ent0", "role": "Effect", "text": "excessive maternal and physician anxiety", "start": 15, "end": 20}]}], "entity_mentions": [{"id": "8308511_1_Ent1", "text": "Unintended exposure to acyclovir", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8308511_1_Ent2", "text": "acyclovir", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8308511_1_Ent0", "text": "excessive maternal and physician anxiety", "entity_type": "Entity", "start": 15, "end": 20}], "lang": "en"}
{"doc_id": "8329789_11", "wnd_id": "8329789_11_1", "text": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses .", "tokens": ["Hydrocortisone", "may", "decrease", "the", "incidence", "of", "mortality", "associated", "with", "cardiac", "arrhythmias", "in", "children", "receiving", "amphotericin", "B", "overdoses", "."], "event_mentions": [{"id": "8329789_11_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "decrease", "start": 2, "end": 3}, "arguments": [{"entity_id": "8329789_11_Ent2", "role": "Treatment", "text": "Hydrocortisone", "start": 0, "end": 1}, {"entity_id": "8329789_11_Ent4", "role": "Treatment_Drug", "text": "Hydrocortisone", "start": 0, "end": 1}, {"entity_id": "8329789_11_Ent3", "role": "Treatment_Disorder", "text": "incidence of mortality", "start": 4, "end": 7}, {"entity_id": "8329789_11_Ent0", "role": "Subject", "text": "cardiac arrhythmias in children", "start": 9, "end": 13}, {"entity_id": "8329789_11_Ent1", "role": "Subject_Age", "text": "children", "start": 12, "end": 13}]}, {"id": "8329789_11_Evt1", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 13, "end": 14}, "arguments": [{"entity_id": "8329789_11_Ent7", "role": "Effect", "text": "incidence of mortality", "start": 4, "end": 7}, {"entity_id": "8329789_11_Ent9", "role": "Treatment_Disorder", "text": "cardiac arrhythmias", "start": 9, "end": 11}, {"entity_id": "8329789_11_Ent5", "role": "Subject", "text": "cardiac arrhythmias in children", "start": 9, "end": 13}, {"entity_id": "8329789_11_Ent6", "role": "Subject_Age", "text": "children", "start": 12, "end": 13}, {"entity_id": "8329789_11_Ent11", "role": "Treatment_Drug", "text": "amphotericin B", "start": 14, "end": 16}, {"entity_id": "8329789_11_Ent8", "role": "Treatment", "text": "amphotericin B overdoses", "start": 14, "end": 17}, {"entity_id": "8329789_11_Ent10", "role": "Treatment_Dosage", "text": "overdoses", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "8329789_11_Ent2", "text": "Hydrocortisone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8329789_11_Ent4", "text": "Hydrocortisone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8329789_11_Ent3", "text": "incidence of mortality", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "8329789_11_Ent7", "text": "incidence of mortality", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "8329789_11_Ent9", "text": "cardiac arrhythmias", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "8329789_11_Ent0", "text": "cardiac arrhythmias in children", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "8329789_11_Ent5", "text": "cardiac arrhythmias in children", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "8329789_11_Ent1", "text": "children", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8329789_11_Ent6", "text": "children", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8329789_11_Ent11", "text": "amphotericin B", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "8329789_11_Ent8", "text": "amphotericin B overdoses", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "8329789_11_Ent10", "text": "overdoses", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "8329789_2", "wnd_id": "8329789_2_1", "text": "OBJECTIVE : To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population .", "tokens": ["OBJECTIVE", ":", "To", "report", "the", "first", "five", "cases", "of", "amphotericin", "B", "overdose", "with", "secondary", "cardiac", "complications", "in", "a", "pediatric", "population", "."], "event_mentions": [{"id": "8329789_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 13, "end": 14}, "arguments": [{"entity_id": "8329789_2_Ent0", "role": "Subject", "text": "first five cases of", "start": 5, "end": 9}, {"entity_id": "8329789_2_Ent3", "role": "Subject_Population", "text": "five", "start": 6, "end": 7}, {"entity_id": "8329789_2_Ent6", "role": "Treatment_Drug", "text": "amphotericin B", "start": 9, "end": 11}, {"entity_id": "8329789_2_Ent5", "role": "Treatment", "text": "amphotericin B overdose", "start": 9, "end": 12}, {"entity_id": "8329789_2_Ent7", "role": "Treatment_Dosage", "text": "overdose", "start": 11, "end": 12}, {"entity_id": "8329789_2_Ent4", "role": "Effect", "text": "cardiac complications", "start": 14, "end": 16}, {"entity_id": "8329789_2_Ent1", "role": "Subject", "text": "a pediatric population", "start": 17, "end": 20}, {"entity_id": "8329789_2_Ent2", "role": "Subject_Age", "text": "pediatric", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "8329789_2_Ent0", "text": "first five cases of", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "8329789_2_Ent3", "text": "five", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8329789_2_Ent6", "text": "amphotericin B", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "8329789_2_Ent5", "text": "amphotericin B overdose", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "8329789_2_Ent7", "text": "overdose", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8329789_2_Ent4", "text": "cardiac complications", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "8329789_2_Ent1", "text": "a pediatric population", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "8329789_2_Ent2", "text": "pediatric", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "834512_2", "wnd_id": "834512_2_1", "text": "The administration of \" sweet spirits of nitre \" ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .", "tokens": ["The", "administration", "of", "\"", "sweet", "spirits", "of", "nitre", "\"", "(", "4", "%", "ethyl", "nitrite", "CH3CH2ONO", "in", "70", "%", "ethyl", "alcohol", ")", "was", "followed", "by", "acute", "methemoglobinemia", "and", "severe", "anoxic", "metabolic", "acidosis", "in", "infant", "twins", ",", "Methylene", "blue", "administration", "reversed", "methemoglobinemia", "in", "both", ",", "but", "one", "twin", "died", "from", "the", "consequences", "of", "hypoxemia", "."], "event_mentions": [{"id": "834512_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "followed", "start": 22, "end": 23}, "arguments": [{"entity_id": "834512_2_Ent3", "role": "Treatment", "text": "\" sweet spirits of nitre \" ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol )", "start": 3, "end": 21}, {"entity_id": "834512_2_Ent4", "role": "Treatment_Drug", "text": "sweet spirits of nitre", "start": 4, "end": 8}, {"entity_id": "834512_2_Ent2", "role": "Effect", "text": "acute methemoglobinemia and severe anoxic metabolic acidosis", "start": 24, "end": 31}, {"entity_id": "834512_2_Ent1", "role": "Subject_Age", "text": "infant", "start": 32, "end": 33}, {"entity_id": "834512_2_Ent0", "role": "Subject", "text": "infant twins", "start": 32, "end": 34}]}, {"id": "834512_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reversed", "start": 38, "end": 39}, "arguments": [{"entity_id": "834512_2_Ent6", "role": "Subject_Age", "text": "infant", "start": 32, "end": 33}, {"entity_id": "834512_2_Ent5", "role": "Subject", "text": "infant twins", "start": 32, "end": 34}, {"entity_id": "834512_2_Ent7", "role": "Treatment", "text": "Methylene blue", "start": 35, "end": 37}, {"entity_id": "834512_2_Ent9", "role": "Treatment_Drug", "text": "Methylene blue", "start": 35, "end": 37}, {"entity_id": "834512_2_Ent8", "role": "Treatment_Disorder", "text": "methemoglobinemia", "start": 39, "end": 40}]}, {"id": "834512_2_Evt2", "event_type": "Adverse_event", "trigger": {"text": "died", "start": 46, "end": 47}, "arguments": [{"entity_id": "834512_2_Ent12", "role": "Treatment", "text": "\" sweet spirits of nitre \" ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol )", "start": 3, "end": 21}, {"entity_id": "834512_2_Ent13", "role": "Treatment_Drug", "text": "sweet spirits of nitre", "start": 4, "end": 8}, {"entity_id": "834512_2_Ent10", "role": "Subject", "text": "one twin", "start": 44, "end": 46}, {"entity_id": "834512_2_Ent11", "role": "Effect", "text": "died from the consequences of hypoxemia", "start": 46, "end": 52}]}], "entity_mentions": [{"id": "834512_2_Ent3", "text": "\" sweet spirits of nitre \" ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol )", "entity_type": "Entity", "start": 3, "end": 21}, {"id": "834512_2_Ent12", "text": "\" sweet spirits of nitre \" ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol )", "entity_type": "Entity", "start": 3, "end": 21}, {"id": "834512_2_Ent4", "text": "sweet spirits of nitre", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "834512_2_Ent13", "text": "sweet spirits of nitre", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "834512_2_Ent2", "text": "acute methemoglobinemia and severe anoxic metabolic acidosis", "entity_type": "Entity", "start": 24, "end": 31}, {"id": "834512_2_Ent1", "text": "infant", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "834512_2_Ent6", "text": "infant", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "834512_2_Ent0", "text": "infant twins", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "834512_2_Ent5", "text": "infant twins", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "834512_2_Ent7", "text": "Methylene blue", "entity_type": "Entity", "start": 35, "end": 37}, {"id": "834512_2_Ent9", "text": "Methylene blue", "entity_type": "Entity", "start": 35, "end": 37}, {"id": "834512_2_Ent8", "text": "methemoglobinemia", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "834512_2_Ent10", "text": "one twin", "entity_type": "Entity", "start": 44, "end": 46}, {"id": "834512_2_Ent11", "text": "died from the consequences of hypoxemia", "entity_type": "Entity", "start": 46, "end": 52}], "lang": "en"}
{"doc_id": "8345435_1", "wnd_id": "8345435_1_1", "text": "Hepatotoxic effects in a child receiving valproate and carnitine .", "tokens": ["Hepatotoxic", "effects", "in", "a", "child", "receiving", "valproate", "and", "carnitine", "."], "event_mentions": [{"id": "8345435_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 5, "end": 6}, "arguments": [{"entity_id": "8345435_1_Ent2", "role": "Effect", "text": "Hepatotoxic effects", "start": 0, "end": 2}, {"entity_id": "8345435_1_Ent0", "role": "Subject", "text": "a child", "start": 3, "end": 5}, {"entity_id": "8345435_1_Ent1", "role": "Subject_Age", "text": "child", "start": 4, "end": 5}, {"entity_id": "8345435_1_Ent4", "role": "Treatment_Drug", "text": "valproate", "start": 6, "end": 7}, {"entity_id": "8345435_1_Ent6", "role": "Combination_Drug", "text": "valproate", "start": 6, "end": 7}, {"entity_id": "8345435_1_Ent3", "role": "Treatment", "text": "valproate and carnitine", "start": 6, "end": 9}, {"entity_id": "8345435_1_Ent5", "role": "Treatment_Drug", "text": "carnitine", "start": 8, "end": 9}, {"entity_id": "8345435_1_Ent7", "role": "Combination_Drug", "text": "carnitine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "8345435_1_Ent2", "text": "Hepatotoxic effects", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8345435_1_Ent0", "text": "a child", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8345435_1_Ent1", "text": "child", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8345435_1_Ent4", "text": "valproate", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8345435_1_Ent6", "text": "valproate", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8345435_1_Ent3", "text": "valproate and carnitine", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8345435_1_Ent5", "text": "carnitine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8345435_1_Ent7", "text": "carnitine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "8360712_1", "wnd_id": "8360712_1_1", "text": "A case is reported of a 40 year old woman treated with intraventricular IL - 2 for leptomeningeal disease who developed progressive cognitive dysfunction .", "tokens": ["A", "case", "is", "reported", "of", "a", "40", "year", "old", "woman", "treated", "with", "intraventricular", "IL", "-", "2", "for", "leptomeningeal", "disease", "who", "developed", "progressive", "cognitive", "dysfunction", "."], "event_mentions": [{"id": "8360712_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "8360712_1_Ent0", "role": "Subject", "text": "a 40 year old woman", "start": 5, "end": 10}, {"entity_id": "8360712_1_Ent1", "role": "Subject_Age", "text": "40 year old", "start": 6, "end": 9}, {"entity_id": "8360712_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "8360712_1_Ent7", "role": "Treatment_Route", "text": "intraventricular", "start": 12, "end": 13}, {"entity_id": "8360712_1_Ent4", "role": "Treatment", "text": "intraventricular IL - 2", "start": 12, "end": 16}, {"entity_id": "8360712_1_Ent6", "role": "Treatment_Drug", "text": "IL - 2", "start": 13, "end": 16}, {"entity_id": "8360712_1_Ent5", "role": "Treatment_Disorder", "text": "leptomeningeal disease", "start": 17, "end": 19}, {"entity_id": "8360712_1_Ent3", "role": "Effect", "text": "progressive cognitive dysfunction", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "8360712_1_Ent0", "text": "a 40 year old woman", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "8360712_1_Ent1", "text": "40 year old", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8360712_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8360712_1_Ent7", "text": "intraventricular", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8360712_1_Ent4", "text": "intraventricular IL - 2", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "8360712_1_Ent6", "text": "IL - 2", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "8360712_1_Ent5", "text": "leptomeningeal disease", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "8360712_1_Ent3", "text": "progressive cognitive dysfunction", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "8360712_2", "wnd_id": "8360712_2_1", "text": "Delayed neurotoxicity of intraventricular interleukin - 2 : a case report .", "tokens": ["Delayed", "neurotoxicity", "of", "intraventricular", "interleukin", "-", "2", ":", "a", "case", "report", "."], "event_mentions": [{"id": "8360712_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 2, "end": 3}, "arguments": [{"entity_id": "8360712_2_Ent1", "role": "Effect", "text": "Delayed neurotoxicity", "start": 0, "end": 2}, {"entity_id": "8360712_2_Ent4", "role": "Treatment_Route", "text": "intraventricular", "start": 3, "end": 4}, {"entity_id": "8360712_2_Ent2", "role": "Treatment", "text": "intraventricular interleukin - 2", "start": 3, "end": 7}, {"entity_id": "8360712_2_Ent3", "role": "Treatment_Drug", "text": "interleukin - 2", "start": 4, "end": 7}, {"entity_id": "8360712_2_Ent0", "role": "Subject", "text": "a case report", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "8360712_2_Ent1", "text": "Delayed neurotoxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8360712_2_Ent4", "text": "intraventricular", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8360712_2_Ent2", "text": "intraventricular interleukin - 2", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "8360712_2_Ent3", "text": "interleukin - 2", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "8360712_2_Ent0", "text": "a case report", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "8384030_2", "wnd_id": "8384030_2_1", "text": "DISCUSSION : Electrolyte disorders associated with foscarnet are reviewed .", "tokens": ["DISCUSSION", ":", "Electrolyte", "disorders", "associated", "with", "foscarnet", "are", "reviewed", "."], "event_mentions": [{"id": "8384030_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "8384030_2_Ent0", "role": "Effect", "text": "Electrolyte disorders", "start": 2, "end": 4}, {"entity_id": "8384030_2_Ent1", "role": "Treatment", "text": "foscarnet", "start": 6, "end": 7}, {"entity_id": "8384030_2_Ent2", "role": "Treatment_Drug", "text": "foscarnet", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "8384030_2_Ent0", "text": "Electrolyte disorders", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8384030_2_Ent1", "text": "foscarnet", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8384030_2_Ent2", "text": "foscarnet", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "8384030_4", "wnd_id": "8384030_4_1", "text": "OBJECTIVE : To report a case of possible foscarnet - induced severe hypomagnesemia and other electrolyte disorders .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "possible", "foscarnet", "-", "induced", "severe", "hypomagnesemia", "and", "other", "electrolyte", "disorders", "."], "event_mentions": [{"id": "8384030_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "8384030_4_Ent0", "role": "Subject", "text": "a case", "start": 4, "end": 6}, {"entity_id": "8384030_4_Ent2", "role": "Treatment", "text": "foscarnet", "start": 8, "end": 9}, {"entity_id": "8384030_4_Ent3", "role": "Treatment_Drug", "text": "foscarnet", "start": 8, "end": 9}, {"entity_id": "8384030_4_Ent1", "role": "Effect", "text": "severe hypomagnesemia and other electrolyte disorders", "start": 11, "end": 17}]}], "entity_mentions": [{"id": "8384030_4_Ent0", "text": "a case", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "8384030_4_Ent2", "text": "foscarnet", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8384030_4_Ent3", "text": "foscarnet", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8384030_4_Ent1", "text": "severe hypomagnesemia and other electrolyte disorders", "entity_type": "Entity", "start": 11, "end": 17}], "lang": "en"}
{"doc_id": "8384030_5", "wnd_id": "8384030_5_1", "text": "The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .", "tokens": ["The", "patient", "experienced", "muscle", "twitches", ",", "tremulousness", ",", "and", "anxiety", "on", "day", "17", "of", "foscarnet", "therapy", "."], "event_mentions": [{"id": "8384030_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8384030_5_Ent0", "role": "Subject", "text": "patient", "start": 1, "end": 2}, {"entity_id": "8384030_5_Ent1", "role": "Effect", "text": "muscle twitches , tremulousness , and anxiety", "start": 3, "end": 10}, {"entity_id": "8384030_5_Ent4", "role": "Treatment_Time_elapsed", "text": "on day 17", "start": 10, "end": 13}, {"entity_id": "8384030_5_Ent3", "role": "Treatment_Drug", "text": "foscarnet", "start": 14, "end": 15}, {"entity_id": "8384030_5_Ent2", "role": "Treatment", "text": "foscarnet therapy", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "8384030_5_Ent0", "text": "patient", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8384030_5_Ent1", "text": "muscle twitches , tremulousness , and anxiety", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "8384030_5_Ent4", "text": "on day 17", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "8384030_5_Ent3", "text": "foscarnet", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8384030_5_Ent2", "text": "foscarnet therapy", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "8404753_3", "wnd_id": "8404753_3_1", "text": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures .", "tokens": ["We", "report", "3", "children", "with", "epilepsy", "who", "developed", "facial", "motor", "tics", "after", "initiation", "of", "CBZ", "for", "complex", "partial", "seizures", "."], "event_mentions": [{"id": "8404753_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "8404753_3_Ent1", "role": "Subject_Population", "text": "3", "start": 2, "end": 3}, {"entity_id": "8404753_3_Ent0", "role": "Subject", "text": "3 children with epilepsy", "start": 2, "end": 6}, {"entity_id": "8404753_3_Ent2", "role": "Subject_Age", "text": "children", "start": 3, "end": 4}, {"entity_id": "8404753_3_Ent5", "role": "Treatment_Disorder", "text": "epilepsy", "start": 5, "end": 6}, {"entity_id": "8404753_3_Ent3", "role": "Effect", "text": "facial motor tics", "start": 8, "end": 11}, {"entity_id": "8404753_3_Ent4", "role": "Treatment", "text": "CBZ", "start": 14, "end": 15}, {"entity_id": "8404753_3_Ent6", "role": "Treatment_Drug", "text": "CBZ", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "8404753_3_Ent1", "text": "3", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8404753_3_Ent0", "text": "3 children with epilepsy", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "8404753_3_Ent2", "text": "children", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8404753_3_Ent5", "text": "epilepsy", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8404753_3_Ent3", "text": "facial motor tics", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "8404753_3_Ent4", "text": "CBZ", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8404753_3_Ent6", "text": "CBZ", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "8404753_7", "wnd_id": "8404753_7_1", "text": "After development of the tics in 2 , CBZ was continued at the same or higher dose , and the tics abated and then ceased spontaneously < or = 6 months .", "tokens": ["After", "development", "of", "the", "tics", "in", "2", ",", "CBZ", "was", "continued", "at", "the", "same", "or", "higher", "dose", ",", "and", "the", "tics", "abated", "and", "then", "ceased", "spontaneously", "<", "or", "=", "6", "months", "."], "event_mentions": [{"id": "8404753_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 1, "end": 2}, "arguments": [{"entity_id": "8404753_7_Ent0", "role": "Effect", "text": "tics", "start": 4, "end": 5}, {"entity_id": "8404753_7_Ent1", "role": "Treatment", "text": "CBZ", "start": 8, "end": 9}, {"entity_id": "8404753_7_Ent2", "role": "Treatment_Drug", "text": "CBZ", "start": 8, "end": 9}, {"entity_id": "8404753_7_Ent3", "role": "Treatment_Dosage", "text": "the same or higher dose", "start": 12, "end": 17}]}], "entity_mentions": [{"id": "8404753_7_Ent0", "text": "tics", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8404753_7_Ent1", "text": "CBZ", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8404753_7_Ent2", "text": "CBZ", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8404753_7_Ent3", "text": "the same or higher dose", "entity_type": "Entity", "start": 12, "end": 17}], "lang": "en"}
{"doc_id": "8435665_2", "wnd_id": "8435665_2_1", "text": "Fatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing tryptophan .", "tokens": ["Fatal", "eosinophilia", "myalgia", "syndrome", "in", "a", "marrow", "transplant", "patient", "attributed", "to", "total", "parenteral", "nutrition", "with", "a", "solution", "containing", "tryptophan", "."], "event_mentions": [{"id": "8435665_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "attributed", "start": 9, "end": 10}, "arguments": [{"entity_id": "8435665_2_Ent1", "role": "Effect", "text": "Fatal eosinophilia myalgia syndrome", "start": 0, "end": 4}, {"entity_id": "8435665_2_Ent0", "role": "Subject", "text": "marrow transplant patient", "start": 6, "end": 9}, {"entity_id": "8435665_2_Ent2", "role": "Treatment", "text": "total parenteral nutrition with a solution containing tryptophan", "start": 11, "end": 19}, {"entity_id": "8435665_2_Ent4", "role": "Treatment_Route", "text": "parenteral", "start": 12, "end": 13}, {"entity_id": "8435665_2_Ent3", "role": "Treatment_Drug", "text": "tryptophan", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "8435665_2_Ent1", "text": "Fatal eosinophilia myalgia syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8435665_2_Ent0", "text": "marrow transplant patient", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8435665_2_Ent2", "text": "total parenteral nutrition with a solution containing tryptophan", "entity_type": "Entity", "start": 11, "end": 19}, {"id": "8435665_2_Ent4", "text": "parenteral", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8435665_2_Ent3", "text": "tryptophan", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "8435665_3", "wnd_id": "8435665_3_1", "text": "Thus , the eosinophilia myalgia syndrome can be associated with parenteral tryptophan administration .", "tokens": ["Thus", ",", "the", "eosinophilia", "myalgia", "syndrome", "can", "be", "associated", "with", "parenteral", "tryptophan", "administration", "."], "event_mentions": [{"id": "8435665_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "8435665_3_Ent0", "role": "Effect", "text": "eosinophilia myalgia syndrome", "start": 3, "end": 6}, {"entity_id": "8435665_3_Ent3", "role": "Treatment_Route", "text": "parenteral", "start": 10, "end": 11}, {"entity_id": "8435665_3_Ent1", "role": "Treatment", "text": "parenteral tryptophan", "start": 10, "end": 12}, {"entity_id": "8435665_3_Ent2", "role": "Treatment_Drug", "text": "tryptophan", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "8435665_3_Ent0", "text": "eosinophilia myalgia syndrome", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "8435665_3_Ent3", "text": "parenteral", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8435665_3_Ent1", "text": "parenteral tryptophan", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "8435665_3_Ent2", "text": "tryptophan", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "8442800_11", "wnd_id": "8442800_11_1", "text": "In one case , disulfiram was the only potential teratogen exposed to the fetus .", "tokens": ["In", "one", "case", ",", "disulfiram", "was", "the", "only", "potential", "teratogen", "exposed", "to", "the", "fetus", "."], "event_mentions": [{"id": "8442800_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exposed", "start": 10, "end": 11}, "arguments": [{"entity_id": "8442800_11_Ent3", "role": "Treatment", "text": "disulfiram", "start": 4, "end": 5}, {"entity_id": "8442800_11_Ent4", "role": "Treatment_Drug", "text": "disulfiram", "start": 4, "end": 5}, {"entity_id": "8442800_11_Ent2", "role": "Effect", "text": "teratogen", "start": 9, "end": 10}, {"entity_id": "8442800_11_Ent0", "role": "Subject", "text": "fetus", "start": 13, "end": 14}, {"entity_id": "8442800_11_Ent1", "role": "Subject_Age", "text": "fetus", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "8442800_11_Ent3", "text": "disulfiram", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8442800_11_Ent4", "text": "disulfiram", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8442800_11_Ent2", "text": "teratogen", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8442800_11_Ent0", "text": "fetus", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8442800_11_Ent1", "text": "fetus", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "8442800_2", "wnd_id": "8442800_2_1", "text": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse .", "tokens": ["Disulfiram", "has", "been", "used", "effectively", "to", "deter", "alcohol", "consumption", "in", "patients", "with", "a", "history", "of", "alcohol", "abuse", "."], "event_mentions": [{"id": "8442800_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used", "start": 3, "end": 4}, "arguments": [{"entity_id": "8442800_2_Ent1", "role": "Treatment", "text": "Disulfiram", "start": 0, "end": 1}, {"entity_id": "8442800_2_Ent2", "role": "Treatment_Drug", "text": "Disulfiram", "start": 0, "end": 1}, {"entity_id": "8442800_2_Ent0", "role": "Subject", "text": "patients with a history of alcohol abuse", "start": 10, "end": 17}, {"entity_id": "8442800_2_Ent3", "role": "Treatment_Disorder", "text": "history of alcohol abuse", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "8442800_2_Ent1", "text": "Disulfiram", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8442800_2_Ent2", "text": "Disulfiram", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8442800_2_Ent0", "text": "patients with a history of alcohol abuse", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "8442800_2_Ent3", "text": "history of alcohol abuse", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "8445549_2", "wnd_id": "8445549_2_1", "text": "Pemphigus vulgaris precipitated by glibenclamide therapy .", "tokens": ["Pemphigus", "vulgaris", "precipitated", "by", "glibenclamide", "therapy", "."], "event_mentions": [{"id": "8445549_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitated", "start": 2, "end": 3}, "arguments": [{"entity_id": "8445549_2_Ent0", "role": "Effect", "text": "Pemphigus vulgaris", "start": 0, "end": 2}, {"entity_id": "8445549_2_Ent1", "role": "Treatment", "text": "glibenclamide", "start": 4, "end": 5}, {"entity_id": "8445549_2_Ent2", "role": "Treatment_Drug", "text": "glibenclamide", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "8445549_2_Ent0", "text": "Pemphigus vulgaris", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8445549_2_Ent1", "text": "glibenclamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8445549_2_Ent2", "text": "glibenclamide", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "8452107_1", "wnd_id": "8452107_1_1", "text": "Piritrexim - induced pulmonary toxicity .", "tokens": ["Piritrexim", "-", "induced", "pulmonary", "toxicity", "."], "event_mentions": [{"id": "8452107_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8452107_1_Ent1", "role": "Treatment", "text": "Piritrexim", "start": 0, "end": 1}, {"entity_id": "8452107_1_Ent2", "role": "Treatment_Drug", "text": "Piritrexim", "start": 0, "end": 1}, {"entity_id": "8452107_1_Ent0", "role": "Effect", "text": "pulmonary toxicity", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "8452107_1_Ent1", "text": "Piritrexim", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8452107_1_Ent2", "text": "Piritrexim", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8452107_1_Ent0", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "8461228_1", "wnd_id": "8461228_1_1", "text": "A 12 year old patient with atrial flutter is presented , in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia .", "tokens": ["A", "12", "year", "old", "patient", "with", "atrial", "flutter", "is", "presented", ",", "in", "whom", "intravenous", "adenosine", "was", "followed", "by", "acceleration", "of", "the", "heart", "rate", "to", "a", "potentially", "dangerous", "arrhythmia", "."], "event_mentions": [{"id": "8461228_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "followed by", "start": 16, "end": 18}, "arguments": [{"entity_id": "8461228_1_Ent1", "role": "Subject_Age", "text": "12 year old", "start": 1, "end": 4}, {"entity_id": "8461228_1_Ent0", "role": "Subject", "text": "12 year old patient with atrial flutter", "start": 1, "end": 8}, {"entity_id": "8461228_1_Ent6", "role": "Treatment_Disorder", "text": "atrial flutter", "start": 6, "end": 8}, {"entity_id": "8461228_1_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 13, "end": 14}, {"entity_id": "8461228_1_Ent3", "role": "Treatment", "text": "intravenous adenosine", "start": 13, "end": 15}, {"entity_id": "8461228_1_Ent4", "role": "Treatment_Drug", "text": "adenosine", "start": 14, "end": 15}, {"entity_id": "8461228_1_Ent2", "role": "Effect", "text": "acceleration of the heart rate to a potentially dangerous arrhythmia", "start": 18, "end": 28}]}], "entity_mentions": [{"id": "8461228_1_Ent1", "text": "12 year old", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "8461228_1_Ent0", "text": "12 year old patient with atrial flutter", "entity_type": "Entity", "start": 1, "end": 8}, {"id": "8461228_1_Ent6", "text": "atrial flutter", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8461228_1_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8461228_1_Ent3", "text": "intravenous adenosine", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8461228_1_Ent4", "text": "adenosine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8461228_1_Ent2", "text": "acceleration of the heart rate to a potentially dangerous arrhythmia", "entity_type": "Entity", "start": 18, "end": 28}], "lang": "en"}
{"doc_id": "8467620_1", "wnd_id": "8467620_1_1", "text": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate .", "tokens": ["Lymphoma", "developing", "in", "a", "patient", "with", "rheumatoid", "arthritis", "taking", "methotrexate", "."], "event_mentions": [{"id": "8467620_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developing", "start": 1, "end": 2}, "arguments": [{"entity_id": "8467620_1_Ent1", "role": "Effect", "text": "Lymphoma", "start": 0, "end": 1}, {"entity_id": "8467620_1_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 3, "end": 8}, {"entity_id": "8467620_1_Ent4", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 6, "end": 8}, {"entity_id": "8467620_1_Ent2", "role": "Treatment", "text": "methotrexate", "start": 9, "end": 10}, {"entity_id": "8467620_1_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "8467620_1_Ent1", "text": "Lymphoma", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8467620_1_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "8467620_1_Ent4", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8467620_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8467620_1_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "8467620_2", "wnd_id": "8467620_2_1", "text": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases , but coincidence can not be excluded .", "tokens": ["The", "mild", "immunosuppression", "that", "occurs", "with", "methotrexate", "therapy", "probably", "places", "patients", "with", "rheumatoid", "arthritis", "at", "added", "risk", "of", "developing", "lymphoproliferative", "diseases", ",", "but", "coincidence", "can", "not", "be", "excluded", "."], "event_mentions": [{"id": "8467620_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developing", "start": 18, "end": 19}, "arguments": [{"entity_id": "8467620_2_Ent1", "role": "Effect", "text": "mild immunosuppression", "start": 1, "end": 3}, {"entity_id": "8467620_2_Ent3", "role": "Treatment", "text": "methotrexate", "start": 6, "end": 7}, {"entity_id": "8467620_2_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 6, "end": 7}, {"entity_id": "8467620_2_Ent0", "role": "Subject", "text": "patients with rheumatoid arthritis", "start": 10, "end": 14}, {"entity_id": "8467620_2_Ent4", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 12, "end": 14}, {"entity_id": "8467620_2_Ent2", "role": "Effect", "text": "lymphoproliferative diseases", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "8467620_2_Ent1", "text": "mild immunosuppression", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8467620_2_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8467620_2_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8467620_2_Ent0", "text": "patients with rheumatoid arthritis", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "8467620_2_Ent4", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "8467620_2_Ent2", "text": "lymphoproliferative diseases", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "8485005_3", "wnd_id": "8485005_3_1", "text": "We report a case of drug - induced Kaposi 's sarcoma ( KS ) on the sole of the right foot in a 71 - year - old man , treated for 6 months with corticosteroid therapy ( prednisolone 25 mg / day ) for pericardial effusion .", "tokens": ["We", "report", "a", "case", "of", "drug", "-", "induced", "Kaposi", "'s", "sarcoma", "(", "KS", ")", "on", "the", "sole", "of", "the", "right", "foot", "in", "a", "71", "-", "year", "-", "old", "man", ",", "treated", "for", "6", "months", "with", "corticosteroid", "therapy", "(", "prednisolone", "25", "mg", "/", "day", ")", "for", "pericardial", "effusion", "."], "event_mentions": [{"id": "8485005_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "8485005_3_Ent0", "role": "Subject", "text": "a case of", "start": 2, "end": 5}, {"entity_id": "8485005_3_Ent5", "role": "Effect", "text": "Kaposi 's sarcoma ( KS )", "start": 8, "end": 14}, {"entity_id": "8485005_3_Ent1", "role": "Subject", "text": "a 71 - year - old man", "start": 22, "end": 29}, {"entity_id": "8485005_3_Ent3", "role": "Subject_Age", "text": "71 - year - old", "start": 23, "end": 28}, {"entity_id": "8485005_3_Ent4", "role": "Subject_Gender", "text": "man", "start": 28, "end": 29}, {"entity_id": "8485005_3_Ent7", "role": "Treatment_Duration", "text": "6 months", "start": 32, "end": 34}, {"entity_id": "8485005_3_Ent6", "role": "Treatment", "text": "6 months with corticosteroid therapy ( prednisolone 25 mg / day )", "start": 32, "end": 44}, {"entity_id": "8485005_3_Ent9", "role": "Treatment_Drug", "text": "prednisolone", "start": 38, "end": 39}, {"entity_id": "8485005_3_Ent8", "role": "Treatment_Dosage", "text": "25 mg / day", "start": 39, "end": 43}, {"entity_id": "8485005_3_Ent2", "role": "Subject", "text": "for pericardial effusion", "start": 44, "end": 47}, {"entity_id": "8485005_3_Ent10", "role": "Treatment_Disorder", "text": "pericardial effusion", "start": 45, "end": 47}]}], "entity_mentions": [{"id": "8485005_3_Ent0", "text": "a case of", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "8485005_3_Ent5", "text": "Kaposi 's sarcoma ( KS )", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "8485005_3_Ent1", "text": "a 71 - year - old man", "entity_type": "Entity", "start": 22, "end": 29}, {"id": "8485005_3_Ent3", "text": "71 - year - old", "entity_type": "Entity", "start": 23, "end": 28}, {"id": "8485005_3_Ent4", "text": "man", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "8485005_3_Ent7", "text": "6 months", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "8485005_3_Ent6", "text": "6 months with corticosteroid therapy ( prednisolone 25 mg / day )", "entity_type": "Entity", "start": 32, "end": 44}, {"id": "8485005_3_Ent9", "text": "prednisolone", "entity_type": "Entity", "start": 38, "end": 39}, {"id": "8485005_3_Ent8", "text": "25 mg / day", "entity_type": "Entity", "start": 39, "end": 43}, {"id": "8485005_3_Ent2", "text": "for pericardial effusion", "entity_type": "Entity", "start": 44, "end": 47}, {"id": "8485005_3_Ent10", "text": "pericardial effusion", "entity_type": "Entity", "start": 45, "end": 47}], "lang": "en"}
{"doc_id": "8503421_2", "wnd_id": "8503421_2_1", "text": "Cholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator .", "tokens": ["Cholesterol", "crystal", "embolization", "-", "associated", "renal", "failure", "after", "therapy", "with", "recombinant", "tissue", "-", "type", "plasminogen", "activator", "."], "event_mentions": [{"id": "8503421_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "8503421_2_Ent0", "role": "Effect", "text": "Cholesterol crystal embolization - associated renal failure", "start": 0, "end": 7}, {"entity_id": "8503421_2_Ent1", "role": "Treatment", "text": "therapy with recombinant tissue - type plasminogen activator", "start": 8, "end": 16}, {"entity_id": "8503421_2_Ent2", "role": "Treatment_Drug", "text": "plasminogen activator", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "8503421_2_Ent0", "text": "Cholesterol crystal embolization - associated renal failure", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "8503421_2_Ent1", "text": "therapy with recombinant tissue - type plasminogen activator", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "8503421_2_Ent2", "text": "plasminogen activator", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "8513656_10", "wnd_id": "8513656_10_1", "text": "The efficacy of single - dose disulfiram as an inhibitor of human P450 2E1 suggests that this modality for manipulating clinical P450 2E1 activity may provide a useful probe for delineating P450 2E1 participation in human drug biotransformation or for the treatment of poisoning by P450 2E1 - activated toxins .", "tokens": ["The", "efficacy", "of", "single", "-", "dose", "disulfiram", "as", "an", "inhibitor", "of", "human", "P450", "2E1", "suggests", "that", "this", "modality", "for", "manipulating", "clinical", "P450", "2E1", "activity", "may", "provide", "a", "useful", "probe", "for", "delineating", "P450", "2E1", "participation", "in", "human", "drug", "biotransformation", "or", "for", "the", "treatment", "of", "poisoning", "by", "P450", "2E1", "-", "activated", "toxins", "."], "event_mentions": [{"id": "8513656_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 44, "end": 45}, "arguments": [{"entity_id": "8513656_10_Ent4", "role": "Treatment_Dosage", "text": "single - dose", "start": 3, "end": 6}, {"entity_id": "8513656_10_Ent2", "role": "Treatment_Drug", "text": "disulfiram", "start": 6, "end": 7}, {"entity_id": "8513656_10_Ent0", "role": "Effect", "text": "poisoning", "start": 43, "end": 44}, {"entity_id": "8513656_10_Ent1", "role": "Treatment", "text": "P450 2E1 - activated toxins", "start": 45, "end": 50}, {"entity_id": "8513656_10_Ent3", "role": "Treatment_Drug", "text": "P450 2E1 - activated toxins", "start": 45, "end": 50}]}], "entity_mentions": [{"id": "8513656_10_Ent4", "text": "single - dose", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "8513656_10_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8513656_10_Ent0", "text": "poisoning", "entity_type": "Entity", "start": 43, "end": 44}, {"id": "8513656_10_Ent1", "text": "P450 2E1 - activated toxins", "entity_type": "Entity", "start": 45, "end": 50}, {"id": "8513656_10_Ent3", "text": "P450 2E1 - activated toxins", "entity_type": "Entity", "start": 45, "end": 50}], "lang": "en"}
{"doc_id": "8551001_3", "wnd_id": "8551001_3_1", "text": "The azathioprine dose was low ( 1 mg / kg ) and pancytopenia occurred after 56 days therapy .", "tokens": ["The", "azathioprine", "dose", "was", "low", "(", "1", "mg", "/", "kg", ")", "and", "pancytopenia", "occurred", "after", "56", "days", "therapy", "."], "event_mentions": [{"id": "8551001_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 13, "end": 14}, "arguments": [{"entity_id": "8551001_3_Ent2", "role": "Treatment", "text": "The azathioprine dose was low ( 1 mg / kg )", "start": 0, "end": 11}, {"entity_id": "8551001_3_Ent4", "role": "Treatment_Drug", "text": "azathioprine", "start": 1, "end": 2}, {"entity_id": "8551001_3_Ent5", "role": "Treatment_Dosage", "text": "1 mg / kg", "start": 6, "end": 10}, {"entity_id": "8551001_3_Ent0", "role": "Effect", "text": "pancytopenia", "start": 12, "end": 13}, {"entity_id": "8551001_3_Ent3", "role": "Treatment_Time_elapsed", "text": "56 days", "start": 15, "end": 17}, {"entity_id": "8551001_3_Ent1", "role": "Treatment", "text": "56 days therapy", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "8551001_3_Ent2", "text": "The azathioprine dose was low ( 1 mg / kg )", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "8551001_3_Ent4", "text": "azathioprine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8551001_3_Ent5", "text": "1 mg / kg", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "8551001_3_Ent0", "text": "pancytopenia", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8551001_3_Ent3", "text": "56 days", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "8551001_3_Ent1", "text": "56 days therapy", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "8551001_4", "wnd_id": "8551001_4_1", "text": "Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine .", "tokens": ["Thiopurine", "methyltransferase", "deficiency", "occurs", "at", "a", "frequency", "of", "one", "in", "300", "and", "is", "associated", "with", "profound", "myelosuppression", "after", "a", "short", "course", "of", "azathioprine", "."], "event_mentions": [{"id": "8551001_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 17, "end": 18}, "arguments": [{"entity_id": "8551001_4_Ent0", "role": "Effect", "text": "profound myelosuppression", "start": 15, "end": 17}, {"entity_id": "8551001_4_Ent3", "role": "Treatment_Time_elapsed", "text": "a short course", "start": 18, "end": 21}, {"entity_id": "8551001_4_Ent1", "role": "Treatment", "text": "a short course of azathioprine", "start": 18, "end": 23}, {"entity_id": "8551001_4_Ent2", "role": "Treatment_Drug", "text": "azathioprine", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "8551001_4_Ent0", "text": "profound myelosuppression", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "8551001_4_Ent3", "text": "a short course", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "8551001_4_Ent1", "text": "a short course of azathioprine", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "8551001_4_Ent2", "text": "azathioprine", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "8579054_3", "wnd_id": "8579054_3_1", "text": "Prolonged used of hydroxyurea in patients with ET may lead to therapy - associated acute leukemia .", "tokens": ["Prolonged", "used", "of", "hydroxyurea", "in", "patients", "with", "ET", "may", "lead", "to", "therapy", "-", "associated", "acute", "leukemia", "."], "event_mentions": [{"id": "8579054_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 13, "end": 14}, "arguments": [{"entity_id": "8579054_3_Ent5", "role": "Treatment_Freq", "text": "Prolonged used", "start": 0, "end": 2}, {"entity_id": "8579054_3_Ent2", "role": "Treatment", "text": "hydroxyurea", "start": 3, "end": 4}, {"entity_id": "8579054_3_Ent3", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 3, "end": 4}, {"entity_id": "8579054_3_Ent0", "role": "Subject", "text": "patients with ET", "start": 5, "end": 8}, {"entity_id": "8579054_3_Ent4", "role": "Treatment_Disorder", "text": "ET", "start": 7, "end": 8}, {"entity_id": "8579054_3_Ent1", "role": "Effect", "text": "therapy - associated acute leukemia", "start": 11, "end": 16}]}], "entity_mentions": [{"id": "8579054_3_Ent5", "text": "Prolonged used", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8579054_3_Ent2", "text": "hydroxyurea", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8579054_3_Ent3", "text": "hydroxyurea", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8579054_3_Ent0", "text": "patients with ET", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "8579054_3_Ent4", "text": "ET", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8579054_3_Ent1", "text": "therapy - associated acute leukemia", "entity_type": "Entity", "start": 11, "end": 16}], "lang": "en"}
{"doc_id": "8589490_2", "wnd_id": "8589490_2_1", "text": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents .", "tokens": ["Pigmentary", "aberrations", "are", "well", "known", "side", "effects", "of", "cytostatic", "chemotherapeutic", "agents", "."], "event_mentions": [{"id": "8589490_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 5, "end": 7}, "arguments": [{"entity_id": "8589490_2_Ent0", "role": "Effect", "text": "Pigmentary aberrations", "start": 0, "end": 2}, {"entity_id": "8589490_2_Ent1", "role": "Treatment", "text": "cytostatic chemotherapeutic agents", "start": 8, "end": 11}, {"entity_id": "8589490_2_Ent2", "role": "Treatment_Drug", "text": "cytostatic chemotherapeutic agents", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "8589490_2_Ent0", "text": "Pigmentary aberrations", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8589490_2_Ent1", "text": "cytostatic chemotherapeutic agents", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "8589490_2_Ent2", "text": "cytostatic chemotherapeutic agents", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "8597009_2", "wnd_id": "8597009_2_1", "text": "Seventy - four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11.6 % of these had blood levels in the toxic range .", "tokens": ["Seventy", "-", "four", "per", "cent", "of", "patients", "with", "epileptogenic", "disorders", "seen", "at", "the", "Emergency", "Unit", "at", "Groote", "Schuur", "Hospital", "were", "on", "phenytoin", "and", "11.6", "%", "of", "these", "had", "blood", "levels", "in", "the", "toxic", "range", "."], "event_mentions": [{"id": "8597009_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 27, "end": 28}, "arguments": [{"entity_id": "8597009_2_Ent2", "role": "Subject_Population", "text": "Seventy - four per cent", "start": 0, "end": 5}, {"entity_id": "8597009_2_Ent0", "role": "Subject", "text": "Seventy - four per cent of patients with epileptogenic disorders", "start": 0, "end": 10}, {"entity_id": "8597009_2_Ent7", "role": "Treatment_Disorder", "text": "epileptogenic", "start": 8, "end": 9}, {"entity_id": "8597009_2_Ent5", "role": "Treatment", "text": "phenytoin", "start": 21, "end": 22}, {"entity_id": "8597009_2_Ent6", "role": "Treatment_Drug", "text": "phenytoin", "start": 21, "end": 22}, {"entity_id": "8597009_2_Ent3", "role": "Subject_Population", "text": "11.6 %", "start": 23, "end": 25}, {"entity_id": "8597009_2_Ent1", "role": "Subject", "text": "11.6 % of these", "start": 23, "end": 27}, {"entity_id": "8597009_2_Ent4", "role": "Effect", "text": "blood levels in the toxic range", "start": 28, "end": 34}]}], "entity_mentions": [{"id": "8597009_2_Ent2", "text": "Seventy - four per cent", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8597009_2_Ent0", "text": "Seventy - four per cent of patients with epileptogenic disorders", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "8597009_2_Ent7", "text": "epileptogenic", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8597009_2_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "8597009_2_Ent6", "text": "phenytoin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "8597009_2_Ent3", "text": "11.6 %", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "8597009_2_Ent1", "text": "11.6 % of these", "entity_type": "Entity", "start": 23, "end": 27}, {"id": "8597009_2_Ent4", "text": "blood levels in the toxic range", "entity_type": "Entity", "start": 28, "end": 34}], "lang": "en"}
{"doc_id": "8641617_3", "wnd_id": "8641617_3_1", "text": "Both patients were then treated with a carboplatin alternative to cisplatin in the following courses , which resulted in neither a relapse of the colitis nor a recurrence of the malignancies up to this time .", "tokens": ["Both", "patients", "were", "then", "treated", "with", "a", "carboplatin", "alternative", "to", "cisplatin", "in", "the", "following", "courses", ",", "which", "resulted", "in", "neither", "a", "relapse", "of", "the", "colitis", "nor", "a", "recurrence", "of", "the", "malignancies", "up", "to", "this", "time", "."], "event_mentions": [{"id": "8641617_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resulted", "start": 17, "end": 18}, "arguments": [{"entity_id": "8641617_3_Ent0", "role": "Subject", "text": "Both patients", "start": 0, "end": 2}, {"entity_id": "8641617_3_Ent2", "role": "Treatment", "text": "carboplatin", "start": 7, "end": 8}, {"entity_id": "8641617_3_Ent3", "role": "Treatment_Drug", "text": "carboplatin", "start": 7, "end": 8}, {"entity_id": "8641617_3_Ent1", "role": "Effect", "text": "neither a relapse of the colitis nor a recurrence of the malignancies", "start": 19, "end": 31}, {"entity_id": "8641617_3_Ent4", "role": "Treatment_Disorder", "text": "colitis", "start": 24, "end": 25}, {"entity_id": "8641617_3_Ent5", "role": "Treatment_Disorder", "text": "malignancies", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "8641617_3_Ent0", "text": "Both patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8641617_3_Ent2", "text": "carboplatin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8641617_3_Ent3", "text": "carboplatin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8641617_3_Ent1", "text": "neither a relapse of the colitis nor a recurrence of the malignancies", "entity_type": "Entity", "start": 19, "end": 31}, {"id": "8641617_3_Ent4", "text": "colitis", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "8641617_3_Ent5", "text": "malignancies", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "8678015_1", "wnd_id": "8678015_1_1", "text": "Albendazole - induced pseudomembranous colitis .", "tokens": ["Albendazole", "-", "induced", "pseudomembranous", "colitis", "."], "event_mentions": [{"id": "8678015_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8678015_1_Ent1", "role": "Treatment", "text": "Albendazole", "start": 0, "end": 1}, {"entity_id": "8678015_1_Ent2", "role": "Treatment_Drug", "text": "Albendazole", "start": 0, "end": 1}, {"entity_id": "8678015_1_Ent0", "role": "Effect", "text": "pseudomembranous colitis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "8678015_1_Ent1", "text": "Albendazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8678015_1_Ent2", "text": "Albendazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8678015_1_Ent0", "text": "pseudomembranous colitis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "8700794_1", "wnd_id": "8700794_1_1", "text": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .", "tokens": ["A", "review", "of", "the", "literature", "found", "11", "children", "and", "2", "adults", "in", "whom", "intranasal", "desmopressin", "was", "associated", "with", "hyponatremia", ",", "all", "of", "whom", "experienced", "seizures", "or", "altered", "mental", "status", "."], "event_mentions": [{"id": "8700794_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 16, "end": 17}, "arguments": [{"entity_id": "8700794_1_Ent1", "role": "Subject_Population", "text": "11", "start": 6, "end": 7}, {"entity_id": "8700794_1_Ent0", "role": "Subject", "text": "11 children and 2 adults", "start": 6, "end": 11}, {"entity_id": "8700794_1_Ent3", "role": "Subject_Age", "text": "children", "start": 7, "end": 8}, {"entity_id": "8700794_1_Ent2", "role": "Subject_Population", "text": "2", "start": 9, "end": 10}, {"entity_id": "8700794_1_Ent4", "role": "Subject_Age", "text": "adults", "start": 10, "end": 11}, {"entity_id": "8700794_1_Ent9", "role": "Treatment_Route", "text": "intranasal", "start": 13, "end": 14}, {"entity_id": "8700794_1_Ent7", "role": "Treatment", "text": "intranasal desmopressin", "start": 13, "end": 15}, {"entity_id": "8700794_1_Ent8", "role": "Treatment_Drug", "text": "desmopressin", "start": 14, "end": 15}, {"entity_id": "8700794_1_Ent5", "role": "Effect", "text": "hyponatremia", "start": 18, "end": 19}, {"entity_id": "8700794_1_Ent6", "role": "Effect", "text": "seizures or altered mental status", "start": 24, "end": 29}]}], "entity_mentions": [{"id": "8700794_1_Ent1", "text": "11", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8700794_1_Ent0", "text": "11 children and 2 adults", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "8700794_1_Ent3", "text": "children", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8700794_1_Ent2", "text": "2", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8700794_1_Ent4", "text": "adults", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8700794_1_Ent9", "text": "intranasal", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8700794_1_Ent7", "text": "intranasal desmopressin", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8700794_1_Ent8", "text": "desmopressin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8700794_1_Ent5", "text": "hyponatremia", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "8700794_1_Ent6", "text": "seizures or altered mental status", "entity_type": "Entity", "start": 24, "end": 29}], "lang": "en"}
{"doc_id": "8700794_5", "wnd_id": "8700794_5_1", "text": "Without other causes for the hyponatremia , she was diagnosed with the syndrome of inappropriate antidiuretic hormone , presumably caused by desmopressin .", "tokens": ["Without", "other", "causes", "for", "the", "hyponatremia", ",", "she", "was", "diagnosed", "with", "the", "syndrome", "of", "inappropriate", "antidiuretic", "hormone", ",", "presumably", "caused", "by", "desmopressin", "."], "event_mentions": [{"id": "8700794_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "diagnosed", "start": 9, "end": 10}, "arguments": [{"entity_id": "8700794_5_Ent2", "role": "Effect", "text": "hyponatremia", "start": 5, "end": 6}, {"entity_id": "8700794_5_Ent0", "role": "Subject", "text": "she", "start": 7, "end": 8}, {"entity_id": "8700794_5_Ent1", "role": "Subject_Gender", "text": "she", "start": 7, "end": 8}, {"entity_id": "8700794_5_Ent3", "role": "Effect", "text": "syndrome of inappropriate antidiuretic hormone", "start": 12, "end": 17}, {"entity_id": "8700794_5_Ent4", "role": "Treatment", "text": "desmopressin", "start": 21, "end": 22}, {"entity_id": "8700794_5_Ent5", "role": "Treatment_Drug", "text": "desmopressin", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "8700794_5_Ent2", "text": "hyponatremia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8700794_5_Ent0", "text": "she", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8700794_5_Ent1", "text": "she", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8700794_5_Ent3", "text": "syndrome of inappropriate antidiuretic hormone", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "8700794_5_Ent4", "text": "desmopressin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "8700794_5_Ent5", "text": "desmopressin", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "8726608_1", "wnd_id": "8726608_1_1", "text": "Does acyclovir increase serum lithium levels ?", "tokens": ["Does", "acyclovir", "increase", "serum", "lithium", "levels", "?"], "event_mentions": [{"id": "8726608_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increase", "start": 2, "end": 3}, "arguments": [{"entity_id": "8726608_1_Ent1", "role": "Treatment", "text": "acyclovir", "start": 1, "end": 2}, {"entity_id": "8726608_1_Ent3", "role": "Treatment_Drug", "text": "acyclovir", "start": 1, "end": 2}, {"entity_id": "8726608_1_Ent5", "role": "Combination_Drug", "text": "acyclovir", "start": 1, "end": 2}, {"entity_id": "8726608_1_Ent0", "role": "Effect", "text": "serum lithium levels", "start": 3, "end": 6}, {"entity_id": "8726608_1_Ent2", "role": "Treatment", "text": "lithium", "start": 4, "end": 5}, {"entity_id": "8726608_1_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 4, "end": 5}, {"entity_id": "8726608_1_Ent6", "role": "Combination_Drug", "text": "lithium", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "8726608_1_Ent1", "text": "acyclovir", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8726608_1_Ent3", "text": "acyclovir", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8726608_1_Ent5", "text": "acyclovir", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8726608_1_Ent0", "text": "serum lithium levels", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "8726608_1_Ent2", "text": "lithium", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8726608_1_Ent4", "text": "lithium", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8726608_1_Ent6", "text": "lithium", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "8726608_2", "wnd_id": "8726608_2_1", "text": "Six days after starting acyclovir she exhibited signs of lithium toxicity .", "tokens": ["Six", "days", "after", "starting", "acyclovir", "she", "exhibited", "signs", "of", "lithium", "toxicity", "."], "event_mentions": [{"id": "8726608_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "8726608_2_Ent4", "role": "Treatment_Time_elapsed", "text": "Six days", "start": 0, "end": 2}, {"entity_id": "8726608_2_Ent3", "role": "Treatment", "text": "Six days after starting acyclovir", "start": 0, "end": 5}, {"entity_id": "8726608_2_Ent5", "role": "Treatment_Drug", "text": "acyclovir", "start": 4, "end": 5}, {"entity_id": "8726608_2_Ent0", "role": "Subject", "text": "she", "start": 5, "end": 6}, {"entity_id": "8726608_2_Ent1", "role": "Subject_Gender", "text": "she", "start": 5, "end": 6}, {"entity_id": "8726608_2_Ent2", "role": "Effect", "text": "lithium toxicity", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "8726608_2_Ent4", "text": "Six days", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8726608_2_Ent3", "text": "Six days after starting acyclovir", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8726608_2_Ent5", "text": "acyclovir", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8726608_2_Ent0", "text": "she", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8726608_2_Ent1", "text": "she", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8726608_2_Ent2", "text": "lithium toxicity", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "8739289_1", "wnd_id": "8739289_1_1", "text": "Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use .", "tokens": ["Transient", "central", "diabetes", "insipidus", "in", "the", "setting", "of", "underlying", "chronic", "nephrogenic", "diabetes", "insipidus", "associated", "with", "lithium", "use", "."], "event_mentions": [{"id": "8739289_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 13, "end": 14}, "arguments": [{"entity_id": "8739289_1_Ent0", "role": "Effect", "text": "Transient central diabetes insipidus", "start": 0, "end": 4}, {"entity_id": "8739289_1_Ent2", "role": "Treatment_Disorder", "text": "chronic nephrogenic diabetes insipidus", "start": 9, "end": 13}, {"entity_id": "8739289_1_Ent1", "role": "Treatment", "text": "lithium", "start": 15, "end": 16}, {"entity_id": "8739289_1_Ent3", "role": "Treatment_Drug", "text": "lithium", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "8739289_1_Ent0", "text": "Transient central diabetes insipidus", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8739289_1_Ent2", "text": "chronic nephrogenic diabetes insipidus", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "8739289_1_Ent1", "text": "lithium", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "8739289_1_Ent3", "text": "lithium", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "8739289_5", "wnd_id": "8739289_5_1", "text": "To the best of our knowledge , this is the first case of lithium - associated CDI and NDI presenting concurrently .", "tokens": ["To", "the", "best", "of", "our", "knowledge", ",", "this", "is", "the", "first", "case", "of", "lithium", "-", "associated", "CDI", "and", "NDI", "presenting", "concurrently", "."], "event_mentions": [{"id": "8739289_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 15, "end": 16}, "arguments": [{"entity_id": "8739289_5_Ent1", "role": "Treatment", "text": "lithium", "start": 13, "end": 14}, {"entity_id": "8739289_5_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 13, "end": 14}, {"entity_id": "8739289_5_Ent0", "role": "Effect", "text": "CDI and NDI", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "8739289_5_Ent1", "text": "lithium", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8739289_5_Ent2", "text": "lithium", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8739289_5_Ent0", "text": "CDI and NDI", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "8742573_2", "wnd_id": "8742573_2_1", "text": "CONCLUSIONS : Jet - injection devices might constitute a helpful method to treat those patients affected by severe human insulin - induced lipoatrophy .", "tokens": ["CONCLUSIONS", ":", "Jet", "-", "injection", "devices", "might", "constitute", "a", "helpful", "method", "to", "treat", "those", "patients", "affected", "by", "severe", "human", "insulin", "-", "induced", "lipoatrophy", "."], "event_mentions": [{"id": "8742573_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treat", "start": 12, "end": 13}, "arguments": [{"entity_id": "8742573_2_Ent3", "role": "Treatment_Route", "text": "Jet - injection", "start": 2, "end": 5}, {"entity_id": "8742573_2_Ent1", "role": "Treatment", "text": "Jet - injection devices", "start": 2, "end": 6}, {"entity_id": "8742573_2_Ent0", "role": "Subject", "text": "patients", "start": 14, "end": 15}, {"entity_id": "8742573_2_Ent2", "role": "Treatment_Disorder", "text": "insulin - induced lipoatrophy", "start": 19, "end": 23}]}, {"id": "8742573_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 21, "end": 22}, "arguments": [{"entity_id": "8742573_2_Ent5", "role": "Treatment", "text": "insulin", "start": 19, "end": 20}, {"entity_id": "8742573_2_Ent6", "role": "Treatment_Drug", "text": "insulin", "start": 19, "end": 20}, {"entity_id": "8742573_2_Ent4", "role": "Effect", "text": "lipoatrophy", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "8742573_2_Ent3", "text": "Jet - injection", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "8742573_2_Ent1", "text": "Jet - injection devices", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "8742573_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8742573_2_Ent5", "text": "insulin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "8742573_2_Ent6", "text": "insulin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "8742573_2_Ent2", "text": "insulin - induced lipoatrophy", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "8742573_2_Ent4", "text": "lipoatrophy", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "8742573_4", "wnd_id": "8742573_4_1", "text": "OBJECTIVE : To evaluate the efficacy of the administration of insulin by a jet - injector device in stopping and reversing severe human insulin - induced lipoatrophy .", "tokens": ["OBJECTIVE", ":", "To", "evaluate", "the", "efficacy", "of", "the", "administration", "of", "insulin", "by", "a", "jet", "-", "injector", "device", "in", "stopping", "and", "reversing", "severe", "human", "insulin", "-", "induced", "lipoatrophy", "."], "event_mentions": [{"id": "8742573_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 25, "end": 26}, "arguments": [{"entity_id": "8742573_4_Ent0", "role": "Effect", "text": "severe human", "start": 21, "end": 23}, {"entity_id": "8742573_4_Ent2", "role": "Treatment", "text": "insulin", "start": 23, "end": 24}, {"entity_id": "8742573_4_Ent3", "role": "Treatment_Drug", "text": "insulin", "start": 23, "end": 24}, {"entity_id": "8742573_4_Ent1", "role": "Effect", "text": "lipoatrophy", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "8742573_4_Ent0", "text": "severe human", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "8742573_4_Ent2", "text": "insulin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "8742573_4_Ent3", "text": "insulin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "8742573_4_Ent1", "text": "lipoatrophy", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "8771575_2", "wnd_id": "8771575_2_1", "text": "Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life - threatening pulmonary dysfunction .", "tokens": ["Acute", "pulmonary", "reactions", "to", "nitrofurantoin", "are", "an", "uncommon", "side", "effect", "of", "therapy", "and", "can", "cause", "minor", "or", "life", "-", "threatening", "pulmonary", "dysfunction", "."], "event_mentions": [{"id": "8771575_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "are", "start": 5, "end": 6}, "arguments": [{"entity_id": "8771575_2_Ent0", "role": "Effect", "text": "Acute pulmonary reactions", "start": 0, "end": 3}, {"entity_id": "8771575_2_Ent2", "role": "Treatment", "text": "nitrofurantoin", "start": 4, "end": 5}, {"entity_id": "8771575_2_Ent3", "role": "Treatment_Drug", "text": "nitrofurantoin", "start": 4, "end": 5}, {"entity_id": "8771575_2_Ent1", "role": "Effect", "text": "can cause minor or life - threatening pulmonary dysfunction", "start": 13, "end": 22}]}], "entity_mentions": [{"id": "8771575_2_Ent0", "text": "Acute pulmonary reactions", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8771575_2_Ent2", "text": "nitrofurantoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8771575_2_Ent3", "text": "nitrofurantoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8771575_2_Ent1", "text": "can cause minor or life - threatening pulmonary dysfunction", "entity_type": "Entity", "start": 13, "end": 22}], "lang": "en"}
{"doc_id": "8792511_2", "wnd_id": "8792511_2_1", "text": "Methemoglobinemia is another common finding among patients receiving dapsone therapy , but rarely does it result in prominent symptoms other than transient pallor .", "tokens": ["Methemoglobinemia", "is", "another", "common", "finding", "among", "patients", "receiving", "dapsone", "therapy", ",", "but", "rarely", "does", "it", "result", "in", "prominent", "symptoms", "other", "than", "transient", "pallor", "."], "event_mentions": [{"id": "8792511_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 7, "end": 8}, "arguments": [{"entity_id": "8792511_2_Ent1", "role": "Effect", "text": "Methemoglobinemia", "start": 0, "end": 1}, {"entity_id": "8792511_2_Ent0", "role": "Subject", "text": "patients", "start": 6, "end": 7}, {"entity_id": "8792511_2_Ent4", "role": "Treatment_Drug", "text": "dapsone", "start": 8, "end": 9}, {"entity_id": "8792511_2_Ent3", "role": "Treatment", "text": "dapsone therapy", "start": 8, "end": 10}, {"entity_id": "8792511_2_Ent2", "role": "Effect", "text": "transient pallor", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "8792511_2_Ent1", "text": "Methemoglobinemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8792511_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8792511_2_Ent4", "text": "dapsone", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8792511_2_Ent3", "text": "dapsone therapy", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8792511_2_Ent2", "text": "transient pallor", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "879939_1", "wnd_id": "879939_1_1", "text": "Acetazolamide - accelerated anticonvulsant osteomalacia .", "tokens": ["Acetazolamide", "-", "accelerated", "anticonvulsant", "osteomalacia", "."], "event_mentions": [{"id": "879939_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "accelerated", "start": 2, "end": 3}, "arguments": [{"entity_id": "879939_1_Ent1", "role": "Treatment", "text": "Acetazolamide", "start": 0, "end": 1}, {"entity_id": "879939_1_Ent2", "role": "Treatment_Drug", "text": "Acetazolamide", "start": 0, "end": 1}, {"entity_id": "879939_1_Ent3", "role": "Treatment_Drug", "text": "anticonvulsant", "start": 3, "end": 4}, {"entity_id": "879939_1_Ent0", "role": "Effect", "text": "anticonvulsant osteomalacia", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "879939_1_Ent1", "text": "Acetazolamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "879939_1_Ent2", "text": "Acetazolamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "879939_1_Ent3", "text": "anticonvulsant", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "879939_1_Ent0", "text": "anticonvulsant osteomalacia", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "8828999_4", "wnd_id": "8828999_4_1", "text": "Several cases of lithium - induced Creutzfeldt - Jakob syndrome have been reported to date ; all of them were elderly patients and a half had \" therapeutic \" lithium serum levels .", "tokens": ["Several", "cases", "of", "lithium", "-", "induced", "Creutzfeldt", "-", "Jakob", "syndrome", "have", "been", "reported", "to", "date", ";", "all", "of", "them", "were", "elderly", "patients", "and", "a", "half", "had", "\"", "therapeutic", "\"", "lithium", "serum", "levels", "."], "event_mentions": [{"id": "8828999_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "8828999_4_Ent3", "role": "Treatment", "text": "lithium", "start": 3, "end": 4}, {"entity_id": "8828999_4_Ent5", "role": "Treatment_Drug", "text": "lithium", "start": 3, "end": 4}, {"entity_id": "8828999_4_Ent2", "role": "Effect", "text": "Creutzfeldt - Jakob syndrome", "start": 6, "end": 10}, {"entity_id": "8828999_4_Ent1", "role": "Subject_Age", "text": "elderly", "start": 20, "end": 21}, {"entity_id": "8828999_4_Ent0", "role": "Subject", "text": "elderly patients", "start": 20, "end": 22}, {"entity_id": "8828999_4_Ent4", "role": "Treatment", "text": "\" therapeutic \" lithium serum levels", "start": 26, "end": 32}, {"entity_id": "8828999_4_Ent6", "role": "Treatment_Drug", "text": "lithium", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "8828999_4_Ent3", "text": "lithium", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8828999_4_Ent5", "text": "lithium", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8828999_4_Ent2", "text": "Creutzfeldt - Jakob syndrome", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "8828999_4_Ent1", "text": "elderly", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8828999_4_Ent0", "text": "elderly patients", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "8828999_4_Ent4", "text": "\" therapeutic \" lithium serum levels", "entity_type": "Entity", "start": 26, "end": 32}, {"id": "8828999_4_Ent6", "text": "lithium", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "8832451_1", "wnd_id": "8832451_1_1", "text": "A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient .", "tokens": ["A", "noninvasive", "method", "in", "the", "differential", "diagnosis", "of", "vecuronium", "-", "induced", "and", "magnesium", "-", "induced", "protracted", "neuromuscular", "block", "in", "a", "severely", "preeclamptic", "patient", "."], "event_mentions": [{"id": "8832451_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "8832451_1_Ent3", "role": "Treatment", "text": "vecuronium", "start": 8, "end": 9}, {"entity_id": "8832451_1_Ent4", "role": "Treatment_Drug", "text": "vecuronium", "start": 8, "end": 9}, {"entity_id": "8832451_1_Ent2", "role": "Effect", "text": "protracted neuromuscular block", "start": 15, "end": 18}, {"entity_id": "8832451_1_Ent1", "role": "Subject_Disorder", "text": "severely preeclamptic", "start": 20, "end": 22}, {"entity_id": "8832451_1_Ent0", "role": "Subject", "text": "severely preeclamptic patient", "start": 20, "end": 23}]}, {"id": "8832451_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "8832451_1_Ent8", "role": "Treatment", "text": "magnesium", "start": 12, "end": 13}, {"entity_id": "8832451_1_Ent9", "role": "Treatment_Drug", "text": "magnesium", "start": 12, "end": 13}, {"entity_id": "8832451_1_Ent7", "role": "Effect", "text": "protracted neuromuscular block", "start": 15, "end": 18}, {"entity_id": "8832451_1_Ent6", "role": "Subject_Disorder", "text": "severely preeclamptic", "start": 20, "end": 22}, {"entity_id": "8832451_1_Ent5", "role": "Subject", "text": "severely preeclamptic patient", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "8832451_1_Ent3", "text": "vecuronium", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8832451_1_Ent4", "text": "vecuronium", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8832451_1_Ent8", "text": "magnesium", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8832451_1_Ent9", "text": "magnesium", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8832451_1_Ent2", "text": "protracted neuromuscular block", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "8832451_1_Ent7", "text": "protracted neuromuscular block", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "8832451_1_Ent1", "text": "severely preeclamptic", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "8832451_1_Ent6", "text": "severely preeclamptic", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "8832451_1_Ent0", "text": "severely preeclamptic patient", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "8832451_1_Ent5", "text": "severely preeclamptic patient", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "8835752_1", "wnd_id": "8835752_1_1", "text": "Hepatobiliary disorders associated with orally administered terbinafine have rarely been reported .", "tokens": ["Hepatobiliary", "disorders", "associated", "with", "orally", "administered", "terbinafine", "have", "rarely", "been", "reported", "."], "event_mentions": [{"id": "8835752_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "8835752_1_Ent0", "role": "Effect", "text": "Hepatobiliary disorders", "start": 0, "end": 2}, {"entity_id": "8835752_1_Ent3", "role": "Treatment_Route", "text": "orally", "start": 4, "end": 5}, {"entity_id": "8835752_1_Ent1", "role": "Treatment", "text": "orally administered terbinafine", "start": 4, "end": 7}, {"entity_id": "8835752_1_Ent2", "role": "Treatment_Drug", "text": "terbinafine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "8835752_1_Ent0", "text": "Hepatobiliary disorders", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8835752_1_Ent3", "text": "orally", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8835752_1_Ent1", "text": "orally administered terbinafine", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "8835752_1_Ent2", "text": "terbinafine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "8840640_1", "wnd_id": "8840640_1_1", "text": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide - chlorhexidine solution as a scolicidal agent .", "tokens": ["A", "patient", "with", "a", "large", "hydatid", "cyst", "of", "the", "left", "lobe", "of", "the", "liver", "developed", "metabolic", "acidosis", "following", "rather", "liberal", "use", "of", "cetrimide", "-", "chlorhexidine", "solution", "as", "a", "scolicidal", "agent", "."], "event_mentions": [{"id": "8840640_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "8840640_1_Ent0", "role": "Subject", "text": "A patient with a large hydatid cyst of the left lobe of the liver", "start": 0, "end": 14}, {"entity_id": "8840640_1_Ent1", "role": "Subject_Disorder", "text": "a large hydatid cyst of the left lobe of the liver", "start": 3, "end": 14}, {"entity_id": "8840640_1_Ent2", "role": "Effect", "text": "metabolic acidosis", "start": 15, "end": 17}, {"entity_id": "8840640_1_Ent5", "role": "Treatment_Dosage", "text": "rather liberal use", "start": 18, "end": 21}, {"entity_id": "8840640_1_Ent3", "role": "Treatment", "text": "rather liberal use of cetrimide - chlorhexidine solution as a scolicidal agent", "start": 18, "end": 30}, {"entity_id": "8840640_1_Ent4", "role": "Treatment_Drug", "text": "cetrimide - chlorhexidine", "start": 22, "end": 25}, {"entity_id": "8840640_1_Ent6", "role": "Treatment_Route", "text": "a scolicidal agent", "start": 27, "end": 30}]}], "entity_mentions": [{"id": "8840640_1_Ent0", "text": "A patient with a large hydatid cyst of the left lobe of the liver", "entity_type": "Entity", "start": 0, "end": 14}, {"id": "8840640_1_Ent1", "text": "a large hydatid cyst of the left lobe of the liver", "entity_type": "Entity", "start": 3, "end": 14}, {"id": "8840640_1_Ent2", "text": "metabolic acidosis", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "8840640_1_Ent5", "text": "rather liberal use", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "8840640_1_Ent3", "text": "rather liberal use of cetrimide - chlorhexidine solution as a scolicidal agent", "entity_type": "Entity", "start": 18, "end": 30}, {"id": "8840640_1_Ent4", "text": "cetrimide - chlorhexidine", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "8840640_1_Ent6", "text": "a scolicidal agent", "entity_type": "Entity", "start": 27, "end": 30}], "lang": "en"}
{"doc_id": "8840640_2", "wnd_id": "8840640_2_1", "text": "Metabolic acidosis induced by cetrimide - chlorhexidine solution in hydatid cyst surgery .", "tokens": ["Metabolic", "acidosis", "induced", "by", "cetrimide", "-", "chlorhexidine", "solution", "in", "hydatid", "cyst", "surgery", "."], "event_mentions": [{"id": "8840640_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8840640_2_Ent0", "role": "Effect", "text": "Metabolic acidosis", "start": 0, "end": 2}, {"entity_id": "8840640_2_Ent3", "role": "Treatment_Drug", "text": "cetrimide", "start": 4, "end": 5}, {"entity_id": "8840640_2_Ent7", "role": "Combination_Drug", "text": "cetrimide", "start": 4, "end": 5}, {"entity_id": "8840640_2_Ent1", "role": "Treatment", "text": "cetrimide - chlorhexidine solution", "start": 4, "end": 8}, {"entity_id": "8840640_2_Ent4", "role": "Treatment_Drug", "text": "chlorhexidine", "start": 6, "end": 7}, {"entity_id": "8840640_2_Ent6", "role": "Combination_Drug", "text": "chlorhexidine", "start": 6, "end": 7}, {"entity_id": "8840640_2_Ent5", "role": "Treatment_Route", "text": "solution", "start": 7, "end": 8}, {"entity_id": "8840640_2_Ent2", "role": "Treatment_Disorder", "text": "hydatid cyst", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "8840640_2_Ent0", "text": "Metabolic acidosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8840640_2_Ent3", "text": "cetrimide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8840640_2_Ent7", "text": "cetrimide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8840640_2_Ent1", "text": "cetrimide - chlorhexidine solution", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "8840640_2_Ent4", "text": "chlorhexidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8840640_2_Ent6", "text": "chlorhexidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8840640_2_Ent5", "text": "solution", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8840640_2_Ent2", "text": "hydatid cyst", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "8850251_1", "wnd_id": "8850251_1_1", "text": "However , dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine - derivative drugs .", "tokens": ["However", ",", "dermatologists", "should", "be", "cautious", "about", "a", "photosensitivity", "reaction", "induced", "by", "mequitazine", "or", "other", "phenothiazine", "-", "derivative", "drugs", "."], "event_mentions": [{"id": "8850251_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "8850251_1_Ent0", "role": "Effect", "text": "photosensitivity", "start": 8, "end": 9}, {"entity_id": "8850251_1_Ent1", "role": "Treatment", "text": "mequitazine", "start": 12, "end": 13}, {"entity_id": "8850251_1_Ent2", "role": "Treatment_Drug", "text": "mequitazine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "8850251_1_Ent0", "text": "photosensitivity", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8850251_1_Ent1", "text": "mequitazine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8850251_1_Ent2", "text": "mequitazine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "8850251_6", "wnd_id": "8850251_6_1", "text": "We experienced 2 cases of mequitazine - induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems .", "tokens": ["We", "experienced", "2", "cases", "of", "mequitazine", "-", "induced", "photosensitivity", "reaction", "in", "patients", "who", "took", "mequitazine", "for", "their", "dermatologic", "problems", "."], "event_mentions": [{"id": "8850251_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "8850251_6_Ent2", "role": "Treatment", "text": "mequitazine", "start": 5, "end": 6}, {"entity_id": "8850251_6_Ent4", "role": "Treatment_Drug", "text": "mequitazine", "start": 5, "end": 6}, {"entity_id": "8850251_6_Ent1", "role": "Effect", "text": "photosensitivity reaction", "start": 8, "end": 10}, {"entity_id": "8850251_6_Ent0", "role": "Subject", "text": "patients", "start": 11, "end": 12}, {"entity_id": "8850251_6_Ent3", "role": "Treatment_Disorder", "text": "dermatologic problems", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "8850251_6_Ent2", "text": "mequitazine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8850251_6_Ent4", "text": "mequitazine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8850251_6_Ent1", "text": "photosensitivity reaction", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8850251_6_Ent0", "text": "patients", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8850251_6_Ent3", "text": "dermatologic problems", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "8862924_1", "wnd_id": "8862924_1_1", "text": "Keratitis in methamphetamine abusers .", "tokens": ["Keratitis", "in", "methamphetamine", "abusers", "."], "event_mentions": [{"id": "8862924_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 1, "end": 2}, "arguments": [{"entity_id": "8862924_1_Ent0", "role": "Effect", "text": "Keratitis", "start": 0, "end": 1}, {"entity_id": "8862924_1_Ent2", "role": "Treatment_Drug", "text": "methamphetamine", "start": 2, "end": 3}, {"entity_id": "8862924_1_Ent1", "role": "Treatment", "text": "methamphetamine abusers", "start": 2, "end": 4}]}], "entity_mentions": [{"id": "8862924_1_Ent0", "text": "Keratitis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8862924_1_Ent2", "text": "methamphetamine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8862924_1_Ent1", "text": "methamphetamine abusers", "entity_type": "Entity", "start": 2, "end": 4}], "lang": "en"}
{"doc_id": "8864370_1", "wnd_id": "8864370_1_1", "text": "BACKGROUND : Methotrexate ( MTX ) may induce liver damage , which in some psoriatics will lead to fibrosis or cirrhosis .", "tokens": ["BACKGROUND", ":", "Methotrexate", "(", "MTX", ")", "may", "induce", "liver", "damage", ",", "which", "in", "some", "psoriatics", "will", "lead", "to", "fibrosis", "or", "cirrhosis", "."], "event_mentions": [{"id": "8864370_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 7, "end": 8}, "arguments": [{"entity_id": "8864370_1_Ent2", "role": "Treatment_Drug", "text": "Methotrexate", "start": 2, "end": 3}, {"entity_id": "8864370_1_Ent1", "role": "Treatment", "text": "Methotrexate ( MTX )", "start": 2, "end": 6}, {"entity_id": "8864370_1_Ent0", "role": "Effect", "text": "liver damage , which in some psoriatics will lead to fibrosis or cirrhosis", "start": 8, "end": 21}, {"entity_id": "8864370_1_Ent3", "role": "Treatment_Disorder", "text": "psoriatics", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "8864370_1_Ent2", "text": "Methotrexate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8864370_1_Ent1", "text": "Methotrexate ( MTX )", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "8864370_1_Ent0", "text": "liver damage , which in some psoriatics will lead to fibrosis or cirrhosis", "entity_type": "Entity", "start": 8, "end": 21}, {"id": "8864370_1_Ent3", "text": "psoriatics", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "8864370_4", "wnd_id": "8864370_4_1", "text": "Methotrexate - induced liver cirrhosis .", "tokens": ["Methotrexate", "-", "induced", "liver", "cirrhosis", "."], "event_mentions": [{"id": "8864370_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8864370_4_Ent1", "role": "Treatment", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "8864370_4_Ent2", "role": "Treatment_Drug", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "8864370_4_Ent0", "role": "Effect", "text": "liver cirrhosis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "8864370_4_Ent1", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8864370_4_Ent2", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8864370_4_Ent0", "text": "liver cirrhosis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "8891729_4", "wnd_id": "8891729_4_1", "text": "We report the case of a patient with chronic lymphocytic leukemia ( CLL ) who developed fatal intravascular autoimmune hemolytic anemia ( AIHA ) after fludarabine treatment .", "tokens": ["We", "report", "the", "case", "of", "a", "patient", "with", "chronic", "lymphocytic", "leukemia", "(", "CLL", ")", "who", "developed", "fatal", "intravascular", "autoimmune", "hemolytic", "anemia", "(", "AIHA", ")", "after", "fludarabine", "treatment", "."], "event_mentions": [{"id": "8891729_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 24, "end": 25}, "arguments": [{"entity_id": "8891729_4_Ent0", "role": "Subject", "text": "a patient with chronic lymphocytic leukemia ( CLL )", "start": 5, "end": 14}, {"entity_id": "8891729_4_Ent4", "role": "Treatment_Disorder", "text": "chronic lymphocytic leukemia", "start": 8, "end": 11}, {"entity_id": "8891729_4_Ent1", "role": "Effect", "text": "fatal intravascular autoimmune hemolytic anemia ( AIHA )", "start": 16, "end": 24}, {"entity_id": "8891729_4_Ent3", "role": "Treatment_Drug", "text": "fludarabine", "start": 25, "end": 26}, {"entity_id": "8891729_4_Ent2", "role": "Treatment", "text": "fludarabine treatment", "start": 25, "end": 27}]}], "entity_mentions": [{"id": "8891729_4_Ent0", "text": "a patient with chronic lymphocytic leukemia ( CLL )", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "8891729_4_Ent4", "text": "chronic lymphocytic leukemia", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "8891729_4_Ent1", "text": "fatal intravascular autoimmune hemolytic anemia ( AIHA )", "entity_type": "Entity", "start": 16, "end": 24}, {"id": "8891729_4_Ent3", "text": "fludarabine", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "8891729_4_Ent2", "text": "fludarabine treatment", "entity_type": "Entity", "start": 25, "end": 27}], "lang": "en"}
{"doc_id": "8903300_2", "wnd_id": "8903300_2_1", "text": "Tetany in a child with AIDS receiving intravenous tobramycin .", "tokens": ["Tetany", "in", "a", "child", "with", "AIDS", "receiving", "intravenous", "tobramycin", "."], "event_mentions": [{"id": "8903300_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 1, "end": 2}, "arguments": [{"entity_id": "8903300_2_Ent3", "role": "Effect", "text": "Tetany", "start": 0, "end": 1}, {"entity_id": "8903300_2_Ent0", "role": "Subject", "text": "a child with AIDS", "start": 2, "end": 6}, {"entity_id": "8903300_2_Ent1", "role": "Subject_Age", "text": "child", "start": 3, "end": 4}, {"entity_id": "8903300_2_Ent2", "role": "Subject_Disorder", "text": "AIDS", "start": 5, "end": 6}, {"entity_id": "8903300_2_Ent6", "role": "Treatment_Route", "text": "intravenous", "start": 7, "end": 8}, {"entity_id": "8903300_2_Ent4", "role": "Treatment", "text": "intravenous tobramycin", "start": 7, "end": 9}, {"entity_id": "8903300_2_Ent5", "role": "Treatment_Drug", "text": "tobramycin", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "8903300_2_Ent3", "text": "Tetany", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8903300_2_Ent0", "text": "a child with AIDS", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "8903300_2_Ent1", "text": "child", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8903300_2_Ent2", "text": "AIDS", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8903300_2_Ent6", "text": "intravenous", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8903300_2_Ent4", "text": "intravenous tobramycin", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "8903300_2_Ent5", "text": "tobramycin", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "8908396_2", "wnd_id": "8908396_2_1", "text": "Insulin - induced lipoatrophy in type I diabetes .", "tokens": ["Insulin", "-", "induced", "lipoatrophy", "in", "type", "I", "diabetes", "."], "event_mentions": [{"id": "8908396_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8908396_2_Ent1", "role": "Treatment", "text": "Insulin", "start": 0, "end": 1}, {"entity_id": "8908396_2_Ent3", "role": "Treatment_Drug", "text": "Insulin", "start": 0, "end": 1}, {"entity_id": "8908396_2_Ent0", "role": "Effect", "text": "lipoatrophy", "start": 3, "end": 4}, {"entity_id": "8908396_2_Ent2", "role": "Treatment_Disorder", "text": "type I diabetes", "start": 5, "end": 8}]}], "entity_mentions": [{"id": "8908396_2_Ent1", "text": "Insulin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8908396_2_Ent3", "text": "Insulin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8908396_2_Ent0", "text": "lipoatrophy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8908396_2_Ent2", "text": "type I diabetes", "entity_type": "Entity", "start": 5, "end": 8}], "lang": "en"}
{"doc_id": "8961730_1", "wnd_id": "8961730_1_1", "text": "Psychotic disorder associated with isoniazid .", "tokens": ["Psychotic", "disorder", "associated", "with", "isoniazid", "."], "event_mentions": [{"id": "8961730_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "8961730_1_Ent0", "role": "Effect", "text": "Psychotic disorder", "start": 0, "end": 2}, {"entity_id": "8961730_1_Ent1", "role": "Treatment", "text": "isoniazid", "start": 4, "end": 5}, {"entity_id": "8961730_1_Ent2", "role": "Treatment_Drug", "text": "isoniazid", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "8961730_1_Ent0", "text": "Psychotic disorder", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8961730_1_Ent1", "text": "isoniazid", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8961730_1_Ent2", "text": "isoniazid", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "8961730_2", "wnd_id": "8961730_2_1", "text": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test .", "tokens": ["We", "evaluated", "a", "patient", "who", "developed", "a", "psychotic", "disorder", "after", "4", "months", "of", "isoniazid", "prophylaxis", "for", "a", "positive", "tuberculosis", "tine", "test", "."], "event_mentions": [{"id": "8961730_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "8961730_2_Ent0", "role": "Subject", "text": "patient", "start": 3, "end": 4}, {"entity_id": "8961730_2_Ent1", "role": "Effect", "text": "psychotic disorder", "start": 7, "end": 9}, {"entity_id": "8961730_2_Ent4", "role": "Treatment_Time_elapsed", "text": "4 months", "start": 10, "end": 12}, {"entity_id": "8961730_2_Ent2", "role": "Treatment", "text": "4 months of isoniazid prophylaxis", "start": 10, "end": 15}, {"entity_id": "8961730_2_Ent3", "role": "Treatment_Drug", "text": "isoniazid", "start": 13, "end": 14}, {"entity_id": "8961730_2_Ent5", "role": "Treatment_Disorder", "text": "tuberculosis", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "8961730_2_Ent0", "text": "patient", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8961730_2_Ent1", "text": "psychotic disorder", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "8961730_2_Ent4", "text": "4 months", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "8961730_2_Ent2", "text": "4 months of isoniazid prophylaxis", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "8961730_2_Ent3", "text": "isoniazid", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8961730_2_Ent5", "text": "tuberculosis", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "897744_1", "wnd_id": "897744_1_1", "text": "Focal glomerulonephritis and interstitial nephritis in methicillin - treated , heroin - related infective endocarditis .", "tokens": ["Focal", "glomerulonephritis", "and", "interstitial", "nephritis", "in", "methicillin", "-", "treated", ",", "heroin", "-", "related", "infective", "endocarditis", "."], "event_mentions": [{"id": "897744_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 8, "end": 9}, "arguments": [{"entity_id": "897744_1_Ent3", "role": "Effect", "text": "Focal glomerulonephritis and interstitial nephritis", "start": 0, "end": 5}, {"entity_id": "897744_1_Ent4", "role": "Treatment", "text": "methicillin", "start": 6, "end": 7}, {"entity_id": "897744_1_Ent6", "role": "Treatment_Drug", "text": "methicillin", "start": 6, "end": 7}, {"entity_id": "897744_1_Ent5", "role": "Treatment_Disorder", "text": "heroin - related infective endocarditis", "start": 10, "end": 15}]}, {"id": "897744_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 12, "end": 13}, "arguments": [{"entity_id": "897744_1_Ent1", "role": "Treatment", "text": "heroin", "start": 10, "end": 11}, {"entity_id": "897744_1_Ent2", "role": "Treatment_Drug", "text": "heroin", "start": 10, "end": 11}, {"entity_id": "897744_1_Ent0", "role": "Effect", "text": "infective endocarditis", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "897744_1_Ent3", "text": "Focal glomerulonephritis and interstitial nephritis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "897744_1_Ent4", "text": "methicillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "897744_1_Ent6", "text": "methicillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "897744_1_Ent1", "text": "heroin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "897744_1_Ent2", "text": "heroin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "897744_1_Ent5", "text": "heroin - related infective endocarditis", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "897744_1_Ent0", "text": "infective endocarditis", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "897744_3", "wnd_id": "897744_3_1", "text": "Discontinuation of methicillin therapy and appropriate antibiotic treatment of endocarditis led to clinical improvement , emphasizing the need to promptly discontinue potential nephrotoxic agents when abnormalities in renal function appear .", "tokens": ["Discontinuation", "of", "methicillin", "therapy", "and", "appropriate", "antibiotic", "treatment", "of", "endocarditis", "led", "to", "clinical", "improvement", ",", "emphasizing", "the", "need", "to", "promptly", "discontinue", "potential", "nephrotoxic", "agents", "when", "abnormalities", "in", "renal", "function", "appear", "."], "event_mentions": [{"id": "897744_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appear", "start": 29, "end": 30}, "arguments": [{"entity_id": "897744_3_Ent1", "role": "Treatment", "text": "methicillin", "start": 2, "end": 3}, {"entity_id": "897744_3_Ent2", "role": "Treatment_Drug", "text": "methicillin", "start": 2, "end": 3}, {"entity_id": "897744_3_Ent3", "role": "Treatment_Drug", "text": "antibiotic", "start": 6, "end": 7}, {"entity_id": "897744_3_Ent5", "role": "Treatment_Disorder", "text": "endocarditis", "start": 9, "end": 10}, {"entity_id": "897744_3_Ent4", "role": "Treatment_Drug", "text": "nephrotoxic agents", "start": 22, "end": 24}, {"entity_id": "897744_3_Ent0", "role": "Effect", "text": "abnormalities in renal function", "start": 25, "end": 29}]}], "entity_mentions": [{"id": "897744_3_Ent1", "text": "methicillin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "897744_3_Ent2", "text": "methicillin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "897744_3_Ent3", "text": "antibiotic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "897744_3_Ent5", "text": "endocarditis", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "897744_3_Ent4", "text": "nephrotoxic agents", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "897744_3_Ent0", "text": "abnormalities in renal function", "entity_type": "Entity", "start": 25, "end": 29}], "lang": "en"}
{"doc_id": "8979664_2", "wnd_id": "8979664_2_1", "text": "over the past 3 years there have been several reports of uveitis associated with rifabutin therapy .", "tokens": ["over", "the", "past", "3", "years", "there", "have", "been", "several", "reports", "of", "uveitis", "associated", "with", "rifabutin", "therapy", "."], "event_mentions": [{"id": "8979664_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 12, "end": 13}, "arguments": [{"entity_id": "8979664_2_Ent0", "role": "Effect", "text": "uveitis", "start": 11, "end": 12}, {"entity_id": "8979664_2_Ent2", "role": "Treatment_Drug", "text": "rifabutin", "start": 14, "end": 15}, {"entity_id": "8979664_2_Ent1", "role": "Treatment", "text": "rifabutin therapy", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "8979664_2_Ent0", "text": "uveitis", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8979664_2_Ent2", "text": "rifabutin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8979664_2_Ent1", "text": "rifabutin therapy", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "9017913_1", "wnd_id": "9017913_1_1", "text": "Immunosuppression elicited by the extensive administration of prednisolone was suspected for the initiation of the generalized mite infestation .", "tokens": ["Immunosuppression", "elicited", "by", "the", "extensive", "administration", "of", "prednisolone", "was", "suspected", "for", "the", "initiation", "of", "the", "generalized", "mite", "infestation", "."], "event_mentions": [{"id": "9017913_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "generalized", "start": 15, "end": 16}, "arguments": [{"entity_id": "9017913_1_Ent1", "role": "Treatment", "text": "extensive administration of prednisolone", "start": 4, "end": 8}, {"entity_id": "9017913_1_Ent2", "role": "Treatment_Drug", "text": "prednisolone", "start": 7, "end": 8}, {"entity_id": "9017913_1_Ent0", "role": "Effect", "text": "mite infestation", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "9017913_1_Ent1", "text": "extensive administration of prednisolone", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "9017913_1_Ent2", "text": "prednisolone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9017913_1_Ent0", "text": "mite infestation", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "9022114_5", "wnd_id": "9022114_5_1", "text": "The authors suggest that in patients with corneal ulcers refractory to conventional treatment who are receiving colchicine , cessation of colchicine therapy should be considered .", "tokens": ["The", "authors", "suggest", "that", "in", "patients", "with", "corneal", "ulcers", "refractory", "to", "conventional", "treatment", "who", "are", "receiving", "colchicine", ",", "cessation", "of", "colchicine", "therapy", "should", "be", "considered", "."], "event_mentions": [{"id": "9022114_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 15, "end": 16}, "arguments": [{"entity_id": "9022114_5_Ent0", "role": "Subject", "text": "patients with corneal ulcers", "start": 5, "end": 9}, {"entity_id": "9022114_5_Ent3", "role": "Treatment_Disorder", "text": "corneal ulcers", "start": 7, "end": 9}, {"entity_id": "9022114_5_Ent1", "role": "Treatment", "text": "colchicine", "start": 16, "end": 17}, {"entity_id": "9022114_5_Ent2", "role": "Treatment_Drug", "text": "colchicine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "9022114_5_Ent0", "text": "patients with corneal ulcers", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "9022114_5_Ent3", "text": "corneal ulcers", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "9022114_5_Ent1", "text": "colchicine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9022114_5_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "9039216_3", "wnd_id": "9039216_3_1", "text": "This severe illness was likely caused by minocycline , and we speculate that minocycline may have acted as a superantigen , causing lymphocyte over - activation and massive cytokine release .", "tokens": ["This", "severe", "illness", "was", "likely", "caused", "by", "minocycline", ",", "and", "we", "speculate", "that", "minocycline", "may", "have", "acted", "as", "a", "superantigen", ",", "causing", "lymphocyte", "over", "-", "activation", "and", "massive", "cytokine", "release", "."], "event_mentions": [{"id": "9039216_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 5, "end": 6}, "arguments": [{"entity_id": "9039216_3_Ent0", "role": "Effect", "text": "severe illness", "start": 1, "end": 3}, {"entity_id": "9039216_3_Ent1", "role": "Treatment", "text": "minocycline", "start": 7, "end": 8}, {"entity_id": "9039216_3_Ent2", "role": "Treatment_Drug", "text": "minocycline", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "9039216_3_Ent0", "text": "severe illness", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "9039216_3_Ent1", "text": "minocycline", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9039216_3_Ent2", "text": "minocycline", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "9052919_3", "wnd_id": "9052919_3_1", "text": "We postulate that cyclosporin , possibly together with ganciclovir , can produce transient brain stem or neuromuscular dysfunction with eye movement abnormality in occasional patients .", "tokens": ["We", "postulate", "that", "cyclosporin", ",", "possibly", "together", "with", "ganciclovir", ",", "can", "produce", "transient", "brain", "stem", "or", "neuromuscular", "dysfunction", "with", "eye", "movement", "abnormality", "in", "occasional", "patients", "."], "event_mentions": [{"id": "9052919_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "produce", "start": 11, "end": 12}, "arguments": [{"entity_id": "9052919_3_Ent2", "role": "Treatment", "text": "cyclosporin", "start": 3, "end": 4}, {"entity_id": "9052919_3_Ent5", "role": "Treatment_Drug", "text": "cyclosporin", "start": 3, "end": 4}, {"entity_id": "9052919_3_Ent6", "role": "Combination_Drug", "text": "cyclosporin", "start": 3, "end": 4}, {"entity_id": "9052919_3_Ent3", "role": "Treatment", "text": "together with ganciclovir", "start": 6, "end": 9}, {"entity_id": "9052919_3_Ent4", "role": "Treatment_Drug", "text": "ganciclovir", "start": 8, "end": 9}, {"entity_id": "9052919_3_Ent7", "role": "Combination_Drug", "text": "ganciclovir", "start": 8, "end": 9}, {"entity_id": "9052919_3_Ent1", "role": "Effect", "text": "transient brain stem or neuromuscular dysfunction with eye movement abnormality", "start": 12, "end": 22}, {"entity_id": "9052919_3_Ent0", "role": "Subject", "text": "occasional patients", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "9052919_3_Ent2", "text": "cyclosporin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9052919_3_Ent5", "text": "cyclosporin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9052919_3_Ent6", "text": "cyclosporin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9052919_3_Ent3", "text": "together with ganciclovir", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "9052919_3_Ent4", "text": "ganciclovir", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9052919_3_Ent7", "text": "ganciclovir", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9052919_3_Ent1", "text": "transient brain stem or neuromuscular dysfunction with eye movement abnormality", "entity_type": "Entity", "start": 12, "end": 22}, {"id": "9052919_3_Ent0", "text": "occasional patients", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "9161656_2", "wnd_id": "9161656_2_1", "text": "OBJECTIVE : To describe a patient with asymptomatic bronchial asthma and hypertension who developed an acute asthma attack after receiving sustained - release verapamil .", "tokens": ["OBJECTIVE", ":", "To", "describe", "a", "patient", "with", "asymptomatic", "bronchial", "asthma", "and", "hypertension", "who", "developed", "an", "acute", "asthma", "attack", "after", "receiving", "sustained", "-", "release", "verapamil", "."], "event_mentions": [{"id": "9161656_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 18, "end": 19}, "arguments": [{"entity_id": "9161656_2_Ent0", "role": "Subject", "text": "a patient with asymptomatic bronchial asthma and hypertension", "start": 4, "end": 12}, {"entity_id": "9161656_2_Ent1", "role": "Subject_Disorder", "text": "asymptomatic bronchial asthma", "start": 7, "end": 10}, {"entity_id": "9161656_2_Ent4", "role": "Treatment_Disorder", "text": "hypertension", "start": 11, "end": 12}, {"entity_id": "9161656_2_Ent2", "role": "Effect", "text": "acute asthma attack", "start": 15, "end": 18}, {"entity_id": "9161656_2_Ent3", "role": "Treatment", "text": "sustained - release verapamil", "start": 20, "end": 24}, {"entity_id": "9161656_2_Ent5", "role": "Treatment_Drug", "text": "sustained - release verapamil", "start": 20, "end": 24}]}], "entity_mentions": [{"id": "9161656_2_Ent0", "text": "a patient with asymptomatic bronchial asthma and hypertension", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "9161656_2_Ent1", "text": "asymptomatic bronchial asthma", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "9161656_2_Ent4", "text": "hypertension", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9161656_2_Ent2", "text": "acute asthma attack", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "9161656_2_Ent3", "text": "sustained - release verapamil", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "9161656_2_Ent5", "text": "sustained - release verapamil", "entity_type": "Entity", "start": 20, "end": 24}], "lang": "en"}
{"doc_id": "9169264_3", "wnd_id": "9169264_3_1", "text": "The case of a patient with infectious mononucleosis treated with cephalexin who later showed a rash is presented and the previous literature is reviewed .", "tokens": ["The", "case", "of", "a", "patient", "with", "infectious", "mononucleosis", "treated", "with", "cephalexin", "who", "later", "showed", "a", "rash", "is", "presented", "and", "the", "previous", "literature", "is", "reviewed", "."], "event_mentions": [{"id": "9169264_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "showed", "start": 13, "end": 14}, "arguments": [{"entity_id": "9169264_3_Ent0", "role": "Subject", "text": "a patient with infectious mononucleosis", "start": 3, "end": 8}, {"entity_id": "9169264_3_Ent4", "role": "Treatment_Disorder", "text": "infectious mononucleosis", "start": 6, "end": 8}, {"entity_id": "9169264_3_Ent2", "role": "Treatment", "text": "cephalexin", "start": 10, "end": 11}, {"entity_id": "9169264_3_Ent3", "role": "Treatment_Drug", "text": "cephalexin", "start": 10, "end": 11}, {"entity_id": "9169264_3_Ent1", "role": "Effect", "text": "rash", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "9169264_3_Ent0", "text": "a patient with infectious mononucleosis", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "9169264_3_Ent4", "text": "infectious mononucleosis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9169264_3_Ent2", "text": "cephalexin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9169264_3_Ent3", "text": "cephalexin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9169264_3_Ent1", "text": "rash", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "9177620_1", "wnd_id": "9177620_1_1", "text": "A possible case of carbamazepine induced pancreatitis .", "tokens": ["A", "possible", "case", "of", "carbamazepine", "induced", "pancreatitis", "."], "event_mentions": [{"id": "9177620_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "9177620_1_Ent0", "role": "Subject", "text": "A possible case", "start": 0, "end": 3}, {"entity_id": "9177620_1_Ent2", "role": "Treatment", "text": "carbamazepine", "start": 4, "end": 5}, {"entity_id": "9177620_1_Ent3", "role": "Treatment_Drug", "text": "carbamazepine", "start": 4, "end": 5}, {"entity_id": "9177620_1_Ent1", "role": "Effect", "text": "pancreatitis", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "9177620_1_Ent0", "text": "A possible case", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9177620_1_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9177620_1_Ent3", "text": "carbamazepine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9177620_1_Ent1", "text": "pancreatitis", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "9184269_1", "wnd_id": "9184269_1_1", "text": "Although risk factors for MTX - induced pulmonary toxicity are poorly understood , the presence in 3 out of 5 of our patients of pre - existing lung disease , represented by diffuse interstitial changes on chest X - ray , and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of MTX pneumonitis .", "tokens": ["Although", "risk", "factors", "for", "MTX", "-", "induced", "pulmonary", "toxicity", "are", "poorly", "understood", ",", "the", "presence", "in", "3", "out", "of", "5", "of", "our", "patients", "of", "pre", "-", "existing", "lung", "disease", ",", "represented", "by", "diffuse", "interstitial", "changes", "on", "chest", "X", "-", "ray", ",", "and", "mild", "bronchial", "asthma", "in", "two", "RA", "patients", "and", "by", "pulmonary", "silicosis", "in", "the", "patient", "with", "PsA", "may", "account", "for", "a", "predisposition", "to", "the", "development", "of", "MTX", "pneumonitis", "."], "event_mentions": [{"id": "9184269_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "9184269_1_Ent4", "role": "Treatment", "text": "MTX", "start": 4, "end": 5}, {"entity_id": "9184269_1_Ent5", "role": "Treatment_Drug", "text": "MTX", "start": 4, "end": 5}, {"entity_id": "9184269_1_Ent3", "role": "Effect", "text": "pulmonary toxicity", "start": 7, "end": 9}, {"entity_id": "9184269_1_Ent0", "role": "Subject", "text": "the presence in 3 out of 5 of our patients of pre - existing lung disease , represented by diffuse interstitial changes on chest X - ray , and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA", "start": 13, "end": 58}, {"entity_id": "9184269_1_Ent1", "role": "Subject_Population", "text": "3 out of 5", "start": 16, "end": 20}, {"entity_id": "9184269_1_Ent2", "role": "Subject_Disorder", "text": "pre - existing lung disease , represented by diffuse interstitial changes on chest X - ray , and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA", "start": 24, "end": 58}]}], "entity_mentions": [{"id": "9184269_1_Ent4", "text": "MTX", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9184269_1_Ent5", "text": "MTX", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9184269_1_Ent3", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "9184269_1_Ent0", "text": "the presence in 3 out of 5 of our patients of pre - existing lung disease , represented by diffuse interstitial changes on chest X - ray , and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA", "entity_type": "Entity", "start": 13, "end": 58}, {"id": "9184269_1_Ent1", "text": "3 out of 5", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "9184269_1_Ent2", "text": "pre - existing lung disease , represented by diffuse interstitial changes on chest X - ray , and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA", "entity_type": "Entity", "start": 24, "end": 58}], "lang": "en"}
{"doc_id": "91848_1", "wnd_id": "91848_1_1", "text": "A retrospective epidemiological study of deaths from hepatic angiosarcoma ( HAS ) in the U.S. showed that during 1964 - - 74 there were 168 such cases , of which 37 ( 22 % ) were associated with previously known causes ( vinyl chloride , ' Thorotrast ' , and inorganic arsenic ) and 4 ( 3.1 % ) of the remaining 131 cases with the use of androgenic - anabolic steroids .", "tokens": ["A", "retrospective", "epidemiological", "study", "of", "deaths", "from", "hepatic", "angiosarcoma", "(", "HAS", ")", "in", "the", "U.S.", "showed", "that", "during", "1964", "-", "-", "74", "there", "were", "168", "such", "cases", ",", "of", "which", "37", "(", "22", "%", ")", "were", "associated", "with", "previously", "known", "causes", "(", "vinyl", "chloride", ",", "'", "Thorotrast", "'", ",", "and", "inorganic", "arsenic", ")", "and", "4", "(", "3.1", "%", ")", "of", "the", "remaining", "131", "cases", "with", "the", "use", "of", "androgenic", "-", "anabolic", "steroids", "."], "event_mentions": [{"id": "91848_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 36, "end": 37}, "arguments": [{"entity_id": "91848_1_Ent2", "role": "Effect", "text": "hepatic angiosarcoma", "start": 7, "end": 9}, {"entity_id": "91848_1_Ent1", "role": "Subject_Population", "text": "37", "start": 30, "end": 31}, {"entity_id": "91848_1_Ent0", "role": "Subject", "text": "37 ( 22 % )", "start": 30, "end": 35}, {"entity_id": "91848_1_Ent4", "role": "Treatment_Drug", "text": "vinyl chloride", "start": 42, "end": 44}, {"entity_id": "91848_1_Ent7", "role": "Combination_Drug", "text": "vinyl chloride", "start": 42, "end": 44}, {"entity_id": "91848_1_Ent3", "role": "Treatment", "text": "vinyl chloride , ' Thorotrast ' , and inorganic arsenic", "start": 42, "end": 52}, {"entity_id": "91848_1_Ent5", "role": "Treatment_Drug", "text": "Thorotrast", "start": 46, "end": 47}, {"entity_id": "91848_1_Ent8", "role": "Combination_Drug", "text": "Thorotrast", "start": 46, "end": 47}, {"entity_id": "91848_1_Ent6", "role": "Treatment_Drug", "text": "inorganic arsenic", "start": 50, "end": 52}, {"entity_id": "91848_1_Ent9", "role": "Combination_Drug", "text": "inorganic arsenic", "start": 50, "end": 52}]}, {"id": "91848_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 64, "end": 65}, "arguments": [{"entity_id": "91848_1_Ent12", "role": "Effect", "text": "hepatic angiosarcoma", "start": 7, "end": 9}, {"entity_id": "91848_1_Ent11", "role": "Subject_Population", "text": "4", "start": 54, "end": 55}, {"entity_id": "91848_1_Ent10", "role": "Subject", "text": "4 ( 3.1 % )", "start": 54, "end": 59}, {"entity_id": "91848_1_Ent13", "role": "Treatment", "text": "androgenic - anabolic steroids", "start": 68, "end": 72}, {"entity_id": "91848_1_Ent14", "role": "Treatment_Drug", "text": "androgenic - anabolic steroids", "start": 68, "end": 72}]}], "entity_mentions": [{"id": "91848_1_Ent2", "text": "hepatic angiosarcoma", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "91848_1_Ent12", "text": "hepatic angiosarcoma", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "91848_1_Ent1", "text": "37", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "91848_1_Ent0", "text": "37 ( 22 % )", "entity_type": "Entity", "start": 30, "end": 35}, {"id": "91848_1_Ent4", "text": "vinyl chloride", "entity_type": "Entity", "start": 42, "end": 44}, {"id": "91848_1_Ent7", "text": "vinyl chloride", "entity_type": "Entity", "start": 42, "end": 44}, {"id": "91848_1_Ent3", "text": "vinyl chloride , ' Thorotrast ' , and inorganic arsenic", "entity_type": "Entity", "start": 42, "end": 52}, {"id": "91848_1_Ent5", "text": "Thorotrast", "entity_type": "Entity", "start": 46, "end": 47}, {"id": "91848_1_Ent8", "text": "Thorotrast", "entity_type": "Entity", "start": 46, "end": 47}, {"id": "91848_1_Ent6", "text": "inorganic arsenic", "entity_type": "Entity", "start": 50, "end": 52}, {"id": "91848_1_Ent9", "text": "inorganic arsenic", "entity_type": "Entity", "start": 50, "end": 52}, {"id": "91848_1_Ent11", "text": "4", "entity_type": "Entity", "start": 54, "end": 55}, {"id": "91848_1_Ent10", "text": "4 ( 3.1 % )", "entity_type": "Entity", "start": 54, "end": 59}, {"id": "91848_1_Ent13", "text": "androgenic - anabolic steroids", "entity_type": "Entity", "start": 68, "end": 72}, {"id": "91848_1_Ent14", "text": "androgenic - anabolic steroids", "entity_type": "Entity", "start": 68, "end": 72}], "lang": "en"}
{"doc_id": "9191742_1", "wnd_id": "9191742_1_1", "text": "Recent studies have shown that under experimental conditions ferrous sulfate may reduce the gastrointestinal absorption of orally administered levothyroxine sodium in patients with primary hypothyroidism .", "tokens": ["Recent", "studies", "have", "shown", "that", "under", "experimental", "conditions", "ferrous", "sulfate", "may", "reduce", "the", "gastrointestinal", "absorption", "of", "orally", "administered", "levothyroxine", "sodium", "in", "patients", "with", "primary", "hypothyroidism", "."], "event_mentions": [{"id": "9191742_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reduce", "start": 11, "end": 12}, "arguments": [{"entity_id": "9191742_1_Ent3", "role": "Treatment", "text": "ferrous sulfate", "start": 8, "end": 10}, {"entity_id": "9191742_1_Ent5", "role": "Treatment_Drug", "text": "ferrous sulfate", "start": 8, "end": 10}, {"entity_id": "9191742_1_Ent8", "role": "Combination_Drug", "text": "ferrous sulfate", "start": 8, "end": 10}, {"entity_id": "9191742_1_Ent2", "role": "Effect", "text": "reduce the gastrointestinal absorption of orally administered levothyroxine sodium", "start": 11, "end": 20}, {"entity_id": "9191742_1_Ent7", "role": "Treatment_Route", "text": "orally", "start": 16, "end": 17}, {"entity_id": "9191742_1_Ent4", "role": "Treatment", "text": "orally administered levothyroxine sodium", "start": 16, "end": 20}, {"entity_id": "9191742_1_Ent6", "role": "Treatment_Drug", "text": "levothyroxine sodium", "start": 18, "end": 20}, {"entity_id": "9191742_1_Ent9", "role": "Combination_Drug", "text": "levothyroxine sodium", "start": 18, "end": 20}, {"entity_id": "9191742_1_Ent0", "role": "Subject", "text": "patients with primary hypothyroidism", "start": 21, "end": 25}, {"entity_id": "9191742_1_Ent1", "role": "Subject_Disorder", "text": "primary hypothyroidism", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "9191742_1_Ent3", "text": "ferrous sulfate", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9191742_1_Ent5", "text": "ferrous sulfate", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9191742_1_Ent8", "text": "ferrous sulfate", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9191742_1_Ent2", "text": "reduce the gastrointestinal absorption of orally administered levothyroxine sodium", "entity_type": "Entity", "start": 11, "end": 20}, {"id": "9191742_1_Ent7", "text": "orally", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9191742_1_Ent4", "text": "orally administered levothyroxine sodium", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "9191742_1_Ent6", "text": "levothyroxine sodium", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "9191742_1_Ent9", "text": "levothyroxine sodium", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "9191742_1_Ent0", "text": "patients with primary hypothyroidism", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "9191742_1_Ent1", "text": "primary hypothyroidism", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "9211543_4", "wnd_id": "9211543_4_1", "text": "Thoracoscopic biopsy to confirm metastasis revealed instead fibrotic lesions apparently attributable to bleomycin or cyclophosphamide .", "tokens": ["Thoracoscopic", "biopsy", "to", "confirm", "metastasis", "revealed", "instead", "fibrotic", "lesions", "apparently", "attributable", "to", "bleomycin", "or", "cyclophosphamide", "."], "event_mentions": [{"id": "9211543_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "attributable", "start": 10, "end": 11}, "arguments": [{"entity_id": "9211543_4_Ent0", "role": "Effect", "text": "fibrotic lesions", "start": 7, "end": 9}, {"entity_id": "9211543_4_Ent2", "role": "Treatment_Drug", "text": "bleomycin", "start": 12, "end": 13}, {"entity_id": "9211543_4_Ent1", "role": "Treatment", "text": "bleomycin or cyclophosphamide", "start": 12, "end": 15}, {"entity_id": "9211543_4_Ent3", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "9211543_4_Ent0", "text": "fibrotic lesions", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "9211543_4_Ent2", "text": "bleomycin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9211543_4_Ent1", "text": "bleomycin or cyclophosphamide", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "9211543_4_Ent3", "text": "cyclophosphamide", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "9215418_1", "wnd_id": "9215418_1_1", "text": "Clinical signs of hypermagnesemia are an uncommon complication following oral administration of magnesium sulfate .", "tokens": ["Clinical", "signs", "of", "hypermagnesemia", "are", "an", "uncommon", "complication", "following", "oral", "administration", "of", "magnesium", "sulfate", "."], "event_mentions": [{"id": "9215418_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 7, "end": 8}, "arguments": [{"entity_id": "9215418_1_Ent0", "role": "Effect", "text": "hypermagnesemia", "start": 3, "end": 4}, {"entity_id": "9215418_1_Ent3", "role": "Treatment_Route", "text": "oral", "start": 9, "end": 10}, {"entity_id": "9215418_1_Ent1", "role": "Treatment", "text": "oral administration of magnesium sulfate", "start": 9, "end": 14}, {"entity_id": "9215418_1_Ent2", "role": "Treatment_Drug", "text": "magnesium sulfate", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "9215418_1_Ent0", "text": "hypermagnesemia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9215418_1_Ent3", "text": "oral", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9215418_1_Ent1", "text": "oral administration of magnesium sulfate", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "9215418_1_Ent2", "text": "magnesium sulfate", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "9220046_2", "wnd_id": "9220046_2_1", "text": "CONCLUSIONS : The risk of drug - induced rhabdomyolysis due to the potential interaction between lovastatin and azithromycin or clarithromycin should be considered before the concomitant use of these agents .", "tokens": ["CONCLUSIONS", ":", "The", "risk", "of", "drug", "-", "induced", "rhabdomyolysis", "due", "to", "the", "potential", "interaction", "between", "lovastatin", "and", "azithromycin", "or", "clarithromycin", "should", "be", "considered", "before", "the", "concomitant", "use", "of", "these", "agents", "."], "event_mentions": [{"id": "9220046_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 9, "end": 10}, "arguments": [{"entity_id": "9220046_2_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 8, "end": 9}, {"entity_id": "9220046_2_Ent1", "role": "Treatment", "text": "lovastatin", "start": 15, "end": 16}, {"entity_id": "9220046_2_Ent4", "role": "Treatment_Drug", "text": "lovastatin", "start": 15, "end": 16}, {"entity_id": "9220046_2_Ent7", "role": "Combination_Drug", "text": "lovastatin", "start": 15, "end": 16}, {"entity_id": "9220046_2_Ent2", "role": "Treatment", "text": "azithromycin", "start": 17, "end": 18}, {"entity_id": "9220046_2_Ent5", "role": "Treatment_Drug", "text": "azithromycin", "start": 17, "end": 18}, {"entity_id": "9220046_2_Ent8", "role": "Combination_Drug", "text": "azithromycin", "start": 17, "end": 18}, {"entity_id": "9220046_2_Ent3", "role": "Treatment", "text": "clarithromycin", "start": 19, "end": 20}, {"entity_id": "9220046_2_Ent6", "role": "Treatment_Drug", "text": "clarithromycin", "start": 19, "end": 20}, {"entity_id": "9220046_2_Ent9", "role": "Combination_Drug", "text": "clarithromycin", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "9220046_2_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9220046_2_Ent1", "text": "lovastatin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9220046_2_Ent4", "text": "lovastatin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9220046_2_Ent7", "text": "lovastatin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9220046_2_Ent2", "text": "azithromycin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "9220046_2_Ent5", "text": "azithromycin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "9220046_2_Ent8", "text": "azithromycin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "9220046_2_Ent3", "text": "clarithromycin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9220046_2_Ent6", "text": "clarithromycin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9220046_2_Ent9", "text": "clarithromycin", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "9247841_3", "wnd_id": "9247841_3_1", "text": "Generalized maculopapular and papular purpuric eruptions are perhaps the most common thionamide - induced reactions .", "tokens": ["Generalized", "maculopapular", "and", "papular", "purpuric", "eruptions", "are", "perhaps", "the", "most", "common", "thionamide", "-", "induced", "reactions", "."], "event_mentions": [{"id": "9247841_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "9247841_3_Ent0", "role": "Effect", "text": "Generalized maculopapular and papular purpuric eruptions", "start": 0, "end": 6}, {"entity_id": "9247841_3_Ent2", "role": "Treatment", "text": "thionamide", "start": 11, "end": 12}, {"entity_id": "9247841_3_Ent3", "role": "Treatment_Drug", "text": "thionamide", "start": 11, "end": 12}, {"entity_id": "9247841_3_Ent1", "role": "Effect", "text": "reactions", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "9247841_3_Ent0", "text": "Generalized maculopapular and papular purpuric eruptions", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "9247841_3_Ent2", "text": "thionamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9247841_3_Ent3", "text": "thionamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9247841_3_Ent1", "text": "reactions", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "9247841_5", "wnd_id": "9247841_5_1", "text": "The observation of cutaneous vasculitis during administration of propylthiouracil suggested that clinical awareness of this complication should be of considerable importance .", "tokens": ["The", "observation", "of", "cutaneous", "vasculitis", "during", "administration", "of", "propylthiouracil", "suggested", "that", "clinical", "awareness", "of", "this", "complication", "should", "be", "of", "considerable", "importance", "."], "event_mentions": [{"id": "9247841_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 5, "end": 6}, "arguments": [{"entity_id": "9247841_5_Ent0", "role": "Effect", "text": "cutaneous vasculitis", "start": 3, "end": 5}, {"entity_id": "9247841_5_Ent1", "role": "Treatment", "text": "propylthiouracil", "start": 8, "end": 9}, {"entity_id": "9247841_5_Ent2", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "9247841_5_Ent0", "text": "cutaneous vasculitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9247841_5_Ent1", "text": "propylthiouracil", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9247841_5_Ent2", "text": "propylthiouracil", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "9291634_6", "wnd_id": "9291634_6_1", "text": "Ten - 17 days after receiving chemotherapy , five patients ( 4 males and 1 female ) with acute lymphoblastic leukemia developed incapacitating myalgias in neck , thighs and arms .", "tokens": ["Ten", "-", "17", "days", "after", "receiving", "chemotherapy", ",", "five", "patients", "(", "4", "males", "and", "1", "female", ")", "with", "acute", "lymphoblastic", "leukemia", "developed", "incapacitating", "myalgias", "in", "neck", ",", "thighs", "and", "arms", "."], "event_mentions": [{"id": "9291634_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 21, "end": 22}, "arguments": [{"entity_id": "9291634_6_Ent6", "role": "Treatment_Time_elapsed", "text": "Ten - 17 days", "start": 0, "end": 4}, {"entity_id": "9291634_6_Ent4", "role": "Treatment", "text": "Ten - 17 days after receiving chemotherapy", "start": 0, "end": 7}, {"entity_id": "9291634_6_Ent7", "role": "Treatment_Route", "text": "chemotherapy", "start": 6, "end": 7}, {"entity_id": "9291634_6_Ent1", "role": "Subject_Population", "text": "five", "start": 8, "end": 9}, {"entity_id": "9291634_6_Ent0", "role": "Subject", "text": "five patients ( 4 males and 1 female ) with acute lymphoblastic leukemia", "start": 8, "end": 21}, {"entity_id": "9291634_6_Ent2", "role": "Subject_Gender", "text": "4 males and 1 female", "start": 11, "end": 16}, {"entity_id": "9291634_6_Ent5", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 18, "end": 21}, {"entity_id": "9291634_6_Ent3", "role": "Effect", "text": "incapacitating myalgias in neck , thighs and arms", "start": 22, "end": 30}]}], "entity_mentions": [{"id": "9291634_6_Ent6", "text": "Ten - 17 days", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "9291634_6_Ent4", "text": "Ten - 17 days after receiving chemotherapy", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "9291634_6_Ent7", "text": "chemotherapy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9291634_6_Ent1", "text": "five", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9291634_6_Ent0", "text": "five patients ( 4 males and 1 female ) with acute lymphoblastic leukemia", "entity_type": "Entity", "start": 8, "end": 21}, {"id": "9291634_6_Ent2", "text": "4 males and 1 female", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "9291634_6_Ent5", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "9291634_6_Ent3", "text": "incapacitating myalgias in neck , thighs and arms", "entity_type": "Entity", "start": 22, "end": 30}], "lang": "en"}
{"doc_id": "9347384_1", "wnd_id": "9347384_1_1", "text": "Carbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients .", "tokens": ["Carbamazepine", "toxicity", "induced", "by", "clarithromycin", "coadministration", "in", "psychiatric", "patients", "."], "event_mentions": [{"id": "9347384_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9347384_1_Ent5", "role": "Treatment_Drug", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "9347384_1_Ent7", "role": "Combination_Drug", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "9347384_1_Ent2", "role": "Effect", "text": "Carbamazepine toxicity", "start": 0, "end": 2}, {"entity_id": "9347384_1_Ent3", "role": "Treatment", "text": "clarithromycin", "start": 4, "end": 5}, {"entity_id": "9347384_1_Ent4", "role": "Treatment_Drug", "text": "clarithromycin", "start": 4, "end": 5}, {"entity_id": "9347384_1_Ent6", "role": "Combination_Drug", "text": "clarithromycin", "start": 4, "end": 5}, {"entity_id": "9347384_1_Ent1", "role": "Subject_Disorder", "text": "psychiatric", "start": 7, "end": 8}, {"entity_id": "9347384_1_Ent0", "role": "Subject", "text": "psychiatric patients", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "9347384_1_Ent5", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9347384_1_Ent7", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9347384_1_Ent2", "text": "Carbamazepine toxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9347384_1_Ent3", "text": "clarithromycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9347384_1_Ent4", "text": "clarithromycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9347384_1_Ent6", "text": "clarithromycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9347384_1_Ent1", "text": "psychiatric", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9347384_1_Ent0", "text": "psychiatric patients", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "9347384_3", "wnd_id": "9347384_3_1", "text": "The present report suggests that clarithromycin coadministration induces increased plasma carbamazepine concentrations , which may result in carbamazepine toxicity .", "tokens": ["The", "present", "report", "suggests", "that", "clarithromycin", "coadministration", "induces", "increased", "plasma", "carbamazepine", "concentrations", ",", "which", "may", "result", "in", "carbamazepine", "toxicity", "."], "event_mentions": [{"id": "9347384_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induces", "start": 7, "end": 8}, "arguments": [{"entity_id": "9347384_3_Ent3", "role": "Treatment", "text": "clarithromycin", "start": 5, "end": 6}, {"entity_id": "9347384_3_Ent6", "role": "Treatment_Drug", "text": "clarithromycin", "start": 5, "end": 6}, {"entity_id": "9347384_3_Ent1", "role": "Effect", "text": "increased plasma carbamazepine concentrations", "start": 8, "end": 12}, {"entity_id": "9347384_3_Ent0", "role": "Subject", "text": "carbamazepine", "start": 10, "end": 11}, {"entity_id": "9347384_3_Ent4", "role": "Treatment", "text": "carbamazepine", "start": 10, "end": 11}, {"entity_id": "9347384_3_Ent5", "role": "Treatment", "text": "carbamazepine", "start": 17, "end": 18}, {"entity_id": "9347384_3_Ent2", "role": "Effect", "text": "carbamazepine toxicity .", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "9347384_3_Ent3", "text": "clarithromycin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9347384_3_Ent6", "text": "clarithromycin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9347384_3_Ent1", "text": "increased plasma carbamazepine concentrations", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "9347384_3_Ent0", "text": "carbamazepine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9347384_3_Ent4", "text": "carbamazepine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9347384_3_Ent5", "text": "carbamazepine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "9347384_3_Ent2", "text": "carbamazepine toxicity .", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "9366852_2", "wnd_id": "9366852_2_1", "text": "Skin necrosis is a rare complication of subcutaneous heparin therapy that usually occurs at injection sites .", "tokens": ["Skin", "necrosis", "is", "a", "rare", "complication", "of", "subcutaneous", "heparin", "therapy", "that", "usually", "occurs", "at", "injection", "sites", "."], "event_mentions": [{"id": "9366852_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 5, "end": 6}, "arguments": [{"entity_id": "9366852_2_Ent0", "role": "Effect", "text": "Skin necrosis", "start": 0, "end": 2}, {"entity_id": "9366852_2_Ent3", "role": "Treatment_Route", "text": "subcutaneous", "start": 7, "end": 8}, {"entity_id": "9366852_2_Ent1", "role": "Treatment", "text": "subcutaneous heparin therapy", "start": 7, "end": 10}, {"entity_id": "9366852_2_Ent2", "role": "Treatment_Drug", "text": "heparin", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "9366852_2_Ent0", "text": "Skin necrosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9366852_2_Ent3", "text": "subcutaneous", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9366852_2_Ent1", "text": "subcutaneous heparin therapy", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "9366852_2_Ent2", "text": "heparin", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "937377_1", "wnd_id": "937377_1_1", "text": "Finally , reserpine toxicity , in particular central nervous system ( CNS ) disturbances , was reported more frequently in patients also receiving barbiturates , suggesting additive CNS effects .", "tokens": ["Finally", ",", "reserpine", "toxicity", ",", "in", "particular", "central", "nervous", "system", "(", "CNS", ")", "disturbances", ",", "was", "reported", "more", "frequently", "in", "patients", "also", "receiving", "barbiturates", ",", "suggesting", "additive", "CNS", "effects", "."], "event_mentions": [{"id": "937377_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 16, "end": 17}, "arguments": [{"entity_id": "937377_1_Ent2", "role": "Treatment", "text": "reserpine", "start": 2, "end": 3}, {"entity_id": "937377_1_Ent5", "role": "Treatment_Drug", "text": "reserpine", "start": 2, "end": 3}, {"entity_id": "937377_1_Ent7", "role": "Combination_Drug", "text": "reserpine", "start": 2, "end": 3}, {"entity_id": "937377_1_Ent0", "role": "Effect", "text": "reserpine toxicity , in particular central nervous system ( CNS ) disturbances", "start": 2, "end": 14}, {"entity_id": "937377_1_Ent3", "role": "Treatment", "text": "also receiving barbiturates ,", "start": 21, "end": 25}, {"entity_id": "937377_1_Ent4", "role": "Treatment_Drug", "text": "barbiturates", "start": 23, "end": 24}, {"entity_id": "937377_1_Ent6", "role": "Combination_Drug", "text": "barbiturates", "start": 23, "end": 24}, {"entity_id": "937377_1_Ent1", "role": "Effect", "text": "additive CNS effects", "start": 26, "end": 29}]}], "entity_mentions": [{"id": "937377_1_Ent2", "text": "reserpine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "937377_1_Ent5", "text": "reserpine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "937377_1_Ent7", "text": "reserpine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "937377_1_Ent0", "text": "reserpine toxicity , in particular central nervous system ( CNS ) disturbances", "entity_type": "Entity", "start": 2, "end": 14}, {"id": "937377_1_Ent3", "text": "also receiving barbiturates ,", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "937377_1_Ent4", "text": "barbiturates", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "937377_1_Ent6", "text": "barbiturates", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "937377_1_Ent1", "text": "additive CNS effects", "entity_type": "Entity", "start": 26, "end": 29}], "lang": "en"}
{"doc_id": "9399776_1", "wnd_id": "9399776_1_1", "text": "Acute pancreatitis after long - term 5 - aminosalicylic acid therapy .", "tokens": ["Acute", "pancreatitis", "after", "long", "-", "term", "5", "-", "aminosalicylic", "acid", "therapy", "."], "event_mentions": [{"id": "9399776_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "9399776_1_Ent0", "role": "Effect", "text": "Acute pancreatitis", "start": 0, "end": 2}, {"entity_id": "9399776_1_Ent3", "role": "Treatment_Time_elapsed", "text": "long - term", "start": 3, "end": 6}, {"entity_id": "9399776_1_Ent1", "role": "Treatment", "text": "long - term 5 - aminosalicylic acid therapy", "start": 3, "end": 11}, {"entity_id": "9399776_1_Ent2", "role": "Treatment_Drug", "text": "5 - aminosalicylic acid", "start": 6, "end": 10}]}], "entity_mentions": [{"id": "9399776_1_Ent0", "text": "Acute pancreatitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9399776_1_Ent3", "text": "long - term", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "9399776_1_Ent1", "text": "long - term 5 - aminosalicylic acid therapy", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "9399776_1_Ent2", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 6, "end": 10}], "lang": "en"}
{"doc_id": "9399776_3", "wnd_id": "9399776_3_1", "text": "A rechallenge , performed in both patients , confirmed the diagnosis of mesalamine - induced pancreatitis .", "tokens": ["A", "rechallenge", ",", "performed", "in", "both", "patients", ",", "confirmed", "the", "diagnosis", "of", "mesalamine", "-", "induced", "pancreatitis", "."], "event_mentions": [{"id": "9399776_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "9399776_3_Ent0", "role": "Subject", "text": "both patients", "start": 5, "end": 7}, {"entity_id": "9399776_3_Ent2", "role": "Treatment", "text": "mesalamine", "start": 12, "end": 13}, {"entity_id": "9399776_3_Ent3", "role": "Treatment_Drug", "text": "mesalamine", "start": 12, "end": 13}, {"entity_id": "9399776_3_Ent1", "role": "Effect", "text": "pancreatitis", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "9399776_3_Ent0", "text": "both patients", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "9399776_3_Ent2", "text": "mesalamine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9399776_3_Ent3", "text": "mesalamine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9399776_3_Ent1", "text": "pancreatitis", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "9403220_2", "wnd_id": "9403220_2_1", "text": "Acute renal failure with severe tubulointerstitial changes in a patient with minimal change nephrotic syndrome treated with enalapril .", "tokens": ["Acute", "renal", "failure", "with", "severe", "tubulointerstitial", "changes", "in", "a", "patient", "with", "minimal", "change", "nephrotic", "syndrome", "treated", "with", "enalapril", "."], "event_mentions": [{"id": "9403220_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 7, "end": 8}, "arguments": [{"entity_id": "9403220_2_Ent1", "role": "Effect", "text": "Acute renal failure with severe tubulointerstitial changes", "start": 0, "end": 7}, {"entity_id": "9403220_2_Ent0", "role": "Subject", "text": "a patient with minimal change nephrotic syndrome", "start": 8, "end": 15}, {"entity_id": "9403220_2_Ent4", "role": "Treatment_Disorder", "text": "minimal change nephrotic syndrome", "start": 11, "end": 15}, {"entity_id": "9403220_2_Ent2", "role": "Treatment", "text": "enalapril", "start": 17, "end": 18}, {"entity_id": "9403220_2_Ent3", "role": "Treatment_Drug", "text": "enalapril", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "9403220_2_Ent1", "text": "Acute renal failure with severe tubulointerstitial changes", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "9403220_2_Ent0", "text": "a patient with minimal change nephrotic syndrome", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "9403220_2_Ent4", "text": "minimal change nephrotic syndrome", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "9403220_2_Ent2", "text": "enalapril", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "9403220_2_Ent3", "text": "enalapril", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "946400_3", "wnd_id": "946400_3_1", "text": "Such a rapid and relentless progression of methyldopa - induced liver injury is undoubtedly rare , but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy .", "tokens": ["Such", "a", "rapid", "and", "relentless", "progression", "of", "methyldopa", "-", "induced", "liver", "injury", "is", "undoubtedly", "rare", ",", "but", "it", "may", "be", "prevented", "by", "careful", "supervision", "of", "patients", "who", "exhibit", "liver", "function", "abnormalities", "early", "in", "the", "course", "of", "therapy", "."], "event_mentions": [{"id": "946400_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "946400_3_Ent1", "role": "Treatment", "text": "methyldopa", "start": 7, "end": 8}, {"entity_id": "946400_3_Ent2", "role": "Treatment_Drug", "text": "methyldopa", "start": 7, "end": 8}, {"entity_id": "946400_3_Ent0", "role": "Effect", "text": "liver injury", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "946400_3_Ent1", "text": "methyldopa", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "946400_3_Ent2", "text": "methyldopa", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "946400_3_Ent0", "text": "liver injury", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "9476721_1", "wnd_id": "9476721_1_1", "text": "Acute dystonia with thalamic and brainstem lesions after initial penicillamine treatment in Wilson 's disease .", "tokens": ["Acute", "dystonia", "with", "thalamic", "and", "brainstem", "lesions", "after", "initial", "penicillamine", "treatment", "in", "Wilson", "'s", "disease", "."], "event_mentions": [{"id": "9476721_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "9476721_1_Ent0", "role": "Effect", "text": "Acute dystonia with thalamic and brainstem lesions", "start": 0, "end": 7}, {"entity_id": "9476721_1_Ent1", "role": "Treatment", "text": "penicillamine", "start": 9, "end": 10}, {"entity_id": "9476721_1_Ent2", "role": "Treatment_Drug", "text": "penicillamine", "start": 9, "end": 10}, {"entity_id": "9476721_1_Ent3", "role": "Treatment_Disorder", "text": "Wilson 's disease", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "9476721_1_Ent0", "text": "Acute dystonia with thalamic and brainstem lesions", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "9476721_1_Ent1", "text": "penicillamine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9476721_1_Ent2", "text": "penicillamine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9476721_1_Ent3", "text": "Wilson 's disease", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "9491301_1", "wnd_id": "9491301_1_1", "text": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose : report of two cases .", "tokens": ["Ballistic", "movements", "due", "to", "ischemic", "infarcts", "after", "intravenous", "heroin", "overdose", ":", "report", "of", "two", "cases", "."], "event_mentions": [{"id": "9491301_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "9491301_1_Ent2", "role": "Effect", "text": "Ballistic movements due to ischemic infarcts", "start": 0, "end": 6}, {"entity_id": "9491301_1_Ent3", "role": "Treatment", "text": "intravenous heroin overdose", "start": 7, "end": 10}, {"entity_id": "9491301_1_Ent4", "role": "Treatment_Drug", "text": "heroin", "start": 8, "end": 9}, {"entity_id": "9491301_1_Ent1", "role": "Subject_Population", "text": "two", "start": 13, "end": 14}, {"entity_id": "9491301_1_Ent0", "role": "Subject", "text": "two cases", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "9491301_1_Ent2", "text": "Ballistic movements due to ischemic infarcts", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "9491301_1_Ent3", "text": "intravenous heroin overdose", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "9491301_1_Ent4", "text": "heroin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9491301_1_Ent1", "text": "two", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9491301_1_Ent0", "text": "two cases", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "9494448_4", "wnd_id": "9494448_4_1", "text": "CONCLUSIONS : Hypersensitivity reactions to cyclosporine are due to Cremophor EL .", "tokens": ["CONCLUSIONS", ":", "Hypersensitivity", "reactions", "to", "cyclosporine", "are", "due", "to", "Cremophor", "EL", "."], "event_mentions": [{"id": "9494448_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 7, "end": 8}, "arguments": [{"entity_id": "9494448_4_Ent0", "role": "Effect", "text": "Hypersensitivity reactions to cyclosporine", "start": 2, "end": 6}, {"entity_id": "9494448_4_Ent1", "role": "Treatment", "text": "Cremophor EL", "start": 9, "end": 11}, {"entity_id": "9494448_4_Ent2", "role": "Treatment_Drug", "text": "Cremophor EL", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "9494448_4_Ent0", "text": "Hypersensitivity reactions to cyclosporine", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "9494448_4_Ent1", "text": "Cremophor EL", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9494448_4_Ent2", "text": "Cremophor EL", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "9517515_2", "wnd_id": "9517515_2_1", "text": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa .", "tokens": ["Second", "cancers", "including", "various", "types", "of", "hematological", "malignancy", "have", "been", "reported", "in", "patients", "with", "hairy", "cell", "leukemia", "treated", "with", "chemotherapy", "or", "interferon", "alfa", "."], "event_mentions": [{"id": "9517515_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 10, "end": 11}, "arguments": [{"entity_id": "9517515_2_Ent1", "role": "Effect", "text": "Second cancers including various types of hematological malignancy", "start": 0, "end": 8}, {"entity_id": "9517515_2_Ent0", "role": "Subject", "text": "patients with hairy cell leukemia", "start": 12, "end": 17}, {"entity_id": "9517515_2_Ent3", "role": "Treatment_Disorder", "text": "hairy cell leukemia", "start": 14, "end": 17}, {"entity_id": "9517515_2_Ent5", "role": "Treatment_Route", "text": "chemotherapy", "start": 19, "end": 20}, {"entity_id": "9517515_2_Ent2", "role": "Treatment", "text": "chemotherapy or interferon alfa", "start": 19, "end": 23}, {"entity_id": "9517515_2_Ent4", "role": "Treatment_Drug", "text": "interferon alfa", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "9517515_2_Ent1", "text": "Second cancers including various types of hematological malignancy", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "9517515_2_Ent0", "text": "patients with hairy cell leukemia", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "9517515_2_Ent3", "text": "hairy cell leukemia", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "9517515_2_Ent5", "text": "chemotherapy", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9517515_2_Ent2", "text": "chemotherapy or interferon alfa", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "9517515_2_Ent4", "text": "interferon alfa", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "9545161_1", "wnd_id": "9545161_1_1", "text": "A 54 - year - old man developed TEN 4 weeks after beginning lamotrigine for complex partial seizures related to a glioblastoma multiforme brain tumor .", "tokens": ["A", "54", "-", "year", "-", "old", "man", "developed", "TEN", "4", "weeks", "after", "beginning", "lamotrigine", "for", "complex", "partial", "seizures", "related", "to", "a", "glioblastoma", "multiforme", "brain", "tumor", "."], "event_mentions": [{"id": "9545161_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "9545161_1_Ent0", "role": "Subject", "text": "A 54 - year - old man", "start": 0, "end": 7}, {"entity_id": "9545161_1_Ent2", "role": "Subject_Age", "text": "54 - year - old", "start": 1, "end": 6}, {"entity_id": "9545161_1_Ent3", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "9545161_1_Ent5", "role": "Effect", "text": "TEN", "start": 8, "end": 9}, {"entity_id": "9545161_1_Ent7", "role": "Treatment_Time_elapsed", "text": "4 weeks", "start": 9, "end": 11}, {"entity_id": "9545161_1_Ent6", "role": "Treatment", "text": "4 weeks after beginning lamotrigine", "start": 9, "end": 14}, {"entity_id": "9545161_1_Ent8", "role": "Treatment_Drug", "text": "lamotrigine", "start": 13, "end": 14}, {"entity_id": "9545161_1_Ent9", "role": "Treatment_Disorder", "text": "complex partial seizures", "start": 15, "end": 18}, {"entity_id": "9545161_1_Ent1", "role": "Subject", "text": "complex partial seizures related to a glioblastoma multiforme brain tumor", "start": 15, "end": 25}, {"entity_id": "9545161_1_Ent4", "role": "Subject_Disorder", "text": "glioblastoma multiforme brain tumor", "start": 21, "end": 25}]}], "entity_mentions": [{"id": "9545161_1_Ent0", "text": "A 54 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "9545161_1_Ent2", "text": "54 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "9545161_1_Ent3", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9545161_1_Ent5", "text": "TEN", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9545161_1_Ent7", "text": "4 weeks", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9545161_1_Ent6", "text": "4 weeks after beginning lamotrigine", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "9545161_1_Ent8", "text": "lamotrigine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9545161_1_Ent9", "text": "complex partial seizures", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "9545161_1_Ent1", "text": "complex partial seizures related to a glioblastoma multiforme brain tumor", "entity_type": "Entity", "start": 15, "end": 25}, {"id": "9545161_1_Ent4", "text": "glioblastoma multiforme brain tumor", "entity_type": "Entity", "start": 21, "end": 25}], "lang": "en"}
{"doc_id": "9550246_4", "wnd_id": "9550246_4_1", "text": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients , especially those with anxiety , may have difficulty managing the increase .", "tokens": ["The", "authors", "suggest", "that", "risperidone", "may", "increase", "affect", "in", "patients", "with", "schizophrenia", "and", "that", "some", "patients", ",", "especially", "those", "with", "anxiety", ",", "may", "have", "difficulty", "managing", "the", "increase", "."], "event_mentions": [{"id": "9550246_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increase", "start": 6, "end": 7}, "arguments": [{"entity_id": "9550246_4_Ent2", "role": "Treatment", "text": "risperidone", "start": 4, "end": 5}, {"entity_id": "9550246_4_Ent3", "role": "Treatment_Drug", "text": "risperidone", "start": 4, "end": 5}, {"entity_id": "9550246_4_Ent1", "role": "Effect", "text": "increase affect", "start": 6, "end": 8}, {"entity_id": "9550246_4_Ent0", "role": "Subject", "text": "patients with schizophrenia", "start": 9, "end": 12}, {"entity_id": "9550246_4_Ent4", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9550246_4_Ent2", "text": "risperidone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9550246_4_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9550246_4_Ent1", "text": "increase affect", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9550246_4_Ent0", "text": "patients with schizophrenia", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "9550246_4_Ent4", "text": "schizophrenia", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "9619226_1", "wnd_id": "9619226_1_1", "text": "Cardiac arrest associated with sulprostone use during caesarean section .", "tokens": ["Cardiac", "arrest", "associated", "with", "sulprostone", "use", "during", "caesarean", "section", "."], "event_mentions": [{"id": "9619226_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "9619226_1_Ent0", "role": "Effect", "text": "Cardiac arrest", "start": 0, "end": 2}, {"entity_id": "9619226_1_Ent1", "role": "Treatment", "text": "sulprostone", "start": 4, "end": 5}, {"entity_id": "9619226_1_Ent2", "role": "Treatment_Drug", "text": "sulprostone", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "9619226_1_Ent0", "text": "Cardiac arrest", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9619226_1_Ent1", "text": "sulprostone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9619226_1_Ent2", "text": "sulprostone", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "9634122_1", "wnd_id": "9634122_1_1", "text": "Flutamide withdrawal syndrome is characterized by a decrease in prostate - specific antigen ( PSA ) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate .", "tokens": ["Flutamide", "withdrawal", "syndrome", "is", "characterized", "by", "a", "decrease", "in", "prostate", "-", "specific", "antigen", "(", "PSA", ")", "after", "flutamide", "withdrawal", "in", "a", "subset", "of", "patients", "with", "progressing", "metastatic", "carcinoma", "of", "the", "prostate", "."], "event_mentions": [{"id": "9634122_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "withdrawal", "start": 18, "end": 19}, "arguments": [{"entity_id": "9634122_1_Ent1", "role": "Effect", "text": "decrease in prostate - specific antigen ( PSA )", "start": 7, "end": 16}, {"entity_id": "9634122_1_Ent2", "role": "Treatment", "text": "flutamide", "start": 17, "end": 18}, {"entity_id": "9634122_1_Ent4", "role": "Treatment_Drug", "text": "flutamide", "start": 17, "end": 18}, {"entity_id": "9634122_1_Ent0", "role": "Subject", "text": "subset of patients with progressing metastatic carcinoma of the prostate", "start": 21, "end": 31}, {"entity_id": "9634122_1_Ent3", "role": "Treatment_Disorder", "text": "progressing metastatic carcinoma of the prostate", "start": 25, "end": 31}]}], "entity_mentions": [{"id": "9634122_1_Ent1", "text": "decrease in prostate - specific antigen ( PSA )", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "9634122_1_Ent2", "text": "flutamide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "9634122_1_Ent4", "text": "flutamide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "9634122_1_Ent0", "text": "subset of patients with progressing metastatic carcinoma of the prostate", "entity_type": "Entity", "start": 21, "end": 31}, {"id": "9634122_1_Ent3", "text": "progressing metastatic carcinoma of the prostate", "entity_type": "Entity", "start": 25, "end": 31}], "lang": "en"}
{"doc_id": "9651465_1", "wnd_id": "9651465_1_1", "text": "METHODS : Double - blind , placebo - controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1.5 hours after challenges with Viokase and Pancrease MT 16 , but not with placebo .", "tokens": ["METHODS", ":", "Double", "-", "blind", ",", "placebo", "-", "controlled", "titrated", "oral", "challenges", "with", "pancreatic", "enzymes", "resulted", "in", "definite", "vomiting", "within", "1", "to", "1.5", "hours", "after", "challenges", "with", "Viokase", "and", "Pancrease", "MT", "16", ",", "but", "not", "with", "placebo", "."], "event_mentions": [{"id": "9651465_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted in", "start": 15, "end": 17}, "arguments": [{"entity_id": "9651465_1_Ent0", "role": "Effect", "text": "vomiting", "start": 18, "end": 19}, {"entity_id": "9651465_1_Ent2", "role": "Treatment_Drug", "text": "Viokase", "start": 27, "end": 28}, {"entity_id": "9651465_1_Ent4", "role": "Combination_Drug", "text": "Viokase", "start": 27, "end": 28}, {"entity_id": "9651465_1_Ent1", "role": "Treatment", "text": "Viokase and Pancrease MT 16", "start": 27, "end": 32}, {"entity_id": "9651465_1_Ent3", "role": "Treatment_Drug", "text": "Pancrease MT 16", "start": 29, "end": 32}, {"entity_id": "9651465_1_Ent5", "role": "Combination_Drug", "text": "Pancrease MT 16", "start": 29, "end": 32}]}], "entity_mentions": [{"id": "9651465_1_Ent0", "text": "vomiting", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9651465_1_Ent2", "text": "Viokase", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "9651465_1_Ent4", "text": "Viokase", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "9651465_1_Ent1", "text": "Viokase and Pancrease MT 16", "entity_type": "Entity", "start": 27, "end": 32}, {"id": "9651465_1_Ent3", "text": "Pancrease MT 16", "entity_type": "Entity", "start": 29, "end": 32}, {"id": "9651465_1_Ent5", "text": "Pancrease MT 16", "entity_type": "Entity", "start": 29, "end": 32}], "lang": "en"}
{"doc_id": "9653495_15", "wnd_id": "9653495_15_1", "text": "In the absence of an ideal dose - intense FU monotherapy regimen , monthly FU with low - dose LV provides a simple and economical means by which to achieve adequate FU efficacy in the treatment of advanced colorectal cancer .", "tokens": ["In", "the", "absence", "of", "an", "ideal", "dose", "-", "intense", "FU", "monotherapy", "regimen", ",", "monthly", "FU", "with", "low", "-", "dose", "LV", "provides", "a", "simple", "and", "economical", "means", "by", "which", "to", "achieve", "adequate", "FU", "efficacy", "in", "the", "treatment", "of", "advanced", "colorectal", "cancer", "."], "event_mentions": [{"id": "9653495_15_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 35, "end": 36}, "arguments": [{"entity_id": "9653495_15_Ent2", "role": "Treatment_Freq", "text": "monthly", "start": 13, "end": 14}, {"entity_id": "9653495_15_Ent0", "role": "Treatment", "text": "monthly FU with low - dose LV", "start": 13, "end": 20}, {"entity_id": "9653495_15_Ent3", "role": "Treatment_Drug", "text": "FU", "start": 14, "end": 15}, {"entity_id": "9653495_15_Ent6", "role": "Combination_Drug", "text": "FU", "start": 14, "end": 15}, {"entity_id": "9653495_15_Ent5", "role": "Treatment_Dosage", "text": "low - dose", "start": 16, "end": 19}, {"entity_id": "9653495_15_Ent4", "role": "Treatment_Drug", "text": "LV", "start": 19, "end": 20}, {"entity_id": "9653495_15_Ent7", "role": "Combination_Drug", "text": "LV", "start": 19, "end": 20}, {"entity_id": "9653495_15_Ent1", "role": "Treatment_Disorder", "text": "advanced colorectal cancer", "start": 37, "end": 40}]}], "entity_mentions": [{"id": "9653495_15_Ent2", "text": "monthly", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9653495_15_Ent0", "text": "monthly FU with low - dose LV", "entity_type": "Entity", "start": 13, "end": 20}, {"id": "9653495_15_Ent3", "text": "FU", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "9653495_15_Ent6", "text": "FU", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "9653495_15_Ent5", "text": "low - dose", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "9653495_15_Ent4", "text": "LV", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9653495_15_Ent7", "text": "LV", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9653495_15_Ent1", "text": "advanced colorectal cancer", "entity_type": "Entity", "start": 37, "end": 40}], "lang": "en"}
{"doc_id": "9660541_3", "wnd_id": "9660541_3_1", "text": "We report a case of MMC - related hemolytic uremic syndrome , and discuss the etiologic parameters , clinical aspects , prognosis and treatment modalities of this severe syndrome .", "tokens": ["We", "report", "a", "case", "of", "MMC", "-", "related", "hemolytic", "uremic", "syndrome", ",", "and", "discuss", "the", "etiologic", "parameters", ",", "clinical", "aspects", ",", "prognosis", "and", "treatment", "modalities", "of", "this", "severe", "syndrome", "."], "event_mentions": [{"id": "9660541_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 7, "end": 8}, "arguments": [{"entity_id": "9660541_3_Ent1", "role": "Treatment", "text": "MMC", "start": 5, "end": 6}, {"entity_id": "9660541_3_Ent2", "role": "Treatment_Drug", "text": "MMC", "start": 5, "end": 6}, {"entity_id": "9660541_3_Ent0", "role": "Effect", "text": "hemolytic uremic syndrome", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "9660541_3_Ent1", "text": "MMC", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9660541_3_Ent2", "text": "MMC", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9660541_3_Ent0", "text": "hemolytic uremic syndrome", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "9681092_1", "wnd_id": "9681092_1_1", "text": "Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction .", "tokens": ["Torsade", "de", "pointes", "resulting", "from", "the", "addition", "of", "droperidol", "to", "an", "existing", "cytochrome", "P450", "drug", "interaction", "."], "event_mentions": [{"id": "9681092_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 3, "end": 4}, "arguments": [{"entity_id": "9681092_1_Ent0", "role": "Effect", "text": "Torsade de pointes", "start": 0, "end": 3}, {"entity_id": "9681092_1_Ent1", "role": "Treatment", "text": "droperidol", "start": 8, "end": 9}, {"entity_id": "9681092_1_Ent3", "role": "Treatment_Drug", "text": "droperidol", "start": 8, "end": 9}, {"entity_id": "9681092_1_Ent2", "role": "Treatment", "text": "cytochrome P450", "start": 12, "end": 14}, {"entity_id": "9681092_1_Ent4", "role": "Treatment_Drug", "text": "cytochrome P450", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "9681092_1_Ent0", "text": "Torsade de pointes", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9681092_1_Ent1", "text": "droperidol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9681092_1_Ent3", "text": "droperidol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9681092_1_Ent2", "text": "cytochrome P450", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "9681092_1_Ent4", "text": "cytochrome P450", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "9681092_13", "wnd_id": "9681092_13_1", "text": "Clinicians should be aware of the dysrhythmic potential of cyclobenzaprine and fluoxetine , monitor for other cytochrome P450 inhibitors , and avoid concomitant drugs known to prolong the QT interval .", "tokens": ["Clinicians", "should", "be", "aware", "of", "the", "dysrhythmic", "potential", "of", "cyclobenzaprine", "and", "fluoxetine", ",", "monitor", "for", "other", "cytochrome", "P450", "inhibitors", ",", "and", "avoid", "concomitant", "drugs", "known", "to", "prolong", "the", "QT", "interval", "."], "event_mentions": [{"id": "9681092_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "potential", "start": 7, "end": 8}, "arguments": [{"entity_id": "9681092_13_Ent0", "role": "Effect", "text": "dysrhythmic", "start": 6, "end": 7}, {"entity_id": "9681092_13_Ent2", "role": "Treatment_Drug", "text": "cyclobenzaprine", "start": 9, "end": 10}, {"entity_id": "9681092_13_Ent4", "role": "Combination_Drug", "text": "cyclobenzaprine", "start": 9, "end": 10}, {"entity_id": "9681092_13_Ent1", "role": "Treatment", "text": "cyclobenzaprine and fluoxetine", "start": 9, "end": 12}, {"entity_id": "9681092_13_Ent3", "role": "Treatment_Drug", "text": "fluoxetine", "start": 11, "end": 12}, {"entity_id": "9681092_13_Ent5", "role": "Combination_Drug", "text": "fluoxetine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9681092_13_Ent0", "text": "dysrhythmic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9681092_13_Ent2", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9681092_13_Ent4", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9681092_13_Ent1", "text": "cyclobenzaprine and fluoxetine", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "9681092_13_Ent3", "text": "fluoxetine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9681092_13_Ent5", "text": "fluoxetine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "968449_2", "wnd_id": "968449_2_1", "text": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera ( PV ) at the time of diagnosis and several times subsequently during therapy with chlorambucil .", "tokens": ["Bone", "marrow", "chromosomes", "were", "studied", "in", "2", "patients", "with", "polycythaemia", "vera", "(", "PV", ")", "at", "the", "time", "of", "diagnosis", "and", "several", "times", "subsequently", "during", "therapy", "with", "chlorambucil", "."], "event_mentions": [{"id": "968449_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "therapy", "start": 24, "end": 25}, "arguments": [{"entity_id": "968449_2_Ent1", "role": "Subject_Population", "text": "2", "start": 6, "end": 7}, {"entity_id": "968449_2_Ent0", "role": "Subject", "text": "2 patients with polycythaemia vera ( PV )", "start": 6, "end": 14}, {"entity_id": "968449_2_Ent3", "role": "Treatment_Disorder", "text": "polycythaemia vera ( PV )", "start": 9, "end": 14}, {"entity_id": "968449_2_Ent2", "role": "Treatment", "text": "chlorambucil", "start": 26, "end": 27}, {"entity_id": "968449_2_Ent4", "role": "Treatment_Drug", "text": "chlorambucil", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "968449_2_Ent1", "text": "2", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "968449_2_Ent0", "text": "2 patients with polycythaemia vera ( PV )", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "968449_2_Ent3", "text": "polycythaemia vera ( PV )", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "968449_2_Ent2", "text": "chlorambucil", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "968449_2_Ent4", "text": "chlorambucil", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "9695308_4", "wnd_id": "9695308_4_1", "text": "It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA .", "tokens": ["It", "was", "concluded", "that", "ANCA", "is", "closely", "related", "to", "the", "pathogenesis", "of", "crescentic", "glomerulonephritis", "and", "that", "treatment", "with", "PTU", "appeared", "to", "induce", "ANCA", "."], "event_mentions": [{"id": "9695308_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 21, "end": 22}, "arguments": [{"entity_id": "9695308_4_Ent1", "role": "Treatment", "text": "PTU", "start": 18, "end": 19}, {"entity_id": "9695308_4_Ent2", "role": "Treatment_Drug", "text": "PTU", "start": 18, "end": 19}, {"entity_id": "9695308_4_Ent0", "role": "Effect", "text": "ANCA", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "9695308_4_Ent1", "text": "PTU", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9695308_4_Ent2", "text": "PTU", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9695308_4_Ent0", "text": "ANCA", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "9701106_4", "wnd_id": "9701106_4_1", "text": "Recently , her serum theophylline levels had increased to the toxic range ( 133.2 micromol / L [ 24 microg / mL ] ) shortly after the addition of zafirlukast ( Accolate , Zeneca Pharmaceuticals , Wilmington , Del ) to her regimen .", "tokens": ["Recently", ",", "her", "serum", "theophylline", "levels", "had", "increased", "to", "the", "toxic", "range", "(", "133.2", "micromol", "/", "L", "[", "24", "microg", "/", "mL", "]", ")", "shortly", "after", "the", "addition", "of", "zafirlukast", "(", "Accolate", ",", "Zeneca", "Pharmaceuticals", ",", "Wilmington", ",", "Del", ")", "to", "her", "regimen", "."], "event_mentions": [{"id": "9701106_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 25, "end": 26}, "arguments": [{"entity_id": "9701106_4_Ent0", "role": "Subject", "text": "her", "start": 2, "end": 3}, {"entity_id": "9701106_4_Ent1", "role": "Subject_Gender", "text": "her", "start": 2, "end": 3}, {"entity_id": "9701106_4_Ent2", "role": "Effect", "text": "theophylline levels had increased to the toxic range", "start": 4, "end": 12}, {"entity_id": "9701106_4_Ent3", "role": "Treatment", "text": "zafirlukast", "start": 29, "end": 30}, {"entity_id": "9701106_4_Ent4", "role": "Treatment_Drug", "text": "zafirlukast", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "9701106_4_Ent0", "text": "her", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9701106_4_Ent1", "text": "her", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9701106_4_Ent2", "text": "theophylline levels had increased to the toxic range", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "9701106_4_Ent3", "text": "zafirlukast", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "9701106_4_Ent4", "text": "zafirlukast", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "9704170_1", "wnd_id": "9704170_1_1", "text": "A 21 - year - old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug - resistant schizophrenia .", "tokens": ["A", "21", "-", "year", "-", "old", "patient", "developed", "rhabdomyolysis", "during", "his", "nineteenth", "week", "of", "treatment", "with", "clozapine", "for", "drug", "-", "resistant", "schizophrenia", "."], "event_mentions": [{"id": "9704170_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "9704170_1_Ent0", "role": "Subject", "text": "A 21 - year - old patient", "start": 0, "end": 7}, {"entity_id": "9704170_1_Ent1", "role": "Subject_Age", "text": "21 - year - old", "start": 1, "end": 6}, {"entity_id": "9704170_1_Ent2", "role": "Effect", "text": "rhabdomyolysis", "start": 8, "end": 9}, {"entity_id": "9704170_1_Ent6", "role": "Treatment_Time_elapsed", "text": "during his nineteenth week", "start": 9, "end": 13}, {"entity_id": "9704170_1_Ent3", "role": "Treatment", "text": "during his nineteenth week of treatment with clozapine", "start": 9, "end": 17}, {"entity_id": "9704170_1_Ent5", "role": "Treatment_Drug", "text": "clozapine", "start": 16, "end": 17}, {"entity_id": "9704170_1_Ent4", "role": "Treatment_Disorder", "text": "drug - resistant schizophrenia", "start": 18, "end": 22}]}], "entity_mentions": [{"id": "9704170_1_Ent0", "text": "A 21 - year - old patient", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "9704170_1_Ent1", "text": "21 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "9704170_1_Ent2", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9704170_1_Ent6", "text": "during his nineteenth week", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "9704170_1_Ent3", "text": "during his nineteenth week of treatment with clozapine", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "9704170_1_Ent5", "text": "clozapine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9704170_1_Ent4", "text": "drug - resistant schizophrenia", "entity_type": "Entity", "start": 18, "end": 22}], "lang": "en"}
{"doc_id": "9719245_2", "wnd_id": "9719245_2_1", "text": "He developed fever , nausea , diarrhea , and malaise and stopped taking on the third day after commencing Pentasa .", "tokens": ["He", "developed", "fever", ",", "nausea", ",", "diarrhea", ",", "and", "malaise", "and", "stopped", "taking", "on", "the", "third", "day", "after", "commencing", "Pentasa", "."], "event_mentions": [{"id": "9719245_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 1, "end": 2}, "arguments": [{"entity_id": "9719245_2_Ent0", "role": "Subject", "text": "He", "start": 0, "end": 1}, {"entity_id": "9719245_2_Ent1", "role": "Subject_Gender", "text": "He", "start": 0, "end": 1}, {"entity_id": "9719245_2_Ent2", "role": "Effect", "text": "fever , nausea , diarrhea , and malaise", "start": 2, "end": 10}, {"entity_id": "9719245_2_Ent5", "role": "Treatment_Time_elapsed", "text": "third day", "start": 15, "end": 17}, {"entity_id": "9719245_2_Ent3", "role": "Treatment", "text": "Pentasa", "start": 19, "end": 20}, {"entity_id": "9719245_2_Ent4", "role": "Treatment_Drug", "text": "Pentasa", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "9719245_2_Ent0", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9719245_2_Ent1", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9719245_2_Ent2", "text": "fever , nausea , diarrhea , and malaise", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "9719245_2_Ent5", "text": "third day", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "9719245_2_Ent3", "text": "Pentasa", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9719245_2_Ent4", "text": "Pentasa", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "9719245_3", "wnd_id": "9719245_3_1", "text": "Pancytopenia associated with 5 - aminosalicylic acid use in a patient with Crohn 's disease .", "tokens": ["Pancytopenia", "associated", "with", "5", "-", "aminosalicylic", "acid", "use", "in", "a", "patient", "with", "Crohn", "'s", "disease", "."], "event_mentions": [{"id": "9719245_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "9719245_3_Ent1", "role": "Effect", "text": "Pancytopenia", "start": 0, "end": 1}, {"entity_id": "9719245_3_Ent2", "role": "Treatment", "text": "5 - aminosalicylic acid", "start": 3, "end": 7}, {"entity_id": "9719245_3_Ent4", "role": "Treatment_Drug", "text": "5 - aminosalicylic acid", "start": 3, "end": 7}, {"entity_id": "9719245_3_Ent0", "role": "Subject", "text": "a patient with Crohn 's disease", "start": 9, "end": 15}, {"entity_id": "9719245_3_Ent3", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "9719245_3_Ent1", "text": "Pancytopenia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9719245_3_Ent2", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "9719245_3_Ent4", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "9719245_3_Ent0", "text": "a patient with Crohn 's disease", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "9719245_3_Ent3", "text": "Crohn 's disease", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "9723127_3", "wnd_id": "9723127_3_1", "text": "Decreased plasma cortisol level during alprazolam treatment of panic disorder : a case report .", "tokens": ["Decreased", "plasma", "cortisol", "level", "during", "alprazolam", "treatment", "of", "panic", "disorder", ":", "a", "case", "report", "."], "event_mentions": [{"id": "9723127_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 4, "end": 5}, "arguments": [{"entity_id": "9723127_3_Ent0", "role": "Effect", "text": "Decreased plasma cortisol level", "start": 0, "end": 4}, {"entity_id": "9723127_3_Ent1", "role": "Treatment", "text": "alprazolam", "start": 5, "end": 6}, {"entity_id": "9723127_3_Ent2", "role": "Treatment_Drug", "text": "alprazolam", "start": 5, "end": 6}, {"entity_id": "9723127_3_Ent3", "role": "Treatment_Disorder", "text": "panic disorder", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "9723127_3_Ent0", "text": "Decreased plasma cortisol level", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "9723127_3_Ent1", "text": "alprazolam", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9723127_3_Ent2", "text": "alprazolam", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9723127_3_Ent3", "text": "panic disorder", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "9725786_1", "wnd_id": "9725786_1_1", "text": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess .", "tokens": ["We", "describe", "a", "renal", "transplant", "recipient", "maintained", "on", "cyclosporine", "and", "prednisone", "developing", "Nocardia", "Asteroides", "brain", "abscess", "."], "event_mentions": [{"id": "9725786_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developing", "start": 11, "end": 12}, "arguments": [{"entity_id": "9725786_1_Ent0", "role": "Subject", "text": "a renal transplant recipient", "start": 2, "end": 6}, {"entity_id": "9725786_1_Ent5", "role": "Treatment_Disorder", "text": "renal transplant recipient", "start": 3, "end": 6}, {"entity_id": "9725786_1_Ent2", "role": "Treatment", "text": "maintained on cyclosporine and prednisone", "start": 6, "end": 11}, {"entity_id": "9725786_1_Ent3", "role": "Treatment_Drug", "text": "cyclosporine", "start": 8, "end": 9}, {"entity_id": "9725786_1_Ent7", "role": "Combination_Drug", "text": "cyclosporine", "start": 8, "end": 9}, {"entity_id": "9725786_1_Ent4", "role": "Treatment_Drug", "text": "prednisone", "start": 10, "end": 11}, {"entity_id": "9725786_1_Ent6", "role": "Combination_Drug", "text": "prednisone", "start": 10, "end": 11}, {"entity_id": "9725786_1_Ent1", "role": "Effect", "text": "Nocardia Asteroides brain abscess", "start": 12, "end": 16}]}], "entity_mentions": [{"id": "9725786_1_Ent0", "text": "a renal transplant recipient", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "9725786_1_Ent5", "text": "renal transplant recipient", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "9725786_1_Ent2", "text": "maintained on cyclosporine and prednisone", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "9725786_1_Ent3", "text": "cyclosporine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9725786_1_Ent7", "text": "cyclosporine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9725786_1_Ent4", "text": "prednisone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9725786_1_Ent6", "text": "prednisone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9725786_1_Ent1", "text": "Nocardia Asteroides brain abscess", "entity_type": "Entity", "start": 12, "end": 16}], "lang": "en"}
{"doc_id": "9726762_1", "wnd_id": "9726762_1_1", "text": "Gemfibrozil - warfarin drug interaction resulting in profound hypoprothrombinemia .", "tokens": ["Gemfibrozil", "-", "warfarin", "drug", "interaction", "resulting", "in", "profound", "hypoprothrombinemia", "."], "event_mentions": [{"id": "9726762_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 5, "end": 6}, "arguments": [{"entity_id": "9726762_1_Ent3", "role": "Treatment_Drug", "text": "Gemfibrozil", "start": 0, "end": 1}, {"entity_id": "9726762_1_Ent4", "role": "Combination_Drug", "text": "Gemfibrozil", "start": 0, "end": 1}, {"entity_id": "9726762_1_Ent1", "role": "Treatment", "text": "Gemfibrozil - warfarin drug interaction", "start": 0, "end": 5}, {"entity_id": "9726762_1_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 2, "end": 3}, {"entity_id": "9726762_1_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 2, "end": 3}, {"entity_id": "9726762_1_Ent0", "role": "Effect", "text": "profound hypoprothrombinemia", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "9726762_1_Ent3", "text": "Gemfibrozil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9726762_1_Ent4", "text": "Gemfibrozil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9726762_1_Ent1", "text": "Gemfibrozil - warfarin drug interaction", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "9726762_1_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9726762_1_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9726762_1_Ent0", "text": "profound hypoprothrombinemia", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "9726762_2", "wnd_id": "9726762_2_1", "text": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil .", "tokens": ["The", "following", "describes", "a", "patient", "on", "a", "stable", "regimen", "of", "warfarin", "who", "developed", "severe", "hypoprothrombinemia", "and", "bleeding", "4", "weeks", "after", "starting", "gemfibrozil", "."], "event_mentions": [{"id": "9726762_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "9726762_2_Ent0", "role": "Subject", "text": "a patient", "start": 3, "end": 5}, {"entity_id": "9726762_2_Ent2", "role": "Treatment", "text": "on a stable regimen of warfarin", "start": 5, "end": 11}, {"entity_id": "9726762_2_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 10, "end": 11}, {"entity_id": "9726762_2_Ent1", "role": "Effect", "text": "hypoprothrombinemia and bleeding", "start": 14, "end": 17}, {"entity_id": "9726762_2_Ent6", "role": "Treatment_Time_elapsed", "text": "4 weeks", "start": 17, "end": 19}, {"entity_id": "9726762_2_Ent3", "role": "Treatment", "text": "4 weeks after starting gemfibrozil", "start": 17, "end": 22}, {"entity_id": "9726762_2_Ent5", "role": "Treatment_Drug", "text": "gemfibrozil", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "9726762_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9726762_2_Ent2", "text": "on a stable regimen of warfarin", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "9726762_2_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9726762_2_Ent1", "text": "hypoprothrombinemia and bleeding", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "9726762_2_Ent6", "text": "4 weeks", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "9726762_2_Ent3", "text": "4 weeks after starting gemfibrozil", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "9726762_2_Ent5", "text": "gemfibrozil", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "9737132_3", "wnd_id": "9737132_3_1", "text": "Pentazocine - induced fibrous myopathy and localized neuropathy .", "tokens": ["Pentazocine", "-", "induced", "fibrous", "myopathy", "and", "localized", "neuropathy", "."], "event_mentions": [{"id": "9737132_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9737132_3_Ent1", "role": "Treatment", "text": "Pentazocine", "start": 0, "end": 1}, {"entity_id": "9737132_3_Ent2", "role": "Treatment_Drug", "text": "Pentazocine", "start": 0, "end": 1}, {"entity_id": "9737132_3_Ent0", "role": "Effect", "text": "fibrous myopathy and localized neuropathy", "start": 3, "end": 8}]}], "entity_mentions": [{"id": "9737132_3_Ent1", "text": "Pentazocine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9737132_3_Ent2", "text": "Pentazocine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9737132_3_Ent0", "text": "fibrous myopathy and localized neuropathy", "entity_type": "Entity", "start": 3, "end": 8}], "lang": "en"}
{"doc_id": "9754850_2", "wnd_id": "9754850_2_1", "text": "Like other atypical neuroleptics olanzapine is considered to show a reduced prevalence of extrapyramidal side effects when compared to classical neuroleptic drugs .", "tokens": ["Like", "other", "atypical", "neuroleptics", "olanzapine", "is", "considered", "to", "show", "a", "reduced", "prevalence", "of", "extrapyramidal", "side", "effects", "when", "compared", "to", "classical", "neuroleptic", "drugs", "."], "event_mentions": [{"id": "9754850_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "show", "start": 8, "end": 9}, "arguments": [{"entity_id": "9754850_2_Ent1", "role": "Treatment", "text": "olanzapine", "start": 4, "end": 5}, {"entity_id": "9754850_2_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 4, "end": 5}, {"entity_id": "9754850_2_Ent0", "role": "Effect", "text": "reduced prevalence of extrapyramidal side effects", "start": 10, "end": 16}, {"entity_id": "9754850_2_Ent3", "role": "Treatment_Drug", "text": "neuroleptic drugs .", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "9754850_2_Ent1", "text": "olanzapine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9754850_2_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9754850_2_Ent0", "text": "reduced prevalence of extrapyramidal side effects", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "9754850_2_Ent3", "text": "neuroleptic drugs .", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "9758325_1", "wnd_id": "9758325_1_1", "text": "Seizures occurred in two patients with probable Alzheimer 's disease who were receiving long - term treatment with metrifonate , an irreversible acetylcholinesterase inhibitor .", "tokens": ["Seizures", "occurred", "in", "two", "patients", "with", "probable", "Alzheimer", "'s", "disease", "who", "were", "receiving", "long", "-", "term", "treatment", "with", "metrifonate", ",", "an", "irreversible", "acetylcholinesterase", "inhibitor", "."], "event_mentions": [{"id": "9758325_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 1, "end": 2}, "arguments": [{"entity_id": "9758325_1_Ent2", "role": "Effect", "text": "Seizures", "start": 0, "end": 1}, {"entity_id": "9758325_1_Ent1", "role": "Subject_Population", "text": "two", "start": 3, "end": 4}, {"entity_id": "9758325_1_Ent0", "role": "Subject", "text": "two patients with probable Alzheimer 's disease", "start": 3, "end": 10}, {"entity_id": "9758325_1_Ent4", "role": "Treatment_Disorder", "text": "Alzheimer 's disease", "start": 7, "end": 10}, {"entity_id": "9758325_1_Ent3", "role": "Treatment", "text": "long - term treatment with metrifonate", "start": 13, "end": 19}, {"entity_id": "9758325_1_Ent5", "role": "Treatment_Drug", "text": "metrifonate", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "9758325_1_Ent2", "text": "Seizures", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9758325_1_Ent1", "text": "two", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9758325_1_Ent0", "text": "two patients with probable Alzheimer 's disease", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "9758325_1_Ent4", "text": "Alzheimer 's disease", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "9758325_1_Ent3", "text": "long - term treatment with metrifonate", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "9758325_1_Ent5", "text": "metrifonate", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "9788533_1", "wnd_id": "9788533_1_1", "text": "Fatal multiple drug intoxication following acute sertraline use .", "tokens": ["Fatal", "multiple", "drug", "intoxication", "following", "acute", "sertraline", "use", "."], "event_mentions": [{"id": "9788533_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 4, "end": 5}, "arguments": [{"entity_id": "9788533_1_Ent0", "role": "Effect", "text": "multiple drug intoxication", "start": 1, "end": 4}, {"entity_id": "9788533_1_Ent1", "role": "Treatment", "text": "acute sertraline use", "start": 5, "end": 8}, {"entity_id": "9788533_1_Ent2", "role": "Treatment_Drug", "text": "sertraline", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "9788533_1_Ent0", "text": "multiple drug intoxication", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "9788533_1_Ent1", "text": "acute sertraline use", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "9788533_1_Ent2", "text": "sertraline", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "9792602_3", "wnd_id": "9792602_3_1", "text": "Within 6 months of pranlukast withdrawal , anemia resolved and urinary sediment and renal function normalized .", "tokens": ["Within", "6", "months", "of", "pranlukast", "withdrawal", ",", "anemia", "resolved", "and", "urinary", "sediment", "and", "renal", "function", "normalized", "."], "event_mentions": [{"id": "9792602_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "withdrawal", "start": 5, "end": 6}, "arguments": [{"entity_id": "9792602_3_Ent3", "role": "Treatment_Time_elapsed", "text": "6 months", "start": 1, "end": 3}, {"entity_id": "9792602_3_Ent1", "role": "Treatment", "text": "pranlukast", "start": 4, "end": 5}, {"entity_id": "9792602_3_Ent2", "role": "Treatment_Drug", "text": "pranlukast", "start": 4, "end": 5}, {"entity_id": "9792602_3_Ent4", "role": "Treatment_Disorder", "text": "anemia", "start": 7, "end": 8}, {"entity_id": "9792602_3_Ent0", "role": "Effect", "text": "anemia resolved and urinary sediment and renal function normalized", "start": 7, "end": 16}, {"entity_id": "9792602_3_Ent5", "role": "Treatment_Disorder", "text": "urinary sediment", "start": 10, "end": 12}, {"entity_id": "9792602_3_Ent6", "role": "Treatment_Disorder", "text": "renal function", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "9792602_3_Ent3", "text": "6 months", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "9792602_3_Ent1", "text": "pranlukast", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9792602_3_Ent2", "text": "pranlukast", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9792602_3_Ent4", "text": "anemia", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9792602_3_Ent0", "text": "anemia resolved and urinary sediment and renal function normalized", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "9792602_3_Ent5", "text": "urinary sediment", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "9792602_3_Ent6", "text": "renal function", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "9796135_1", "wnd_id": "9796135_1_1", "text": "A 65 - year - old woman with angina pectoris presented with syncope after sublingual ingestion of isosorbide dinitrate ( 5 mg ) .", "tokens": ["A", "65", "-", "year", "-", "old", "woman", "with", "angina", "pectoris", "presented", "with", "syncope", "after", "sublingual", "ingestion", "of", "isosorbide", "dinitrate", "(", "5", "mg", ")", "."], "event_mentions": [{"id": "9796135_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 10, "end": 11}, "arguments": [{"entity_id": "9796135_1_Ent0", "role": "Subject", "text": "A 65 - year - old woman with angina pectoris", "start": 0, "end": 10}, {"entity_id": "9796135_1_Ent1", "role": "Subject_Age", "text": "65 - year - old", "start": 1, "end": 6}, {"entity_id": "9796135_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "9796135_1_Ent5", "role": "Treatment_Disorder", "text": "angina pectoris", "start": 8, "end": 10}, {"entity_id": "9796135_1_Ent3", "role": "Effect", "text": "syncope", "start": 12, "end": 13}, {"entity_id": "9796135_1_Ent6", "role": "Treatment_Route", "text": "sublingual ingestion", "start": 14, "end": 16}, {"entity_id": "9796135_1_Ent4", "role": "Treatment", "text": "sublingual ingestion of isosorbide dinitrate ( 5 mg )", "start": 14, "end": 23}, {"entity_id": "9796135_1_Ent7", "role": "Treatment_Drug", "text": "isosorbide dinitrate", "start": 17, "end": 19}, {"entity_id": "9796135_1_Ent8", "role": "Treatment_Dosage", "text": "5 mg", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "9796135_1_Ent0", "text": "A 65 - year - old woman with angina pectoris", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "9796135_1_Ent1", "text": "65 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "9796135_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9796135_1_Ent5", "text": "angina pectoris", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9796135_1_Ent3", "text": "syncope", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9796135_1_Ent6", "text": "sublingual ingestion", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "9796135_1_Ent4", "text": "sublingual ingestion of isosorbide dinitrate ( 5 mg )", "entity_type": "Entity", "start": 14, "end": 23}, {"id": "9796135_1_Ent7", "text": "isosorbide dinitrate", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "9796135_1_Ent8", "text": "5 mg", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "9796135_2", "wnd_id": "9796135_2_1", "text": "Elderly patients for whom nitrate has been prescribed should be warned of the occurrence of hypotension , leading to unconsciousness .", "tokens": ["Elderly", "patients", "for", "whom", "nitrate", "has", "been", "prescribed", "should", "be", "warned", "of", "the", "occurrence", "of", "hypotension", ",", "leading", "to", "unconsciousness", "."], "event_mentions": [{"id": "9796135_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurrence", "start": 13, "end": 14}, "arguments": [{"entity_id": "9796135_2_Ent1", "role": "Subject_Age", "text": "Elderly", "start": 0, "end": 1}, {"entity_id": "9796135_2_Ent0", "role": "Subject", "text": "Elderly patients", "start": 0, "end": 2}, {"entity_id": "9796135_2_Ent4", "role": "Treatment", "text": "nitrate", "start": 4, "end": 5}, {"entity_id": "9796135_2_Ent5", "role": "Treatment_Drug", "text": "nitrate", "start": 4, "end": 5}, {"entity_id": "9796135_2_Ent2", "role": "Effect", "text": "hypotension", "start": 15, "end": 16}, {"entity_id": "9796135_2_Ent3", "role": "Effect", "text": "unconsciousness", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "9796135_2_Ent1", "text": "Elderly", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9796135_2_Ent0", "text": "Elderly patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9796135_2_Ent4", "text": "nitrate", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9796135_2_Ent5", "text": "nitrate", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9796135_2_Ent2", "text": "hypotension", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9796135_2_Ent3", "text": "unconsciousness", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "9796135_4", "wnd_id": "9796135_4_1", "text": "Syncope in a 65 - year - old woman after nitrate ingestion .", "tokens": ["Syncope", "in", "a", "65", "-", "year", "-", "old", "woman", "after", "nitrate", "ingestion", "."], "event_mentions": [{"id": "9796135_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 9, "end": 10}, "arguments": [{"entity_id": "9796135_4_Ent3", "role": "Effect", "text": "Syncope", "start": 0, "end": 1}, {"entity_id": "9796135_4_Ent0", "role": "Subject", "text": "a 65 - year - old woman", "start": 2, "end": 9}, {"entity_id": "9796135_4_Ent1", "role": "Subject_Age", "text": "65 - year - old", "start": 3, "end": 8}, {"entity_id": "9796135_4_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "9796135_4_Ent5", "role": "Treatment_Drug", "text": "nitrate", "start": 10, "end": 11}, {"entity_id": "9796135_4_Ent4", "role": "Treatment", "text": "nitrate ingestion", "start": 10, "end": 12}, {"entity_id": "9796135_4_Ent6", "role": "Treatment_Route", "text": "ingestion", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9796135_4_Ent3", "text": "Syncope", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9796135_4_Ent0", "text": "a 65 - year - old woman", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "9796135_4_Ent1", "text": "65 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "9796135_4_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9796135_4_Ent5", "text": "nitrate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9796135_4_Ent4", "text": "nitrate ingestion", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "9796135_4_Ent6", "text": "ingestion", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "9819544_1", "wnd_id": "9819544_1_1", "text": "Naproxen - associated sudden sensorineural hearing loss .", "tokens": ["Naproxen", "-", "associated", "sudden", "sensorineural", "hearing", "loss", "."], "event_mentions": [{"id": "9819544_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "9819544_1_Ent1", "role": "Treatment", "text": "Naproxen", "start": 0, "end": 1}, {"entity_id": "9819544_1_Ent2", "role": "Treatment_Drug", "text": "Naproxen", "start": 0, "end": 1}, {"entity_id": "9819544_1_Ent0", "role": "Effect", "text": "sudden sensorineural hearing loss", "start": 3, "end": 7}]}], "entity_mentions": [{"id": "9819544_1_Ent1", "text": "Naproxen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9819544_1_Ent2", "text": "Naproxen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9819544_1_Ent0", "text": "sudden sensorineural hearing loss", "entity_type": "Entity", "start": 3, "end": 7}], "lang": "en"}
{"doc_id": "9819544_3", "wnd_id": "9819544_3_1", "text": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID - related permanent sensorineural hearing loss .", "tokens": ["This", "article", "reports", "the", "case", "of", "an", "otherwise", "healthy", "patient", "who", "experienced", "permanent", "sensorineural", "hearing", "loss", "after", "a", "brief", "course", "of", "naproxen", "and", "reviews", "the", "literature", "on", "NSAID", "-", "related", "permanent", "sensorineural", "hearing", "loss", "."], "event_mentions": [{"id": "9819544_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "9819544_3_Ent0", "role": "Subject", "text": "an otherwise healthy patient", "start": 6, "end": 10}, {"entity_id": "9819544_3_Ent1", "role": "Effect", "text": "permanent sensorineural hearing loss", "start": 12, "end": 16}, {"entity_id": "9819544_3_Ent2", "role": "Treatment", "text": "a brief course of naproxen", "start": 17, "end": 22}, {"entity_id": "9819544_3_Ent4", "role": "Treatment_Duration", "text": "brief course", "start": 18, "end": 20}, {"entity_id": "9819544_3_Ent3", "role": "Treatment_Drug", "text": "naproxen", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "9819544_3_Ent0", "text": "an otherwise healthy patient", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "9819544_3_Ent1", "text": "permanent sensorineural hearing loss", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "9819544_3_Ent2", "text": "a brief course of naproxen", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "9819544_3_Ent4", "text": "brief course", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "9819544_3_Ent3", "text": "naproxen", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "9831311_1", "wnd_id": "9831311_1_1", "text": "Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and calcitriol are secondary hyperparathyroidism and vitamin D intoxication , potassium loss also should be kept in mind .", "tokens": ["Although", "major", "hazards", "of", "treatment", "of", "hypophosphatemic", "osteomalacia", "with", "phosphate", "and", "calcitriol", "are", "secondary", "hyperparathyroidism", "and", "vitamin", "D", "intoxication", ",", "potassium", "loss", "also", "should", "be", "kept", "in", "mind", "."], "event_mentions": [{"id": "9831311_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "major hazards", "start": 1, "end": 3}, "arguments": [{"entity_id": "9831311_1_Ent4", "role": "Treatment_Disorder", "text": "hypophosphatemic osteomalacia", "start": 6, "end": 8}, {"entity_id": "9831311_1_Ent1", "role": "Treatment", "text": "hypophosphatemic osteomalacia with phosphate and calcitriol", "start": 6, "end": 12}, {"entity_id": "9831311_1_Ent2", "role": "Treatment_Drug", "text": "phosphate", "start": 9, "end": 10}, {"entity_id": "9831311_1_Ent5", "role": "Combination_Drug", "text": "phosphate", "start": 9, "end": 10}, {"entity_id": "9831311_1_Ent3", "role": "Treatment_Drug", "text": "calcitriol", "start": 11, "end": 12}, {"entity_id": "9831311_1_Ent6", "role": "Combination_Drug", "text": "calcitriol", "start": 11, "end": 12}, {"entity_id": "9831311_1_Ent0", "role": "Effect", "text": "secondary hyperparathyroidism and vitamin D intoxication , potassium loss", "start": 13, "end": 22}]}], "entity_mentions": [{"id": "9831311_1_Ent4", "text": "hypophosphatemic osteomalacia", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9831311_1_Ent1", "text": "hypophosphatemic osteomalacia with phosphate and calcitriol", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "9831311_1_Ent2", "text": "phosphate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9831311_1_Ent5", "text": "phosphate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9831311_1_Ent3", "text": "calcitriol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9831311_1_Ent6", "text": "calcitriol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9831311_1_Ent0", "text": "secondary hyperparathyroidism and vitamin D intoxication , potassium loss", "entity_type": "Entity", "start": 13, "end": 22}], "lang": "en"}
{"doc_id": "9831311_4", "wnd_id": "9831311_4_1", "text": "Progressive hypokalemia developed during phosphate treatment .", "tokens": ["Progressive", "hypokalemia", "developed", "during", "phosphate", "treatment", "."], "event_mentions": [{"id": "9831311_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "9831311_4_Ent0", "role": "Effect", "text": "Progressive hypokalemia", "start": 0, "end": 2}, {"entity_id": "9831311_4_Ent1", "role": "Treatment", "text": "phosphate", "start": 4, "end": 5}, {"entity_id": "9831311_4_Ent2", "role": "Treatment_Drug", "text": "phosphate", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "9831311_4_Ent0", "text": "Progressive hypokalemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9831311_4_Ent1", "text": "phosphate", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9831311_4_Ent2", "text": "phosphate", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "9846036_4", "wnd_id": "9846036_4_1", "text": "Clozapine , an atypical antipsychotic , can be toxic at doses 4 times a moderate dose .", "tokens": ["Clozapine", ",", "an", "atypical", "antipsychotic", ",", "can", "be", "toxic", "at", "doses", "4", "times", "a", "moderate", "dose", "."], "event_mentions": [{"id": "9846036_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "be", "start": 7, "end": 8}, "arguments": [{"entity_id": "9846036_4_Ent2", "role": "Treatment", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "9846036_4_Ent4", "role": "Treatment_Drug", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "9846036_4_Ent0", "role": "Effect", "text": "toxic", "start": 8, "end": 9}, {"entity_id": "9846036_4_Ent1", "role": "Treatment", "text": "doses 4 times a moderate dose", "start": 10, "end": 16}, {"entity_id": "9846036_4_Ent3", "role": "Treatment_Dosage", "text": "4 times a moderate dose", "start": 11, "end": 16}]}], "entity_mentions": [{"id": "9846036_4_Ent2", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9846036_4_Ent4", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9846036_4_Ent0", "text": "toxic", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9846036_4_Ent1", "text": "doses 4 times a moderate dose", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "9846036_4_Ent3", "text": "4 times a moderate dose", "entity_type": "Entity", "start": 11, "end": 16}], "lang": "en"}
{"doc_id": "9846036_6", "wnd_id": "9846036_6_1", "text": "To date , only 1 death attributable to risperidone overdose has been reported .", "tokens": ["To", "date", ",", "only", "1", "death", "attributable", "to", "risperidone", "overdose", "has", "been", "reported", "."], "event_mentions": [{"id": "9846036_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "attributable", "start": 6, "end": 7}, "arguments": [{"entity_id": "9846036_6_Ent0", "role": "Subject", "text": "1", "start": 4, "end": 5}, {"entity_id": "9846036_6_Ent1", "role": "Subject_Population", "text": "1", "start": 4, "end": 5}, {"entity_id": "9846036_6_Ent2", "role": "Effect", "text": "death", "start": 5, "end": 6}, {"entity_id": "9846036_6_Ent4", "role": "Treatment_Drug", "text": "risperidone", "start": 8, "end": 9}, {"entity_id": "9846036_6_Ent3", "role": "Treatment", "text": "risperidone overdose", "start": 8, "end": 10}, {"entity_id": "9846036_6_Ent5", "role": "Treatment_Dosage", "text": "overdose", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "9846036_6_Ent0", "text": "1", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9846036_6_Ent1", "text": "1", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9846036_6_Ent2", "text": "death", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9846036_6_Ent4", "text": "risperidone", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9846036_6_Ent3", "text": "risperidone overdose", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9846036_6_Ent5", "text": "overdose", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "984862_1", "wnd_id": "984862_1_1", "text": "A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed postprandial hyperglycemia and glycosuria during a period of topical administration of a corticosteroid cream , halcinonide cream 0.1 % , under occlusion .", "tokens": ["A", "patient", "with", "psoriasis", "is", "described", "who", "had", "an", "abnormal", "response", "to", "the", "glucose", "tolerance", "test", "without", "other", "evidence", "of", "diabetes", "and", "then", "developed", "postprandial", "hyperglycemia", "and", "glycosuria", "during", "a", "period", "of", "topical", "administration", "of", "a", "corticosteroid", "cream", ",", "halcinonide", "cream", "0.1", "%", ",", "under", "occlusion", "."], "event_mentions": [{"id": "984862_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 23, "end": 24}, "arguments": [{"entity_id": "984862_1_Ent0", "role": "Subject", "text": "A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes", "start": 0, "end": 21}, {"entity_id": "984862_1_Ent4", "role": "Treatment_Disorder", "text": "psoriasis", "start": 3, "end": 4}, {"entity_id": "984862_1_Ent1", "role": "Subject_Disorder", "text": "an abnormal response to the glucose tolerance test without other evidence of diabetes", "start": 8, "end": 21}, {"entity_id": "984862_1_Ent2", "role": "Effect", "text": "postprandial hyperglycemia and glycosuria", "start": 24, "end": 28}, {"entity_id": "984862_1_Ent3", "role": "Treatment", "text": "a period of topical administration of a corticosteroid cream , halcinonide cream 0.1 % , under occlusion", "start": 29, "end": 46}, {"entity_id": "984862_1_Ent5", "role": "Treatment_Drug", "text": "halcinonide", "start": 39, "end": 40}, {"entity_id": "984862_1_Ent6", "role": "Treatment_Route", "text": "cream", "start": 40, "end": 41}]}], "entity_mentions": [{"id": "984862_1_Ent0", "text": "A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes", "entity_type": "Entity", "start": 0, "end": 21}, {"id": "984862_1_Ent4", "text": "psoriasis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "984862_1_Ent1", "text": "an abnormal response to the glucose tolerance test without other evidence of diabetes", "entity_type": "Entity", "start": 8, "end": 21}, {"id": "984862_1_Ent2", "text": "postprandial hyperglycemia and glycosuria", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "984862_1_Ent3", "text": "a period of topical administration of a corticosteroid cream , halcinonide cream 0.1 % , under occlusion", "entity_type": "Entity", "start": 29, "end": 46}, {"id": "984862_1_Ent5", "text": "halcinonide", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "984862_1_Ent6", "text": "cream", "entity_type": "Entity", "start": 40, "end": 41}], "lang": "en"}
{"doc_id": "9855339_4", "wnd_id": "9855339_4_1", "text": "We suspect that nefazodone inhibits metabolism of tacrolimus .", "tokens": ["We", "suspect", "that", "nefazodone", "inhibits", "metabolism", "of", "tacrolimus", "."], "event_mentions": [{"id": "9855339_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "inhibits", "start": 4, "end": 5}, "arguments": [{"entity_id": "9855339_4_Ent1", "role": "Treatment", "text": "nefazodone", "start": 3, "end": 4}, {"entity_id": "9855339_4_Ent2", "role": "Treatment_Drug", "text": "nefazodone", "start": 3, "end": 4}, {"entity_id": "9855339_4_Ent0", "role": "Effect", "text": "metabolism of tacrolimus", "start": 5, "end": 8}]}], "entity_mentions": [{"id": "9855339_4_Ent1", "text": "nefazodone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9855339_4_Ent2", "text": "nefazodone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9855339_4_Ent0", "text": "metabolism of tacrolimus", "entity_type": "Entity", "start": 5, "end": 8}], "lang": "en"}
{"doc_id": "9865241_1", "wnd_id": "9865241_1_1", "text": "CONCLUSION : We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning .", "tokens": ["CONCLUSION", ":", "We", "report", "a", "case", "of", "the", "use", "of", "pamidronate", "for", "significant", "hypercalcemia", "secondary", "to", "acute", "vitamin", "D", "poisoning", "."], "event_mentions": [{"id": "9865241_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 11, "end": 12}, "arguments": [{"entity_id": "9865241_1_Ent0", "role": "Subject", "text": "a case", "start": 4, "end": 6}, {"entity_id": "9865241_1_Ent1", "role": "Treatment", "text": "pamidronate", "start": 10, "end": 11}, {"entity_id": "9865241_1_Ent4", "role": "Treatment_Drug", "text": "pamidronate", "start": 10, "end": 11}, {"entity_id": "9865241_1_Ent2", "role": "Treatment_Disorder", "text": "hypercalcemia", "start": 13, "end": 14}, {"entity_id": "9865241_1_Ent3", "role": "Treatment_Drug", "text": "vitamin D", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "9865241_1_Ent0", "text": "a case", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9865241_1_Ent1", "text": "pamidronate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9865241_1_Ent4", "text": "pamidronate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9865241_1_Ent2", "text": "hypercalcemia", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9865241_1_Ent3", "text": "vitamin D", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "9865241_4", "wnd_id": "9865241_4_1", "text": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication .", "tokens": ["The", "use", "of", "pamidronate", "for", "hypercalcemia", "secondary", "to", "acute", "vitamin", "D", "intoxication", "."], "event_mentions": [{"id": "9865241_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 4, "end": 5}, "arguments": [{"entity_id": "9865241_4_Ent0", "role": "Treatment", "text": "pamidronate", "start": 3, "end": 4}, {"entity_id": "9865241_4_Ent2", "role": "Treatment_Drug", "text": "pamidronate", "start": 3, "end": 4}, {"entity_id": "9865241_4_Ent1", "role": "Treatment_Disorder", "text": "hypercalcemia secondary to acute vitamin D intoxication", "start": 5, "end": 12}]}, {"id": "9865241_4_Evt1", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 6, "end": 7}, "arguments": [{"entity_id": "9865241_4_Ent3", "role": "Effect", "text": "hypercalcemia", "start": 5, "end": 6}, {"entity_id": "9865241_4_Ent4", "role": "Treatment", "text": "vitamin D", "start": 9, "end": 11}, {"entity_id": "9865241_4_Ent5", "role": "Treatment_Drug", "text": "vitamin D", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "9865241_4_Ent0", "text": "pamidronate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9865241_4_Ent2", "text": "pamidronate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9865241_4_Ent3", "text": "hypercalcemia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9865241_4_Ent1", "text": "hypercalcemia secondary to acute vitamin D intoxication", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "9865241_4_Ent4", "text": "vitamin D", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9865241_4_Ent5", "text": "vitamin D", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "9876809_1", "wnd_id": "9876809_1_1", "text": "Ticlopidine - induced phenytoin toxicity .", "tokens": ["Ticlopidine", "-", "induced", "phenytoin", "toxicity", "."], "event_mentions": [{"id": "9876809_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9876809_1_Ent1", "role": "Treatment", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "9876809_1_Ent2", "role": "Treatment_Drug", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "9876809_1_Ent5", "role": "Combination_Drug", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "9876809_1_Ent3", "role": "Treatment_Drug", "text": "phenytoin", "start": 3, "end": 4}, {"entity_id": "9876809_1_Ent4", "role": "Combination_Drug", "text": "phenytoin", "start": 3, "end": 4}, {"entity_id": "9876809_1_Ent0", "role": "Effect", "text": "toxicity", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "9876809_1_Ent1", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9876809_1_Ent2", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9876809_1_Ent5", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9876809_1_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9876809_1_Ent4", "text": "phenytoin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9876809_1_Ent0", "text": "toxicity", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "9876809_3", "wnd_id": "9876809_3_1", "text": "A 72 - year - old white man suddenly developed combative behavior , refused to leave his room , stopped eating , and began falling to the floor 6 weeks after being given ticlopidine .", "tokens": ["A", "72", "-", "year", "-", "old", "white", "man", "suddenly", "developed", "combative", "behavior", ",", "refused", "to", "leave", "his", "room", ",", "stopped", "eating", ",", "and", "began", "falling", "to", "the", "floor", "6", "weeks", "after", "being", "given", "ticlopidine", "."], "event_mentions": [{"id": "9876809_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "9876809_3_Ent0", "role": "Subject", "text": "A 72 - year - old white man", "start": 0, "end": 8}, {"entity_id": "9876809_3_Ent1", "role": "Subject_Age", "text": "72 - year - old", "start": 1, "end": 6}, {"entity_id": "9876809_3_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "9876809_3_Ent3", "role": "Subject_Gender", "text": "man", "start": 7, "end": 8}, {"entity_id": "9876809_3_Ent4", "role": "Effect", "text": "combative behavior , refused to leave his room , stopped eating , and began falling to the floor", "start": 10, "end": 28}, {"entity_id": "9876809_3_Ent6", "role": "Treatment_Time_elapsed", "text": "6 weeks", "start": 28, "end": 30}, {"entity_id": "9876809_3_Ent5", "role": "Treatment", "text": "6 weeks after being given ticlopidine", "start": 28, "end": 34}, {"entity_id": "9876809_3_Ent7", "role": "Treatment_Drug", "text": "ticlopidine", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "9876809_3_Ent0", "text": "A 72 - year - old white man", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "9876809_3_Ent1", "text": "72 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "9876809_3_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9876809_3_Ent3", "text": "man", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9876809_3_Ent4", "text": "combative behavior , refused to leave his room , stopped eating , and began falling to the floor", "entity_type": "Entity", "start": 10, "end": 28}, {"id": "9876809_3_Ent6", "text": "6 weeks", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "9876809_3_Ent5", "text": "6 weeks after being given ticlopidine", "entity_type": "Entity", "start": 28, "end": 34}, {"id": "9876809_3_Ent7", "text": "ticlopidine", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "9876812_1", "wnd_id": "9876812_1_1", "text": "Clinicians should be aware of the possibility that vinorelbine may cause SIADH and possibly hypokalemia .", "tokens": ["Clinicians", "should", "be", "aware", "of", "the", "possibility", "that", "vinorelbine", "may", "cause", "SIADH", "and", "possibly", "hypokalemia", "."], "event_mentions": [{"id": "9876812_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 10, "end": 11}, "arguments": [{"entity_id": "9876812_1_Ent1", "role": "Treatment", "text": "vinorelbine", "start": 8, "end": 9}, {"entity_id": "9876812_1_Ent2", "role": "Treatment_Drug", "text": "vinorelbine", "start": 8, "end": 9}, {"entity_id": "9876812_1_Ent0", "role": "Effect", "text": "SIADH and possibly hypokalemia", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "9876812_1_Ent1", "text": "vinorelbine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9876812_1_Ent2", "text": "vinorelbine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9876812_1_Ent0", "text": "SIADH and possibly hypokalemia", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "9876812_2", "wnd_id": "9876812_2_1", "text": "CONCLUSIONS : Because of its structural similarity to the other vinca alkaloids , vinorelbine is believed to be responsible for SIADH in our patient .", "tokens": ["CONCLUSIONS", ":", "Because", "of", "its", "structural", "similarity", "to", "the", "other", "vinca", "alkaloids", ",", "vinorelbine", "is", "believed", "to", "be", "responsible", "for", "SIADH", "in", "our", "patient", "."], "event_mentions": [{"id": "9876812_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "responsible", "start": 18, "end": 19}, "arguments": [{"entity_id": "9876812_2_Ent1", "role": "Treatment", "text": "vinorelbine", "start": 13, "end": 14}, {"entity_id": "9876812_2_Ent2", "role": "Treatment_Drug", "text": "vinorelbine", "start": 13, "end": 14}, {"entity_id": "9876812_2_Ent0", "role": "Effect", "text": "SIADH", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "9876812_2_Ent1", "text": "vinorelbine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9876812_2_Ent2", "text": "vinorelbine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9876812_2_Ent0", "text": "SIADH", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "9876812_3", "wnd_id": "9876812_3_1", "text": "OBJECTIVE : To describe onset of syndrome of inappropriate antidiuretic hormone ( SIADH ) associated with vinorelbine therapy for advanced breast cancer .", "tokens": ["OBJECTIVE", ":", "To", "describe", "onset", "of", "syndrome", "of", "inappropriate", "antidiuretic", "hormone", "(", "SIADH", ")", "associated", "with", "vinorelbine", "therapy", "for", "advanced", "breast", "cancer", "."], "event_mentions": [{"id": "9876812_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 14, "end": 16}, "arguments": [{"entity_id": "9876812_3_Ent0", "role": "Effect", "text": "syndrome of inappropriate antidiuretic hormone ( SIADH )", "start": 6, "end": 14}, {"entity_id": "9876812_3_Ent1", "role": "Treatment", "text": "vinorelbine", "start": 16, "end": 17}, {"entity_id": "9876812_3_Ent2", "role": "Treatment_Drug", "text": "vinorelbine", "start": 16, "end": 17}, {"entity_id": "9876812_3_Ent3", "role": "Treatment_Disorder", "text": "advanced breast cancer", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "9876812_3_Ent0", "text": "syndrome of inappropriate antidiuretic hormone ( SIADH )", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "9876812_3_Ent1", "text": "vinorelbine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9876812_3_Ent2", "text": "vinorelbine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9876812_3_Ent3", "text": "advanced breast cancer", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "9886213_1", "wnd_id": "9886213_1_1", "text": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy .", "tokens": ["Disseminated", "muscular", "cysticercosis", "with", "myositis", "induced", "by", "praziquantel", "therapy", "."], "event_mentions": [{"id": "9886213_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "9886213_1_Ent0", "role": "Effect", "text": "Disseminated muscular cysticercosis with myositis", "start": 0, "end": 5}, {"entity_id": "9886213_1_Ent2", "role": "Treatment_Drug", "text": "praziquantel", "start": 7, "end": 8}, {"entity_id": "9886213_1_Ent1", "role": "Treatment", "text": "praziquantel therapy", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "9886213_1_Ent0", "text": "Disseminated muscular cysticercosis with myositis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "9886213_1_Ent2", "text": "praziquantel", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9886213_1_Ent1", "text": "praziquantel therapy", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "9892272_1", "wnd_id": "9892272_1_1", "text": "Massive subfascial hematoma after alteplase therapy for acute myocardial infarction .", "tokens": ["Massive", "subfascial", "hematoma", "after", "alteplase", "therapy", "for", "acute", "myocardial", "infarction", "."], "event_mentions": [{"id": "9892272_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "9892272_1_Ent0", "role": "Effect", "text": "Massive subfascial hematoma", "start": 0, "end": 3}, {"entity_id": "9892272_1_Ent2", "role": "Treatment_Drug", "text": "alteplase", "start": 4, "end": 5}, {"entity_id": "9892272_1_Ent1", "role": "Treatment", "text": "alteplase therapy", "start": 4, "end": 6}, {"entity_id": "9892272_1_Ent3", "role": "Treatment_Disorder", "text": "acute myocardial infarction", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "9892272_1_Ent0", "text": "Massive subfascial hematoma", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9892272_1_Ent2", "text": "alteplase", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9892272_1_Ent1", "text": "alteplase therapy", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9892272_1_Ent3", "text": "acute myocardial infarction", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "9892272_2", "wnd_id": "9892272_2_1", "text": "Physicians should be aware of the possible association between the use of alteplase and the development of subfascial hemorrhage .", "tokens": ["Physicians", "should", "be", "aware", "of", "the", "possible", "association", "between", "the", "use", "of", "alteplase", "and", "the", "development", "of", "subfascial", "hemorrhage", "."], "event_mentions": [{"id": "9892272_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 15, "end": 16}, "arguments": [{"entity_id": "9892272_2_Ent1", "role": "Treatment", "text": "alteplase", "start": 12, "end": 13}, {"entity_id": "9892272_2_Ent2", "role": "Treatment_Drug", "text": "alteplase", "start": 12, "end": 13}, {"entity_id": "9892272_2_Ent0", "role": "Effect", "text": "subfascial hemorrhage", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "9892272_2_Ent1", "text": "alteplase", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9892272_2_Ent2", "text": "alteplase", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9892272_2_Ent0", "text": "subfascial hemorrhage", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "9925865_1", "wnd_id": "9925865_1_1", "text": "CONCLUSION : Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population .", "tokens": ["CONCLUSION", ":", "Lipoid", "pneumonia", "as", "a", "result", "of", "mineral", "oil", "aspiration", "still", "occurs", "in", "the", "pediatric", "population", "."], "event_mentions": [{"id": "9925865_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 6, "end": 7}, "arguments": [{"entity_id": "9925865_1_Ent2", "role": "Effect", "text": "Lipoid pneumonia", "start": 2, "end": 4}, {"entity_id": "9925865_1_Ent4", "role": "Treatment_Drug", "text": "mineral oil", "start": 8, "end": 10}, {"entity_id": "9925865_1_Ent3", "role": "Treatment", "text": "mineral oil aspiration", "start": 8, "end": 11}, {"entity_id": "9925865_1_Ent0", "role": "Subject", "text": "pediatric", "start": 15, "end": 16}, {"entity_id": "9925865_1_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "9925865_1_Ent2", "text": "Lipoid pneumonia", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "9925865_1_Ent4", "text": "mineral oil", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9925865_1_Ent3", "text": "mineral oil aspiration", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "9925865_1_Ent0", "text": "pediatric", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9925865_1_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "9934637_1", "wnd_id": "9934637_1_1", "text": "An unusual cause of burn injury : unsupervised use of drugs that contain psoralens .", "tokens": ["An", "unusual", "cause", "of", "burn", "injury", ":", "unsupervised", "use", "of", "drugs", "that", "contain", "psoralens", "."], "event_mentions": [{"id": "9934637_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 2, "end": 3}, "arguments": [{"entity_id": "9934637_1_Ent0", "role": "Effect", "text": "burn injury", "start": 4, "end": 6}, {"entity_id": "9934637_1_Ent1", "role": "Treatment", "text": "use of drugs that contain psoralens .", "start": 8, "end": 15}, {"entity_id": "9934637_1_Ent2", "role": "Treatment_Drug", "text": "psoralens", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "9934637_1_Ent0", "text": "burn injury", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9934637_1_Ent1", "text": "use of drugs that contain psoralens .", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "9934637_1_Ent2", "text": "psoralens", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "9988365_2", "wnd_id": "9988365_2_1", "text": "Eosinophilia has been encountered from 0.2 to 61.7 % in clozapine - treated patients , mostly with a transient course and spontaneous remission .", "tokens": ["Eosinophilia", "has", "been", "encountered", "from", "0.2", "to", "61.7", "%", "in", "clozapine", "-", "treated", "patients", ",", "mostly", "with", "a", "transient", "course", "and", "spontaneous", "remission", "."], "event_mentions": [{"id": "9988365_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "encountered", "start": 3, "end": 4}, "arguments": [{"entity_id": "9988365_2_Ent1", "role": "Effect", "text": "Eosinophilia", "start": 0, "end": 1}, {"entity_id": "9988365_2_Ent2", "role": "Treatment", "text": "clozapine", "start": 10, "end": 11}, {"entity_id": "9988365_2_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 10, "end": 11}, {"entity_id": "9988365_2_Ent0", "role": "Subject", "text": "patients", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "9988365_2_Ent1", "text": "Eosinophilia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9988365_2_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9988365_2_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9988365_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
